World Health Organization Global Tuberculosis Control 2009 Epidemiology, Strategy, Financing Nonserial Publication 2009

G l o b a l T u b e r c u l o s i s C o n t r o l 2 0 0 9
E P I D E MI O L O G Y S T R A T E G Y F I N A N C I N G
WHO REPORT 2009
Global Tuberculosis Control

EPIDEMIOLOGY, STRATEGY, FINANCING
WHO Library Cataloguing-in-Publication Data Global tuberculosis control : epidemiology, strategy, nancing : WHO report 2009. 1.Tuberculosis, Pulmonary prevention and control. 2.Tuberculosis, Pulmonary epidemiology. 3.Cost of illness. 4.Treatment outcome. 5.National health programs organization and administration. 6.Financing, Health. 7.Statistics. I.World Health Organization. ISBN 978 92 4 156380 2 WHO/HTM/TB/2009.411 (NLM classication: WF 300)
World Health Organization 2009 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications whether for sale or for noncommercial distribution should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specic companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. Cover design by Tom Hiatt, WHO Stop TB Department. Of the estimated 9.3 million new cases of TB that occurred in 2007, 1.4 million (15%) were infected with HIV. The WHO African Region accounted for 79% of these HIV-positive TB cases, followed by the WHO South-East Asia Region (11%). In the absence of appropriate treatment, the mortality rate in HIV-positive TB cases is high. However, this rate can be signicantly reduced if provider-initiated HIV testing is made available to all TB patients and if interventions such as early antiretroviral therapy are made available to those who are HIV-positive. The cover image is a dot chart showing the relative contribution of countries (blue dots) and WHO regions (green dots) to the global burden of HIV-positive TB. Designed by minimum graphics Printed in Switzerland
Contents
Acknowledgements Abbreviations Key points Introduction Chapter 1. Epidemiology Goals, targets and indicators for TB control TB incidence, prevalence and mortality Incidence Prevalence Mortality Summary of progress towards MDG and Stop TB Partnership impact targets Improving measurement of progress towards the 2015 impact targets: the WHO Global Task Force on TB Impact Measurement Measurement of incidence Measurement of prevalence Measurement of mortality Status of impact measurement in HBCs at the end of 2008 Case notications Total case notications Case notications disaggregated by sex Case detection rates Case detection rate, all sources (DOTS and non-DOTS programmes) Case detection rate, DOTS programmes Outcomes of treatment in DOTS programmes New smear-positive cases Re-treatment cases Comparison of treatment outcomes in HIV-positive and HIV-negative TB patients Progress towards reaching targets for case detection and treatment success Summary Chapter 2. Strategy Data reported to WHO in 2008 DOTS expansion and enhancement DOTS coverage and numbers of patients treated Political commitment Early case detection through quality-assured bacteriology Standardized treatment with supervision, and patient support Drug supply and management system Monitoring and evaluation Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations Collaborative TB/HIV activities Diagnosis and treatment of MDR-TB Poor and vulnerable populations Contribute to health system strengthening based on primary health care Integration in primary health care
v vii 1 5 6 6 7 7 12 12 14 16 16 19 20 20 22 22 22 23 23 26 27 27 29 30 30 32 34 35 35 35 37 37 40 41 41 43 43 49 54 54 54
GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 iii
Chapter 3.
Alignment with broader planning and nancing frameworks Human resource development Infection control Practical Approach to Lung Health Engage all care providers Publicprivate mix approaches International Standards for Tuberculosis Care Empower people with TB, and communities through partnership Advocacy, communication and social mobilization Community participation in TB care Patients Charter for Tuberculosis Care Enable and promote research Summary Financing Data reported to WHO in 2008 NTP budgets, available funding and funding gaps High-burden countries All countries Total costs of TB control High-burden countries All countries Comparisons with the Global Plan High-burden countries All countries Budgets and costs per patient Expenditures compared with available funding and changes in the number of patients treated Global Fund nancing High-burden countries All countries Funding gaps and the global nancial crisis Summary
Conclusions Annex 1. Proles of high-burden countries Annex 2. Methods Data collection and verication an overview Epidemiology and surveillance Implementation of the Stop TB Strategy Financing Annex 3. The Stop TB Strategy, case reports, treatment outcomes and estimates of TB burden Explanatory notes Summary by WHO region Africa The Americas Eastern Mediterranean Europe South-East Asia Western Pacic Annex 4. Surveys of tuberculosis disease and availability of death registration data at WHO, by country and year
55 55 55 56 57 57 58 58 58 58 58 58 59 60 60 60 60 63 64 64 67 69 69 69 71 72 74 74 74 75 77 78 79 171 173 174 180 181 187 188 191 197 217 237 249 269 281 301
iv WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL
Acknowledgements
This report was produced by a core team of 15 people: Rachel Bauquerez, Lopold Blanc, Ana Bierrenbach, Annemieke Brands, Karen Ciceri, Dennis Falzon, Katherine Floyd, Philippe Glaziou, Christian Gunneberg, Tom Hiatt, Mehran Hosseini, Andrea Pantoja, Mukund Uplekar, Catherine Watt and Abigail Wright. Overall coordination was provided by Lopold Blanc and Katherine Floyd. The data collection form was developed by Mehran Hosseini and Catherine Watt, with input from a variety of other staff. Mehran Hosseini organized and led implementation of all aspects of data management (including collection, uploading, validation, review and follow-up with countries), with support from Tom Hiatt. Andrea Pantoja and Ins Garcia conducted all review and follow-up of the nancial data that are presented in Chapter 3, Annex 1 and Annex 3. Rachel Bauquerez, Annemieke Brands, Dennis Falzon, Christian Gunneberg, Mehran Hosseini, Abigail Wright and Matteo Zignol reviewed data and contributed to preparation of follow-up messages for data related to epidemiology and implementation of the Stop TB Strategy, the results of which appear in Chapters 1 and 2 and in Annexes 1 and 3. Data for the European Region were collected and validated jointly by WHO and the European Centre for Disease Prevention and Control, an agency of the European Union based in Stockholm, Sweden. Report writing was led by Katherine Floyd, Philippe Glaziou and Mukund Uplekar. Karin Bergstrm, Lopold Blanc, YoungAe Chu, Dennis Falzon, Giuliano Gargioni, Christian Gunneberg, Mehran Hosseini, Knut Lonnrth, Pierre-Yves Norval, Ikushi Onozaki, Fabio Scano, Lana Velebit, Karin Weyer, Abigail Wright and Matteo Zignol contributed text for particular sections of Chapter 2. Ana Bierrenbach and Andrea Pantoja provided input to and careful review of Chapters 1 and 3, respectively. Haileyesus Getahun, Paul Nunn, Mario Raviglione and Diana Weil provided input to and careful review of various sections of the report. Karen Ciceri edited the entire report. Philippe Glaziou, Mehran Hosseini and Catherine Watt analysed surveillance and epidemiological data and prepared the gures and tables for Chapter 1. Mehran Hosseini analysed data about implementation of the Stop TB Strategy and prepared the gures and tables for Chapter 2, with support from Dennis Falzon, Christian Gunneberg and Tom Hiatt. Andrea Pantoja analysed the nancial data and prepared the gures and tables for Chapter 3, with support from Ins Garcia. The country proles that appear in Annex 1 were designed by Annemieke Brands, Philippe Glaziou, Andrea Godfrey, Mehran Hosseini, Andrea Pantoja and Catherine Watt. Their production was led by Mehran Hosseini (epidemiology and strategy) and Andrea Pantoja (nancing), with support from Tom Hiatt and Anne Guilloux. Input to particular sections of the proles was provided by Rachel Bauquerez, Ins Garcia, Young-Ae Chu, Katherine Floyd, Giuliano Gargioni, Haileyesus Getahun, Malgorzata Grzemska, Wiesiek Jakubowiak, Daniel Kibuga, Knut Lonnrth, Ikushi Onozaki, Salah Ottmani, Anglica Salomao, Mukund Uplekar, Pieter van Maaren, Lana Velebit and Abigail Wright. Annemieke Brands coordinated the review of these proles by countries. Katherine Floyd, Philippe Glaziou and Andrea Pantoja prepared Annex 2 (methods). Tom Hiatt prepared Annex 3 (key statistics for regions and individual countries), with support from Mehran Hosseini. Ana Bierrenbach prepared summaries of existing and planned surveys of the prevalence of tuberculosis (TB) disease and the availability of mortality data from vital registration systems, which are presented in Annex 4. In addition to the core report team and the staff mentioned above, the report beneted from the input of many others at the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS), particularly for data collection and review. Among those listed below, we thank in particular Amal Bassili, Andrei Dadu, Khurshim Alad Hyder, Daniel Kibuga, Rafael Lopez-Olarte, Masaki Ota and Anglica Salomo for their major contribution to data collection and review. WHO headquarters Geneva and UNAIDS. Pamela Baillie, Victoria Birungi, Eleanor Gouws, Ernesto Jaramillo, Robert Matiru, Fuad Mirzayev and Alasdair Reid. WHO African Region. Ayodele Awe, Rufaro Chatora, Thierry Comolet, Ntakirutimana Dorothe, Joseph Imoko, Joel Kangangi, Bah Keita, Daniel Kibuga, Mwendaweli Maboshe, Vainess Mfungwe, Ishmael Nyasulu, Wilfred Nkhoma, Anglica Salomo, Neema Simkoko and Henriette Wembanyama. WHO Region of the Americas. Raimond Armengol, Albino Beletto, Mirtha del Granado, John Ehrenberg, Marlene Francis, Rafael Lopez-Olarte, Rodolfo Rodriguez-Cruz and Yamil Silva.
GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 v
WHO Eastern Mediterranean Region. Imad Alamin, Samiha Baghdadi, Amal Bassili, Yuriko Egami, Sevil Huseynova, Keiko Inaba, Ridha Jebeniani, Wasiq Khan, Aaiyd Munim, Syed Karam Shah, Akihiro Seita, Ireneaus Sindani, Bashir Suleiman and Khaled Sultan. WHO European Region. Pierpaolo de Colombani, Andrei Dadu, Lucica Ditiu, Nedret Emiroglu, Ajay Goel, Sbastien Inizan, Bahtygul Karriyeva, Srdan Matic, David Mercer, Roman Spataru, Gombogaram Tsogt, Martin van den Boom, Rusovich Valentin, Elena Yurasova and Richard Zaleskis. WHO South-East Asia Region. Mohammed Akhtar, Erwin Cooreman, Aime De Muynck, Puneet Dewan, Khurshid Alam Hyder, Hans Kluge, Partha P Mandal, Firdosi Mehta, Nani Nair, Suvanand Sahu, Kim Son Il, Sombat Thanprasertuk, Fraser Wares and Supriya Warusavithana. WHO Western Pacic Region. Cornelia Hennig, Giampaolo Mezzabotta, Linh Nguyen, Katsunori Osuga, Masaki Ota, Jacques Sebert, Bernard Tomas, Jamhoih Tonsing, Pieter Van Maaren, Michael Voniatis, Rajendra Yadav and Liu Yuhong. The main purpose of this report is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress in control of the disease at global, regional and country levels. This analysis is based on data about notications of TB cases and the outcomes of treatment (from surveillance systems) as well as data related to the implementation and nancing of the Stop TB Strategy. Data are supplied primarily by national TB control programme managers who lead work on surveillance, strategy and nancing in countries. These people are listed in Annex 3, and we thank them all for their invaluable contribution and collaboration. The principal source of nancial support for WHOs work on monitoring and evaluating TB control is the United States Agency for International Development, without which it would be impossible to produce this report. Data collection and analysis are also supported by funding from the governments of Australia, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Japan, Luxembourg, the Netherlands, Norway, Sweden, Switzerland and the United Kingdom as well as by contributions from the European Union, the European Commission, and the Bill & Melinda Gates Foundation. We acknowledge with gratitude the support of these agencies. Finally, we thank Sue Hobbs for her excellent work on the design and layout of this report. Sue has worked with the Stop TB Department on this project for many years, and her contribution is greatly appreciated. As usual, her exibility and efciency guarantee that this report is published on 24 March, World TB Day.
vi WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL
Abbreviations
ACSM AFB AFR AFRO AIDS AMR AMRO ARI ART BMU BRAC CPT CTBC DHIS DOT DOTS DRS DST ECDC EMR EMRO ENRS EQA EUR EURO FDC FIDELIS FIND GDF GLC GLI Global Fund Global Plan GNI HBC
HIV
advocacy, communication and social mobilization acid-fast bacilli WHO African Region WHO Regional Ofce for Africa acquired immunodeciency syndrome WHO Region of the Americas WHO Regional Ofce for the Americas annual risk of infection antiretroviral therapy basic management unit Bangladesh Rural Advancement Committee co-trimoxazole preventive therapy community-based TB care District Health Information Software directly observed treatment the basic package that underpins the Stop TB Strategy drug resistance surveillance or survey drug susceptibility testing European Centre for Disease Prevention and Control WHO Eastern Mediterranean Region WHO Regional Ofce for the Eastern Mediterranean Electronic National Record System external quality assurance WHO European Region WHO Regional Ofce for Europe xed-dose combination (or FDC anti-TB drug) Fund for Innovative DOTS Expansion, managed by the Union Foundation for Innovative New Diagnostics Global TB Drug Facility Green Light Committee Global Laboratory Initiative The Global Fund to ght AIDS, Tuberculosis and Malaria Global Plan to Stop TB, 20062015 gross national income high-burden country of which there are 22 that account for approximately 80% of all new TB cases arising each year human immunodeciency virus
human resource development International Statistical Classication of Diseases IEC information, education, communication IPT isoniazid preventive therapy IRR incidence rate ratio ISTC International Standards for Tuberculosis Care KAP knowledge, attitudes and practice MDG Millennium Development Goal MDR multidrug resistance (resistance to, at least, isoniazid and rifampicin) MDR-TB multidrug-resistant tuberculosis NGO nongovernmental organization NRL national reference laboratory NTP national tuberculosis control programme or equivalent OpenMRS Open Medical Records System PAL Practical Approach to Lung Health PPM PublicPrivate Mix PPP PublicPrivate Partnerships RDBMS relational database management system SCC short-course chemotherapy SEAR WHO South-East Asia Region SEARO WHO Regional Ofce for South-East Asia SRL supranational reference laboratory SRLN supranational reference laboratory network TB tuberculosis TBTEAM TB Technical Assistance Mechanism UNAIDS Joint United Nations Programme on HIV/AIDS UNITAID international facility for the purchase of drugs to treat HIV/AIDS, malaria and TB USAID United States Agency for International Development WHA World Health Assembly WHO World Health Organization WHO-CHOICE CHOosing Interventions that are CostEffective WPR WHO Western Pacic Region WPRO WHO Regional Ofce for the Western Pacic XDR-TB TB caused by MDR strains that are also resistant to a uoroquinolone and, at least, one second-line injectable agent (amikacin, kanamycin and/or capreomycin)
HRD ICD-10
GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 vii
Key points
On trouvera les points essentiels du rapport 2009 de lOMS relatif la lutte antituberculeuse dans le monde sur le site Web indiqu ci-dessous: Los puntos principales del informe mundial de 2009 de la OMS sobre la tuberculosis se pueden consultar en el sitio web que se indica ms abajo:
www.who.int/tb/publications/global_report/2009/key_points/
1.
This report is the 13th annual report on global control of tuberculosis (TB) published by the World Health Organization (WHO) in a series that started in 1997. Its main purpose is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress in controlling the disease at global, regional and country levels, in the context of global targets set for 2015. Results are based primarily on data reported to WHO via its standard TB data collection form in 2008 and on the data that were collected every year from 1996 to 2007. The 196 countries and territories that reported data in 2008 account for 99.6% of the worlds estimated number of TB cases and 99.7% of the worlds population.
2. The main targets for global TB control are (i) that the incidence of TB should be falling by 2015 (MDG Target 6.c), (ii) that TB prevalence and death rates should be halved by 2015 compared with their level in 1990, (iii) that at least 70% of incident smear-positive cases should be detected and treated in DOTS programmes and (iv) that at least 85% of incident smear-positive cases should be successfully treated. The latest data suggest (i) that the incidence rate has been falling since 2004, (ii) that prevalence and death rates will be halved in at least three of six WHO regions by 2015 compared with a baseline of 1990, but that these targets will not be achieved for the world as a whole, (iii) that the case detection rate reached 63% in 2007 and (iv) that the treatment success rate reached 85% in 2006.
3. Globally, there were an estimated 9.27 million incident cases of TB in 2007. This is an increase from 9.24 million cases in 2006, 8.3 million cases in 2000 and 6.6 million cases in 1990. Most of the estimated number of cases in 2007 were in Asia (55%) and Africa (31%), with small proportions of cases in the Eastern Mediterranean Region (6%), the European Region (5%) and the Region of the Americas (3%). The ve countries that rank rst to fth in terms of total numbers of cases in 2007 are India (2.0 million), China (1.3 million), Indonesia (0.53 million), Nigeria (0.46 million) and South Africa (0.46 million). Of the 9.27 million incident TB cases in 2007, an estimated 1.37 million (15%) were HIV-positive; 79% of these HIV-positive cases were in the African Region and 11% were in the South-East Asia Region. 4. Although the total number of incident cases of TB is increasing in absolute terms as a result of population growth, the number of cases per capita is falling. The rate of decline is slow, at less than 1% per year. Globally, rates peaked at 142 cases per 100 000 population in 2004. In 2007, there were an estimated 139 incident cases per 100 000 population. Incidence rates are falling in ve of the six WHO regions (the exception is the European Region, where rates are approximately stable). 5. There were an estimated 13.7 million prevalent cases of TB in 2007 (206 per 100 000 population), a decrease from 13.9 million cases (210 per 100 000 population) in 2006.
GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 1
6. An estimated 1.3 million deaths occurred among HIVnegative incident cases of TB (20 per 100 000 population) in 2007. There were an additional 456 000 deaths among incident TB cases who were HIV-positive; these deaths are classied as HIV deaths in the International Statistical Classication of Diseases (ICD-10). The 456 000 deaths among HIV-positive incident TB cases equate to 33% of HIV-positive incident cases of TB and 23% of the estimated 2 million HIV deaths in 2007. 7. Prevalence and mortality rates are falling globally and in all six WHO regions. The Region of the Americas as well as the Eastern Mediterranean and South-East Asia regions are on track to achieve the Stop TB Partnership targets of halving prevalence and death rates by 2015, compared with a baseline of 1990. The Western Pacic Region is on track to halve the prevalence rate by 2015, but the mortality target may be narrowly missed. Neither the prevalence nor the mortality targets will be met in the African and European regions. The gulf between prevalence and mortality rates in 2007 and the targets in these two regions make it unlikely that 1990 prevalence and death rates will be halved by 2015 for the world as a whole.
10. There were an estimated 0.5 million cases of multidrugresistant TB (MDR-TB) in 2007. There are 27 countries (of which 15 are in the European Region) that account for 85% of all such cases. The countries that rank rst to fth in terms of total numbers of MDR-TB cases are India (131 000), China (112 000), the Russian Federation (43 000), South Africa (16 000) and Bangladesh (15 000). By the end of 2008, 55 countries and territories had reported at least one case of extensively drugresistant TB (XDR-TB). 11. The WHO Global Task Force on TB Impact Measurement has produced recommendations about how to measure progress in reducing rates of TB incidence, prevalence and mortality (the three major indicators of impact). These include systematic analysis of national and subnational notication data combined with improved surveillance systems to measure incidence, surveys of the prevalence of TB disease in 21 global focus countries between 2008 and 2015, and strengthening of vital registration systems to measure TB mortality among other causes of death. Implementation of Task Force recommendations is necessary to improve measurement of progress towards the global targets set for 2015 as well as to measure progress in TB control in subsequent years. 12. The Stop TB Strategy is WHOs recommended approach to reducing the burden of TB in line with global targets. The six major components of the strategy are: pursue high-quality DOTS expansion and enhancement; address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations; contribute to health system strengthening based on primary health care; engage all care providers; empower people with TB, and communities through partnership; and enable and promote research. The Stop TB Partnerships Global Plan to Stop TB, 20062015 sets out the scale at which the interventions included in the Stop TB Strategy need to be implemented to achieve the 2015 targets. 13. In 2007, 5.5 million TB cases were notied by DOTS programmes (99% of total case notications). This included 2.6 million smear-positive cases. The case detection rate of new smear-positive cases under DOTS (that is, the percentage of estimated incident cases that were notied and treated in DOTS programmes) was 63%, a small increase from 62% in 2006 but still 7% short of the target of 70% rst set for 2000 (and later reset to 2005) by the World Health Assembly (WHA) in 1991. The target was met in 74 countries and in two regions the Region of the Americas (73%) and the Western Pacic Region (77%). The South-East Asia Region (69%) almost met the target. The case detection rate was 60% in the Eastern Mediterranean Region, 51% in the European Region and 47% in the African Region.
8. The estimated numbers of HIV-positive TB cases and deaths in 2007 are approximately double the numbers published by WHO in previous years. This does not mean that the number of HIV-positive TB cases and the number of TB deaths among HIV-positive people doubled between 2006 and 2007. New data that became available in 2008, particularly from provider-initiated HIV testing in the African Region, were used (i) to estimate the numbers of cases and deaths in 2007 and (ii) to revise previous estimates of the numbers of cases and deaths that had occurred in earlier years. The numbers of HIV-positive TB cases and deaths are estimated to have peaked in 2005, at 1.39 million cases (15% of all incident cases) and 480 000 deaths. 9. The latest estimates of the numbers of HIV-positive TB cases and deaths were based, as usual, on estimates of HIV prevalence in the general population published by the Joint United Nations Programme on HIV/AIDS, or UNAIDS. The new data that became available in 2008 were direct measurements of the proportion of TB cases that are coinfected with HIV in 64 countries (up from 15 countries in 2007). These 64 direct measurements suggest that HIV-positive people are about 20 times more likely than HIV-negative people to develop TB in countries with a generalized HIV epidemic (compared with a previous estimate of six), and between 26 and 37 times more likely to develop TB in countries where HIV prevalence is lower (compared with a previous estimate of 30). These higher estimates were used to estimate the number of HIV-positive TB cases in countries for which direct measurements were not available.
2 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL
14. Globally, the rate of treatment success for new smearpositive cases treated in DOTS programmes in 2006 reached the target of 85% rst set by the WHA in 1991. Three regions the Eastern Mediterranean (86%), Western Pacic (92%), and South-East Asia (87%) regions met the target, as did 59 countries. The treatment success rate was 75% in the African Region and the Region of the Americas, and 70% in the European Region. 15. In 20062007, the Western Pacic Region and 36 countries met both the target of a case detection rate of at least 70% and the target of a treatment success rate of at least 85% for new smear-positive cases. The SouthEast Asia Region is close to achieving both targets. Kenya became the rst country in sub-Saharan Africa to achieve both targets. 16. There has been major progress in implementing interventions such as testing TB patients for HIV and providing co-trimoxazole preventive therapy (CPT) and antiretroviral therapy (ART) to HIV-positive TB patients. Globally, 1 million TB patients (16% of notied cases) knew their HIV status in 2007. The greatest progress in HIV testing was in the African Region, where 0.5 million TB patients (37% of all notied cases) knew their HIV status in 2007. Of the 250 000 HIV-positive TB patients, 0.2 million were enrolled on CPT and 0.1 million were started on ART. In both cases, gures were higher than those reported to WHO in previous years. 17. Despite the progress that has been made with scaling up collaborative TB/HIV activities, progress in HIV testing is outpacing progress in the provision of CPT and ART. The number of HIV-positive TB patients being treated with CPT and ART is small compared with the 0.3 million TB patients known to be HIV-positive, and smaller still compared with the estimated 1.4 million HIV-positive TB cases (many of whom are not detected in DOTS programmes, given a case detection rate of 47%). Case detection in DOTS programmes as well as collaborative TB/HIV activities need to be expanded to ensure that (i) many more people know their HIV status and (ii) that those who are HIV-positive, with and without TB, have access to appropriate and timely treatment and care. 18. Globally, just under 30 000 cases of MDR-TB were notied to WHO in 2007, mostly by European countries and South Africa. This was 8.5% of the estimated global total of smear-positive cases of MDR-TB. Of the notied cases, 3681 were started on treatment in projects or programmes approved by the Green Light Committee (GLC), and are thus known to be receiving treatment according to international guidelines. This is equivalent to 1% of the estimated global total of smear-positive cases of MDR-TB. The number of patients started on treatment in GLC-approved projects and programmes is expected to increase to around 14 000 in 2009, equivalent to 4% of the smear-positive cases of MDR-TB estimated to
exist globally. To meet the targets set in the Global Plan, diagnosis and treatment of MDR-TB need to be rapidly scaled up, especially in the three countries that account for 57% of global cases: China, India and the Russian Federation. 19. Diagnostic and treatment services for TB are integrated into primary health care in most countries. 20. National plans for TB control are aligned with national health strategies in more than half of the 22 highburden countries (HBCs). Most NTPs are also involving other ministries, associations and institutions in the development of their plans. With renewed emphasis on health system strengthening, there is a strong basis for closer collaboration on key challenges such as sustainable nancing, human resource development, infection control and health information systems. 21. The contribution of publicprivate mix (PPM) initiatives to detection and treatment of TB cases is difcult to quantify in most countries, but examples such as Pakistan and the Philippines (where publicprivate partnerships accounted for 19% and 8% of all notications in 2007, respectively) illustrate their potential to contribute to increased case detection. The contribution of communities to diagnosis and treatment of TB is also hard to quantify. Many countries require guidance and support to design, implement and evaluate advocacy, communication and social mobilization activities (ACSM). 22. A total of US$ 3.0 billion is available for TB control in 2009 in 94 countries that reported data, and which account for 93% of the worlds TB cases: of this total, 87% is funding from governments (including loans), 9% is funding from Global Fund grants and 4% is funding from donors other than the Global Fund. Most of the available funding is in the European Region (US$ 1.4 billion, mostly in the Russian Federation), followed by the African Region (US$ 0.6 billion) and the Western Pacic Region (US$ 0.3 billion). The funding gaps identied by these 94 countries amount to US$ 1.2 billion in 2009. 23. The total of US$ 4.2 billion required for full implementation of country plans in these 94 countries in 2009 is mostly for DOTS (US$ 3 billion, or 72%). The other major components are MDR-TB (US$ 0.5 billion, or 12%; 76% of the total for MDR-TB is accounted for by the Russian Federation and South Africa), collaborative TB/HIV activities (US$ 120 million, or 3%) and ACSM (US$ 100 million, or 2%). The remaining 11% includes PPM, surveys of the prevalence of TB disease, community-based TB care and a variety of miscellaneous activities. 24. In the 22 HBCs where 80% of the worlds TB cases occur, a total of US$ 2.2 billion is available in 2009, a small increase of US$ 27 million compared with 2008 but substantially above the US$ 1.2 billion that was spent on
TB control in 2002 (when WHO began nancial monitoring of TB control). Most of the increased funding since 2002 has come from domestic funding in Brazil, China and the Russian Federation, and external nancing from the Global Fund. The HBCs reported a combined funding gap of US$ 0.50.7 billion in 2009 (the range reects uncertainty about the level of funding from provincial governments in South Africa). 25. The total of US$ 2.9 billion required for full implementation of country plans in the 22 HBCs in 2009 is mostly for DOTS (US$ 2 billion, or 69%). The other major components are MDR-TB (US$ 0.4 billion, or 14%; 88% of this total is accounted for by the Russian Federation and South Africa), TB/HIV (US$ 90 million, or 3%) and ACSM (US$ 70 million, or 2%). The remaining 12% includes PPM, surveys of the prevalence of TB disease, community TB care and a variety of miscellaneous activities. 26. Of the US$ 2.2 billion available in the 22 HBCs in 2009, 88% is from HBC governments, 8% (US$ 169 million) is from the Global Fund and 4% (US$ 94 million) is from grants from sources other than the Global Fund. The distribution of funding sources is different when the Russian Federation and South Africa are excluded: the government contribution to available funding drops to 70%, the Global Fund contribution increases to 19% and grants from sources besides the Global Fund account for 11%.
27. The gap between the available funding reported by the 22 HBCs in 2009 and the funding requirements for these countries according to the Global Plan in 2009 is US$ 0.8 billion. The gap between the available funding reported by the 94 countries with 93% of global cases in 2009 and the funding required for these countries in 2009 according to the Global Plan is US$ 1.6 billion. Most of the extra funding required according to the Global Plan is for MDR-TB diagnosis and treatment in the South-East Asia and Western Pacic regions (mostly in India and China), and for DOTS and collaborative TB/ HIV activities in Africa. 28. The global burden of TB is falling slowly, and at least three of six WHO regions are on track to achieve global targets for reducing the number of cases and deaths that have been set for 2015. However, while increasing numbers of TB cases have access to high-quality antiTB treatment as well as to related interventions such as ART, an estimated 37% of incident TB cases are not being treated in DOTS programmes, up to 96% of incident cases with MDR-TB are not being diagnosed and treated according to international guidelines, the majority of HIV-positive TB cases do not know their HIV status and the majority of HIV-positive TB patients who do know their HIV status do not have access to ART. To accelerate progress in global TB control, these numbers need to be reduced using the range of interventions and approaches included in the Stop TB Strategy.
Introduction
This report is the 13th annual report on global control of tuberculosis (TB) published by the World Health Organization (WHO) in a series that started in 1997. Its main purpose is to provide a comprehensive and up-to-date assessment of the TB epidemic and to report on progress in controlling the disease at global, regional and country levels, in the context of global targets set for 2015. The principal targets are that the incidence of TB should be falling by 2015 (MDG Target 6.c), that TB prevalence and death rates should be halved by 2015 compared with their level in 1990, that at least 70% of incident smear-positive cases should be detected and treated in DOTS programmes, and that at least 85% of new sputum smear-positive cases should be successfully treated.1,2,3,4 Results are based primarily on data reported to WHO via its standard TB data collection form in 2008 and on the data that were collected each year 19962007. The 196 countries and territories that reported data in 2008 account for 99.6% of the worlds estimated TB cases and 99.7% of the worlds population. The report is structured in three major chapters. CHAPTER 1 focuses on epidemiology. It includes WHOs latest estimates of the epidemiological burden of TB (incidence, prevalence and mortality), case notications reported for 2007, estimates of the case detection rate for new smearpositive cases as well as for all types of case between 1995 (when reliable monitoring began) and 2007, and treatment outcomes between 1994 and 2006 for new and re-treatment cases. Particular attention is given to two topics. The rst is updated estimates of the numbers of TB cases and deaths among HIV-positive people, which have been revised substantially upwards using new data that became available in 2008. The second is recent recommendations about how to improve measurement of the epidemiological burden of TB and monitoring of progress towards impact targets (i.e. reductions in incidence, prevalence and mortality) from 2009 onwards, which have been made by WHOs Global Task Force on TB Impact Measurement. CHAPTER 2 analyses progress in implementing WHOs Stop TB Strategy, which is designed to achieve the global targets set for 2015.5 The strategy was launched in 2006 and is built on the foundations of the DOTS strategy, the internationally-recommended approach to TB control advocated by WHO from the mid-1990s until 2005. The six major components of the strategy (DOTS implementation; addressing TB/HIV, MDR-TB and the needs of poor and vulnerable populations; contributing to health-system strengthening based on primary health care; engaging all care providers; empowering people with TB, and communities; and pro-
moting research) are addressed in turn. Wherever possible, comparisons are made with the targets for scaling up interventions that were set in the Stop TB Partnerships Global Plan to Stop TB. Examples of how different components of the strategy can be implemented based on recent country experience and which have wider applicability are also highlighted. These include scaling up publicprivate collaboration in Pakistan, treatment of multidrug-resistant TB (MDR-TB) in Estonia and Latvia, introducing electronic recording and reporting in Myanmar, and provision of antiretroviral treatment (ART) in Africa. CHAPTER 3 analyses nancing for TB control. The data presented include the budgets of national TB control programmes (NTPs), and available funding and funding gaps for these budgets, between 2002 (when reliable monitoring began) and 2009; estimates of the total costs of TB control, which include NTP budgets plus the costs associated with use of general health-system staff and infrastructure that are usually not included in NTP budgets; comparisons of funding needs set out in the Global Plan with countries assessments of their funding needs; per patient costs and budgets; and expenditures compared with available funding and changes in the number of patients treated. Progress with planning and budgeting for TB control and the possible consequences of the global nancial crisis that developed in 2008 are also highlighted. The main part of the report ends with a summary of the major conclusions from all three chapters (CONCLUSIONS). The remainder of the report consists of four annexes. These include country proles for the 22 high-burden countries (ANNEX 1), an explanation of methods (ANNEX 2), countryspecic data for 19902007 (ANNEX 3), and a summary of the countries where surveys of the prevalence of TB disease have been conducted or are planned and the countries for which mortality data from vital registration systems are available in a central WHO database (ANNEX 4).
1
The Millennium Development Goals are described in full at unstats. un.org/unsd Resolution WHA44.8. Tuberculosis control programme. In: Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. Volume III, 3rd ed. (19851992). Geneva, World Health Organization, 1993 (WHA44/1991/REC/1). Stop Tuberculosis Initiative. Report by the Director-General. Fifty-third World Health Assembly. Geneva, 1520 May 2000 (A53/5, 5 May 2000). Dye C et al. Targets for global tuberculosis control. International Journal of Tuberculosis and Lung Disease, 2006, 10:460462. Raviglione MC, Uplekar MW. WHOs new Stop TB Strategy. Lancet, 2006, 367:952955. The Global Plan to Stop TB, 20062015. Stop TB Partnership and WHO. Geneva, World Health Organization, 2006 (WHO/HTM/STB/2006.35).
CHAPTER 1
Epidemiology
WHO has assessed the status of the TB epidemic and progress in control of the disease every year since 1997. This assessment has included estimates of TB incidence, prevalence and mortality (from 1990 onwards); analysis of case notications (from 1995) and treatment outcomes (from 1994) in around 200 (of 212) countries and territories, following the start of reliable recording and reporting in 1995; and analysis of progress towards the global targets for case detection and treatment success established by the World Health Assembly (WHA) in 1991. Since 2006, WHO has also assessed progress towards achieving the impact targets related to incidence, prevalence and mortality that have been set for 2015 within the framework of the Millennium Development Goals (MDGs) and by the Stop TB Partnership. This chapter provides WHOs latest assessment of the status of the TB epidemic and progress towards achieving the global targets using data reported by 196 countries and territories (accounting for 99.6% of the worlds estimated number of TB cases and 99.7% of the worlds population) in 2008 as well as data reported in previous years. It is structured in seven major sections. The rst denes the global targets and indicators for TB control set for 2005, 2015 and 2050. The second section presents the latest estimates of TB incidence, prevalence and mortality, including estimates for 2007 and for the period since 1990, and discusses whether the world as a whole and specic regions are on track to reach the 2015 MDG and Stop TB Partnership targets. The estimates of TB incidence and mortality include important updates to previously published estimates of the numbers of HIV-positive TB cases and deaths. Building on the second section, the third section provides an overview of recent recommendations from the WHO Global Task Force on TB Impact Measurement about how to measure progress towards the 2015 impact targets. These recommendations focus on strengthening surveillance (of cases and deaths) in all countries and on implementing surveys of the prevalence of TB disease in 21 global focus countries. Recent examples of how the recommendations can be applied in practice are provided. The fourth section presents TB notication data for 2007, including for men and women separately. The fth section includes the latest estimates of the case detection rate, the sixth section reports treatment outcomes in 2006, and the seventh section assesses regional and country progress towards achieving the targets for both case detection and treatment success. The chapter ends with a summary of the main results and conclusions. The methods used to produce the results presented in this chapter are explained in ANNEX 2. Throughout this chapter, particular attention is given to the 22 high-burden countries
(HBCs) that collectively account for 80% of incident TB cases globally. Additional data are provided for HBCs in ANNEX 1 and for all countries in ANNEX 3.
1.1
Goals, targets and indicators for TB control
The global targets and indicators for TB control were developed within the framework of the MDGs as well as by the Stop TB Partnership and the WHA (TABLE 1.1).1,2 The impact targets are to halt and begin to reverse the incidence of TB by 2015 and to reduce by 50% prevalence and mortality rates by 2015 relative to 1990 levels. The incidence target is part of MDG Target 6.c, while the targets for reducing prevalence and death rates were based on a resolution of the year 2000 meeting of the Group of Eight (G8) industrialized countries, held in Okinawa, Japan. The outcome targets to achieve a case detection rate of new smear-positive cases of at least 70% and to reach a treatment success rate of at least 85% for such cases were rst established by the WHA in 1991. Within the MDG framework, these indicators were dened as the proportion of cases detected and cured under DOTS. The ultimate goal of eliminating TB, dened as the occurrence of less than 1 case per million population per year by 2050, was set by the Stop TB Partnership. The Stop TB Strategy,3 launched by WHO in 2006, sets out the major interventions that should be implemented to achieve the MDG, Stop TB Partnership and WHA targets. These are divided into six broad components: (i) pursuing high-quality DOTS expansion and enhancement; (ii) addressing TB/HIV, MDR-TB and the needs of poor and vulnerable populations; (iii) contributing to health-system strengthening based on primary health care; (iv) engaging all care providers; (v) empowering people with TB, and communities through partnership; and (vi) enabling and promoting research. The Global Plan to Stop TB, launched by the Stop TB Partnership in 2006, sets out how, and at what scale, the Stop TB Strategy should be implemented over the decade 20062015, and the funding requirements.2 This means that in addition to the targets shown in TABLE 1.1, the Global Plan also includes input targets (funding required per year) and output targets (for example, the number of patients with MDR-TB who should be
1
Dye C et al. Targets for global tuberculosis control. International Journal of Tuberculosis and Lung Disease, 2006, 10:460462. The Global Plan to Stop TB, 20062015: actions for life towards a world free of tuberculosis. Geneva, World Health Organization, 2006 (WHO/ HTM/STB/2006.35). The Stop TB Strategy: building on and enhancing DOTS to meet the TBrelated Millennium Development Goals. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.368).
TABLE 1.1 Goals, targets and indicators for TB control HEALTH IN THE MILLENNIUM DEVELOPMENT GOALS Goal 6: Combat HIV/AIDS, malaria and other diseases
Target 6c: Halt and begin to reverse the incidence of malaria and other major diseases Indicator 6.9: Incidence, prevalence and death rates associated with TB Indicator 6.10: Proportion of TB cases detected and cured under DOTS
treated each year, number of TB patients to be tested for HIV, number of HIV-positive TB patients who should be enrolled on antiretroviral therapy (ART)). This chapter focuses on the ve principal indicators that are used to measure the impact and outcomes of TB control: incidence, prevalence and deaths (impact indicators), and case detection and treatment success rates (outcome indicators). An analysis of progress towards achieving other targets is provided in CHAPTER 2 and CHAPTER 3.
Stop TB Partnership targets

By 2005: At least 70% of people with sputum smearpositive TB will be diagnosed (i.e. under the DOTS strategy), and at least 85% successfully treated. The targets of a case detection rate of at least 70% and a treatment success rate of at least 85% were rst set by the World Health Assembly of WHO in 1991. The global burden of TB (per capita prevalence and death rates) will be reduced by 50% relative to 1990 levels. The global incidence of active TB will be less than 1 case per million population per year.
1.2
TB incidence, prevalence and mortality
1.2.1 Incidence
Based on surveillance and survey data (ANNEXES 2, 3 and 4), WHO estimates that 9.27 million new cases of TB occurred in 2007 (139 per 100 000 population), compared with 9.24 million new cases (140 per 100 000 population) in 2006. Of these 9.27 million new cases, an estimated 44% or 4.1 million (61 per 100 000 population) were new smearpositive cases (TABLE 1.2; FIGURE 1.1). India, China, Indo-
By 2015: By 2050:
TABLE 1.2 Estimated epidemiological burden of TB, 2007

INCIDENCEa ALL FORMS
PER POPULATION 1000s NUMBER 1000s 100 000 POP PER YEAR
PREVALENCEa ALL FORMS

PER
MORTALITY HIV-NEGATIVE
PER
SMEAR-POSITIVE
PER NUMBER 100 000 POP 1000s PER YEAR
HIV-POSITIVE
PER NUMBER 100 000 POP 1000s PER YEAR
HIV PREV. IN INCIDENT TB CASESb %
NUMBER 100 000 POP NUMBER 100 000 POP 1000s PER YEAR 1000s PER YEAR
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
India China Indonesia Nigeria South Africa Bangladesh Ethiopia Pakistan Philippines DR Congo Russian Federation Viet Nam Kenya Brazil UR Tanzania Uganda Zimbabwe Thailand Mozambique Myanmar Cambodia Afghanistan
1 169 016 1 328 630 231 627 148 093 48 577 158 665 83 099 163 902 87 960 62 636 142 499 87 375 37 538 191 791 40 454 30 884 13 349 63 884 21 397 48 798 14 444 27 145 4 201 761 792 378 909 820 555 064 889 278 1 745 394 1 776 440 6 668 374
1 962 1 306 528 460 461 353 314 297 255 245 157 150 132 92 120 102 104 91 92 83 72 46 7 423 2 879 295 583 432 3 165 1 919 9 273
168 98 228 311 948 223 378 181 290 392 110 171 353 48 297 330 782 142 431 171 495 168 177 363 32 105 49 181 108 139
873 585 236 195 174 159 135 133 115 109 68 66 53 49 49 42 40 39 37 37 32 21 3 245 1 188 157 259 190 1 410 859 4 062
75 44 102 131 358 100 163 81 130 174 48 76 142 26 120 136 298 62 174 75 219 76 77 150 17 47 21 81 48 61
3 305 2 582 566 772 336 614 481 365 440 417 164 192 120 114 136 132 95 123 108 79 96 65 11 301 3 766 348 772 456 4 881 3 500 13 723
283 194 244 521 692 387 579 223 500 666 115 220 319 60 337 426 714 192 504 162 664 238 269 475 38 139 51 280 197 206
302 194 86 79 18 70 53 46 36 45 20 18 10 5.9 12 13 6.9 10 10 5.4 11 8.2 1 058 357 33 97 56 497 276 1 316
26 15 37 53 38 44 64 28 41 72 14 20 26 3.1 29 41 52 15 45 11 77 30 25 45 3.6 17 6.3 28 16 20
30 6.8 5.4 59 94 0.4 23 1.4 0.3 6.0 5.1 3.1 15 2.5 20 16 28 3.9 17 0.9 1.8 0.0 339 378 7.9 7.7 8.1 40 15 456
2.5 0.5 2.4 40 193 0.3 28 0.9 0.3 10 3.6 3.5 39 1.3 49 52 213 6.0 82 1.9 13 0 8.1 48 0.9 1.4 0.9 2.3 0.8 6.8
5.3 1.9 3.0 27 73 0.3 19 2.1 0.3 5.9 16 8.1 48 14 47 39 69 17 47 11 7.8 0 14 38 11 3.5 9.8 4.6 2.7 15
High-burden countries AFR AMR EMR EUR SEAR WPR Global

a b
Incidence and prevalence estimates include TB in people with HIV. Prevalence of HIV in incident TB cases of all ages.
FIGURE 1.1 Estimated number of new TB cases, by country, 2007
Estimated number of new TB cases (all forms) 0999 10009999 10 00099 999 100 000999 999 1 000 000 No estimate
FIGURE 1.2 Estimated TB incidence rates, by country, 2007
Estimated new TB cases (all forms) per 100 000 population 024 2549 5099 100299 300 No estimate
FIGURE 1.3 Estimated HIV prevalence in new TB cases, 2007
HIV prevalence in new TB cases, all ages (%) 04 519 2049 50 No estimate
nesia, Nigeria and South Africa rank rst to fth in terms of the total number of incident cases; the estimated numbers of cases in these and other HBCs in 2007 are also shown in TABLE 1.2. Asia (the South-East Asia and Western Pacic regions) accounts for 55% of global cases and the African Region for 31%; the other three regions (the Americas, European and Eastern Mediterranean regions) account for small fractions of global cases. The magnitude of the TB burden within countries can also be expressed as the number of incident cases per 100 000 population (FIGURE 1.2). Among the 15 countries with the highest estimated TB incidence rates, 13 are in Africa, a phenomenon linked to high rates of HIV coinfection (FIGURE 1.3; FIGURE 1.4).
FIGURE 1.4 Fifteen countries with the highest estimated TB incidence rates per capita (all forms; grey bars) and corresponding incidence rates of HIV-positive TB cases (red bars), 2007
Swaziland South Africa Djibouti Zimbabwe Namibia Botswana Lesotho Sierra Leone Zambia Cambodia Mozambique
Incidence of TB among people infected with HIV

Among the 9.27 million incident cases of TB in 2007, an estimated 1.37 million (14.8%) were HIV-positive ( TABLE 1.2). This number, although double the estimate of 0.7 million cases in 2006 that WHO published in 2008,1 does not mean that the number of HIV-positive cases of TB doubled between 2006 and 2007; rather, new data that became available during 2008 have been used to estimate both the number of HIV-positive TB cases in 2007 and to revise estimates of the number of such cases that occurred in previous years. The global number of incident HIV-positive TB cases is estimated to have peaked in 2005, at 1.39 million. In 2007, as in previous years, the African Region accounted for most (79%)
1
Togo Cte dIvoire Gabon Congo 0 200 400 600 800 1000 1200
Incidence (per 100 000 population per year)
Global tuberculosis control: surveillance, planning, nancing. WHO report 2008. Geneva, World Health Organization, 2008 (WHO/HTM/ TB/2008.393).
BOX 1.1
Revising estimates of the numbers of TB cases and deaths among HIV-positive people
This report includes estimates of the numbers of HIV-positive TB cases and deaths that are substantially higher than those published in previous years. It is estimated that, in 2007, there were 1.37 million incident cases of HIV-positive TB (14.8% of total incident cases) and 456 000 deaths from TB among HIV-positive people (equivalent to 26% of deaths from TB in HIV-positive and HIV-negative people, and 23% of an estimated 2 million HIV-related deaths).1 These estimated numbers of TB cases and deaths among HIV-positive people in 2007 are approximately double those published in previous reports. This does not mean that the numbers of HIV-positive TB cases and TB deaths among HIV-positive people doubled between 2006 and 2007. Instead, new data that became available during 2008 have been used to estimate both (i) the numbers of HIVpositive TB cases and deaths in 2007 and (ii) to revise previous estimates of the numbers of cases and deaths that occurred in earlier years. The revised estimates suggest that the number of HIV-positive TB cases and deaths peaked in 2005 at 1.39 million incident cases (15.1% of total incident cases) and 480 000 deaths. As for previous reports in this series, the estimates are based on the latest global estimates of HIV prevalence among the general population (all ages) published by the Joint United Nations Programme on HIV/AIDS (UNAIDS).1 What is new for this report is that direct measurements of the prevalence of HIV in TB patients were available from a much larger number of countries. These direct measurements were mostly from provider-initiated HIV testing of TB patients (49 countries, up from 13 countries in the previous year). Provider-initiated HIV testing has been rapidly expanded since 20052006, notably in African countries (see also CHAPTER 2). For a further 15 countries, direct measurements were available from surveys or sentinel surveillance (up from two countries in the previous year). These 64 direct measurements were used to estimate the number of incident HIVpositive TB cases in 64 countries that account for 32% of the estimated total of 1.37 million HIV-positive TB cases. These direct measurements provide strong evidence that the relative risk of developing TB in HIV-positive people as compared with HIV-negative people (the incidence rate ratio, or IRR) is higher than previously estimated. The IRR was estimated as 20.6 (95% condence interval (CI) 15.427.5) in 2007 in countries with a generalized HIV epidemic (i.e. countries where the prevalence of HIV is above 1% in the general population), as 26.7 (95% CI 20.434.9) in countries where the prevalence of HIV in the general population is between 0.1% and 1%, and 36.7 (95% CI 11.6116) in countries where the prevalence of HIV in the general population is less than 0.1%. These IRR estimates compare with previous estimates of 6, 6 and 30, respectively.2 Higher estimates are consistent with reductions in the estimates of HIV prevalence in the general population published in 2007 by UNAIDS (which by denition lead to an increase in previous IRR estimates for any given level of HIV prevalence among TB patients) and with evidence that the IRR increases as the HIV epidemic matures. The wide condence intervals around these IRRs illustrate that large uncertainty remains, although the greatest uncertainty is for countries with a low HIV prevalence that have only a small impact on global estimates. The new IRR gures were used to produce indirect estimates of the number of HIV-positive TB cases in 104 countries for which direct measurements of the prevalence of HIV in TB patients were not available. To increase the reliability of these estimates, the coverage of HIV surveillance among TB patients needs to be improved. Furthermore, indirect methods will become more problematic as the coverage and impact of antiretroviral therapy (ART) increases. More data are needed, particularly from national HIV programmes, to better understand the impact of ART on the incidence of TB.
1
HIV-positive TB cases, followed by the South-East Asia Region (mainly India) with 11% of total cases (FIGURE 1.5). South Africa accounted for 31% of cases in the African Region. As for earlier reports in this series, the new estimates were produced using the latest global estimates of HIV prevalence among the general population (all ages) published by the Joint United Nations Programme on HIV/AIDS (UNAIDS).1 There are two new and related changes to the data and methods used for this report. First, direct measurements of the prevalence of HIV in TB patients were available from a much larger number of countries (from provider-initiated HIV testing in 49 countries and surveys or sentinel surveillance in 15 countries). Second, these direct measurements suggest that the risk of developing TB in HIV-positive people compared with HIV-negative people (the incidence rate ratio, or IRR) is higher than previously estimated (for example, 20.6 compared with the previous estimate of 6 in countries with a high prevalence of HIV in the general population). New and higher estimates of the IRR were used to produce indirect estimates of the number of HIV-positive TB cases in 104 countries for which direct measurements of the prevalence of HIV in TB patients were not available.2 The new estimates and associated data and methods are summarized in BOX 1.1 and explained in more detail in ANNEX 2. Estimates for all countries are included in ANNEX 3.
Estimated incidence of MDR-TB

Estimates of the burden of multidrug resistant TB (MDR-TB) are presented by country, disaggregated by smear status, in ANNEX 3. Most of the current information about the proportion of TB cases with MDR-TB comes from drug susceptibility testing (DST) of samples from patients in whom MDR-TB is diagnosed in public health facilities under conditions dened by the WHO/IUATLD Global Project on Drug Resistance Surveillance (DRS).3 These conditions include documented satisfactory performance of laboratories based on external quality assurance (EQA) and an adequate record of every patients treatment history. Such data are available for new and re-treatment cases for 113 and 102 countries, respectively. Using a set of widely measurable, independent variables that are predictive of the frequency of MDR-TB (such as gross national income (GNI)
1
http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/latestEpiData. asp These earlier estimates of the IRR were based on a thorough review of the evidence conducted in 20002001. See Corbett EL et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 2003, 163:10091021.
http://www.unaids.org/en/KnowledgeCentre/HIVData/ Epidemiology/latestEpiData.asp UNAIDS does not produce estimates of HIV prevalence in the general population for the remaining 44 countries and territories. For this reason, estimates of the number of HIV-positive TB cases in these countries and territories were not produced. Anti-tuberculosis drug resistance in the world, 4th report: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.394).
FIGURE 1.5 Geographical distribution of estimated number of HIV-positive TB cases, 2007. For each country (red circles) and WHO region (grey circles), the number of incident TB cases arising in people with HIV is shown as a percentage of the global total of such cases.
AFR South Africa SEAR Nigeria India Zimbabwe Kenya Ethiopia UR Tanzania WPR Mozambique EUR Zambia Uganda AMR Malawi Cte dIvoire Russian Federation China EMR Indonesia Thailand Cameroon Rwanda DR Congo 1 2 5 10 20 50 90
FIGURE 1.6 Countries with the highest numbers of estimated MDR-TB cases, 2007. Horizontal lines denote 95% condence intervals. The source of estimates is drug resistance surveillance or surveys (DRS, in red) or modelling (in grey).
India China Russian Federation South Africa Bangladesh Pakistan Indonesia Philippines Nigeria Kazakhstan Ukraine Uzbekistan DR Congo DPR Korea Viet Nam Ethiopia Tajikistan Myanmar Azerbaijan Kenya Mozambique Peru Zimbabwe Thailand Cte dIvoire Republic of Korea Sudan Republic of Moldova Afghanistan UR Tanzania 2000 10 000 Number of cases
DRS Model 50 000 100 000
Percentage of global estimated HIV-positive TB cases
per capita, the ratio of re-treatment to new patients, and the failure rate associated with rst-line treatments), it is possible to estimate the frequency of MDR-TB in countries where it has not been measured directly. The general methods used to produce these estimates are presented in ANNEX 2, while ANNEX 3 denes whether the direct or indirect method was used for each country. In 2007, there were an estimated 9.27 million rst episodes of TB and an additional 1.16 million subsequent episodes of TB (episodes occurring in patients who had already experienced at least one previous episode of TB in the past and who had received at least one month of anti-TB treatment). Among these, 10.4 million episodes of TB (rst and subsequent), an estimated 4.9% or 511 000 were cases of MDR-TB. Of these, 289 000 were among new cases (3.1% of all new cases) and 221 000 were among cases that had been previously treated for TB (19% of all previously treated cases). Of the 511 000 incident cases of MDR-TB in 2007, 349 000 (68%) were smear-positive. The countries with the largest number of cases of MDR-TB, ranked in decreasing order, are shown in FIGURE 1.6.
FIGURE 1.7 Estimated incidence of TB and prevalence of HIV for the African subregion most affected by HIV (Africa high-HIV), 19902007
Estimated TB incidence
Cases per 100 000 population/year
400 350 300 250 200
HIV prevalence in general population

3.5
Percentage
3.0 2.5 2.0
Trends in incidence since 1990 and progress towards MDG Target 6.c
From series of notication data and surveys (ANNEXES 2, 3 and 4), the global incidence of TB per capita appears to have peaked in 2004 and is now in decline (FIGURE 1.7; FIGURE 1.8). This peak and subsequent decline follow a similar pattern to the trend in HIV prevalence in the general population (FIGURE 1.7). The reason why the number of incident cases
1.5
1990
1995
2000
2005
FIGURE 1.8 Global rates of TB incidence, prevalence and mortality, including in people with HIV, 19902007
Incidence (all forms, including HIV)
140 Cases per 100 000 population/year 135 130 125
Prevalence (all forms, including HIV)

Cases per 100 000 population 280 260 240 220
Mortality (including HIV)

31 Deaths per 100 000 population/year 30 29 28 27
1990
1995
2000
2005
in absolute terms is increasing (see above), while incidence rates per capita are falling, is population growth. In the African, Eastern Mediterranean, European and South-East Asia regions, the decline in incidence per capita is more than compensated for by increases in population size. Trends in incidence rates vary among regions (FIGURE 1.9). Rates are falling in seven of nine epidemiological subregions (see ANNEX 2 for denition of the countries in each subregion), stable in Eastern Europe and increasing in African countries with a low prevalence of HIV. Among the WHO regions, incidence is falling slowly in all regions except the European Region, where it is approximately stable. When the time periods 19951999 and 20052007 are compared, the estimated average rate of change in TB incidence (all forms) per 100 000 population was fastest in African countries with high HIV prevalence and in the Eastern European subregion (FIGURE 1.10). The rate at which incidence was declining slowed in the Central European subregion and, to a lesser extent, in the Eastern Mediterranean subregion. In the other subregions, incidence was falling at a similar rate in both time periods. The continued fall in the global incidence rate reinforces data presented in the last two reports in this series.1 If veried by further monitoring, the data show that MDG target 6.c was met by 2005 (incidence rates peaked in 2004), well ahead of the target date of 2015.
million in 2006 (TABLE 1.2). Of these 13.7 million prevalent cases, an estimated 687 000 (5%) were HIV-positive. From trends in TB incidence combined with assumptions about the duration of disease in different categories of case (ANNEX 2), the global prevalence of TB is estimated to have been in decline since 1990 (FIGURE 1.8). This decline is in contrast to the rise in TB incidence in the 1990s, which can be explained by a decrease in the average duration of disease as the fraction of cases treated in DOTS programmes increased, combined with a comparatively short duration of disease among HIV-positive cases (which has partly compensated for an increase in the incidence of HIV-positive TB cases). Regional trends in TB prevalence from 1990 to 2007 as well as projections up to 2015 (based on extrapolation of the trend in 20052007) are shown in FIGURE 1.11. Prevalence has been declining in the Eastern Mediterranean Region, the Region of the Americas, the South-East Asia Region and the Western Pacic Region since 1990, and all four regions are on track to at least halve prevalence rates by 2015 (prevalence has already halved compared with the 1990 level in the Region of the Americas). In the African and European regions, prevalence rates increased substantially during the 1990s, and by 2007 were still far above the 1990 level in the African Region and just back to the 1990 level in the European Region. Projections indicate that neither region will reach the target of halving the 1990 prevalence rate by 2015, and in the African Region it is unlikely that prevalence will be back to 1990 levels by 2015. The gap between the 2015 targets and current prevalence rates in these two regions mean that the world as a whole is unlikely to meet the Stop TB Partnership target of halving the prevalence rate by 2015.
1.2.3 Mortality
An estimated 1.32 million HIV-negative people (19.7 per 100 000 population) died from TB in 2007, and there were an additional 456 000 TB deaths among HIV-positive people (TABLE 1.2).2 Revisions in the estimated number of incident cases of TB that are coinfected with HIV (SECTION 1.2.1; BOX 1.1) explain why the estimates of TB deaths among HIVpositive people are higher than those published in 2008.3 Deaths from TB among HIV-positive people account for 23% of the estimated 2 million HIV deaths that occurred in 2007 (BOX 1.1).4 Revisions to estimates of the number of incident cases of TB that are HIV-positive before 2007 have also led to upward
1
1.2.2 Prevalence
There were an estimated 13.7 million prevalent cases in 2007 (206 per 100 000 population), a slight decrease from 13.9
4
Global tuberculosis control: surveillance, planning, nancing. WHO report 2007. Geneva, World Health Organization, 2007 (WHO/HTM/ TB/2007.376); Global tuberculosis control: surveillance, planning, nancing. WHO report 2008. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.393). Estimates of TB deaths in HIV-positive and HIV-negative people are presented separately because TB deaths in HIV-positive people are classied as HIV deaths in the International Statistical Classication of Diseases (ICD-10). Of the 456 000 TB deaths among HIV-positive people in 2007, an estimated 226 000 were cases that were treated and 230 000 were untreated cases. http://www.unaids.org/en/KnowledgeCentre/HIVData/Epidemiology/latestEpiData.asp
FIGURE 1.9 Trends in estimated incidence rates in nine subregions, 19902007

Africa high-HIV
220 400 210 200 350 190 300 180 170 160 200 150 30 35 40 45
Africa low-HIV
50
Central Europe
250
Eastern Europe
Cases (all forms) per 100 000 population/year
High-income countries
Eastern Mediterranean
100 90
20
109
18 80 16
108
107 70 14 60 12 50 105 106
Latin America
85 80 75 70 65 60 55 50 185 190 195
South-East Asia
Western Pacific
200 135
130
125
120
1990
1995
2000
2005
1990
1995
2000
2005
1990
1995
2000
2005
revisions to estimates of mortality rates before 2007 (BOX 1.1). From trends in TB incidence combined with assumptions about case fatality rates among different categories of case (ANNEX 2), the global TB mortality rate (including TB deaths in HIV-positive people) is estimated to have increased during the 1990s; this trend was reversed around the year 2000, and mortality rates are now in decline (FIGURE 1.8). Regional trends in TB mortality rates from 1990 to 2007 as well as projections up to 2015 (based on extrapolation of the trend in 20052007) are shown in FIGURE 1.12. Mortality rates have been declining in the Eastern Mediterranean Region, the Region of the Americas, the South-East Asia Region and the Western Pacic Region since 1990. The decline has been relatively steady in the Region of the Americas and the Western Pacic Region, while the decline was faster in the Eastern Mediterranean and South-East Asia
regions after 2000. Of these four regions, three are on track to at least halve mortality rates by 2015. In the Western Pacic Region, the mortality target will be narrowly missed unless the current rate of decline accelerates from 2008. In the African and European regions, mortality rates increased substantially during the 1990s. Although this trend has been reversed (around 2000 in the European Region and around 2005 in the African region), mortality rates in 2007 were still far above the 1990 level in the African Region and just back to the 1990 level in the European Region. Projections indicate that neither region will reduce mortality rates back to even 1990 levels by 2015, and will certainly not halve mortality rates compared with 1990. The gulf between the 2015 targets and current mortality rates in these two regions mean that the world as a whole is unlikely to meet the Stop TB Partnership target of halving the mortality rate by 2015.
FIGURE 1.10 Changes in annual rates of incidence during 19951999 and 20052007, nine epidemiological subregions. Data points were randomly jittered horizontally to avoid over-plotting. The horizontal red line indicates no change in incidence. Data points above the red line indicate that incidence increased; the further from the line, the faster the increase. In subregion Africa high-HIV, incidence increased during 19951999 and decreased during 20052007. In central Europe, the rate of decline decreased between 19951999 and 20052007. A linear model was tted to the data and tted lines with uncertainty bounds were added to provide a visual aid.
Africa high-HIV
10 6 4 2 -4 0 0 -6 -2 -5 -4
19951999 20052007 19951999 20052007 19951999 20052007
Africa low-HIV
Central Europe
-2
-8
Eastern Europe
10 Rate of change in incidence rate (% year) 2 0 -2
0 0 -4 -6 -5 -8
-5
19951999
20052007
19951999
20052007
19951999
20052007
Latin America
10 0 -1 5 -2 -3 -4 -5 -5 -6
South-East Asia
10
Western Pacific
-5
19951999
20052007
19951999
20052007
19951999
20052007
1.2.4 Summary of progress towards MDG and Stop TB Partnership impact targets
The three major indicators of impact incidence, prevalence and mortality rates per 100 000 population are falling globally. If veried by further monitoring, MDG target 6.c was met globally by 2005 (incidence rates peaked in 2004), and in ve of six WHO regions (the exception being the European Region, where rates are approximately stable). The targets to halve prevalence and death rates by 2015 compared with 1990, set by the Stop TB Partnership, are more demanding. If the average rates of change in 20052007
persist, prevalence and death rates will fall quickly enough to meet the 2015 targets in the Region of the Americas and in the Eastern Mediterranean and South-East Asia regions. The Western Pacic Region will reach the target of halving the prevalence rate, but the mortality target may be narrowly missed unless the current rate of decline accelerates. Neither the prevalence nor the mortality targets will be met in the African and European regions. The gap between prevalence and mortality rates in 2007 and the targets in these two regions suggest that 1990 prevalence and death rates will not be halved by 2015 for the world as a whole.
Standardized prevalence rate
FIGURE 1.11 Progress towards achieving the target of halving prevalence by 2015 compared with the level of 1990, by WHO region. The y-axis displays standardized prevalence rates, with the baseline set at the 1990 level in each region (black horizontal line) and regional targets set at 50% of the 1990 level (red horizontal line). Trends for 20082015 are forecast using an exponential regression of estimated prevalence rates over the period 20052007.
AFR
1.0 1.4 0.9
AMR
1.0 0.9
EMR
1.2
0.8 0.7
0.8 0.7
1.0 0.6 0.8 0.5 0.4 0.4 0.4 0.5 0.6
EUR
1.0 1.2
SEAR
1.0
WPR
0.9
0.9
0.8 1.0 0.7 0.8 0.7 0.6 0.6 0.8
0.5 0.6
0.5
1990 1995 2000 2005 2010 2010 1990 1995 2000 2005 2010 2010 1990 1995 2000 2005 2010 2010
Standardized mortality rate
FIGURE 1.12 Progress towards achieving the target of halving mortality from TB by 2015 compared with the level of 1990, by WHO region. The y-axis displays standardized mortality rates, with the baseline set at the 1990 level in each region (black horizontal line) and regional targets set at 50% of the 1990 level (red horizontal line). Trends for 20082015 are forecast using an exponential regression of estimated mortality rates over the period 20052007. Mortality rates represented in these graphs are excluding deaths from TB in HIVpositive people.
AFR
1.0 0.9 0.8
AMR
1.0
EMR
1.2
0.9
0.8 1.0 0.7 0.7 0.6 0.8 0.5 0.6 0.4 0.5 0.6
EUR
1.4 1.0
SEAR
1.0
WPR
0.9 1.2 0.8
0.9
0.8 1.0 0.7 0.7 0.8 0.6 0.6 0.6 0.5 0.5
1990 1995 2000 2005 2010 2010 1990 1995 2000 2005 2010 2010 1990 1995 2000 2005 2010 2010
1.3
Improving measurement of progress towards the 2015 impact targets: the WHO Global Task Force on TB Impact Measurement
As explained in SECTION 1.1, the impact targets for reducing rates of TB incidence, prevalence and mortality are the focus of international and national efforts to control TB. Demonstrating whether or not they are achieved is of major importance for individual countries, the United Nations, WHO and the Stop TB Partnership, and a variety of technical, nancial and development agencies. The estimates of TB incidence, prevalence and mortality and their trends presented in SECTION 1.2 are based on the best available data and analytical methods, both of which were reviewed and endorsed by a group of experts in mid-2008.1 Nonetheless, with better surveillance systems, additional survey data, more in-depth analysis of existing surveillance and programmatic data and further renement of analytical methods, these estimates could be improved in the period up to 2015 (and beyond). With the exception of Eritrea in 2005, the last nationwide and population-based surveys of the prevalence of TB disease in the African Region were undertaken between 1957 and 1961; in many countries, such surveys have never been done (ANNEX 4). Notication systems are estimated
TABLE 1.3 WHO policy package for measuring rates of TB incidence, prevalence and mortality, 20082015 and beyond General
1. Improve surveillance systems to include all (or almost all) incident cases in TB case notication data and to account for all (or almost all) TB deaths in vital registration systems. 2. Strengthen national capacity to monitor and evaluate the TB epidemic and to measure progress in TB control. 3. Review and update periodically the data, assumptions and analytical methods used to produce WHO estimates of TB incidence, prevalence and mortality rates. 4. Report by Task Force on whether 2015 MDG and Stop TB Partnership targets are achieved (or not), shortly after 2015.
Measuring TB incidence rates

5. Analyse periodically the reliability and coverage of case notication data using a standard framework, in order to estimate the total number of incident TB cases and trends in incidence rates. 6. Certify and/or validate TB notication data for countries where analyses using the standard framework show that TB notication data are a close proxy (direct measure) of TB incidence. 7. Cross-validate estimates of TB incidence using TB mortality data from vital registration systems.
to capture only around 5070% of incident cases in most countries (SECTION 1.5), and within these systems reporting can be incomplete (CHAPTER 2, SECTION 2.2.7). Only 10% of the estimated 1.5 million TB-attributable deaths (in HIVnegative people) in 2005 were recorded in vital registration systems and reported to WHO by August 2008.2 The gures for the South-East Asia and Western Pacic regions, which account for 55% of the worlds TB cases, were <0.1% and 2.6% respectively. These observations show how much progress is needed to achieve the ultimate goal of measuring TB incidence and mortality directly from surveillance data (that is, that ultimately all TB cases are included in case notication data and that vital registration systems account for all (or almost all) TB deaths). In this context, WHO established a Global Task Force on TB Impact Measurement (hereafter the Task Force) in June 2006. The Task Force includes experts in TB epidemiology, representatives from major technical and nancial agencies, and representatives from countries with a high burden of TB. Its mandate is to produce a robust, rigorous and widelyendorsed assessment of whether the 2015 targets for reductions in TB incidence, prevalence and mortality are achieved at global level, for each WHO region and in individual countries; to regularly report on progress towards these targets in the years leading up to 2015; and to strengthen national capacity in monitoring and evaluation of TB control. Better data and better analysis of these data can be used to identify where and why cases are not being detected, and form the basis for implementing appropriate components of the Stop TB Strategy (CHAPTER 2). Following three Task Force meetings (June 2006, December 2007 and September 2008) and two years of work by the secretariat in WHO, clear policies and recommendations for how to measure incidence, prevalence and mortality from 2008 onwards, with a focus on the 2015 impact targets, have been agreed upon. These are explained in full in a forthcoming WHO policy paper,3 with the key elements summarized in the form of a policy package ( TABLE 1.3).
1.3.1 Measurement of incidence

For improved measurement of incidence (its absolute value and trend), the policy package focuses on a systematic approach
1
Measuring TB prevalence rates

8. Survey the prevalence of TB disease in 21 global focus countries according to WHO guidelines and Task Force recommendations. 9. Produce indirect estimates of TB prevalence based on estimates of TB incidence and the duration of TB disease for countries where surveys of the prevalence of TB disease are not implemented.
Measuring TB mortality rates

10. Develop national vital registration systems to reliably record all TB deaths. 11. Initiate sample vital registration where national vital registration systems are not yet available. 12. Produce indirect estimates of TB mortality using estimates of TB incidence and case fatality rates for countries without reliable national or sample vital registration systems.
Evaluating the impact of TB control

13. Conduct studies periodically to evaluate the impact of control on rates of TB incidence, prevalence and mortality.
These experts were members of the WHO Global Task Force on TB Impact Measurement and external experts in epidemiology and statistics. The review also formed part of the TB component of the forthcoming update to the Global Burden of Disease, due for publication in 2010. Korenromp EL et al. State of the Art Review. The measurement and estimation of tuberculosis mortality. International Journal of Tuberculosis and Lung Disease, 2009 (in press). Measuring progress in TB control: WHO policy and recommendations [policy paper]. Geneva, World Health Organization, 2009 (in press). The policy paper is based on (i) a comprehensive review of methods to measure incidence, prevalence and mortality (Dye C et al. Measuring tuberculosis burden, trends and the impact of control programmes. Lancet Infectious Diseases ; published online 16 January 2008 (available at http://infection.thelancet.com) and (ii) background papers prepared for Task Force meetings and associated discussions. The policy paper was endorsed by the Task Force during its meeting in September 2008. It was also reviewed by WHOs Strategic and Technical Advisory Group on TB (STAG-TB) in June 2008.
FIGURE 1.13 Framework for estimation and measurement of TB incidence using surveillance data
Are data reliable and complete?
Good coverage, with no missing reports No duplicates No misclassication Data internally consistent Data externally consistent
If not, IMPROVE surveillance system
Do changes in notications over time reect trends in incidence?
Assess changes in case-nding effort or in case denitions Assess changes in TB determinants Examine historical and political events with possible impact on TB and/or reporting
Evaluate epidemiological TRENDS and IMPACT of TB control
Do notications include all incident TB cases?
Capturerecapture studies Apply onion model to identify where cases may be lost/missed Cross-validate estimates of TB incidence with TB deaths recorded in vital registration system
UPDATE estimates of burden if appropriate, CERTIFY or VALIDATE surveillance data
to assessing the quality and coverage of TB notication data. This approach consists of three core components (FIGURE 1.13). The rst is an assessment of the quality of available TB notication data; this includes checking the completeness of reporting (with a benchmark that 100% of reporting units should report data each quarter) and assessing whether there are duplicate or misclassied records. It also includes analysis of the internal and external consistency of data using national and subnational data. Internal consistency means that data are consistent over time and space (or, if not, that variation can be explained), while external consistency means that data are consistent with existing evidence about the epidemiology of TB (for example, the proportion of pulmonary cases that are smear-positive, and the ratio of male to female cases). The results of the analysis of completeness, duplications, misclassications and internal or external consistency can be used as the basis for identifying where and how surveillance needs to be strengthened. The second component of the framework concerns analysis of trends in notication data, with the aim of assessing the extent to which they reect trends in rates of TB incidence and the extent to which they reect changes in other factors (such as programmatic efforts to nd and treat more cases). Distinguishing between changes that are due to incidence and changes that are due to other factors is crucial when using notication data to estimate trends in the rates of TB incidence and case detection. The analysis in the second component of the framework should be used to determine whether time series of TB notications are a good proxy for trends in TB incidence, or the extent to which they need to be adjusted for other factors before using them as a measure of trends in TB incidence. If TB notications are a good proxy
for trends in TB incidence, they can be used reliably to assess whether incidence is falling (MDG Target 6.c) or not. Even when available notication data are complete and of high quality, and when they appear to be a good proxy of trends in TB incidence, they are not sufcient to estimate TB incidence in absolute terms. To do this, analysis of whether all TB cases are being captured in ofcial notication systems is required (as was done for most countries when the rst estimates of the global burden of TB were produced in 1997; see ANNEX 2). The major reasons why cases are missed from ofcial notication data have been dened in the so-called onion model,1 and include laboratory errors, lack of notication of cases by public and private providers, failure of cases accessing health services to be identied as TB suspects and lack of access to health services. Operational research (such as capturerecapture studies) as well as supporting evidence (such as the knowledge and practices of health-care staff related to denition of TB suspects, the extent to which regulations about notication of cases are observed and population access to health services) can be used to estimate the fraction of cases that are missing from ofcial notication data. It is also possible to assess the coverage of notication data, and to cross-validate estimates of TB incidence produced using other methods, by analysing the number of TB deaths recorded in vital registration systems. The objective is that the results from using this framework are used in one of two ways. If a countrys TB surveillance data are shown to be a close proxy for TB incidence, the data will be certied or validated as a direct measure of TB inci1
As referred to in FIGURE 1.13. For a full explanation, see Measuring progress in TB control: WHO policy and recommendations [policy paper]. Geneva, World Health Organization, 2009 (in press).
BOX 1.2
Estimating TB incidence following in-depth analysis of surveillance and programmatic data during the period 19962006: an example from Kenya
The incidence of TB in Kenya was indirectly estimated from TB notication data in 1997, as part of a global effort to estimate the global epidemiological burden of TB. The estimate was based on an expert assessment that the percentage of incident smear-positive cases being notied was 57% (i.e. 57% case detection rate). Until 2006, the trend in TB incidence before and after 1997 was assumed to be the same as the trend in TB notications (of all forms of TB case). Kenya has experienced a generalized HIV epidemic since the early 1980s and substantial efforts to improve the quality and coverage of TB diagnosis and treatment services were made from 2001 onwards. This made it difcult to disentangle the effect of HIV (which affects TB incidence) from the effect of programme performance on TB notications, which in turn made it difcult to estimate the trend in TB incidence. Between September 2006 and December 2007, estimates of the absolute value of TB incidence and the trend in TB incidence were jointly reviewed by WHO and the NTP. This was done in the context of new evidence and new analysis. The major new sources of evidence were (i) data on trends in HIV-positive and HIV-negative TB notications separately (ii) a direct measure of the prevalence of HIV among TB patients (iii) a recent survey of the prevalence of HIV in the general population and (iv) evidence about how programme performance had changed during the period 19962006. Both (i) and (ii) became available following the introduction and rapid expansion of provider-initiated HIV testing for TB patients in 2005. Evidence about programme performance during the period 19962006 was compiled during 2007. The four principal indicators used were: the number of health units where TB diagnosis was available, the number of health units where TB treatment was available, the number of NTP staff at national, provincial and district level, and NTP funding. For all four of these indicators, there was a clear relationship with trends in TB notications from 2001 to 2006, while HIV-related data suggested that the HIV epidemic peaked around 2000 and had not caused any increase in TB incidence from 2001 to 2006. In combination, these new data provided strong evidence that the increase in TB notications after 2001 was due to programmatic improvements (and not increases in TB incidence). This led to a downward revision in the estimate of TB incidence in 2006, an adjustment of the estimated trend in TB incidence, and an upward revision in the estimated case detection rate (to 70%). The original estimate of TB incidence (and case detection) in 1997 was left unchanged. To allow reliable measurement of trends in TB incidence from 2007 onwards, maintaining high rates of HIV testing for TB patients is essential. This will allow trends in HIV-positive and HIV-negative TB notications to be separated. Trends in HIV-negative TB notications can be used to measure changes in case-nding. Comparison of trends in HIV-positive and HIV-negative TB notications can be used to assess the impact of HIV on TB incidence. Efforts to strengthen routine surveillance, including the introduction of new recording and reporting forms and expanded use of electronic recording and reporting systems, have begun.
For further details, see Mansoer J et al. New methods for estimating the tuberculosis case detection rate. Bulletin of the World Health Organization, 2009 (in press).
BOX 1.3
Estimating TB incidence using capture-recapture methods: an example from Egypt

The NTP in Egypt compiled evidence that most TB cases have access to health-care services provided by public or private facilities as part of a multi-country operational research project in the Eastern Mediterranean. The number of TB cases experiencing symptoms and seeking care but not being diagnosed is therefore expected to be low. Nonetheless, when patients are diagnosed and treated by providers that are not linked to the NTP, it is unlikely that they are recorded in ofcial notication data. Quantifying the proportion of cases that are diagnosed by non-NTP providers (the extent to which there is under-notication) may therefore allow a more accurate estimate of the total number of cases in the country as well as the proportion that are being detected by the NTP (the case detection rate). To assess the extent to which cases were being missed in ofcial notication data and in turn to update estimates of TB incidence and the case detection rate, the Ministry of Health in Egypt together with the WHO Ofce for the Eastern Mediterranean implemented a capturerecapture study in 2008. Study registers for listing TB cases were introduced in a nationally representative sample of non-NTP health facilities in the private and public sectors. The list of cases in these registers was then compared with the list of notied cases for the same period. Using capturerecapture log-linear models, the number of cases missed by all sources was estimated by comparing (i) the number of cases observed in each source of data independently with (ii) the number of common cases among all sources (that is, the overlap in cases). Analyses were undertaken for the whole sample and for sputum smear-positive cases only. Revised estimates of TB incidence in Egypt based on capturerecapture analysis
NOTIFICATION DATA (2007) ALL CASES SS+ CASES WHO ORIGINAL ESTIMATES (2007) ALL CASES SS+ CASES WHO REVISED ESTIMATES (2007) ALL CASES SS+ CASES
New TB cases Rates (per 100 000 population/year) Case detection rate (%)
9 459 13
4 887 6.5
17 517 24 54
7 882 10.5 62
15 873 21 60
6 765 9 72
For capturerecapture estimates to be valid, certain conditions must be met. In particular, three or more sources of data should be available to allow adjustment for dependencies among the sources of data. This was the case in Egypt: the three available sources were the NTP registry, the study registers of private non-NTP providers and the study registers of public non-NTP providers. Based on the study results, the case detection rate for smear-positive cases was revised upwards to 72% (from 62%). The case detection rate for all cases was revised upwards to 60% (from 54%). Similar studies in other countries where all (or almost all) cases have access to health services could also help to revise existing TB estimates.
dence. If a countrys surveillance data are found to include only a fraction of cases, this fraction will be estimated and used to update estimates of incidence (and by extension the case detection rate). Findings will also be used to identify the measures needed to strengthen surveillance so that the standards required for data to be certied or validated can be met. Recent examples of how different components of the framework can be implemented in practice are provided in BOX 1.2, BOX 1.3 and BOX 1.4.
1.3.2 Measurement of prevalence

There are two methods for estimating the prevalence of TB. The rst is direct measurement using a cross-sectional population-based survey. Such surveys are only feasible if the estimated prevalence of smear-positive TB is around 100 per 100 000 population or more (otherwise the sample size required to measure prevalence with sufcient precision is so large that a survey is impractical in terms of cost and logistics). Even with the global average of around 100 cases
per 100 000 population, a sample size of around 200 000 and a budget of US$ 12 million is usually required. Since prevalence typically falls more quickly than TB incidence in response to control efforts, a series of surveys conducted at relatively wide intervals (for example, 10 years) can be very useful for capturing large changes in the epidemiological burden of TB in high-burden or high-incidence countries (recent examples from HBCs include China, where surveys were implemented in 1990 and 2000, with a third planned for 2010; and the Philippines, where surveys were implemented in 1997 and 2007, with a third planned for 2017). In countries where the burden of TB is lower, prevalence can also be estimated indirectly as TB incidence multiplied by the average duration of disease (ANNEX 2). Although the ultimate goal for all countries is to measure progress in TB control using routinely-collected surveillance data, the Task Force has identied 21 countries where nationwide population-based surveys of the prevalence of TB disease during the period 20082015 are a priority for the
BOX 1.4
Estimating TB incidence using mortality data from a vital registration system: an example from Brazil
WHO estimates of TB incidence are based on notication data, surveys of the annual risk of infection, surveys of the prevalence of TB disease combined with estimates of the average duration of disease, and mortality data from vital registration systems combined with estimates of the case fatality rate. Where several sources of evidence exist, greatest weight is attached to the most reliable data. For most countries, incidence is indirectly estimated from TB case notication data and an expert assessment of the percentage of incident TB cases being notied. When case-nding efforts do not change much over time, trends in TB incidence are often assumed to mirror trends in TB case notication rates (ANNEX 2). Until 2005, these methods were used to estimate TB incidence and its trend in Brazil. By 2005, the Ministry of Health of Brazil had greatly improved the TB notication system and the death registration component of the vital registration system. This included extending coverage of both systems throughout the country, validating data and systematically linking records within and between the two databases. Linkage of records within the TB notication database and implementation of procedures to distinguish between new and re-treatment or transfer-in records were used to identify duplicate records. This showed that notications had been articially inated and that the cure rate had been underestimated (see table below). Removal of duplicate records increased the gap between the number of new TB cases notied and the number of new TB cases estimated by WHO, highlighting the need for a review of existing estimates. The effect of removing duplicate records from the database of TB case notications, 2005
DUPLICATES REMOVED NEW NOTIFIED CASES BEFORE AFTER NOTIFICATION RATE BEFORE AFTER CHANGE (%) BEFORE CURED (%) AFTER CHANGE (%)
19 064
81 330
74 113
44.2
40.2
-9.7
60.5
64.5
+6.7
Estimates of TB incidence in Brazil are now based on an analysis of TB deaths recorded in the vital registration system. The case fatality rate was calculated by cross-linking the case-based TB notication database and the mortality database. Incidence in 2005 was then estimated as the number of TB deaths in the mortality database divided by the case fatality rate (estimated as the number of deaths in the mortality database divided by the number of cases in the notication database, with appropriate adjustments for the proportion of records in both systems that could be linked and a minor adjustment for the coverage of TB mortality records). Since the mortality information system was judged by the local authorities to have higher coverage than the TB notication system, and since it is unlikely that the case fatality rate had changed markedly in recent years, the trend in incidence over time was estimated by assuming that the trend in the TB incidence rate was the same as the trend in the TB mortality rate from 2001 to 2005. This suggested that incidence was falling at a rate of 3.3% per year. Incidence in absolute terms for years before 2005 was also based on this trend (see table below). Original and revised WHO estimates of TB incidence using TB mortality data, 2005
NOTIFICATIONS ORIGINAL ESTIMATE OF INCIDENCE REVISED ESTIMATE OF INCIDENCE
New TB cases Incidence or notication rate (per 100 000 population/year) Case detection rate
74 113 40
111 050 60 69%
95 408 51 78%
FIGURE 1.14 The 21 global focus countries where a national prevalence of TB disease survey is recommended in the period 20082015 (red), and extended list of countries meeting the criteria (grey)
purposes of global and regional measurements of progress in TB control (FIGURE 1.14). The list includes 12 African countries plus Pakistan and all but one of the nine HBCs in the South-East Asia and Western Pacic regions (the exception is India, where subnational surveys have already been implemented and further such surveys are planned). Countries were selected according to various criteria,1 including their estimated prevalence of smear-positive TB, their share of the global and regional numbers of estimated TB cases, their case detection rate, HIV prevalence in the general population and the availability (or not) of data from an earlier survey. Existing plans and funding for surveys and the capacity of technical agencies to provide assistance were also considered. Most of these countries were already committed to the planning and implementation of surveys before their inclusion on the list developed by the Task Force. However, this inclusion means that particular efforts to support the successful design and implementation of surveys in these countries are being made by the Task Force and its partners. To date, these efforts have included workshops to support 10 countries (eight African countries plus Pakistan and Thailand) to develop survey protocols consistent with recent guidelines,2 expert review of protocols, facilitating the provision of advice about Global Fund applications or reprogramming of existing grants, and country missions.
coded according to the International Statistical Classication of Diseases (ICD-10), and data are of proven completeness and accuracy (see BOX 1.4 for an example from Brazil). To make this possible, many countries will need to develop a vital registration system, or substantially strengthen an existing system (see also ANNEX 4). In the meantime, sample vital registration combined with verbal autopsy may provide an interim solution. Where neither national nor sample vital registration systems exist, TB mortality can be estimated using estimates of TB incidence and the case fatality rate (ANNEX 2).
1.3.4 Status of impact measurement in HBCs at the end of 2008

The status at the end of 2008 of the three major components of impact measurement highlighted above in-depth analysis of routine surveillance data; surveys of the prevalence of TB disease; and analysis of mortality records from vital registration data or surveys is shown for the 22 HBCs in TABLE 1.4.3 An in-depth analysis of surveillance data was reported to have been undertaken by 12 countries in the past ve years, although the extent to which these analyses were in
1
1.3.3 Measurement of mortality

The best way to measure the number of deaths from TB is via a national vital registration system in which deaths are
3
For a full explanation, see the Report of the second meeting of the WHO Task Force on TB Impact Measurement. Geneva, 67 December 2007. Geneva, World Health Organization, 2007 (unpublished). World Health Organization (17 authors). Assessing tuberculosis prevalence through population-based surveys. Manila, World Health Organization, 2007. Data for other countries were reported but require further validation by the Task Force secretariat.
TABLE 1.4 Measurement of incidence, prevalence and mortality carried out (20002007) and planned (20082015)
IN-DEPTH ANALYSIS OF ROUTINE SURVEILLANCE DATA CARRIED OUT PLANNED PREVALENCE OF DISEASE SURVEYa CARRIED OUT PLANNED ANALYSIS OF VITAL REGISTRATION DATA (MORTALITY RECORDS) CARRIED OUT PLANNED
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Y Y Y Y N N N N Y Y Y Y Y Y Y Y N N 12
Y Y Y Y Y N N N N Y Y Y Y Y Y Y Y Y N N 14
Y, subnational Y Y Y Y N Y Y N N N Y, subnational N Y, subnational Y N 10
Y, subnational Y Y Y Y Y Y N Y Y N Y Y N Y N Y Y N 14
N N Y N Y N N N N Y N Y N N N N N N N N 4
N N Y N Y N N N N Y N Y N N Y N N N N N 5
High-burden countriesb
a b
Indicates information not provided. National survey unless otherwise specied. The last row of the table shows the number of countries answering yes to each question.
line with the framework developed by the Task Force in 2008 (FIGURE 1.13) is not known. Such analyses are planned by a further 14 countries, offering an excellent opportunity to apply (and test) this framework in practice. Surveys of the prevalence of TB disease have been undertaken in all of the ve HBCs in the South-East Asia Region (two nationwide surveys and three subnational surveys) and in all four HBCs in the Western Pacic Region (all of which were nationwide surveys) between 2000 and 2007. With further surveys already planned in seven of these nine HBCs,1 all of which are among the 21 global focus countries selected by the Task Force, the South-East Asia and Western Pacic regions are particularly well placed to measure impact between 2000 and 2015. China is best placed to measure whether or not the Stop TB Partnership target of halving prevalence between 1990 and 2015 is achieved, since it has already conducted surveys in 1990 and 2000, with a third survey planned for 2010. Besides the nine HBCs in the SouthEast Asia and Western Pacic regions, no other HBCs have conducted a survey of the prevalence of TB disease since 2000. Nonetheless, six of the African HBCs as well as Pakistan are planning to implement surveys between 2008 and 2010. This includes Ethiopia; while not on the original list of 21 countries, a survey in this country would considerably increase the share of the population and estimated TB cases surveyed in the African Region. Among the remaining coun-
tries shown in FIGURE 1.14 (Ghana, Malawi, Mozambique, Rwanda, Sierra Leone and Zambia), all except Mozambique and Sierra Leone have plans to implement surveys starting in 2009 or 2010. If these planned surveys are to be successfully implemented, there are several major challenges that need to be overcome. These include closing funding gaps2 and delays in procuring X-ray equipment. As already highlighted above, few HBCs have analysed TB mortality using data from vital registration systems or mortality surveys. The countries where mortality data from vital registration systems have been used to quantify TB deaths are Brazil, the Russian Federation and South Africa, while Indonesia has conducted a mortality survey. This clearly demonstrates the need for general strengthening of national information and general health information systems in many countries.
This includes a survey planned in the Philippines in 2017. The exceptions where future surveys are not yet planned are Bangladesh and Viet Nam, where implementation of nationwide surveys was only recently completed. Most countries have included surveys in Global Fund proposals. However, development of study protocols has shown that the funding requested is often too low. Reprogramming of existing grants or application for supplementary funding is required. A few countries have not yet secured funding and plan to apply to the Global Fund in round 9. The deadline for round 9 applications is July 2009.
1.4 Case notications

1.4.1 Total case notications
The 196 countries reporting to WHO in 2008 notied 5.6 million new and relapse cases in 2007, of which 2.6 million (46%) were new smear-positive cases ( TABLE 1.5; FIGURE 1.15). Of these notications, 5.5 million (99%) were from DOTS programmes, including 2.6 million (47%) new smearpositive cases (also 99% of total notications of smearpositive cases). The African Region (22%), South-East Asia Region (36%) and Western Pacic Region (25%) together accounted for 83% of all notied new and relapse cases and for similar proportions of new smear-positive cases in 2007. Among new pulmonary cases reported by DOTS programmes (TABLE 1.5), 57% were new smear-positive (a minimum of 65% expected). A total of 37.3 million new and relapse cases, and 18.1 million new smear-positive cases, were notied by DOTS programmes in the 13 years between 1995 (when reliable recording began) and 2007.
1.4.2 Case notications disaggregated by sex

Notications disaggregated by sex were reported for new pulmonary smear-positive TB cases from DOTS programmes by 170 countries. Of 2.55 million notications (99.2% of total notications in DOTS areas and 98.3% of all notications), 1.65 million were male and 0.9 million were female, giving a male:female ratio of 1:8. The distribution of the male:female ratio across age groups in the nine epidemiological subregions is shown in FIGURE 1.16. For those aged 14 years, more men than women were detected with TB globally. The male:female ratio was consistently <1 in the 014 year-old age group, but increased in older age groups in most subregions. In the subregions of Central Europe, Eastern Europe, the Eastern Mediterranean and Latin America, the shape of the male:female ratio curve is concave. Reasons for this pattern and for differences compared with other regions are not well understood. One of the factors associated with the male:female ratio in smear-positive TB patients is the prevalence of HIV in the general population. Relatively more women than men are
TABLE 1.5 Case notications, 2007

NEW CASES NEW AND RELAPSE CASES DOTS WHOLE COUNTRY SMEARPOSITIVE DOTS WHOLE COUNTRY SMEAR-NEGATIVE/ UNKNOWN DOTS WHOLE COUNTRY EXTRAPULMONARY DOTS WHOLE COUNTRY RE-TREATMENT CASES EXCLUDING RELAPSE DOTS WHOLE COUNTRY % OF NEW PULMONARY CASES SMEARPOSITIVEb WHOLE COUNTRY
OTHERa
WHOLE DOTS COUNTRY DOTS
1 India 2 China 3 Indonesia 4 Nigeria 5 South Africa 6 Bangladesh 7 Ethiopia 8 Pakistan 9 Philippines 10 DR Congo 11 Russian Federation 12 Viet Nam 13 Kenya 14 Brazil 15 UR Tanzania 16 Uganda 17 Zimbabwe 18 Thailand 19 Mozambique 20 Myanmar 21 Cambodia 22 Afghanistan
1 295 943 979 502 275 193 82 417 315 315 147 342 128 844 230 468 140 588 99 810 127 338 97 400 106 438 66 759 59 371 40 909 40 277 54 793 37 651 129 081 35 601 28 769
74 757
592 587 465 877 160 617 44 016 135 604 104 296 38 040 88 747 86 566 66 099 33 103 54 457 38 360 34 211 24 520 21 303 10 583 28 487 18 214 42 588 19 421 13 213
38 444 2 125 142 561 149 119 838 155 572 105 288 972 441 666 412
398 862 430 634 102 613 32 088 105 631 23 152 43 500 103 629 49 422 10 968 73 560 17 554 49 869 20 566 20 521 13 713 21 964 17 156 13 064 41 826 7 120 8 251
23 065
206 840 36 612 8 048 4 044 45 738 16 106 45 269 33 986 1 513 18 737 11 704 18 675 18 032 9 318 12 526 4 460 6 381 7 485 5 020 40 002 8 412 6 227 565 135 223 320 31 389 75 299 45 094 295 857 78 479 749 438
10 318 566 135 223 322 32 564 76 898 53 623 295 866 88 538 770 811
179 686 66 437 467 3 824 38 304 899 3 632 1 988 2 406 87 586 944 10 285 5 224 2 721 703 1 137 393 4 466 894 411 996 74 165 10 462 4 338 121 936 194 733 73 005 478 639
5 704 412 476 11 045 127 354 194 736 77 144 488 782
548 548 792 688 131 57 218 951 2 837
704 416 220 4 438 6 701
60 52 61 58 56 82 47 46 64 86 31 76 43 62 54 61 33 62 58 50 73 62 57 58 69 53 39 61 55 57
63 57 58 69 53 39 61 55 57
High-burden countries 4 519 809 AFR AMR EMR EUR SEA WPR Global 1 251 642 208 419 375 857 322 132 2 007 111 1 325 173 5 490 334
4 527 807 2 120 909 1 251 735 218 426 378 895 350 529 2 007 193 1 365 284 561 091 114 307 155 558 97 156 972 390 656 883
1 605 663 1 608 162 408 936 52 053 135 441 154 365 622 776 529 296 408 964 55 041 136 865 165 777 622 795 548 024
5 572 062 2 557 385 2 580 700
1 902 867 1 937 466
a b
Indicates zero or all cases notied under DOTS; no additional cases notied under non-DOTS. Cases not included elsewhere in table. Expected percentage of new pulmonary cases that are smear-positive is 6580%.
FIGURE 1.15 Tuberculosis notication rates, by country, 2007
Notified TB cases (new and relapse) per 100 000 population 024 2549 5099 100 No report
detected with TB in countries where the prevalence of HIV in the general population exceeds 1% ( FIGURE 1.17). The reasons for higher TB notication rates in men are poorly understood. Possible explanations include biological differences between men and women in certain age groups that affect the risk of being infected as well as the risk of infection progressing to active disease, and/or differences in the societal roles of men and women that inuence their risk of exposure to TB and access to care (gender differences). The observation that TB notication rates tend to be more equal between men and women in countries with a high prevalence of HIV supports the hypothesis of biological differences (that can be lessened by immunological suppression due to HIV), but other non-biological factors may play an important role. A total of 101 countries reported notications of new cases of extrapulmonary TB disaggregated by age and sex (these countries accounted for 50% of total notications of extrapulmonary TB). There were 195 002 male cases and 180 310 female cases, giving a male:female ratio of 1:1. The ratio among new extrapulmonary patients is much lower than the ratio for smear-positive TB patients (FIGURE 1.18); understanding the reasons for this difference and their programmatic implications requires further investigation and research. In general, there is a need for gender-based analysis to investigate the range of biological, epidemiological, demographic, social and economic variables that affect gender differentials in the incidence and notication of TB.
1.5
Case detection rates
1.5.1 Case detection rate, all sources (DOTS and non-DOTS programmes)
The 2.6 million new smear-positive cases notied in 2007 from all sources (that is, from DOTS and non-DOTS programmes) represent 64% of the 4.1 million estimated cases (TABLE 1.2; TABLE 1.6). This is a small increase from a gure of 63% in 2006, following a slow increase from 35% to 43% between 1995 and 2001 and a more rapid increase from 43% to 60% between 2001 and 2005 (FIGURE 1.19). The improvement that occurred between 2001 and 2007 was attributable mostly to increases in the numbers of new smear-positive cases reported in the Eastern Mediterranean, South-East Asia and Western Pacic regions (TABLE 1.6). The case detection rate of smear-positive cases in 2007 (for DOTS and non-DOTS programmes) was 70% in the Western Pacic Region (78%) and the Region of the Americas (76%), followed by the South-East Asia Region (69%). The African Region had the lowest case detection rate (47%) (TABLE 1.6 ; FIGURE 1.20 ). The Region of the Americas and the European Region reported the largest numbers of new smear-positive cases from outside DOTS programmes (FIGURE 1.20 ). The 5.3 million new TB cases (all forms) that were notied in 2007 represent 57% of the 9.3 million estimated new cases. The case detection rate for all new cases was highest in the European Region (75%), followed by the Region of the Americas (71%) and the Western Pacic Region (68%) (FIGURE 1.20 ).
FIGURE 1.16 Sex ratio (M/F) by age group in nine epidemiological subregions, 2007
Africa high-HIV Africa low-HIV Central Europe
1.6
1.8
1.6 1.4 1.4 1.2 1.2 1.0
2 1.0 1
0.8
0.8
Eastern Europe
4.0 3.5 Sex ratio (M/F) 3.0 2.5 2.0 1.5 1.0 1 2 3 4
1.4
1.2
1.0
0.8
0.6
Latin America
2.0 3.5
South-East Asia
Western Pacific
3.0 1.8 2.5 1.6 2.0 1.4 1.5 1.2 1.0 1.0
2.5
2.0
1.5
1.0
014
1524
2534
3544
4554
5564
65+
014
1524
2534
3544
4554
5564
65+
014
1524
2534
3544
4554
5564
65+
Age (years)
FIGURE 1.17 Distribution of sex ratios (M/F) in notied new smear-positive TB cases, by HIV epidemic level in the general population. The error bars denote 95% condence intervals of the mean sex ratio within each HIV epidemic level. Horizontal random jitter was applied to data points to reduce over-plotting.
FIGURE 1.18 Distribution density of sex ratios (M/F) in new smear-positive TB cases (red) and in new extrapulmonary TB cases (grey). The vertical lines denote the mean sex ratio.
1.2
4 Sex ratio (M/F) of new smear-positive TB cases
1.0
0.8 2 Density 0 0.4 -2 -4

<0.1% 0.1%1% >1%
0.6
0.2
Estimated prevalence of HIV in general population
3 Sex ratio (M/F)
TABLE 1.6 Case detection rate for new smear-positive cases (%), 19952007a
DOTS PROGRAMMES
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
WHOLE COUNTRY
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1 India 2 China 3 Indonesia 4 Nigeria 5 South Africa 6 Bangladesh 7 Ethiopia 8 Pakistan 9 Philippines 10 DR Congo 11 Russian Federation 12 Viet Nam 13 Kenya 14 Brazil 15 UR Tanzania 16 Uganda 17 Zimbabwe 18 Thailand 19 Mozambique 20 Myanmar 21 Cambodia 22 Afghanistan High-burden countries AFR AMR EMR EUR SEAR WPR Global
a
0.3 0.9 1.0 1.7 6.9 12 23 30 44 56 60 15 29 11 11 32 11 18 22 32 30 31 11 12 12 31 30 21 30 12 11 43 64 80 37 15 77 31 17 53 53 66 17 18 75 72 31 28 25 38 59 60 1.3 4.4 7.4 12 19 20
64 68 80 80 73 68 20 23 77 78 65 66 27 28 50 67 75 75 59 61 45 49 86 82 72 72 64 69 50 51 48 51 32 27 74 72 49 49 62 61 63 64 64 65 47 72 52 53 67 77 47 73 60 51 69 77
37 40 37 38 22 34 39 34 12 * 3 14 * * * * * * *
46 45 34 34 * * * *
49 49 53 59 34 33 45 65 * 15 27 * * * * * 70 * * * * * 61 * * * 13 31 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
60 * * * 75 * * * * * 49 * * 82 * * * * * * * * 61 47 76 46 50 62 78 60
64 * * * * * * * * * 48 * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * * *
6.8 23 66 63 60 71 23 23 24 26 30 24 25 31 30 30 3.7 2.0 2.8 5.2 13 53 50 47 49 47
75 90 119 21 23 26 24 * * 13 * *
95 78 25 26 * * 5.4 * 65 59 * 83 * * 31 37 * 58 72 73 * * * * * * * * * * * * * * * *
70 72 77 78
6.4 14 15 20
35 40 54
1.0 1.7 40 47 30 59 58 60 61 60 43
2.5 * 42 77 * 73 * *
9.1 13
0.4 0.4 2.9 9 18 44 52 57 64 69 71 0.5 1.1 1.0 1.8 5.0 5.6 7.5 9.5 15 34 78 83 83 82 84 87 56 60 60 53 61 63 57 58 56 52 53 51 48 86 89 84 65 68 70 43 51 51 50 49
85 78 75 64 74 67 63 * * * * * * * * * * * * * *
37 40 43 47
59 77 84 85 73 73 66
3.8 3.7 7.0 7.4 8.9 17
76 75 82
82 78
60 60 60 51 47 47 55 49 45 44 42 53 50 47 45 45 0.3 5.2 22 41 48 76 68 27 30 34 50 60 69 4.2 12 11 18 29 39
47 48 47 36 36 32 74 74 77 45 46 47 62 62 68 37 45 52
51 56
43 54 60 58 48 37 * * * 43 * * * 27 30 29
59 55 27
78 88 102 111 116
40 34 44 48 54 50 48 57
8.4 14
17 20 23 26 31 35 43 53 60 36 43 25 12 18 37 37 42 27 14 26 38 43 45 46 45 49 57 32 34 39 22 24 26 33 44 55 39 50 65 46 62 46 37 62 77
31 36 37 38 33 68 25 64 28 36 43 69 27 63 29 44 42 74 24 58 29 48 47 71 34 58 30 43
39 39 43 73 32 46 37 44 41 73 27 47 38 43
41 42 47 56 42 73 30 43 42 43 44 74 32 43 45 43 46 74 34 53 50 52 47 76 39 48 57 67
64 65 47 78 52 58 67 78 47 76 60 55 69 78
23 26 30 35 37 26 26 29 33 36 12 10 12 19 21 2.6 3.5 4.6 11 11 1.4 4.0 5.5 8.0 14 15 28 31 33 31 11 16
18 22 25 28 32 37 44 52 58
62 63
35 40 40 41
42 42
43 45 49 56
63 64
Indicates not available. Estimates for all years are recalculated as new information becomes available and techniques are rened, so they may differ from those published previously. No additional data beyond DOTS report, either because country is 100% DOTS, or because no non-DOTS report was received.
FIGURE 1.19 Progress towards the 70% case detection target. (a) Open circles mark the number of new smear-positive cases notied under DOTS 19952007, expressed as a percentage of estimated new cases in each year. Closed circles show the total number of smear-positive cases notied (DOTS and non-DOTS) as a percentage of estimated cases. (b) As (a), but for all new cases (excluding relapses).
A
80 WHO target Case detection rate, smear-positive cases (%) 70 60 50 40 30 20 10 0 1990 1995 2000 2005 2010 2015
1.5.2 Case detection rate, DOTS programmes

In 2007, over 99% of all notied cases of smear-positive TB were from DOTS programmes and the case detection rate under DOTS was 63% (TABLE 1.6; FIGURE 1.19). This was a small improvement compared with 2006. National estimates of the case detection rate of new smear-positive cases suggest that 74 countries met the 70% target in 2007, down from 78 in 2006 (ANNEX 3). At regional level, the case detection rate was lowest in the African (47%) and European (51%) regions and highest in the Western Pacic Region (77%) (TABLE 1.6; FIGURE 1.20 ; FIGURE 1.21). The Western Pacic Region (since 2005) and the Region of the Americas (since 2006) are the only regions to have exceeded the 70% target, although the South-East Asia Region (at 69%) falls just short. The particularly low gure for case detection under DOTS in the European Region compared with the case detection rate (in DOTS and non-DOTS programmes) of all forms of TB of 75% (FIGURE 1.20) is explained by two factors: incomplete geographical coverage of DOTS and lack of emphasis on sputum smear microscopy.1 The implication that DOTS programmes in the African Region especially need to improve case detection comes with an important caveat. Efforts to assess improvements in case detection in this region have been hampered by the upward trend in incidence linked to the spread of HIV infection, such that it has been difcult to disentangle the effect of better programme performance and the HIV epidemic on increases in case notications (see also SECTION 1.3 and BOX 1.2). More in-depth analyses of existing surveillance and programmatic data as well as data from forthcoming surveys of the prevalence of TB disease (TABLE 1.4) may indicate that case detection is higher than stated in this report.
DOTS begins
B
80 70 Case detection rate, all new cases (%) 60 50 40 30 20 10 0 1990 1995 2000 2005 2010 2015
DOTS begins
FIGURE 1.20 Proportion of estimated cases notied under DOTS (grey portion of bars) and non-DOTS (red portion of the bar) in 2007 for (a) new smear-positive cases and (b) all new cases. The number of notied cases (in thousands) is shown in or above each portion or each bar.
(a) New smear-positive
90 80 WHO target 70 Case detection rate (%) 0.01 60 50 40 30 20 10 0 AFR AMR EMR EUR SEAR WPR WHO region 561 114 156 97 972 657 0.1 8.1 5.5 0.1 Case detection rate (%) 9.5 90 80 9.7 70 60 50 0.1 40 30 20 10 0 AFR AMR EMR EUR SEAR WPR WHO region 1195 199 366 297 1892 1265 3.0 0.1 28 38
(b) All new cases
Countries in the European Region report substantial numbers of cases in whom disease is diagnosed by methods other than sputum smear microscopy. These cases are not necessarily smear-negative.
Although case detection of new smear-positive cases in DOTS programmes improved globally between 2006 and 2007, the increment between 2006 and 2007 (an extra 55 000 cases) was less than 1%, the smallest reported annual increase since 19951996 ( TABLE 1.6 ; FIGURE 1.19 ; FIGURE 1.22). Most of the small increase in detected cases was attributable to India and Pakistan (in Pakistan this is linked to countrywide efforts to develop and scale up partnerships between the NTP and private providers, as described more fully in CHAPTER 2), and to a lesser extent Nigeria and South Africa (FIGURE 1.23). In the South-East Asia Region, the acceleration in case-nding after 2000 was attributable mostly to progress in Bangladesh, India, Indonesia and Myanmar. The Western Pacic Region is dominated by China, where case-nding expanded rapidly between 2002 and 2005; subsequently, little progress has been made (TABLE 1.6 ; ANNEX 1). China and India accounted for an estimated 27% of all undetected new smear-positive cases in 2007. Nigeria accounted for 10% of undetected cases. These three countries are among eight HBCs that together accounted for 57% of all new smear-positive cases not detected by DOTS programmes in 2007 (FIGURE 1.24). DOTS programmes detected 5.2 million new cases in 2007 (99% of all notications) out of a total of 9.27 million estimated cases (TABLE 1.2; TABLE 1.5). This is equivalent to a case detection rate (all new cases) of 56% in 2007, a 2% increase from 54% in 2006.
FIGURE 1.21 Smear-positive case detection rate under DOTS, by WHO region, 19952007. Heavy line shows global DOTS case detection rate.
80 70 60 Case detection rate (%) 50 AMR 40 30 20 10 SEAR 0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 EMR EUR AFR WHO target WPR
FIGURE 1.22 Smear-positive case detection rate within DOTS areasa for highburden countries (red) and the world (grey), 19952007
80 Case detection within DOTS areas (%)
60
40
20
0 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1.6
Outcomes of treatment in DOTS programmes
Calculated as DOTS case detection rate of new smear-positive cases divided by DOTS coverage
1.6.1 New smear-positive cases

A total of 2.5 million new smear-positive cases were registered for treatment in DOTS programmes in 2006, approximately the same number that were notied that year ( TABLE 1.7). The biggest discrepancies, where registered cases exceeded notications, were in the Region of the Americas (Brazil) and in the Russian Federation and South Africa. Globally, the rate of treatment success was 85% in 2006 (TABLE 1.7; TABLE 1.8). This means that 52% of the smearpositive cases estimated to have occurred in 2006 were treated successfully by DOTS programmes. Among all the patients treated under DOTS, 9.7% had no known outcome (defaulted, transferred, not evaluated). Treatment results for 13 consecutive cohorts (19942006) of new smear-positive patients show that the success rates have been 80% or higher in DOTS areas since 1998, even though the number of patients increased 10-fold from 240 000 in 1994 to 2.5 million in 2006 (TABLE 1.8). The target for treatment success was reached at global level in 2006 because of the high treatment success rates reported from the South-East Asia and Western Pacic regions (87% and 92%, respectively; the latter gure is high enough to warrant further validation of the data). The DOTS treatment success rate reached or exceeded 85% in ten HBCs (TABLE 1.7), seven of which were in the South-East
FIGURE 1.23 Contributions to the global increase in the number of new smear-positive cases notied under DOTS made by high-burden countries, 20062007
India Pakistan South Africa Nigeria Russian Federation DR Congo Myanmar Bangladesh Brazil Ethiopia Uganda Philippines Afghanistan Cambodia Mozambique UR Tanzania Thailand Kenya Viet Nam Zimbabwe China Indonesia -30 -20 -10 0 10 20 30 40 50 60 70 80
Contribution to increase (%)
TABLE 1.7 Treatment outcomes for new smear-positive cases treated under DOTS, 2006 cohort
TREATMENT OUTCOMES (%) a REGSTD (%) COMPLETED TREATMENT TRANSFAILED DEFAULTED FERRED % EST b CASES SUCCESSFULLY NOT TREATMENT TREATED EVALD SUCCESS (%) UNDER DOTS
NOTIFIED
REGISTEREDa
CURED
DIED
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
553 797 468 291 175 320 39 903 131 099 101 967 36 674 65 253 85 740 63 488 29 989 56 437 39 154 32 463 24 724 20 364 12 718 29 081 18 275 40 241 19 294 12 468 2 056 740 555 361 114 680 131 820 100 102 938 572 662 273 2 502 808
553 302 470 436 175 320 39 903 139 516 101 761 36 674 65 589 85 797 63 488 30 745 56 470 39 154 34 818 24 724 20 364 16 205 28 856 18 275 40 350 19 349 12 468 2 073 564 562 884 116 925 132 001 94 266 937 764 663 261 2 507 101
100 100 100 100 106 100 100 101 100 100 103 100 100 107 100 100 127 99 100 100 100 100 101 101 102 100 94 100 100 100
84 92 83 65 63 91 69 75 80 82 56 90 73 33 80 29 54 71 82 77 90 80 81 65 55 75 61 84 89 78
2.1 1.7 8.5 11 11 0.8 15 13 7.9 4.6 2.7 2.3 12 39 4.5 41 6.0 6.3 1.1 7.3 3.1 4.9 5.6 10 20 11 9.3 3.6 3.1 6.3
4.6 1.5 2.1 5.8 7.3 3.2 4.8 2.8 2.3 5.4 12 2.6 4.5 4.2 7.9 5.7 7.6 8.2 10 5.5 3.0 2.1 3.9 6.2 4.4 2.8 8.4 4.1 2.1 4.2
2.3 0.8 0.6 1.9 1.7 0.5 0.5 0.6 1.0 1.3 15 1.0 0.3 0.1 0.2 0.6 0.1 1.8 0.9 3.2 0.3 1.1 1.5 1.2 0.9 1.0 8.9 1.8 0.9 1.6
6.4 0.6 4.6 10 9.1 2.0 4.5 6.2 3.9 4.9 9.6 1.6 7.3 8.3 3.2 13 5.3 5.8 4.5 5.0 1.6 2.1 4.6 7.7 6.3 6.1 7.2 5.4 1.4 5.0
0.8 2.9 1.7 2.2 5.2 1.5 5.1 2.4 2.4 2.2 4.8 2.1 2.7 3.3 4.0 4.7 8.4 2.9 1.9 1.9 1.6 5.6 2.4 4.1 3.2 2.7 3.2 1.2 2.8 2.5
0.03 0 0 3.6 2.9 0.6 1.0 0 2.0 0 0 0.7 0 12 0 6.9 19 4.0 0 0 0 4.6 0.9 5.3 10 1.2 2.3 0.2 1.1 2.2
86 94 91 76 74 92 84 88 88 86 58 92 85 72 85 70 60 77 83 84 93 84 87 75 75 86 70 87 92 85
55 75 67 16 60 59 23 44 66 51 27 79 61 50 42 33 24 57 40 94 58 53 56 36 55 45 35 59 71 52
Treatment success 85% (treatment success for UR Tanzania 84.7%, global 84.5%). Cohort: cases diagnosed during 2006 and treated/followed-up through 2007. See TABLE A2.1 and accompanying text for denitions of treatment outcomes. If the number registered was provided, this (or the sum of the outcomes, if greater) was used as the denominator for calculating treatment outcomes. If the number registered was missing, then the number notied (or the sum of the outcomes, if greater) was used as the denominator. Est: estimated cases for 2006 (as opposed to notied or registered for treatment).
FIGURE 1.24 Smear-positive TB cases undetected by DOTS programmes in eight high-burden countries, 2007. Numbers indicate the percentage of all missed cases that were missed by each country.
300 Cases not found by DOTS programmes (thousands) 19
200 10 7.9 100 6.5 5.0 3.6 2.9 2.8
India
Nigeria
China
Ethiopia
Indonesia Bangladesh Pakistan
DR Congo
TABLE 1.8 Treatment success for new smear-positive cases treated under DOTS (%), 19942006 cohortsa
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
83 94 94 65 73 74 74 80 71 91 73 80 67 84 87 59 76 82 68 80 90 77
79 96 91 49 71 61 70 80 65 91 75 73 39 66 91 83 62 78 87 69 74 91 79
79 96 81 32 69 72 73 82 48 62 90 77 76 33 78 54 79 94 78 57 83 86 72 77 93 77
82 96 54 73 73 78 72 67 83 64 67 85 65 77 40 62 67 82 91 45 81 63 82 79 72 72 93 79
84 97 58 73 74 80 74 66 84 70 68 93 77 91 76 62 70 68 82 95 33 83 70 81 77 76 72 95 81
82 96 50 75 60 81 76 70 87 69 65 92 78 89 78 61 73 77 71 81 93 87 81 69 83 83 77 73 94 80
84 95 87 79 66 83 80 74 88 78 68 92 80 73 78 63 69 69 75 82 91 86 84 72 81 83 77 83 92 82
85 96 86 79 65 84 76 77 88 77 67 93 80 67 81 56 71 75 78 81 92 84 84 71 82 83 75 84 93 82
87 93 86 79 68 84 76 78 88 78 67 92 79 75 80 60 67 74 78 81 92 87 83 73 83 84 76 85 90 82
86 94 87 78 67 85 70 79 88 83 61 92 80 83 81 68 66 73 76 81 93 86 84 73 83 83 75 85 91 83
86 94 90 73 70 90 79 82 87 85 59 93 80 81 81 70 54 74 77 84 91 89 86 74 82 83 74 87 91 84
86 94 91 75 71 91 78 83 89 85 58 92 82 77 82 73 68 75 79 84 93 90 86 76 78 83 71 87 92 85
86 94 91 76 74 92 84 88 88 86 58 92 85 72 85 70 60 77 83 84 93 84 87 75 75 86 70 87 92 85
Indicates not available. See notes for TABLE 1.7.
Asia and Western Pacic regions, and in 59 countries (up from 57 the previous year) in total (ANNEX 3). Treatment success rates of 90% or more were reported in Bangladesh, Cambodia, China, Indonesia and Viet Nam. Treatment success rates in other regions in 2006 were 75% in the African Region, 86% in the Eastern Mediterranean Region (where the target was reached for the rst time in 2006), 70% in the European Region (the lowest recorded since 1996) and 75% in the Region of the Americas (TABLE 1.7; TABLE 1.8). In the Region of the Americas, the treatment success rate has been worsening since 2002, related to the geographical expansion of DOTS to those parts of countries where health services are weaker. There was no evaluation of treatment outcome for 10% of patients in the region as a whole. Relatively low treatment success rates in the European Region are explained in large part by high rates of death and treatment failure in the Russian Federation, which are linked among other factors to drug resistance. Here, the treatment success rate was 58% in 2006, the lowest level since WHO began monitoring this indicator in 1995. Death and default rates remain high in the African Region, linked to high rates
of HIV coinfection and weak health services: one or other of these indicators exceeded 10% in Mozambique, Nigeria and Uganda. However, Kenya achieved a treatment success rate of 85% in 2006 and the United Republic of Tanzania achieved a treatment success rate of 84.7%, indicating that it is possible to achieve the target of 85% in settings where a high proportion of patients are HIV-positive. Cure was not conrmed (by a nal, negative sputum smear) for large numbers of patients in Brazil (39%), Ethiopia (15%), Nigeria (11%), Pakistan (13%), South Africa (11%) and Uganda (41%). Variation in treatment outcomes among regions (TABLE 1.7; FIGURE 1.25) raises important questions about the quality of treatment, the quality of the data and how quickly these will improve in future.
1.6.2 Re-treatment cases

A total of 564 131 patients were re-treated in DOTS programmes in 2006 (TABLE 1.9), an increase from 531 228 patients in 2005. The re-treatment success rate in 2006 was 70%. As expected from the results of treating new patients, re-treatment success rates were lowest in the European
FIGURE 1.25 Outcomes for those patients not successfully treated in (a) DOTS and (b) non-DOTS areas, by WHO region, 2006 cohort
(a) DOTS
WPR SEAR EUR EMR AMR AFR
Region (42%) and highest in the Western Pacic Region (87%).
1.6.3 Comparison of treatment outcomes in HIV-positive and HIV-negative TB patients

Data on the outcomes of treatment for HIV-positive and HIVnegative TB patients were reported separately by between 31 and 55 countries, depending on the category of case (FIGURE 1.26 ; smear-negative and extrapulmonary cases are presented as one category, since separate analysis showed very similar treatment outcomes for these two types of case). These countries were mostly in the Region of the Americas and the European Region. There were few data for African countries (only for Ghana, Lesotho, Mauritania, Mauritius, Namibia and Zambia), even though Africa accounts for 79% of estimated HIV-positive cases. The data that were reported show lower treatment success rates among HIV-positive patients, due mainly to higher death rates and, to a lesser extent, higher default rates. A similar pattern existed for two regions that could be analysed separately (the Region of the Americas and the European Region; data not shown).
10
20 % of cohort
30
40
(b) non-DOTS
WPR SEAR EUR EMR AMR AFR 0 20 40 % of cohort Died Failed Defaulted Transferred Not evaluated 60 80 100
1.7
Progress towards reaching targets for case detection and treatment success
The global targets for both case detection (70%) and treatment success (85%) were achieved in 36 countries (up from 33 in 20052006) including four HBCs: China, Kenya, the Philippines and Viet Nam (FIGURE 1.27; FIGURE 1.28). Kenya is the rst country in sub-Saharan Africa that is assessed to have achieved both targets, following new analysis of TB incidence and the case detection rate (BOX 1.2) and a treatment success rate that reached 85% for the rst time in the 2006 cohort. Indonesia dropped out of the target zone (FIGURE 1.28) in 2007, possibly as a consequence of a temporary cessation of funding from a Global Fund grant delaying implementation of some programmatic activities. The only region to have reached both targets is the Western Pacic Region, although the South-East Asia Region is very close. The Region of the Americas could achieve both targets if treatment outcomes could be improved by reducing the proportion of patients for whom treatment outcome is not evaluated. The African and European regions perform worst on both indicators. Progress can also be directly compared with the expectations set out in the Global Plan ( TABLE 1.10 ), which was designed to achieve the MDG, Stop TB Partnership and WHA targets set for 2015 (SECTION 1.1). The case detection rate for new smear-positive cases in DOTS programmes in 2007, at 63%, lags behind the milestone of 68% in the Global Plan. The detection of smear-negative and extrapulmonary cases also lags behind the Global Plan, and by a larger amount (51% estimated for 2007 compared with the Global Plan milestone of 69%). More positively, progress in the treatment success rate is ahead of the Global Plan, at 85% compared with 83%. In addition, the absolute number of smear-pos-
TABLE 1.9 Re-treatment outcomes for smear-positive cases treated under DOTS, 2006 cohort a
TREATMENT OUTCOMES (%) COMPLETED REGISTERED CURED TREATMENT DIED FAILED DEFAULTED TRANSFERRED NOT EVALD TREATMENT SUCCESS (%)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
259 130 78 146 4 227 4 605 43 225 4 211 2 846 5 566 3 293 6 345 17 109 7 500 3 945 4 955 4 639 1 357 929 2 191 1 818 8 866 1 389 1 132 467 424 98 957 12 282 14 039 51 866 290 910 96 159 564 213
45 85 61 60 56 70 54 59 63 63 33 79 71 15 38 33 54 53 63 50 48 74 54 49 37 58 34 47 80 52
26 4.7 16 17 10 7.1 16 18 17 3.7 4.7 4.3 7.8 28 39 43 3.0 8.6 2.1 20 37 5 19 17 18 18 7.4 25 6.3 18
7.1 2.3 4.5 3.6 5.1 4.5 8.0 4.2 5.4 7.6 14 5.9 7.1 5.7 12 8.4 17 13 12 12 6.2 2.7 6.4 6.9 6.1 4.0 14 7.1 3.0 6.9
4.2 2.2 2.5 7.1 9.0 2.2 2.1 3.1 4.4 3.2 26 5.2 0.9 1.7 0.6 1.0 0.5 5.5 1.8 6.5 2.2 2.3 5.0 5.4 2.7 3.3 19 4.5 2.6 5.6
15 1.2 11 9.7 12 3.9 4.3 11 4.7 14 14 3.2 8.3 16 3.9 10 6.7 7.2 7.0 7.4 1.9 2.2 12 11 14 11 12 14 1.7 11
1.7 5.1 5.0 2.6 3.5 3.5 4.9 4.2 2.5 2.6 7.7 2.9 4.7 11 4.0 4.3 6.6 4.9 14 4.4 4.3 6.3 3.1 4.5 5.9 4.7 5.4 2.0 5.1 3.4
0.02 0 0 0 3.5 8.4 11 0.2 3.4 6.2 0 0.1 0 23 2.0 0 12 7.5 0 0 0 7.9 0.9 6.3 16 1.6 7.7 0.2 1.0 2.5
72 89 77 77 67 77 69 77 80 67 38 83 79 43 78 76 57 62 65 70 85 79 73 66 55 76 42 72 87 70

a
Indicates not available. Treatment success 85%. See notes for TABLE 1.7.
FIGURE 1.26 Treatment outcomes for HIV-positive and HIV-negative TB patients, 2006 cohort. The numbers under the bars are the numbers of patients included in the cohort.
100 Cured Completed 80 Percentage of cohort Died Failed 60 Defaulted 40 Transferred Not evaluated 20
0 HIV+ HIV(12 931) (722 667) New smear-positive (data from 55 countries) HIV+ HIV(18 298) (601 518) New smear-negative and extrapulmonary (data from 48 countries) HIV+ (4765) HIV(80 293)
Re-treatment (data from 31 countries)
FIGURE 1.27 DOTS status in 2007, countries close to targets. 100 countries reported treatment success rates 70% or over and DOTS detection rates 50% or over. 36 countries (including 5 countries out of range of graph) have reached both targets; 2 in the African Region, 8 in the Region of the Americas, 6 in the Eastern Mediterranean Region, 6 in the European Region, 2 in the South-East Asia Region and 12 in the Western Pacic Region.
100
MALTA NAURU WALLIS & FUTUNA
BOSNIA & HERZEGOVINA
95
CHINA CAMBODIA ALBANIA BANGLADESH VANUATU EL SALVADOR LEBANON MAURITIUS INDONESIA LAO PDR TURKEY SLOVENIA TUNISIA VIET NAM
TARGET ZONE
itive patients treated in DOTS programmes in 2007 (2.1 million) was higher than the number forecast in the Global Plan (1.8 million) because the estimated incidence of TB in 2007 was higher than anticipated by the Global Plan.
90 Treatment success (%)
The latest estimates of the global burden of TB show that there 85 were 9.27 million new cases of TB in 2007 (including 1.37 mil80 lion cases among HIV-positive people), 1.32 million deaths from TB in HIV-negative people 75 with an additional 0.46 million TB deaths in HIV-positive 70 people, and 13.7 million preva50 60 70 80 90 100 110 120 lent cases (of which 687 000 DOTS case detection rate (new smear-positive, %) were HIV-positive cases). There were 0.5 million cases of MDRTB, of which 0.3 million were among people not previously treated for TB and 0.2 million were among previously treated TB cases. The estimates of cases and deaths in HIV-positive people in 2007 as well as in previous years are substantially higher than those published in previous years by WHO, and are based on new data that became available in 2008 and associated updates to analytical methods. The revised estimates suggest that TB cases and deaths from TB in HIVpositive people peaked in 2005, at 1.39 million and 0.48 million respectively. Collectively, these statistics show that TB remains a major global health problem. The total number of global cases is FIGURE 1.28 still increasing in absolute terms as a DOTS progress in high-burden countries, 20062007. Treatment success refers to result of population growth. Nonethecohorts of patients registered in 2005 or 2006, and evaluated, respectively, by the end less, the number of incident cases per of 2006 or 2007. Arrows mark progress in treatment success and DOTS case detection rate. Countries should enter the graph at top left, and proceed rightwards to the target capita is falling globally, in ve out zone. Countries from AFR, AMR, EMR and EUR are shown in red, those from SEAR and of six WHO regions (the exception is WPR are shown in black. Europe, where rates are approximately 100 CHINA stable) and in seven out of nine epideTARGET ZONE BANGLADESH CAMBODIA INDONESIA miological subregions (the exceptions VIET NAM 90 PAKISTAN DR PHILIPPINES CONGO UR TANZANIA are Eastern Europe and African counINDIA AFGHANISTAN tries with a low prevalence of HIV in MYANMAR KENYA ETHIOPIA 80 MOZAMBIQUE the general population). If the global THAILAND UGANDA BRAZIL NIGERIA trend is conrmed by further monitor70 SOUTH ZIMBABWE ing, MDG Target 6.c will have been AFRICA met by 2005 (following a peak in the 60 incidence rate in 2004), well ahead of RUSSIAN FEDERATION the target date of 2015. The more challenging targets of halving prevalence 50 and death rates by 2015 compared with a baseline of 1990, set by the 40 0 20 40 60 80 100 120 Stop TB Partnership, are unlikely to DOTS case detection rate (new smear-positive, %) be achieved globally because of the
DR CONGO ZAMBIA UR TANZANIA PARAGUAY MYANMAR KYRGYZSTAN TIMOR-LESTE PUERTO RICO BULGARIA CHINA, HONG KONG SAR NIGER PANAMA MEXICO DENMARK KUWAIT PERU DOMINICAN REPUBLIC THAILAND MADAGASCAR NAMIBIA GUINEA GEORGIA BAHAMAS ISRAEL POLAND BELGIUM BOTSWANA SOUTH AFRICA LITHUANIA LATVIA CAMEROON KAZAKHSTAN BRAZIL JORDAN COLOMBIA NEW ZEALAND
KIRIBATI SOMALIA NEPAL PAKISTAN
ALGERIA MALDIVES GUAM MICRONESIA CUBA PHILIPPINES NICARAGUA NEW CALEDONIA MONGOLIA CHINA, MACAO SAR SYRIAN ARAB PORTUGAL EGYPT URUGUAY REPUBLIC DPR KOREA TFYR SRI LANKA MOROCCO MACEDONIA FRENCH POLYNESIA INDIA CHILE BAHRAIN NORTHERN SINGAPORE KENYA TURKMENISTAN MARIANA IS SERBIA AFGHANISTAN IRAN BRUNEI DARUSSALAM BOLIVIA ROMANIA VENEZUELA
1.8 Summary
Treatment success (%)
TABLE 1.10 DOTS expansion and enhancement in 2007: country reports compared with expectations given in the Global Plan
COUNTRY REPORTS a GLOBAL PLAN (MILLIONS OR PERCENTAGES)
Number of new smear-positive cases notied under DOTS Estimated number of new smear-positive cases New smear-positive case detection rate under DOTS Number of new smear-positive cases successfully treated under DOTS Number of new smear-positive cases registered for treatment under DOTS New smear-positive treatment success rate, 2006 Number of new smear-negative and extrapulmonary cases notied under DOTS Estimated number of new smear-negative and extrapulmonary cases New smear-negative and extra-pulmonary case detection rate under DOTS
a
2.5 4.0 63% 2.1 2.5 85% 2.6 5.1 51%
2.2 3.2 68% 1.8 2.2 83% 3.1 4.5 69%
Includes only those countries in the Global Plan, i.e. countries in sub-regions Central Europe and Established Market Economies are excluded here.
enormous gap between rates in 2007 and the 2015 target in the African and European regions. However, three of six WHO regions are on track to meet both targets: these are the Eastern Mediterranean and South-East Asia regions, and the Region of the Americas. The Western Pacic Region is on track to achieve the prevalence target, but progress will have to accelerate from 2008 onwards, otherwise the mortality target may be narrowly missed. Implementation of recommendations for measuring progress towards the impact targets that have been made by the Global Task Force on TB Impact Measurement, including more in-depth analyses of the quality and coverage of existing surveillance data, surveys of the prevalence of TB disease in 21 global focus countries and strengthening of vital registration systems to improve the measurement of mortality, will considerably improve measurement of progress towards the impact targets as well as measurement of progress in TB control after 2015. The WHA target of successfully treating 85% of new smear-positive patients was achieved at global level in 2006. It has also been achieved in three regions: in the Eastern Mediterranean Region (for the rst time) and in the SouthEast Asia and Western Pacic regions, as well as in 59 countries (up from 57 the previous year). Treatment success rates remain well below the target in the other regions, especially the European Region.
With 5.2 million cases notied in DOTS programmes (99% of the total notied globally), of which 2.6 million (44%) were new smear-positive cases (also 99% of the total notied globally), the case detection rate for new smear-positive TB under DOTS was 63% in 2007, a very small increase from 62% in 2006. Much of the progress that did take place was in India and Pakistan, which in Pakistan was linked in particular to countrywide efforts to develop partnerships between the NTP and private providers. The percentage of estimated cases notied by DOTS and non-DOTS programmes combined was 64%. The slow rate of progress reinforces the observation in last years report that progress in case detection has slowed since 2005 and that the WHA target of a case detection rate of at least 70%, originally set for 2000 and later reset to 2005, is still some way from being achieved. More positively, the Western Pacic Region and the Region of the Americas have achieved the target, as have 74 countries; at 69%, the South-East Asia Region is very close to doing so. The Western Pacic Region and 36 countries (up from 33 in 2006/7) appear to have achieved both the case detection and treatment success targets. Reaching the case detection target at global level requires greater efforts to detect and treat cases in all regions, using the range of interventions and approaches dened in the Stop TB Strategy that are discussed in the next chapter.
CHAPTER 2
Strategy
Two landmark documents in global TB control the Stop TB Strategy1 and the Global Plan to Stop TB2 were launched in 2006. The Stop TB Strategy, developed by WHO, sets out the interventions that need to be implemented to achieve the MDG, Stop TB Partnership and World Health Assembly targets discussed in CHAPTER 1. The Global Plan to Stop TB, developed by the Stop TB Partnership, sets out how, and at what scale, the strategy should be implemented over the decade 20062015 (see also CHAPTER 1). To monitor implementation of the strategy, WHO has asked countries to report on the implementation of TB control activities according to the strategys major components and subcomponents (TABLE 2.1; TABLE 2.2) since 2007. In the 2008 round of data collection, countries were asked to report on activities implemented in 2007 and on activities planned for 2008 (see ANNEX 2 for further details about the data that were collected). In a few cases, projections for 2009 were also requested. This chapter, structured in seven main sections, summarizes the major ndings on global progress in implementing the Stop TB Strategy. Wherever possible, comparable data reported in previous years are also presented, to illustrate trends over time. The rst section provides an overview of the completeness of reporting for each component of the Stop TB Strategy. The next six sections cover each of the six major components of the strategy in turn: pursue highquality DOTS expansion and enhancement; address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations; contribute to health system strengthening based on primary health care; engage all care providers; empower people with TB, and communities through partnership; and enable and promote research.3 Further details about the implementation of all major components and subcomponents of the Stop TB Strategy are provided for each of the 22 HBCs in ANNEX 1.
TABLE 2.1 Components of the Stop TB Strategy

1. Pursue high-quality DOTS expansion and enhancement a. Secure political commitment, with adequate and sustained nancing b. Ensure early case detection, and diagnosis through quality-assured bacteriology c. Provide standardized treatment with supervision, and patient support d. Ensure effective drug supply and management e. Monitor and evaluate performance and impact 2. Address TB-HIV, MDR-TB, and the needs of poor and vulnerable populations a. Scale up collaborative TB/HIV activities b. Scale up prevention and management of multidrug-resistant TB (MDR-TB) c. Address the needs of TB contacts, and of poor and vulnerable populations, including women, children, prisoners, refugees, migrants and ethnic minorities 3. Contribute to health system strengthening based on primary health care a. Help improve health policies, human resource development, nancing, supplies, service delivery and information b. Strengthen infection control in health services, other congregate settings and households c. Upgrade laboratory networks, and implement the Practical Approach to Lung Health (PAL) d. Adapt successful approaches from other elds and sectors, and foster action on the social determinants of health 4. Engage all care providers a. Involve all public, voluntary, corporate and private providers through PublicPrivate Mix (PPM) approaches b. Promote use of the International Standards for TB Care (ISTC) 5. Empower people with TB, and communities through partnership a. Pursue advocacy, communication and social mobilization b. Foster community participation in TB care c. Promote use of the Patients Charter for TB Care 6. Enable and promote research a. Conduct programme-based operational research, and introduce new tools into practice b. Advocate for and participate in research to develop new diagnostics, drugs and vaccines
TABLE 2.2 Technical elements of the DOTS strategy

Case detection through quality-assured bacteriology Case detection among symptomatic patients self-reporting to health services, using sputum smear microscopy. Sputum culture is also used for diagnosis in some countries, but direct sputum smear microscopy should still be performed for all suspected cases. Standardized treatment with supervision and patient support Standardized short-course chemotherapy using regimens of 68 months for at least all conrmed smear-positive cases. Good case management includes directly observed treatment (DOT) during the intensive phase for all new smear-positive cases, during the continuation phase of regimens containing rifampicin and during the entirety of a re-treatment regimen. In countries that have consistently documented high rates of treatment success, DOT may be reserved for a subset of patients, as long as cohort analysis of treatment results is provided to document the outcome of all cases. An effective drug supply and management system Establishment and maintenance of a system to supply all essential anti-TB drugs and to ensure no interruption in their availability. Monitoring and evaluation system, and impact measurement Establishment and maintenance of a standardized recording and reporting system, allowing assessment of treatment results (see TABLE 2.7).
1
The Stop TB Strategy: building on and enhancing DOTS to meet the TBrelated Millennium Development Goals. Geneva, World Health Organization, 2006 (WHO/HTM/TB/2006.368). The Global Plan to Stop TB, 20062015: actions for life towards a world free of tuberculosis. Geneva, World Health Organization, 2006 (WHO/ HTM/STB/2006.35). At the end of 2008, the wording used to describe the six components of the strategy was updated based on lessons learnt and feedback received. For the updated wording, see TABLE 2.1.
TABLE 2.3 Reporting on implementation of the Stop TB Strategy, 2007. Number of countries (out of 196 countries reporting) answering given percentage of questions on each sub-component of the strategy.
COMPLETENESS OF REPORTING <50% 5075% 7590% >90%
1. DOTS expansion and enhancement Political commitment Overview of services for diagnosis and treatment of TB Laboratory diagnostic services Drug management Monitoring and evaluation, including impact measurement* 2. TB/HIV, MDR-TB and other challenges Collaborative TB/HIV activities Mechanisms for collaboration and policy development HIV-testing for TB patients, provision of CPT and ART Intensied TB case-nding and IPT for HIV-positive people Treatment outcomes of HIV-positive TB patients Management of MDR-TB Policy and stage of implementation Diagnosis and treatment of MDR-TB Treatment outcomes of MDR-TB patients High-risk groups and special situations 3. Health system strengthening Health system stengthening and integration of TB control within primary health care Practical Approach to Lung Health (PAL) Human resource development 4. Engaging all care providers PublicPrivate and PublicPublic Mix approaches (PPM) International Standards for Tuberculosis Care 5. Empowering people with TB, and communities Advocacy, communication and social mobilization (ACSM) Community participation in TB control Patients Charter for Tuberculosis Care 6. Enabling and promoting research Operational research Research to develop new diagnostics, drugs and vaccines
* include data on case notications by type and age/sex and treatment outcomes.
4 12 23 14 0
15 13 9 16 0
0 14 17 166 36
177 157 147 0 160
17 55 89 0 11 24 138 21 24 35 16 77 29 16 32 33 30 28
6 33 12 0 11 15 54 15 0 15 28 118 1 3 4 14 38 4
17 14 12 133 21 22 0 19 2 24 13 0 24 24 5 0 5 6
156 92 83 63 153 135 4 141 170 122 139 1 142 153 155 149 123 158
2.1
Data reported to WHO in 2008
The data that were reported to WHO in 2008 are summarized in TABLE 2.3.1 A total of 196 (out of 212) countries and territories (hereafter countries) reported data; these countries collectively account for 99.6% of the worlds estimated TB cases. Among countries which reported, at least 75% of the requested data were provided by 7080% of countries for most sections of the data collection form. The topics for which reporting of data was much less complete were collaborative TB/HIV activities, treatment outcomes for patients with multidrug-resistant TB (MDR-TB), and publicpublic and publicprivate mix (PPM). For HBCs specically, a similar pattern existed (data not shown).
FIGURE 2.1 Number of countries and territories implementing DOTS (out of a total of 212), 19912007
200 180
150 Number of countries
100
50
1991
1993
1995
1997
1999
2001
2003
2005
2007
2.2 DOTS expansion and enhancement

2.2.1 DOTS coverage and numbers of patients treated
The total number of countries implementing DOTS increased steadily from 1995 to 2003, and has since remained stable at around 180 countries (FIGURE 2.1). All 22 HBCs have had DOTS programmes since 2000. DOTS coverage within
1
The wording used in TABLE 2.3 is the wording used on the 2008 data collection form, which was distributed before the update to the wording of the Stop TB Strategy presented in TABLE 2.1.
TABLE 2.4 Progress in DOTS implementation, 19952007

PERCENT OF POPULATION COVERED BY DOTS 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
1.5 49 6.0 47 41 39 2.0 4.3 47 50 15 98 97 60 24 43 12 16 5.4 6.7 43 22
2.0 60 14 30 0 65 39 8.0 2.0 51 2.3 95 100 0 100 0 0 1.1 100 59 80 32 46 48 12 8.2 12 55 32
2.3 64 28 40 13 80 48 15 60 2.3 93 100 0 100 100 0 4.0 84 60 88 12 36 56 50 18 17 16 57 37
9.0 64 80 45 22 90 64 8.0 17 60 5.0 96 100 3.0 100 100 100 32 95 60 100 11 43 61 55 33 22 29 58 43
14 64 90 45 66 90 63 8.0 43 62 5.0 99 100 7.0 100 100 12 59 64 100 14 45 56 65 51 23 36 57 47
30 68 98 47 77 92 85 9.0 90 70 12 100 100 7.0 100 100 100 70 100 77 99 15 55 71 68 65 26 49 67 57
45 68 98 55 77 95 70 24 95 70 16 100 100 32 100 100 100 82 100 84 100 12 61 70 73 71 31 60 68 62
52 78 98 55 98 95 95 44 98 70 25 100 100 25 100 100 100 100 100 88 100 38 68 81 73 77 39 66 77 69
67 91 98 60 100 99 95 66 100 75 25 100 100 34 100 100 100 100 100 95 100 53 79 85 78 87 41 77 90 77
84 96 98 65 93 99 70 79 100 75 45 100 100 52 100 100 100 100 100 95 100 68 87 83 83 90 46 89 94 83
91 100 98 65 94 99 90 100 100 100 83 100 100 68 100 100 100 100 100 95 100 81 94 88 88 97 59 93 98 89
100 100 98 75 100 100 100 100 100 100 84 100 100 86 100 100 100 100 100 95 100 97 98 92 93 98 67 100 100 93
100 100 100 91 100 100 95 99 100 100 100 100 100 75 100 100 100 100 100 95 100 97 98 93 91 97 75 100 100 94
Zero indicates that a report was received, but the country had not implemented DOTS. Indicates that no report was received.
FIGURE 2.2 DOTS coverage by WHO region, 2007. The red portion of each bar shows DOTS coverage as a percent of the population. The numbers in each bar show the population (in millions) within (red portion) or outside (grey portion) DOTS areas.
100 59 78 16 226 2.9 7.0
80 DOTS coverage (%)
60 733 40 32 539 664 1742 1769
20
AFR
AMR
EMR EUR WHO region
SEAR
WPR
countries has also increased since 1995 (TABLE 2.4). By the end of 2007, 94% of the worlds population lived in countries that had adopted DOTS, and population coverage was reported to exceed 90% in all regions except Europe (FIGURE 2.2). However, 100% DOTS coverage does not mean that all providers in a country are implementing the DOTS strategy (see also SECTION 2.5). As reported in greater detail in CHAPTER 1, 5.5 million new and relapse cases of TB were notied by DOTS programmes in 2007, of which 2.6 million (47%) were new sputum smear-positive cases. These numbers represented 98.5% and 99.1% of total TB case notications (that is, notications from DOTS and non-DOTS programmes combined), respectively. The percentage of all estimated new cases of smear-positive TB detected by DOTS programmes the case detection rate was 63% globally in 2007; the case detection rate for all cases was 56%. A cumulative total of 37.3 million new and relapse cases have been treated in DOTS programmes in the 13 years from 1995 (when reliable records began) to 2007. Globally, the treatment success rate was 85% in the 2006 cohort. The Western Pacic Region has
achieved both global targets related to DOTS implementation (a case detection rate of 70% and a treatment success rate of 85%), and the South-East Asia Region and the Region of the Americas are close to doing so. The other three regions (African, European and Eastern Mediterranean regions) are much further from achieving these targets. This short summary of the data that are presented in much greater detail in CHAPTER 1 provides a context for the information provided in the rest of this chapter.
2.2.2 Political commitment

Scaling up implementation of all components of the Stop TB Strategy while maintaining strong basic DOTS services requires sustained political commitment. Indicators of political commitment include the existence of a national strategic plan for TB control and the percentage of total funding required for TB control that is funded from domestic sources. A total of 155 countries (84% of those reporting), including all HBCs, had a national strategic plan for TB control, including all countries in the African, Eastern Mediterranean
and South East Asia regions that reported data. Domestic funding between 2002 and 2009 has increased in absolute terms in almost all of the HBCs; examples of countries with particularly large increases are Brazil, China, Indonesia, Mozambique, Nigeria and the Russian Federation. However, as a percentage of total funding for TB control, domestic funding has been relatively stable or has fallen in all of the 20 HBCs for which an assessment can be made (there are insufcient data for South Africa and Thailand). Additional information about national plans and nancial indicators in HBCs are included in ANNEX 1. Further details about nancing for TB control in all countries are provided in CHAPTER 3 and ANNEX 3.
2.2.3 Early case detection through quality-assured bacteriology

Sputum smear microscopy is the primary tool for diagnosis of TB in most countries. Among reporting countries, 83% (136/164) used sputum smear microscopy for all individuals with suspected pulmonary TB in all diagnostic sites in 2007.
TABLE 2.5 Stock-outs of laboratory reagents and of rst-line anti-TB drugs, 2007
LABORATORY REAGENTS AND SUPPLIES CENTRAL PERIPHERAL FIRST-LINE ANTI-TB DRUGS CENTRAL PERIPHERAL
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
N N Not applicable N N N N N N N Y N N N N Y N Y N N N 3/21 10/37 6/38 2/22 4/41 0/10 5/32 27/180
Some units N Some units N N Some units Some units N N N N N N Some units Some units N Some units N N N 7/22 16/36 6/39 3/22 10/40 3/11 5/32 43/180
N N N Y Y N Y N Y Y Y N N N Y Y N N N N Y 9/20 13/36 3/34 3/22 3/41 0/10 10/31 32/174
N Some units N Some units N N Some units N Some units Some units Y N N N Some units Some units N Some units N N N 9/22 15/36 5/36 2/22 6/40 0/11 7/31 35/176
High-burden countries a AFR (46) b AMR (44) EMR (22) EUR (53) SEAR (11) WPR (36) Global (212)
Indicates information not provided. In the lower part of the table the numerator of each fraction is the number of countries reporting stock-outs; the denominator is the number of countries providing information. The number of countries in each region is shown in parentheses.
TABLE 2.6 Coverage of laboratory services, high-burden countries, 2007

ACCESS TO DIAGNOSTIC SERVICES SPUTUM SMEAR NATIONAL REFERENCE LABORATORY (NRL) a PER 100 000 POP CULTURE PER 5 MILLION POPb DST PER 10 MILLION POPb LABORATORIES INCLUDED IN EXTERNAL QUALITY ASSURANCE (EQA) FOR SPUTUM SMEAR MICROSCOPY NUMBER %
POPULATION THOUSANDS
NUMBER OF LABS
NUMBER OF LABS
NUMBER OF LABS
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
1 169 016 1 328 630 231 627 148 093 48 577 158 665 83 099 163 902 87 960 62 636 142 499 87 375 37 538 191 791 40 454 30 884 13 349 63 884 21 397 48 798 14 444 27 145 4 201 761 765 283 599 140 555 064 611 415 1 745 394 1 621 633 5 897 929
Y Y N Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y 20 34 29 18 43 10 27 161
12 184 3 294 4 855 794 249 753 833 1 131 2 374 1 205 4 048 737 930 4 044 717 716 180 1 023 252 324 201 500 41 344 8 547 13 874 4 094 6 744 20 090 7 341 60 690
1.0 0.2 2.1 0.5 0.5 0.5 1.0 0.7 2.7 1.9 2.8 0.8 2.5 2.1 1.8 2.3 1.3 1.6 1.2 0.7 1.4 1.8 1.0 1.1 2.3 0.7 1.1 1.2 0.5 1.0
11 327 41 2 15 4 1 3 3 1 965 17 5 193 3 3 1 65 1 2 3 1 1 667 110 1 487 162 2 216 129 459 4 563
0.05 1.2 0.9 0.1 1.5 0.1 0.1 0.1 0.2 0.1 34 1.0 0.7 5.0 0.4 0.5 0.4 5.1 0.2 0.2 1.0 0.2 2.0 0.7 12 1.5 18 0.4 1.4 3.9
11 187 11 1 10 2 1 1 3 1 280 2 1 38 1 2 1 14 1 1 1 570 45 111 36 762 43 224 1 221
0.1 1.4 0.5 0.1 2.1 0.1 0.1 0.1 0.3 0.2 20 0.2 0.3 2.0 0.2 0.6 0.7 2.2 0.5 0.2 0.7 1.4 0.6 1.9 0.6 12 0.2 1.4 2.1
11 386 3 294 4 855 347 241 753 360 2 374 1 023 37 1 819 716 0 1 023 252 54 186 360 29 080 4 466 9 040 2 158 284 18 372 6 262 40 582
93 100 100 44 97 100 32 100 85 4.0 45 100 0 100 100 17 93 72 70 52 65 53 4.2 91 85 67
High-burden countries (22) AFR AMR EMR EUR SEAR WPR Global
a b
Indicates information not provided; labs, laboratories; pop, population. In the lower part of the table the number of countries answering yes to this question is shown. To provide culture for diagnosis of paediatric, extrapulmonary and ss/HIV+ TB, as well as DST for re-treatment and failure cases, most countries will need one culture facility per 5 million population and one DST facility per 10 million population. However, for countries with large populations ( country name and numbers shown in italics), one laboratory for culture and DST in each major administrative area (e.g. province) may be sufcient. See also note in country proles (ANNEX 1).
This included 17 of the 22 HBCs. In Mozambique, South Africa and Zimbabwe, only some patients were screened by microscopy; no data were reported by Viet Nam. Laboratory supplies for microscopy were also generally reported to be adequate. Among all countries, 15% (27/180) reported stock-outs at the central level and 24% (43/180) reported stock-outs at the peripheral level (TABLE 2.5). Three HBCs (Mozambique, Viet Nam and Zimbabwe) reported stock-outs at the central level (Bangladesh did not provide any data). Seven HBCs reported stock-outs at the peripheral level in some units, while Bangladesh and Viet Nam did not report data (TABLE 2.5). The average number of microscopy laboratories exceeds the target of at least 1 per 100 000 population in four regions (TABLE 2.6). The average number in the Western Pacic Region is 0.5 per 100 000 population, reecting a
comparatively low number of laboratories relative to population size in the largest country in the region (China). Besides China, other HBCs with a relatively low number of microscopy laboratories per 100 000 population include Bangladesh, Myanmar, Nigeria and Pakistan. External quality assurance (EQA) was conducted for a high proportion of laboratories in the South-East Asia and Western Pacic regions (91% and 85% respectively), with much lower gures in other regions. Among the HBCs, coverage of EQA was reported as 100% in seven countries: Bangladesh, China, Indonesia, the Philippines, Uganda, Mozambique and Thailand. Laboratories with the capacity to provide culture and DST services are essential for diagnosis of drug-resistant TB; culture services are also important for diagnosis of smearnegative TB, especially in settings where the prevalence of
HIV is high. However, capacity to perform culture and DST was seriously limited in most HBCs in 2007 ( TABLE 2.6). Only seven HBCs (Brazil, Cambodia, China, the Russian Federation, South Africa, Thailand and Viet Nam) had at least one culture laboratory per 5 million population (the currently recommended level); for more than half of the HBCs, the gure was below 0.5. The Russian Federation is exceptional, with 34 culture laboratories per 5 million population. Four regions have more than one culture laboratory per 5 million population, but the distribution of laboratories among countries in these regions is uneven. A similar pattern exists for DST. Only ve HBCs reported having at least 1 laboratory with DST capacity per 10 million population (the currently recommended level): Brazil, China, the Russian Federation (20 per 10 million population), South Africa and Thailand. Among the remaining HBCs, most had less than 1 laboratory with DST capacity per 20 million population. While 94% of all countries that reported data (161/171) indicated that a national reference laboratory (NRL) was available (TABLE 2.6), the functionality and/or performance of these laboratories is mostly unknown. Two HBCs (Indonesia and Pakistan) indicated that no NRL was available, although all had plans to establish one within the next 12 years. Most laboratories with capacity to test for drug susceptibility, including many NRLs, are able only to provide DST of rst-line drugs. The emergence of extensively drug-resistant TB (XDR-TB) in an increasing number of countries globally highlights the importance of access to DST of second-line drugs. These services were available to 63 of 142 reporting countries (44%) in 2007, either within or outside the country; however, their quality is unclear, and only nine HBCs had access to second-line DST. In Africa, very few countries apart from South Africa have any capacity (or access to capacity) to diagnose MDR-TB and XDR-TB. In response to the need to increase the availability of quality-assured culture and DST services including secondline DST, the supranational reference laboratory network (SRLN) is being expanded. Currently, there are 26 SRLs: two in the African Region, ve in the Region of the Americas, 11 in the European Region, one in the Eastern Mediterranean Region, two in the South-East Asian Region and ve in the Western Pacic Region (FIGURE 2.3). All regions have plans to expand these networks, and in some regions a formalized evaluation and accreditation process is being developed. Notwithstanding the expansion of the SRLN, the general shortage of laboratory capacity to provide culture and DST based on conventional technologies demonstrates the need for rapid introduction of new diagnostic tools. In order to facilitate the development of policy to guide the implementation of new diagnostic tools, WHO has established a structured process for evaluating and translating research ndings into policy and practice (the latest WHO policy on TB diagnosis is summarized in BOX 2.1).1 Such policy guidance needs
1
BOX 2.1
Recent WHO policy changes in diagnosis of TB

1. WHO policy on smear microscopy and case detection With the prerequisite of a functional external microscopy quality assurance (EQA) system, with blinded rechecking, the new denition of a smear-positive TB case is a patient with one or more initial sputum smear examinations positive for acid fast bacilli (AFB). Further information including evidence for this policy can be found at: http:// www.who.int/tb/dots/laboratory/policy/en/index1.html 2. WHO policy on the use of liquid medium for culture and drug susceptibility testing (DST) in middle-income and low-income countries WHO recommends the use of commercial liquid systems (the standard of care for TB diagnosis and patient management in developed countries) for culture and DST in middle-income and low-income countries, within the context of national laboratory strengthening plans and using a phased approach to implementation at the country level. Further information including prerequisites for the phased introduction of this technology can be found at: http://www.who.int/tb/dots/ laboratory/policy/en/index3.html 3. WHO policy on the use of molecular line probe assays WHO recommends the use of molecular line probe assays for the rapid detection of MDR-TB cases, within the context of national laboratory strengthening plans and using a phased approach to implementation at the country level. Further information including prerequisites for the phased introduction of this technology can be found at: http:// www.who.int/tb/publications/2008/who_htm_tb_2008_392.pdf 4. WHO policy recommendations on DST of second-line anti-TB drugs An Expert Group convened by WHO in 2007 reviewed current evidence and re-conrmed that the laboratory diagnosis of MDR-TB and XDR-TB under good laboratory practice is reliable and reproducible. In addition, this consultative process culminated in an interim policy guidance document summarizing available evidence on the secondline DST methods, and providing recommendations for which drugs to test as well as the critical concentrations. The document also provides programmatic advice on designing diagnostic algorithms, required laboratory capacity and safety requirements. The Expert Group also developed a detailed outline for the update of the 2001 technical guidelines for DST of second-line drugs, incorporating the newer technologies. A writing committee was established with the aim of releasing the updated guidelines by the middle of 2009. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs can be found at: http://www.who.int/tb/publications/2008/who_ htm_tb_2008_392.pdf
Moving research ndings into new WHO policies. Geneva, World Health Organization, 2008 (available at http://www.who.int/tb/dots/laboratory/policy/en/index4.html; accessed January 2009).
FIGURE 2.3 Tuberculosis supranational reference laboratory network, 2007
Supranational reference laboratory
BOX 2.2
The Global Laboratory Initiative (GLI)

The GLI is part of the Stop TB Partnership, with a secretariat housed in WHO. Its major objectives include providing global standards for laboratory services, promoting quality assurance and adequate laboratory biosafety, accelerating human resource development for laboratory activities, and facilitating partnerships that will enable the establishment or expansion of laboratory services capable of absorbing new technologies. A current example is a GLI project that aims to accelerate access to new diagnostic tools for MDR-TB that have recently been endorsed by WHO. The project is being implemented in 16 of the high MDR-TB burden countries (for denition of these countries see TABLE 2.10 ), in close collaboration with the Foundation for Innovative New Diagnostics and the Global Drug Facility, with funding from UNITAID.
to be followed by implementation (a process referred to as retooling; see also SECTION 2.7).1 Most regions have introduced one or more new tools (for example, liquid culture and DST, endorsed by WHO in 2007; and molecular line probe assays, endorsed by WHO in 2008). Ongoing monitoring will be used to assess the uptake of these tools and their impact on diagnosis and treatment outcomes. In most resource-constrained countries, uptake of new tools requires considerable strengthening of laboratory infrastructure, deployment of additional human resources and funding for the purchase of new technologies. To help to address these challenges, the Global Laboratory Initiative (GLI) was established in 2007 (BOX 2.2).
2.2.4 Standardized treatment with supervision, and patient support

In 2007, all of the 146 countries reporting data, including all HBCs, provided treatment with standardized short-course chemotherapy (SCC). There were 105 countries using the six-month Category I regimen and 23 countries using an eight-month regimen that does not include rifampicin in the continuation phase of treatment. The remaining 18 countries did not specify the regimen that was being used. Of the HBCs, four use an eight-month regimen (Ethiopia, Nigeria, Pakistan and Uganda), of which two (Pakistan and Nigeria) plan to switch to the six-month regimen in 2009. Of the 35
1
Moving research ndings into new WHO policies. Geneva, World Health Organization, 2008 (available at http://www.who.int/tb/dots/laboratory/policy/en/index4.html; accessed January 2009).
countries that reported using regimens based on intermittent treatment, 18 use thrice-weekly treatment in the continuation phase only, ve use a thrice-weekly regimen throughout treatment and ve use a twice-weekly regimen in the continuation phase; seven countries did not state what kind of intermittent regimen was used. Fixed-dose combinations (FDCs) of two, three or four drugs were being used by 75 countries during the two-month intensive phase of treatment, while 61 countries were using two-drug FDCs in the continuation phase of treatment. Among 167 reporting countries, 79 (including 13 HBCs) purchased paediatric formulations of anti-TB drugs. Health-care workers are the main providers of directly observed therapy (DOT) during the initial phase of treatment in 86% (150/174) of reporting countries, with a community or family member being the main provider in the remaining countries. In 63% (109/173) of reporting countries, healthcare workers are also the main providers of DOT in the continuation phase of treatment. Among HBCs, DOT was provided in some units and/or for some patients only in Thailand, for some patients in all units in Myanmar, and for some units only in Uganda and Zimbabwe. In almost all reporting countries (90%, 166/180), including all HBCs, anti-TB drugs are provided free of charge to all patients being treated with the Category I regimen under DOTS. Patient support to encourage adherence to treatment was reported mainly by countries in the European Region; examples included incentives and enablers such as food parcels and tickets for public transport, and provision of psychological counselling.
BOX 2.3
Providing technical assistance for TB control: the role of TBTEAM

The TB Technical Assistance Mechanism, known as TBTEAM, was established by the Stop TB Partnership in 2007. TBTEAM is designed to facilitate access to high-quality, well-coordinated technical assistance, which is widely recognized as being needed to fully implement the Stop TB Strategy and the Global Plan. TBTEAM has developed a roster of experts, tools for tracking missions and training opportunities around the world, as well as a directory of technical partners. Requests for technical assistance can be sent to the TBTEAM secretariat based in WHO headquarters, either directly or via channels such as WHO country ofces and TBTEAM focal points at regional and country levels. By the end of 2008, 839 missions and events had been recorded in the TBTEAM database, and 60 of the 81 requests for technical assistance had been responded to successfully. TBTEAM has also provided nancial support for 140 country missions. A recent external assessment of TBTEAM acknowledged the service provided by TBTEAM to countries in need of technical assistance as well as its efforts to provide funding for such assistance. This assessment has also provided guidance related to the future direction of TBTEAM, including how to best engage all partners. A plan to implement the recommendations of the external assessment is being developed following broad agreement with these recommendations during a meeting of TBTEAM partners in October 2008. Further details about TBTEAM are available at: http://www.stoptb. org/wg/tbteam
2.2.5 Drug supply and management system

Most countries (82%, 142/174) reported an uninterrupted supply of rst-line TB drugs at the central level; the gure was similar (80%, 141/176) for the peripheral level ( TABLE 2.5). Stock-outs at both central and peripheral levels were most frequent in the African Region, and included stock-outs at the peripheral level in six of the regions nine HBCs. Notably, no stock-outs were reported by countries in the South-East Asia Region. The continuing occurrence of stock-outs demonstrates the need for better planning of procurement, monitoring of drug supplies and distribution capacity. More timely ordering of drugs by principal recipients of Global Fund grants and closer coordination between principal recipients and NTPs would also help in some countries. Fewer countries reported data about the availability of second-line anti-TB drugs. Shortages at the central level occurred in 15% of reporting countries (25/168); the gure at peripheral level was slightly lower (11%, 18/162). Shortages occurred mostly in the Region of the Americas (seven countries), the African Region (ve countries) and the European Region (seven countries). Among HBCs, only the Democratic Republic of the Congo reported shortages of second-line drugs. At the global level, the Stop TB Partnerships Global Drug Facility (GDF) and Green Light Committee (GLC) are contrib-
uting to strengthened drug supply and drug management systems.1 By the end of 2008, the GDF had provided rstline anti-TB drugs to 89 countries and the GLC has approved the use of second-line drugs in 134 projects in 60 countries (see also SECTION 2.3.2). Funding from UNITAID is also allowing the development of stockpiles of anti-TB drugs and the establishment of a strategic revolving fund to provide lines of credit for the purchase of second-line drugs. Grants from UNITAID have already supported the supply of qualityassured paediatric formulations to more than 50 countries. Additional rst-line anti-TB drugs were prequalied by WHO in 2008, and more dossiers for prequalication were submitted for second-line drugs and paediatric formulations of rstline drugs. Besides supplying drugs, the GDF has also given priority to building capacity in drug procurement and management, for example through country missions and workshops. With the expansion of the TB Technical Assistance Mechanism known as TBTEAM (BOX 2.3), it is anticipated that technical assistance for drug management as well as many other components of TB control will be increased.
2.2.6 Monitoring and evaluation

Routine monitoring of TB control is crucial to understand trends in the TB epidemic and progress in TB control. Col-
Information about the work of the GDF, the GLC and UNITAID was provided by their secretariats rather than through the annual data collection form.
TABLE 2.7 TB data management and recording and reporting systems, 2007
DATA FOR INDIVIDUAL TB PATIENTS ACCESSIBLE AT NTP CENTRAL OFFICE TB DATA STORED IN A RELATIONAL DATABASE MANAGEMENT SYSTEMa TB DATA FROM ALL THE BASIC MANAGEMENT UNITS RECEIVED BY CENTRAL NTP OFFICE CASE-FINDING, 2007 TREATMENT OUTCOMES, 2006 NTP PRODUCES ANNUAL REPORT
STAND-ALONE
WEB-BASED
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
N Y N N N N N N N N Y N Y Y N N N N N Y N 5/21 9/37 23/38 13/22 40/43 2/11 28/33 115/184
N N N Y N N N Y N Y N N N N Y Y 5/21 10/37 7/38 10/22 19/42 4/11 12/31 62/181
N Y N N Y N Y N N N Y N N N N 4/21 2/37 4/38 4/22 8/42 0/11 5/31 23/181
Y Y N Y Y Y Y Y Y Y Y N N N Y N Y Y 13/19 22/35 20/31 17/22 29/35 7/11 21/28 116/162
Y Y N Y Y Y Y N Y Y Y N N N Y N Y Y 12/19 22/33 20/30 16/22 27/35 7/11 21/28 113/159
Y Y Y Y N Y Y Y Y N Y Y N Y Y Y Y Y Y Y Y 18/21 29/37 24/38 18/22 27/41 9/11 20/31 127/180
High-burden countriesb AFR (46)c AMR (44) EMR (22) EUR (53) SEAR (11) WPR (36) Global (212)
Indicates information not provided or not applicable. A relational database management system (RDBMS) is an application or system that allows users to store and easily access a large amount of data. It is usually accessible to several people at the same time and allows users to enter/upload and edit/update the data. It also allows users to produce standard and/or customized analyses and reports. In the lower part of the table the numerator of each fraction is the number of countries providing an afrmative answer (i.e. yes); the denominator is the number of countries providing information. The number of countries in each region is shown in parentheses.
lection of data on key indicators allows documentation of achievements, identication of challenges, better estimation of the epidemiological burden of TB and informed planning. Monitoring is most informative when there are clear targets or benchmarks of good performance for the indicators on which data are collected, when data management practices ensure that data are complete, accurate and reported on time, when data are analysed using appropriate methods and when data are used to inform the design and implementation of interventions to control TB. In 2007, 63% (115/184) of NTPs had access to data for individual patients (as opposed to aggregated data for cohorts of patients) at the central ofce ( TABLE 2.7). This included ve HBCs (Brazil, Cambodia, China, the Russian Federation and the United Republic of Tanzania), and a particularly high proportion of countries in the European and
Western Pacic regions (93% and 85% of reporting countries, respectively). In the remaining countries, data at the central ofce were received from lower administrative levels in an aggregated format. Among these countries, around 20% could not conrm whether or not data about case notications and treatment outcomes had been reported by all management units (for example, all districts). About 30% of the remaining countries with aggregated data reported that some data were missing. This highlights the need for greater efforts to ensure complete reporting of data, and for better monitoring of the completeness of reporting at the central level (see also SECTION 1.3 in CHAPTER 1). Many countries produce an annual report, including 71% of the 180 reporting countries and almost all countries in the Eastern Mediterranean and South-East Asia regions (TABLE 2.7).
The optimum system for managing data is a relational database management system (RDBMS). This allows a large amount of data to be entered or uploaded, validated, stored, edited and updated, with access by multiple users. It also allows the production of standard and customized analyses and reports. To date, however, the use of such systems is relatively limited. Less than 50% of countries have an RDBMS, with around one quarter of these being web-based systems (including four HBCs Brazil, China, Pakistan and South Africa). Some of these systems were customized for a particular country.1 Other countries use spreadsheet-based systems (e.g. Excel) to hold and analyse their data. Management and analysis of data is much more difcult as well as time-consuming in such systems, and as a result data can be lost or errors introduced. More countries need to introduce an RDBMS to improve data quality and to facilitate management, analysis, presentation and use of data. Existing options include OpenMRS (Open Medical Records System), DHIS (District Health Information System) or ENRS (Electronic National Record System), which are all open-access and generic software.2 While generic, these systems can be adapted to the needs of particular countries and are supported by a global community of developers and implementers. A recent example of the successful introduction of an open-source RDBMS is provided in BOX 2.4. Besides routine recording and reporting of data, evaluation of trends in incidence, prevalence and mortality (impact measurement) requires in-depth analysis of surveillance data (case notications and mortality data from vital registration systems) and programmatic data, combined with periodic surveys of the prevalence of TB disease in some countries. The latest WHO estimates of trends in incidence, prevalence and mortality, recent recommendations about how impact measurement should be done and the latest data on progress at country level are provided in CHAPTER 1.
BOX 2.4
Introducing District Health Information Software (DHIS) in Myanmar

DHIS is a exible, open-source (free-of-charge) software that was developed in 1994 to facilitate collection, transmission, storage, analysis, presentation and use of the health information systems programme (HISP; www.hisp.org). It was piloted in several countries in Africa and Asia including Ethiopia, India, Malawi, Mozambique, Nigeria, Myanmar, South Africa, the United Republic of Tanzania and Viet Nam. Given the dynamic nature of data management, the software is designed to be exible and can be adapted to changing needs at local and national levels. The NTP in Myanmar had long recognized the value of an electronic recording and reporting system, but it had proved difcult to identify a suitable solution. In 2007, following discussions between the NTP and WHO staff, it was agreed to explore the option of DHIS. With the assistance of consultants who are part of a network of developers, DHIS was customized for use in Myanmar, and staff at central and state or divisional levels were trained. The system was then tested for six months, during which programming bugs were identied and removed. In early 2008, 32 staff from the central unit of the NTP, all state or divisional TB ofcers and all statistical clerks were trained. The 14 (out of 17) states and divisions that implement NTP services were equipped with a computer. The DHIS was installed in June and July 2008, with on-the-job training provided by staff from WHO. The system was tested in the last six months of 2008 by all the states and divisions, and remaining programming bugs were resolved by consultants. Further supervisory visits and refresher training courses are planned for 2009. DHIS has already reduced the workload associated with data management and analysis. The experience of Myanmar shows that when there is strong commitment from the NTP, sufcient funding, external expertise and appropriate training, the DHIS can be successfully adapted and implemented to manage TB data in a high-burden country. The exibility of the software allows for rapid and low-cost customization (instead of development from scratch). The DHIS could be relevant in many other countries.
2.3 Address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations
2.3.1 Collaborative TB/HIV activities
Globally, the latest data suggests that there were 1.4 million new HIV-positive TB cases in 2007 (out of a total of 9.3 million incident cases of TB). This estimate is much higher than gures previously published by WHO in this series of annual reports. In this context, it is important to highlight that the estimated total number of incident TB cases (HIV-positive and HIV-negative combined) has changed only slightly. The reason for the much higher estimated number of HIV-positive TB cases is that the proportion of incident cases of TB who are estimated to be infected with HIV has been revised upwards, based on much more extensive data about HIV prevalence in TB patients. These data became available mostly in 2008 following the rapid expansion of routine HIV testing since 20052006, notably in African countries (as documented below). Further details about these new estimates, and the
methods used to produce them, are provided in CHAPTER 1 and ANNEX 2 respectively. The African Region accounts for 79% of estimated HIV-positive TB cases; most of the remaining cases are in the South-East Asia Region (TABLE 2.8). Collaborative TB/HIV activities are essential to ensure that HIV-positive TB patients are identied and treated appropriately, and to prevent TB in HIV-positive people.3 These activities include establishing mechanisms for collaboration between TB and HIV programmes (coordinating bodies, joint TB/HIV planning, monitoring and evaluation, HIV surveillance); infection control in health-care and congregate settings; HIV testing of TB patients and, for those TB patients infected with HIV, co-trimoxazole preventive therapy (CPT)
1 2
http://www.who.int/tb/err/catalogue See: http://openmrs.org, DHIS (www.hisp.org) or ENRS (www.emro.who. int/stb/enrs.htm). Interim policy on collaborative TB/HIV activities. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.330; WHO/HTM/ HIV/2004.1).
TABLE 2.8 HIV testing and treatment in TB patients, by WHO region, 2007
NUMBER OF TB PATIENTS WITH KNOWN HIV STATUS (THOUSANDS) % OF NOTIFIED TB PATIENTS TESTED FOR HIV % OF TESTED TB PATIENTS HIV-POSITIVE % OF ESTIMATED HIV-POSITIVE TB CASESa IDENTIFIED BY TESTING % OF IDENTIFIED HIV-POSITIVE TB PATIENTS STARTED ON CPT % OF IDENTIFIED HIV-POSITIVE TB PATIENTS STARTED ON ART REGIONAL DISTRIBUTION OF ESTIMATED HIV-POSITIVE TB CASES
AFR AMR EMR EUR SEAR WPR Global

a
492 114 4.2 169 122 95 996
37 49 1.1 35 5.5 6.6 16
51 13 12 2.5 15 7.0 30
23 44 2.3 16 12 13 22
66 36 35 52 37 45 63
33 77 65 16 17 28 34
79 2.4 1.5 3.1 11 3.7 100
Includes estimated HIV-positive TB cases in countries which did not provide information on testing.
FIGURE 2.4 Mechanisms for collaboration and national policies for collaborative TB/HIV activities, 63 priority countries, 20062007. Numbers under bars show the percentage of total estimated HIV-positive TB cases accounted for by reporting countries.
60 44 44 46 49 52 49 52 47 52 44 34 52 2006 2007
Number of countries
42 40
42
43
26 20
29
31
Coordinating body (70%)
Joint NTP and NAP plan (94%)
HIV surveillance among TB patients (88%)
HIV counselling and testing of TB patients (96%)
CPT for HIV-positive ART for HIV-positive Intensified TB case TB patients TB patients finding among (95%) (96%) HIV-positive people (96%)
Isoniazid preventive therapy (70%)
Infection control (67%)
FIGURE 2.5 HIV testing for TB patients, all countries, 20022007. Number (bars) and percentage (line) of notied new and re-treatment TB cases for which the HIV status of the patient was recorded in the TB register. The numbers under each bar show the number of countries reporting data, followed by the percentage of total estimated HIV-positive TB cases accounted for by reporting countries.
1200 16% Number of TB patients with known HIV status (thousands) 1000 800 8.5% 600 8 400 200 0 4.2% 0.5% 2002 2003 2004 2005 2006 2007 (9, 30%) (92, 46%) (84, 51%) (118, 79%) (131, 88%) (135, 96%) 3.2% 6 4 2 0 12 10 Percentage of TB cases 12% 14 18 16
and antiretroviral therapy (ART); and intensied TB casending among people living with HIV followed by isoniazid preventive therapy (IPT) for those without active TB.
Mechanisms for collaboration and policy development

Among 63 countries that have been identied as priorities for the implementation of collaborative TB/HIV interventions at global level1 and which collectively account for 97% of estimated HIV-positive cases worldwide, approximately two-thirds had established coordinating bodies, developed a joint TB/HIV plan and were undertaking HIV surveillance by 2007 (FIGURE 2.4). Around 50 of these 63 countries had policies for HIV counselling and testing among TB patients, as well as for the provision of CPT and ART to those coinfected with HIV. A relatively high number of countries (n=52) also had policies for intensied case-nding among HIV-positive people. In contrast, a smaller number of countries had policies related to IPT (29 countries) and infection control (34 countries). While there was variation in the extent to which mechanisms for collaboration or policies were in place in 2007, there was generally an improvement compared with 2006 (the exceptions were joint TB/HIV planning and provision of CPT). When all countries that reported data are con1
Refers to 41 countries that were identied as priorities at global level in 2002 and that account for 97% of estimated HIV-positive TB cases globally, plus 22 additional countries that UNAIDS has dened as having a generalized HIV epidemic. See ANNEX 2 for a list of the 63 countries.
FIGURE 2.6 HIV testing for TB patients, 2007
Percentage of notified TB cases with known HIV status 014 1549 5074 75 No data
sidered, the number of countries with policies is much higher, but the fraction of the global number of HIV-positive TB cases covered is almost the same (data not shown).
HIV testing of TB patients

The provision of HIV testing for TB patients is a critical entry point to interventions for both treatment and prevention. There was a substantial increase in the number of TB patients with known HIV status between 2002 and 2007, from 21 806 patients across nine countries in 2002 (less than 1% of notied TB cases) to 1.0 million patients across 135 countries in 2007 equivalent to 16% of notied TB cases (FIGURE 2.5). In the African Region, the HIV status of 491 755 TB patients was known in 2007; this represented 37% of all notied cases, up from 22% in 2006 ( TABLE 2.8). These aggregated gures conceal considerable variation in testing rates among countries (FIGURE 2.6). Among countries with a high prevalence of HIV among TB patients, Kenya, Malawi, Lesotho, Rwanda and Swaziland stand out as having the highest testing rates in 2007. Globally, there were 65 countries (14 in the African Region) where the HIV status of more than 50% of notied TB cases was known; these countries include 23 of the 63 countries that have been dened as high TB/HIV burden countries, and collectively account for 23% of the estimated total number of HIVpositive TB cases.1 This progress in knowledge of HIV status of TB patients is impressive, although the high variability in current testing rates also shows that there is much further scope for improvement.
This increase in numbers of TB patients with known HIV status may be explained in part by the increase in the number of countries reporting data and the share of the global number of HIV-positive TB cases accounted for by reporting countries (see numbers and percentages below the bars of FIGURE 2.5). Clearer evidence that the provision of HIV testing has increased since 2004 is presented in FIGURE 2.7. This shows the number of TB patients with known HIV status in 60 countries that reported data for all four years 2004 2007. The number of TB patients with known HIV status in 11 African countries representing 48% of estimated HIVpositive TB cases globally (and 61% of cases in the African Region, data not shown) increased almost seven times in four years, while the percentage of all notied cases with known status increased from 7.6% to 48%. Outside the African Region, the number of patients with known HIV status also increased, but by a much smaller amount in absolute terms. Across all reporting countries (n=119), a total of 296 995 HIV-positive TB patients were identied. These detected patients represent 22% of the estimated number of incident HIV-positive TB cases in 2007, although there was considerable variation among regions (TABLE 2.8).
The total of 65 countries is higher than the total of 49 countries for which direct measurements of HIV prevalence in TB patients were used to estimate the global total of HIV-positive TB cases. For the additional 15 countries (which are mostly islands with small populations), estimates of HIV in the general population are not available and these countries are not included in global estimates of HIV-positive cases.
FIGURE 2.7 HIV testing in the 60 countries that reported data for each year 20042007. The number above each bar shows the percentage of notied TB cases that were tested for HIV.
400 Number of TB patients with known HIV status (thousands) 11 African countries (48% of global estimated HIV-positive TB cases in 2007) 49 non-African countries (1.9% of global estimated HIV-positive TB cases in 2007) 48
Provision of CPT and ART to HIV-positive TB patients

A major reason for promoting HIV testing in TB patients is to facilitate provision of CPT and ART to HIV-positive patients. The number of HIV-positive TB patients treated with CPT has steadily increased in absolute terms, reaching almost 200 000 in 2007. However, this has been accompanied by a fall in the percentage of TB patients in whom HIV is diagnosed who are treated with CPT, to 63% in 2007 (FIGURE 2.8). A similar pattern exists for ART. The total number of HIV-positive patients enrolled on ART has grown steadily, reaching around 90 000 patients in 2007, but the proportion of diagnosed HIV-positive patients started on treatment fell to 34%. In the African Region specically, the proportion of patients in whom HIV infection was diagnosed and who were started on CPT reached 66% in 2007; the gure for ART was 33% ( TABLE 2.8). These gures for CPT and ART show that the provision of treatment interventions is not keeping pace with the increase in HIV testing. For ART, a possible explanation is the disparity between the number of health facilities offering TB treatment as well as HIV testing and counselling, and the number of facilities where ART is provided (BOX 2.5).
300
34
200 19 100 7.6 0 2004 2005 2006 2007 41 31
45
52
FIGURE 2.8 Co-trimoxazole preventive therapy for HIV-positive TB patients, 20022007. The numbers under each bar show the number of countries reporting data, followed by the percentage of total estimated HIV-positive TB cases accounted for by reporting countries.
Percentage of identified HIV-positive TB patients started on CPT 250 Number of TB patients (thousands) 96% 200 83% 77% 150 77% 63% 60 100 50% 40 20 0 80 120 100
Intensied TB case-nding and provision of IPT among HIV-positive people

Screening for TB among HIV-positive people attending HIV care services was provided to 0.6 million people in 2007, up from 0.2 million in 2005 (FIGURE 2.10 ). This is a small fraction (2.2%) of the 33 million people estimated to be living with HIV. Of those in HIV care, almost 0.2 million were found to have TB, equivalent to 14% of the estimated 1.4 million incident HIV-positive TB cases globally. This high proportion suggests that if screening for TB increased beyond its currently low levels, TB case-nding would improve. Provision of IPT continues to be extremely limited (FIGURE 2.10 ). Globally, less than 30 000 people were reported to have been started on IPT in 2007 equivalent to just 0.1% of the 33 million people estimated to be infected with HIV. The low number of people being treated with IPT is inconsistent with the policies that have been established. While 100 countries reported the existence of an IPT policy, only 29 reported any provision of IPT in 2007 (although this was an increase from 26 countries in 2006).
50
2002 (5, 27%)
2003 2004 2005 2006 2007 (27, 31%) (25, 29%) (39, 51%) (55, 64%) (60, 88%)
FIGURE 2.9 Antiretroviral therapy for HIV-positive TB patients, 20032007. The numbers under each bar show the number of countries reporting data, followed by the percentage of total estimated HIV-positive TB cases accounted for by reporting countries.
70% Number of TB patients (thousands) 80 52% 60 35% 40 20 20 40% 34% 40 Percentage of identified HIV-positiveTB patients started on ART 100 80
60
2003 (47, 10%)
2004 (25, 27%)
2005 (47, 55%)
2006 (69, 65%)
2007 (73, 73%)
Progress against Global Plan targets

The Global Plan details the progress required to implement collaborative TB/HIV activities for each year 20062015 within the framework of the goal of universal access to ART by 2010. The milestones or targets included for each year in the Global Plan provide a benchmark against which progress in practice can be assessed. A comparison of Global Plan expectations with implementation reported by countries in 2007 is shown in TABLE 2.9, for all regions combined and for the African Region. Among the 171 countries considered in the Global Plan, the absolute number of patients tested for HIV reached about half of the target in the Global Plan
BOX 2.5
Providing antiretroviral therapy (ART) to HIV-positive TB patients: access barriers limit progress
Data from eight countries (that account for 18% of the estimated global burden of HIV-positive TB cases) show that TB patients have poorer access to ART than to HIV testing. This may be a limiting factor in scaling up the provision of ART to HIV-positive TB patients and may result in unnecessary deaths. The percentage of estimated HIV-positive TB cases identied by the NTPs of these eight countries increased substantially during 20052007, from 9% to 22%. This matched an increase in the proportion of notied TB cases with known HIV status, which rose from 8% to 23% (FIGURE). However, the number of patients placed on ART did not increase at the same pace. Compared with 2005, an additional 30 392 HIV-positive TB cases were identied in 2007 in the eight countries providing data, but only an additional 8261 patients were started on ART. This meant that an increasing number of diagnosed HIV-positive TB patients were not receiving ART. In 2007, there was at least one HIV testing facility for every two health-care facilities where anti-TB treatment was available ( TABLE). However, each ART facility was shared by ve TB treatment facilities. HIV treatment services need to be decentralized and combined with TB services to improve access to ART for HIV-positive TB patients. The provision of CPT is better. The proportion of diagnosed HIV-positive TB patients receiving CPT increased from 58% in 2005 to 65% in 2007, and CPT was provided to 15% of all estimated HIV-positive TB patients. Although data on the number of facilities providing CPT are not available, it is likely that CPT is more often available at TB clinics than ART. HIV testing for TB patients, and provision of ART and CPT to HIV-positive TB patients, 8 countries,a 20052007. The numbers beside each point on the red line show the percentage of notied TB cases with known HIV status. The numbers on the other three lines show the percentage of total estimated HIV-positive TB cases accounted for by the patients detected and treated.
120 100 80 60 40 8% 12% 9% 20 5% 0 2% 2005
a
Provision of TB treatment, HIV testing and counselling, and ART, 8 countries,a 2007
NUMBER OF FACILITIES PROVIDING TB TREATMENT NUMBER OF FACILITIES PROVIDING HIV TESTING AND COUNSELLINGb NUMBER OF FACILITIES PROVIDING ART b
23%
TB patients with known HIV status
10%
Detected HIV-positive 22% TB patients 15% HIV-positive TB patients on CPT 6% HIV-positive TB patients on ART 2007
8% 3%
Burkina Faso DR Congo Ethiopia Malawi Myanmar Rwanda Uganda UR Tanzania Total
a
462 1 205 833 551 324 450 1 261 2 500 7 586
454 286 1 005 504 291 312 554 1 035 4 441
76 209 272 163 32 165 286 204 1 407
Number of patients (thousands)
2006
Data shown are for the following 8 countries, which provided complete data for the years 20052007: Burkina Faso, DR Congo, Ethiopia, Malawi, Myanmar, Rwanda, Uganda and UR Tanzania.
For comparison, this table shows the 8 countries included in the gure. Source: Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2008. Geneva, World Health Organization, 2008.
FIGURE 2.10 Intensied TB case-nding and IPT provision among HIV-positive people, 2007. Numbers above bars show the proportion of estimated HIV-positive people screened for TB (graph a) and the proportion of HIV-positive people without TB started on IPT (graph b). Numbers under bars show the number of countries reporting data followed by the percentage of total estimated HIV-positive people (graph a) and HIV-positive people without active TB (graph b) accounted for by reporting countries.
(a)
800 Number of HIV-positive people screened for TB (thousands) 2.2 600 Number of HIV-positive people without active TB started on IPT (thousands) 30 29 28 27 26 25 24 2005 (10, 24%) 2006 (25, 28%) 2007 (42, 46%) 0.09 0.09 0.1
(b)
400 0.61
0.98
200
0 2005 (14, 36%) 2006 (44, 50%) 2007 (71, 54%)
TABLE 2.9 Collaborative TB/HIV activities, 2007: country reports compared with expectations given in the Global Plan
GLOBAL COUNTRY REPORTS AND LATEST ESTIMATES a AFRICA COUNTRY REPORTS AND LATEST ESTIMATES
GLOBAL PLAN
GLOBAL PLAN
(MILLIONS OR PERCENTAGES)
(MILLIONS OR PERCENTAGES)
HIV-testing for TB patients, provision of CPT and ART Number of TB patients tested for HIV Total number of notied TB cases including new, re-treatment and other cases Proportion of all notied TB cases that were tested for HIV Number of diagnosed HIV-positive TB cases enrolled on CPT Number of diagnosed HIV-positive TB cases Proportion of all HIV-positive TB cases enrolled on CPT Number of diagnosed HIV-positive TB cases enrolled on ART Number of diagnosed HIV-positive TB cases eligible for ART Proportion of all HIV-positive TB cases enrolled on ART Intensied TB case-nding and IPT for people with HIV Number of HIV-positive people attending HIV services screened for TB Number of HIV-positive people attending HIV services Proportion of HIV-positive people attending HIV services screened for TB Number of eligible HIV-positive people offered IPT Estimated number of HIV-positive people eligible for IPT Proportion of estimated number of HIV-positive people eligible for IPT who received IPT
a
0.9b 3.7c 27% c,d 0.2 0.3 72% e 0.1 0.3 34% f 0.6 3.5 27% g 0.03h 26 0.2% i
2.0 3.5 56% 0.6 1.1 53% 0.3 0.5 53% 14 19 72% 1.5 31 4.8%
0.5b 1.3c 39% c,d 0.2 0.3 76% e 0.1 0.3 33% f 0.3 2.7 21% g 0.02h 20 0.1% i
0.9 1.6 58% 0.5 0.9 56% 0.3 0.4 58% 13 17 76% 1.4 27 5.0%
c d e f g h
Includes only those countries in the Global Plan, i.e. countries in sub-regions Central Europe and Established Market Economies are excluded here. Includes patients reported from DOTS and non-DOTS areas. Maximum number included for each country is the number of notied cases multiplied by the population coverage of collaborative TB/HIV activities anticipated by the Global Plan. Numbers of notied TB cases are weighted according to the population coverage of collaborative TB/HIV activities anticipated by the Global Plan. Only the 116 countries (33 in Africa) that provided both numerator and denominator are included in this percentage. Only the 58 countries (27 in Africa) that provided both numerator and denominator are included in this percentage. Only the 66 countries (22 in Africa) that provided both numerator and denominator are included in this percentage. Only the 62 countries (11 in Africa) that provided both numerator and denominator are included in this percentage. While the Global Plan includes only people newly diagnosed with HIV in this indicator, country reports include all HIV-positive people eligible for IPT, regardless of year of diagnosis. Only the 32 countries (8 in Africa) that provided the numerator are included in the denominator of this percentage.
FIGURE 2.11 Antiretroviral therapy for HIV-positive TB patients: country reports compared with the Global Plan, 20062009. Data from country reports are notied cases (20062007) and projections (20082009). The numbers under each bar represent the number of countries reporting data, followed by the percentage of total estimated HIV-positive TB cases accounted for by reporting countries.
400 Global Plan Number of TB patients (thousands) Country report 300
200
100
2006 (54, 65%)
2007 (61, 73%)
2008 (66, 77%)
2009 (53, 49%)
in 2007, and provision of CPT and of ART both reached about one-third of the Global Plan targets. In terms of the percentage of TB cases found to be HIV-positive and who were enrolled on CPT, the comparison is much more favourable: for the world as a whole, 72% of TB cases in whom HIV infection was diagnosed were started on CPT in 2007 based on country reports, compared with the target of 53% for 2007 in the Global Plan. For ART, the gures were 34% and 53%, respectively. Findings were similar for the African Region specically. The differences between the absolute numbers of people receiving CPT and ART in the Global Plan and country reports are mostly attributable to the shortfall in HIV testing. For patients to be treated with either CPT or ART, they must rst be tested for and diagnosed with HIV. Among those found to be HIV-positive, lack of access to ART at local health facilities may also be a factor in the low uptake of ART (BOX 2.5). For ART specically among TB/HIV interventions, countries were requested to provide projections of the number of HIV-positive patients who would be started on ART in 2008 and 2009, as well as gures for the actual provision of ART in 2007. These data are compared with the Global Plan targets
TABLE 2.10 Number of MDR-TB cases estimated, notied and expected to be treated, 27 high MDR-TB burden countries and WHO regions
ESTIMATED CASES, 2007 % OF ALL TB CASES WITH MDR-TB NUMBER OF MDR-TB CASES NUMBER OF SS+ MDR-TB CASES NUMBER OF MDR-TB CASES, 2007 NOTIFIED % OF ESTIMATED SS+ MDR-TB CASES NOTIFIED, 2007 EXPECTED NUMBER OF MDR-TB CASES TO BE TREATED
2008
2009
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
India China Russian Federation South Africa Bangladesh Pakistan Indonesia Philippines Nigeria Kazakhstan Ukraine Uzbekistan DR Congo Viet Nam Ethiopia Tajikistan Myanmar Azerbaijan Republic of Moldova Kyrgyzstan Belarus Georgia Armenia Lithuania Bulgaria Latvia Estonia
5.4 7.5 21 2.8 4.0 4.3 2.3 4.6 2.4 32 19 24 2.8 4.0 1.9 23 4.7 36 29 17 16 13 17 17 12 14 20 5.7 2.4 3.2 3.8 17 4.8 6.3 4.9
130 526 112 348 42 969 15 914 14 506 13 218 12 209 12 125 11 700 11 102 9 835 9 450 7 336 6 468 5 979 4 688 4 181 3 916 2 231 1 290 1 101 728 486 464 371 202 123 435 470 75 657 10 214 23 049 92 554 173 660 135 411 510 545
99 639 76 154 31 397 10 708 7 694 7 939 6 427 6 451 6 934 9 540 5 568 6 936 4 137 4 199 3 086 3 286 2 331 3 109 1 656 813 758 590 373 339 217 129 85 300 496 45 029 7 261 14 120 67 440 124 826 89 926 348 602
146 79 5 297 7 350 568 45 5568 484 82 145 600 196 896 322 870 269 125 314 82 98 80 23 616 8 841 2 522 487 16 062 918 948 29 778
0.1 0.1 17 69 8.8 0.6 58 7.0 2.0 4.7 26 6.3 54 40 115 46 33 93 38 76 94 7.9 20 35 3.4 24 0.7 1.1 8.5
450 388 4 221 5 252 150 250 100 620 500 1 562 334 523 100 45 125 20 466 280 50 120 120 15 676 9 337 3 670 966 8 414 1 496 1 572 25 455
900 9 897 250 250 1 000 4 266 720 756 200 150 490 540 50 120 100 19 689 4 070 4 046 707 17 457 1 724 1 573 29 577
High MDR-TB burden countries AFR AMR EMR EUR SEAR WPR Global
Indicates information not provided.
for ART in FIGURE 2.11. Among reporting countries, anticipated progress is encouraging, with projected numbers close to or above the Global Plan targets (note that the lower projection of patients to be treated in absolute terms in 2009 compared with 2008 is due to fewer countries reporting data for 2009). Intensied case-nding and provision of IPT is far from Global Plan targets ( TABLE 2.9). The target for 2007 was to screen 14 million HIV-positive people for TB; the actual gure reported was 0.6 million. Overall, implementation of TB/HIV interventions falls short of the Global Plan targets, although data from individual countries show that these targets are achievable.
2.3.2 Diagnosis and treatment of MDR-TB

The most recent estimates suggest that, globally, there were 510 545 cases of MDR-TB in 2007. This estimate is based on data from drug resistance surveys or routine surveillance (DRS)1 for 113 (new cases) and 102 (re-treatment cases) countries,2 and statistical modelling for other countries (see ANNEX 2). Cases of MDR-TB are very unevenly distributed, with 27 countries (of which 15 are in Eastern Europe) accounting for 85% of all cases (TABLE 2.10 ). These 27 countries
1
WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, World Health Organization, 2008 (WHO/HTM/ TB/2008.394). Full details are provided in The WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Fourth global report. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.394).
FIGURE 2.12 Countries that had reported at least one case of XDR-TB by the end of 2008
1 case reported No case reported
FIGURE 2.13 Diagnostic DST for new and re-treatment cases, by WHO region, 2007. The numbers under each bar show the number of countries reporting data, followed by the percentage of total estimated cases of MDR-TB accounted for by reporting countries.
30 % of new cases tested
have been identied as priorities for improved diagnosis and management of MDR-TB at the global level. By the end of 2008, 55 countries and territories had reported at least one case of XDR-TB (FIGURE 2.12), including ve that reported cases for the rst time in 2007 (Colombia, Oman, Qatar, the United Arab Emirates and Uzbekistan).
20
Diagnosis and notication

10
0 AFR (11, 49%) AMR EMR (20, 62%) (12, 22%) EUR (47, 77%) SEARa (3, 4.4%) WPRa Global (17, 63%) (110, 47%)
30 % of re-treatment cases tested
20
10
0 AFR (12, 39%) AMR (19, 73%) EMR EUR (11, 23%) (46, 90%)
SEARa (3, 6.3%)
WPRa Global (16, 35%) (107, 60%)
Data from India and China excluded as fewer than <0.1% of notied cases were tested.
Diagnosis of MDR-TB requires DST services to be available and used (see also SECTION 2.2.3 above on Early case detection through quality-assured bacteriology). In 2007, 220 467 tests for drug susceptibility were reported by 122 countries, with 46% of these tests conducted in the European Region and 34% in the African Region (mostly for retreatment cases in South Africa). Countries reporting DST data accounted for only 47% of the estimated total number of new cases of MDR-TB, and for 60% of the estimated total number of previously treated cases of MDR-TB (FIGURE 2.13). The proportion of new cases for whom DST was undertaken worldwide was 2%, although testing was much more common in the European Region (22% of new cases, with 45/53 countries reporting) ( FIGURE 2.13). The proportion of re-treatment cases for whom DST was undertaken was higher (4.7% across all regions). Among TB cases tested for drug susceptibility in 2007, 29 778 cases of MDR-TB were diagnosed and notied (TABLE 2.10 ; FIGURE 2.14); 54% of these cases were in Europe (TABLE 2.10 ). Although there is evidence that notications are increasing (FIGURE 2.14), the number of MDR-TB cases
notied in 2007 represented only 6% of the 0.5 million cases estimated to exist worldwide (and 9% of estimated cases of smear-positive MDR-TB). This average conceals higher gures for several high MDR-TB burden countries: the number of notied cases was above 70% of the estimated number of cases in Belarus, Estonia, Kazakhstan and Lithuania and above one-third of estimated cases in Georgia, Latvia, the Republic of Moldova and South Africa. Globally, a small increase in provision of treatment for MDR-TB is anticipated between 2008 and 2009 (TABLE 2.10 ; FIGURE 2.14), including in India and the Russian Federation. To date, most notications have been from programmes and projects that were not afliated to the Green Light Committee, or GLC (FIGURE 2.14). The GLC was established in 2000,1 with the purpose of enhancing access to qualityassured second-line drugs at competitive prices and ensuring that treatment was provided according to WHO guidelines.2 In 2007, the 3 681 patients who were treated in GLC-approved projects represented 0.7% of estimated MDR-TB cases. Current data indicate that this will increase to 14 136 patients in 2009 (FIGURE 2.14), or about 3% of estimated cases and 4% of estimated smear-positive cases of MDR-TB. Outside GLC-approved projects, it is not known how many notied cases are enrolled on treatment, and of these how many received treatment that is in line with WHO guidelines.
FIGURE 2.14 Notied cases of MDR-TB (20042007) and projected numbers of patients to be enrolled on treatment (20082009). The numbers under each bar show the number of countries reporting data, followed by the percentage of total estimated cases of MDR-TB accounted for by reporting countries.
40 GLC Number of patients (thousands) 30 23 20 17 19 non-GLC 30 25 30
10
0 2004 (100, 28%) 2005 (107, 52%) 2006 (110, 79%) 2007 (125, 82%) 2008 (106, 91%) 2009 (89, 61%)
Notified
Projected
Scaling-up diagnosis and treatment

In recognition of the comparatively small share of the global burden of MDR-TB that is diagnosed and appropriately treated, the GLC has intensied its efforts to enable rapid expansion of MDR-TB diagnosis and treatment according to the latest WHO recommendations.3 This includes building partnerships with major funding agencies (such as the Global Fund and UNITAID) and recent initiatives (such as the Global Laboratory Initiative and TBTEAM), and introducing mechanisms designed to speed up the review of applications. The result of these efforts was evident in 2008, when the annual number of reviewed applications was the highest to date. Among 43 applications that were reviewed, 39 projects were approved, including projects in 7 countries that had not previously beneted from GLC support (Belarus, Bulgaria, Cameroon, Ethiopia, Mozambique, the Republic of Serbia and the United Republic of Tanzania). These 39 projects will treat a cumulative total of about 20 000 MDR-TB patients during their lifetime, three times more than the total number of patients to be treated by projects approved in 2007. By the end of 2008, a total of 134 projects in 60 countries covering a cumulative total of approximately 50 000 patients had been approved by the GLC. Most of these countries were in the European Region (15 countries) and the Region of the Americas (14 countries), followed by the African Region (12 countries), the Western Pacic Region (7 countries), the Eastern Mediterranean Region (6 countries) and the South-East Asia Region (6 countries).4 The number of patients enrolled for treatment in GLC projects is expected to increase more than three-fold in 2008 compared with 2007; GLC-approved
treatments would then represent a larger share of the global number of MDR-TB patients on treatment (FIGURE 2.14). An overview of the latest status of progress in introducing and scaling-up treatment of patients with MDR-TB, as reported by countries, is shown in TABLE 2.11. The most advanced of the 27 high MDR-TB burden countries appear to be Estonia, Georgia, Latvia, Kazakhstan and the Republic of Moldova, with all of the assessed components of MDR-TB management in place. The experience of Estonia and Latvia in managing MDR-TB within their NTPs is summarized in BOX 2.6. Among the remaining 27 high MDR-TB burden countries, all except South Africa have submitted an application to the GLC; national guidelines have been developed for the management of drug-resistant TB in 17 countries; and 20 countries have reported that they are scaling up activities. In Nigeria, Pakistan and Tajikistan, progress is limited to an application to the GLC or approval of a GLC project.
Treatment outcomes
Given that it takes 1824 months to treat MDR-TB, in 2008 the WHO TB data collection form requested treatment outcome data for patients treated in 2004 and interim outcomes for patients started on treatment in 2005 and 2006. Annual MDR-TB cohorts were reported by 40, 53 and 65 countries for 2004, 2005 and 2006 respectively. As expected, in several countries with larger cohorts (such as the Democratic Republic of the Congo, Morocco and the Philippines), the proportion of cases started on treatment in 2006 who had not yet completed treatment was much higher than the proportion reported for patients who were started on treatment in 2004.
1 2
http://www.who.int/tb/challenges/mdr/greenlightcommittee/en/ Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. Geneva, World Health Organization, 2008 (WHO/HTM/TB/2008.402). Data related to GLC operations were provided by the GLC secretariat, with the exception of projections for MDR-TB patients expected to be treated in 20082009, which were reported by countries via the annual WHO data collection form. Green Light Committee. Annual Report 2007. Geneva, Switzerland, 2008 (WHO/HTM/TB/2008.409).
TABLE 2.11 Management of drug-resistant TB, high MDR-TB burden countries and WHO regions, 2007
DRUG RESISTANCE SURVEILLANCE CONDUCTED APPLIED TO GLC GLCAPPROVED PROJECTS PILOTED SCALING UP INITIATED FULLY INTEGRATED INTO ACTIVITIES OF NTP MDR-TB DATA REPORTED
NATIONAL GUIDELINES
TRAINING MATERIAL
TRAINING CONDUCTED
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
India China Russian Federation South Africa Bangladesh Pakistan Indonesia Philippines Nigeria Kazakhstan Ukraine Uzbekistan DR Congo Viet Nam Ethiopia Tajikistan Myanmar Azerbaijan Republic of Moldova Kyrgyzstan Belarus Georgia Armenia Lithuania Bulgaria Latvia Estonia
Y Y Y Y N N Y Y N Y Y Y Y Y Y Y Y Y N N Y Y Y N Y Y
Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 26 18 14 7 17 8 8 72
Y Y Y N Y Y Y Y N Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y 24 7 14 6 13 6 7 53
Y Y N Y Y N Y Y Y N Y Y Y N Y Y N Y Y N Y N Y Y 17 24 25 13 24 9 11 106
Y Y Y Y Y N Y Y N Y Y Y N N Y N Y Y Y Y N Y N Y Y 18 12 20 9 20 7 6 74
Y Y Y Y Y N N Y N Y Y Y N N N Y Y Y Y Y Y Y N Y Y 18 17 23 8 21 5 10 84
Y Y Y Y N N Y Y N Y Y Y Y N N N Y Y Y Y Y Y Y Y Y Y 20 10 17 8 28 7 8 78
N N Y Y N N N N N Y Y N N N N N N Y N N Y N N N Y Y 8 12 13 6 22 3 6 62
Y Y Y Y N N N Y Y Y N Y Y N Y N Y Y Y Y Y Y Y Y Y Y Y 21 23 25 14 45 5 13 125
High MDR-TB burden countriesa 20 AFR (46) b AMR (44) EMR (22) EUR (53) SEAR (11) WPR (36) Global (212)
a b
22 21 8 33 6 19 109
Indicates information not provided. The lower part of table shows the number of countries answering yes to each question. The number of countries in each region is shown in parentheses.
The size of most country cohorts in 2004 was too small to allow any useful analysis (there were fewer than 40 cases in 26 countries, of which 13 had cohorts of fewer than 10 patients). The nine countries with cohorts of around 100 or more patients are shown in FIGURE 2.15. The highest treatment success rates have been achieved in the Philippines (73%) and Latvia (71%), both of which have GLC-approved projects, followed by the USA (61%). Treatment success rates ranged from 53% to 58% in Brazil and the Democratic Republic of the Congo, as well as in GLC projects in Peru and the Russian Federation. Outcomes were especially poor in two countries without GLC projects: Romania (38%, with a large proportion of patients dying or failing treatment) and Morocco (25%, with over half the cohort lost to follow up). To improve our understanding of treatment outcomes
BOX 2.6
Controlling multidrug-resistant tuberculosis (MDR-TB) in Estonia and Latvia

A decade ago, Estonia and Latvia were considered to be the MDR-TB hotspots of the world, with the highest prevalence of MDR-TB among TB cases ever reported (23% and 13% in 1999, respectively). DOTS was initiated countrywide in Latvia in 1995 and in Estonia in 2000, in advance of other countries of the former Soviet Union. By 2006, the treatment success rate for new smear-positive cases was 68% in Estonia and 73% in Latvia. DOTS-Plus pilot programmes for the treatment of MDR-TB were launched in 1999 in Latvia and 2002 in Estonia, and were rapidly expanded to achieve nationwide coverage. These MDR-TB treatment programmes included provision of quality-assured drug susceptibility testing to all TB patients and use of molecular diagnostic tools for the rapid screening of MDR-TB. Infection control measures were implemented in in-patient and out-patient settings, including major renovation and upgrading of existing hospital wards. Outpatient treatment with patient support such as food packages and transport vouchers was made available during the continuation phase of treatment. Despite struggling with social issues among TB patients, such as alcohol misuse and drug dependency as well as homelessness and increasing rates of coinfection with HIV, both countries have made signicant progress in bringing TB and MDR-TB under control. Treatment success rates for the latest MDR-TB cohorts with complete data were 71% in Latvia (2005 cohort) and 54% in Estonia (2005). Between 2002 and 2007, the total number of MDR-TB cases per 100 000 population/year that were detected decreased by an average of 6% per year in Estonia and 14% in Latvia. Latvia opened the rst WHO collaborating centre for MDR-TB management training. The example of these two countries as well as the collaborating centre provide important models for MDR-TB management elsewhere. Notication rates of TB and MDR-TB, Estonia and Latvia, 19982007
Estonia
TB notifications per 100 000 population (log scale) 100
10
1 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Latvia
TB notifications per 100 000 population (log scale) 100
10
1 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
TB cases (new and relapse)
MDR-TB cases (new and re-treatment)
for patients with MDR-TB, more data from more countries, including data from GLC-approved projects and treatment provided outside the framework of the GLC, are needed.
FIGURE 2.15 MDR-TB treatment outcomes in nine countries, 2004 cohort. The number of patients in the cohort is shown under each bar. Countries ranked by cure rate.
100
Progress against Global Plan targets

As with collaborative TB/HIV activities, the Global Plan sets out the progress required in provision of treatment for MDRTB cases for each year 20062015. During 2007, the targets for the number of patients to be diagnosed and treated for MDR-TB were reviewed and revised to make the targets for 2010 comparable to the goal of universal access to ART by 2010.1 The principal 2010 targets for MDR-TB are: (i) to offer diagnostic DST to all previously treated and chronic TB cases as well as to 90% of new TB cases with a high risk of having MDR-TB (for example, contacts of MDR-TB cases and those for whom treatment is failing after three months); and (ii) to enrol all those in whom MDR-TB is diagnosed in GLCapproved or equivalent treatment programmes. Despite the progress that has been made in some countries documented above, the number of MDR-TB patients notied in 2007 and country projections of the number of MDR-TB patients to be enrolled on treatment in 2008 and 2009 fall far behind the expectations of the Global Plan (TABLE 2.10 ; FIGURE 2.14 ; FIGURE 2.16). In 2008, the Global Plan recommended that
1
80 Percentage of cohort
60
40
20
Philippines Latvia (99) (214) Completed
Peru Russian Brazil (423) Federation (321) (241) Died Failed
DR Congo (175)
Romania Morocco USA (819) (171) (128) Transferred Not evaluated
Cured
Defaulted
The Global MDR-TB and XDR-TB response plan 20072008. Geneva, World Health Organization, 2007 (WHO/HTM/STB/2007.387).
migrant workers and cross-border populations was reported by 47 (27%) and 35 (20.0%) countries, respectively (including seven HBCs). About one 50 fth of countries stated that special attention was 40 given to providing TB care among the homeless, India slum dwellers, minorities, drug dependent individu30 als and people living with diabetes. Russian China Federation Routine screening for TB among immigrants is 20 undertaken in 36 countries (20%), including two South Africa HBCs. In 154 countries (88%) including 20 HBCs, 10 no differentiation is made between the provision of 0 TB care for immigrants and non-immigrants. HowGlobal Country Global Country Global Country Global Country Global Country Global Country Plan projection Plan projection Plan projection Plan projection Plan projection Plan projection ever, in other settings, immigrants with TB have AFR AMR EMR EUR SEAR WPR either to pay for their TB treatment (four countries) or be repatriated (12 countries). The repatriation may be immediately on diagnosis of TB (two countries) or around 100 000 MDR-TB patients (including 10 000 patients after the initial phase of treatment (10 countries). with XDR-TB) should be enrolled on treatment, which is more Despite complex emergency situations, TB care continthan three times higher than notications (for 2007) or counues to be provided in Afghanistan, Iraq, Somalia and Sudan, try projections (for 2008 and 2009). thanks to close collaboration and coordination among variDifferences between Global Plan expectations for ous partners. TB services that were temporarily disrupted in 2008 and country projections vary by region, as shown in areas heavily affected by the typhoon Nargis in Myanmar FIGURE 2.16. In particular, targets set in the Global Plan are were restored swiftly, under the leadership of the NTP. far above country projections in the three regions with the highest number of MDR-TB cases: the European Region, the 2.4 Contribute to health system South-East Asia Region (principally India) and the Western strengthening based on primary Pacic Region (where most cases are in China). In the African health care Region and the Region of the Americas, projections of the Achieving all the health-related MDGs requires strengthennumber of patients treated for MDR-TB treatment are ahead ing of health systems. In the past 23 years, greater emphaof Global Plan targets. sis has been placed on such strengthening at national and The relatively small numbers of MDR-TB cases diagnosed international levels. A prominent example is the International and treated to date, the modest projections of the patients to Health Partnership (IHP+)1 established in September 2007, be treated in the near future and the fact that only 25% of which aims to accelerate the scale-up of health services to countries have reported XDR-TB all demonstrate how much achieve the health-related MDG and universal access targets work remains to be done to improve the availability and provia the development and implementation of country comvision of diagnosis and treatment for MDR-TB and XDR-TB. pacts. These country compacts commit development partA ministerial meeting on MDR-TB and XDR-TB to be held in ners to predictable funding for national plans that are both Beijing in April 2009, with representation from all 27 high results-oriented and address health system constraints. By MDR-TB burden countries, will provide a foundation for globthe end of 2008, 10 countries had been fully inaugurated as al efforts to accelerate provision of diagnosis and treatment IHP+ countries: Burundi, Cambodia, Ethiopia, Kenya, Madafor MDR-TB from 2009 onwards. gascar, Mali, Mozambique, Nepal, Nigeria and Zambia.2 A 2.3.3 Poor and vulnerable populations second example is the renewed commitment of WHO as well as its Member States and partners to primary health care Although routine investigation of close contacts of TB (PHC) in 2008, 30 years on from the original launch of PHC patients is known to help early case detection, TB contact as a means to achieve the goal of health-for-all. investigation is not yet a routine activity of TB control proThere are various ways to monitor how NTPs and their grammes in most countries. A total of 82 countries reported partners are contributing to health system strengthening. that TB contact investigation activities were implemented; This section discusses the topics on which data were availamong these, 63 reported that a total of 1.4 million contacts able from the 2008 data collection form. had been screened, of whom 3.8% (53 981) had active TB. The remaining 19 countries reported either on the number 2.4.1 Integration in primary health care of contacts screened or the number of TB cases diagnosed Diagnosis and treatment of TB are integrated fully into PHC among contacts, but not both. services in almost all countries. Twenty HBCs (and 83% of Among the 176 countries and territories addressing TB in high-risk groups, 57 (32%) including seven HBCs were pro1 The + in the title recognizes that there are number of other partnerviding TB care to refugees and displaced people in 2007. ships addressing system strengthening elements. 2 http://www.internationalhealthpartnership.net Adaptation of TB control services to meet the needs of
Number of patients (thousands)
FIGURE 2.16 Country projections of MDR/XDR-TB patients to be enrolled on treatment in 2008 compared with the Global Plan
all countries) reported that TB control services were delivered through PHC facilities. Similarly, laboratory services for diagnosis of TB are usually integrated into general laboratory services: 86% of laboratories performing sputum smear microscopy in HBCs (80% across all countries) are general laboratories. Procurement, distribution and stock management of anti-TB drugs are undertaken together with other essential drugs management in 10 HBCs and in 64% (110/173) of all reporting countries.
FIGURE 2.17 Alignment of NTP plans and budgets with other planning frameworks and initiatives, high-burden countries, 2007
25 National plan/framework exists NTP plan and budget aligned with national plan/framework
20 Number of countries
15
10
2.4.2 Alignment with broader planning and nancing frameworks

A high proportion of HBCs reported alignment of NTP plans and budgets with broader planning and nancing frameworks (FIGURE 2.17). Contributing to health-system strengthening is an explicit component of the national strategic plan for TB control in 19 HBCs. However, there appears to be more scope for NTPs to involve the full range of stakeholders in planning and strategy development (FIGURE 2.18).
National health plan
Poverty reduction strategy paper
National plan for human resources for health
Medium-term expenditure framework for health
Sector-wide approach (SWAp)
FIGURE 2.18 Involvement of different stakeholders in the development of national TB control strategies and plans
MoH planning department Professional associations Hospital administration Drug regulatory body Ministry of Interior/Justice Ministry of Defence Ministry of Education National health insurance 0 5 10 Number of HBCs 15 20
2.4.3 Human resource development

A comprehensive strategic plan for human resource development (HRD) should ensure both nancing and guidance for an adequate, competent and performing workforce for TB control, integrated within overall health workforce plans and strategies. Plans should be based on a recent needs assessment and include: (i) a clear vision and goal, and associated objectives and strategies; (ii) denition of training and staffing needs for all components of the Stop TB Strategy; (iii) up-to-date job descriptions; (iv) provision for updating of the TB training curricula of various health cadres where appropriate; (v) ongoing training for existing staff at all levels of the health system; and (vi) systematic supervision and monitoring of recruitment and training needs. A total of 94 countries including 14 HBCs have conducted a recent needs assessment, and 90 countries including 14 HBCs have a comprehensive plan for HRD for TB control (TABLE 2.12). Six countries that reported having a plan had not conducted any needs assessment. Among the HRD plans that do exist, most could be strengthened. For example, only seven HBCs have considered training and stafng needs for all the major components of the Stop TB Strategy. Job descriptions of staff involved in the implementation of the Stop TB strategy were up-to-date in 120 countries, including 19 HBCs. Among the 22 HBCs, 18 had a designated person for HRD at the central level of the NTP. However, a full-time member of staff was available in only six countries: Afghanistan, Nigeria, Pakistan, the Russian Federation, South Africa and the United Republic of Tanzania. Information regarding staff positions, vacancies and the training status of staff is essential for HRD, but routine monitoring of staff availability, turnover and training appears weak across HBCs. Only 9 HBCs provided at least some information about the availability of staff trained in TB control at health care facilities. In all but two countries, the information was incomplete or contradictory.
Training related to TB control is included in the basic curriculum of doctors, nurses and laboratory technicians in 141, 133 and 135 countries, respectively (including 18, 16 and 18 HBCs). Nonetheless, monitoring missions to HBCs have shown that the work on updating basic curricula is often not formalized. Compared with data reported in 2007, data reported in 2008 suggest only modest improvements in HRD. Reporting weaknesses including inconclusive, contradictory and incomplete data. The main conclusion based on these data remains the same as last year: major strengthening of HRD for TB control is urgently needed in many countries in all regions, especially in HBCs.
2.4.4 Infection control

Infection control is a combination of measures aimed at minimizing the risk of TB transmission through early identication of individuals with suspected and known TB, and proper management of these people. Infection control for TB includes organizational, administrative, environmental and personal protective controls, each of which needs to be implemented using a patient-centred approach that minimizes the risk of stigma for TB patients and TB suspects. The importance of
TABLE 2.12 Human resource development (HRD) for TB control, 2007

HRD PLAN INCLUDES TRAINING NEEDS IN
HRD NEEDS ASSESSMENT COMPREHENSIVE STRATEGIC HRD PLAN MANAGEMENT OF MDR-TB COLLABO- PUBLIC RATIVE PUBLIC MIX TB/HIV APPROACHES ACTIVITIES (PPM)
HRD PLAN INCLUDES STAFFING NEEDS IN

MANAGEMENT OF MDR-TB COLLABOPUBLIC RATIVE PUBLIC MIX TB/HIV APPROACHES ACTIVITIES (PPM) JOB DESCRIPTIONS UP TO DATE
DOTS
ACSM
DOTS
ACSM
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Y Y Y N Y Y N Y N Y N Y Y N N N Y Y Y N Y Y 14 17 19 16 16 8 18 94
Y N Y Y N Y Y Y Y Y N Y N Y Y N N Y N Y N Y 14 18 18 18 13 10 13 90
Y Y Y Y Y Y Y Y Y Y Y Y Y 13 17 19 19 14 10 13 92
Y Y Y Y Y N Y Y Y Y Y Y 11 17 19 15 15 9 13 88
Y Y Y Y Y Y Y Y Y Y Y Y Y 13 16 19 14 14 10 13 86
Y Y Y Y Y Y Y Y Y N Y Y 11 15 17 16 10 7 10 75
Y Y Y Y Y Y Y Y Y Y Y Y 12 17 18 18 15 8 12 88
Y Y N Y Y Y N Y Y Y Y Y Y 11 16 16 19 13 9 10 83
Y Y N Y Y N N Y Y Y Y Y 9 15 15 15 13 8 10 76
Y Y N Y Y Y N N Y Y Y Y Y 10 12 16 14 13 9 9 73
Y Y N Y Y Y N N Y N Y Y 8 12 15 16 9 7 6 65
Y Y N Y Y Y N N Y N Y Y 8 12 16 17 12 7 8 72
All None All All All Some None All All All All All 19 24 21 16 24 10 25 120
High-burden countriesa AFR (46) AMR (44) EMR (22) EUR (53) SEAR (11) WPR (36) Global (212)
Indicates not applicable (no plan, or activity not implemented). Lower part of table shows the number of countries with afrmative answer (for last column, the number of countries where all or almost all job descriptions were up to date). The number of countries in each region is shown in parentheses.
implementing these measures has been highlighted by the transmission of MDR/XDR-TB in settings where HIV care is provided. Updated WHO policy guidance on controlling TB infection in health-care and congregate settings as well as within households is now available. Measures to control infection need to be implemented throughout the health system. While some measures are TB-specic, others are relevant to all infectious diseases. Infection control also requires a multi-disciplinary team (comprising, for example, health staff as well as building surveyors and architects), and interventions to improve TB control can improve collaboration across these disciplines. Data reported in 2008 suggest that infection control is at an early stage of development in most countries and that better indicators are needed to monitor implementation. No country provided data about actual implementation of interventions, although 75% (131/175) of countries had a policy
on TB infection control in hospitals in 2007. The number of countries that reported the existence of a policy on TB infection control in clinics, prisons and military barracks was 114, 94 and 69 respectively.
2.4.5 Practical Approach to Lung Health

The Practical Approach to Lung Health (PAL) is a patientcentred approach to improving the quality of diagnosis and treatment for common respiratory illnesses in primary healthcare facilities. It is designed to ensure a consistent approach to diagnosis and treatment at different levels of the healthcare system, efcient use of resources (for example, by ensuring that care is provided at the most appropriate level of the health system and that drugs are used rationally), and coordination among TB control services and other health-care services. Implementation requires adaptation of guidelines according to existing national health policies and available
resources. At the end of 2008, 70 countries including nine HBCs had a plan to initiate PAL. Nine countries were piloting PAL and 11 were in the process of expanding it beyond pilot sites (including one HBC, South Africa). National guidelines for PAL were available or in preparation in 21 countries. PAL implementation is totally or partially funded by the Global Fund in 19 countries, including three HBCs.
BOX 2.7
Forging publicprivate partnerships (PPP) for TB care and control in Pakistan

Pakistans large and diverse private health sector (both prot and not-for-prot) is extensively used by TB patients. In recent years, successive NTP managers have given high priority to developing viable partnerships with health-care providers in this sector by using a systematic approach that is consistent with the steps recommended in WHO guidelines.1 Introducing PPM began with a situational analysis that was used to design a range of PPM models suitable for the following types of provider: NGO clinics with and without laboratories; individual general practitioners; general practitioners who are grouped in clusters or linked to NGOs involved in social franchising; private clinics and hospitals; and informal providers (including both those who practise conventional medicine and those who do not). Developing national operational guidelines as a foundation for countrywide implementation was followed by establishing and funding staff positions specically for PPM at national, provincial and district levels. The government also made a strong nancial commitment, with 39% of the domestic funding available for TB control allocated to PPM in the 20052010 development plan. The operational guidelines provide practical advice on several key topics, including the role of agreements with decision makers at district level; creation and maintenance of PPP coordination committees at provincial and district levels (with similar functions to those of the national steering committee); identication and selection of private partners; the value of a memorandum of understanding and how to develop one; training and certication of providers; monitoring and supervision; recording and reporting; and how to ensure that the general public is properly informed. Many partners are now contributing to TB control via PPP schemes, and evidence of their contribution to case detection is emerging. A WHO-assisted mission conducted in 2008 found that in 2007, PPM initiatives accounted for almost 20% of total notications (39 635) and just over 20% of notications of new smear-positive cases (20 129). The table below presents data from three provinces that together had 90% of all registered TB patients in 2007. In the three provinces combined, 51% of all cases detected by non-NTP providers were new sputum smear positive cases while among those detected in the public sector, 36% were new sputum smear-positive cases.
PROVINCE OR CITY NUMBER OF TB CASES NOTIFIED IN 2007 % OF NOTIFICATIONS FROM PPP NUMBER OF NEW SMEAR-POSITIVE TB CASES NOTIFIED IN 2007 % OF NOTICATIONS FROM PPP
2.5 Engage all care providers

2.5.1 Publicprivate mix approaches
Besides the network of health facilities directly within the jurisdiction of the NTP, diagnosis and treatment of TB are provided by a wide array of public, voluntary, corporate and private providers in many countries. Partnerships with these providers are essential to ensure delivery of TB services that are in line with international standards and to achieve global targets (notably the target for case detection). The Stop TB Strategy envisages that NTPs will engage all relevant care providers for TB care and control through PPM approaches. In 2008, all countries were asked to provide information about the number of different types of providers1 that had been engaged formally in TB control and the number of new TB cases referred and treated by major categories of public and private providers involved in PPM initiatives. Unfortunately, while most countries have begun implementing PPM-related activities, data were usually too incomplete to make an accurate assessment of the contribution of PPM to case detection and treatment. This suggests that very few countries are using the revised recording and reporting forms recommended by WHO, which are designed to allow disaggregated analysis of referrals and treatment by category of provider (at a minimum on an annual basis from selected facilities). By 2007, only nine HBCs had started systematically to record the source of referral of patients and where they were receiving treatment, and a smaller number were extracting data from these records in a systematic way. The best example of a country that was able to report data was the Philippines, where PPM initiatives that have been implemented in 40% of the country account for 9% of national notications (ANNEX 1). It is also evident that PPM initiatives are capable of making a major contribution to notications in Pakistan (BOX 2.7), although here results are from a special study rather than routinely reported data. In the absence of precise data, countries were also asked to assess the contribution of different providers to referral and treatment by stating whether all, some or no providers in a given category were contributing to diagnosis and treatment. Almost half of the HBCs have managed to involve all health institutions belonging to the public sector health-care network, such as public hospitals, medical college hospitals, army health facilities and prison health facilities. Facilities
1
TOTAL
PPP
TOTAL
PPP
North West Frontier Sindh (excluding Karachi City) Karachi City Punjab
1
30 699 30 798 14 887 131 742
5 485 1 943 7 531 24 676
18% 6% 51% 19%
11 886 14 718 6 882
1 961 147 3 625
16% 1% 53% 30%
47 926 14 396
Engaging all care providers in TB control. Guidance on implementing publicprivate mix approaches. Geneva, World Health Organization, 2006 (WHO/ HTM/TB/2006.360).
Private providers were categorized as private hospitals, private practitioners, NGO/mission clinics and hospitals, corporate (business) health services and private medical college hospitals. Public providers were categorized as general public hospitals, public medical college hospitals, health/social insurance services, prison/detention centres and military facilities.
operated by health insurance agencies were fully engaged with NTP in about one third of the HBCs. Most HBCs have also started to involve at least some private practitioners, private hospitals and NGO health facilities in referral to the NTP, diagnosis according to programme guidelines and/or treatment with anti-TB drugs supplied by the NTP. More countries reported that all of these providers were engaged in national TB control in 2008 compared with 2007. Several HBCs including Bangladesh, China, India, Indonesia, Kenya, the United Republic of Tanzania, Pakistan and the Philippines have used context-specic, innovative and NTP-led approaches to engage diverse care providers in TB control.
Only seven HBCs reported involving patient-centred organizations or networks in advocacy activities and/or DOTS implementation. Forging partnerships with other organizations and networks that have expertise in the area of ACSM is an important strategy that can help to address the generally limited capacity of NTPs in this technical area.
2.6.2 Community participation in TB care

Community and patient empowerment are central to a human rights approach to care of TB patients and prevention of the disease. In addition, country experience shows that activities that foster community and patient empowerment can have a positive impact on case detection and treatment outcomes. Unfortunately, the available data do not shed much light on the activities that are being implemented at local level, although some descriptions are provided in ANNEX 1. Eight HBCs reported on the number of basic management units in the country that involved community members as treatment supporters, and only two HBCs reported data about the number of patients who were referred by general members of the community for TB screening or who were cared for in the community during treatment. The scarcity of information on the scope and nature of community involvement within countries indicates the need for greater emphasis and related guidance on this important aspect of TB care and control.
2.5.2 International Standards for Tuberculosis Care

Launched on World TB Day in 2006, the International Standards for Tuberculosis Care1 provide an excellent basis for standardizing management practices across providers of TB care and are also an effective tool for advocating scale up of PPM implementation. A suggested initial step towards their application is to have the standards endorsed by relevant associations of health professionals. This step has been carried out by at least one professional association in about a quarter of reporting countries including 13 HBCs. One third of all reporting countries were using the standards to promote the engagement of non-NTP care providers. A higher proportion of reporting countries (about 50%, including 14 HBCs) have incorporated the standards into the curricula of medical schools; about 40% of countries (including 13 HBCs) have integrated them into NTP training material.
2.6.3 Patients Charter for Tuberculosis Care

Launched alongside the International Standards for Tuberculosis Care, the Patients Charter for Tuberculosis Care2 outlines the rights and responsibilities of TB patients. An essential rst step for many countries is translation of the charter into local languages. Many countries are also likely to require some guidance on the most effective way to use the charter; to date, information about its actual use is limited (see also ANNEX 1).
2.6 Empower people with TB, and communities through partnership

2.6.1 Advocacy, communication and social mobilization
An ACSM strategy involves three distinct sets of activities: advocacy aimed at inuencing leaders or decision-makers, communication channelled to individuals and small groups, and social mobilization to empower and secure support for efforts in TB control from civil society and the community as a whole. All HBCs report implementing ACSM activities that target the general public, TB suspects and patients, health-care providers and policy-makers. However, it is unclear from country reports whether the ACSM activities are a part of a strategic ACSM plan that supports the goals of the NTP; it is also unclear whether the impact of ACSM activities is being evaluated. Strategic planning of ACSM should begin with a survey of knowledge, attitudes and practices to identify the challenges to be addressed and the audiences to which ACSM activities need to be targeted. It also allows programmes to establish baseline indicators so that progress can be monitored and impact evaluated. It is encouraging that 16 HBCs have conducted or have plans to conduct such a survey (see ANNEX 1).
2.7 Enable and promote research

To help pilot, evaluate and scale up the various components and sub-components of the Stop TB Strategy, an increasing number of countries appear to be recognizing the importance of programme-based operational research. A total of 89 countries including 20 HBCs reported that research activities related to TB control were implemented in 2007, up from 49 countries in 2006. Among these countries, almost 400 research projects were reported. Four HBCs (Bangladesh, China, India and the Russian Federation) as well as Mexico listed more than 20 research topics that were being addressed. These topics were related to the basic elements of DOTS components (49 countries), collaborative TB/HIV activities (39 countries), MDR-TB and XDR-TB (39 countries), PAL (10 countries), and social mobilization and community
1
International standards for tuberculosis care: diagnosis, treatment, public health. The Hague, Tuberculosis Coalition for Technical Assistance, 2006. The Patients charter for tuberculosis care: patients rights and responsibilities. World Care Council, 2006.
involvement (22 countries). Research on tobacco and diabetes as risk factors for TB, retooling (the introduction of new technologies) and evaluation or feasibility studies related to new technologies was also reported. Fifteen countries implemented surveys of anti-TB drug resistance in 2007. A literature search showed that papers related to TB were published from all but one HBC. Information from the Stop TB Partnerships three working groups on the development of new tools for TB control also shows that over 100 sites are involved in clinical trials to develop new diagnostics, drugs and vaccines. Most of these sites are in countries where TB is endemic. Eleven countries have provided reports about their experience with the development and introduction of new diagnostics. With several potential new tools moving from the stage of discovery to clinical trials, increasing participation of countries in the evaluation of these tools is required.
2.8 Summary
Progress in implementing the Stop TB Strategy varies across components and among countries. The rst component and foundation of the strategy DOTS is the most widely implemented. It is also the component for which progress is closest to matching the expectations contained in the Global Plan: the global case detection rate was 63% in 2007 and the treatment success rate 85% in 2006. Nonetheless, urgent improvements in the provision of services for laboratory culture and DST are needed in many countries, and there are countries that continue to report stock-outs of rst-line drugs. Besides DOTS implementation, diagnosis and treatment of MDR-TB and collaborative TB/HIV activities (both under component 2) are the other major parts of the Stop TB Strategy for which implementation can best be quantied. There is clear evidence of progress in implementing interventions such as HIV testing of TB patients and provision of CPT and ART to HIV-positive TB patients, particularly in the African Region. In 2007, 37% of TB patients in the African Region knew their HIV status, 0.2 million HIV-positive TB patients were enrolled on CPT and 0.1 million HIV-positive TB patients were started on ART; in each case, gures were higher than those reported in previous years. Nonetheless, the numbers of HIV-positive TB patients accessing services for provision of CPT and ART remain small compared with the estimated 1.4 million HIV-positive TB cases. Collaborative TB/HIV activities need to be scaled up to ensure that many more people know their HIV status and many more HIV-positive
people, with and without TB, have access to appropriate treatment and care. Progress in diagnosing MDR-TB and treating patients with the disease is mostly conned to the European Region and South Africa. Globally, just under 30 000 cases of MDR-TB were notied to WHO in 2007, or 8.5% of the estimated global total of smear-positive cases of MDR-TB. Of these notied cases, 3681 were started on treatment in projects or programmes afliated to the GLC (and are thus known to be providing treatment according to international guidelines), which represents only 1% of the smear-positive cases of MDR-TB estimated to exist globally. Although the number of patients started on treatment is expected to increase to around 14 000 in 2009, this still represents only 4% of the smear-positive cases of MDR-TB estimated to exist globally. To meet the targets set in the Global Plan, diagnosis and treatment need to be rapidly expanded, especially in China, India and the Russian Federation. The extent to which components 36 of the Stop TB Strategy are being implemented is less well understood, because to date progress is more difcult to quantify. The integration of diagnosis and treatment of TB into primary health care in almost all countries as well as reported alignment with broader health sector planning frameworks and expansion of PAL (all part of component 3) are encouraging. However, considerable work on HRD and infection control is needed in many countries in all regions. PPM and the ISTC (component 4) are being introduced and expanded in an increasing number of countries, and examples from specic countries such as Pakistan and the Philippines demonstrate the potential of PPM to contribute to increased case detection. In order to better understand the relative contribution of different providers to the detection, referral and treatment of cases requires much greater use of routine recording and reporting forms that allow disaggregated analysis for different categories of provider. ACSM (component 5) is still a new area for many countries. Much more guidance and technical support are necessary to ensure that interventions are appropriately designed and evaluated. Finally, while operational research and the introduction of new tools (both part of component 6) are occurring, the information available for this report was comparatively limited. This chapter concludes that there is a need in most countries for major scaling up of the interventions and approaches included in the Stop TB Strategy. For this to be feasible, increased funding is required. Financing is the topic of the next chapter.
CHAPTER 3
Financing
Implementing the Stop TB Strategy at the scale required to achieve the 2015 targets for global TB control (see also CHAPTER 1 and CHAPTER 2) requires accurate budgeting of the nancial resources required, mobilization of the necessary funding and spending of available funds such that TB control outcomes are improved. Analysis of budgets and funding for TB control was introduced into the annual WHO report on global TB control in 2002, and expenditures have been reported on since 2004. This chapter provides WHOs latest analysis of nancing of TB control. As with the previous two chapters, emphasis is placed on 22 high-burden countries (HBCs), but analyses for all countries reporting nancial data are also included. The chapter is structured in eight major sections. The rst section summarizes the data that were reported to WHO in 2008. The next six sections present the budgets of national TB control programmes (NTPs) from 2002 to 2009 and the sources of funding and funding gaps for these budgets; the total costs of TB control (including the cost of resources that are used within the general health system as well as the costs included in NTP budgets), also for 20022009; comparisons of funding requirements reported by countries with estimated funding requirements that were contained in the Global Plan to Stop TB, for the period 20062009; per patient costs and budgets in 2009; a comparison of expenditures with available funding and with changes in the number of cases that have been detected and treated; and the contribution of the Global Fund to nancing for TB control. The eighth section discusses why funding gaps persist and the possible consequences of the global nancial crisis for TB control. Further details are also provided in ANNEX 1 and ANNEX 3. rst time in ve years following a comprehensive planning and budgeting effort that was facilitated by use of the WHO planning and budgeting tool (BOX 3.1).2 Expenditure data for 2007 were reported by all HBCs except South Africa and Uganda (data not shown). Considerable clarication and verication of nancial data by WHO are still required, but the quality of the data when rst submitted continues to improve. In 2008, this was notable for the African Region, the Region of the Americas and the South-East Asia Region. Improvements were probably facilitated by related work on planning and budgeting undertaken with 35 African countries in 2007 and with nine countries from the South-East Asia Region in 2008, as well as close collaboration with countries in the Region of the Americas during regional meetings.
3.2 NTP budgets, available funding and funding gaps

3.2.1 High-burden countries
NTP budgets in the 22 HBCs amount to US$ 2.5 billion in 2009, almost three times their level in 2002 (TABLE 3.1; FIGURE 3.2; FIGURE 3.3). The Russian Federation has the highest budget (US$ 1.2 billion), followed by South Africa (US$ 352 million), China (US$ 225 million), India (US$ 100 million) and Brazil (US$ 64 million). These ve countries account for 80% of the NTP budgets reported for 2009 by the 22 HBCs. The eight HBCs in the African Region (excluding South Africa) had a combined budget of US$ 225 million in 2009, only 10% of the total for all 22 HBCs. Much of the increase in NTP budgets since 2007 is explained by an increase in the budget for MDR-TB (FIGURE 3.2), almost all of which (US$ 372 million, or 88% of a total of US$ 422 million) is accounted for by the Russian Federation and South Africa (ANNEX 1). Nonetheless, NTP budgets increased in most HBCs between 2007 and 2009, and NTP budgets have increased substantially in all HBCs except Viet Nam since 2002 (FIGURE 3.4 ; ANNEX 1). In 20022006, activities to support the DOTS component of the Stop TB Strategy accounted for the largest proportion of NTP budgets (FIGURE 3.2). However, budgets for collaborative TB/HIV activities, ACSM, PPM and MDR-TB are much more in evidence in 2009 compared with previous years ( FIGURE 3.2; FIGURE 3.5). This suggests that many HBCs are
1
3.1
Data reported to WHO in 2008
WHO received nancial data from 158 out of 212 (75%) countries and territories in 2008, similar to the number that reported data in 2007.1 Complete budget data for 2009 were provided by 102 countries ( FIGURE 3.1), 98 countries provided complete budget data for 2008 and 92 countries provided complete expenditure data for 2007. Overall, countries reporting nancial data accounted for 98% of the global burden of TB. The countries that provided nancial reports accounted for 97% or more of the regional burden of TB in ve WHO regions, with a lower gure of 83% for the European Region. This is the most complete reporting of nancial data to WHO since nancial monitoring began in 2002. Complete budget data for 2009 were reported by all HBCs except South Africa (FIGURE 3.1). Of particular note is Thailand, which provided complete budget data for the
Global tuberculosis control: surveillance, planning and nancing. WHO report 2008. Geneva, World Health Organization, 2008 (WHO/HTM/ TB/2008.393). See http://www.who.int/tb/dots/planning_budgeting_tool/en/index. html
FIGURE 3.1 Reporting of nancial data, NTP budgets for 2009
Status of budget data for 2009 Not available Complete Partial
TABLE 3.1 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), high-burden countries, 2009
AVAILABLE FUNDING GOVERNMENT (EXCLUDING LOANS) GRANTS (EXCLUDING GLOBAL FUND) COST OF UTILIZATION OF GENERAL HEALTH-CARE SERVICES
NTP BUDGET
LOANS
GLOBAL FUND
FUNDING GAP
TOTAL TB CONTROL COSTSa
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
100 225 80 44 352 15 26 54 23 53 1 249 13 37 64 25 17 17 50 25 11 11 10 2 501
9.2 163 34 7.3 4.9 1.1 10 7.9 1.6 1 014 5.3 6.6 50 7.1 1.3 0.6 46 6.4 1.2 1.1 0.2 1 379
37 11 0 0 1.1 0 0 0 0 0 0 1.0 0.6 0 0 0 0 0 0 0 0 50
9.8 0.7 13 4.4 0 1.0 12 0 3.3 1.4 4.3 12 1.5 4.7 0.1 4.1 0 7.9 5.3 1.3 5.4 93
14 41 17 13 9.2 6.2 6.4 10 11 6.9 3.9 2.5 0 5.4 4.8 3.4 0.8 4.4 0 4.6 4.1 169
30 9.8 16 19 0.1 18 25 4.4 37 226 0 15 11 7.4 11 9.4 3.2 6.0 4.3 3.7 0.3 457
38 0 4.8 11 251 5.8 8.5 3.8 11 12 24 13 5.1 28 4.2 1.2 4.1 1.0 5.9 1.9 2.5 1.2 438
138 225 85 55 603 21 35 58 34 66 1 273 27 42 92 29 18 22 51 31 13 13 11 2 939
High-burden countries
Indicates not available. Calculated as NTP budget plus the cost of utilization of general health-care services.
FIGURE 3.2 NTP budgets by line item, high-burden countries, 20022009

3000 2500 US$ millions 2000 1500 1164 1000 908 500 0 2002a 2003b 2004 2005 2006 2007 2008 2009c 922 1306 1479 2501 2200 2267 Unknownd Other PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTS
c d
Estimates assume budget 2002 equal to expenditure 2002 (Ethiopia), budget 2003 (Afghanistan, Bangladesh, Mozambique and Uganda) or expenditure 2003 (Russian Federation and Zimbabwe). Estimates assume budget 2003 equal to expenditure 2003 (Russian Federation and Zimbabwe). Estimates assume budget 2009 equal to budget 2008 for South Africa. Unknown applies to Afghanistan 20022004, Russian Federation 20022003 and Mozambique 20022003. In these years, a breakdown by line item was not available.
FIGURE 3.3 NTP budgets by source of funding, high-burden countries, 20022009

3000 2500 US$ millions 2000 1500 1164 1000 500 0 908 922 1479 1306 2501 2200 2267 Unknownd Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)
2002a 2003b 2004 2005 2006
2007 2008 2009c
c d
Estimates assume budget 2002 equal to expenditure 2002 (Ethiopia), budget 2003 (Afghanistan, Bangladesh, Mozambique and Uganda) or expenditure 2003 (Russian Federation and Zimbabwe). Estimates assume budget 2003 equal to expenditure 2003 (Russian Federation and Zimbabwe). Estimates assume budget 2009 equal to budget 2008 for South Africa. Unknown applies to Afghanistan 2004, DR Congo 2002, Nigeria 2002, South Africa 20072009 and UR Tanzania 2007. In these years, a breakdown by funding source was not available or only partially available.
expanding the range of interventions to control TB, in line with the Stop TB Strategy. The large budget increases described above have been accompanied by big improvements in available funding (FIGURE 3.3; FIGURE 3.4). Funding for NTP budgets in the 22 HBCs reached US$ 1.8 billion in 2009, up from US$ 0.8 billion in 2002. Governments of HBCs have provided most of the available funding since 2002; this funding amounts to US$ 1.4 billion in 2009 (57% of the total budget, and 85% of the available funding) (TABLE 3.1).1 Financing from the Global Fund has become more important since 2004, reaching US$ 169 million (7% of the total budget and 10% of the available funding) in 2009. The Global Fund accounts for 65% of total grant funding for HBCs in 2009. Grants provided to HBCs from sources other than the Global Fund have not changed much since 2002, and in 2009 account for 4% of the total budget (and 5% of available funding). Despite these increases in funding, funding gaps that total US$ 457 million (18% of the total budget) have been reported for 2009; this could be as high as US$ 0.7 billion if the funding gap in South Africa could be accurately quantied (TABLE 3.1).2 All HBCs except Viet Nam reported funding gaps in 2009. In India, Indonesia and Pakistan, these gaps may be reduced or closed by funding from grants from the Global Fund approved in round 8 or via the so-called rolling continuation channel of funding (ANNEX 1). Most of the additional domestic funding since 2002 (government funding including loans) has come from three countries only: Brazil, China and the Russian Federation (an extra US$ 717 million in 2009 compared with 2002). These three countries plus Thailand will fund 77% or more of their NTP budgets from domestic sources in 2009 (TABLE 3.1). In other HBCs, increases in funding have come mainly from the Global Fund. In 2009, grants from the Global Fund will nance around one-third or more of the NTP budget in seven countries: Bangladesh, the Philippines, Cambodia, Afghanistan, Nigeria, Uganda and Viet Nam (in that order). In addition, grants from sources besides the Global Fund will nance one third or more of the NTP budget in Afghanistan, Mozambique, Myanmar, Kenya and Viet Nam (TABLE 3.1). In absolute terms, the largest funding gaps are those reported by the Russian Federation, the Democratic Republic of the Congo, India, Pakistan, Nigeria and Ethiopia (in that order), which together account for 78% of reported funding gaps. The Russian Federation alone accounts for 50% of the total funding gaps reported by HBCs. Proportionally, the largest gaps are (in order) in the Democratic Republic of the Congo, Ethiopia, Uganda, Zimbabwe, Pakistan, Nigeria, Kenya, Myanmar and Cambodia; funding gaps in these countries represent more than one-third of the required budget ( TABLE 3.1). Only three HBCs reported no funding gap
1
Figures would probably be higher if complete information on funding from provincial governments in South Africa were available. The 11% of NTP budgets for which funding is unknown, which is accounted for by South Africa, is likely to be a mixture of funding from provincial governments and a funding gap (ANNEX 1).
FIGURE 3.4 NTP budgets and available funding, high-burden countries, 20022009
Afghanistan
15 10 5 20 18 16 14 12 10 8
Bangladesh
60 50 40
Brazil
10 8 6 30 20 4
Cambodia
250 200 150 100
China
DR Congo
50 40 30 20 10 25
Ethiopia
90 20 15 10 5 80 70 60 50 40
India
80 70 60 50 40 30 20 10
Indonesia
35 30 25 20 15 10 5
Kenya
Mozambique
15 US$ millions 20 15 10 5 5 10
Myanmar
40 30 20 10
Nigeria
50 40 30 20 10
Pakistan
22 20 18 16 14 12
Philippines
Russian Federation
1200 1100 1000 900 800 700 600 350 300 250 200 150 100
South Africa
50 49 48 47 46 45
Thailand
16 14 12 10 8 6 4 2
2003 2005 2007 2009
Uganda
20 15 10 5
2003 2005 2007 2009
UR Tanzania
Viet Nam
16 15 14 13 12 11 10
2003 2005 2007 2009
Zimbabwe
15
2003
2005
2007
2009
10 NTP budget Available funding
2003
2005
2007
2009
or a negligible funding gap: Afghanistan, Bangladesh and Viet Nam.
3.2.2 All countries

WHO began collecting nancial data from all countries (in addition to the 22 HBCs) in 2003 and reported these data for the rst time in 2004. Total NTP budgets in 2009, by WHO region and source of funding, are shown for the 103 countries for which data are available (22 HBCs and 81 other countries) in FIGURE 3.6.1 Globally, these countries account for 93% of incident TB cases; at regional level, they account
1
The total of 103 countries is one more than the total of 102 countries mentioned in section 3.1, since South Africa is included in FIGURE 3.6 with the assumption that the budget for 2009 would be the same as the budget reported for 2008.
for almost all TB cases in the African, Eastern Mediterranean, South-East Asia and Western Pacic regions (8999.6%, depending on the region), for 85% of the regional total in the Region of the Americas (up from 74% in 2008), and for 66% of the regional total in the European Region. NTP budgets amount to US$ 3.6 billion in 2009, up from US$ 2.6 billion in 2008 (for countries with 91% of global cases) and US$ 1.6 billion in 2007 (also for countries that accounted for 91% of TB cases globally). The funding gaps reported by these 103 countries total US$ 0.9 billion, of which US$ 0.5 billion is in the European Region. This is somewhat surprising given the relative wealth of the European Region. Overall, the reported funding gap is more than double the US$ 385 million reported for 2008. Budgetary funding gaps as a proportion of the total bud-
FIGURE 3.5 NTP budgets by line item, high-burden countries,a 2009

Myanmar Bangladesh Thailand Afghanistan China India Russian Federation Viet Nam Ethiopia Indonesia Brazil Uganda UR Tanzania Nigeria Pakistan Cambodia Philippines DR Congo Kenya Mozambique Zimbabwe South Africa 0 10 20 30 40 50 % of NTP budget 60 70 80 90 100 DOTS MDR-TB TB/HIV PPM/PAL ACSM/CBTC Other
Data for South Africa are for 2008. Countries ranked according to DOTS budget.
FIGURE 3.6 Regional distribution of NTP budgets by source of funding, 22 high-burden countries and 81 non high-burden countries, 2009. Numbers in parentheses above bars show the percentage of all estimated incident cases of TB in the region that are accounted for by the countries included in the bar. Numbers in parentheses on the x-axis show the number of countries contributing to each bar.
1.4 1.2 1.0 2.0 US$ billions 0.8 0.6 (71%) 0.6 (29%) 1.2 (37%) 3.0 2.5 (80%) 2.5 Unknown Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans) 1.1 (13%)
1.5
0.6 0.4 0.2
1.0 0.2 (54%) 0.06 (31%) HBC (1) Non-HBC (16) 0.06 (59%) HBC (2) 0.3 (95%) 0.1 (32%) 0.03 (4.6%) HBC (1) Non-HBC (16) HBC (5) Non-HBC (5) HBC (4) 0.3 (93%) 0.5 0.04 (3.3%) 0 HBC (9) Non-HBC (19) Non-HBC (12) Non-HBC (13) HBC (22) Non-HBC (81)
0.1 (18%)
AFR
AMR
EMR
EUR
SEAR
WPR
All regions
get were higher for non high-burden countries compared with HBCs in the African, European and South-East Asia regions. Funding gaps as a proportion of the total budget were similar for Brazil and non-HBCs in the Region of the Americas. Funding gaps were lower for non high-burden countries relative to HBCs in the Eastern Mediterranean and Western Pacic regions. Overall, NTP budgets per incident TB case were higher for HBCs compared with non-HBCs in the African Region and the European Region, and much lower for HBCs compared with non-HBCs in the Region of the Americas and the Eastern Mediterranean, South-East Asia and Western Pacic regions.
3.3 Total costs of TB control

NTP budgets include only part of the resources needed to control TB. Specically, they do not include the costs associated with using general health-service staff resources and infrastructure for TB control, both of which are used when TB patients are hospitalized or visit outpatient facilities during treatment. For the 22 HBCs combined, the total cost of TB control will reach almost US$ 2.9 billion in 2009 if funding gaps can be closed, almost three times higher than the US$ 1.2 billion actual expenditures estimated for 2002 (FIGURES 3.73.10 ; TABLE 3.1). The total of US$ 2.9 billion is mostly for DOTS (US$ 2 billion, or 69%). The other major components are MDR-TB (US$ 0.4 billion, or 14%; 88% of this total is accounted for by the Russian Federation and South Africa), TB/HIV (US$ 90 million, or 3%) and ACSM
FIGURE 3.7 Total TB control costs by line item, high-burden countries,a 20022009
3000 2500 2047 US$ millions 2000 1500 1160 1000 500 0 1469 1292 1627 2116 2939 2696 Unknownd Othere Clinic visits Hospitalization NTP budget
FIGURE 3.8 Total TB control costs by source of funding, high-burden countries,a 20022009
3000 2500 2047 2116 US$ millions 2000 1500 1000 500 1469 1160 1292 1627 2939 2696 Unknownd Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)
2002b 2003 2004 2005 2006
2007 2008 2009c
2002b 2003 2004 2005 2006
2007 2008 2009c
c d e
Total TB control costs for 20022007 are based on expenditure data, whereas those for 20082009 are based on budget data. Estimates assume costs 2002 equal to costs 2003 for Afghanistan, Bangladesh, Mozambique, Nigeria, Uganda and Zimbabwe. Estimates assume costs 2009 equal to costs 2008 for South Africa. Unknown applies to Russian Federation 2003. Other includes costs for uorography in the Russian Federation that are not reected in NTP budget or NTP expenditure data.
c d
Total TB control costs for 20022007 are based on expenditure data, whereas those for 20082009 are based on budget data. Estimates assume costs 2002 equal to costs 2003 for Afghanistan, Bangladesh, Mozambique, Nigeria, Uganda and Zimbabwe. Estimates assume costs 2009 equal to costs 2008 for South Africa. Unknown applies to South Africa 20082009.
(US$ 70 million, or 2%). The remaining 12% includes PPM, surveys of the prevalence of TB disease, community TB care and a variety of miscellaneous activities. Total costs have increased year-on-year since 2002 across all HBCs, a pattern that is repeated in most individual countries (FIGURE 3.9). Exceptions are Bangladesh and Viet Nam; however, the apparently low expenditures in these countries in 2007 probably reect only partial reporting of expenditures. The steady climb in the total resources available for TB control in Brazil, China and India since 2002 is impressive. Increases in projected costs during 20022009 arise because of the large increases in NTP budgets (described above) and, to a much lesser extent, because of the higher costs of clinic visits and hospitalization that are associated with treating more patients (FIGURE 3.7). As in previous years, the Russian Federation and South Africa rank rst and second in terms of total costs. Together, they account for US$ 1.9 billion (64%) of the total of US$ 2.9 billion (FIGURE 3.10 ; TABLE 3.1). China (US$ 225 million), India (US$ 138 million), Brazil (US$ 92 million) and Indonesia (US$ 85 million) rank third to sixth. These six countries account for 82% of the total cost of TB control in the 22 HBCs in 2009. In South Africa, there are two major reasons for the high cost of TB control estimated for 2009. One is the large costs associated with maintaining around 8000 TB beds in district hospitals and specialized TB hospitals at a unit price per bed-day of around US$ 100 and US$ 40, respectively. The second is a large budget for the diagnosis and treatment of MDR-TB (ANNEX 2; SECTION 3.2). The largest components of the budget for MDR-TB are for renovating and constructing infrastructure in line with a national policy of hospitalizing all patients with MDR-TB for at least six months; improving infection control in MDR-TB and XDRTB units as well as in general district hospitals; and providing second-line anti-TB drugs for the enrolment of around 5000 patients on treatment. High costs in the Russian Federation
in 2009 are associated with continued stafng and maintenance of an extensive network of TB hospitals and sanatoria; a large budget for second-line anti-TB drugs to treat MDR-TB patients (US$ 133 million, with an estimated total of about 4000 cases to be enrolled on treatment in 2009); and continued use of uorography for mass population screening. Funding for the general health-service staff and infrastructure used by TB patients during clinic visits and hospitalization is assumed to be provided by governments (ANNEX 2). This assumption, together with the implicit assumption that health systems have sufcient capacity to support the treatment of a growing numbers of patients in 2009,1 means that the resources available for TB control are estimated to have increased from US$ 1.2 billion in 2002 to US$ 2.2 billion in 2009 (FIGURE 3.8). For all HBCs, the estimated gap between the funding already available and the total cost of TB control is between US$ 0.5 and US$ 0.7 billion in 2009.2 Of the US$ 2.2 billion available in the 22 HBCs in 2009, 88% is from HBC governments, 8% (US$169 million) is from the Global Fund and 4% (US$ 94 million) is from grants from sources other than the Global Fund. The distribution of funding sources is different when the Russian Federation and South Africa are excluded: the government contribution to available funding drops to 70%, the Global Fund contribution increases to 19%, and grants from sources besides the Global Fund account for 11%. As in previous years, there is considerable variation in the distribution of funding sources among countries (FIGURE 3.11; TABLE 3.1). For example, Afghanistan is highly dependent on grant nancing and four other countries (Ban1
Nonetheless, the capacity of health systems to manage an increasing number of TB patients warrants further analysis, particularly in countries where the number of patients will need to increase substantially to achieve the MDG and related Stop TB Partnership targets for TB control. The range reects uncertainty about the level of funding from provincial governments in South Africa.
FIGURE 3.9 Total TB control costs, high-burden countries, 20022009

Afghanistan
14 12 10 8 6 4 2 20 18 16 14 12 10 8 50 40 6 4
Bangladesh
90 80 70 60
Brazil
12 10
Cambodia
200
China
150 8 100
DR Congo
60 50 40 30 20 30 25 20 15 10
Ethiopia
130 120 110 100 90 80 70
India
80 70 60 50 40 30
Indonesia
40 35 30 25 20 15 10
Kenya
Mozambique
30 US$ millions 25 20 15 1 5 16 14 12 10 8 6 4
Myanmar
50 40 30 20 10
Nigeria
50 40 30 20 10
Pakistan
32 30 28 26 24 22
Philippines
Russian Federation
600 1200 1100 1000 900 800 700 600 500 550 500 450 400 350
South Africa
50
Thailand
18 16 14 12 10 8 6 4
Uganda
25 20 15 10
UR Tanzania
45
40
35
Viet Nam
28 26 24 22 20 18 10 15 20
Zimbabwe
2500 2000 1500
22 HBCs
2003
2005
2007
2009
2003
2005
2007
2009
2003
2005
2007
2009
2003
2005
2007
2009
2003
2005
2007
2009
FIGURE 3.10 Total TB control costs by country, high-burden countries, 20022009

3000 2696 2500 2047 2000 US$ millions 1627 1500 1160 1000 1469 1292 2116 2939 All other HBCs DR Congo Kenya UR Tanzania Indonesia Nigeria Brazil India China South Africa Russian Federation 500
0 2002 2003 2004 2005 2006 2007 2008 2009
FIGURE 3.11 Total TB control costs by source of funding, 21 high-burden countries, a 2009
Thailand Brazil Russian Federation China Viet Nam India Philippines Bangladesh Indonesia Mozambique UR Tanzania Nigeria Kenya Ethiopia Cambodia Myanmar Pakistan Zimbabwe DR Congo Uganda Afghanistan 0 10 20 30 40 50 60 70 80 90 100
a
Government (excluding loans) Government (excluding loans), general health system Loans Grants (excluding Global Fund) Global Fund Gap
Data for South Africa not included as sources of funding are not known for most components of the budget. Countries ranked according to government contribution, i.e. government plus loans.
% of total TB control costs
FIGURE 3.12 gladesh, Cambodia, Mozambique and MyanGovernment contribution (including loans) to total TB control costs by gross mar) rely on grants to cover at least 40% of national income (GNI) per capita, 19 high-burden countries,a 2009 the total resources needed for TB control. In 100 SOUTH AFRICA THAILAND nine HBCs, grant funding accounts for more BRAZIL than 50% of the currently available fund80 CHINA RUSSIAN FEDERATION VIET NAM ing in 2009 (Afghanistan, Cambodia, the INDIA 60 Democratic Republic of the Congo, Kenya, BANGLADESH PHILIPPINES UR INDONESIA Mozambique, Myanmar, Pakistan, Uganda, MOZAMBIQUE TANZANIA 40 KENYA and Zimbabwe). In contrast, grant nancing NIGERIA ETHIOPIA DR CONGO PAKISTAN CAMBODIA contributes less than 2% of the total funding 20 UGANDA required in 2009 in Brazil, the Russian Federation and Thailand. 0 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 The share of the total costs nanced by GNI per capita (log ) HBC governments is closely related to avera age income levels (FIGURE 3.12), although Data on GNI per capita not available for Afghanistan, Myanmar and Zimbabwe. there appears to be scope to increase the government contribution in several countries (for FIGURE 3.13 example, Indonesia, Pakistan and the Russian Federation).
Government contribution to total TB control costs (%)
e
3.3.2 All countries

Total costs for 20062009 can be estimated for 111 countries that collectively account for 93% of TB cases globally (FIGURE 3.13).1 The total costs of TB control will increase from US$ 2.6 billion in 2006 to US$ 4.3 billion in 2009 (if funding gaps in 2009 can be closed). DOTS implementation accounts for the largest single share of these costs, but the share for MDR-TB and a range of other interventions is increasing. The share of total costs accounted for by collaborative TB/HIV activities and ACSM remains small. For 89 countries outside the 22 HBCs for which data are available, trends in total costs by region and for all regions combined are shown in FIGURE 3.14. Costs are generally
1
Total TB control costs by line item, 22 high-burden countries and 89 other countries,a 20062009
5 4.3 4 US$ billions 3 2 1 0 2006
a
3.9
2.6
2.8
Otherb ACSM TB/HIV MDR-TB DOTSc
2007
2008
2009
b c
These 111 countries account for 93% of the global total of 9.27 million incident cases of TB estimated in 2007. Other includes PPM, PAL, CBTC, operational research, surveys and other. DOTS includes the cost of clinic visits and hospitalization.
These 111 countries reported data for at least two of the years 2006 2009. For countries that did not report data in all four years, costs were estimated using data for the two or three years for which data were reported.
FIGURE 3.14 Total TB control costs by region, 89 non high-burden countries, 20062009. Numbers in parentheses show the number of countries included in the analysis in each region.
DOTSa
40
MDR-TB
TB/HIV
ACSM
Otherb
Total AFR (20)
35 25
250 200 150 100 50
AMR (18)
100
EMR (12)
80 60 40 20 700 600 500 400 300 200 100 35 30 25 20 15 10 5 0 40
US$ millions
EUR (18) SEAR (5) WPR (16)
40 30 20 10
All regions (89)
1200 1000 800 600 400 200
2008
2008
2008
2008
2008
2006
2007
2009
2006
2007
2009
2006
2007
2009
2006
2007
2009
2006
2007
2009
2006
2007
2008
a b
DOTS includes the cost of clinic visits and hospitalization. Other includes PPM, PAL, CBTC, operational research, surveys and other.
2009
FIGURE 3.15 Total TB control costs: the Global Plan compared with country plansa and available funding, high-burden countries, 20062009
3.5
3.0 2.9 Otherb ACSM TB/HIV MDR-TB DOTSc
3.0 2.5
US$ billions 2.0 2.0 2.4 2.1 2.1
2.8
2.7 2.2 2.2
2.0 1.5 1.0 0.5 0
1.9
Global Plan
Country plans
Available funding
Global Plan
Country plans
Available funding
Global Plan
Country plans
Available funding
Global Plan
Country plans
Available funding
2006
a b c
2007
2008
2009
Costs of country plans are based on expenditures (20062007) and budgets (20082009). Other includes PPM, PAL, CBTC, operational research, surveys and other. DOTS includes the cost of clinic visits and hospitalization.
increasing (the exception being countries in the South-East Asia Region where the trend is relatively at) and are mostly accounted for by DOTS implementation.
3.4 Comparisons with the Global Plan

The Global Plan sets out what needs to be done between 2006 and 2015 to achieve the 2015 targets for TB control that have been set within the context of the Millennium Development Goals (MDGs) and by the Stop TB Partnership (see also CHAPTER 1 and CHAPTER 2). To assess the extent to which planning and nancing for TB control at country level are aligned with the Global Plan, the nancial resources estimated to be required for TB control in the Global Plan can be compared with the nancial data reported by countries.

The cost of TB control and available funding reported by countries during the period 20062009 are compared with the funding requirements included in the Global Plan in FIGURE 3.15.1 In 2006, actual costs (based on expenditure data) were slightly above those estimated to be required in the Global Plan, although there were shortfalls for collaborative TB/HIV activities and ACSM. From 2007 to 2009, the total funding requirements set out in country plans almost match those included in the Global Plan (for example, US$ 2.9 billion and US$ 3.0 billion respectively in 2009). However, available funding falls short of the amounts included in country plans and the Global Plan. The gap was US$ 0.3 billion in 2007 and US$ 0.8 billion in 2009. For MDR-TB and collaborative TB/HIV activities, the funding estimated to be required in the Global Plan is much higher than the funding estimated to be required by countries. For MDR-TB, the shortfall is mainly accounted for by China and India. In contrast, the funding estimated to be required for DOTS by countries is higher than the funding estimated to be required in the Global Plan. These aggregated comparisons conceal the fact that ve HBCs have planned costs consistent with those detailed in
the Global Plan in 2009: Brazil, Cambodia, the Democratic Republic of the Congo, Thailand and the United Republic of Tanzania. In addition, there are ve countries in which the discrepancy is due to the mid-2007 revision of the MDR-TB component of the Global Plan to include much more ambitious targets.2 With the exception of MDR-TB, country plans are consistent with the Global Plan in China, Indonesia, the Philippines, the Russian Federation and Viet Nam (ANNEX 1). For collaborative TB/HIV activities, the shortfall is mainly in Cambodia, the Democratic Republic of the Congo, Ethiopia, Kenya, India, Mozambique, Myanmar, Nigeria, Uganda and Zimbabwe. In these countries, the shortfall is exaggerated because the funding requirements for several collaborative TB/HIV activities (including the most costly ones such as ART) are part of the budgets of national AIDS control programmes, rather than NTPs.3 For ACSM, there are ve countries with ACSM budgets comparable to or larger than those indicated in the Global Plan: Brazil, Cambodia, Kenya, Pakistan and the Philippines. Country-by-country comparisons with the Global Plan are presented in ANNEX 1.
3.4.2 All countries

The nancial data submitted to WHO allow total TB control costs for 2009 to be estimated for 94 of the 171 countries that were included in the Global Plan (22 HBCs and 72 other countries).4 These 94 countries account for 93% of all incident cases of TB arising each year.5
1
See ANNEX 2 for an explanation of how costs for individual countries were derived from the Global Plan. The Global MDR-TB & XDR-TB response plan, 20072008. Geneva, World Health Organization, 2007 (WHO/HTM/TB/2007.387). In most of the countries that reported data, the costs of HIV testing, co-trimoxazole preventive therapy and antiretroviral treatment were part of the budgets of national AIDS control programmes rather than the budgets of NTPs. Of the 103 countries included in FIGURE 3.6, nine were not considered in the Global Plan cost estimates. All of the 171 countries included in the Global Plan accounted for 98% of TB cases globally in 2004.
FIGURE 3.16 Total TB control costs in 22 high-burden countries and 72a other countries: the Global Plan compared with country plans and available funding, 2009. Numbers in parentheses above bars show the percentage of all estimated incident cases of TB in the region that are accounted for by the countries included in the bar. Numbers in parentheses on the x-axis show the number of countries contributing to each bar.
2.0
1.9 (64%)
4.5 4.0
3.9 (93%)
4.2 (93%)
1.5
1.5 (88%)
1.4 (64%)
3.5 3.0
3.0 (93%)
US$ billions
1.1 (88%)
Available funding Otherb ACSM TB/HIV MDR-TB DOTSc
2.5
0.7 (64%) 0.7 (99%) 0.6 (96%) 0.3 0.2 0.2 (84%) 0.2 (91%) 0.2 (84%) (84%) (91%) 0.3 (99%) 0.1 (91%) 0.3 (99%) 0.4 0.4 (96%) (96%)
1.0
2.0 1.5 1.0 0.5 0
0.6 (88%)
0.5
0
Global Plan Country Available Global plans funding Plan Country Available Global plans funding Plan Country Available Global plans funding Plan Country Available Global plans funding Plan Country Available Global plans funding Plan Country Available plans funding
Global Plan
Country plans
Available funding
AFR (28)
a
AMR (16)
EMR (14)
EUR (9)
SEAR (10)
WPR (17)
All regions (94)
b c
Canada, Cyprus, Malta, the Netherlands, Portugal, Serbia, Slovakia, the former Yugoslav Republic of Macedonia and Switzerland are excluded because they were not included in the Global Plan. Other includes PPM, PAL, CBTC, operational research, surveys and other. DOTS includes the cost of clinic visits and hospitalization.
A regional comparison of costs planned by countries with the costs included in the Global Plan is shown for these 94 countries in FIGURE 3.16. Overall, country plans indicate planned costs of US$ 4.2 billion in 2009 (up from US$ 3.1 billion in 2008 and US$ 2.3 billion in 2007), compared with US$ 3.9 billion in the Global Plan, and available funding of US$ 3.0 billion. Of the available funding of US$ 3.0 billion, 87% is funding from governments (including loans), 9% is funding from Global Fund grants and 4% is funding from donors other than the Global Fund. The total of US$ 4.2 billion required for full implementation of country plans in these countries in 2009 is mostly for DOTS (US$ 3.0 billion, or 72%). The other major components are MDR-TB (US$ 0.5 billion, or 12%; 76% of the total for MDR-TB is accounted for by the Russian Federation and South Africa), collaborative TB/HIV activities (US$ 120 million, or 3%) and ACSM (US$ 100 million, or 2%). The remaining 11% includes PPM, surveys of the prevalence of TB disease, community TB care and a variety of miscellaneous activities. The apparent similarity between the Global Plan and country plans when data are aggregated for all countries is distorted by the comparatively high cost of country plans in the European Region. As FIGURE 3.16 makes clear, the funding estimated to be required for MDR-TB in country plans falls far short of Global Plan estimates in the South-East Asia and Western Pacic regions. This is consistent with the relatively small number of cases of MDR-TB that countries in these regions (notably China and India) expect to diagnose and treat in 2009 (as documented in CHAPTER 2). Country plans also indicate lower planned spending on collaborative TB/HIV activities compared with the Global Plan in the African Region, which has 79% of the estimated global total of HIV-positive TB cases. This is consistent with data on the
current level of implementation of collaborative TB/HIV activities (CHAPTER 2), although the difference (as noted above) is exaggerated because the planned activities and associated funding of national AIDS control programmes are not included in the data reported by NTPs.1 It is only in the Eastern Mediterranean Region and the Region of the Americas that country plans appear to be consistent with the Global Plan. Excluding the European Region, the funding gaps reported by countries amount to US$ 0.6 billion in 2009 (US$2.3 billion required compared with US$ 1.7 billion available). Compared with the needs set out in the Global Plan, the gap is US$ 1.6 billion (US$ 3.2 billion required according to the Global Plan compared with available funding of US$ 1.6 billion). In the European Region, the funding available in 2009 exceeds the funding estimated to be required in the Global Plan. One explanation is the reductions anticipated in the Global Plan in the use of hospitalization during treatment, which are not happening in practice. These differences between the funding requirements set out in country plans and the Global Plan suggest that country planning, budgeting and nancing lag behind the Global Plan in three major areas: DOTS and collaborative TB/HIV activities in Africa, and diagnosis and treatment of MDR-TB in the European, South-East Asia and Western Pacic regions (and within these regions, in the Russian Federation, India and China in particular).
1
This may also explain the higher costs of collaborative TB/HIV activities in the Global Plan compared with country plans in the South-East Asia Region. For example, the only TB/HIV-related costs included in the NTP budget in India are those for HIV testing of TB patients, which is a relatively inexpensive intervention. In India, it is not known to what extent other activities are budgeted for and funded by the national AIDS control programme.
WHO has developed a planning and budgeting tool that is designed to help countries to align their plans and budgets with the Stop TB Strategy and the targets set out in the Global Plan, as well as to produce more accurate country-specic estimates of the nancial resources required to achieve these targets.1 The development and use of this tool is described in BOX 3.1.
BOX 3.1
Planning and budgeting for TB control: the WHO TB planning and budgeting tool
The WHO TB planning and budgeting tool is designed to help countries to develop comprehensive plans and budgets for TB control within the framework of the Stop TB Strategy and the Global Plan to Stop TB, and to use these as the basis for resource mobilization from national governments and donors. The tool was developed with support from USAIDs TB Control Assistance Program, and can be downloaded (together with accompanying documentation) from the Stop TB Departments web site http://www.who.int/tb/dots/planning_budgeting_tool/en/. Major advantages of using the tool include: (i) it allows plans and budgets to be set out comprehensively in one place in a standardized format; (ii) it offers a ready-made list of inputs and activities to consider when planning and budgeting for each component of the Stop TB Strategy; (iii) it includes epidemiological and demographic projections as well as information about the targets set out in the Global Plan; (iv) it provides a solid foundation for resource mobilization from national and local governments as well as donors such as the Global Fund; (v) it is easy to revise or update plans and budgets because it is set out in Excel; and (vi) it automatically produces summary analyses in the form of gures and tables. Overall, these benets should help to improve the quality of planning and budgeting. A draft version of the tool was developed in AprilMay 2006. Following extensive eld-testing in countries in the African and SouthEast Asia regions and the Region of the Americas, a nal version with was produced by January 2007. The tool was translated into English, French, Spanish and Russian. Promotion and practical application of the tool started in 2007. Four planning and budgeting workshops were conducted: two in the African Region for a total of 34 countries; one in the South-East Asia region for nine countries: and one in the Region of the Americas for 11 countries. Two training workshops have also been conducted: one for seven countries in Latin America and one for three countries in the Western Pacic Region. During these workshops, feedback about the tool was very positive. Other examples of how the tool has been disseminated include presentations at workshops for the development of Global Fund proposals, presentations at international meetings and regional NTP manager meetings; a training workshops for technical partners and staff from WHO regional and country ofces, and inclusion of the tool in an international course on management and budgeting organized annually by the International Union Against Tuberculosis and Lung Disease. To date, 27 countries are known to have used the tool to budget their national strategic plans for TB control. The Democratic Republic of the Congo, Ethiopia, Kenya, Mozambique, Myanmar, Thailand and Zambia are examples of countries that have developed particularly comprehensive and detailed plans and budgets using the tool. Most of the countries that have attended one of the workshops have used the tool to budget at least some of the components of the Stop TB Strategy. Others have used it to develop the budget component of a Global Fund proposal. A recent example is Indonesia, whose proposal was rated Category 1 (recommended for funding with no or minor clarications). In future, the tool could provide the basis for National Strategy Applications (NSAs) to the Global Fund.
3.5 Budgets and costs per patient

Budgets and costs per patient in HBCs are shown in TABLE 3.2. The budget for rst-line anti-TB drugs per patient is lowest in Cambodia (US$ 18) and highest in Brazil (US$ 121), Thailand (US$ 161) and the Russian Federation (US$ 308). In most countries, the budget is in the range US$ 2040, with a median of US$ 33. The budget per patient for DOTS treatment also varies. Only two countries (India and Myanmar) have budgets below US$ 100 per patient. A total of four countries have budgets in the range US$ 100200 per patient, four are in the range US$ 200300 and seven are in the range US$ 300600.2 The four countries with a budget per patient exceeding US$ 600 are Brazil, Mozambique, the Russian Federation and Thailand. Of these, all except Mozambique are middle-income countries where budgets are expected to be higher, although the budget of US$ 9292 per patient in the Russian Federation is exceptionally high compared with all other HBCs. As noted in SECTION 3.2, these high costs can be explained by extensive use of hospitalization during treatment. In 2009, the total cost per patient treated in a DOTS programme is estimated at under US$ 100 in only one country: Myanmar. It is in the range US$ 100300 in seven countries, and US$ 300500 in nine countries (up from three in 2007 and 2008). Four countries have much higher costs: Brazil, Mozambique, the Russian Federation and Thailand. As already noted, three of these countries are middle-income countries with generally higher prices for the inputs needed for TB control, while the Russian Federation also has large budgets for MDR-TB treatment as well as maintenance of hospital infrastructure. The relatively high cost for Mozambique relative to other African countries is mainly due to comprehensive budgeting for collaborative TB/HIV activities. Among the low-income countries, there is no obvious relationship between the cost per patient treated and GNI per capita. For example, in India the cost per patient treated is low relative to income levels, while in the Democratic Republic of the Congo and Mozambique this cost is relatively high compared with GNI per capita (data not shown). Overall, budgets and costs per patient are generally increasing, with a median increase of 350% per patient in the NTP budget per patient and a median increase in the total cost per patient of 240% (although the median increase for rst-line drugs was only 20%).
1
See http://www.who.int/tb/dots/planning_budgeting_tool/en/index. html Figures were not calculated for South Africa because the nancial data available for 2009 were not complete. See also FIGURE 3.1.
TABLE 3.2 Total TB control costs and NTP budgets per patient for DOTS treatment, high-burden countries, 2009
2009 (US$) FIRST-LINE DRUGS BUDGET NTP BUDGET (EXCLUDING MDR-TB) TOTAL COST (EXCLUDING MDR-TB) FIRST-LINE DRUGS BUDGET CHANGES SINCE 2002, (FACTORa) NTP BUDGET (EXCLUDING MDR-TB) TOTAL COST (EXCLUDING MDR-TB)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
22 28 48 25 24 24 58 34 27 308 50 21 121 28 74 68 161 28 33 18 37 33
80 226 288 351 104 166 205 112 359 9292 120 331 812 407 327 396 810 679 73 264 329 327
111 226 307 442 144 220 221 193 447 9491 254 378 1234 480 351 491 827 847 87 329 368 351
2.2 1.7 1.5 0.5 1.2 0.9 1.0 0.7 0.8 4.7 1.5 0.6 2.7 0.7 1.4 2.3 1.3 1.9 0.4 0.5 1.2
3.5 1.7 2.5 2.7 1.3 3.8 4.5 0.9 3.9 2.0 1.4 6.4 4.9 5.0 7.0 12 9.8 3.5 2.0 1.1 3.5
1.9 1.7 2.3 2.0 1.2 3.4 2.4 1.0 2.6 2.5 1.3 3.9 2.6 2.6 5.2 7.0 6.2 1.6 1.7 3.2 2.4
High-burden countries (median value)
Indicates not available. Calculated as 2009 value divided by 2002 value.
FIGURE 3.17 NTP budgets, available funding and expenditures by region, 19 high-burden countries,a 2007
1200 1000 800 600 400 200 0 AFR
a
3.6 Expenditures compared with available funding and changes in the number of patients treated
Countries that have received large increases in funding face two important challenges: to spend the extra money, and to translate extra spending into improved rates of case detection and treatment success. To date, WHO has been able to conduct analyses for the HBCs only. The ability to mobilize resources can be assessed by comparing available funding with budgets, and the ability to use nancial resources can be assessed by comparing expenditures with available funding (TABLE 3.3 ; FIGURE 3.17; FIGURE 3.18). The latest year for which data are available for all three indicators is 2007. In 2007, Bangladesh, Ethiopia, India and Indonesia were the most successful of the HBCs in mobilizing funds for their budgets, while Afghanistan, Cambodia, Myanmar and Uganda were least successful (TABLE 3.3). Most HBCs reported spending a high proportion of their available funding, and in some cases the funds that were raised and spent exceeded the original budget ( TABLE 3.3).1 Three countries had expenditures that appeared to be particularly low relative to available funding: Bangladesh, Mozambique and Viet Nam. Review of the nancial data reported by these
1
NTP budgets Available funding Expenditures
US$ millions
AMR
EMR
EUR
SEAR
WPR
AFR excludes South Africa and Uganda. SEAR excludes Thailand.
This explains why the value of expenditures in 2007 as a percentage of the available funding prospectively reported in 2007 (nal column of TABLE 3.3) exceeds 100.
TABLE 3.3 NTP budgets, available funding and expenditures (US$ millions), high-burden countries, 2007
AVAILABLE FUNDING AS % OF NTP BUDGET EXPENDITURES AS % OF AVAILABLE FUNDINGc
FIGURE 3.18 Change in NTP expenditure and change in all types of patients treated under DOTS, 20 high-burden countries,a,b,c 20032007
Bangladesh Viet Nam Afghanistan Ethiopia Zimbabwe Indonesia Philippines Mozambique Cambodia Myanmar China India South Africa UR Tanzania DR Congo Pakistan Kenya Nigeria Russian Federation Brazil -100 0 100 200 300 400 Percentage change 20032007 500 600 % change in all new cases treated under DOTS 20032007 % change NTP expenditure 20032007
NTP BUDGET
AVAILABLE FUNDINGa
EXPENDITURESb
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
63 272 59 29 378 21 8.9 29 19 24 1 078 16 29 51 8.2 11 3.9 11 16 8.5 14
63 181 59 20 21 8.9 18 17 15 846 12 18 42 4.2 2.6 8.9 3.1 4.0 3.2 1 347
67 188 27 21 2.2 8.2 10 20 15 991 4.3 18 59 11 2.2 40 3.5 3.1 5.0 2.2 1 498
100 66 100 69 100 100 62 89 62 78 77 63 82 38 68 78 19 47 22 70d
106 104 46 105 11 92 55 117 105 117 35 97 140 83 40 100 124 71 86d
a b
High-burden countries 2 151
a b c
Countries ranked by percentage change in NTP expenditure. Expenditure data not available for Thailand and Uganda. Comparison for Kenya is between 2007 and 2004. For South Africa the comparison is between 2006 and 2005. Expenditure data for Afghanistan, Bangladesh and Viet Nam appear incomplete. See also FIGURE 3.9.
Indicates not available. Based on budget data, reported prospectively in 2007. Based on actual expenditures, reported in 2008. Figures can be above 100% when additional funds were mobilized after reporting of data about budgets and sources of funding in 2007. Mean values.
countries suggests that this reects underreporting of expenditure data, at least in Bangladesh and Viet Nam (see also FIGURE 3.9). When country data for the HBCs are aggregated by region (FIGURE 3.17), the ability to mobilize resources was best in the South-East Asia Region and the Region of the Americas, and worst in the Eastern Mediterranean Region. The ability to spend available resources was best in the Western Pacic Region and the Region of the Americas. It appeared to be worst in the South-East Asia, but this nding is affected by apparent underreporting of expenditures in Bangladesh and a temporary cessation of funding from a Global Fund grant in Indonesia. The ability to translate spending into an increased number of detected and treated patients can be assessed by comparing changes in expenditures 20032007 with changes in the number of TB patients treated in 20032007 (FIGURE 3.18 ; 2007 is the most recent year for which both case notication and expenditure data are available). Of the 20 HBCs for which data were available, all except one (the United Republic of Tanzania) of the 16 countries that increased spending between 2003 and 2007 also increased the number of new cases that were detected and treated in DOTS programmes
(a similar relationship applied for new smear-positive cases specically; data not shown). For the United Republic of Tanzania, the explanation may be that much of the increased expenditure was for collaborative TB/HIV activities, which (with the exception of intensied TB case-nding in people who are HIV-positive) are not expected to increase the number of cases detected and treated in DOTS programmes. The relationship between increased expenditure and changes in the total number of patients treated was, however, variable. In Brazil, Indonesia, Pakistan and the Russian Federation, the increase in the number of patients treated under DOTS exceeded or approached the increase in expenditures. In Brazil and the Russian Federation, increasing the number of cases treated under DOTS should be easier than in other countries, since it requires mainly a substitution of DOTS for non-DOTS treatment rather than an increase in total case notications. There was an almost one-to-one relationship between increased expenditures and increased notications of new cases under DOTS in Pakistan. At the other end of the spectrum, four countries (Afghanistan, Bangladesh, Ethiopia and Viet Nam) reported lower expenditures in 2007 compared with 2003, although none of these countries reported a fall in the number of cases treated. While the data
FIGURE 3.19 Global Fund commitments for TB control by region, as of end 2008a
WPR 20% (US$ 755 million) AFR 29% (US$ 1131 million)
are plausible for Ethiopia (given high investments in 2003), it seems likely that expenditures have been underreported in the other three countries.
3.7 Global Fund nancing

After eight rounds of proposals, the total value of approved proposals in the HBCs is US$ 2.3 billion; the amounts in the Phase 1 grant agreements (that is, for grants covering the rst two years of the proposal) total US$ 632 million (data not shown). The Global Fund is the single most important source of external nancing in HBCs (65% of total grant nancing); seven countries (Afghanistan, Bangladesh, Cambodia, Nigeria, the Philippines, Uganda and Viet Nam) rely on grants from the Global Fund to nance more than 25% of their NTP budgets. Only Myanmar does not have a Global Fund grant. By the end of 2008, US$ 719 million had been disbursed. Across all grants and countries, the actual disbursement rate is very similar to the expected rate,1 although there is variation among countries. Disbursements were higher than expected in 16 out of 56 grants, similar to what is expected in six grants and less than expected in 34 grants (data not shown). Countries for which disbursements are particularly low in relation to the expected disbursement of funds include Bangladesh (round 5), India (round 3), Indonesia (round 5, probably linked to a temporary cessation of funding in 2007), Kenya (round 2) and Uganda (round 6).
SEAR 22% (US$ 867 million)
AMR 6% (US$ 229 million) EMR 10% (US$ 382 million) EUR 13% (US$ 502 million)
Proportion of estimated global incident cases of TB that are accounted for by each region
WPR 21%
AFR 31%
SEAR 34%
AMR 3% EMR 6% EUR 5%
Refers to the total budgets approved in rounds 18.
FIGURE 3.20 Global Fund commitments and proposal approval rate by round. Numbers under bars show the number of TB proposals approved in each round.
1000 62 60 800 US$ millions 40 37 39 40 30 20 200 10 0 0 50 51 51 Approval rate (%) 50 600 38 70
3.7.2 All countries

In eight funding rounds between 2002 and 2008, the Global Fund approved proposals worth a total of US$ 3.9 billion for TB control in 102 countries, out of total commitments for HIV, TB and malaria of around US$ 15 billion.2 The African Region has the single largest share of grants for TB control, at 29% (FIGURE 3.19), which is similar to its share of the global burden of TB (31%). The South-East Asia and Western Pacic regions have the second and third highest funding in absolute terms, but less than might be expected given their share of the global burden of TB (42% of total funding compared with 55% of estimated cases). The share of total funding approved for the Eastern Mediterranean Region, the European Region and the Region of the Americas (10%, 13% and 6% respectively) is much higher than these regions share of the global burden of TB (6%, 5% and 3%). The value of approved proposals for TB control was highest in absolute terms in round 8 and relatively high in rounds 2, 5 and 6 (FIGURE 3.20 ). The percentage of proposals that were approved was highest in round 6, at 62%.3
1
400
Round 1 (16)
Round 2 (28)
Round 3 (20)
Round 4 (19)
Round 5 (24)
Round 6 (35)
Round 7 (19)
Round 8 (29)
Grant amount phase 1, i.e. 2-year funding Total budget approved, i.e. 5-year funding Approval rate
The expected rate assumes that disbursements are spread evenly over the two- or ve-year period of the grant agreement following the programme start date. The Global Fund has committed US$ 15.2 billion in rounds 18 for HIV, TB and malaria; grant agreements worth US$ 10.3 billion have been signed and US$ 7.2 billion has been disbursed. See www.theglobalfund. org/en/commitmentsdisbursements. Calculated as the number of proposals approved divided by the number of proposals reviewed by the Global Funds Technical Review Panel.
An analysis of the components of TB control for which countries requested funding in rounds 6 to 8 is presented in BOX 3.2.
BOX 3.2
Funding requested from the Global Fund in rounds 6 to 8

The Global Fund issued eight calls for proposals between 2002 and 2008. For rounds 68, it is possible to analyse the components of TB control for which countries sought funds according to the major components of the Stop TB Strategy. In rounds 68, the Global Fund approved 85 TB proposals. Most of the funding that was approved was for DOTS (56%), which was dened to include programme management and supervision, laboratory strengthening, training, patient support, human resource development, rst-line drugs and monitoring and evaluation. In round 8, there was a clear increase in the total funds approved for DOTS compared with previous rounds. This increase was mainly accounted for by increased funding for laboratory strengthening and an increase in the expected number of patients to be treated in DOTS programmes. Management of MDR-TB, including coordination activities, secondline drugs and laboratory strengthening specic to the diagnosis of drug resistance, was the second largest component (20%). The funds approved for MDR-TB increased steadily in absolute terms between round 6 and round 8, linked to an increase in the planned number of patients to be treated for MDR-TB. ACSM and community-based TB care accounted for 11% of requested funding in rounds 6 to 8. The remaining funding that was approved in rounds 6 to 8 was accounted for by health system strengthening, including the Practical Approach to Lung Health (5%), activities to control TB in high-risk populations and infection control (4%), collaborative TB/HIV activities (3%) and activities to engage all care providers (1%). Although it is likely that some of the costs for publicprivate mix initiatives are included under other headings (such as rst-line drugs and programme management), the amount appears surprisingly small given the need to ensure that all providers diagnose and treat TB patients according to the International Standards for Tuberculosis Care. A possible explanation for the small amount of funding requested for collaborative TB/HIV activities is that funds were requested mainly for coordination activities, while the funds for interventions such as CPT and ART are requested via HIV proposals. In future, the funding requested for infection control is expected to increase, linked to new policy guidance.
3.8 Funding gaps and the global nancial crisis

The global nancial crisis that developed in 2008 has been followed by either a halt to economic growth or an economic recession in most of the worlds biggest economies, including the United States, Japan, Germany, the United Kingdom, Italy, Spain and the European Union as a whole. The International Monetary Fund has predicted that the global economy will grow by just 0.5% in 2009 (compared with 3.4% in 2008), its lowest rate for 60 years.1 The consequences of economic slowdown and recession will be widespread, and the likely implications for global health are already being debated.2,3 The consequences for nancing of TB control specically are unpredictable, but while funding in 2009 is slightly higher than in previous years, funding gaps are likely to become more difcult to ll. In the next 23 years, the WHO nancial monitoring system set up in 2002 will allow changes in the total level of funding as well as sources of funding in the aftermath of the global nancial crisis to be identied. The 22 HBCs have reported a combined funding gap for TB control in the range of US$ 0.50.7 billion in 2009, while the funding gap reported for 111 countries (the 22 HBCs plus 89 other countries) amounts to US$ 0.91.1 billion in 2009. The main options for lling these funding gaps are (i) increasing the number and size of grants awarded for TB control by the Global Fund and other major donors and (ii) an increase in domestic funding. There does appear to be potential to increase grants from the Global Fund. The US$ 3.9 billion committed thus far for TB control (SECTION 3.7) represents 25% of total commitments to date. If funds were split evenly among the three global health priorities supported by the Global Fund (AIDS, TB and malaria), grants for TB control would be US$ 5.0 billion, or US$1.1 billion more than their existing level. With commitments currently spread over 11 years, this would be equivalent to around US$ 460 million per year, instead of the current value of approximately US$ 350 million per year. An increase in nancing for TB control from the Global Fund to US$ 500 million per year would reduce but certainly not eliminate the funding gaps that have been reported. However, if funding gaps in four middle-income countries with greater domestic resources (Brazil, China, the Russian Federation and South Africa) are excluded, the gaps reported by HBCs fall to about US$ 200 million in 2009. In the
1
IMF Survey Magazine [Online magazine] (available at http://www.imf. org/external/pubs/ft/survey/so/2009/res012809a.htm; accessed February 2009). The Financial Crisis and Global Health. Report of a High-Level Consultation, World Health Organization, Geneva, 19 January 2009 [Information Note 2009/1]. Geneva, World Health Organization, 2009 (available athttp:// www.who.int/mediacentre/events/meetings/2009_nancial_crisis_ report_en_.pdf; accessed February 2009). The global nancial crisis: an acute threat to health. Lancet, 2009, 373:355356.
TABLE 3.4 Financial indicators,a high-burden countries, 2009

TOTAL TB NTP BUDGET PER CAPITA (US$) CONTROL COSTS PER CAPITA (US$) FUNDING GAP PER CAPITA (US$) GOVERNMENT EXPENDITURE ON HEALTH PER CAPITA (US$) b TOTAL EXPENDITURE ON HEALTH PER CAPITA (US$) b GOVERNMENT HEALTH SPENDING USED FOR TB CONTROL (%) c TB GAP AS PERCENTAGE OF GENERAL GOVERNMENT HEALTH SPENDINGc
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
0.08 0.2 0.3 0.3 7.2 0.1 0.3 0.3 0.2 0.8 8.9 0.1 0.9 0.3 0.6 0.5 1.3 0.8 1.1 0.2 0.7 0.3 1.2
0.1 0.2 0.4 0.4 12.3 0.1 0.4 0.3 0.4 1.0 9.0 0.3 1.1 0.5 0.7 0.6 1.6 0.8 1.4 0.3 0.9 0.4 1.5
0.02 0.01 0.1 0.1 0.001 0.2 0.1 0.05 0.6 1.6 0 0.4 0.1 0.2 0.3 0.7 0.05 0.3 0.1 0.3 0.01 0.2
6.8 31 12 8.4 182 3.4 3.9 2.5 14 1.7 171 9.6 11 164 9.5 6.4 9.2 63 9.2 0.4 6.9 4.0 33
36 81 26 27 437 12 6.4 15 37 5.0 277 38 24 371 17 22 21 98 15 4.0 29 20 73
1.8 0.5 3.2 4.6 4.0 11 14 2.9 64 5.2 3.3 11 0.3 7.9 9.9 18 1.3 16 62 14 11 13
0.4 0.02 0.6 1.6 0.02 5.9 6.3 0.4 37 0.9 0 3.7 0.04 2.0 5.8 7.8 0.1 3.2 21 3.9 0.3 4.8
High-burden countries (mean value)
a b c
Indicates not available. For denition of how nancial indicators are calculated see ANNEX 2. Data for South Africa are for 2008. Latest data available are for 2005. Source: National health accounts [online database]. Geneva, World Health Organization, 2008. The indicators in these columns will be overestimates if government health expenditure has increased since 2005. Furthermore, there is uncertainty around the denominator used to calculate these indicators.
89 non-HBCs that reported data, funding gaps amount to US$ 120 million in 2009 (instead of US$ 423 million) when upper middle-income countries (dened as those with a GNI per capita of US$ 3706) are excluded. Filling funding gaps via the Global Fund appears much more feasible in this context, but still depends on (i) the submission of high-quality and sufciently ambitious proposals including well-justied budgets and (ii) the criteria used to determine which countries are eligible to apply for funding. While funding gaps currently identied by low and lowermiddle income countries could in theory be closed via applications to the Global Fund, closing gaps in upper-middle income countries as well as the additional gap that will open up if all countries plan in line with the Global Plan will require other sources of funding. The two other major options are external resource mobilization from donors other than the Global Fund and an increase in domestic nancing. Besides grant funding from the Global Fund, the (United States) Presidents Emergency Plan for AIDS Relief is the other major source of donor funding for health. The plan supports HIV prevention, treatment and care, of which collaborative TB/HIV activities is one part, in most of the African HBCs as well as Viet Nam. With billions of dollars per year avail-
able through this plan, it is important that collaborative TB/ HIV activities and related aspects of TB control (for example, laboratory strengthening) are supported as much as possible. UNITAID1 is also a source of donor funding for TB diagnostics and anti-TB drugs. At the end of 2008, UNITAID had committed support for rst-line and second-line anti-TB drugs in 66 countries up to 2011. This support includes funding for rstline anti-TB drugs provided through the Global Drug Facility (GDF) for 876 000 patients during the period 20072009 and for a further 4530 patients for the rst two years of grants approved in round 6 of the Global Fund; funding for second-line anti-TB drugs for the treatment of 4716 patients with MDR-TB during 20072011; and funding for paediatric anti-TB drugs provided through the GDF for 750 000 patients during 20072010. Increasing domestic nancing for TB control would mean a major shift from trends during the period 20022009, when almost all of the increase in domestic funding among the 22 HBCs was accounted for by Brazil, China and the Russian Federation. Two ways to assess the extent to which countries can mobilize more domestic funds are (i) to compare the percent1
http://www.unitaid.eu/
age of funding being provided from domestic sources with a countrys national income (measured as GNI per capita) to assess differences between countries with similar income levels (FIGURE 3.12) and (ii) to compare costs and funding gaps per capita with total government health expenditure per capita (TABLE 3.4). Comparing countries with similar income levels and a similar TB burden suggests that there is scope for increasing domestic funding in several countries, including Indonesia (compared with the Philippines), Pakistan (compared with India) and Kenya (compared with Viet Nam). Comparing costs and funding gaps per capita with government health expenditure suggests that the countries with the most capacity to fund TB control from domestic resources are Brazil, China and Thailand, followed by India, the Philippines, Indonesia and the Russian Federation. The countries with the least capacity to increase funding from domestic sources include the African countries (except South Africa) as well as Cambodia and Myanmar. Furthermore, much of the gap between the expectations set out in the Global Plan and existing country plans is accounted for by MDR-TB treatment in China and India. While affected by the global nancial crisis, these countries economies are still expected to grow by 6.75% and 5% respectively in 2009.1
3.9 Summary
The nancial data reported to WHO in 2008 are the most complete since nancial monitoring began in 2002, with more than 100 countries that collectively account for 93% of the worlds estimated TB cases providing the entire budget and funding data that were requested. Expenditure data continue to be more challenging to report, but 92 countries submitted a complete report in 2008.
The data show that funding for TB control has increased year-on-year since 2002. Among 94 countries that reported complete data, which account for 93% of TB cases globally and which were among the 171 countries considered in the Global Plan, available funding reached US$ 3.0 billion in 2009. Most of this funding (87%) will be provided by national governments, with the remainder provided by the Global Fund (9%) and other donors (4%). Among the 22 HBCs in which 80% of incident cases of TB occur, a total of US$ 2.2 billion is available in 2009, a small increase of US$ 27 million compared with 2008 but substantially above the US$ 1.2 billion that was spent on TB control in 2002. Most of the increased funding in HBCs since 2002 has come from domestic funding in Brazil, China and the Russian Federation, and external nancing from the Global Fund. Of the US$ 2.2 billion available in the 22 HBCs in 2009, 88% is from HBC governments, 8% (US$ 169 million) is from the Global Fund and 4% (US$ 94 million) is from grants from sources other than the Global Fund. The distribution of funding sources is strikingly different when the Russian Federation and South Africa are excluded: the government contribution to available funding drops to 70%, the Global Fund contribution increases to 19% and grants from sources besides the Global Fund account for 11%. Despite the increase in funding for TB control that has occurred over the past eight years, large funding gaps remain. Countries have identied funding gaps of US$ 1.2 billion in 2009. The gap is larger still, at US$ 1.6 billion, when available funding is compared with the funding requirements for 2009 that were estimated in the Global Plan. To close these funding gaps, additional resources will need to be mobilized from domestic sources as well as donors. This will be a major challenge in the context of a global nancial crisis.
IMF Survey Magazine [Online magazine] (available at http://www.imf. org/external/pubs/ft/survey/so/2009/res012809a.htm; accessed February 2009).
Conclusions
The main purpose of WHOs annual report on global TB control is to provide a comprehensive and up-to-date assessment of the TB epidemic and progress in controlling the disease at global, regional and country levels, in the context of global targets set for 2015. The latest estimates of the global burden of TB are that there were 9.3 million incident cases of TB and 13.7 million prevalent cases of TB in 2007. There were also 1.3 million deaths from TB among HIV-negative people in 2007, and an additional 456 000 deaths among HIV-positive TB cases equivalent to 23% of the total deaths attributed to HIV. The number of incident cases is increasing slowly in absolute terms due to population growth, with 86% of incident cases in Africa and Asia. Nonetheless, the number of incident cases per capita is falling slowly, both globally (with a rate of decline of less than 1% per year) and in all six WHO regions except the European Region (where rates are approximately stable). Incidence rates appear to have peaked globally in 2004, and if this is conrmed by further monitoring MDG Target 6.c to halt and reverse incidence by 2015 will have been achieved ten years ahead of the target date. Prevalence and mortality rates are also falling globally and in all six WHO regions. At least three of the six WHO regions the Eastern Mediterranean and South-East Asia regions as well as the Region of the Americas are on track to achieve the Stop TB Partnerships targets of halving prevalence and mortality rates by 2015 compared with their level in 1990. The Western Pacic Region is on track to halve the prevalence rate by 2015, but the mortality target may be narrowly missed. The African and European regions are far from achieving both targets, and for this reason it is unlikely that 1990 prevalence and death rates will be halved by 2015 for the world as a whole. The Stop TB Strategy is WHOs recommended approach to reducing the burden of TB in line with global targets; the Stop TB Partnerships Global Plan to Stop TB has set out the scale at which the interventions included in the strategy need to be implemented in each year 2006 to 2015. To date, DOTS is the component of the strategy that is most widely implemented and for which progress is closest to the milestones included in the Global Plan. In 2007, 5.5 million cases were notied by DOTS programmes, including 2.6 million new smear-positive cases. This is equivalent to a case detection rate of 63%, 7% short of the WHA target of detecting at least 70% of incident cases of smear-positive TB and 5% less than the Global Plan milestone of 68% for 2007. In 2006, 85% of the new smear-positive TB patients that were detected by DOTS programmes were successfully treated, exactly meeting the second WHA target. There
has also been progress in scaling up collaborative TB/HIV activities, especially in the African Region. Globally, 1 million TB patients (16% of notied cases) knew their HIV status in 2007, including 37% of notied cases in the African Region. Of the 250 000 TB patients who were known to be HIV-positive in Africa, 0.2 million were enrolled on CPT and 0.1 million were started on ART. Just under 30 000 cases of MDR-TB were notied to WHO in 2007, mostly by European countries and South Africa, and the number of cases of MDRTB diagnosed and treated according to international guidelines is expected to increase to 14 000 in 2009. Even so, the implementation of collaborative TB/HIV activities falls short of milestones set in the Global Plan, and the expansion of diagnosis and treatment of MDR-TB falls far short of Global Plan milestones, notably in the three countries where almost 60% of the worlds 0.5 million estimated cases of MDR-TB occur: China, India and the Russian Federation. The extent to which other components of the Stop TB Strategy are being implemented is less well understood, because to date progress is more difcult to quantify. However, the integration of diagnosis and treatment into primary health care in most countries, reported alignment of strategic planning for TB control with broader health sector planning frameworks, examples of how public-private mix initiatives can contribute to increased case detection in countries such as Pakistan and the Philippines, and increased attention to advocacy, communication and social mobilization are encouraging. Despite reductions in the global burden of TB, an estimated 37% of cases of smear-positive TB are not being treated in DOTS programmes; more than 90% of incident cases of MDR-TB are not being diagnosed and treated according to international guidelines; the majority of HIV-positive TB cases do not know their HIV status; and the majority of HIVpositive TB patients who do know their HIV status are not yet accessing ART. To accelerate progress in global TB control, these numbers need to be reduced using the range of interventions and approaches included in the Stop TB Strategy, with the necessary nancial backing. In 2009, US$ 3 billion is available for TB control, which is US$ 1.2 billion less than countries own estimates of their funding requirements and US$ 1.6 billion short of the funding required according to the Global Plan. Most of the extra funding required according to the Global Plan is for MDR-TB diagnosis and treatment in the South-East Asia and Western Pacic regions (mostly in India and China), and for DOTS and collaborative TB/HIV activities in Africa. In the context of a global nancial crisis, closing these funding gaps will be a major challenge.
ANNEX 1
Proles of high-burden countries
COUNTRY PROFILE
Afghanistan
Despite a difcult situation on the ground, Afghanistan achieved a case detection rate of over 60% in 2007. The treatment success rate fell below 85% for the 2006 cohort after four years above the target. TB control services are an integral part of the package of services delivered through the primary health-care system at district and provincial levels. This package is implemented largely by NGOs; a network of partners has been developed at national and international levels to provide coordinated support to the NTP. The sustainability of activities is unclear, given the unstable security situation in many areas, particularly in the southern and south-eastern regions. The involvement of private practitioners has begun but needs to be expanded beyond pilot projects. Furthermore, several components of TB control have not yet been addressed, including the management of MDR-TB, the development of collaborative TB/HIV activities and the implementation of contact investigation.
| SURVEILLANCE AND EPIDEMIOLOGY

Population (thousands) a Estimates of epidemiological burden, 2007b Incidence All forms of TB (thousands of new cases per year) All forms of TB (new cases per 100 000 pop/year) Rate of change in incidence rate (%), 20062007 New ss+ cases (thousands of new cases per year) New ss+ cases (per 100 000 pop/year) HIV+ incident TB cases (% of all TB cases) Prevalence All forms of TB (thousands of cases) All forms of TB (cases per 100 000 pop) 2015 target for prevalence (cases per 100 000 pop) Mortality All forms of TB (thousands of deaths per year) All forms of TB (deaths per 100 000 pop/year) 2015 target for mortality (deaths per 100 000 pop/year) Multidrug-resistant TB (MDR-TB) MDR-TB among all new TB cases (%) MDR-TB among previously treated TB cases (%) 27 145
ALL IN HIV+ PEOPLE
TB notication rate (new and relapse), 2007
46 168 0 21 76 0 65 238 218 8.2 30 25 3.3 36
0 0 0 0 0 0 0 0
New ss/unk 40 30 20 30 20 10 0 1995 Defaulted
Rate* (% of all) 59102 (28%) 103123 (28%) 124145 (44%) No data * Per 100 000 pop
Total notications, 2007 Notied new and relapse cases (thousands) Notied new and relapse cases (per 100 000 pop/year) Notied new ss+ cases (thousands) Notied new ss+ cases (per 100 000 pop/year) as % of new pulmonary cases sex ratio (male/female) DOTS case detection rate (% of estimated new ss+) Notied new extrapulmonary cases (thousands) as % of notied new cases Notied new ss+ cases in children (<15 years) (thousands) as % of notied new ss+ cases
New extrapulmonary 5 4 3 2 1 2000 2005 2000 2005 0 1995 2000 2005 Data not reported Relapse Re-treatment
29 106 13 49 62 0.5 64 6.2 22 0.7 5.0
Case notications
Notification rate (DOTS and non-DOTS cases/100 000 pop)
New ss+ 60 40 20 0 1995
10 0 1995 Failed
2000
2005
Unfavourable treatment outcomes, 2006 cohorts
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB 0 1 2
Transferred
Not evaluated
3 0
3 0
3 0
8 0
Percentage
DOTS coverage (%) Notication rate (new & relapse cases/100 000 pop) % notied new & relapse cases reported under DOTS Notication rate (new ss+ cases/100 000 pop) % notied new ss+ cases reported under DOTS Case detection rate (all new cases, %) Case detection rate (new ss+ cases, %) Treatment success (new ss+ patients, %) Re-treatment success (ss+ patients, %)
2000 15 34 100 14 100 20 18 85 78
2001 12 47 100 22 100 28 29 84
2002 38 62 100 29 100 35 39 87
2003 53 60 100 28 100 34 37 86
2004 68 76 100 34 100 43 45 89
2005 81 87 100 40 100 50 52 90 89
2006 97 98 100 48 100 55 63 84 79
2007 97 106 100 49 100 61 64
Note: notication, case detection and treatment success rates are for the whole country (i.e. DOTS and non-DOTS cases combined).
AFGHANISTAN
| DOTS EXPANSION AND ENHANCEMENT

Overview of services for diagnosis of TB and treatment of patients
Description of basic management unit Regional hospital, provincial hospital, district hospital, comprehensive health centre, basic health centre 991/991
Political commitment
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20092013) Yes (established 2003) Yes (established 2008)
Number of units (DOTS/total), 2007 Location of NTP services Rural District hospital, comprehensive health centre, basic health centre Urban Regional hospital, provincial hospital, professional hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural District hospital, comprehensive health centre, basic health centre Urban Regional hospital, provincial hospital, professional hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge? External review missions
Financial indicators, 2009

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded % 1.7 12 11 97
Yes
Per capita health nancial indicators, 2009

Yes (all suspects) US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 0.3 0.4 0.01 4.0 20
All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2(HR)ZE/6(HE) All patients in all units last: 2007 next: 2009
Quality-assured bacteriology
National reference laboratory? Yes
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 500 545 Smear per 100 000 1.8 1.9 EQA 360 545 % adeq perf 86% 71% Culture Number per 5 000 000 1 1 0.2 0.2 Number DST per 10 000 000 EQA % adeq perf
Note: for routine diagnosis, there should be at least one laboratory providing smear microscopy per 100 000 population. To provide culture for diagnosis of paediatric, extrapulmonary and ss/HIV+ TB, as well as DST of re-treatment and failure cases, most countries will need one culture facility per 5 million population and one DST facility per 10 million population. EQA column shows number of laboratories for which EQA was done. Adeq perf; adequate performance for microscopy based on results of EQA.
System for managing drug supplies and laboratory equipment

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 No Peripheral level 2006 No No 2007 No No
Monitoring and evaluation system, and impact measurement

NTP publishes annual report? Yes (since 2005) % of BMUs reporting to next level in 2007 Case-nding 100% Treatment outcomes 100% Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No No No Yes, national No No last next 2010
| MDR-TB, TB/HIV AND OTHER CHALLENGES

2005 2006 Number (% of estimated ss+ MDR-TB) 1 266 (%) (%) 0 1 318 (%) (%) 0 1 371 (%) (%) 0 2007
Multidrug-resistant TB (MDR-TB)
Estimated incidence of ss+ MDR cases Diagnosed and notied Registered for treatment GLC non-GLC
AFGHANISTAN
| MDR-TB, TB/HIV AND OTHER CHALLENGES (continued)

Detection and treatment of HIV in TB patients, 2007
TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 0 0
HIV testing for TB patients
Data not reported
Screening for TB in HIV-positive patients, 2007

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 0
CPT and ART for HIV-positive TB patients

Data not reported
High-risk groups, 2007

Number of close contacts of ss+ TB patients screened Number of TB cases identied among contacts % of contacts with TB Contacts started on IPT % of contacts without TB on IPT
| CONTRIBUTING TO HEALTH SYSTEM STRENGTHENING

Lack of basic infrastructure, scarce human resources and security problems are formidable challenges to strengthening health systems that also affect TB control. The NTP is addressing these challenges jointly with other stakeholders by aligning its planning and implementation processes with other planning processes, including the national plan for human resources for health and the general health-sector development plan. The NTP, which is implemented mostly through contracted NGOs as part of an integrated package of primary health care, is also developing approaches to use the private sector to implement public health interventions.
Practical Approach to Lung Health (PAL), 2007

Number of health-care facilities providing PAL services 0 As % of total number of health-care facilities 0
| ENGAGING ALL CARE PROVIDERS

Public-public and public-private approaches (PPM), 2007
Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 3 () 2 () % total notied TB Diagnosed Treated 0.8 2.7 0.8 2.7
International Standards for Tuberculosis Care (ISTC)

ISTC endorsed by professional organizations? ISTC included in medical curriculum? No
| EMPOWERING PEOPLE WITH TB, AND COMMUNITIES

Advocacy, communication and social mobilization (ACSM)
The NTP has integrated ACSM into the National Strategic Plan for TB Control. In 20072008, primary and secondary research was used to conduct a national situation analysis and the rst National ACSM Strategy 20092013 was developed. Funding for ACSM activities, outlined in the national ACSM strategy, was secured through round 8 of the Global Fund. Developing national implementation capacity and social mobilization capacity in remote areas in a complex security situation are the major challenges to ACSM faced by the NTP.
Community participation in TB care and Patients Charter

The NTP has involved Afghan communities in TB control through NGOs, community organizations and public sector community health workers who are involved in case detection, treatment support, counselling, follow-up and management of suspect TB cases in hard-to-access rural areas of the country. The NTP has also involved religious leaders in its awareness campaigns. Affected communities and TB patients participate in decision-making forums such as the country coordination mechanism and the Board of the national Stop TB Partnership. No data on use of the Patients Charter were reported.
| ENABLING AND PROMOTING RESEARCH

Programme-based operational research, 2007
Operational research budget (% of NTP budget) 14%
AFGHANISTAN
| FINANCING
a. NTP budget by source of funding
Decreased budget requirement in 2009 is in line with revised strategic plan 20092013; greatly increased funding from Global Fund and other donors in 2009
20 19 14 15 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)
b. NTP budget line items in 2009

DOTS implementation accounts for 88% of the budget, with considerable investment in programme management and supervision
Other 8% ACSM/CBTC 4% NTP staff 12% Lab supplies & equipment 15% First-line drugs 11%
15 US$ millions
10
10
5
Data not available
3.1
3.8
4.0
Programme management & supervision 50%
0 2002 2003 2004 2005 2006 2007 2008 2009
c. NTP budget by line item

Budget for operational research and community TB care reduced in 2009 following revision of strategic plan
20 19 14 15 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
d. NTP funding gap by line item

Funding gaps within DOTS mainly for routine programme management, rst-line drugs and laboratory supplies and equipment
20 15 US$ millions 10 5
Data not available
15 11 9.3 4.0 1.5 0.3
15 US$ millions
10
10
5
Data not available
3.1
3.8
4.0
Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
0 -5 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009
e. Total TB control costs by line item
f. Per patient costs, budgets and expenditures2

Considerable uctuation in all indicators but available funding per patient has risen since 2007
800 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
Hospitalization costs are for 200 TB beds; outpatient costs based on 71 visits per new ss+ TB patient during treatment and 68 visits per new ss and extrapulmonary patients
20 16 15 US$ millions 11 Clinic visits Hospitalization NTP budget
600
US$ 3.8
Data not available
10
400
5 1.6
3.7 1.8
200 3.3 0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009
g. Global Plan compared with country reportse

Global Plan estimates of funding requirements are higher than country expenditures and projected funding requirements, mainly due to a higher forecast of patients to be treated in the Global Plan
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
h. NTP budget and funding gap by Stop TB Strategy component (US$ millions)
2009 BUDGET GAP
DOTSf US$ millions 20 15 10 5 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
DOTS expansion and enhancement TB/HIV, MDR-TB and other challenges Health system strengthening Engage all care providers People with TB, and communities Research and surveys Other
8.8 0 0 0 0.4 0 0.8
2.2 -0.1 0 -0.1 -0.8 -0.1 -0.8
2006 2007 2008 2009
2006 2007 2008 2009
Afghanistan report
Global Plan
| SOURCES, METHODS AND ABBREVIATIONS

ag 1
Please see footnotes page 169. Total TB control costs for 20032004 are based on available funding, whereas those for 20052007 are based on expenditure, and those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20052007 is based on the amount of funding actually received, using retrospective data; available funding for 20032004 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
indicates not available or not applicable; pop, population; ss+, sputum smear-positive; ss, sputum smear-negative pulmonary; unk, pulmonary sputum smear not done or result unknown.
COUNTRY PROFILE
Bangladesh
Bangladesh increased the case detection rate of new smear-positive cases to 66% in 2007 and has maintained a treatment success rate exceeding 90% since 2004. The provision of EQA has expanded to almost all peripheral-level laboratories. Support from the GDF has secured an uninterrupted supply of drugs. Community-based DOTS through village doctors (Damien Foundation) and community health volunteers (BRAC) ensures supervised drug intake. Programmatic guidelines for MDR-TB and TB/HIV were developed in 2008. The Damien Foundation expanded its MDR-TB treatment project and supported the development of a regional reference laboratory, and the NTP will soon begin enrolling patients in an MDR-TB treatment programme. Major challenges include limited capacity for diagnosis of smearnegative and extrapulmonary TB, and MDR-TB. Weak coordination among health-care providers is a major challenge for TB control in large urban areas.

ALL IN HIV+ PEOPLE
353 223 1.0 159 100 0.3 614 387 319 71 45 39 3.5 20
1.0 0.6 0.1 0.3 0.2 0.5 0.3 0.4 0.3

New ss/unk 30 20 10 0 12 8 4 0 1995
New extrapulmonary 5 4 3 2 1 2 1 0 1995 Relapse 3 Re-treatment
147 93 104 66 82 2.0 66 16 11 1.4 1.3
Case notications
New ss+ 80 60 40 20 0 1995
2000
2005
1995
2000
2005
2000
2005
0 1995
2000
2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB 0 1 2 3 4
Failed
Defaulted
Transferred
Not evaluated
5 0
3 0
5 0
10
Percentage
2000 92 54 79 28 93 22 26 81 72
2001 95 54 84 29 95 22 27 83
2002 95 57 88 32 98 23 31 84 69
2003 99 60 100 36 100 25 35 85 127
2004 99 65 100 42 100 28 40 90 81
2005 99 80 100 55 100 34 54 91 80
2006 100 93 100 65 100 40 65 92 77
2007 100 93 100 66 100 41 66
BANGLADESH

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Upazilla Health Complex Yes Chest disease clinic, district Hospital 753/753
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20062010) Yes (established ) No (planned )

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member Health-care worker, community member 2(HRZE)/4(HR)3 All patients in all units last: 2007 next: 2010 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 39 56 4.2 99
Urban Chest disease clinic, district hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Upazilla Health Complex Urban Chest disease clinic, district hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.1 0.1 0.0006 3.4 12
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 753 753 Smear per 100 000 0.5 0.5 EQA 753 753 % adeq perf 88% Culture Number per 5 000 000 4 4 0.1 0.1 Number 2 2 DST per 10 000 000 0.1 0.1 EQA 0 0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No 2005 No Peripheral level 2006 No No 2007 No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since ) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No Yes, national No No No last 2007 next 2009

BANGLADESH

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied
Data not reported

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register

Data not reported


The health-care system in the public sector is constrained by a lack of human resources, which affects access to TB services in rural areas. NGOs work in close collaboration with the government to provide essential primary health-care services, including integrated services to control TB, in many areas. TB control is well aligned with the national health plan, the SWAP and the Medium-term Expenditure Framework for health. The NTP is a leader in engaging informal health-care providers to provide public health services, including the use of village doctors to nd TB cases and support anti-TB treatment.

Number of health-care facilities providing PAL services As % of total number of health-care facilities

Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 101 () 2 455 () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? ISTC included in medical curriculum? No No

An ACSM consultant participated in the 2007 National Programme Review to assess progress and helped to draft recommendations for future ACSM activities. A KAP survey is planned for 2009, and the national ACSM strategy is being nalized.

Community-based services are widely available in the country, primarily through two important NGOs that provide services in accordance with NTP policy. DOT in rural areas is provided through female community health volunteers (as part of a primary health-care package), village doctors, cured patients and community opinion-leaders. Activities to raise awareness among communities, identify suspected TB cases and trace defaulters are widely implemented. In urban areas, DOT is usually available at a health facility. No data on use of the Patients Charter were reported.

Operational research budget (% of NTP budget) 0.7%
BANGLADESH
| FINANCING
Decreased budget in 2008 and 2009
25 22 20 US$ millions 15 12 10 7.0 5
Data not available

90% of budget is for DOTS, with a substantial share for programme management and supervision
21 15
18
17
Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)
First-line drugs 22% Operational research/surveys 1% ACSM/CBTC 4% PPM 1% TB/HIV 1% MDR-TB 3% Lab supplies & equipment 2% Programme management & supervision 61%
NTP staff 5%
0 2002 2003 2004 2005 2006 2007 2008 2009

Within DOTS, large decrease in budget for NTP staff in 2008
25 22 20 US$ millions 15 12 10 7.0 5
Data not available

Surplus within DOTS in 2009 mainly for laboratory supplies and equipment; funding gap within MDR-TB is for second-line drugs
3 2.6 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
21 15
18
17
Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
2 US$ millions 1.0 0.09 0.1 0
0 2002 2003 2004 2005 2006 2007 2008 2009
-1 2002 2003 2004 2005 2006 2007 2008 2009
e. Total TB control costs by line item1

Hospitalization costs are for 696 dedicated TB beds; costs for clinic visits based on 27 visits per patient during treatment; NTP budget accounts for the largest share of TB control costs
25 21 20 17 US$ millions 15 10 5
Data not available

Decreased total costs in 2007; expenditure data appear incomplete in 2007
Data not available
19 18 15
Clinic visits Hospitalization NTP budget US$
150
10 7.7
100
50
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Country report not in line with Global Plan; targets for MDR-TB patients to be treated in Global MDR/XDR-TB Response Plan much higher than scaling-up planned by NTP
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
14 0.5 0 0.2 0.5 0.2 0
0.4 0 0 0 0.5 0 0
2006 2007 2008 2009
2006 2007 2008 2009
Bangladesh report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 20032007 are based on expenditure, whereas those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20042007 is based on the amount of funding actually received, using retrospective data; available funding for 2003 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
COUNTRY PROFILE
Brazil
Government commitment to promoting social services has increased the visibility of TB as a public health problem, and funding for TB control has increased substantially in recent years. DOTS expansion has progressed and TB control activities have prioritized 315 of a total of 5565 municipalities accounting for 70% of the countrys TB cases. TB services are integrated into the primary health-care system. The process of decentralizing TB control management to state and municipality levels is continuing. Collaborative TB/HIV activities have been implemented and scaled up. About 14% of the 72% of TB patients tested for HIV infection are found to be HIV-positive. Special initiatives to control TB in vulnerable groups such as indigenous populations and prisoners have been implemented in collaboration with relevant governmental organizations and NGOs. Despite the progress made in controlling TB, rates of case detection and treatment success are still below the global targets.

ALL IN HIV+ PEOPLE
92 48 3.2 49 26 14 114 60 62 8.4 4.4 3.6 0.9 5.4
13 6.8 2.8 5.9 3.1 6.5 3.4 2.5 1.3

New ss/unk 30 20 10 0 10 8
Rate* (% of all) 931 (16%) 3242 (29%) 4383 (55%) * Per 100 000 pop
New extrapulmonary 6 4 2 0 1995 Relapse 6 4 2 0 1995 Re-treatment
75 39 38 20 63 2.1 69 10 14 0.7 1.9
Case notications
New ss+ 30 20 10 0 1995 2000 2005
6 4 2 0 2000 2005 1995 2000 2005
1995
2000
2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB (2004 cohort) 0 5 10
Failed
Defaulted
Transferred
Not evaluated
15 0
10
15
20 0
10 Percentage
15
20 0
10 0
10
15
20
2000 7.0 45 6.8 24 9.6 72 73 71 40
2001 32 42 11 22 11 65 70 55 23
2002 25 45 11 23 12 77 76 80 60
2003 34 44 21 22 23 74 75 77 64
2004 52 47 51 23 53 83 82 76 49
2005 68 43 63 23 62 81 82 76 48
2006 86 41 79 22 79 79 82 73 47
2007 75 39 89 20 89 78 78
BRAZIL

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Primary health-care unit Yes Primary health-care units and hospitals 7411/9818

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) Some patients in some units Health-care worker, community member, family member Health-care worker, community member, family member 2(HR)ZE/4(HR) All patients in all units last: 2006 next: 2009 % 80 86 0.3 82
Urban Primary health-care units and hospitals NTP services part of general primary health-care network? Location where TB diagnosed Rural Primary health-care unit Urban Primary health-care units and hospitals Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 0.3 0.5 0.1 164 371
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 4 044 4 044 Smear per 100 000 2.1 2.1 EQA 1 819 2 022 % adeq perf 75% Culture Number per 5 000 000 193 232 5.0 0.6 Number 38 38 DST per 10 000 000 2.0 2.0 EQA 17 27 % adeq perf 82%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? Central level 2006 Yes No 2007 No No 2005 No Peripheral level 2006 All units No 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% No Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes No No Yes, sub-national Yes Yes last 2008 1996 2006 2007 next 2009 Ongoing 2007 2008
MDR-TB, TB/HIV AND OTHER CHALLENGES

2005 2006 Number (% of estimated ss+ MDR-TB) 1 098 373 (34%) 347 (32%) 0 347 1 077 399 (37%) 309 (29%) 0 309 1 056 832 (79%) 321 (30%) 0 321 2007
BRAZIL

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 57 593 72 8 141 63 0 0 8 141 100
% TB patients tested for HIV

The proportion of TB patients screened for HIV continues to increase
100 80 60 40 20 0 2004 2005 2006 2007


In 2006 and 2007, 100% of HIV-positive TB patients received ART. Data on provision of CPT are not recorded by the NTP
100 % of reported HIV-positive TB patients 80 60 40 20 0 2004 2005 2006 2007 on ART on CPT


The health-care system is relatively strong and there is an extensive and decentralized primary health-care infrastructure into which TB control is integrated. TB control is aligned with the general national health plan.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector () () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? By which organizations: ISTC included in medical curriculum? Yes Yes

The NTP has a national ACSM strategy and is engaged in a wide range of ACSM activities. The Brazilian health system requires that municipalities and states have a health council comprising health professionals, managers and service users. There are six TB and 27 AIDS forums involved in increasing engagement with civil society. Activities with policy-makers and organizations working with drug users, the homeless and prison populations have been carried out to better engage these groups in TB control. In 2008, three national television and radio campaigns were broadcast to raise awareness about TB. A KAP survey was conducted in 2008.

The NTP is engaging civil society and empowering communities by training staff in health councils on awareness about TB. These health councils, which operate at federal, state and municipal levels of government, are comprised of health professionals, managers and service users. The NTP is also engaging communities by strengthening the national Stop TB Partnership, encouraging TB NGOs to create state forums and nancing a range of NGO projects.

BRAZIL
| FINANCING
NTP budget and government funding have more than tripled since 2002, demonstrating increased political commitment
80 61 60 US$ millions 40 24 51 64 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Most of the budget is for DOTS (67%) and MDR-TB (16%)
Other 2% Operational research/surveys 7% ACSM/CBTC 5% PPM 0.4% TB/HIV 3% First-line drugs 13%
NTP staff 8%
40 20
MDR-TB 16% Programme management & supervision 30%
20
14
16
0 2002 2003 2004 2005 2006 2007 2008 2009
Lab supplies & equipment 16%

Increased budget for routine programme management activities and MDR-TB
80 61 60 US$ millions 40 24 51 64 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for routine programme management activities
15 11 US$ millions 10 5.9 5 6.2 0 9.0 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
40 20
20
14
16
0 2002 2003 2004 2005 2006 2007 2008 2009
2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization costs are for 2500 dedicated TB beds; costs for clinic visits based on 12 visits per patient in 2008 and 2009
100 88 80 US$ millions 60 40 20 0 2002 2003 2004 2005 2006 2007 2008 2009 38 39 62 53 55 88 92 Clinic visits Hospitalization NTP budget

Increasing cost per patient since 2002 as newer elements of TB control are introduced; increased expenditures in 2007
1000 US$ 500 0 2002 2003 2004 2005 2006 2007 2008 2009

Implemented (2006-2007) and planned (2008-2009) activities are consistent with or ahead of the Global Plan, except for PPM/PAL (in other)
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
43 12 0.3 0.3 3.0 4.6 0.9
6.7 1.1 0.3 0.3 0.1 2.0 0.8
2006 2007 2008 2009
2006 2007 2008 2009
Brazil report
Global Plan

ag 1
COUNTRY PROFILE
Cambodia
The NTP has sustained high treatment success rates of over 90% for more than a decade. Although the case detection rate is assessed to be less than 70%, the results of a recent national population census suggest that this target may have been achieved. In 2007, the NTP published a national strategic plan for the TB laboratory network and guidelines for diagnosis and treatment of TB in children. The third national seroprevalence survey showed a further decline in HIV prevalence among TB patients from 11.8% in 2003 to 7.8% in 2007. Collaborative TB/HIV activities and community-based DOTS have been further expanded. An MDR-TB project initiated by an NGO in partnership with the NTP has demonstrated the feasibility of expanding implementation to public sector facilities outside the capital. However, human resource capacity, and laboratory capacity to perform smear microscopy, culture, DST and new diagnostic technologies, remain major challenges.

ALL IN HIV+ PEOPLE
72 495 1.0 32 219 7.8 96 664 464 13 89 60 0 3.1
5.6 38 9.6 1.9 13 2.8 19 1.8 13

New ss/unk 60 40 20 0 60 40 20 0 1995 Defaulted
New extrapulmonary 8 6 4 2 0 1995 Transferred Relapse 8 6 4 2 0 1995 Re-treatment
36 246 19 134 73 1.1 61 8.4 24 0.1 0.6
Case notications
New ss+ 160 120 80 40 0 1995
2000
2005
1995 Failed
2000
2005
2000
2005
2000
2005
2000
2005
Not evaluated Data not reported
3 0
Percentage
2000 99 148 100 116 100 27 50 91 90
2001 100 147 100 110 100 27 48 92 92
2002 100 186 100 130 100 35 57 92 89
2003 100 209 100 140 100 40 62 93 87
2004 100 225 100 138 100 43 62 91 86
2005 100 255 100 150 100 49 68 93 76
2006 100 244 100 136 100 48 62 93 85
2007 100 246 100 134 100 49 61
CAMBODIA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health centre Yes Referral hospital 77/77
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20062010) Yes (established 2001) No (planned )

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2(HR)ZE/4(HR) All patients in all units last: 2006 next: NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 10 27 14 65
Urban Referral hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Former district hospital Urban Referral hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.7 0.9 0.3 6.9 29
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 201 205 Smear per 100 000 1.4 1.4 EQA 186 205 % adeq perf 70 Culture Number per 5 000 000 3 5 1.0 1.7 Number 1 1 DST per 10 000 000 0.7 0.7 EQA 1.0 1.0 % adeq perf 100%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No No 2005 No Peripheral level 2006 No No 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 1995) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No Yes, national Yes, national Yes, national No No last 2002 2002 2001 next 2010 2010 Ongoing

2005 2006 Number (% of estimated ss+ MDR-TB) 92 (%) (%) 0 93 (%) (%) 0 94 16 (17%) 11 (12%) 11 2007
CAMBODIA


Between 2006 and 2007 the proportion of TB patients screened for HIV almost quadrupled
60 % TB patients tested for HIV
40
20

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 11 641 5 318 46 1 801 15 0.8
% of reported HIV-positive TB patients
0 2004 2005 2006 2007

The proportion of HIV-positive TB patients receiving ART fell substantially in 2007 compared with 2006
60 on ART on CPT
77
40

20
0 2004 2005 2006 2007

Control of TB is fully integrated into the primary health-care system, within which it has contributed to strengthening laboratory capacity. TB control is well aligned with the national health plan, the SWAP and with the Medium-term Expenditure Framework for health. The NTP is a leader in engaging private pharmacies to deliver public health interventions.


Number of providers collaborating with the NTP Number collaborating (total number of providers) Public sector Private sector () 1 358 ()
c

% total notied TB Diagnosed Treated 2.3

The NTP participated in an ACSM workshop and drafted a 12-month action plan for implementation of ACSM activities and a national strategic plan. Materials for World TB Day included a 10-minute video of senior ministry ofcials, health care staff and TB patients explaining what they were doing to stop TB. A communication strategy to raise awareness about TB among indigenous communities in north-east Cambodia was also developed. IEC materials produced by the NTP are widely used, including by NGOs.

Approximately 50% of public health centres in the country are implementing activities to involve communities in TB control; the target is to increase this to >80% by 2010. In areas where the initiative has been implemented, treatment supporters (DOT watchers) are often involved in other support groups or NGOs and are supervised regularly by health centre staff. The Patients Charter is not yet being used in health facilities.

CAMBODIA
| FINANCING
Continued increase in budget with increased funding in 2009; Global Fund is now the main source of nancing
15 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

DOTS accounts for almost half (49%) of the NTP budget; large share of the budget is for ACSM, especially compared with other HBCs
Other 14% First-line drugs 6% NTP staff 5%
11 US$ millions 10 5.9 5 4.3 6.6 6.9 7.0 8.5 9.2
ACSM/CBTC 20%
PPM 5% 0 2002 2003 2004 2005 2006 2007 2008 2009 TB/HIV 8% MDR-TB 4% Lab supplies & equipment 9%

Large increase in budgets for DOTS and ACSM since 2004
15 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gaps have persisted and within DOTS are mainly for programme management and supervision
6 4.5 US$ millions 4 4.0 3.4 2.2 2 1.2 2.3 2.3 3.7 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
11 US$ millions 10 5.9 5 4.3 6.6 6.9 7.0 8.5 9.2
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased cost, expenditure and available funding per patient but declining rst-line drugs budget per patient; expenditures close to available funding
350 300 250 US$ 200 150 100 50 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
Cost of clinic visits based on 64 visits per patient during treatment for new TB patients; hospitalization costs are for 1200 TB beds
15 13 11 US$ millions 10 6.2 5 4.9 3.9 6.5 7.2 6.2 Clinic visits Hospitalization NTP budget
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Global Plan funding requirements higher for DOTS and TB/HIV due to higher projections of patients to be treated (ss/extrapulmonary under DOTS and HIV+ TB patients on ART, respectively); country plan ahead of Global Plan for other categories
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf US$ millions 10 5 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
5.2 1.3 0 0.5 2.2 0 1.5
2.3 0.6 0 0.2 0.5 0 0.2
2006 2007 2008 2009
2006 2007 2008 2009
Cambodia report
Global Plan

ag 1
COUNTRY PROFILE
China
China is maintaining high case detection and treatment success rates. Efforts to improve access to TB care are being accelerated in order to achieve faster reductions in prevalence and mortality. Capacity building to improve the quality of data and analysis will contribute to an improved understanding of TB epidemiology in the country and a better understanding of the situation of hard-to-reach populations such as migrants, ethnic minorities and the elderly. There is a need to plan for rapid scale-up of programmatic management of MDR-TB, including sustainable nancing for human resources, quality-assured laboratories and second-line drugs. Collaboration and coordination between the public health sector and the general and specialized hospitals are a challenge given the nancing arrangements for public health services in hospitals.

Population (thousands) a Estimates of epidemiological burden, 2007b Incidence All forms of TB (thousands of new cases per year) All forms of TB (new cases per 100 000 pop/year) Rate of change in incidence rate (%), 20062007 New ss+ cases (thousands of new cases per year) New ss+ cases (per 100 000 pop/year) HIV+ incident TB cases (% of all TB cases) Prevalence All forms of TB (thousands of cases) All forms of TB (cases per 100 000 pop) 2015 target for prevalence (cases per 100 000 pop) Mortality All forms of TB (thousands of deaths per year) All forms of TB (deaths per 100 000 pop/year) 2015 target for mortality (deaths per 100 000 pop/year) Multidrug-resistant TB (MDR-TB) MDR-TB among all new TB cases (%) MDR-TB among previously treated TB cases (%) 1 328 630
ALL IN HIV+ PEOPLE
1 306 98 1.0 585 44 1.9 2 582 194 164 201 15 12 5.0 26
25 1.9 0.4 8.6 0.7 12 0.9 6.8 0.5

New ss/unk
New extrapulmonary 4 3 2 1 0 1995 8 6 4 2 0 1995 Relapse 10 8 6 4 2 2000 2005 0 1995 2000 2005 Re-treatment
980 74 466 35 52 2.4 80 37 3.9 2.1 0.5
Case notications
New ss+ 40 30 20 10 0 1995 40 30 20 10
2000
2005
0 1995
2000
2005
2000
2005
Failed
Defaulted
Transferred
30 0
3 0
3 0
Percentage
2000 68 36 78 16 90 32 34 93 89
2001 68 37 78 16 90 33 34 95 92
2002 78 36 83 15 92 33 33 92 88
2003 91 47 90 21 96 41 45 93 89
2004 96 61 97 29 98 54 65 94 89
2005 100 68 100 36 100 64 80 94 90
2006 100 71 100 35 100 68 80 94 89
2007 100 74 100 35 100 71 80
CHINA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Village health clinic Yes District TB dispensary 2681/2681

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE3/4HR3 All patients in all units last: 2008 next: 2009 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 77 77 0.5 96
Urban Community health service station NTP services part of general primary health-care network? Location where TB diagnosed Rural County TB dispensary Urban District TB dispensary Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.2 0.2 0.01 31 81
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 3 294 3 294 Smear per 100 000 0.2 0.2 EQA 3 294 3 294 % adeq perf 98% Culture Number per 5 000 000 327 507 1.2 1.9 Number 187 187 DST per 10 000 000 1.4 1.4 EQA 13 33 % adeq perf 100%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 Yes No 2007 No No 2005 Yes Peripheral level 2006 Some units No 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 2004) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national Yes, national Yes, sub-national Yes No last 2006 2000 2000 19972005 2000 next 2008 2010 2010 Ongoing 2010

CHINA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 34 557 3.3 1 187 4.8 679 57 519 44

In 2007, 3% of TB patients were screened for HIV
4 % TB patients tested for HIV 3 2 1 0

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 39 866 16 931 42 899
2004
2005
2006
2007

In 2007 the proportion of HIV-positive TB patients receiving ART decreased while the proportion of those receiving CPT doubled
70 60 50 40 30 20 10 0 2004 2005 2006 2007 on ART on CPT
2.3 0 0

Number of close contacts of ss+ TB patients screened Number of TB cases identied among contacts % of contacts with TB Contacts started on IPT % of contacts without TB on IPT 828 931 43 577 5

A major challenge to strengthening health systems is the lack of coordination between disease-specic control programmes and the hospital sector, where the focus on public health is weak and where most revenue is generated through user charges. The NTP has started to bridge this gap by improving referral and notication linkages between general hospitals and TB dispensaries, building on the existing web-based electronic notication system for communicable diseases.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 47 696 (47 696) () % total notied TB Diagnosed Treated


A national ACSM strategy that includes impact indicators has been developed. A major component of this strategy is a year-round national Stop TB campaign that is supported by an ambassador who is a well-known folk singer. The campaign coordinates a variety of activities including a TB knowledge contest organized through a prominent Chinese web portal; close collaboration with the mass media including TB-specic programming and public service announcements on television; campaigns to increase awareness about TB in schools and local communities; and public events on World TB Day featuring the vice minister and other senior ofcials of the Ministry of Health, the TB ambassador and NTP programme managers. Courses for training provincial health promotion staff about IEC materials, developing communication strategies, and monitoring and evaluation have also been held.

Activities to raise community awareness are being implemented. Treatment support by community, township and village health workers is due to be introduced with funding from the Global Fund round 8 grant. No data on use of the Patients Charter were reported.

CHINA
| FINANCING
NTP budget more than doubled since 2002 with minimal funding gap in 2009; now beneting from Global Fund round 1 Rolling Continuation Channel
300 250 US$ millions 200 150 100 50 0 2002 2003 2004 2005 2006 2007 2008 2009 98 95 155 120 194 272 219 225 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

82% of budget is for DOTS; budget for MDR-TB relatively small
Other 1% Operational research/surveys 0.1% ACSM/CBTC 4% PPM 7% TB/HIV 4% MDR-TB 3%
First-line drugs 12%
NTP staff 22%

Budget for MDR-TB diagnosis and treatment has more than tripled since 2007 but remains small; apart from DOTS, largest budget is for PPM
300 250 US$ millions 200 155 150 100 50 0 2002 2003 2004 2005 2006 2007 2008 2009 98 95 120 194 272 219 225 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gaps within DOTS are for routine programme management and supervision
100 80 US$ millions 60 40 28 20 0 2002 2003 2004 2005 2006 2007 2008 2009 14 28 18 9.8 91 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
f. Per patient costs, budgets and expenditures2,3

Increased cost, budget and expenditure per patient since 2006 as more elements of the Stop TB Strategy are implemented; budgets, available funding and expenditures very similar
Clinic visits Hospitalization NTP budget 300 250 200 US$ 150 100 50 0 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
All costs for TB control are included in the NTP budget
300 219 US$ millions 200 157 108 100 61 80 149 188 225
0 2002 2003 2004 2005 2006 2007 2008 2009
2002
2003
2004
2005
2006
2007
2008
2009

Higher projections of patients to be treated mean country estimates of funding requirements for DOTS higher than Global Plan estimates; in contrast, plans and associated funding requirements for enrolment of patients on MDR-TB treatment are far below Global Plan targets
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
400 US$ millions 300 200 100 0
DOTSf
MDRTB
TB/HIVg
ACSM
Other
Total
184 16 0 16 7.9 0.3 1.2
9.8 0 0 0 0 0 0
2006 2007 2008 2009
2006 2007 2008 2009
2006 2007 2008 2009
China report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 20022007 are based on expenditure, whereas those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20042007 is based on the amount of funding actually received, using retrospective data; available funding for 20022003 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap. Estimates of expenditure are based on received funding.
COUNTRY PROFILE
Democratic Republic of the Congo

The case notication rate increased in 2007 following intensive efforts to implement the Stop TB Strategy. Treatment success rates are above target at 86%. Major efforts are required to expand collaborative TB/HIV activities and diagnosis and treatment of MDR-TB. The diagnostic capacity of the NRL has improved and the construction of a larger NRL will be completed in 2008. Recurrent shortages of drugs and supplies, including HIV test kits, need to be addressed. The health system faces considerable obstacles with regard to basic infrastructure, human resources and security problems. TB control is well aligned with the national health plan, the SWAP, and with the Medium-term Expenditure Framework for health. Despite increased funding in recent years, large funding gaps remain.

ALL IN HIV+ PEOPLE
245 392 2.6 109 174 5.9 417 666 138 51 82 18 2.3 10
14 23 2.1 5.1 8.1 7.2 12 6.0 9.6

New ss/unk 30 20 10 0 1995 40 30 20 10 0 1995
New extrapulmonary 10 8 6 4 2 2000 2005 0 1995 2000 2005 0 1995 2000 2005 4 2 Relapse 6 Re-treatment
100 159 66 106 86 1.1 61 19 20 3.2 4.8
Case notications
New ss+ 125 100 75 50 25 0 1995 2000 2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB (2004 cohort) 0 2 4 6
Failed
Defaulted
Transferred
Not evaluated
8 10 12 0
10 15 20 Percentage
25 0
3 0
20
40
60
80 100
2000 70 120 100 71 100 33 47 78
2001 70 128 100 81 100 33 49 77
2002 70 132 100 83 100 32 47 78 67
2003 75 153 100 97 100 36 53 83 72
2004 75 164 100 109 100 38 59 85 71
2005 100 165 100 111 100 39 60 85 74
2006 100 158 100 105 100 38 59 86 67
2007 100 159 100 106 100 39 61
DEMOCRATIC REPUBLIC OF THE CONGO

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health centre, referral health centre, hospital Yes Health centre or hospital 1205/1205

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (if TB is conrmed) All patients in all units % 3.1 21 64 30
Urban Health centre, referral health centre NTP services part of general primary health-care network? Location where TB diagnosed Rural Health centre or hospital Urban Health centre or hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 0.8 1.0 0.6 1.7 5.0
Health-care worker, community member, family member Health-care worker, community member, family member 2(HRZE)/4(HR) All patients in all units last: next:
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 1 205 1 545 Smear per 100 000 1.9 2.4 EQA 1 023 1 545 % adeq perf 60% Culture Number per 5 000 000 1 1 0.1 0.1 Number 1 1 DST per 10 000 000 0.2 0.2 EQA 1.0 1.0 % adeq perf 0%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 Yes Peripheral level 2006 Some units Some units 2007 No Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% No Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes No No Yes, sub-national No No last 2005 1999 next 2010

2005 2006 Number (% of estimated ss+ MDR-TB) 4 087 178 (4.4%) 178 (4.4%) 0 178 4 112 118 (2.9%) 118 (2.9%) 0 118 4 137 82 (2.0%) 79 (1.9%) 0 79 2007


The proportion of TB patients screened for HIV has increased steadily over the past three years but remains low
10

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 277 202
0 2004 2005 2006 2007

The proportion of patients receiving ART has declined by two thirds from 2006 to 2007 while the provision of CPT has steadily increased


Limited basic infrastructure, shortage of human resources and security problems in several areas are challenges affecting health systems in general and TB control in particular. The NTP is addressing these challenges jointly with other stakeholders by aligning its NTP plan with the national health plan, the SWAP and the Medium-term Expenditure Framework for health.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector () 551 () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? ISTC included in medical curriculum? No Yes

A KAP survey is planned for 2009.

Communities have been involved in TB control in ve areas, through inclusion of family or community members as treatment supporters. However, no administrative area has full coverage of community-based services. One large patient organization is involved in TB treatment in 33 health centres in the capital and is committed to expanding a wide range of activities. TB indicators in the area have been steadily increasing since community-based services were launched in 1999.

| FINANCING
Large increase in budget since 2008 after major revision of strategic plan and budget; funding has grown but large funding gap remains
60 49 40 26 20 10 6.6 TB/HIV 20% 0 2002 2003 2004 2005 2006 2007 2008 2009 12 11 24 53 Unknown Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Largest share of budget is for DOTS (44%), Other (23%) and collaborative TB/HIV activities (20%)
First-line drugs 7% NTP staff 14%
US$ millions
Other 23% Operational research/surveys 0.3% ACSM/CBTC 7% PPM 0.4%
Programme management & supervision 10% Lab supplies & equipment 13% MDR-TB 6%

Within DOTS, increased budget is for NTP staff and laboratory supplies and equipment; also noticeable increase in budget for TB/HIV and ACSM
60 53 49 40 26 20 10 6.6 0 2002 2003 2004 2005 2006 2007 2008 2009 12 11 24 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gaps for all major budget categories; within DOTS in 2008 and 2009 gaps are mainly for dedicated NTP staff and laboratory supplies and equipment
40 32 30 US$ millions 20 10
Data not available
37
15 9.1 3.7 2.0 2.1
US$ millions
0 -10 2002 2003 2004 2005 2006 2007 2008 2009

Cost of clinic visits based on 76 visits for new patients during treatment; minimal reliance on hospitalization
70 60 50 US$ millions 40 30 20 10 0 2002 2003 2004 2005 2006 2007 2008 2009 16 12 12 15 17 26 60 66 Clinic visits Hospitalization NTP budget

Increasing cost per patient since 2005 as newer elements of TB control introduced; expenditure similar to available funding suggesting good absorption capacity
500 400 300 US$ 200 100 0 2002 2003 2004 2005 2006 2007 2008 2009 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget

Country plan in line with the Global Plan in 2008 and 2009 except for TB/HIV; full implementation requires funding gaps to be closed
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf US$ millions 60 40 20 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
23 14 0.2 0.2 3.5 0.2 12
11 12 0.2 0.2 2.9 0.2 10
2006 2007 2008 2009
2006 2007 2008 2009
DR Congo report
Global Plan

ag 1
COUNTRY PROFILE
Ethiopia
In 2007, the Ministry of Health expanded the network of general health-care facilities and engaged health extension workers and private health clinics in a concerted effort to increase the case detection rate. Increases in the NTP budget for laboratory strengthening activities and intensied case-nding among HIV patients are expected to contribute to an improved case detection rate. Five regional laboratories are being rebuilt and equipped to conduct culture, DST and line-probe assays, in collaboration with GLI/FIND/WHO. Although constrained by staff shortages, the NTP benets from the global focus on the health worker crisis and the associated development of strategies to treat, train, and retain health workers. Piloting of MDR-TB treatment is under way, and a national survey of the prevalence of TB disease is planned for 20092010.

ALL IN HIV+ PEOPLE
314 378 2.6 135 163 19 481 579 156 76 92 20 1.6 12
61 74 3.0 21 26 31 37 23 28
New ss/unk
New extrapulmonary 100 80 60 2 1 0 1995 2 1 0 1995 3 Relapse Re-treatment 3
129 155 38 46 47 1.2 28 45 36 2.3 6.0
Case notications
New ss+ 60 40 20 0 1995 200 150 100 50
40 20 2000 2005 0 1995 2000 2005
2000
2005
0 1995
2000
2005
2000
2005
Failed
Defaulted
Transferred
Not evaluated
10 0
3 0
2 4 Percentage
6 0
8 10 12
2000 85 131 100 44 100 39 31 80 71
2001 70 133 100 46 100 36 30 76 64
2002 95 151 100 50 100 39 30 76 60
2003 95 157 100 53 100 39 31 70 60
2004 70 160 100 54 100 39 31 79 54
2005 90 157 100 49 100 39 28 78 56
2006 100 151 100 45 100 38 27 84 69
2007 95 155 100 46 100 40 28
ETHIOPIA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health centre Yes Health centre or hospital 580/611
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20072010) Yes (established 2007) No (planned 2009)

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member Health-care worker, community member 2(HRZE)/6(HE) All patients in all units last: 2002 next: NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 4.0 27 11 31
Urban Health centre or hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Health center Urban Health centre or hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.3 0.4 0.2 3.9 6.4
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 833 1 000 Smear per 100 000 1.0 1.2 EQA 512 % adeq perf Culture Number per 5 000 000 1 6 0.1 0.4 Number 1 6 DST per 10 000 000 0.1 0.7 EQA 0 6.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 No Peripheral level 2006 No No 2007 Some units Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes Yes (since 2004) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No Yes, national No Yes, national No No last 2005 next 2009

2005 2006 Number (% of estimated ss+ MDR-TB) 3 088 (%) (%) 0 3 088 (%) (%) 0 3 086 145 (4.7%) (%) 0 2007
ETHIOPIA
| MDR-TB, TB/HIV AND OTHER CHALLENGES (CONTINUED)

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 20 723 16 6 342 10 4 529 71 2 658 42

In 2007 there was a six-fold increase in the proportion of TB patients screened for HIV compared with 2006

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 58 000 7 879 14 2,000 3.4 2 381 4.3
2004
2005
2006
2007

The provision of ART to HIV-positive TB patients almost doubled in 2007 compared with 2006, while the provision of CPT has fallen


The public health-care system, into which TB control is fully integrated, is constrained by a lack of human resources and difculties in providing outreach services, particularly in rural areas. Expansion of the network of general health-care facilities will improve access to health care and ultimately help to achieve targets for TB control. TB control is aligned with this expansion of health care through the national health plan and the SWAP.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 96 (96) 108 () % total notied TB Diagnosed Treated 1.8 1.8


ACSM has been integrated into the National Strategic Plan 20082010. A KAP survey is planned for 2009, and an ACSM Task Force has been established.

The successful Health Extension Programme employs almost 30 000 health service extension workers, the majority of whom are women who are trained and supervised and who receive salaries. This programme is the backbone of every intervention carried out at the community level and is designed to provide preventive services, including the detection and referral of TB suspects, in all rural villages. No data on use of the Patients Charter were reported.

ETHIOPIA
| FINANCING
Large increase in budget in 2008 and 2009 but large funding gaps; Global Fund is the main source of nancing
30 26 26 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Plan and budget developed for almost every component of the Stop TB Strategy; DOTS is the largest component (71%) followed by TB/HIV (14%)
Other 3% Operational research/surveys 2% ACSM/CBTC 8% PPM 1% NTP staff 6% TB/HIV 14% Programme management & supervision 13% Lab supplies & equipment 38% First-line drugs 14%
US$ millions
20
11 10
Data not available
8.9 6.8 6.8 6.4 MDR-TB 1%
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased budget within DOTS mainly for laboratory supplies and equipment, including establishment of 6 culture and DST sites and country-wide expansion of health facilities; bigger budget for TB/HIV is for scale-up to additional 340 sites
30 26 26 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for rst-line drugs (2009) and laboratory supplies and equipment (20082009)
20
18 14
15 US$ millions
US$ millions
20
10
11 10
Data not available
8.9 6.8 6.8 6.4
Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
5
Data not available
0.5
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Big increase in costs and budget per patient from 2008 as activities broadened in line with the Stop TB Strategy
250 200 150 100 50 0 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
Costs for clinic visits based on 66 outpatient visits per new TB patient to health facilities during treatment; very limited use of hospitalization
20 15 11 10 7.1 9.4 10 11
0 2002 2003 2004 2005 2006 2007 2008 2009
US$
2002
2003
2004
2005
2006
2007
2008
2009

Country implementation behind Global Plan targets 20062007; country plans for 20082009 ahead of Global Plan for DOTS, in contrast to other components of TB control, although difference for TB/HIV probably exaggerated after downward revision in estimate of HIV prevalence
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
80 US$ millions 60 40 20 0
DOTSf
MDRTB
TB/HIVg
ACSM
Other
Total
19 3.9 0 0.1 2.1 0.6 0.9
12 3.3 0 0.1 1.6 0.6 0.1
2006 2007 2008 2009
2006 2007 2008 2009
2006 2007 2008 2009
Ethiopia report
Global Plan

ag 1
COUNTRY PROFILE
India
All Ministry of Health facilities in India were providing DOTS services by 2006, and there are ongoing initiatives to collaborate with the public sector beyond the Ministry of Health, and with NGOs, medical colleges and private practitioners. This collaboration has helped to achieve a case detection rate of 68% (2007) and a treatment success rate of 86% (2006). Services to control MDR-TB are now available in designated sites within six states, with culture and DST facilities offered in ve state-level laboratories. Weak laboratory capacity is a major barrier to scaling-up MDR-TB services. Collaborative TB/HIV activities have considerable scope for expansion. Launching of a coalition of associations of medical professionals by the Indian Medical Association has been a major step in engaging the private sector. Ensuring the rational use of anti-TB drugs outside the Revised National TB Control Programme is crucial.

Population (thousands) a Estimates of epidemiological burden, 2007b Incidence All forms of TB (thousands of new cases per year) All forms of TB (new cases per 100 000 pop/year) Rate of change in incidence rate (%), 20062007 New ss+ cases (thousands of new cases per year) New ss+ cases (per 100 000 pop/year) HIV+ incident TB cases (% of all TB cases) Prevalence All forms of TB (thousands of cases) All forms of TB (cases per 100 000 pop) 2015 target for prevalence (cases per 100 000 pop) Mortality All forms of TB (thousands of deaths per year) All forms of TB (deaths per 100 000 pop/year) 2015 target for mortality (deaths per 100 000 pop/year) Multidrug-resistant TB (MDR-TB) MDR-TB among all new TB cases (%) MDR-TB among previously treated TB cases (%) 1 169 016
ALL IN HIV+ PEOPLE
1 962 168 0 873 75 5.3 3 305 283 293 331 28 21 2.8 17
103 8.8 4.1 36 3.1 52 4.4 30 2.5

New ss/unk
New extrapulmonary 20 15 10 5 0 1995 10 8 6 4 2 2000 2005 0 1995 Transferred 2000 2005 5 0 1995 Relapse 20 15 10 Re-treatment
1 296 111 593 51 60 2.3 68 207 17 12 2.0
Case notications
New ss+ 60 40 20 0 1995 100 80 60 40 20 2000 2005
0 1995
2000
2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB 0 2 4 6
Failed
Defaulted
Not evaluated
8 0
6 0
10
15
20 0
2 0
0.2
0.4
0.6
Percentage
2000 30 107 23 33 27 63 45 34 70
2001 45 102 44 36 48 59 49 54 58
2002 52 98 52 37 62 56 49 60 72
2003 67 98 76 39 83 56 53 76 70
2004 84 102 93 44 95 57 59 82 73
2005 91 102 99 45 100 57 60 86 71
2006 100 107 100 48 100 59 64 86 72
2007 100 111 100 51 100 61 68
INDIA

Description of basic management unit Designated microscopy centres, most of which are part of general primary health-care facilities 634/634
Number of units (DOTS/total), 2007 Location of NTP services Rural General health-care facilities in public, private and NGO sectors

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded % 46 61 1.8 70
Urban General health-care facilities in public, private, NGO and corporate sectors NTP services part of general primary health-care network? Location where TB diagnosed Rural Designated microscopy centres, most of which are part of general primary health-care facilities Yes
Urban Designated microscopy centres, most of which are part of general primary health-care facilities Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions Yes (all suspects) All patients in all units Health-care worker, community member Health-care worker, community member 2HRZE3/4HR3 All patients in all units last: 2006 next: 2009

US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 0.1 0.1 0.02 6.8 36
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 12 184 13 000 Smear per 100 000 1.0 1.1 EQA 11 386 13 000 % adeq perf 81% Culture Number per 5 000 000 11 17 0.05 0.1 Number 11 17 DST per 10 000 000 0.1 0.1 EQA 8.0 17 % adeq perf 75%

Central level 2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No 2006 No No 2007 No No Peripheral level 2005 Yes 2006 No No 2007 Some units No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 2001) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, sub-national Yes, national Yes, sub-national No No last 2007 2000 20002003 19952006 next 2008 Ongoing Ongoing Ongoing

2005 2006 Number (% of estimated ss+ MDR-TB) 96 663 34 (0.04%) 34 (0.04%) 0 34 98 155 33 (0.03%) 33 (0.03%) 0 33 99 639 146 (0.15%) 88 (0.09%) 0 88 2007
INDIA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 80 425 5.5 9 324 9.0 724 7.8 162 1.7

The proportion of TB patients screened for HIV is low but continues to increase steadily

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 277 760 50 586 18 7 130 2.6
0 2004 2005 2006 2007

Among HIV-positive TB cases, 2% received ART and 8% received CPT in 2007
8 6 4 2 0 2004 2005 2006 2007

on ART on CPT

TB control is fully integrated into general primary health-care services. Major challenges include poor primary health-care infrastructure in rural areas in several states, and unregulated private health care leading to widespread irrational use of rst-line and second-line anti-TB drugs. The NTP is coordinating with the National Rural Health Mission, which is a reform initiative whose goal is to improve primary health care in rural areas. The NTP has also established several initiatives to improve TB care in the private sector, including collaboration with the Indian Medical Association.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 142 (143) 20 983 () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? By which organizations: Indian Medical Association, 2007; key members of other professional associations in their individual capacity, March 2008 ISTC included in medical curriculum? No Yes

A KAP survey was conducted in 2005 and a second survey is planned for 2010. Field visits have shown that state and district capacity to implement ACSM activities needs to be strengthened, and the RNTCP has taken steps to do this. For example, an agency has been hired to produce new IEC materials and to support states and districts to implement ACSM activities.

As part of the national strategy to control TB, DOT is provided by health workers or trained community volunteers who are not family members in areas where health facilities are far from patients homes. Intensied community-based activities are ongoing in areas with marginalized populations, particularly in urban slums and tribal populations. Community-based treatment of MDR-TB has been initiated in two states. No data on use of the Patients Charter were reported in 2008.

INDIA
| FINANCING
Large increase in budget in 2009, with funding gap likely to be funded through Global Funds Rolling Continuation Channel mechanism
100 80 66 US$ millions 60 40 20 0 2002 2003 2004 2005 2006 2007 2008 2009 36 42 44 47 63 100 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

First-line drugs and NTP staff account for 61% of the budget; some rstline drugs are used in PPM schemes; budget for MDR-TB small in context of estimated number of cases
Other 12% Operational research/surveys 2% First-line drugs 27% ACSM/CBTC 7% PPM 2% MDR-TB 1% Lab supplies & equipment 5% Programme management & supervision 10% NTP staff 34%
72

Within DOTS, the budgets for rst-line drugs and NTP staff have increased, primarily to maintain an adequate buffer stock and to increase salaries
100 80 US$ millions 66 60 40 20 0 2002 2003 2004 2005 2006 2007 2008 2009 36 42 44 47 63 100 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap in 2009 likely to be closed via Global Fund; within DOTS gaps to be lled are mainly for rst-line drugs and dedicated NTP staff
40 30 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
72
30 US$ millions
20
10
0 2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization costs are for 11 750 dedicated TB beds; costs for clinic visits are based on an average of 27 visits to a health facility for DOT per TB patient
140 120 100 US$ millions 80 62 60 40 63 80 91 91 111 109 138 Clinic visits Hospitalization NTP budget

Increasing cost, budget, available funding and expenditure per patient since 2002 as more elements of Stop TB Strategy implemented; higher budget for rst-line drugs in 2009 due to purchase of buffer stock
120 100 80 US$ 60 40 20 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
20 0 2002 2003 2004 2005 2006 2007 2008 2009 0 2002 2003 2004 2005 2006 2007 2008 2009

Country implementation of DOTS in line with Global Plan, but plan for expanding of MDR-TB treatment falls short of targets in the Global MDR/XDR-TB Response Plan; NTP budget for TB/HIV small because most activities funded through HIV budgets
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
76 0.8 0 2.3 6.9 1.6 12
23 0.2 0 0.7 2.1 0.5 3.5
2006 2007 2008 2009
2006 2007 2008 2009
India report
Global Plan

ag 1
COUNTRY PROFILE
Indonesia
Implementation of the TB control programme in 2007 was affected by a temporary cessation of a Global Fund grant; the case detection rate decreased to 68% from 73% in 2006. Basic DOTS services were not affected, but the introduction of new initiatives was delayed. Notably, the treatment success rate has remained at 91% despite operational difculties. Four laboratories have been accredited for drug susceptibility testing by an SRL. An application to the GLC was approved for provision of services in MDR-TB pilot sites. A series of tuberculin surveys have been initiated to provide better measurement of TB incidence, and a sentinel study has been designed to improve reporting of TB mortality. Limited outreach of the primary health-care system in rural areas and linkages with the hospital sector are some of the major challenges to TB control.

ALL IN HIV+ PEOPLE
528 228 2.4 236 102 3.0 566 244 221 91 39 46 2.0 20
16 6.9 11 5.6 2.4 8.0 3.5 5.4 2.4

New ss/unk 50 40 30 20 10 4 3 2 1 0 2000 2005 1995 2000 2005 1 0 1995 1 0 1995
New extrapulmonary 3 2 Relapse 3 2 Re-treatment
275 119 161 69 61 1.4 68 8.0 3.0 1.8 1.1
Case notications
New ss+ 100 80 60 40 20 0 1995 2000 2005
0 1995
2000
2005
2000
2005
Failed
Defaulted
Transferred
5 0
3 0
10
15 0
Percentage
2000 98 40 100 25 97 12 20 87 72
2001 98 43 100 25 100 16 21 86 83
2002 98 71 100 35 100 27 30 86 78
2003 98 79 100 42 100 31 37 87 78
2004 98 94 100 58 100 38 53 90 82
2005 98 113 100 70 100 46 66 91 78
2006 98 121 100 77 100 51 73 91 77
2007 100 119 100 69 100 51 68
INDONESIA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health community centre (Puskesmas) Yes Urban Health community centre (Puskesmas) NTP services part of general primary health-care network? Location where TB diagnosed Rural Microscopic health centre (PRM) and independent health centre (PPM) Yes (for certain income groups) All patients in all units Health-care worker, community member Community member, family member 2HRZE/4HR3 All patients in all units last: 2007 next: 2009 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) Urban Microscopic health centre (PRM) and independent health centre (PPM) Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions Microscopy health centre and independent health centre 441/441

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded % 43 46 3.2 80

US$ 0.3 0.4 0.1 12 26
National reference laboratory? No (planned for 2010)
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 4 855 Smear per 100 000 2.1 EQA 4 855 % adeq perf Culture Number per 5 000 000 41 41 0.9 0.9 Number 11 11 DST per 10 000 000 0.5 0.5 EQA 3.0 4.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No No 2005 Peripheral level 2006 No No 2007 Some units No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 98% 97% Yes (since 2005) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national Yes, sub-national Yes, sub-national Yes Yes last 2007 2004 2007 2004 2007 2007 next 2008 2009 2012 2012 2012

2005 2006 Number (% of estimated ss+ MDR-TB) 6 588 (%) (%) 0 6 508 59 (0.91%) (%) 0 6 427 (%) (%) 0 2007
INDONESIA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 288 0.1 146 0.9

In 2007 the proportion of TB patients screened for HIV remained very low
0.12 0.10 0.08 0.06 0.04 0.02 0 2004 2005 2006 2007

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 11 141 11 141 100 5 975 54 0 0

Data not reported


Provision of services in rural areas, and lack of coordination between public health programmes and the hospital sector, where the focus on public health is weak and user charges provide the main source of revenue, are the main health systems barriers to TB control. The NTP has strengthened the capacity of laboratories and of human resources for TB care and control in a way that has beneted the entire system. Initiatives to link hospitals are being scaled up using the ISTC; these standards are also helping to engage the hospital sector in providing general public health services.

ENGAGING ALL CARE PROVIDERS Public-public and public-private approaches (PPM), 2007
Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 83 (555) 141 (685) % total notied TB Diagnosed Treated


The ACSM framework is aligned with the National Strategic Plan 20062010. Modules and guidelines on ACSM have been nalized. A KAP survey is planned for 2009.

Communities are being involved in many parts of the country, although the form of involvement varies depending on social practices, geographical setting and the availability of stakeholders. Activities are often initiated by members of the community including traditional leaders, volunteers and health workers, as well as by various NGOs and their community workers. No data on use of the Patients Charter were reported in 2008.

INDONESIA
| FINANCING
Budget has more than doubled since 2002; increased budget in 2009 accompanied by increased government funding, but also funding gap for rst time in ve years
100 80 US$ millions 60 40 20 0 2002 2003 2004 2005 2006 2007 2008 2009 34 39 32 53 57 59 80 69 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

DOTS accounts for 70% of NTP budget; share for MDR-TB is low, although Indonesia is estimated to have the seventh highest number of MDR-TB cases globally
Other 3% Operational research/surveys 4% ACSM/CBTC 8% PPM 5% TB/HIV 5% MDR-TB 5% Lab supplies & equipment 14% Programme management & supervision 36% First-line drugs 15%
NTP staff 5%

Increased budget for programme management and laboratory supplies/equipment, with plans to establish 10-15 culture centres and 8 DST centres
100 80 US$ millions 60 40 20 0 2002 2003 2004 2005 2006 2007 2008 2009 34 39 32 53 57 59 80 69 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for laboratory equipment and EQA
30 25 US$ millions 20 16 15 10 5 0 2002 2003 2004 2005 2006 2007 2008 2009 2.8 24

Costs for hospitalization estimated as zero; costs for clinic visits based on estimate that a new TB patient visits a health facility 16 times during treatment
100 85 80 US$ millions 60 40 21 20 0 2002 2003 2004 2005 2006 2007 2008 2009 24 39 45 40 32 74 Clinic visits Hospitalization NTP budget

Decreasing NTP expenditures per patient from 2004 to 2007, but will increase in 2008 and 2009 if all available funding is spent
350 300 250 US$ 200 150 100 50 0 2002 2003 2004 2005 2006 2007 2008 2009 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget

Country projections of funding requirements consistent with Global Plan for DOTS, but far less than Global Plan for MDR-TB because country plan for scaling-up treatment is less ambitious than targets in the Global MDR/XDR-TB Response Plan
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
57 8.4 0.1 3.8 6.1 2.8 2.5
10 4.5 0.04 1.2 0.2 0.1 0
2006 2007 2008 2009
2006 2007 2008 2009
Indonesia report
Global Plan

ag 1
COUNTRY PROFILE
Kenya
According to the latest surveillance data and estimates of TB incidence, Kenya is the rst country in sub-Saharan Africa to have achieved the global targets for both case detection and treatment success. The estimates of case detection were reassessed in 2007 following a thorough review of epidemiological and programmatic data, including of new data that became available when routine HIV testing of TB patients was introduced. Collaborative TB/HIV activities are widely implemented, with 79% of notied TB patients tested for HIV and 37% of HIVpositive TB patients accessing ART in 2007. Programmatic management of MDR-TB has been initiated in Nairobi. The NTP needs to continue expanding community TB care and PPM initiatives to further improve access to treatment. The main challenges to TB control include the high turnover of health staff, including those employed at the central TB unit, and high demand for training of health-care workers.

ALL IN HIV+ PEOPLE
132
63
353 169 4.8 7.0 53 22 142 59 48 120 319 63 24 65 13 1.9 7.9 32 84 15 39

New ss/unk 150 100 50 0 1995 60 40 20 0 1995
New extrapulmonary 10 8 Relapse 30 20 10 0 1995 Re-treatment
106 284 38 102 43 1.4 72 18 17 1.1 2.8
Case notications
New ss+ 150 100 50 0 1995
6 4 2
2000
2005
2000
2005
2000
2005
0 1995
2000
2005
2000
2005
Failed
Defaulted
Transferred
0.5
1 0
4 6 8 Percentage
10 0
2000 100 205 90 92 91 49 58 80 76
2001 100 228 100 98 100 54 61 80 77
2002 100 244 100 104 100 56 63 79 77
2003 100 271 100 113 100 60 65 80 75
2004 100 290 100 119 100 64 68 80 76
2005 100 288 100 113 100 69 70 82 77
2006 100 296 100 107 100 77 72 85 79
2007 100 284 100 102 100 80 72
KENYA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Dispensaries and health centres Yes Health centre 136/136

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE/4HR All patients in all units last: 2000 next: 2009 % 21 30 11 60
Urban Health centres NTP services part of general primary health-care network? Location where TB diagnosed Rural Health centre Urban Health centre Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 930 930 Smear per 100 000 2.5 2.4 EQA 37 136 % adeq perf 100% Culture Number per 5 000 000 5 5 0.7 0.6 Number 1 1 DST per 10 000 000 0.3 0.3 EQA 1.0 1.0 % adeq perf 100%


NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 1994) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes No Yes, sub-national Yes, sub-national No No last 2007 2007 1995 next 2008 2009 2009

2005 2006 Number (% of estimated ss+ MDR-TB) 2 196 44 (2.0%) (%) 0 2 060 89 (4.3%) (%) 0 2 016 82 (4.1%) 6 (0.30%) 0 6 2007
KENYA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 91 841 79 43 954 69 51,731 100 16 324 37

The proportion of TB patients screened for HIV continues to increase steadily, reaching 79% in 2007
100 % TB patients tested for HIV 80 60 40 20 0

2004
2005
2006
2007

The proportion of HIV-positive TB patients receiving ART declined slightly in 2007; no data on the provision of CPT were reported for 2006
100 80 60 40 20 0 2004 2005 2006 2007 on ART on CPT


The capacity and coverage of the NTP have been improved through gradual integration into the primary health-care system. The NTP has also successfully engaged NGOs, FBOs, the business sector and the private sector in creating coordinated mechanisms for the delivery of TB control and, in the future, other public health interventions.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 222 (296) 382 () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? By which organizations: KAPTLD-Kenya Association for the Prevention of TB and Lung Disease, KMA-Kenya Medical Association, KPA-Kenya Paediatric Association ISTC included in medical curriculum? No Yes

An ACSM unit within the Division of Leprosy, TB and Lung Disease in the Ministry of Health has been established. A KAP survey is planned for 2008.

Of 136 basic management units, 41 offer community-based treatment support. Patients in whom TB is diagnosed choose a relative, a friend or a neighbour to provide support during their treatment. In areas where community-based activities have been implemented, community health workers give talks about TB in the community, refer suspects for TB testing and trace defaulters. No data on use of the Patients Charter were reported in 2008.

KENYA
| FINANCING
Greatly increased NTP budget since 2005; while funding has also grown substantially from both government and grants, large funding gaps remain
50 40 US$ millions 30 20 11 10 0 2002 2003 2004 2005 2006 2007 2008 2009 5.2 13 10 PPM 1% TB/HIV 18% Lab supplies & equipment 9% MDR-TB 3% 30 29 39 37 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Large share of budget is for DOTS (43%) and TB/HIV (18%); share of budget for ACSM and community TB care is higher than in most other HBCs
Other 4% Operational research/surveys 6% First-line drugs 6% NTP staff 8% ACSM/CBTC 25% Programme management & supervision 20%

Increased budget for NTP staff, laboratory supplies and equipment, and MDR-TB (mostly to ensure appropriate infection control in one inpatient facility) in 20082009; disease prevalence survey included in budget for 2009
50 40 US$ millions 30 20 11 10 0 2002 2003 2004 2005 2006 2007 2008 2009 5.2 13 10 30 29 39 37 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Biggest funding gap is for ACSM; disease prevalence survey planned for 20092010 is also not funded
25 21 20 US$ millions 15 15 10 5 1.1 0 2002 2003 2004 2005 2006 2007 2008 2009 3.3 3.2 11 15
2.3

Hospitalization costs are for 2000 dedicated TB beds
50 44 40 US$ millions 30 22 20 12 10 0 2002 2003 2004 2005 2006 2007 2008 2009 7.8 9.2 12 16 42 Clinic visits Hospitalization NTP budget

Increased costs, budget, available funding and expenditures per patient; expenditure and available funding are very similar
500 400 300 200 100 0 2002 2003 2004 2005 2006 2007 2008 2009 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget

Country plan for 20082009 in line with Global Plan, including TB/HIV activities (although some TB/HIV costs are not part of the NTP budget, which explains the lower funding in the country report)
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
US$
2009 BUDGET GAP
DOTSf 50 40 30 20 10 0
2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
US$ millions
16 7.9 0 0.3 9.2 2.4 1.4
3.1 0.5 0 0.01 8.0 2.4 0.8
2006 2007 2008 2009
2006 2007 2008 2009
Kenya report
Global Plan

ag 1
COUNTRY PROFILE
Mozambique
Although the case detection rate has been increasing, the detection rate of new smear-positive cases remains below 50%. Treatment success rates continue to be below target for both new and re-treatment cases. While all districts are implementing DOTS, access to health care is poor given the limitations of the health system infrastructure. Collaborative TB/HIV activities are expanding; in 2007, 70% of notied TB cases were tested for HIV, 33% of HIV-positive patients were put on ART and 93% were given CPT. Programmatic management of MDR-TB has begun. Increased nancial ows from the Global Fund and other donors have alleviated funding constraints. However, the shortage of a skilled workforce, slow funding disbursements and weak absorptive capacity continue to limit programme implementation.

ALL IN HIV+ PEOPLE
92
44
431 204 2.6 1.8 37 15 174 71 47 108 504 144 27 127 18 3.5 3.3 22 102 17 82
New ss/unk 80 60 40 20 0 1995 10 0 1995 30 20
New extrapulmonary 8 6 4 2 0 1995 5 0 1995 Relapse 15 10 Re-treatment
38 176 18 85 58 49 5.0 14 0.3 1.8
Case notications
New ss+ 100 80 60 40 20 0 1995 2000 2005
2000
2005
2000
2005
2000
2005
2000
2005
Failed
Defaulted
Transferred
15 0
2 0
4 Percentage
8 0
10
15
2000 100 116 100 73 100 28 47 75 71
2001 100 118 100 75 100 28 45 78 68
2002 100 133 100 80 100 29 45 78 67
2003 100 146 100 82 100 31 45 76 68
2004 100 155 100 85 100 32 46 77
2005 100 162 100 87 100 34 47 79 70
2006 100 168 100 87 100 36 49 83 65
2007 100 176 100 85 100 39 49
MOZAMBIQUE

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Centro de saude rural (rural health facility) Yes Urban Centro de saude urbano (urban health facility) NTP services part of general primary health-care network? Location where TB diagnosed Rural Centro de saude rural-Sede (at BMU head-ofce level) Yes (all suspects) All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2(HRZE)/4(HR) All patients in all units last: 2006 next: 2009 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) Urban Centro de saude urbano-Sede (at BMU head-ofce level) Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions Centro de saude urbano-Sede (at BMU head-ofce level) 169/169

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded % 26 40 16 76

US$ 1.1 1.4 0.3 9.2 15
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Smear Number 2007 2008 252 252 per 100 000 1.2 1.2 EQA 252 252 % adeq perf 97% 1 3 Culture Number per 5 000 000 0.2 0.7 Number 1 1 0.5 0.5 DST per 10 000 000 EQA 1.0 1.0 % adeq perf 100%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? Yes Central level 2006 No No 2007 Yes No 2005 Yes Peripheral level 2006 No No 2007 Some units Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 2006) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes No No Yes, national No No last 2006 1999 next 2009 2008

2005 2006 Number (% of estimated ss+ MDR-TB) 1 482 115 (7.8%) 77 (5.2%) 0 77 1 474 129 (8.8%) 129 (8.8%) 0 129 1 464 163 (11%) 163 (11%) 0 163 2007
MOZAMBIQUE


Between 2006 and 2007 the proportion of TB patients screened for HIV almost tripled

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 326 517 3 039 0.9 12 857 3.9 676 0.2
2004
2005
2006
2007

The proportion of HIV-positive TB patients receiving ART has declined while the proportion of those receiving CPT has increased dramatically


The main health systems barriers affecting TB control are a shortage of skilled human resources for health and poor access to the primary health-care system into which the NTP is integrated. Improvements in laboratory capacity and training of human resources are beneting both the NTP and the primary health-care system.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 41 (41) 5 () % total notied TB Diagnosed Treated 0.9 0.9


Community forums were organized during World TB Day 2008. A KAP survey is planned for 2009.

Community-based activities are continuing through an NGO that supports the NTP. Community volunteers have been trained to provide treatment support, contact tracing, sputum transport and awareness-raising activities, in rural areas. There are volunteers in many districts, but the initiative has not been implemented uniformly. Plans to expand geographical coverage and involve other partners are ongoing. The Patients Charter is not yet in use.

Operational research budget (% of NTP budget) 0.6 %
MOZAMBIQUE
| FINANCING
Greatly increased budget since 2007 following re-assessment of funding needs in line with Stop TB Strategy; funding has also grown from government and donors including the Global Fund (round 7) and USAID
30 25 20 12 10
Data not available

Largest components of budget are DOTS (41%), Other (31%) and collaborative TB/HIV activities (21%)
First-line drugs 4% NTP staff 8% Other 31% Programme management & supervision 8%
25
US$ millions
11
8.0
6.9
7.7
Lab supplies & equipment 21% Operational research/surveys 0.3% ACSM/CBTC 4% PPM 0.1% TB/HIV 21% MDR-TB 3%
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased budget for TB/HIV, and within Other, increased budget for high-risk groups (prisoners) and childhood TB; budget within DOTS includes establishment of two regional reference laboratories and purchase of new laboratory equipment
30 25 20 12 10
Data not available

Funding gap within DOTS mainly for laboratory supplies and equipment, and routine programme management
25
11
8.0
6.9
7.7
8 6.1 5.3 3.8 2.9 2

Data not available
6 US$ millions
6.0
2.5
US$ millions
0.4
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization costs 20082009 based on reduced number of dedicated TB beds (from 4512 to 2258) in the country; outpatient costs based on 90 visits to a health facility per new TB patient during treatment

Large uctuation in available funding per patient
1000 800 600
20
17 12
400 200
Data not available
Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
10
Data not available
8.0 3.9 3.7
US$ 0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Implementation of TB control behind Global Plan 20062007 but country assessment of funding required 20082009 in line with Global Plan difference for TB/HIV is due to some activities being funded and implemented by national HIV/AIDS control programme
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf 50 40 30 20 10 0
2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
US$ millions
10 5.9 0 0.02 0.9 0.1 7.6
2.4 1.3 0 0.02 0.4 0.05 1.8
2006 2007 2008 2009
2006 2007 2008 2009
Mozambique report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 20032005 and 2007 are based on expenditure, whereas those for 2006 are based on available funding, and those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20042005 and 2007 is based on the amount of funding actually received, using retrospective data; available funding for 20022003, 2006 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
COUNTRY PROFILE
Myanmar
Results from the prevalence survey in Yangon and increasing case notications in the FIDELIS project suggest that the TB burden in Myanmar is underestimated and that current estimates need to be reviewed. A GLC-approved MDR-TB project and a project providing IPT for HIVpositive people began in 2008. Data from the second national drug resistance survey will be available in 2009; TB/HIV surveillance data indicate that 11% of TB patients are coinfected with HIV. Cohort review meetings have been expanded across poorly performing townships alongside innovative activities for improved case-nding, including sputum collection points, mobile teams and contact tracing. PPM-DOTS has been scaled up to more than 150 out of 325 townships. The large budget gap for TB control and uncertainty about the supply of rstline anti-TB drugs beyond 2009 remain major challenges.

ALL IN HIV+ PEOPLE
83 171 0 37 75 11 79 162 206 6.3 13 26 4.0 16
9.1 19 4.8 3.2 6.5 4.6 9.3 0.9 1.9

New ss/unk
Subnational data not reported
New extrapulmonary 100 80 60 40 20 10 5 0 1995 10 5 0 1995 15 Relapse 15 Re-treatment
129 265 43 87 50 1.9 116 40 32 0.3 0.7
Case notications
New ss+ 100 80 60 40 20 0 1995 2000 2005 100 80 60 40 20
0 1995
2000
2005
0 1995
2000
2005
2000
2005
2000
2005
Failed
Defaulted
Transferred
30 0
8 0
4 6 Percentage
8 0
2000 77 67 100 38 100 36 50 82 74
2001 84 92 96 46 98 50 61 81 74
2002 88 122 100 52 100 67 69 81 75
2003 95 161 100 58 100 88 78 81 70
2004 95 203 100 66 100 113 88 84 74
2005 95 223 100 76 100 125 102 84 71
2006 95 253 100 83 100 142 111 84 70
2007 95 265 100 87 100 149 116
MYANMAR

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Rural health centre for drug distribution only Yes Township TB centre 314/324

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units % 11 25 62 60
Urban Township TB centre NTP services part of general primary health-care network? Location where TB diagnosed Rural Township TB centre Urban Township TB centre Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 0.2 0.3 0.1 0.4 4.0
Health-care worker, community member, family member Health-care worker, community member, family member 2(HRZE)/4(HR) All patients in all units last: 2007 next: 2010
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 324 324 Smear per 100 000 0.7 0.7 EQA 54 324 % adeq perf 52% Culture Number per 5 000 000 2 2 0.2 0.2 Number 1 1 DST per 10 000 000 0.2 0.2 EQA % adeq perf


NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 97% 97% Yes (since 1995) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes No Yes, national No No last 2007 2006 2003 next 2008 2009

2005 2006 Number (% of estimated ss+ MDR-TB) 2 287 (%) (%) 0 2 309 666 (29%) (%) 0 2 331 600 (26%) (%) 0 2007
MYANMAR

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 2 825 2.1 873 9.6 846 97 437 50

The proportion of TB patients screened for HIV was low and stable from 2005 to 2007

0 2004 2005 2006 2007

The proportion of HIV-positive TB patients receiving ART and CPT increased from 2005, reaching 50% and 97% in 2007 respectively


The national health system operates under severe resource constraints, with limited human resources and poor outreach services in some areas. The NTP, in conjunction with the HIV and malaria control programmes, is attempting to improve the management of general health systems and supervisory and delivery capacity at the township level, with funding from the Three Diseases Fund. The NTP is also scaling up initiatives to engage the private sector in TB control and is helping to improve the capacity of the Myanmar Medical Association to provide services for public health.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 4 (365) 856 () % total notied TB Diagnosed Treated 0.1 9.1 0.1 9.1


A KAP survey is planned for 2009.

The community is involved in all basic management units in the country, although not in all health centres. Involvement has been initiated through public health centres and NGOs, which organize community-based treatment support, sensitization activities and referral of suspects. The presence of community health workers and various NGOs throughout the country mean that there is potential for countrywide coverage of community-based TB care. No data on use of the Patients Charter were reported in 2008.

MYANMAR
| FINANCING
Increased funding from 2006 from Three Diseases Fund, but large funding gaps remain
20 17 15 US$ millions 16 15 11 10 5.5 5 2.8 6.3 5.8 Programme management & supervision 17% NTP staff 21% 2002 2003 2004 2005 2006 2007 2008 2009 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Almost all (92%) of the budget is for DOTS implementation
Other 0.4% ACSM/CBTC 2% PPM 1% TB/HIV 0.3% MDR-TB 4% Lab supplies & equipment 12%
First-line drugs 43%

Decreased budget in 2009 mainly because buffer stock of rst-line drugs was included in 2008 budget
20 17 15 US$ millions 16 15 11 10 5.5 5 2.8 6.3 5.8 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for rst-line drugs, routine programme management and supervision, and dedicated NTP staff
15 13 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
US$ millions
10
9.3 7.7
5 2.2 0
4.2
4.2
3.7
4.3
0 2002 2003 2004 2005 2006 2007 2008 2009
2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization costs are for 1500 dedicated TB beds; costs for clinic visits based on 28 clinic visits during TB treatment for 20022005 and 3 visits for 20062009, reecting more reliance on community-based DOT

High rst-line drugs budget per patient 20062008 reects planned purchase of buffer stock; expenditures almost the same as available funding suggesting good absorption capacity
100 US$
10 6.8 5 3.1 3.4 4.0 5.0 4.9
50
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Country implementation behind Global Plan targets (20062007), in part due to lack of funds; country assessment of funding required for DOTS 20082009 higher than Global Plan due to higher projections of patients to be treated; country plan for scaling up MDR-TB treatment has less ambitious targets than the Global MDR/XDR-TB Response Plan
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
10 0.5 0 0.1 0.2 0 0.05
3.8 0.3 0 0.1 0.2 0 0.04
2006 2007 2008 2009
2006 2007 2008 2009
Myanmar report
Global Plan

ag 1
COUNTRY PROFILE
Nigeria
The Stop TB Strategy is being implemented in all 774 local government areas following increased funding from diverse sources including the Global Fund. At least two health facilities in each area have fully functional DOTS services. The case detection rate has been increasing steadily but remains relatively low. However, although the outcome of treatment was not evaluated for a high proportion of patients, the treatment success rate was 76%. Collaborative TB/HIV activities are being scaled up, and 32% of TB cases are screened for HIV at major health facilities. As part of the programmatic management of MDR-TB, two national and six zonal laboratories are being set up. PPM and community-based TB care activities are being expanded. Major challenges include human resource constraints, coordinating multiple partners, setting up a commodity management system and closing remaining funding gaps.

ALL IN HIV+ PEOPLE
460 311 2.6 195 131 27 772 521 141 138 93 18 1.8 9.4
123 83 2.7 43 29 62 42 59 40
New ss/unk 3 2 1 1 0 1995 0 1996 1 0 1995
New extrapulmonary 2 Relapse 3 2 Re-treatment
82 56 44 30 58 1.4 23 4.0 5.0 1.2 2.7
Case notications
New ss+ 40 30 20 10 0 1995
25 20 15 10 5
2000
2005
0 1995
2000
2005
2000
2005
2001
2006
2000
2005
Failed
Defaulted
Transferred
Not evaluated
8 0
8 0
10
15 0
3 0
Percentage
2000 47 21 100 14 100 7.4 12 79 71
2001 55 36 66 18 81 12 15 79 71
2002 55 29 78 17 89 9.1 13 79 73
2003 60 33 100 21 100 9.7 15 78
2004 65 41 100 24 100 12 17 73 73
2005 65 44 100 25 100 13 18 75 66
2006 75 49 100 28 100 15 20 76 77
2007 91 56 100 30 100 17 23
NIGERIA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Primary health centre Yes General hospital 701/774

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units % 16 33 4.6 57
Urban General hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Primary and general hospital Urban General hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

Health-care worker, community member, family member Health-care worker, community member, family member 2(HRZE)/6(HE) All patients in all units last: 2008 next: 2009
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 794 1 138 Smear per 100 000 0.5 0.8 EQA 347 1 138 % adeq perf 93% Culture Number per 5 000 000 2 9 0.1 0.3 Number 1 9 DST per 10 000 000 0.1 0.6 EQA 9.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 No Peripheral level 2006 No 2007 No Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 2000) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national No No No last 2007 next 2008 2009

2005 2006 Number (% of estimated ss+ MDR-TB) 6 971 (%) (%) 0 6 957 (%) (%) 0 6 934 45 (0.65%) (%) 0 2007
NIGERIA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 27 849 32 6 275 5.1 1 953 31

The proportion of TB patients screened for HIV tripled between 2006 and 2007

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 233 495 86 897 37 15 418 6.6 0.03
2004
2005
2006
2007

No data were reported on ART; data on the provision of CPT were reported for the rst time
50 40 30 20 10 0 2004 2005 2006 2007 on ART on CPT
76


The public health-care system, into which TB control is fully integrated, is constrained by a lack of human resources and difculties in providing outreach services - particularly in rural areas. A wide range of hospitals and other tertiary institutions that are not yet linked to the NTP are available in urban areas; an unregulated private health sector is a problem throughout the country. Initiatives are ongoing to engage these various providers.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector () 410 () % total notied TB Diagnosed Treated 4.6 4.6

ISTC endorsed by professional organizations? By which organizations: Nigeria Medical Association ISTC included in medical curriculum? No Yes

A KAP survey was conducted in 2008 to rene the ACSM component of the National TB Control Strategy 20062010. An ACSM consultant participated in the 2008 national programme review to assess progress towards ACSM targets and drafted recommendations for future ACSM activities.

Community-based services are currently implemented in six pilot states in the country, based on national guidelines which are fully in accordance with global policy. Careful attention is given to ensuring high-quality care and raising awareness about TB. Wide expansion of community-based services is planned by the end of 2009.

NIGERIA
| FINANCING
Increased NTP budget after re-assessment of funding needs; funding has also grown but large funding gaps remain
60 48 44 US$ millions 40 29 25 20 13 8.6 0 2002 2003 2004 2005 2006 2007 2008 2009 8.4 TB/HIV 13% MDR-TB 6% Lab supplies & equipment 22% 14 Unknown Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Laboratory budget includes introduction of molecular tests at national level; share of budget for ACSM (including community TB care) is large compared with most HBCs
Other 3% Operational research/surveys 1% ACSM/CBTC 22% First-line drugs 7% NTP staff 12%
PPM 2%

Increasing budget for DOTS and ACSM, and to a lesser extent for MDR-TB, with plan to treat 50 MDR-TB patients if approved by GLC
60 48 44 US$ millions 40 29 25 20 13 8.6 0 2002 2003 2004 2005 2006 2007 2008 2009 8.4 14 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for laboratory supplies and equipment
30 24 20 19 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
US$ millions
10 6.6
Data not available
8.8 4.9 2.3 5.3
0 2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization costs based on estimate that 2030% of new TB patients were hospitalized for average of 56 days 20052006, and 7% of new TB patients hospitalized for 14 days in 20072009
70 60 50 US$ millions 57 55 Clinic visits Hospitalization NTP budget

Expenditures have increased in line with available funding, showing good absorption capacity (20032007)
600 500 400 US$ 300 200 100 0 2002 2003 2004 2005 2006 2007 2008 2009 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
40 30 20 10 0 2002 2003 2004 2005 2006 2007 2008 2009 9.8

Data not available
28 23 13 17

Country implementation of TB control activities (20062007) in line with the Global Plan for DOTS only; country plan (20082009) falls short of Global Plan for community TB care and TB/HIV
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
100 US$ millions 80 60 40 20 0
DOTSf
MDRTB
TB/HIVg
ACSM
Other
Total
23 8.7 0.7 1.0 9.9 0.4 0.7
8.7 5.2 0.3 0.5 3.8 0.3 0.5
2006 2007 2008 2009
2006 2007 2008 2009
2006 2007 2008 2009
Nigeria report
Global Plan

ag 1
COUNTRY PROFILE
Pakistan
The case detection rate is increasing and is just below target at 67%, while the treatment success rate has reached 88%. PPM initiatives account for an increasing share of notications, notably from tertiary hospitals and a social franchising project involving private clinics that is implemented by an NGO in ve cities. A new recording and reporting system introduced in 2008 will allow precise quantication of the contribution of PPM to total notications. An EQA system has been implemented and is being expanded to cover the entire TB microscopy network. However, the network of services for culture and DST is inadequate. MDR-TB case management has been initiated, and collaborative TB/HIV activities have not yet been scaled up. A much needed TB prevalence survey is planned in 2009. ACSM activities have been expanded, although the national Stop TB Partnership launched in 2004 is not yet fully functional.

ALL IN HIV+ PEOPLE
297 181 0 133 81 2.1 365 223 215 48 29 25 3.2 35
6.2 3.8 6.2 2.2 1.3 3.1 1.9 1.4 0.9

New ss/unk 80 60 40 30 20 10 0 2000 2005 1995 Defaulted 2000 2005
New extrapulmonary 3 2 1 0 1995 Transferred 2000 2005 Relapse 3 2 1 0 1996 2001 2006 Re-treatment
230 141 89 54 46 1.1 67 34 15 3.5 3.9
Case notications
New ss+ 60 40 20 0 1995 Died
20 0 2000 2005 1995 Failed
Not evaluated
New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB 0 2 4 6 0 1 2 3 4 0 5 10 15 0 1 2 3 4 5 0 2 4 6 8 10
Percentage
2000 9.0 7.7 100 2.3 100 4.1 2.8 74 54
2001 24 23 53 7.4 57 12 9.1 77
2002 44 35 90 11 94 19 13 78 66
2003 66 46 100 14 100 25 17 79 66
2004 79 61 100 20 100 33 25 82 78
2005 100 90 100 31 100 49 38 83 76
2006 100 110 100 41 100 59 50 88 77
2007 99 141 100 54 100 76 67
PAKISTAN

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural District hospital, subdistrict hospital, TB clinic Yes Diagnostic centre 1130/1130
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes, (20052010) Yes (established 2001) Yes (established 2004)

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units % 19 24 14 53
Urban Tertiary care, teaching hospital, district hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural All except basic health units, dispensaries Urban All except basic health units, dispensaries Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

Health-care worker, community member, family member Family member 2HRZE/6HE All patients in all units last: 2008 next: 2009
National reference laboratory? No (planned for 2008)
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 1 131 1 131 Smear per 100 000 0.7 0.7 EQA 360 906 % adeq perf 44% Culture Number per 5 000 000 3 5 0.1 0.1 Number 1 1 DST per 10 000 000 0.1 0.1 EQA 0 0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No No 2005 No Peripheral level 2006 Some units No 2007 Some units No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes Yes (since 2001) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No Yes, national Yes, national Yes Yes last 1987 1987 2006 2008 next 2009 2009

PAKISTAN

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied
Data not reported


Data not reported


TB services are fully integrated into the public health care system. Human resource constraints and difculties in providing outreach services, particularly in rural areas and conict zones, affect services to control TB. In urban areas many hospitals and other tertiary institutions are not yet fully linked to the NTP, and an unregulated private health sector is a problem throughout the country. The NTP has collaborated with other public health programmes to improve the capacity of laboratories, human resources and supervision and monitoring. Innovative approaches for engaging hospitals, NGOs and the private sector are being scaled up.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 19 () 5 005 (100 030) % total notied TB Diagnosed Treated 0.5 19 0.5 19


ACSM activities continue to be prioritized. The revised National ACSM Strategy is in place, and a National Steering Committee on ACSM is operational. There is strong collaboration with the private sector for use of mass media and with NGOs for social mobilization. National guidelines on monitoring and evaluation in the private sector are available. Major challenges for the NTP are ensuring continued commitment to ACSM at all levels of the NTP, developing strong evidence of Scams contribution to increasing rates of case detection and treatment success, and implementing Global Fund-related workplan in a timely manner.

There are >100 000 lady health workers working in the public sector who assist national preventive and curative programmes, including the NTP. In parts of the country, religious leaders have been actively engaged in raising awareness of TB. Patients are included in the country coordination mechanism. The Patients Charter has been translated into local languages and widely distributed to health facilities. Coalitions of community-based organizations are being established in 57 districts. A pilot initiative to promote TB messages in schools has also been initiated.

PAKISTAN
| FINANCING
NTP budget 10 times higher in 2009; funding increased due to increased donor nancing; funding gap will be reduced if US$ 25 million Global Fund round 8 application is successful
60 50 US$ millions 40 30 22 20 10 0 2002 2003 2004 2005 2006 2007 2008 2009 5.4 5.9 19 21 29 54 54 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Most of the budget is for DOTS (51%) and PPM/PAL/CBTC/ACSM (29%)
Other 6% Operational research/surveys 6% First-line drugs 24% ACSM/CBTC 19% NTP staff 4% PPM 6% TB/HIV 2% MDR-TB 11% Programme management & supervision 13% Lab supplies & equipment 9%

Major growth in DOTS budget since 2002; from 2008 big increases in budgets for PPM (with over 1000 private providers engaged), ACSM, MDR-TB; most of the budget within operational research is for a disease prevalence survey
60 50 US$ millions 40 30 21 20 10 0 2002 2003 2004 2005 2006 2007 2008 2009 5.4 5.9 19 21 29 54 54 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Increased funding gap in 2008; MDR-TB gap to be nanced through public sector funds and other donors; large ACSM gap to be lled with funding from round 6 Global Fund grant
50 40 US$ millions 30 20 10 1.6 0 -10 2002 2003 2004 2005 2006 2007 2008 2009 16 10 8.3 11 37 25 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Costs and budget per patient increasing as new elements of Stop TB Strategy are introduced; rst-line drugs budget highest in 2009 due to purchase of buffer stock
300 250 200 US$ 150 100 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
Almost all costs for TB control will be included in the NTP budget after 2008 if funds are mobilized and spent; lower use of hospitalization as DOTS expands
70 60 50 US$ millions 40 30 20 10 0 2002 2003 2004 2005 2006 2007 2008 2009 5.0 6.4 8.8 8.6 16 13 57 58 Clinic visits Hospitalization NTP budget
50 0 2002 2003 2004 2005 2006 2007 2008 2009

Country assessment of funding requirements lower than Global Plan estimates, except for TB/HIV, ACSM and Other
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf US$ millions 100 80 60 40 20 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
27 7.1 2.5 3.0 10 3.2 0.7
10 5.7 2.5 1.2 7.8 0.8 -3.0
2006 2007 2008 2009
2006 2007 2008 2009
Pakistan report
Global Plan

ag 1
COUNTRY PROFILE
Philippines
Case detection and treatment success rates have exceeded the global targets since 2004. PPM initiatives have been further expanded, and their contribution to the national case detection rate reached 9% in 2007, with only 40% population coverage. The country is now scaling up programmatic management of drug-resistant TB to include areas beyond Metro Manila, expanding services for TB in children and addressing TB in high-risk groups including among the HIV-infected, the urban poor and the prison population. The third prevalence survey in 2007 showed a 34% decrease in bacteriologically-conrmed TB compared with the 1997 survey. The survey results will help re-estimate the burden of TB in the Philippines and improve understanding of risk factors. Government commitment is strong, and the increases in funding from domestic sources and the Global Fund grant have helped to reduce funding gaps.

ALL IN HIV+ PEOPLE
255 290 1.8 115 130 0.3 440 500 400 36 41 44 4.0 21
0.9 1.0 2.4 0.3 0.3 0.4 0.5 0.3 0.3

New ss/unk
New extrapulmonary 4 3 2 1 0 1995 Defaulted 20 0 1995 Transferred 1 0 1995 60 40 Relapse 3 2 Re-treatment
141 160 87 98 64 2.4 75 1.5 1.1 0.8 1.0
Case notications
New ss+ 150 100 50 0 1995 250 200 150 100 50 2000 2005
0 1995
2000
2005
2000
2005
2000
2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB (2004 cohort) 0 2 4 6 8
Failed
Not evaluated
10 0
5 0
10 Percentage
15
20 0
3 0
2000 90 157 75 88 75 48 59 88
2001 95 138 100 76 100 40 52 88
2002 98 149 100 82 100 46 57 88
2003 100 164 100 90 100 52 64 88 76
2004 100 158 100 94 100 50 69 87 53
2005 100 162 100 97 100 52 71 89
2006 100 171 100 99 100 56 75 88 80
2007 100 160 100 98 100 54 75
PHILIPPINES

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Rural health unit Yes Health centre 3075/3075

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE/4HR All patients in all units last: 2008 next: NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 35 56 2.9 81
Urban Health centre NTP services part of general primary health-care network? Location where TB diagnosed Rural Rural health unit Urban Health centre Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.2 0.4 0.05 14 37
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 2 374 2 374 Smear per 100 000 2.7 2.6 EQA 2 374 2 374 % adeq perf Culture Number per 5 000 000 3 3 0.2 0.2 Number 3 3 DST per 10 000 000 0.3 0.3 EQA 3.0 3.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 No Peripheral level 2006 No No 2007 No Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes Yes (since 2001) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national Yes, national Yes, national No No last 2007 2007 2004 next 2008 2017 2017

2005 2006 Number (% of estimated ss+ MDR-TB) 6 430 274 (4.3%) 191 (3.0%) 191 6 442 403 (6.3%) 133 (2.1%) 133 6 451 568 (8.8%) 313 (4.9%) 313 2007
PHILIPPINES

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 46 0.03 0

0.06
0.04
0.02
0 2004 2005 2006 2007


Data not reported


The NTP has been actively engaged in improving primary health care and community outreach for better delivery of integrated TB services, including laboratory services and delivery of treatment. Successful engagement of the private sector is being scaled up nationwide, partially through the social insurance system.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 4 () 5 237 (10 000) % total notied TB Diagnosed Treated 8.6


An ACSM review mission was followed by the development of a national ACSM strategy. A KAP survey conducted in 2007 included a mapping exercise which was used to identify the ACSM activities in which different partners were involved. An ACSM Working Group comprising the government, NGOs and private partners has been formed to facilitate coordination in implementing strategic activities. There are 270 patient-centered organizations or networks involved in activities to advocate TB control and implement DOTS.

In rural health facilities where NGO support is not available, community health workers assist staff in 95% of public health facilities, visiting the homes of patients who are supported mostly by family members to ensure adequate treatment progress. Community-based support for the continuation phase of MDR-TB treatment has been available since 2006 through a joint effort between public and private services and the community. No data on use of the Patients Charter were reported in 2008.

PHILIPPINES
| FINANCING
Increased funding from the Global Fund; funding gaps remain but likely to be partially lled by the government in 2009
30 23 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Largest component of budget is DOTS (45%) but share for MDR-TB (32%) is also large, especially compared with other HBCs
Other 3% Operational research/surveys 1% ACSM/CBTC 9% NTP staff 22% PPM 9% TB/HIV 1% MDR-TB 32% Programme management & supervision 0.2% Lab supplies & equipment 2% First-line drugs 21%
US$ millions
20 16 15 16
20 17
21 19
10
0 2002 2003 2004 2005 2006 2007 2008 2009

Major increase in budget for management of patients with MDR-TB, with plan to treat 1000 patients in 2009
30 23 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for dedicated NTP staff; operational research underfunded since 2007
6 4.4 US$ millions 4 2.7 2.1 2 3.9 4.6 3.8 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
US$ millions
20 16 15 16
20 17
21 19
10
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Cost of clinic visits during treatment based on 120 visits per new ss+ patient and 24 visits per new ss-/extrapulmonary patient during treatment
40 31 30 US$ millions 22 20 21 23 23 23 32 34 Clinic visits Hospitalization NTP budget

Increased cost, budget and expenditure per patient since 2006, reecting strengthening of TB control including expansion of MDR-TB treatment
250 200 150 US$ 100 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
10
50 0 2002
0 2002 2003 2004 2005 2006 2007 2008 2009
2003
2004
2005
2006
2007
2008
2009

Country assessment of funding requirements in line with or higher than Global Plan, except for MDR-TB; despite expansion of MDR-TB treatment, numbers treated are below the targets of the Global MDR/XDR-TB Response Plan
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf US$ millions 50 40 30 20 10 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
10 7.3 0 2.1 2.1 0.3 0.6
3.4 0.04 0 0.01 0.02 0.3 0
2006 2007 2008 2009
2006 2007 2008 2009
Philippines report
Global Plan

ag 1
COUNTRY PROFILE
Russian Federation
The revised national TB control strategy has been expanded to all regions and a considerable number of penitentiary TB services, with particular attention to improving diagnosis and treatment of MDR-TB. Four regions are implementing MDR-TB projects approved by the GLC; an additional 19 regions have either submitted applications to the GLC or are preparing applications. A federal centre for monitoring TB control has been established to improve the quality of surveillance as well as to conduct operational research and provide technical support to regions. TB projects nanced through a World Bank loan have received upgraded laboratory equipment and an improved supply of consumables. The rst phase of a Global Fund grant has been successfully implemented, and continued funding has been approved. Major challenges include high rates of MDR-TB among new and previously treated cases combined with an inadequate supply of second-line drugs, poor infection control in TB units and laboratories, and a shortage of appropriately qualied staff. The treatment success rate remains low at 58%, while the case detection rate for new smear-positive cases is 49%.

ALL IN HIV+ PEOPLE
157 110 2.1 68 48 16 164 115 34 25 18 3.7 13 49
26 18 3.4 9.0 6.3 13 9.0 5.1 3.6

New ss/unk 80 60 40 10 8 6 4 2 2000 2005 0 1995 Defaulted 2000 2005
New extrapulmonary 10 8 6 4 2 0 1995 Transferred 2000 2005 Relapse Re-treatment 80 60 40 20 0 1995
127 89 33 23 31 2.9 49 12 9.9 0.1 0.2
Case notications
New ss+ 30 20 10 0 1995
20 0 1995 Failed
2000
2005
2000
2005
Died New ss+ New ss+ HIV+ New ss+ HIV New ss New extrapulmonary Re-treatment MDR-TB (2004 cohort) 0 5 10
15 0
10
20
30 0
10
20
30 0
10
Percentage
2000 12 95 8.3 19 13 81 37 68 49
2001 16 90 11 18 15 78 37 67 48
2002 25 88 14 19 19 78 40 67 46
2003 25 85 14 20 22 78 43 61 45
2004 45 84 25 21 32 78 47 60 39
2005 83 89 54 23 70 78 49 58 37
2006 84 87 76 23 93 76 48 58 38
2007 100 89 100 23 100 75 49
RUSSIAN FEDERATION

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Dispensary No Central city hospital 354/354

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) Yes Health-care worker, community member Health-care worker, community member 2HRZE/4HR5 All patients in all units last: 2006 next: NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 81 82 5.2 82
Urban Dispensary NTP services part of general primary health-care network? Location where TB diagnosed Rural Central rayon hospital Urban Central city hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 8.9 9.0 1.6 171 277
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 4 048 4 048 Smear per 100 000 2.8 2.9 EQA % adeq perf Culture Number per 5 000 000 965 965 34 34 Number 280 280 DST per 10 000 000 20 20 EQA % adeq perf
Note: for routine diagnosis, there should be at least one laboratory providing smear microscopy per 100 000 population. To provide culture for diagnosis of paediatric, extrapulmonary and ss-/HIV+ TB, as well as DST of re-treatment and failure cases, most countries will need one culture facility per 5 million population and one DST facility per 10 million population. EQA column shows number of laboratories for which EQA was done. Adeq perf; adequate performance for microscopy based on results of EQA.

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No 2005 No Peripheral level 2006 No No 2007 No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 66% Yes (since 1991) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national Yes, national Yes, sub-national Yes Yes last 2007 2007 2007 20022006 2007 2007 next 2008 2008 2008 2008 2008

2005 2006 Number (% of estimated ss+ MDR-TB) 30 455 6 581 (22%) 451 (1.5%) 451 30 926 3949 (13%) 391 (1.3%) 391 31 397 5297 (17%) 211 (0.67%) 211 2007
RUSSIAN FEDERATION

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 87 444 41 2 401 9.3

The percentage of TB patients tested for HIV was 41% in 2007, a slight decrease compared with 2005 and 2006

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 267 513 146 105 55 5 985 2.2 5 768 2.2
2004
2005
2006
2007

60 on ART on CPT
40

20
0 2004 2005 2006 2007

The main health system-related challenges for TB control are lack of integration between disease-specic public health programmes and the primary healthcare network, and inadequate linkages between the civilian and penitentiary health-care services. Integration of TB control into primary health-care services has started, and the links between TB control and the penitentiary system are improving.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 5 285 (5 285) () % total notied TB Diagnosed Treated

ISTC endorsed by professional organizations? By which organizations: Russian association of phtisiologists ISTC included in medical curriculum? Yes Yes

There are 140 patient-centered organizations or networks involved in TB advocacy activities and DOTS implementation.

The Russian Red Cross is involved in activities related to increased case-nding in the community in two districts. The Patients Charter is not being used.

RUSSIAN FEDERATION
| FINANCING
Substantial increase in funding needs for 20082009, with most funding provided by the government; funding gap is just over US$ 200 million in 2009
1500 1249 1070 US$ millions 1000 721 500 316
Data not available

Largest budget component is for staff dedicated to TB control (including those working in TB hospitals), followed by TB hospitals (which includes all running costs besides staff)
Other 18% First-line drugs 3%
Operational research/surveys 0.1% ACSM/CBTC 0.005% TB/HIV 0.3% MDR-TB 11%
NTP staff 36%
382
428
Programme management & supervision 0.1% TB hospitals 28% Lab supplies & equipment 4%
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased funding needs for 20082009 mostly reects newly available data about the non-staff budget required for TB hospitals; MDR budget is for 4200 patients in 2008 and 9800 patients in 2009
1500 1249 1070 US$ millions 1000 721 500 316
Data not available

Funding gap within DOTS is for dedicated staff and within MDR-TB the gap is for second-line drugs
250 200 150 US$ millions 100 50 0 -50 -100 2002 2003 2004 2005 2006 2007 2008 2009
Data not available
382
428
Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB TB hospitals DOTSd
233
226
98 43
42
Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB TB hospitals DOTSd
0 2002 2003 2004 2005 2006 2007 2008 2009

Highest costs and budget per patient among all HBCs; total costs, budget and expenditure per patient are increasing
12 000 10 000 8 000 US$ 6 000 4 000 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
Increasing total costs as more information about the costs associated with TB hospitals are included; other includes uorography
1500 1273 1015 776 1094 Unknown Other NTP budget
US$ millions
1000
500 245 142 0 294
366 2 000 0
2002 2003 2004 2005 2006 2007 2008 2009
2002
2003
2004
2005
2006
2007
2008
2009

Costs for TB control in country report much higher in total and for DOTS than costs estimated in Global Plan; costs for MDR-TB are lower, due to smaller numbers of patients to be treated compared with the targets of the Global MDR/XDR-TB Response Plan
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
890 137 0 0 0.1 1.8 220
123 104 0 0 0 0 0
2006 2007 2008 2009
2006 2007 2008 2009
Russian Federation report
Global Plan

ag Please see footnotes page 169.
1
Total TB control costs for 20022007 are based on expenditure, whereas those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20042007 is based on the amount of funding actually received, using retrospective data; available funding for 20022003 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
COUNTRY PROFILE
South Africa
The case detection rate has remained above target since 2003; however, treatment success rates have remained low, with high default and death rates. South Africa reports the highest number of conrmed MDR-TB and XDR-TB cases in the region. Collaborative TB/HIV activities are being scaled up across the country. In 2007, almost 40% of notied TB patients were tested for HIV, and 35% and 67% of HIV-positive TB patients were provided with ART and CPT respectively. New approaches to trace treatment defaulters are being tested in selected areas. Considerable efforts have been made to estimate the funding requirements for TB control, although decentralization of planning and budgeting to provinces makes this challenging. A comprehensive costing study aimed at improving the accuracy of current estimates of funding needs and funding gaps is planned for 2009.

ALL IN HIV+ PEOPLE
461
336
948 691 0.9 0.9 174 117 358 242 73 336 692 384 112 230 39 1.8 6.7 168 345 94 193
New ss/unk 250 200 120 80 40 0 1995
New extrapulmonary 80 60 40 20 0 1995 Relapse Re-treatment 200 150 100 50 0 1995
315 649 136 279 56 1.2 78 46 16 4.4 3.3
Case notications
New ss+ 300 200 100 0 1995
150 100 50 2000 2005 0 1995 2000 2005
2000
2005
2000
2005
2000
2005
Failed
Defaulted
Transferred
Not evaluated
15 0
10 0
10 Percentage
15
20 0
12 0
2000 77 333 82 167 82 43 76 63 50
2001 77 322 78 182 85 44 70 61 50
2002 98 462 99 212 99 53 72 68 53
2003 100 483 100 247 100 53 77 67 52
2004 93 562 97 266 96 56 78 69 56
2005 94 564 96 262 96 55 75 71 58
2006 100 628 100 272 100 60 77 74 67
2007 100 649 100 279 100 62 78
SOUTH AFRICA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Primary health care clinic, district hospital Yes Districts 53/53

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) Some patients in all units %
Urban Primary health care clinic, district hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Primary health care facility, district hospital Urban Primary health care facility, district hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) 7.2 12 182 437
Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE/4(HR) All patients in all units last: 2003 next: 2009
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 249 249 Smear per 100 000 0.5 0.5 EQA 241 249 % adeq perf 93% Culture Number per 5 000 000 15 18 1.5 1.8 Number 10 10 DST per 10 000 000 2.1 2.0 EQA 10 10 % adeq perf 100%
Note: for routine diagnosis, there should be at least one laboratory providing smear microscopy per 100 000 population. To provide culture for diagnosis of paediatric, extrapulmonary and ss-/HIV+ TB, as well as DST of re-treatment and failure cases, most countries will need one culture facility per 5 million population and one DST facility per 10 million population. EQA column shows number of laboratories for which EQA was done. Adeq perf; adequate performance for microscopy based on results of EQA.

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No Yes 2005 No Peripheral level 2006 No All units 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% No Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, sub-national No Yes, national No Yes last 20012002 2007 next 2009 2010 2009 2010

2005 2006 Number (% of estimated ss+ MDR-TB) 10 312 2000 (19%) (%) 0 10 553 6716 (64%) (%) 0 10 708 7350 (69%) (%) 0 2007
SOUTH AFRICA


The proportion of TB patients tested for HIV continues to increase steadily
40
20

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 379 672 150 092 40 15 521 4.1 5 642 1.5
0 2004 2005 2006 2007

The proportion of HIV-positive TB patients receiving CPT fell considerably in 2007



Number of providers collaborating with the NTP Number collaborating (total number of providers) Public sector Private sector () ()
c

ISTC endorsed by professional organizations? ISTC included in medical curriculum? No Yes
% total notied TB Diagnosed Treated


By 2007, community-based care for MDR-TB patients had been introduced in selected districts in the provinces of KwaZulu-Natal and the Western Cape. Community-based care is included within national policy and guidelines, although implementation is variable. No data on use of the Patients Charter were reported in 2008.

SOUTH AFRICA
| FINANCING
Substantial increase in funding needs for 20072008; without complete information from provinces, sources of funding for a large part of the budget (mostly for MDR-TB) are unknown
400 378 352 300 US$ millions Unknown Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)
Data not available

Share of budget for MDR-TB highest among HBCs
MDR-TB 19%
200
Programme management & supervision 1% NTP staff 3% First-line drugs 4% ACSM/CBTC 2% Other 1% TB/HIV 8%
100
Budget information available only from 2006
78
MDR-TB hospitals 49%
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased budget is mainly for MDR-TB, a large part of which is for the new hospital bed capacity required for MDR/XDR-TB patients
400 378 352 300 US$ millions Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB hospitals MDR-TB DOTSd
Data not available
Data on the funding available for TB control in South Africa are currently incomplete due to difculties in compiling information about funding allocations at provincial level. From discussions among WHO, the NTP and staff in the national treasury, it seems likely that funding gaps do exist, especially for MDR/XDR-TB. The NTP is planning to conduct a comprehensive assessment of funding needs and funding gaps in 2009.
200
100
Budget information available only from 2006
78
0 2002 2003 2004 2005 2006 2007 2008 2009

Estimated cost of hospitalization is based on 8112 dedicated TB beds for new TB patients; cost for hospitalization (MDR-specic) covers new bed capacity required to hospitalize patients for 6 months, and is mostly unfunded
800 603 429 400 287 200
Total cost information available only from 2005 Data not available

Total cost, budget and expenditures per patient are increasing
600 US$ millions
363
US$
Clinic visits Hospitalization Hospitalization (MDR-specific) NTP budget
2500 2000 1500 1000 500

Total cost and budget data available only from 2005
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009
g. Global Plan compared to country reportse

Country assessment of funding required for DOTS and MDR-TB is higher than the estimates in the Global Plan; for MDR-TB, this reects current national policy that MDR/XDR-TB patients should be hospitalized for at least 6 months, and higher projections of patients to be treated
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
DOTSf 600 US$ millions 200 100 0

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
DATA NOT AVAILABLE
2006 2007 2008 2009
2006 2007 2008 2009
South Africa report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 20052007 are based on expenditure, whereas those for 2008 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20052006 is based on the amount of funding actually received, using retrospective data.
COUNTRY PROFILE
Thailand
The case detection rate reached 72% in 2007, and the treatment success rate improved to 77% in 2006. Reasons why the treatment success rate is below the global target of 85% include high default and mortality rates, and incomplete reporting from care providers in Bangkok. Integrated TB/HIV services are widely available; in 2007, almost 70% of notied TB cases were screened for HIV, and 32% and 67% of HIV-positive TB patients were treated with ART and CPT, respectively. The latest survey of drug resistance found that 1.7% of new cases and 34.5% of previously treated cases have MDR-TB. Most patients with MDR-TB are managed by public and private providers that are not linked to the NTP. The NRL is a designated supranational laboratory for the region. However, quality assurance of the extensive laboratory network remains a challenge. In the context of recent health sector reforms, the TB cluster in Bangkok is responsible for technical guidance and surveillance. In 2008, a comprehensive analysis of the funding required for TB control indicated that around US$ 50 million per year is needed.

ALL IN HIV+ PEOPLE
91 142 0 39 62 17 123 192 168 14 21 15 1.7 35
15 24 0.002 5.4 8.5 7.7 12 3.9 6.0

New ss/unk 60 40 20 0 1995 Failed 15 10 5 0 1995 Defaulted
New extrapulmonary 4 3 2 Relapse 3 2 1 0 1995 Re-treatment
55 86 28 45 62 2.4 72 7.5 14 0.1 0.3
Case notications
New ss+ 60 40 20 0 1995
1 0 1995 Transferred
2000
2005
2000
2005
2000
2005
2000
2005
2000
2005
Not evaluated
30 0
6 0
4 6 Percentage
10 0
6 0
10
2000 70 56 100 29 100 38 48 69
2001 82 81 100 46 100 55 76 75 49
2002 100 80 100 41 100 55 68 74 62
2003 100 88 100 46 100 60 74 73 62
2004 100 88 100 45 100 60 74 74 56
2005 100 92 100 47 100 63 77 75 74
2006 100 89 100 46 100 60 74 77 62
2007 100 86 100 45 100 58 72
THAILAND

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Community Hospital Yes Provincial hospitals 847/847
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20062015) No (planned 2010) No (planned 2010)

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) Some patients in some units % 92 92 1.3 94
Urban General and regional hospital or BMA health centre NTP services part of general primary health-care network? Location where TB diagnosed Rural District hospitals Urban Provincial hospitals Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE/4HR All patients in all units last: 2007 next: 2009
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 1 023 1 023 Smear per 100 000 1.6 1.6 EQA 1 023 1 023 % adeq perf Culture Number per 5 000 000 65 65 5.1 5.1 Number 14 14 DST per 10 000 000 2.2 2.2 EQA 14 14 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No No 2005 Yes Peripheral level 2006 No No 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 89% 89% Yes (since 2007) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes No Yes, national No No last 2007 2006 2006 next 2008 2012

THAILAND


The proportion of TB patients screened for HIV increased substantially between 2006 and 2007

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 23 593 2 747
2004
2005
2006
2007

The proportion of HIV-positive TB patients receiving ART in 2007 was the same as in 2006; the proportion of patients receiving CPT has increased slightly


Extensive reform of the health sector, including decentralization and the establishment of a national health insurance scheme, has generated challenges for TB control. Notable examples include their effect on managerial capacity, human resources, and monitoring and evaluation. Reform has also presented opportunities in the form of better coverage of basic health-care services and reduced bureaucracy. The NTP has repositioned itself by shifting its focus from service delivery to technical assistance, and is working towards strengthened and integrated management and surveillance.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 985 (985) 78 (354) % total notied TB Diagnosed Treated 100 100



Activities to involve communities in TB control are mostly restricted to migrant populations. There are plans to scale-up community-based activities throughout the country. No data on use of the Patients Charter were reported in 2008.

THAILAND
| FINANCING
National budget for TB control is mainly nanced by the Government; funding gap expected to be closed with Global Fund round 8
60 Budgets for TB control for the years 2002-2007 are only for the TB cluster in Bangkok. During 2008 the NTP conducted a planning and budgeting exercise that enabled the budget to be estimated for the entire country. Budgets presented here for 2008 and 2009 are an outcome of this exercise, and reflect the budget required for the entire country. 6.0 0 2002 2003 2004 2005 2006 2007 2008 2009 8.5 4.1 4.7 4.3 49 50 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Largest share of the budget is for staff, rst-line drugs and programme management and supervision
ACSM/CBTC 1% PPM 4% TB/HIV 4% MDR-TB 3% Lab supplies & equipment 2% Programme management & supervision 6% NTP staff 60% First-line drugs 19%
US$ millions
40
20

Within DOTS, the largest budget is for NTP staff; budget for PPM increased in 2009
60 49 40 50 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS is mainly for dedicated NTP staff; almost 80% of budget for PPM is unfunded
6 4.5 US$ millions 4 1.6 2 3.6 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
US$ millions
20 6.0 0 2002 2003 2004 2005 2006 2007 2008 2009 8.5 4.0 4.7 4.3
0 2002 2003 2004 2005 2006 2007 2008 2009

Costs for hospitalization and clinic visits represent a very small share of total costs, with hospitalization of 5% of new TB patients for an average of 5 days, and 8 clinic visits for new cases during treatment
60 Data for 20022006 not shown because they were only for the TB cluster in Bangkok. Data for 20072009 are for the entire country. 50 41 51 Clinic visits Hospitalization NTP budget

NTP budget per patient is high compared with other HBCs in South-East Asia Region, as expected given Thailands middle-income status; budget per patient for rst-line drugs specically highest among HBCs
1000 800 600 400 Data for 20022006 not shown because they were only for the TB cluster in Bangkok. Data for 20072009 are for the entire country. Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
US$ millions
40
20 200 0 2002 2003 2004 2005 2006 2007 2008 2009 2002 2003 2004 2005 2006 2007 2008 2009

Country assessment of funding required for TB control far higher than Global Plan estimate, mainly due to higher budget for rst-line drugs and NTP staff
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
US$
2009 BUDGET GAP
DOTSf 50 40 30 20 10 0
2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
44 3.6 0 2.0 0.4 0 0
0.4 1.1 0 1.6 0 0 0
US$ millions
2006 2007 2008 2009
2006 2007 2008 2009
Thailand report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 2007 are based on expenditure, whereas those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 2007 is based on the amount of funding actually received, using retrospective data; available funding for 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
COUNTRY PROFILE
Uganda
DOTS is implemented throughout the country, but the case detection rate has been below target and relatively stable since 2001. The treatment success rate remains low because of the high proportion of patients who die, default from treatment or for whom the treatment outcome is not evaluated. Training on collaborative TB/HIV activities based on standardized national guidelines has been provided to around half of the districts. Inadequate funding, linked in part to problems with disbursement of Global Fund grants, has hampered the progress of the national programme. Shortages of rst-line anti-TB drugs have also been reported. To improve current estimates of the epidemiological burden of TB, a survey of the prevalence of TB disease is planned for 2009; however, there is inadequate funding for this project.

ALL IN HIV+ PEOPLE
102
39
330 128 5.7 8.6 42 14 136 45 39 132 426 103 29 93 35 0.5 4.4 20 64 16 52
New ss/unk 80 60 40 20 0 1995 5 0 1995 15 10
New extrapulmonary 8 6 4 2 0 1995 Relapse 8 6 4 2 0 1995 Re-treatment
41 132 21 69 61 1.5 51 4.5 11 0.6 2.7
Case notications
New ss+ 100 80 60 40 20 0 1995 2000 2005
2000
2005
2000
2005
2000
2005
2000
2005
Failed
Defaulted
Transferred
Not evaluated
10 0
0.5
1 0
10 Percentage
15
20 0
2000 100 123 100 70 100 34 51 63 64
2001 100 145 100 68 100 38 47 56 63
2002 100 155 100 73 100 38 47 60 55
2003 100 154 100 75 100 37 47 68 60
2004 100 156 100 75 100 39 48 70 68
2005 100 142 100 71 100 37 47 73
2006 100 136 100 68 100 38 48 70 76
2007 100 132 100 69 100 39 51
UGANDA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health centre Yes Hospital 80/80

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (if TB is conrmed) All patients in some units Health-care worker, community member, family member Health-care worker, community member, family member 2(HRZ)E2/6HE All patients in all units last: 2008 next: 2009 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 7.5 14 9.9 37
Urban Hospital NTP services part of general primary health-care network? Location where TB diagnosed Rural Health centre Urban Hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.5 0.6 0.3 6.4 22
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 716 741 Smear per 100 000 2.3 2.3 EQA 716 741 % adeq perf 81% Culture Number per 5 000 000 3 4 0.5 0.6 Number 2 2 DST per 10 000 000 0.6 0.6 EQA 2.0 2.0 % adeq perf 100%

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? Yes Central level 2006 No Yes 2007 No Yes 2005 Yes Peripheral level 2006 Some units Some units 2007 Some units Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 99% Yes (since 2003) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data No Yes, national Yes, national Yes, sub-national No No last 1970 1997 next 2009 2009 Ongoing

2005 2006 Number (% of estimated ss+ MDR-TB) 508 46 (9.1%) (%) 0 497 (%) (%) 0 485 7 (1.4%) 7 (1.4%) 0 7 2007
UGANDA

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 15 844 38 9 526 24 380 4.0 220 2.3

The proportion of TB cases tested for HIV continues to increase

HIV+ patients in HIV care or ART register Screened for TB as % of HIV+ patients in HIV care or ART register Started on TB treatment as % of HIV+ patients in HIV care or ART register Started on IPT as % of HIV+ patients without TB in HIV care or ART register 244 969 71 647 29 3 566 1.5 121 0.1
2004
2005
2006
2007

Provision of CPT and ART under-reported in 2007
60 % of reported HIV-positive TB patients on ART on CPT
40

20
0 2004 2005 2006 2007

The main weaknesses of the health system a shortage of qualied personnel, poor access to primary health care and low levels of funding for health care have had a negative impact on the NTP, which is integrated into the primary health-care system. The NTP is improving the capacities of laboratories and human resources through training, monitoring and quality control, all of which benet the entire health-care system. Engagement of communities by the NTP is strengthening the role of civil society in the country.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 80 (269) 252 () % total notied TB Diagnosed Treated


The NTP works in close collaboration with the ACSM Working Group of the national Stop TB Partnership to guide and implement ACSM activities. A national ACSM strategy for control of TB and TB/HIV has been developed.

Community-based care has been available throughout the country since 2005. Patient support in rural areas is usually provided by neighbours or friends who are in regular contact with the health services. In urban areas, this support is usually provided by family members. Activities to raise awareness about TB are conducted mostly through sensitization of village leaders in rural areas, and through media campaigns in urban areas. The Patients Charter is being used.

UGANDA
| FINANCING
Increasing NTP budget and increasing funding gaps
20 17 15 US$ millions 10 6.0 4.4 11 15 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

DOTS implementation accounts for 62% of budget, followed by ACSM including community TB care
Other 0.01% Operational research/surveys 12% First-line drugs 23%
ACSM/CBTC 10% NTP staff 7% PPM 12% TB/HIV 1% MDR-TB 2% Lab supplies & equipment 12% Programme management & supervision 21%
10 5.2 5
Data not available
0 2002 2003 2004 2005 2006 2007 2008 2009

Within DOTS, increased funding needs for programme management and supervision activities; operational research includes budget for disease prevalence survey in 2009
20 17 15 US$ millions 10 6.0 4.4 11 15 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS is mainly for rst-line drugs and routine programme management; half of the budget required for a disease prevalence survey is unfunded
15 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
11 US$ millions 10 7.0 5 3.3

Data not available
9.3
10 5.2
Data not available
4.3 2.4 0.7
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

To date, expenditure data have not been reported
Cost of clinic visits based on 12 visits for DOT per TB patient (2003 2009); small number of visits to health facilities reects role of community volunteers
400
300 US$
10 6.0 5
Data not available
200
4.5 2.8
4.5
5.0
100
Data not available
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Biggest difference between country report and Global Plan is collaborative TB/HIV activities, which at least in part reects funding and implementation of some activities by the national AIDS control programme; expenditure data are not available to allow comparison for 2006 and 2007
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
50 US$ millions 40 30 20 10 0
DOTSf
MDRTB
TB/HIVg
ACSM
Other
Total
11 0.6 0.002 2.0 1.8 2.1 0
6.1 0.4 0.002 2.0 1.1 1.1 0
2006 2007 2008 2009
2006 2007 2008 2009
2006 2007 2008 2009
Uganda report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 20032007 are based on available funding, whereas those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20032009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
COUNTRY PROFILE
United Republic of Tanzania

The case detection rate has been relatively stable since 2001 and well below the global target. The treatment success rate for new smearpositive TB cases reached the global target in 2006. Following rapid expansion of collaborative TB/HIV activities, 50% of TB cases are being tested for HIV and 31% and 72% of HIV-positive TB cases are being provided with ART and CPT, respectively. Further expansion of TB/HIV activities, scale-up of community-based TB care, and formal collaboration with the private sector are expected to improve rates of case detection and treatment success. Programmatic management of MDR-TB began in 2007 on a small scale. A survey of the prevalence of disease in 2009 and the results of an in-depth analysis of surveillance data will be used to update existing estimates of the epidemiological burden of TB.

ALL IN HIV+ PEOPLE
120
56
297 139 4.4 5.2 49 20 120 49 47 136 337 107 32 78 21 1.1 7.9 28 70 20 49
New ss/unk 80 60 40 20 0 1995 40 30 20 10 0 1995 2 0 1995
New extrapulmonary 6 4 Relapse Re-treatment 10 8 6 4 2 2000 2005 2000 2005 0 1995 2000 2005
59 147 25 61 54 1.7 51 13 22 0.4 1.7
Case notications
New ss+ 80 60 40 20 0 1995
2000
2005
2000
2005
Failed
Defaulted
Transferred
Not evaluated
15 0
0.2
0.4
0.6
0.8 0
5 0
5 0
Percentage
2000 100 161 100 71 100 46 52 78 73
2001 100 177 100 71 100 48 51 81 76
2002 100 169 100 68 100 47 48 80 77
2003 100 168 100 68 100 47 49 81 75
2004 100 167 100 69 100 48 51 81 76
2005 100 159 100 66 100 47 50 82 77
2006 100 150 100 63 100 47 50 85 78
2007 100 147 100 61 100 48 51
UNITED REPUBLIC OF TANZANIA

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Health centers and dispensaries Yes Hospitals and health centres 157/157
National strategic plan? Mechanism for national interagency coordination? National Stop TB Partnership? Yes (20042009) No (planned 2009) No (planned 2009)

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units % 29 39 8.2 70
Urban Hospitals and health centres NTP services part of general primary health-care network? Location where TB diagnosed Rural Health centres and dispensaries Urban Hospitals and health centres Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

Health-care worker, community member, family member Health-care worker, community member, family member 2HRZE /4HR All patients in all units last: next:
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 717 717 Smear per 100 000 1.8 1.7 EQA 717 % adeq perf Culture Number per 5 000 000 3 3 0.4 0.4 Number 1 1 DST per 10 000 000 0.2 0.2 EQA 1.0 1.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? No Central level 2006 No No 2007 No No 2005 No Peripheral level 2006 No All units 2007 No No

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 100% 100% Yes (since 1992) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national Yes, national Yes, national No No last 2007 2004 2007 next 2008 2009

2005 Multidrug-resistant TB (MDR-TB) Estimated incidence of ss+ MDR cases Diagnosed and notied Registered for treatment GLC non-GLC 1 350 10 (0.74%) (%) 0 2006 Number (% of estimated ss+ MDR-TB) 1 327 13 (0.98%) (%) 0 1 301 169 (13%) (%) 0 2007


The proportion of TB patients tested for HIV increased dramatically in 2007, reaching 50%
40
20

0 2004 2005 2006 2007

The proportion of HIV-positive TB patients receiving ART and CPT improved between 2006 and 2007


The NTP is fully integrated into the primary health-care system, and planning and budgeting for TB control have been successfully harmonized with sectorwide planning frameworks. Refurbishment of laboratories to support TB diagnosis has helped to strengthen overall laboratory capacity. Shared resources such as transport facilities and the reporting network have been used to reduce transaction costs for the entire health system. Further integration of the procurement system is planned.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector () 12 () % total notied TB Diagnosed Treated


An ACSM strategy has been drafted, and a KAP survey is planned for 2009. A club for former TB patients was recently established.

The NTP has started to involve patients and communities in delivering care and in activities to sensitize the general population about TB in selected areas of the country. These activities will be scaled up to cover 31 districts by the end of 2010. No data on use of the Patients Charter were reported in 2008.

Operational research budget (% of NTP budget)
| FINANCING
Increased NTP budget since 2008 reects new plan for TB control and re-assessment of funding needs; increased funding from government and Global Fund since 2008
30 23 US$ millions 20 25 Unknown Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Largest component of the budget is NTP staff, unlike other African HBCs, followed by TB/HIV
PPM 2% ACSM/CBTC 13% Operational research/surveys 3% Other 2% First-line drugs 7%
TB/HIV 21%
10 5.5 5.3
8.8
7.6
8.1
8.2
MDR-TB 5% Lab supplies & equipment 7% Programme management & supervision 2% NTP staff 38%
0 2002 2003 2004 2005 2006 2007 2008 2009

Budget for all major components of TB control increased in 2008, notably for DOTS, TB/HIV and ACSM
30 23 US$ millions 20 25 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for rst-line drugs and dedicated NTP staff
8 7.4 Unknown Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
6 US$ millions 5.0 4 2.1 2 0.6 1.1 0.4 Data not

available
10 5.5 5.3
8.8
7.6
8.1
8.2
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Cost of hospitalization based on 1900 TB dedicated beds (20022005) and 7% of new TB patients hospitalized for 14 days (20062009)
35 30 US$ millions 25 27 29 Clinic visits Hospitalization NTP budget

Increasing expenditure, budget and total cost per patient since 2006
400 15 11 10 9.8 12 5.8 US$ 200 0 2002 2003 2004 2005 2006 2007 2008 2009 2002 2003 2004 2005 2006 2007 2008 2009
20 15 10 5 0

Country assessment of funding requirements 20062007 less than Global Plan, and focused on DOTS; greater similarity with Global Plan 20082009, except for TB/HIV, which may reect funding and implementation of activities by national AIDS control programme as well as NTP
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
13 6.6 0 0.4 3.1 0.7 0.4
3.8 1.7 0 0.03 1.3 0.4 0.3
2006 2007 2008 2009
2006 2007 2008 2009
United Republic of Tanzania report
Global Plan

ag 1
COUNTRY PROFILE
Viet Nam
The preliminary results of the 2007 national survey of the prevalence of TB disease indicate that prevalence is higher than previously estimated. Although estimating TB incidence from the prevalence of TB disease is not straightforward, the survey also suggests that TB incidence may be higher, and the case detection rate lower, than previously estimated. Survey ndings have prompted the NTP to accelerate implementation of PPM, ACSM and other components of the Stop TB Strategy, especially among population groups that have difculty in accessing health-care services.

ALL IN HIV+ PEOPLE
150 171 1.0 66 76 8.1 192 220 182 21 24 16 2.7 19
12 14 1.8 4.2 4.8 6.0 6.9 3.1 3.5

New ss/unk 30 20 10 0 1995 30 20 10 0 1995
New extrapulmonary 10 8 6 4 2 1 Relapse 2 Re-treatment
97 111 54 62 76 2.8 82 19 21 0.1 0.2
Case notications
New ss+ 80 60 40 20 0 1995
2000
2005
2000
2005
2000
2005
0 1995
2000
2005
0 1995
2000
2005
Failed
Defaulted
Transferred
Not evaluated
6 0
6 0
2 Percentage
4 0
4 0
0.5
2000 100 114 100 67 100 58 82 92 79
2001 100 113 100 68 100 59 84 93 85
2002 100 117 100 70 100 61 87 92 85
2003 100 112 100 68 100 59 86 92 85
2004 100 117 100 70 100 62 89 93 84
2005 100 112 100 65 100 60 84 92 83
2006 100 113 100 65 100 61 86 92 83
2007 100 111 100 62 100 61 82
VIET NAM

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Commune health post Yes District TB unit 680/680

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in all units Health-care worker Health-care worker last: 2006 next: 2011 NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 39 69 3.3 100
Urban NTP services part of general primary health-care network? Location where TB diagnosed Rural District TB unit Urban Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 0.1 0.3 0 9.6 38
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 737 Smear per 100 000 0.8 EQA % adeq perf Culture Number per 5 000 000 17 30 1.0 1.7 Number 2 DST per 10 000 000 0.2 EQA 2.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? Yes Central level 2006 No No 2007 Yes 2005 No Peripheral level 2006 No No 2007 Yes

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes Yes, national last 2007 2006 next

VIET NAM

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 14 377 15 627 5.2

10
0 2004 2005 2006 2007


Data not reported


The NTP is integrated into a relatively strong primary health-care system. However, reforms aimed at decentralizing and separating disease-specic control programmes from clinical services are ongoing and may affect the NTP, which is working to ensure effective services for referring patients and exchange of information where separation is anticipated. A further challenge, the large private health care sector throughout the country where rst-line and second-line anti-TB drugs are often used irrationally, is being addressed by the NTP through scale-up of PPM.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector 42 () () % total notied TB Diagnosed Treated 3.2 4.6

ISTC endorsed by professional organizations? By which organizations: ISTC included in medical curriculum?

A KAP survey is planned for 2008. On World TB Day, all provinces hold meetings to raise awareness of TB at community level, and TB is featured in radio and television programmes. Advocacy meetings for managers in the health sector have been organized in 8 provinces. Advocacy meetings for political leaders have also been organized in 8 regions (which cover 60/64 provinces), one outcome of which was a letter to the Ministry of Health requesting greater support for provincial efforts in TB control, including support for recruitment and retention of adequately-qualied staff.

Community involvement in TB control is in place in hard-to-reach areas as part of the primary health-care package. The project is currently being geographically expanded to cover all hard-to-reach areas in the country. Community-based care is also provided by voluntary treatment supporters in many areas. No data on use of the Patients Charter were reported in 2008.

VIET NAM
| FINANCING
Decreased funding from the government in 20082009, compensated for by increased funding from donors
20 17 15 US$ millions 12 10 11 9.8 13 11 16 13 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

Largest component of budget is for DOTS (71%), followed by MDR-TB
First-line drugs 36% Other 3% Operational research/surveys 2% ACSM/CBTC 6% PPM 1% TB/HIV 6% MDR-TB 12% NTP staff 16% Programme management & supervision 5%
0 2002 2003 2004 2005 2006 2007 2008 2009

Increased budget for MDR-TB in 2008 and 2009; within DOTS decreased budget for NTP staff and programme management
20 17 15 US$ millions 12 10 11 9.8 13 11 16 13 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

No funding gap was reported for 20082009
5 4 US$ millions 3 2 1 0.2 0 2002 2003 2004 2005 2006 2007 2008 2009 3.7 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
0 2002 2003 2004 2005 2006 2007 2008 2009

Cost of clinic visits based on 66 visits per TB patient; hospitalization costs based on estimate that there are 6481 TB beds
30 23 29 27 21 US$ millions 20 18 22 17 23 Clinic visits Hospitalization NTP budget

Expenditure comparatively low in 2007; Fluctuation in all indicators
350 300 250 US$ 200 150 Total TB control costs NTP budget NTP available funding NTP expenditure First-line drugs budget
10
100 50
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Targets for MDR-TB patients to be treated in Global MDR/XDR-TB Response Plan much higher than scaling-up planned by NTP
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP

2006 2007 2008 2009
MDRTB
TB/HIVg
ACSM
Other
Total
9.5 2.3 0 0.1 0.8 0.3 0.4
0 0 0 0 0 0 0
2006 2007 2008 2009
2006 2007 2008 2009
Viet Nam report
Global Plan

ag 1
COUNTRY PROFILE
Zimbabwe
The TB control programme has been adversely affected by a lack of adequate nancial, human and material resources. The recording and reporting system is unable to provide reliable data on DOTS implementation, collaborative TB/HIV activities or MDR-TB management. Funding from round 5 of the Global Fund grant and the successful round 8 Global Fund application should help revive basic TB control in the country. However, without a functional health-care system, progress is likely to be slow.

ALL IN HIV+ PEOPLE
104
72
782 539 2.6 5.5 40 25 298 189 69 95 714 205 35 265 70 1.9 8.3 36 270 28 213
New ss/unk 300 200 100 0 1995
New extrapulmonary 80 60 40 20 15 10 5 0 1995 Relapse 40 30 20 10 0 1995 Re-treatment
40 302 11 79 33 1.1 27 6.4 16 0.3 3.1
Case notications
New ss+ 150 100 50 0 1995
20 0 1995
2000
2005
2000
2005
2000
2005
2000
2005
2000
2005
Failed
Defaulted
Transferred
Not evaluated
20 0
0.2
0.4
0.6 0
4 Percentage
10 0
10
15
20
2000 100 402 100 114 100 59 45 69
2001 100 440 100 120 100 58 44 71 61
2002 100 460 100 124 100 57 42 67 63
2003 100 411 100 112 100 48 36 66 54
2004 100 431 100 112 100 50 36 54 53
2005 100 385 100 100 100 45 32 68 60
2006 100 335 100 96 100 41 32 60 57
2007 100 302 100 79 100 37 27
ZIMBABWE

Description of basic management unit Number of units (DOTS/total), 2007 Location of NTP services Rural Rural health centre Yes Hospital 64/64

(see nal page for detailed presentation) Government contribution to NTP budget (incl loans) Government contribution to total cost TB control (incl loans) Government health spending used for TB control NTP budget funded Yes (all suspects) All patients in some units 2(HRZE)/4(HR) All patients in all units last: 2008 next: NTP budget per capita Total costs for TB control per capita Funding gap per capita Government health expenditure per capita (2005) Total health expenditure per capita (2005) % 3.7 22 18 46
Urban Urban clinic NTP services part of general primary health-care network? Location where TB diagnosed Rural District hospital Urban Hospital Diagnosis free of charge? Treatment supervised? Intensive phase Continuation phase Category I regimen Treatment free of charge External review missions

US$ 1.3 1.6 0.7 9.2 21
All TB laboratories performing EQA of smear microscopy or DST under the supervision of the National Reference Laboratory Number 2007 2008 180 180 Smear per 100 000 1.3 1.3 EQA 0 12 % adeq perf Culture Number per 5 000 000 1 1 0.4 0.4 Number 1 1 DST per 10 000 000 0.7 0.7 EQA 0 1.0 % adeq perf

2005 Stock-outs of laboratory supplies? Stock-outs of rst-line anti-TB drugs? Yes Central level 2006 No Yes 2007 Yes Yes 2005 Yes Peripheral level 2006 Some units Some units 2007 Some units Some units

NTP publishes annual report? % of BMUs reporting to next level in 2007 Case-nding Treatment outcomes 98% 98% Yes (since ) Burden and impact assessment In-depth analysis of routine surveillance data Prevalence of disease survey Prevalence of infection survey Drug resistance survey Mortality survey Analysis of vital registration data Yes No No Yes, sub-national No Yes last 2007 1995 2007 next 2008 2010 2008

ZIMBABWE

TB patients for whom the HIV test result was known as % of all notied TB patients TB patients with positive HIV test as % of all estimated HIV+ TB cases HIV+ TB patients started or continued on CPT as % of HIV+ TB patients notied HIV+ TB patients started or continued on ART as % of HIV+ TB patients notied 5 252 13 4 373 6.1 4 373 100

2007 is the rst year for which data are available on HIV testing among TB patients

2004
2005
2006
2007

Data on the provision of ART to HIV-positive TB patients are not available; all HIV-positive TB patients receive CPT


Since they were rst introduced, activities to control TB have been fully integrated within primary health-care services. The roles and responsibilities of different levels of the health system are clearly dened for TB control. The main health system challenges are shortages of adequately trained staff due to high turnover and emigration, insufcient access to and availability of laboratory diagnostic services (including reagents, materials and staff), and insufcient funding for supervision, monitoring and evaluation and training at all levels.


Number of providers collaborating with the NTPc Number collaborating (total number of providers) Public sector Private sector () () % total notied TB Diagnosed Treated


In 2008, the main ACSM activity was commemoration of World TB Day. This included events attended by the Minister of Health and several MPs, and broadcasting of three radio programmes that featured TB.

There are ongoing efforts to improve the quality and scope of community-based activities, both to ensure the quality of care and to increase the demand for services to control TB.

ZIMBABWE
| FINANCING
Increased budget in 2009 with increased funding from external donors other than the Global Fund; large funding gap remains
20 17 16 15 US$ millions 13 13 Gap Global Fund Grants (excluding Global Fund) Loans Government (excluding loans)

DOTS implementation accounts for the highest share of the budget, followed by ACSM; operational research includes surveys of MDR/XDR and HIV among TB patients
Other 3% Operational research/surveys 9% First-line drugs 17%
ACSM/CBTC 20%
NTP staff 4% Programme management & supervision 4%
10 5.2
Data not available
3.9 PPM 3% TB/HIV 20%
0 2002 2003 2004 2005 2006 2007 2008 2009
MDR-TB 4%

Within DOTS, increased budget for laboratory is primarily to equip the second culture and DST laboratory in the capital city
20 17 16 15 US$ millions 13 13 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd

Funding gap within DOTS mainly for laboratory supplies and equipment
15 11 US$ millions 10 9.4 Other Operational research/surveys PPM/PAL/ACSM/ CBTC TB/HIV MDR-TB DOTSd
10 5.2 5
Data not available
5 2.2
Data not available
5.0 2.6 1.3
3.9
0 2002 2003 2004 2005 2006 2007 2008 2009
0 2002 2003 2004 2005 2006 2007 2008 2009

Hospitalization based on estimates that 85% of new ss+ patients and 55% of new ss/extrapulmonary patients are hospitalized for 14 and 21 days respectively
25 22 20 17 US$ millions 15 10 5.9 5
Data not available

Increasing cost, budget and available funding per patient from 2007
Clinic visits Hospitalization NTP budget US$
600 500 400 300 200 100 0 2002 2003 2004 2005 2006 2007 2008 2009
Data not available
9.4 7.5 6.5 6.7
0 2002 2003 2004 2005 2006 2007 2008 2009

Country implementation of TB control activities 20062007 focused on DOTS only; country plan for 20082009 incorporates other elements of Stop TB Strategy; biggest difference with Global Plan is in estimated funding requirements for TB/HIV
2006 2007 2008 2009 2006 2007 2008 2009 2006 2007 2008 2009
2009 BUDGET GAP
US$ millions
50 40 30 20 10 0
DOTSf
MDRTB
TB/HIVg
ACSM
Other
Total
7.0 4.3 0.3 0.6 3.5 1.6 0.3
3.0 2.7 0.2 0.6 1.6 1.1 0.1
2006 2007 2008 2009
2006 2007 2008 2009
2006 2007 2008 2009
Zimbabwe report
Global Plan

ag 1
Please see footnotes page 169. Total TB control costs for 2003 and 20062007 are based on expenditure, whereas those for 20042005 are based on available funding, and those for 20082009 are based on budgets. Estimates of the costs of clinic visits and hospitalization are WHO estimates based on data provided by the NTP and from other sources. See Methods for further details. NTP available funding for 20062007 is based on the amount of funding actually received, using retrospective data; available funding for 20042005 and 20082009 is based on prospectively reported budget data, and estimated as the total budget minus any reported funding gap.
Footnotes
a b c d
f g
World population prospects the 2006 revision. New York, United Nations Population Division, 2007. For data sources and analytical methods, see Annexes 2 and 3. For a denition of public and private sector and the categories of provider considered in each case, see Chapter 2 and the 2008 WHO TB data collection form. DOTS includes the following components: rst-line drugs, NTP staff, programme management and supervision, and laboratory supplies and equipment. Estimates in the Global Plan were presented at regional rather than country level. See Methods for explanation of calculation of individual country estimates from regional estimates. Other includes budget for PPM, PAL, operational research, surveys and other. DOTS includes the cost of clinic visits and hospitalization. Global Plan estimates cover the full costs of collaborative TB/HIV activities, but these costs may be budgeted for by either the NTP or the National AIDS Control Programme. In this graph, country reports include only the NTP budget. This may explain the apparent discrepancy between the Global Plan and country reports.
ANNEX 2
Methods
A.2.1 Data collection and verication an overview

Every year since 1995, WHO has requested information about TB control from all countries and territories via a standard data collection form that is sent to NTPs or other relevant public health authorities.1 The latest form, which was identical for all countries,2 was distributed in mid-2008. It had three major components: case notications and treatment outcomes; data related to implementation of the Stop TB Strategy; and nancing. Forms returned to WHO are systematically reviewed by staff in country and regional ofces and at headquarters. An acknowledgement message that includes follow-up questions if appropriate (for example if some data are missing or if responses appear inconsistent with those from previous years) is sent back to the NTP correspondent (or equivalent) and used as the basis for producing a nal dataset. In the WHO European Region only, data collection and verication are undertaken jointly by the WHO regional ofce and the European Centre for Disease Prevention and Control (ECDC). Finalized data are used to compile country proles (such as those that appear in ANNEX 1) as well as the summary analyses that appear in CHAPTERS 13 and the regional and country-specic data presented in ANNEX 3 and ANNEX 4. Regional analyses are generally undertaken for the six WHO regions (that is, the African Region, the Region of the Americas, the Eastern Mediterranean Region, the European Region, the South-East Asia Region and the Western Pacic Region). For analyses of epidemiological trends at the regional level, the African Region is divided into countries with low and high rates of HIV infection (with high dened as an infection rate of 4% in adults aged 1549 years in 2004, as estimated by UNAIDS); central and eastern Europe (countries of the former Soviet states plus Bulgaria and Romania) are also distinguished; and countries in western Europe are analysed together with other high-income countries.3 The countries within each of the resulting nine subregions are: Africa countries with high HIV prevalence: Botswana, Burkina Faso, Burundi, Cameroon, the Central African Republic, Chad, the Congo, Cte dIvoire, the Democratic Republic of the Congo, Equatorial Guinea, Ethiopia, Gabon, Kenya, Lesotho, Liberia, Malawi, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Swaziland, Uganda, the United Republic of Tanzania, Zambia, Zimbabwe. Africa countries with low HIV prevalence: Algeria, Angola, Benin, Cape Verde, the Comoros, Eritrea, the Gambia, Ghana, Guinea, Guinea-Bissau, Madagascar, Mali, Mauritania, Mauritius, the Niger, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Togo. Central Europe: Albania, Bosnia and Herzegovina, Croatia, Hungary, Montenegro, Poland, Serbia, Slovakia, the former Yugoslav Republic of Macedonia, Turkey. Eastern Europe: Armenia, Azerbaijan, Belarus, Bulgaria, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, the Re-
public of Moldova, Romania, the Russian Federation, Tajikistan, Turkmenistan, Ukraine, Uzbekistan. Eastern Mediterranean: Afghanistan, Djibouti, Egypt, the Islamic Republic of Iran, Iraq, Jordan, Lebanon, the Libyan Arab Jamahiriya, Morocco, Oman, Pakistan, Somalia, the Sudan, the Syrian Arab Republic, Tunisia, the West Bank and Gaza Strip, Yemen. High-income countries: Andorra, Antigua and Barbuda, Australia, Austria, the Bahamas, Bahrain, Barbados, Belgium, Bermuda, the British Virgin Islands, Brunei Darussalam, Canada, the Cayman Islands, China Hong Kong Special Administrative Region, China Macao Special Administrative Region, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, French Polynesia, Germany, Greece, Guam, Iceland, Ireland, Israel, Italy, Japan, Kuwait, Luxembourg, Malta, Monaco, the Netherlands, the Netherlands Antilles, New Caledonia, New Zealand, Norway, Portugal, Puerto Rico, Qatar, the Republic of Korea, San Marino, Saudi Arabia, Singapore, Slovenia, Spain, Sweden, Switzerland, Trinidad and Tobago, the Turks and Caicos Islands, the United Arab Emirates, the United Kingdom, the United States, the United States Virgin Islands. Latin America: Anguilla, Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, the Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Montserrat, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Uruguay, Venezuela. South-East Asia: Bangladesh, Bhutan, the Democratic Peoples Republic of Korea, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste. Western Pacic: American Samoa, Cambodia, China, Cook Islands, Fiji, Kiribati, the Lao Peoples Democratic Republic, Malaysia, the Marshall Islands, Micronesia, Mongolia, Nauru, Niue, the Northern Mariana Islands, Palau, Papua New Guinea, the Philippines, Samoa, Solomon Islands, Tokelau, Tonga, Vanuatu, Viet Nam, Wallis and Futuna. Before publication, country proles are reviewed by NTPs; ANNEX 1 and ANNEX 3 are also reviewed by regional and country ofces. NTPs that respond to WHO are asked to update information for earlier years where possible. As a result, the data (case notications, treatment outcomes, etc.) presented in this report may differ from those published in previous reports. The annual data collection form used by WHO is designed for collection of aggregated national data. It is not recom1
Posted at http://www.who.int/entity/tb/publications/global_report/ 2009. In previous years, separate questionnaires were sent to HBCs and other countries, and questions related to TB/HIV were more detailed for a set of global priority countries. As dened by the World Bank. High-income countries are those with a per capita gross national income (GNI) of US$ 11 116 or more.
TABLE A2.1 Denitions of tuberculosis cases and treatment outcomes

A. DEFINITIONS OF TUBERCULOSIS CASES CASE OF TUBERCULOSIS A patient in whom tuberculosis has been conrmed by bacteriology or diagnosed by a clinician. DEFINITE CASE A patient with positive culture for the Mycobacterium tuberculosis complex. In countries where culture is not routinely available, a patient with one sputum smear positive for acid-fast bacilli (AFB+) is also considered a denite case. PULMONARY CASE A patient with tuberculosis disease involving the lung parenchyma. SMEAR-POSITIVE PULMONARY CASE A patient with one or more initial sputum smear examinations (direct smear microscopy) AFB+. SMEAR-NEGATIVE PULMONARY CASE A patient with pulmonary tuberculosis not meeting the above criteria for smear-positive disease. Diagnostic criteria should include: at least two sputum smear examinations negative for AFB; and radiographic abnormalities consistent with active pulmonary tuberculosis; and no response to a course of broadspectrum antibiotics (except in a patient for whom there is laboratory conrmation or strong clinical evidence of HIV infection); and a decision by a clinician to treat with a full course of antituberculosis chemotherapy; or positive culture but negative AFB sputum examinations. EXTRAPULMONARY CASE A patient with tuberculosis of organs other than the lungs (e.g. pleura, lymph nodes, abdomen, genitourinary tract, skin, joints and bones, meninges). Diagnosis should be based on one culture-positive specimen, or histological or strong clinical evidence consistent with active extrapulmonary disease, followed by a decision by a clinician to treat with a full course of antituberculosis chemotherapy. A patient in whom both pulmonary and extrapulmonary tuberculosis has been diagnosed should be classied as a pulmonary case. NEW CASE A patient who has never had treatment for tuberculosis or who has taken antituberculosis drugs for less than one month. RE-TREATMENT CASE A patient previously treated for TB, who is started on a re-treatment regimen after previous treatment has failed (treatment after failure), who returns to treatment having previously defaulted (see below; treatment after default), or who was previously declared cured or treatment completed and is diagnosed with bacteriologically positive (sputum smear or culture) TB (relapse). B. DEFINITIONS OF TREATMENT OUTCOMES (expressed as a percentage of the number registered in the cohort) CURED A patient who was initially smear-positive and who was smearnegative in the last month of treatment and on at least one previous occasion. COMPLETED TREATMENT A patient who completed treatment but did not meet the criteria for cure or failure. This denition applies to pulmonary smear-positive and smear-negative patients and to patients with extrapulmonary disease. DIED A patient who died from any cause during treatment. FAILED A patient who was initially smear-positive and who remained smear-positive at month 5 or later during treatment. DEFAULTED A patient whose treatment was interrupted for 2 consecutive months or more. TRANSFERRED OUT A patient who transferred to another reporting unit and for whom the treatment outcome is not known. SUCCESSFULLY TREATED A patient who was cured or who completed treatment. COHORT A group of patients in whom TB has been diagnosed, and who were registered for treatment during a specied time period (e.g. the cohort of new smear-positive cases registered in the calendar year 2005). This group forms the denominator for calculating treatment outcomes. The sum of the above treatment outcomes, plus any cases for whom no outcome is recorded (e.g. still on treatment in the European Region) should equal the number of cases registered. Some countries monitor outcomes among cohorts dened by smear and/or culture, and dene cure and failure according to the best laboratory evidence available for each patient.
mended for collection of data within countries. Recommendations about recording and reporting of data within countries, starting from the lowest administrative level, are available in other WHO publications.1
A2.2 Epidemiology and surveillance A2.2.1 Data collected

The section of the data collection form on epidemiology and surveillance requested data about TB case notications in 2007, HIV testing for TB patients in 2007, testing of TB patients for MDR-TB in 2007, treatment outcomes for TB patients registered during 2006, and treatment outcomes for MDR-TB patients registered in 2004, 2005 and 2006 (with nal outcomes requested for the 2004 cohort and interim outcomes requested for the 2005 and 2006 cohorts). The main case denitions are given in TABLE A2.1. The data collection form used in the WHO European Region asked for additional data, including a breakdown of all TB cases by age, sex, HIV status and geographical origin (for example, patients born outside the country or noncitizens). Data on case notications classied according to diagnosis based on culture (as well as sputum smears) were also requested.
A2.2.2 Estimates of TB incidence, prevalence and mortality general approach and data sources
Estimates of TB incidence, prevalence and mortality are based on a consultative and analytical process. They are revised annually to reect new information gathered through surveillance (case notications and death registrations) and from special studies (including surveys of the prevalence of disease and in-depth analysis of surveillance data). Full details about estimation methods are provided in publications in peer-reviewed journals.2,3,4 In 2007, WHO also prepared a series of country-by-country explanations of these estimates (for each country, there is one Word le with a text explanation of the key methods, and one Excel le that sets out the data, assumptions and calculations), as well as a general overview of methods. These documents were designed to be accessible to those without expertise in epidemiology, and will be updated in 2009. The documents are available from WHO upon request. Two more recent publications provide up-to-date guidance about how TB incidence, prevalence and mortality should
WHO recommendations for recording and reporting are described at: http://www.who.int/tb/dots/r_and_r_forms/en/index.html Dye C et al. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. Journal of the American Medical Association, 1999, 282:677686. Corbett EL et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine, 2003, 163:10091021. Dye C et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Journal of the American Medical Association, 2005, 293:27672775.
be measured1,2 based on the work of the WHO Global Task Force on TB Impact Measurement. These documents can be read in conjunction with the list of countries where surveys of the prevalence of TB disease have been implemented or are planned in the near future (ANNEX 4), with the set of countries that now register deaths by cause of death and provide these data to WHO (ANNEX 4), and with existing or planned work on impact measurement as reported by the HBCs (ANNEX 1, see Monitoring and evaluation, and impact measurement sections of country proles). Where population sizes are needed to calculate TB indicators, we use the latest revision of estimates provided by the United Nations Population Division.3 These estimates sometimes differ from those made by countries. Discrepancies in population estimates that make a difference to TB estimates published by WHO are explained in the country notes at the beginning of ANNEX 3. Until 2008, most analyses were undertaken using Excel software. During 2008, a new system for producing estimates using R software4 has been developed and run in parallel with analyses undertaken in Excel. Following checks that have veried that both systems produce the same results, full substitution of Excel with R will occur in 2009. Advantages of programming the calculations required to produce estimates of TB incidence, prevalence and mortality in R include enhanced reliability, efciency, and transparency of methods and results. The software also provides much greater capacity to use Monte Carlo simulations to analyse the sensitivity of estimates to different parameters and to produce condence intervals as well as point estimates.
TABLE A.3.1 summarizes the number of countries for which each method is used. The Stblo coefcient (equation 3) has conventionally been assumed to be a constant, with an empirically derived value in the range 4060. This coefcient relates the annual risk of infection (ARI) (% per year) to the incidence of sputum smear-positive cases (per 100 000 population per year). There is increasing evidence to suggest that the Stblo coefcient is not constant5 and that its value is difcult to predict.6 For this reason, use of this method to estimate incidence is being phased out. Once incidence has been estimated for a reference year, estimates of incidence for each country in surrounding years (back to 1990, forward to 2007) are made in one of ve ways: 1. From country-specic time-series of case notications, based on the assumption that the trend in incidence (of all forms of TB) is the same as the trend in notications of all new and relapse TB cases.7 Time-series of notications are constructed in one of three ways. If the rate of change in case notications has been roughly constant through time, exponential trends are tted to the notication series. If the case notication rate has varied through time, the trend is estimated as a three-year moving average of the notication rate. For countries with a small population, a high estimated case detection rate and surveillance data of high quality, incidence is allowed to mirror annual changes in notications (on the basis that such changes are stochastic and to avoid substantial year-to-year uctuation in the case detection rate). 2. From regional time-series of case notications that are constructed using data from a subset of countries in the region for which notication data are considered to be reliable, with the assumption that the trend in incidence (of all forms of TB) is the same as the regional trend in notications of all new and relapse TB cases. This method is used for countries where case notications are assessed to be an unreliable guide to trends in TB incidence (for example because the amount of effort invested in compiling and reporting data is known to have changed, or because reports are clearly erratic and changing in a way that cannot be attributed to real changes in the epidemiology of TB). The aggregated regional trend is based on tting an exponential trend for the subregions of Africa
1
A2.2.3 Estimates of TB incidence, 19902007

Estimates of the incidence of TB for each country are rst made for a reference year using one of the four equations shown below. The reference year is the year for which a best estimate of incidence is available. For most countries (n=148) this is 1997, when a global consultation process was used to produce estimates of incidence for all countries. For an increasing number of countries, the reference year is more recent and is the year in which a survey of the prevalence of TB disease or a rigorous analysis of surveillance data was carried out. case notications proportion of cases detected prevalence duration of condition
incidence =
incidence =
2
3 4
incidence = annual risk of infection x Stblo coefcient 3 incidence = deaths proportion of incident cases that die 4
Dye C. et al. Measuring tuberculosis burden, trends and the impact of control programmes. Lancet Infectious Diseases (published online 16 January 2008; http://infection.thelancet.com). Measuring progress in TB control: WHO policy and recommendations (policy paper). Geneva, World Health Organization, 2009 [in press]. World population prospects the 2006 revision. New York, United Nations Population Division, 2007. http://www.r-project.org Dye C. Breaking a law: tuberculosis disobeys Stblos rule. Bulletin of the World Health Organization, 2008, 86:4. van Leth F, Van der Werf MJ, Borgdorff MW. Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bulletin of the World Health Organization, 2008, 86:2026. The term case notication, as used here, means that TB is diagnosed in a patient and is reported within the national surveillance system, and then to WHO.
low-HIV, Latin America, South-East Asia and the Western Pacic. The aggregated trend is based on a moving average for the subregions of Africa high-HIV, Central Europe, Eastern Europe, the Eastern Mediterranean and Established Market Economies. 3. From ARI data from tuberculin surveys. For a small and decreasing number of countries, trends in incidence are estimated from trends in the ARI, as measured in a series of tuberculin surveys. 4. From the assumption that TB incidence has been stable. For a few countries with no reliable data from which trends in incidence can be assessed (examples are Iraq and Pakistan, where data are hard to interpret and which are atypical within their own regions), the TB incidence rate per capita is assumed to have remained constant before and after the reference year. 5. From trends in TB mortality. For two countries (Brazil and South Africa), trends in incidence are estimated from trends in TB mortality, as measured from vital registration data. Further details are available in the publications and other reference material cited in A2.2.2. TABLE A.3.1 in ANNEX 3 summarizes the number of countries for which each method is used.
t =
h. 1 + h ( 1)
To estimate from empirical data, equation 5 was rearranged as follows: = t.(1h) h.(1t) 6
A2.2.4 Estimates of the prevalence of HIV among incident cases of TB, 19902007
The prevalence of HIV among incident TB cases was directly estimated from country-specic and empirical data wherever possible. For the estimates published in this report, such data were available for 64 countries from either national surveys (7 countries), sentinel surveillance systems (8 countries) or provider-initiated HIV testing results of at least 50% of notied new cases (49 countries). Before using results from routine HIV testing with no adjustment for the coverage of HIV testing, the relationship between estimates of the prevalence of HIV among TB patients and testing coverage was explored. This showed that there was no clear relationship between HIV prevalence and testing coverage (for example, that HIV prevalence fell as testing coverage increased). For this reason, no attempt was made to adjust estimates of HIV prevalence among TB patients to account for testing coverage. For all remaining countries (that is, for countries where surveillance data were not available or where the percentage of TB patients being tested was below 50%), the prevalence of HIV was estimated indirectly according to equation 5, where t is HIV prevalence among incident TB cases, h is HIV prevalence in the general population (from the latest time-series published by UNAIDS) and is the incidence rate ratio (IRR) (that is, the incidence rate of TB in HIV-positive people divided by the incidence rate of TB in HIV-negative people).1
1
Using data from 44 countries where HIV prevalence in the general population has been estimated by UNAIDS as an independent variable, a linear model of logit-transformed t was tted using logit-transformed h. When applied to data from 2007, the model indicates an estimated slope that is not signicantly different from 1 (FIGURE A.2.1). A model with a slope constrained to 1 was run separately for three levels of HIV epidemic. These were dened as HIV prevalence greater to or equal than 1% in the general population (high HIV), prevalence between 0.1% and 1% (medium HIV) and prevalence lower than 0.1% (low HIV, FIGURE A2.1). When exponentiated, the intercept equals the incidence rate ratio . When data for 2007 were used, its value was 20.6 (95% condence interval 15.427.5) for high HIV, which is much higher than the estimate of 6 that has been used in previous years. The estimated IRR for medium HIV was 26.7 (95% condence interval 20.434.9) and for low HIV, 36.7 (11.6116). The predicted IRRs were also used to calculate the prevalence of HIV in TB cases for the years 19902006, using equa-
FIGURE A2.1 Relationship between the prevalence of HIV in TB patients and the prevalence of HIV in the general population
Logit (HIV prevalence in TB patients)
4
HIV prevalence in general population <0.1% 0.1%1% >1%
Data on HIV prevalence in the general population are unpublished data provided to WHO by UNAIDS.
8 6 4 Logit (HIV prevalence in the general population)
tion 5. Although existing data suggest that the IRR increases as HIV epidemics mature, there is large uncertainty about its trend. Therefore, estimates of HIV prevalence among TB cases in years before 2007 are more uncertain than the estimates for 2007. Given a much higher estimate of the IRR compared with previous years, estimates of the number of HIV-positive cases published in this report (CHAPTER 1; ANNEX 1; ANNEX 3) are much higher than those published in previous years. Moreover, and as a direct consequence, estimates of TB mortality are also higher than estimates published in previous years. This is because mortality rates among HIV-positive TB cases are estimated to be much higher than those in HIV-negative TB cases (see also A2.2.6).
For each of the four categories dened in step 2, the proportion treated under DOTS is calculated as DOTS notications divided by the estimated total incidence, and is calculated separately for a) smear-positive cases and b) other types of case. The maximum proportion of cases that are untreated is estimated by smear status, based on previous reviews of data about access to health services, drug availability, healthcare infrastructure and other qualitative information. The proportion of cases that are treated outside DOTS programmes is estimated as either non-DOTS notications divided by estimated incidence or as 100% minus the proportion treated under DOTS minus the maximum untreated proportion, whichever is larger. Once the DOTS and non-DOTS proportions have been calculated, the remainder is assumed to be untreated. 4. The average duration of disease is specied for each of the 12 subcategories resulting from step 3. The duration of disease is assumed to be shorter for cases treated in DOTS programmes, and shorter among untreated HIVpositive TB cases. 5. The overall duration of disease is estimated as a weighted average, using the numbers of cases in each of the 12 subcategories and the average duration of disease estimated for each of these 12 subcategories. For the parameters used to estimate the average duration of disease, please consult the reference material cited in A2.2.2.
A2.2.5 Estimates of TB prevalence rates, 19902007

For all countries and all years, the prevalence of TB is generally estimated as incidence multiplied by the duration of disease (using equation 2 above). The exception is the reference year described in A2.2.5, if incidence in that year was based on the results of a prevalence survey (that is, equation 2 was used to estimate incidence in the reference year). The duration of disease is estimated based on three considerations: a. whether TB cases are HIV-positive or HIV-negative; b. whether TB cases are sputum smear-positive or not; c. whether TB cases are treated in DOTS programmes, treated outside DOTS programmes, or untreated. Five steps are used to estimate the average duration of disease in any given year and in any given country. 1. TB cases (the total number of estimated incident cases) are divided into two categories: cases that are HIV-positive and cases that are HIV-negative. The methods used to estimate the proportion of cases that are HIV-positive are described above in A2.2.4. 2. HIV-positive and HIV-negative cases are subdivided according to whether they are sputum smear-positive or not (thus giving four categories of incident TB case). Fot countries in all subregions except Latin America, it is assumed that 45% of HIV-negative and 35% of HIVpositive TB cases are sputum smear-positive. These two assumptions are based on observational data on the natural history of TB.1 For countries in the Latin America subregion, it is assumed that 55% of HIV-negative and 45% of HIV-positive TB cases are sputum smear-positive. 3. Cases in each of the four categories resulting from step 2 are subdivided into three further subcategories: treated under DOTS, treated outside DOTS programmes, and untreated. This results in 12 categories of incident case.
1
A2.2.6 Estimates of TB mortality rates, 19902007

The number of deaths from TB is estimated by multiplying TB incidence in each year by the estimated case fatality rate. Case fatality rates are rst estimated for each of the 12 subcategories of case described in A.2.2.5. The estimated case fatality rate for each subcategory is then multiplied by the number of incident cases in each subcategory (as described in Steps 13 in A.2.2.5). The following points are worth highlighting: case fatality rates are estimated to be lowest for cases treated in DOTS programmes, higher for cases that are treated outside DOTS programmes and highest for cases that are not treated at all. No adjustment to account for whether patients have drug-resistant TB or not is made; the case fatality rate for HIV-positive TB patients who are treated in DOTS programmes is assumed to be 10%. Patients who are HIV-positive and treated in non-DOTS programmes are assumed to have a higher case fatality rate, which is estimated on a country-by-country basis. No adjustment to account for whether or not patients are on antiretroviral treatment (ART) is made; the case fatality rate for untreated cases is assumed to be the same in all countries. This is an 83% case fatality rate for HIV-positive and sputum-smear positive cases; a 70% case fatality rate for HIV-negative and sputum-smear positive cases; a 74% case fatality rate for HIV-positive cases that are sputum-smear negative;
Dye C et al. Global burden of tuberculosis: estimated incidence, prevalence and mortality by country. Journal of the American Medical Association, 1999, 282:677686.
and a 20% case fatality rate for HIV-negative cases that are sputum-smear negative; the difference in the case fatality rate between smearpositive cases and other cases is assumed to be smaller among HIV-positive cases than among HIV-negative cases. This is because smear-negative status in an HIVpositive individual is not necessarily indicative of less severe disease.
A2.2.7 Estimates of MDR-TB

The proportion of new and retreatment cases with MDR-TB in 2007 was estimated using data from drug resistance surveys or routine surveillance (DRS)1 for 113 (new cases) and 102 (retreatment cases) countries, respectively. For countries without empirical data, estimates of the proportion of new and retreatment cases with MDR-TB were made using statistical models that have been described elsewhere.2 The number of incident MDR cases m was computed according to the following equation, where n is the probability of MDR in new cases (with no history of previous treatment), r is the probability of MDR in re-treatment cases, c is the number of incident episodes of TB, n is the number of rst episodes of MDR-TB and r is the number of any other subsequent episodes: m=
c
i
i=n,r
The incidence of subsequent episodes of MDR-TB was estimated using the following equation:
r
cr =
cn
Here, n is the number of newly notied TB cases and r is the number of notied re-treatment cases that occurred in 2007. The re-treatment ratio r/n was estimated as an average of the values observed in the three years 20052007. Two quasi-binomial logistic regression models, in which the proportion of cases with MDR-TB was the dependent variable, were tted for new cases and re-treatment cases separately. The independent variables used in the model for new cases were epidemiological region as dened in previously published analyses, the log of gross national income (GNI) per capita in 2008,3 and the re-treatment ratio r/n. The independent variables used in the model for re-treatment cases were epidemiological region (dened as for new cases), the prevalence of HIV in new TB cases and the reported rate of treatment failure in the cohort of new cases treated in 2006. Model ts were assessed using plots of binned residuals4 against various inputs of interest dened by the selected predictors, and estimates for both new and retreatment cases were adjusted to correct for over-dispersion.5 For both new and retreatment cases, the reported proportion of all TB cases that are re-treatment cases was a major inuence on estimates of the number of cases that
have MDR-TB. In this context, it is important to note that retreatment cases may be misclassied as new cases in some settings for example, if the time taken to collect information about previous treatment is too short, if there is pressure to meet targets for case detection of new cases at the local level, and if there are errors in recording and reporting. If the proportion of cases that are retreatment cases has been underestimated, then the point estimates of the number of MDR cases will be too low and condence intervals will underestimate the true uncertainty that is associated with these point estimates. Estimates for 2005 and 2006 were produced by assuming that the probability of MDR-TB among new and retreatment cases has remained constant during the three years 20052007. Estimates of the number of incident cases of MDR-TB, disaggregated by smear status, are presented in ANNEX 3. The method used to derive estimates of the frequency of MDR-TB in new and re-treatment cases (based on direct measurement from DRS or indirect estimation from modelling) is also presented in ANNEX 3. All re-treatment cases were assumed to be smear-positive. In some countries (for example, Australia and the United States), routine data on drug sensitivity were not available for new and retreatment cases separately; for these countries, only an estimate of the total number of MDRTB cases is presented in ANNEX 3. Estimates of the number of smear-positive cases of MDR-TB in the years 20052007 are also presented in the country proles that appear in ANNEX 1. These estimates can be used to set targets for detection and treatment of MDR-TB cases by NTPs. It should be noted that estimates of the numbers of MDR cases presented in this report may substantially differ from those previously published by WHO. Differences are due to changes in estimation methods and new data, as opposed to real changes in the epidemiological burden of MDR-TB.
A2.2.8 Case notication and case detection

The term case notication, as used here, means that TB is diagnosed in a patient and is reported within the national surveillance system, and then to WHO. While the emphasis is on new smear-positive cases, we also present the numbers of all
1
Anti-tuberculosis drug resistance in the world. Fourth global report: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Geneva, World Health Organization, 2008 (WHO/HTM/ TB/2008.394). Zignol M et al. Global incidence of multidrug-resistant tuberculosis. Journal of Infectious Diseases, 2006, 194:479485. World Bank, 2008. See devdata.worldbank.org/data-query (accessed in December 2008). Gelman A and Hill J. Data Analysis Using Regression and Multilevel/ Hierarchical Models, Cambridge University Press, 2006. Over-dispersion was measured by comparing the sum of squared standardized residuals to a 2 distribution with nk degrees of freedom, where n is the number of data points and k is the number of estimated model parameters. In quasi-binomial logistic models, the standard deviation has the form: n(1 ) , where > 1 is the over-dispersion parameter. The over-dispersion parameter was estimated to be > 9 for both new and retreatment cases. Without adjustment for over-dispersion, condence intervals would be too narrow, and the precision of estimates would be overstated.
TB cases reported smear-positive and smear-negative pulmonary cases in addition to those in whom extrapulmonary disease is diagnosed. The number of cases notied in any year is the sum of new and relapse cases. Case reports that represent a second registration of the same patient or episode (that is, re-treatment after failure or default) are presented separately. The case detection rate is calculated as the number of cases notied in a given year divided by the number of incident cases estimated for that year, expressed as a percentage. Case detection is presented in three main ways: (a) for new smear-positive cases (excluding relapse cases); (b) for all new cases (all clinical forms of TB, excluding relapse cases); and (c) for smear-positive cases and all new cases, in DOTS programmes only. annual new smearpositive notications (DOTS) 7 estimated annual new smearpositive incidence (country)
maps that show subnational variation in notication rates. Geographical variation in notication rates may reect true differences in TB incidence, or variation in other factors such as efforts to nd and diagnose cases. If variation in notication rates is greater than would be expected by chance, further investigation to understand the reasons is warranted.
A2.2.9 Outcomes of treatment

The treatment success rate in DOTS programmes is dened as the percentage of new smear-positive patients who are cured (negative on sputum smear examination), plus the percentage who complete a course of treatment, without bacteriological conrmation of cure (TABLE A2.1). Cure and completion are among the six mutually exclusive treatment outcomes.1 The sum of cases assigned to these outcomes, plus any additional cases registered but not assigned to an outcome, adds up to 100% of cases registered (that is, the treatment cohort). In this report, the country proles that appear in ANNEX 1 show trends in treatment success rates for all notied cases (i.e. cases notied by DOTS and non-DOTS programmes) from 2000 to 2006. This indicator allows assessment of national changes in treatment success rates as well as the overall improvements that have been achieved as DOTS programmes have expanded. Where there has been substantial geographical expansion of DOTS since 2000, treatment success rates for DOTS and non-DOTS areas combined may be considerably different (typically lower) than treatment success rates for DOTS programmes specically. Trends in treatment success rates for DOTS programmes only are presented in ANNEX 3. We also compare the number of new smear-positive cases registered for treatment with the number of cases notied as smear-positive. All notied cases should be registered for treatment, and the numbers notied and registered should therefore be the same (discrepancies can arise, however, for example, when subnational reports are not received at the national level). If the number registered for treatment is not provided, we take as the denominator for treatment outcomes the number notied for that cohort year. If the sum of the six outcome categories is greater than the number registered (or the number notied), we use this sum as the denominator. The number of patients presenting for a second or subsequent course of treatment, and the outcome of further treatment, are indicative of NTP performance and levels of drug resistance. We present in this report, where data are available, the numbers of patients registered for re-treatment, and the outcomes of re-treatment, for each of four registration categories: smear-positive re-treatment after relapse; failure; default; and other re-treatment (including pulmonary smearnegative and extrapulmonary). The assessment of treatment outcomes for a given calendar year always lags case notications by one year, to ensure
1
DOTS case detection = rate
Case detection rate
annual new smearpositive notications (country) = estimated annual new smearpositive incidence (country) 8
The global target of a 70% case detection applies to the DOTS case detection rate in equation 7. Even when a country has not achieved full geographical coverage of DOTS, we use the incidence estimated for the whole country as the denominator of the DOTS case detection rate, as in equation 7. The DOTS case detection rate and the case detection rate for the whole country are identical when a country reports only from DOTS areas. This generally happens when DOTS coverage is 100%, but in some countries where DOTS is implemented in only part of the country, no TB notications are received from the non-DOTS areas. Furthermore, in some countries where DOTS coverage is 100%, patients may seek treatment from non-DOTS providers that, in some cases, notify TB cases to the national authorities. Although these indices are termed rates, they are actually ratios. The number of cases notied is usually smaller than the estimated incidence because of incomplete coverage by health services, under-diagnosis, or decient recording and reporting. However, the calculated rate of case detection can exceed 100% if case-nding has been intense in an area with a backlog of existing cases, if there has been over-reporting (for example, double-counting) or over-diagnosis, or if estimates of incidence are too low. If the expected number of cases per year is very low (for example, less than one), the case detection rate can vary markedly from year to year because of chance. Whenever this index comes close to or exceeds 100%, we attempt to investigate, as part of the joint planning and evaluation process with NTPs, which of these explanations is correct. For the rst time, the country proles in ANNEX 1 include
Treatment of tuberculosis: guidelines for national programmes, 3rd ed. Geneva, World Health Organization, 2003 (WHO/CDS/TB/2003.313).
that all patients registered during that calendar year have completed treatment. For MDR-TB patients, who have longer treatment regimens, the lag is three years.
A2.3
Implementation of the Stop TB Strategy
The strategy section of the questionnaire described in A2.1 was structured around the six major components and subcomponents of the Stop TB Strategy: pursue high-quality DOTS expansion and enhancement; address TB/HIV, MDRTB and the needs of poor and vulnerable populations; contribute to health-systems strengthening based on primary health care; engage all care providers; empower people with TB, and communities through partnership; and promote and enable research. In 2008, greater emphasis was placed on the collection of quantitative data in a shorter and more userfriendly format, compared with the data collection form used in 2007. There was positive feedback about these changes, although the data that were reported show that it remains difcult for many countries to report accurate and quantitative data about several key elements of TB control. Examples include data related to the contribution of public-public and public-private mix (PPM) to case notications and treatment, community-based TB care (CBTC), human resource development (HRD), the number of laboratories and the number of laboratory tests being done for different types of case, and advocacy, communication and social mobilization (ACSM). Specic additional details about data collection or analysis for DOTS implementation, collaborative TB/HIV activities, diagnosis and treatment of MDR-TB and case detection through quality-assured bacteriology are provided below.
as those within prisons) notify cases to the NTP. These cases are considered non-DOTS cases, even if they are notied from within DOTS areas. However, when certain groups of patients treated by DOTS services receive special regimens or management (for example, nomads placed on longer courses of treatment), these are considered DOTS cases. As the number of countries that are not implementing DOTS or that have not yet achieved national coverage is now small, DOTS coverage is becoming a less relevant indicator. DOTS coverage as described above is a crude indicator of the actual proportion of people who have access to DOTS services. Where countries are able to provide more precise information about access to DOTS services, this information is reported in the country notes of ANNEX 3. The case detection rate (dened above in A2.2.8) is a more precise measure of DOTS implementation but is also more demanding of data.
A2.3.2 Collaborative TB/HIV activities

In 2002, questions on collaborative TB/HIV activities were introduced into the WHO data collection form for the rst time and sent to 41 priority countries. These countries were selected because they accounted for 97% of the estimated global number of HIV-positive TB cases.2 From 20032005, data on three aspects of collaborative TB/HIV activities were requested from all countries: HIV testing of TB patients, and provision of CPT and of ART to those TB patients found to be HIV positive. In 2005, all questions were sent to the 41 countries described above and to an additional 22 countries.3 These countries were added to the list of countries that were sent the full set of questions because they were dened by UNAIDS as having a generalized HIV epidemic (UNAIDS 2004).4 In 2006 and 2007, all questions were sent to all 63 countries. In 2008, all questions were sent to all countries. For those indicators that require both a numerator and a denominator, countries reported only the numerator or only the denominator. Given this incompleteness in reporting, estimates of the proportion of HIV-positive TB cases treated with CPT and ART, and the proportion of TB cases tested that were HIV-positive, were based on matched data, that is, reported gures are based on data from only those countries that
1
A2.3.1 DOTS and the Stop TB Strategy

Before the launch of the Stop TB Strategy in 2006, NTPs reporting to WHO were classied as either DOTS or nonDOTS, based on the elements listed in TABLES 2.1 AND 2.2 (see CHAPTER 2). To be classied as a country implementing DOTS in a given year, a country must have ofcially accepted and adopted the DOTS strategy in that year (or earlier), and must have implemented its four technical components in at least part of the country. Based on NTP responses to standard questions about policy and usually on further discussion with the NTP we accept or revise each countrys own determination of its DOTS status. DOTS coverage is dened as the percentage of the national population living in areas where health services have adopted DOTS. Areas are the lowest administrative or basic management units1 in the country (townships, districts, counties, etc.). If an area (with its one or more health facilities) is considered by the NTP to have been a DOTS area in any given year, then all the cases registered and reported by the NTP in that area are considered DOTS cases, and the population living within the boundaries of that area counts towards the national DOTS coverage. In some cases, treatment providers that are not following DOTS guidelines (for example, private practitioners, or public health services outside the NTP such
The basic management unit is dened in terms of responsibility for management, supervision and monitoring. It may have several treatment facilities, one or more laboratories, and one or more hospitals. The dening aspect is the presence of a manager or coordinator who oversees TB control activities for the unit and who maintains a master register of all TB patients being treated, which is used to monitor the programme and report on indicators to higher levels. The 41 countries are Angola, Botswana, Brazil, Burkina Faso, Burundi, Cambodia, Cameroon, the Central African Republic, Chad, China, the Congo, Cte dIvoire, Djibouti, the Democratic Republic of the Congo, Ethiopia, Ghana, Haiti, India, Indonesia, Kenya, Lesotho, Malawi, Mali, Mozambique, Myanmar, Namibia, Nigeria, the Russian Federation, Rwanda, Sierra Leone, South Africa, the Sudan, Swaziland, Thailand, Togo, Uganda, Ukraine, the United Republic of Tanzania, Viet Nam, Zambia and Zimbabwe. The 22 countries are the Bahamas, Barbados, Belize, Benin, the Dominican Republic, Equatorial Guinea, Eritrea, Estonia, Gabon, Guatemala, Guinea, Guinea-Bissau, Guyana, Honduras, Jamaica, Liberia, Madagascar, the Niger, Panama, Somalia, Suriname, and Trinidad and Tobago. HIV prevalence estimates for 2004 (unpublished data) Geneva, Joint United Nations Programme on HIV/AIDS.
provided data on both the numerator and the denominator. Indicators for monitoring and evaluating collaborative TB/HIV activities are available from WHO.1
A2.3.3 Diagnosis and management of MDR-TB

In addition to the standard data collection form, we also use data compiled through the monitoring process of the Green Light Committee. In CHAPTER 2, particular attention is given to 27 countries that have been prioritized at global level. These countries were dened using the following criteria: the estimated number of MDR-TB cases exceeds 4000 per year; and/or the proportion of TB cases that is estimated to have MDR-TB exceeds 10%.
A2.3.4 Early case detection through quality-assured bacteriology

Between 2003 and 2005, data about laboratory services were collected from HBCs using a stand-alone questionnaire. In 2006, questions on laboratory services were introduced into the annual WHO data collection form for the rst time, and data were requested from all countries. In 2007, questions were asked about the presence of a national reference laboratory (NRL), the number of microscopy, culture and DST laboratories, the number of microscopy laboratories for which external quality assurance (EQA) was carried out, the frequency of stock-outs of reagents at central and peripheral levels, and collaboration with non-NTP laboratories. These questions were retained in 2008, and supplemented by questions about the uptake of new technologies and country plans to absorb new diagnostic tools. Overall, the quality of the laboratory data that were reported was poor and inconsistent with previous reports. This suggests that essential linkages between NTPs and laboratory services have not yet been established or are weak in many countries. It is also possible that reporting is hindered by insufcient understanding of the laboratory component of the Stop TB strategy.
collected directly from countries using a two-page questionnaire included in the standard WHO data collection form (described above in A2.1). NTP managers were asked to complete four tables. The rst two tables required a summary of the NTP budget for scal years 2008 and 2009, in US dollars, by line item and source of funding (including a column for funding gaps). The third table requested NTP expenditure data for 2007, by line item and source of funding. The fourth table requested information about the way in which general health infrastructure is used for TB control (for example, the number of beds dedicated to TB patients that are available, the number of outpatient visits that patients need to make to a health facility during treatment and the average length of stay when patients are admitted to hospital). Estimates of the number of patients who would be treated in 2008 and 2009 were also requested for (a) new smear-positive cases (b) new smear-negative and extrapulmonary cases, (c) HIVpositive TB patients on ART and (d) cases with MDR-TB. Line items for the budget tables are designed to be in line with the Stop TB Strategy and to allow for comparisons with the cost categories used in the Global Plan. A total of 14 line items were dened: rst-line drugs; dedicated NTP staff; routine programme management and supervision activities; laboratory supplies and equipment; PAL; PPM; second-line drugs for MDR-TB; management of MDR-TB (budget excluding second-line drugs); collaborative TB/HIV activities; ACSM; community-based care; operational research; surveys of disease prevalence and infection; and all other budget lines for TB (e.g. technical assistance). The relationship of these items to the Stop TB Strategy and the Global Plan and the categories used for presentation of nancial analyses in this report are shown in TABLE A2.2.
A2.4.2 Data entry and analysis

A standardized Microsoft Excel worksheet was created, which generates nancial tables and related gures for each country that reported data for each year 20022009. The workbook also contains additional worksheets for summary analyses and for the data required as inputs to the country-specic analyses (for example, unit costs for bed-days and outpatient clinic visits, national health account statistics). This system allows a systematic analysis of each countrys data, which in turn is used to determine which countries, other than HBCs, have provided data of sufcient quality to be included in the main gures and tables of the report. This country worksheet includes 13 tables and related gures: NTP budget by line item for each year 20022009. Line items were grouped to allow for comparisons with the Stop TB Strategy and the Global Plan. This grouping, both for the budget categories used in 20062009 and for those used in 20022005, is explained in TABLE A2.2. NTP budget by line item for each year 20022009, according to the categories used in each round of data collection.
A2.4 Financing A2.4.1 Data collected

Data were collected from six main sources: NTPs, the WHOCHOICE team,2 the WHO National Health Accounts statistics, Global Fund proposals and databases, previous WHO reports in this series, and epidemiological and nancial analyses carried out for the Global Plan.3 In 2008, data were
1
A guide to monitoring and evaluation for collaborative TB/HIV activities. Geneva, World Health Organization, 2004 (WHO/HTM/TB/2004.342 and WHO/HIV/2004.09; available at http://www.who.int/hiv/pub/ tb/en/guidetomonitoringevaluationtb_hiv.pdf; accessed January 2008). The WHO-CHOICE (CHOosing Interventions that are Cost-Effective) team conducts work on the costs and effects of a wide range of health interventions. The Global Plan to Stop TB, 20062015: methods used to assess costs, funding and funding gaps. Geneva, Stop TB Partnership and World Health Organization, 2006 (WHO/HTM/STB/2006.38).
TABLE A2.2 Categories used to present the nancial analyses in this report and their relationship to the Stop TB Strategy, the Global Plan, the budget line items used in the WHO data collection form and the budget lines used in previous WHO reports
CATEGORIES USED FOR FINANCIAL ANALYSES IN THIS REPORT, 20022009 STOP TB STRATEGY GLOBAL PLAN BUDGET LINE ITEMS, 20062008 BUDGET LINE ITEMS, PRE- 2006
DOTS
Component 1
DOTS
First-line anti-TB drugs; NTP staff; routine programme management and supervision activities; laboratory supplies and equipment Second-line drugs for MDR-TB; management of MDR-TB (excluding second-line drugs) Collaborative TB/HIV activities ACSM PPM, PAL, community-based TB care, operational research and special surveys of prevalence of disease and of infection. Other for all other budget lines for TB (e.g. technical assistance)
First-line anti-TB drugs; NTP staff; buildings, vehicles, equipment; all other budget lines for TB Second-line anti-TB drugs
MDR-TB
Component 2
MDR-TB or DOTS-Plusa
TB/HIV ACSM Other (includes PPM, PAL, community-based TB care, operational research, surveys and other)
a
TB/HIV Component 5 Components 35 and 6 ACSM New approaches to DOTS (includes PAL, PPM and community-based TB care). Operational research, surveys and other were not included as specic categories
Collaborative TB/HIV activities New initiatives to increase case detection and cure rates for PPM, PAL and community-based TB care; other. Operational research and surveys were not included as a specic category
DOTS-Plus is the term used to describe the management of MDR-TB patients according to international guidelines at the time of the development of the Global Plan.
NTP budget by source of funding for each year 2002 2009, with the funding sources dened as government contribution (excluding loans), loans, Global Fund grants, grants (excluding Global Fund) and funding gap. NTP expenditures by source of funding for 20022007, with funding sources as dened for NTP budgets. NTP expenditures by line item for each year 2002 2007. Line items were grouped, as for budgets, to allow for comparisons with the Global Plan and the Stop TB Strategy (TABLE A2.2). NTP expenditure by line item for each year 20022007, according to the categories used in each round of data collection. Funding gap by line item for each year 20022009. Line items were grouped as for budget and expenditure tables (TABLE A2.2). Total costs of TB control by funding source for each year 20022009, with funding sources as dened for NTP budgets. Total costs of TB control by line item for each year 20022009, with line items dened as NTP budget items, hospitalization and clinic visits. Per patient costs, NTP budget, available funding, expenditures and budget for rst-line anti-TB drugs. Comparison of NTP budget, available funding and expenditure for 20032007 by line item.1 Financial indicators for 2008 and 2009, which were dened as government contribution to NTP budgets (as a percentage), government contribution to total TB control costs (as a percentage), the proportion of the NTP budget for which funding is available, the NTP budget per capita, total TB control costs per capita, the funding gap per capita, total expenditure on health per
capita, and general government expenditure on health per capita. Comparison of total costs based on the country report with total costs implied by the Global Plan, for 2006 2009. Budget data for 20022007 and expenditure data for 2003 2006 were taken from the forms used in previous years, while budget data for 20082009 and expenditure data for 2007 were taken from the 2008 data collection form. Total TB control costs were estimated by adding costs for hospitalization and outpatient clinic visits to either NTP expenditures (for 20022007) or NTP budgets (for 20082009). Expenditures were used in preference to budgets for 20022007 because they reect actual costs, whereas budgets can be higher than actual expenditures (for example, when large budgetary funding gaps exist or when the NTP does not spend all the available funding). When expenditures are known for 2008 and 2009, they will be used instead of budget data to calculate, retrospectively, the total cost of TB control in these years. For countries other than HBCs, expenditures before 2003 are not available in our database. For some HBCs, expenditures were not available for 20022007. In this case, we estimated expenditures based on available funding, which was calculated as the total budget minus the funding gap. The exceptions were South Africa and Thailand, which reported budget and expenditure data for the rst time in 2006 and 2008, respectively. In previous annual reports, costs in South Africa were based on costing studies undertaken in the mid-to-late 1990s and costs in Thailand were not calculated because data were absent. Given the availability of new information the previous cost estimates for 20022004 (South-Africa) and 20022007 (Thailand) were revised by assuming that per patient costs in these years would be as for 2006 (South Africa) and 2008 (Thailand). Total costs were then estimated by multiplying total case notications in each year by the estimated cost per patient treated.
Expenditure data are available for a larger set of countries in 2003 compared with 2002. For this reason, comparisons are with 2003.
The total cost of outpatient clinic visits was estimated in two steps. First, the unit cost (in US$)1 of a visit was multiplied by the average number of visits required per patient (estimated on the WHO data collection form) to give the cost per patient treated. This was done separately for (a) new smear-positive cases and (b) new smear-negative and extrapulmonary cases. Second, the cost per patient treated was multiplied by the number of patients notied (for 2002 2007) or the number of patients whom the NTP expects to treat (for 20082009). The total costs for the two categories of patient were then summed. The cost of hospitalization was generally calculated in the same way, replacing the unit cost of a clinic visit with the unit cost of a bed-day. However, the number of dedicated TB beds was used to calculate the cost of hospitalization when the total cost of these beds is higher than the total cost estimated by multiplying the countrys estimate of the number of bed-days per patient by the number of patients treated. For HBCs, this was the case for 11 countries that have dedicated TB beds: Bangladesh, Brazil, Cambodia, Ethiopia, India, Kenya, Mozambique, Myanmar, the Russian Federation, South Africa and Viet Nam. We assumed that all clinic visits and hospitalization are funded by the government, because staff and facility infrastructure are the major inputs included in the unit cost estimates and these are typically not funded by donors. Per patient costs, budgets, available funding and expenditures were calculated by dividing the relevant total by the number of cases notied (for 20022007) and the number of patients whom the NTP expects to treat (for 20082009). Since the total costs of TB control for 20022007 were based on expenditure data, it is possible that the total TB control cost per patient treated is less than the NTP budget per patient treated when the funding gap is large or there is a signicant budgetary under-spend. In addition, for 2002 2007, expenditures per patient were sometimes higher than the available funding per patient. This can occur when the NTP budget funding gap is reduced after the reporting of budget data to WHO (since available funding is estimated as the total budget minus the funding gap). To try to eliminate this problem, the data collection form has allowed countries to update budget data reported in the previous round of data collection since 2005 (for example in the 2005 round of data collection, countries were able to update 2005 budget data originally reported in 2004; in the 2008 round of data collection, countries were able to update 2008 budget data originally reported in 2007). Costs based on country reports reect actual country plans for TB control. To address the question of whether these costs are in line with the Global Plan, the regional costs that appear in the Global Plan were converted into estimates for individual countries. While these costs should be seen as approximations only, they can be used to identify important similarities and differences between country reports and the Global Plan. Differences may occur if the intervention coverage and rates of scale up (for example, the number of TB patients to be treated or the number of
HIV-positive TB patients to be enrolled on ART) planned by countries since 2006 are more or less ambitious than the projections included in the Global Plan, and/or if countryspecic budget development is based on input prices that are more or less than the average regional prices used in the Global Plan. A further reason for discrepancies is that, while the Global Plan includes the full cost of collaborative TB/ HIV activities, the budget for these activities that is reported by NTPs may include only the budget managed by the NTP, and not the budget for such activities that is managed by the national AIDS control programme. In the 2007 and 2008 rounds of data collection, we were able to improve our understanding of both TB and HIV budgets for collaborative TB/ HIV activities in several countries (for example, in Kenya and the United Republic of Tanzania). TABLE A2.3 summarizes the methods used to convert regional costs as they appear in the Global Plan into estimates for individual countries. All budget and expenditure data are reported in nominal prices (that is, prices are not adjusted for ination) rather than in constant prices (that is, all prices are adjusted to a common year). This means that values given for individual countries in this series of reports for 20022008 do not have to be adjusted, which makes it easier for country staff to review the data for previous years. Once the data were entered, any queries were discussed with NTP staff and the appropriate WHO regional and country ofce, and a nal set of charts and tables was produced. High-burden countries For HBCs specically, seven of these charts plus a summary table appear in the proles for each country at ANNEX 1: NTP budget by funding source 20022009; NTP budget line items in 2009, according to the line items used in the 2008 round of data collection; NTP budget by line item 20022009, with line items as dened in the rst column of TABLE A2.2; NTP funding gap by line item, with line items as dened in the rst column of TABLE A2.2; total TB control costs by line item 20022009; per patient costs, budgets, available funding, expenditures and budget for rst-line anti-TB drugs 20022009; costs according to country reports compared with costs implied by the Global Plan for 20062009; and a summary table including the NTP budget and funding gap by component of the Stop TB Strategy for 2009.2 In some instances, the review process led to revisions to data included in previous annual reports. For this reason, gures sometimes differ from those published in the 20022008 reports. Nine nancial indicators appear in the proles for each country at ANNEX 1. These indicators were calculated as follows:
Average costs in the WHO-CHOICE database are reported in local currency units. These were converted into US$ using exchange rate data provided in the IMF International nancial statistics yearbook. Washington, DC, International Monetary Fund, 2003. A full set of charts and data is available upon request to tbdocs@who. int.
TABLE A2.3 Methods used to allocate regional costs in the Global Plan to individual countries
COSTS NUMBER OF HIV+ TB PATIENTS ENROLLED ON ART NTP BUDGET FOR DOTS, EXCLUDING NEW APPROACHES NTP BUDGET FOR NEW APPROACHES TO DOTS IMPLEMENTATION BUDGET FOR ACSM BUDGET FOR ART FOR HIV+ TB PATIENTS, AND OTHER COLLABORATIVE TB/HIV ACTIVITIES NTP BUDGET FOR MDR-TB TREATMENT COSTS ASSOCIATED WITH UTILIZATION OF GENERAL HEALTH SERVICES, FINANCED FROM GENERAL HEALTH FACILITY BUDGETS
COUNTRY
NUMBERS OF PATIENTS
NUMBER OF SS+ AND SS/EP PATIENTS TREATED IN DOTS PROGRAMMES
NUMBER OF MDR-TB PATIENTS TREATED IN DOTS-PLUS PROGRAMMES
184 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL Estimates were made for each country as a joint effort by the Stop TB Partnership and UNAIDS for the Global Plan. Country-specic numbers were therefore already available and no allocation process was required. The NTP budget per patient in each country in 2005 was used in the Global Plan to estimate a budget per patient for the region as a whole, with each country weighted according to its share of regional cases. To return to country-specic estimates, we used the NTP budget per patient in each country that was used in the Global Plan. This is the NTP budget reported in the 2005 WHO TB control report, excluding second-line drugs and collaborative TB/HIV activities. The NTP budget for each country that underpinned the Global Plan regional calculations was then multiplied by the number of cases to be treated (estimated as explained in column 2). Global Plan cost estimates were rst made for a standard population of 500 000, or in the case of culture and DST laboratories for a population of 5 million, based on regional unit prices. These unit costs were then multiplied by a factor according to the size of the regional population to be covered (e.g. if the population to be covered was 100 million, the unit cost was multiplied by 200, or by 20 in the case of culture and DST laboratories). To estimate costs for each country, Global Plan costs for each region were allocated to each country according to its share of the regional population. The number of TB/ HIV patients on ART was multiplied by the unit cost of providing ART, estimated by UNAIDS for each country as part of the development of the Global Plan. For other activities, the number of patients was allocated to a country according to its share of the regional TB/HIV burden and then multiplied by the country-specic unit cost used in the Global Plan. Calculated as the number of MDR-TB cases to be treated multiplied by a country-specic unit cost. Countryspecic unit costs estimated by adjusting the regional cost used in the Global Plan according to GNI per capita (except for the cost of drugs, which were assumed to be the same in all countries). Calculated on a per patient basis for each country according to the inputs reported in the 2007 WHO data collection form. Unit costs for hospitalization and outpatient visits are WHO country-specic estimates as opposed to the DCPP regional estimates used in the Global Plan. Costs for diagnostic tests among TB suspects were included in the Global Plan, but were not included in the country-specic estimates because there are no comparative data from countries (the number of such tests is not requested on the WHO data collection form).
Afghanistan Bangladesh Cambodia China India Indonesia Myanmar Pakistan Philippines Thailand Viet Nam
Global Plan regional numbers allocated to each country according to its share of the regional burden of TB (in 2004).
Global Plan regional numbers allocated to each country according to its estimated share of the regional burden of MDR-TB cases in 2003 (source: DOTS-Plus Working Group).
Brazil Russian Federation
Global Plan regional numbers allocated to each country according to its share of the regional burden of TB (in 2004), then adjusted according to target level of DOTS population coverage set out in the Global Plan.
DR Congo Ethiopia Kenya Mozambique Nigeria South Africa Uganda UR Tanzania Zimbabwe
Global Plan regional numbers allocated to each country according to its share of regional cases treated under DOTS (in 2004).
DCPP indicates Disease Control Priorities Project of the World Bank; DOTS-Plus, the term used for the management of MDR-TB patients according to international guidelines at the time of the development of the Global Plan; DST, drug susceptibility testing; HIV+, HIV-positive; NTP, national tuberculosis control programme; ss+, sputum smear-positive; ss, sputum smear-negative; EP, extrapulmonary.
Government contribution to the NTP budget (including loans). This was calculated as the sum of funds for the NTP from the government (including loans), divided by the total NTP budget. Government contribution to the total cost of TB control (including loans). This was calculated as the sum of funds from the government (including funds for the NTP and funds for resources within the general healthcare system that are used for TB control), divided by the total cost of TB control. Government health spending used for TB control. This was calculated as the total cost of TB control divided by general government expenditure on health.1 Percentage of the NTP budget that is funded. This was estimated as the available funding (the sum of funds from the government, including loans, plus funds from the Global Fund and other donors), divided by the total NTP budget. NTP budget per capita, total TB control costs per capita and funding gap per capita. These indicators were calculated as the total NTP budget, total cost of TB control and the funding gap, respectively, divided by the population of the country. Government health expenditure per capita and total health expenditure per capita.1 These estimates show how much money is spent on health care by the government, and how much is spent in total (including expenditures in the private sector), per capita. To assess whether increased spending on TB control has resulted in an increase in the number of cases detected and treated in DOTS programmes, the change in total NTP expenditures between 2003 and 2007 was compared with the change between 2003 and 2007 in (a) the total number of TB cases treated in DOTS programmes and (b) the total number of new smear-positive cases treated in DOTS programmes. This was done for all HBCs for which the necessary data existed (not all countries have reported expenditure data for both years). Finally, the associations between GNI per capita in 2007 and government contributions to total NTP budgets and TB
control costs were examined. Data on GNI per capita were taken from World development indicators database.2 Other countries For countries other than the HBCs, the data provided on the 2008 data collection form were used to assess NTP budgets by region in 2009 and to compare these data with the budgets reported by the HBCs. Only countries that submitted complete data of sufcient quality (for example, data whose subtotals and totals were consistent by both line item and funding source) were used. In addition, trends in total costs were assessed by using data from all countries with sufcient data from 2006 to 2009. Costs were analysed according to the components of the Stop TB Strategy. Estimates were also made of the costs implied by the Global Plan for the 171 countries in the regions covered by the plan, as described above for the 22 HBCs. These values were aggregated for each WHO region for the subset of countries that (a) provided a complete budget report to WHO and (b) were included in the Global Plan. The total number of countries (apart from HBCs) meeting both criteria was 72. These aggregated values were then compared with costs according to country reports.
A2.4.3 Global Fund contribution to TB control

Available funding from the Global Fund was evaluated both for HBCs and for other countries, as announced after the rst eight rounds of funding. Total approved funding at the end of 2008, disbursements to the end of 2008, the time taken between approval of a proposal and the signature of grant agreements, and the time taken between the signing of the grant agreement and the rst disbursement of funds was assessed. Also assessed was how the total value of grants awarded for TB control had evolved between rounds 1 and 8, and the approval rate. The approval rate was calculated as the number of proposals considered by the Global Fund Technical Review Panel in each round divided by the number of proposals approved in each round (including proposals approved after appeal). This approval rate was compared with applications for funding for malaria and HIV.
National health accounts [online database]. Geneva, World Health Organization, 2008. Accessed in December 2008: devdata.worldbank.org/data-query.
ANNEX 3
The Stop TB Strategy, case reports, treatment outcomes and estimates of TB burden
Explanatory notes Summary by WHO region Africa The Americas Eastern Mediterranean Europe South-East Asia Western Pacic
Explanatory notes
The following tables present detailed data, rst summarized by WHO region, then by country (grouped by WHO region).1 Unless otherwise specied, rates are per 100 000 population,2 using the total population of a country (not, for example, only the population covered by DOTS, or only HIV+ve people). Estimates for all years are recalculated as new information becomes available and techniques are rened, so they may differ from those published previously.
and of the number of MDR-TB cases (for all forms and smear-positive cases), 2007.
TABLE A3.3 Estimated incidence of TB (all forms) in all people, 19902007

The current estimates (numbers and rates per 100 000 population) of TB incidence from 1990 to 2007, including in HIVnegative and HIV-positive people.
NTP manager (or equivalent) and/or person(s) responsible for completing data collection form
The people named on the data collection form returned to WHO in 2008. This list acknowledges the contribution of NTP managers and others; those named are not necessarily the current NTP managers.
TABLE A3.4 Estimated incidence, prevalence and mortality rates, 20002007

The estimated incidence of TB in HIV-positive people, expressed as incident cases per 100 000 population (both HIV-infected and un-infected people are included in the denominator), 20002007. The estimated prevalence of TB (including cases in HIVnegative and HIV-positive people), 20002007. Estimated mortality from TB in HIV-negative people (both HIV-infected and un-infected people are included in the denominator), 20002007. Estimated mortality from TB in HIV-positive people (both HIV-infected and un-infected people are included in the denominator), 20002007.
TABLE A3.1 Methods and assumptions for estimation of TB incidence, prevalence and mortality
The principal assumptions and methods used to estimate TB incidence (including incidence of TB in HIV-positive people), prevalence and mortality, and the prevalence of MDR among new and re-treatment cases for each country. See ANNEX 2 for details of calculations.
TABLE A3.2 Estimated burden of TB, 1990 and 2007

For 1990 (baseline year for MDG): estimates of incidence (all forms and smear-positive); prevalence and mortality. For 2007: estimates of incidence (all forms and smearpositive), prevalence and mortality, in all people and in HIV-infected people only. Incidence, prevalence and mortality presented as absolute numbers and as rates per 100 000 population. Estimated prevalence of HIV infection in incident TB cases, 2007. Estimates of the percentage of TB cases that are MDR (calculated for new and re-treatment cases separately)
TABLE A3.5 Case notications and case detection rates, DOTS and non-DOTS combined, 2007
Case notications by history of treatment (new or re-treatment), by site (pulmonary or extrapulmonary) and by smear status (smear-positive, smear-negative or unknown). See TABLE A2.1 for denitions of case types. Proportions of case types and estimated case detection rate for DOTS and nonDOTS cases combined. Population, source: World population prospects the 2006 revision. New York, United Nations Population Division, 2007. All notied : all notied cases, including new cases (new smear-positive, new smear-negative/unknown/not done, other new and new extrapulmonary), re-treatment cases (relapse, treatment after failure, treatment after default and other re-treatment) and other cases (cases in patients for whom it is not known whether they have previously been treated for TB). New and relapse : new and relapse cases, including new smear-positive, new smear-negative/unknown/not done,
The WHO Global TB Database, which includes data for previous years (revised as appropriate), is available at http://www.who.int/tb/ country/global_tb_database/en/ World population prospects the 2006 revision. New York, United Nations Population Division, 2007.
other new, new extrapulmonary and (smear-positive) relapse cases (for the WHO European Region only, cases reported as previous treatment history unknown are also included). Other new : new cases for which the site of disease is not recorded. Re-treatment cases : smear-positive cases in patients previously treated for TB. (Other re-treat. includes re-treatment cases for which the outcome of previous treatment is not known, and smear-negative re-treatment cases including smear-negative relapse cases). Other : cases in patients for whom it is not known whether they have previously been treated for TB, and chronic cases (smear-positive cases in patients who have previously received re-treatment regimens). New pulm. Lab. conrmed : new cases of pulmonary TB in which the diagnosis has been conrmed by smear and/or culture examination. Detection rate, all new : the number of notied new cases divided by the estimated number of incident cases (expressed as a percentage). Detection rate, new ss+ : the number of notied new smearpositive cases divided by the estimated number of incident smear-positive cases (expressed as a percentage). SS+ (% of pulm.): the percentage of all notied new pulmonary cases that are notied as smear-positive. SS+ (% of new+relapse) : the percentage of notied new and relapse cases that are notied as new smear-positive. Extrapulm. (% of new+relapse) : the percentage of all new and relapse cases that are extrapulmonary. Re-treatment (% of new+re-treatment): the percentage of all notied cases that are notied as re-treatment cases.
Collaborative TB/HIV activities, 20062007

TB pts tested for HIV: the number of TB patients who were tested for HIV. TB pts HIV-positive : the number of TB patients who tested positive for HIV. HIV+ TB pts CPT: the number of HIV-positive TB patients who received co-trimoxazole preventive therapy during their anti-TB treatment. HIV+ TB pts ART: the number of HIV-positive TB patients who received antiretroviral therapy during their anti-TB treatment. Data for 2006 were requested in the data collection form in 2007 and in 2008. For those countries that provided data for 2006 in 2007 but not in 2008, the data provided in 2007 are shown.
Multidrug-resistant (MDR) TB, 2007

Lab-conrmed MDR : the number of laboratory-conrmed cases of MDR-TB identied among patients (new and retreatment) in whom TB was diagnosed in 2007. DST in new cases : the number of new TB cases in 2007 for whom drug sensitivity testing (DST) was performed at the start of treatment. MDR in new cases : the number of new cases who were identied as MDR-TB based on DST at the start of treatment. Re-treatment DST: the number re-treatment cases registered in 2007 for whom DST was performed at the start of treatment. Re-treatment MDR : the number of re-treatment cases identied as MDR-TB based on DST at the start of treatment.
TABLE A3.8 Treatment outcomes, 2006 cohort

The outcomes of treatment of new smear-positive cases treated under DOTS, new smear-positive cases treated under non-DOTS, and re-treatment cases treated under DOTS (all re-treatment cases combined). Note that when the outcomes of different groups of re-treatment cases are available, they are presented in TABLE A3.9.
TABLE A3.6 DOTS coverage, case notications and case detection rates, 2007
As for TABLE A3.5, but for DOTS notications only. DOTS coverage : the percentage of the national population living in areas where health services have adopted DOTS.
TABLE A3.7 Laboratory services, collaborative TB/HIV activities and management of MDR-TB, 20062007
Laboratory services
Numbers of laboratories : the numbers of laboratories working with the NTP that perform smear microscopy, culture or DST, and the number of laboratories performing smear microscopy that are included in external quality assurance (EQA).
TABLE A3.9 DOTS re-treatment outcomes, 2006 cohort

The outcomes of re-treatment of smear-positive cases treated under DOTS after relapse, treatment failure or default. For those countries which are not able to provide outcomes separately for the different groups of re-treatment cases, outcomes are shown in TABLE A3.8 only.
TABLE A3.10 DOTS treatment success and case detection rates, 19942007
The rates of successful treatment (the proportion of registered cases who cured or completed treatment) for new smear
positive cases treated under DOTS from 1994 to 2006 and smear-positive case detection rates under DOTS from 1995 to 2007.
TABLE A3.13 TB case notications, 19802007 TABLE A3.14 TB case notication rates, 19802007 TABLE A3.15 New smear-positive cases notied, 19932007 TABLE A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), 2009 Notes
These notes include data provided to WHO in non-standard formats, additional information reported by countries and other observations.
TABLE A3.11 New smear-positive case notication by age and sex, DOTS and non-DOTS, 2007
The breakdown, by age and sex, of new smear-positive cases notied from the whole country. Some countries cannot provide the breakdown for all notied new smear-positive cases; other countries cannot provide the breakdown for new smearpositive cases alone (see COUNTRY NOTES).
TABLE A3.12 New smear-positive case notication rates by age and sex, DOTS and non-DOTS, 2007
The rates of notication of new smear-positive cases by age and sex (DOTS and non-DOTS cases). Rates are missing where the breakdown of smear-positive notied cases is not provided, or where age-specic and sex-specic population data are not available. In the regional summary table, rates are calculated excluding those countries for which the breakdown of notied cases or population by age and sex is missing.
SUMMARY BY WHO REGION
Table A3.1
Methods of estimates
Methods are presented by country (see regional sections of this annex). There is no regional summary for this table.
Table A3.2
All forms* number rate 2 879 434 294 636 582 767 431 518 3 165 139 1 919 306 9 272 799 139 1 374 048 21 4 062 013 61 484 085 7 13 722 534 206 687 024 10 1 771 733 27 456 218 7 363 32 105 49 181 108 1 080 328 33 356 20 517 42 322 146 042 51 483 136 4 4 5 8 3 1 187 713 157 225 258 877 189 951 1 409 708 858 539 150 17 47 21 81 48 378 115 14 845 7 179 14 813 51 115 18 019 48 2 1 2 3 1 3 766 069 348 043 772 039 455 580 4 880 642 3 500 160 475 38 139 51 280 197 540 164 16 678 10 258 21 161 73 021 25 741 68 2 2 2 4 1 734 891 40 616 104 300 63 765 537 616 290 546 93 4 19 7 31 16 377 535 7 892 7 726 8 096 40 465 14 503 48 <1 1 <1 2 <1 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate
Estimated burden of TB, 1990 and 2007

TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident TB number rate number rate cases, 2007 (%) 38 11 3.5 9.8 4.6 2.7 15 Percentage of new re-treat 2 2 3 10 3 4 3 8 14 27 43 18 24 19 MDR, 2007 Number among All cases Smear-positive 75 657 10 214 23 049 92 554 173 660 135 411 510 545 45 029 7 261 14 120 67 440 124 826 89 926 348 602
Incidence, 1990 All forms* Smear-positive* number rate number rate 232 149 57 395 99 510 43 963 689 251 397 633 29 45 8 26 5 53 26
Prevalence, 1990 All forms* number rate
TB mortality, 1990 All forms* number rate
AFR AMR EMR EUR SEAR WPR
860 042 415 623 419 455 318 540 2 646 286 1 954 134
168 57 110 37 202 129
373 360 223 876 186 491 143 062 1 189 326 878 939
73 31 49 17 91 58
1 654 085 598 017 868 989 439 626 7 242 230 4 842 675
324 82 227 52 554 320
Global
6 614 081
125
2 995 054
57
15 645 621
296
1 519 900
* Incidence, prevalence and mortality estimates include patients with HIV. Estimates labelled "HIV+" are estimates of HIV+ TB cases in all people. Estimates for all years are re-calculated as new information becomes available and techniques are refined, so they may differ from those published previously. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.3
Number of cases 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Estimated incidence of TB (all forms) in all people, 19902007

Rate (per 100 000 population) 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 168 57 110 37 202 129 183 55 109 36 201 127 194 54 110 37 199 126 206 52 109 38 198 124 218 50 109 40 196 123 230 48 109 42 195 121 242 46 109 45 194 120 257 45 108 47 192 119 275 43 107 49 191 118 296 42 107 50 190 116 319 40 107 51 189 115 343 39 106 51 188 114 364 38 106 50 187 113 379 37 106 49 185 112 383 35 105 49 184 111 379 34 105 49 183 110 371 33 105 49 182 109 363 32 105 49 181 108 125 125 126 126 127 128 129 131 132 134 136 138 141 142 142 141 140 139
1990
1991
1992
1993
1994
1995
860 042 962 684 1 049 154 1 144 912 1 244 488 1 354 099 1 457 871 1 593 492 1 747 230 1 926 456 2 135 150 2 347 968 2 557 357 2 725 652 2 824 866 2 863 387 2 870 765 2 879 434 415 623 408 987 401 292 393 343 384 962 376 797 368 617 360 528 352 823 345 176 338 008 330 965 324 415 318 006 311 897 306 017 300 239 294 636 419 455 429 421 442 594 451 118 462 914 473 393 483 201 489 400 497 708 507 006 516 769 525 495 533 979 542 116 550 322 560 010 571 155 582 767 318 540 308 459 314 704 326 181 341 420 363 185 389 505 409 910 428 724 437 374 445 657 445 527 440 916 435 397 432 139 432 704 432 102 431 518 2 646 286 2 679 787 2 713 371 2 746 866 2 780 040 2 812 714 2 844 806 2 876 331 2 907 313 2 937 815 2 967 878 2 997 483 3 026 592 3 055 214 3 083 367 3 111 072 3 138 330 3 165 139 1 954 134 1 953 163 1 952 822 1 949 018 1 949 523 1 948 576 1 949 824 1 950 655 1 949 201 1 944 776 1 942 425 1 939 819 1 940 021 1 934 413 1 930 914 1 927 186 1 923 413 1 919 306
Global
6 614 081 6 742 501 6 873 937 7 011 438 7 163 347 7 328 763 7 493 825 7 680 316 7 883 001 8 098 603 8 345 888 8 587 256 8 823 280 9 010 797 9 133 506 9 200 376 9 236 004 9 272 799
Estimates for all years are re-calculated as new information becomes available and techniques are refined, so they may differ from those published previously. Data can be downloaded from www.who.int/tb
Table A3.4
Prevalence of TB (all forms) 2001 461 50 200 67 390 255 254 248 237 225 217 210 206 480 48 187 63 370 250 497 46 181 62 337 235 501 43 172 60 309 218 500 41 159 55 296 207 487 38 150 52 286 201 475 38 139 51 280 197 41 5 24 7 42 20 24 2002 2003 2004 2005 2006 2007 2000 2001 43 5 23 7 40 20 24
Estimated incidence, prevalence and mortality rates (per 100 000 population), 20002007
Mortality (excluding HIV+) 2002 45 5 22 7 38 19 23 2003 47 4 22 7 35 18 23 2004 47 4 21 7 32 17 22 2005 47 4 20 6 30 16 21 2006 46 4 19 6 29 16 20 2007 45 4 17 6 28 16 20 2000 49 1 1 <1 4 <1 7 2001 52 1 1 <1 4 <1 7 2002 51 <1 1 <1 4 <1 7 Mortality HIV+ 2003 53 <1 1 1 3 <1 7 2004 53 <1 1 1 3 <1 7 2005 53 <1 1 <1 3 <1 7 2006 49 <1 1 <1 2 <1 7 2007 48 <1 1 <1 2 <1 7
Incidence of HIV+ TB cases
2000
2001
2002
2003
2004
2005
2006
2007
2000
123 4 3 2 9 2
133 4 3 2 9 2
142 4 3 3 9 2
148 4 3 4 9 3
149 4 3 4 9 3
145 4 3 4 9 3
141 4 4 5 9 3
136 4 4 5 8 3
436 51 203 68 417 260
Global
17
19
20
21
21
21
21
21
259
Rates are per 100 000 population (total country population, including HIV-positive and HIV-negative people). Estimates for all years are re-calculated as new information becomes available and techniques are refined, so they may differ from those published previously. Data (including for years 1990 to 1999) can be downloaded from www.who.int/tb
Table A3.5
Estimated incidence and case detection rates Estimated incidence Case detection rate all forms ss+ all new new ss+ number number % % ss+ (% of pulm.) 58 69 53 39 61 55 57 46 14 13 45 55 41 30 48 49 18 15 20 15 15 6 10 9 4 32 14 10 2 879 434 294 636 582 767 431 518 3 165 139 1 919 306 9 272 799 4 062 013 57 64 1 187 713 157 225 258 877 189 951 1 409 708 858 539 41 71 63 75 60 68 47 76 60 55 69 78 Proportions . ss+ Extrapulm. Re-treat. (% of (% of (% of new+relapse) new+relapse) new+re-treat.)
Case notifications and case detection rates, DOTS and non-DOTS combined, 2007
Population All notified thousands number 408 964 55 041 136 865 165 777 622 795 548 024 770811 2980 280 105 47 121 112 987 328 674 6 701 2 759 521 223 322 32 564 76 898 53 623 295 866 88 538 1 184 990 0 0 798 8 57 116 9 993 9 560 25 841 115 293 62 302 12 086 1 346 1 638 4 887 23 131 4 033 16 908 4 304 2 652 4 150 80 523 4 450 45 171 5 395 48 118 317 91 082 68 661 792 704 131 416 220 4 438 668 500 125 098 262 337 141 324 930 587 631 675
New and relapse . number rate
Notified TB cases, DOTS and non-DOTS combined New pulmonary New extra- Other Re-treatment cases . New pulm. ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. Other lab. confirm. number rate number number number number number number number number number
792 378 909 820 555 064 889 278 1 745 394 1 776 440
1 326 692 230 175 383 364 478 299 2 202 149 1 446 866
1 251 735 218 426 378 895 350 529 2 007 193 1 365 284
158 24 68 39 115 77
561 149 119 838 155 572 105 288 972 441 666 412
71 13 28 12 56 38
Global
6 668 374
6 067 545
5 572 062
84
2 580 700
39 1 937 466
ss+ indicates sputum smear-positive; ss-, sputum smear-negative; unk., sputum smear result unknown; re-treat., re-treatment; pulm. lab. confirmed, pulmonary case confirmed by positive smear or culture. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.6
. . Other number 792 688 131 57 218 951 2 837 2 723 811 9 272 799 4 062 013 56 63 668 442 119 082 261 551 127 865 930 536 616 335 2 879 434 294 636 582 767 431 518 3 165 139 1 919 306 1 187 713 157 225 258 877 189 951 1 409 708 858 539 41 67 63 69 60 66 47 73 60 51 69 77 58 69 53 39 61 55 57 New pulm. lab. confirm. number ss+ (% of pulm.) Estimated incidence and case detection rate Estimated incidence DOTS case detection rate all forms ss+ all new new ss+ number number % %
DOTS coverage, case notifications and case detection rates, 2007

Proportions . ss+ Extrapulm. Re-treat. (% of (% of (% of new+relapse) new+relapse) new+re-treat.) 45 55 41 30 48 50 47 18 15 20 14 15 6 14 10 9 4 33 14 10 13

408 936 52 053 135 441 154 365 622 776 529 296 749 438 2 976 277 668 46 616 112 332 319 691 223 320 31 389 75 299 45 094 295 857 78 479 1 184 986 0 0 798 8 57 111 9 684 9 559 25 517 115 290 60 507 12 086 1 327 1 638 4 602 23 131 3 832 16 908 4 059 2 652 4 032 80 520 4 161 45 171 5 076 48 113 302 91 082 65 012 Collaborative TB/HIV activities 2006 TB pts HIV-positive 147 406 13 885 275 5 339 21 630 4 043 192 578 144 507 66 670 996 043 296 995 196 933 90 492 137 760 96 58 275 5 220 1 098 53 262 8 997 126 1 184 2 550 551 491 755 113 559 4 160 169 397 121 872 95 300 250 546 14 619 477 6 710 17 964 6 679 186 941 879 102 405 6 660 1 946 76 547 9 259 272 138 3 062 1 214 HIV+ TB pts CPT TB pts HIV-positive HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007 Lab-confirmed DST MDR Re-treatment Re-treatment MDR in new cases in new cases DST MDR 8 772 2 522 486 16 062 918 948 29 708 523 13 061 2 216 76 601 1 649 10 231 104 281 47 532 87 7 351 31 89 8 137 7 043 4 183 938 22 228 1 275 1 596 37 263 709 1 839 377 8 572 287 468 12 252 % Not eval. Success 75 75 86 70 87 92 85 35 108 20 320 5 703 10 509 62 9 799 65 8 970 36 15 153 123 4 662 0 346 Number of cases Notified Regist'd 5 10 1 2 0 1 2 % Not eval. 1 144 198 48 0 4 58 94 26 25 15 4 23 0 46 8 31 3 42 3 4 1 6 6 5 3 0 0 0 1 0 0 10 9 2 2 8 0 3 57 0 2 3 0 10 0 46 82 20 Number Regist'd 94 72 33 46 8 65 98 957 12 282 14 039 51 866 290 910 96 159 564 213 Not eval. 49 37 58 34 47 80 52 17 18 18 7 25 6 18 7 6 4 14 7 3 7 5 3 3 19 4 3 6 11 14 11 12 14 2 11 5 6 5 5 2 5 3 6 16 2 8 0 1 2 Success 66 55 76 42 72 87 70 New smear-positive cases, non-DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTransCured eted Died Failed Default ferred 8 6 6 7 5 1 5 3 4 3 3 3 1 3
DOTS coverage %
TB cases reported from DOTS services New pulmonary New extraOther Re-treatment cases ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. number rate number number number number number number number
93 91 97 75 100 100
1 251 642 208 419 375 857 322 132 2 007 111 1 325 173
158 23 68 36 115 75
561 091 114 307 155 558 97 156 972 390 656 883
71 13 28 11 56 37
Global
94
5 490 334
82
2 557 385
38
1 902 867
Table A3.7
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, 20062007
Laboratory services, 2007
Number of labs working with NTP smear culture DST
Smear labs included in EQA
TB pts tested for HIV
8 547 13 874 4 094 6 744 20 090 7 997
110 1 487 162 2 216 129 463
45 111 36 762 43 224
4 466 9 040 2 158 284 18 372 6 262
285 826 94 578 3 657 191 698 89 418 39 650
Global
61 346
4 567
1 221
40 582
704 827
ART indicates antiretroviral therapy; CPT, co-trimoxazole preventive therapy; DST, drug susceptibility testing; EQA, external quality assurance; HIV+, HIV-positive; pts, patients. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.8
Treatment outcomes, 2006 cohort
Number of cases Notified Regist'd
% of notif regist'd
New smear-positive cases, DOTS % of cohort ComplTransCured eted Died Failed Default ferred
555 361 114 680 131 820 100 102 938 572 662 273
562 884 116 925 132 001 94 262 937 764 663 261
101 102 100 94 100 100
65 55 75 61 84 89
10 20 11 9 4 3
6 4 3 8 4 2
1 1 1 9 2 1
Global
2 502 808
2 507 097
100
78
Not eval. indicates not evaluated (percentage of registered cases for which outcomes were not recorded); success, sum of cured and completed; cases regist'd, the denominator for calculating treatment outcomes. The number of cases registered for treatment in 2006 is used as the denominator for calculating treatment outcomes unless it is less than the sum of outcomes, in which case the sum of outcomes is used. If the number of cases registered is not reported, then the number of cases notified in 2006 is used, or the sum of outcomes if the latter is greater. Data can be downloaded from www.who.int/tb
Table A3.9
After failure, DOTS % of cohort % Success Died 9 7 6 13 8 6 9 14 14 3 3 58 100 832 55 10 8 5 18 3 1 64 8 18 7 22 14 13 13 8 9 10 16 6 5 6 6 3 2 4 3 33 0 15 0 2 62 27 72 37 60 69 9 409 2 699 2 435 6 285 78 994 1 010 56 27 44 27 58 50 18 14 23 9 8 16 5 6 4 15 8 7 4 2 4 17 4 2 7 26 21 19 19 11 6 9 4 5 2 5 5 16 0 8 0 8 74 41 67 36 66 66 Died 66 64 78 54 74 87 74 34 106 49 9 3 798 410 1 322 3 927 23 308 1 341 50 20 50 27 52 58 12 8 22 9 8 11 Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, 2006 cohort
Relapse, DOTS % of cohort
Number regist'd
ComplCured eted
Died
TransFailed Default ferred
Not eval.
AFR AMR EMR EUR SEAR WPR 1
44 530 5 851 8 193 19 893 108 887 60 180
60 50 67 46 67 82
7 14 11 8 7 6
7 5 4 12 7 3
8 3 3 15 5 3
12 9 8 10 12 2
5 5 4 5 2 5
1 14 2 4 0 1
Global
247 534
67
Table A3.10 DOTS treatment success and case detection rates, 19942007
DOTS new smear-positive case detection rate (%)
2003 73 83 83 75 85 91 83 84 85 85 11 16 18 22 25 28 32 37 44 52 58 62 74 82 83 74 87 91 76 78 83 71 87 92 75 75 86 70 87 92 23 26 12 3 1 15 26 26 10 3 4 28 30 29 12 5 5 31 35 33 19 11 8 33 37 36 21 11 14 31 36 43 25 12 18 37 37 42 27 14 26 38 43 45 32 22 33 39 45 49 34 24 44 50 46 57 39 26 55 65 46 62 46 37 62 77 47 72 52 53 67 77 47 73 60 51 69 77 63 2004 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 71 82 83 75 84 93 82 82 73 83 84 76 85 90 2002
DOTS new smear-positive treatment success (%)
1994
1995
1996
1997
1998
1999
2000
59 76 82 68 80 90
62 78 87 69 74 91
57 83 86 72 77 93
63 82 79 72 72 93
70 81 77 76 72 95
69 83 83 77 73 94
72 81 83 77 83 92
Global
77
79
77
79
81
80
82
Treatment success, sum of cured and completed; DOTS new smear-positive case detection rate, notified new smear-positive cases divided by estimated incident cases. Figures for all years are updated as new information becomes available and/or techniques are refined, so they may differ from those published previously. Data can be downloaded from www.who.int/tb
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, 2007
65+ 12 850 7 805 8 472 6 577 56 505 91 686 183 895 28 155 212 311 231 413 164 218 115 452 80 344 72 176 47 554 477 454 10 102 1 719 3 735 353 10 144 2 102 56 594 11 479 18 893 7 100 78 671 39 574 77 008 10 501 15 998 8 888 81 784 37 234 43 857 7 248 12 044 5 975 60 475 34 619 24 129 5 630 9 003 4 444 43 330 28 916 12 281 3 707 6 743 2 469 28 955 26 189 7 431 4 819 5 333 4 813 16 092 33 688 17 755 3 322 5 549 585 16 515 3 828 110 773 26 572 36 706 17 025 186 977 99 401 173 892 26 531 34 748 27 750 214 333 108 791 586 045 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 All 3544 114 887 20 804 26 430 25 447 197 583 119 903 505 054 4554 67 203 17 690 21 449 24 318 166 464 112 114 409 238 5564 32 878 11 488 16 514 11 366 118 021 102 025 292 292 65+ 20 281 12 624 13 805 11 390 72 597 125 374 256 071 Male/female ratio 1.3 1.6 1.2 2.5 2.0 2.3 1.8
014
1524
2534
Male 3544
4554
5564
7 653 1 603 1 814 232 6 371 1 726
54 179 15 093 17 813 9 925 108 306 59 827
96 884 16 030 18 750 18 862 132 549 71 557
71 030 13 556 14 386 19 472 137 108 85 284
43 074 12 060 12 446 19 874 123 134 83 198
20 597 7 781 9 771 8 897 89 066 75 836
Global
19 399
265 143
354 632
340 836
293 786
211 948
For some countries, breakdown of notified cases by age and sex is missing, or is provided for a subset of cases. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, 2007
65+ 117 23 82 13 133 130 84 3 37 46 36 32 6 1 4 0 4 1 70 15 32 11 49 28 137 15 38 14 60 28 119 12 40 9 55 24 94 10 42 7 52 27 74 10 51 5 55 34 33 014 1524 2534 Female 3544 4554 5564 65+ 53 11 47 6 33 41 26 014 5 1 3 0 3 1 3 1524 68 17 31 13 56 34 40 2534 154 19 39 21 77 40 58 All 3544 157 17 43 20 88 40 55 4554 135 16 48 20 98 51 57 5564 106 16 63 12 112 66 60 65+ 81 16 64 9 79 83 52
014
1524
2534
Male 3544
4554
5564
4 1 2 0 2 1
66 20 29 15 63 39
171 23 41 29 92 51
195 22 45 30 120 56
179 23 54 33 141 74
142 22 75 21 170 96
Global
43
68
74
82
89
Rates are per 100 000 population of each age/sex group. Rates are calculated excluding those countries for which breakdown of notified cases or population by age and sex is missing. Data can be downloaded from www.who.int/tb
Table A3.13 TB case notifications, 19802007

1986 1 179 378 235 511 235 943 354 954 1 686 681 1 160 130 4 852 597 202 96 94 96 93 1 186 800 227 599 287 352 365 346 1 789 186 1 274 124 5 130 407 199 1 243 560 224 687 322 306 359 735 1 920 644 1 331 512 5 402 444 203 1 251 735 218 426 378 895 350 529 2 007 193 1 365 284 5 572 062 196 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
1985
AFR AMR EMR EUR SEAR WPR Global Number reporting 93 94 95 93 93 91 89 85 84 91 93 91 94 93 93 92 98 97
219 802 224 102 240 263 258 842 264 928 296 627 301 683 333 842 373 550 365 432 418 530 412 414 432 997 418 995 550 183 504 309 585 773 598 821 689 253 750 086 783 930 861 423 1 004 557 1 079 333 227 697 248 122 237 274 238 465 226 812 227 186 227 206 233 192 241 834 239 594 231 186 252 215 253 255 166 458 241 854 258 188 256 656 254 980 262 886 240 619 238 580 230 403 233 678 228 448 522 110 514 791 433 271 234 482 171 652 186 344 230 427 288 805 280 126 261 441 234 620 315 483 109 087 201 620 119 374 121 745 145 373 136 232 233 878 171 734 141 748 165 904 191 744 207 375 348 921 346 104 324 580 319 220 308 401 298 933 302 602 290 606 277 143 267 232 242 429 231 651 248 519 242 425 243 691 290 031 322 080 353 361 349 795 373 765 373 081 368 433 373 670 358 978 837 901 915 952 1 076 211 1 244 819 1 275 299 1 323 509 1 413 418 1 520 444 1 667 348 1 735 860 1 719 365 1 747 252 1 322 709 1 287 176 1 298 759 1 401 096 1 470 352 1 308 981 1 279 041 1 464 312 1 414 228 1 414 141 1 488 126 1 551 516 356 452 355 337 461 550 462 181 540 985 615 153 651 840 655 006 716 427 741 913 894 073 760 863 754 463 718 783 724 290 824 954 873 425 870 920 834 599 820 469 786 285 805 105 811 482 980 890 2 512 883 2 604 408 2 773 149 2 758 009 2 788 077 2 947 752 3 127 176 3 321 895 3 556 428 3 611 472 3 740 203 3 719 878 3 121 030 3 035 457 3 178 151 3 400 323 3 653 659 3 523 295 3 649 452 3 820 985 3 737 852 3 845 409 4 103 257 4 406 540 195 194 194 196 193 198 197 199 201 197 196 192 187 179 178 191 196 193 199 196 196 195 206 204
% reporting
92
92
92
93
91
94
From 1995 on, number shown is all notified new and relapse cases (DOTS and non-DOTS). Figures for all years are updated as new information becomes available, so they may differ from those published previously. Data can be downloaded from www.who.int/tb
Table A3.14 TB case notification rates, 19802007

1988 78 34 77 33 133 49 70 69 71 69 57 55 56 59 63 60 61 63 61 62 65 69 75 79 82 84 74 33 70 32 135 50 82 32 61 29 131 59 78 34 80 27 131 50 80 34 27 29 97 49 75 22 49 28 93 46 96 31 28 28 92 46 86 33 28 33 97 51 97 32 33 37 100 54 97 32 30 41 88 53 108 32 50 40 84 50 115 29 36 43 95 49 117 28 29 43 90 47 126 27 34 42 89 47 143 27 38 43 92 47 150 26 40 41 94 57 160 27 45 40 101 67 157 26 54 41 105 73 161 25 59 41 112 75 158 24 68 39 115 77 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 71 34 82 35 124 45 66

Number of cases 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 4 <1 <1 <1 <1 20 4 <1 <1 <1 <1 20 5 <1 <1 <1 <1 21 Rate (per 100 000 population) 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 264 659 136 987 58 720 110 614 372 867 388 142 277 591 142 556 57 947 106 700 369 583 416 954 326 831 139 253 74 923 111 772 382 171 379 698 349 142 135 153 69 140 89 199 481 332 383 613 362 527 131 294 60 959 94 275 510 053 376 109 402 431 129 944 69 101 86 239 561 939 371 806 459 983 127 575 76 125 83 455 606 730 372 528 513 029 125 815 81 313 101 657 673 171 453 812 551 031 126 345 94 775 92 233 779 530 579 566 550 001 124 810 113 864 96 101 857 371 671 612 561 064 125 189 131 882 109 901 938 637 671 243 561 149 119 838 155 572 105 288 972 441 666 412 19 13 5 5 23 14 19 21 18 5 10 22 15 19 36 18 11 12 25 20 21 44 17 13 13 25 24 24 45 18 13 12 25 25 24 51 17 16 13 25 23 24 54 16 15 10 31 23 25 54 16 13 11 32 22 25 59 15 14 10 35 22 26 65 15 15 9 37 22 28 71 14 16 12 41 26 31 75 14 18 10 47 33 35 73 14 21 11 51 38 37 73 14 24 12 55 38 39 71 13 28 12 56 38 39 . Global Fund 97 21 28 35 49 70 299 Funding gap 158 44 52 555 70 19 898 Cost of utilization of general health-care services 333 70 25 986 59 261 1 735 Total TB control costs 704 487 176 2907 348 570 5 191 Completeness of budget data 59 39 64 31 91 47 48 46 21 19 9 29 7 129
1980
1981
1982
1983
1984
1985
1986
1987
58 37 184 44 79 27
57 39 176 43 85 27
60 37 144 40 97 34
62 37 75 39 110 34
62 34 53 38 110 39
67 34 56 36 112 44
66 33 67 36 117 46
Global
56
58
60
59
58
61
63
Rates are per 100 000 population. From 1995 on, number shown is notification rate of new and relapse cases. Figures for all years are updated as new information becomes available and/or techniques are refined, so they may differ from those published previously. Data can be downloaded from www.who.int/tb
Table A3.15 New smear-positive cases notified, 19902007
1990
1991
1992
1993
1994
1995
22 654 1 542 1 587
23 067 1 486 1 512
25 840 1 368 2 304
2 769 84
3 023 76
3 218 81
107 012 98 265 20 260 45 771 317 355 222 813
121 005 137 645 20 428 83 568 313 430 241 737
212 910 138 932 46 851 104 444 357 882 314 271
Global
28 636
29 164
32 811
811 476
917 813 1 175 290 1 331 989 1 371 331 1 414 648 1 507 579 1 535 217 1 621 460 1 726 396 1 948 797 2 223 480 2 413 759 2 537 916 2 580 700
Rates are per 100 000 population. Figures for all years are updated as new information becomes available and/or techniques are refined, so they may differ from those published previously. Data can be downloaded from www.who.int/tb
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), 2009
NTP budget
Government (excluding loans)
Loans
Available funding Grants (excluding Global Fund)
371 417 151 1921 289 308
60 180 60 1328 107 202
1 2 0 0 38 11
Global
3 457
1 936
52
Completeness of budget data indicates percentage of countries providing complete financial data. Data can be downloaded from www.who.int/tb
AFRICA
Africa
| NTP MANAGER (OR EQUIVALENT) AND/OR PERSON(S) RESPONSIBLE FOR COMPLETING DATA COLLECTION FORM
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte dIvoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe Soane Alihalassa Maria da Conceio Palma; Celestino Teixeira Grace Kangwagye Nkubito Sary Mathurin Dembl; Tandaogo Saouadogo Donatien Nkurunziza; Damas Ntisigana Tsala Franois Ottou; Adolphe Nkou Bikoe Maria da Luz Lima Oumar Abdelhadi Ongouo hermann; Antoine Ngoulou Jacquemin Kouakou; Aicha Diakite Andr Ndongosieme Mineab Sebhatu Bekele Chaka; Azmera Molla Toung Mve Mdard; Gnevive Angue Nguema Adama Jallow; Kejaw Saidykhan Frank Adae Bonsu Namory Keita; Fod Ciss Joseph Kimagut Sitienei; Hillary Kipruto; Joel Kangangi Llaang Maama; Tseliso Malata Martin Rakotonjanahary; Rarivoson Benjamin Ibrahim Idana; Felix Salaniponi; John Kwanjana Diallo Alimata Naco Sidina Ould Mohamed Ahmed; Mohamed Ould Salem F. Rujeedawa Paula Samogudo; Roberta Pastore; Zaina Cuna Rosalia Indongo Marafa Boulacar; Moumouni Kadi M. Kabir; Osahon Jeremie I. Ogbeiwi Michel Gasana; Evariste Gasana Aleixo Rodrigues de Sousa Pires Mame Bocar Lo; Awa Hlne Diop Foday Dafae; Saffa Kamara Lindiwe Mvusi; Omphemetse Mokgatlhe; Letta Seshoka Themba Dlamini; Thabo Hlophe Fantch Awokou Francis Adatu-Engwau; Joseph Imoko Saidi Egwaga; Emmanuel Nkiligi Nathan Kapata; M. Maboshe Charles Sandy; Nicholas Siziba
This list shows the people named on the data collection form sent to WHO in 2008, not necessarily the current NTP manager. It is intended as an acknowledgement rather than a directory.
Table A3.1
TB/HIV Indirect Indirect Indirect Routine Routine Indirect Routine Indirect Indirect Indirect Indirect Routine Survey Indirect Indirect Indirect Indirect Indirect Survey Indirect Indirect Routine Indirect Indirect Indirect Routine Indirect Indirect Routine Routine Indirect Indirect Indirect Routine Routine Indirect Indirect Indirect Indirect Indirect Indirect Routine Routine Indirect DRS Model DRS DRS Model Model Model Model DRS Model Model Model DRS Model Model Model DRS Model DRS Model DRS Model Model DRS Model DRS Model Model Model Model DRS Model Model Model DRS Model DRS Model DRS DRS DRS Model DRS DRS DRS DRS Model Model Model DRS Model Model Model Model DRS Model Model Model Model Model Model Model DRS Model DRS Model DRS Model Model DRS Model DRS Model Model Model Model DRS Model Model Model DRS Model DRS Model DRS DRS DRS Model DRS Model DRS DRS 0.05 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.05 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 3.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 3.4 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 Source of estimates MDR (new) MDR (re-treat) Cfr ss+ HIVDOTS non-DOTS Duration ss+HIVDOTS non-DOTS Duration ss-HIVDOTS non-DOTS
Methods and assumptions for estimation of TB incidence, prevalence and mortality, Africa
Reference year
Incidence est. based on
Trend
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe
1997 1997 2000 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 2006 1997 1997 1997 1997 1997 1997 2006 2002 1997 1997 1997 1997 1997 1997 1997 1997 2001 1997 1997 1997 1997 1997 1997
ARI Notif. ARI Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Prev. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Mort. Notif. Notif. Notif. Notif. Notif. Notif.
Country notifs, exp. Group, exp. Country notifs, exp. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Country notifs, exp. Group, moving ave. Group, moving ave. Country notifs, exp. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Group, exp. Group, moving ave. Country notifs, moving ave. Group, exp. Country notifs, exp. Country notifs, exp. Group, exp. Country notifs, moving ave. Country notifs, moving ave. Group, exp. Country notifs, exp. Country notifs, moving ave. Country notifs, exp. Group, exp. Country notifs, exp. Group, moving ave. Group, moving ave. Group, exp. Group, moving ave. Group, moving ave. Group, exp. Group, exp. Group, exp. Country notifs, exp. Country notifs, moving ave. Country notifs, moving ave. Group, exp. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave.
indicates no estimate; ARI, annual risk of infection; ave, average; C-ReC., capture re-capture; CDR, case detection rate; DRS, drug resistance survey; exp., exponential; HIV+, HIV-positive; HIV-, HIV-negative; Mort., mortality (vital registration); Notif(s)., notification(s); Prev., disease prevalence survey; ss+, sputum smear-positive; ss-, sputum smear-negative. See Annex 2 (methods) for details. Data can be downloaded from www.who.int/tb
Table A3.2
TB mortality, 1990 All forms* number rate All forms* number rate 19 156 57 48 777 287 8 206 91 13 761 731 33 437 226 31 225 367 35 556 192 798 151 14 985 345 32 203 299 352 42 15 190 403 80 995 420 245 333 392 1 299 256 4 629 95 314 267 378 5 408 406 4 415 258 47 632 203 26 928 287 3 727 220 132 357 353 12 782 637 10 393 277 49 360 251 48 144 346 39 345 319 9 923 318 282 22 92 295 431 15 905 767 24 802 174 460 149 311 38 606 397 159 101 33 613 272 28 32 33 662 574 460 600 948 13 674 1 198 28 263 429 101 785 330 120 291 297 60 337 506 104 400 782 2 879 434 363 1 080 328 136 1 187 713 150 378 115 48 3 766 069 475 540 164 68 734 891 93 377 535 48 38 1.8 8.1 75 657 429 9 089 1 296 9 414 8 193 6 187 15 349 6 318 8 837 3 4 596 31 423 14 431 373 739 61 094 2 257 506 7 409 5 200 755 63 345 9 653 2 025 1 196 32 791 6 840 1 065 18 43 676 10 695 2 324 123 356 14 469 4 203 6 700 335 598 10 980 7 970 39 377 56 233 41 954 71 961 1 53 14 500 55 73 83 145 82 <1 122 163 23 74 15 74 170 30 32 55 45 169 481 54 6 235 55 34 1 204 516 16 83 149 34 114 691 962 121 128 139 352 539 8 577 21 041 3 563 5 251 14 227 13 432 14 465 359 6 111 13 608 158 6 376 33 306 108 957 547 2 009 135 311 2 208 1 936 20 694 11 598 1 602 53 226 4 787 4 474 22 092 18 386 17 021 4 359 125 37 165 6 088 10 928 194 731 15 926 72 14 706 13 14 478 173 710 5 055 11 921 41 865 48 508 22 956 39 784 25 124 39 279 96 158 78 68 141 126 19 169 173 174 108 41 163 166 113 88 124 94 142 238 119 112 132 138 140 10 174 294 77 131 164 45 119 15 247 358 443 181 136 120 193 298 150 3 181 454 3 295 2 868 2 166 5 372 2 211 3 093 <1 1 609 10 998 5 051 131 259 21 383 790 177 2 593 1 820 264 22 171 3 379 709 419 11 477 2 394 373 6 15 287 3 743 813 43 175 5 064 1 471 2 345 117 459 3 843 2 789 13 782 19 681 14 684 25 186 <1 19 5 175 19 25 29 51 29 <1 43 57 8 26 5 26 59 10 11 19 16 59 168 19 2 82 19 12 <1 71 180 6 29 52 12 40 242 337 42 45 49 123 189 18 942 50 105 12 222 11 707 59 514 55 040 36 088 1 487 18 464 53 618 696 18 287 112 028 417 066 2 382 6 495 481 175 5 045 6 908 82 928 41 944 4 678 119 842 11 410 14 918 82 137 42 447 73 931 17 471 494 107 752 11 038 41 543 771 507 57 390 378 57 939 48 55 169 335 911 9 266 49 358 131 636 136 253 46 115 95 298 56 294 135 622 403 647 195 280 425 497 83 485 582 666 469 134 579 379 404 353 448 276 319 568 398 417 305 599 559 39 504 532 292 521 590 240 468 55 941 692 812 750 426 337 387 714 215 4 544 648 4 707 4 096 3 094 7 675 3 159 4 419 1 2 298 15 712 7 216 187 369 30 547 1 129 253 3 705 2 600 377 31 672 4 827 1 013 598 16 396 3 420 533 9 21 838 5 347 1 162 61 678 7 235 2 101 3 350 167 799 5 490 3 985 19 688 28 116 20 977 35 980 <1 27 7 250 28 36 41 73 41 <1 61 82 12 37 8 37 85 15 16 28 22 84 240 27 3 118 28 17 <1 102 258 8 42 74 17 57 345 481 61 64 70 176 270 700 5 684 1 643 3 649 10 210 8 685 7 159 166 4 330 9 690 54 3 405 24 722 51 102 442 793 76 421 1 011 936 12 138 6 527 747 24 435 5 282 2 325 9 371 14 167 11 142 2 353 48 27 200 2 124 5 443 137 845 12 403 42 7 982 4 8 715 111 924 3 619 9 058 28 686 31 504 13 661 35 343 2 33 18 194 69 102 39 31 100 90 6 90 128 82 87 16 92 76 55 52 70 44 65 263 62 48 102 90 75 4 127 102 38 93 128 26 64 5 149 230 317 138 93 78 115 265 21 1 926 519 2 945 4 105 2 923 4 434 2 681 4 178 <1 1 501 14 088 6 000 200 144 23 275 542 202 3 337 2 204 244 14 588 4 542 796 483 11 293 3 412 466 6 17 480 1 518 968 58 974 6 829 1 863 2 943 93 702 3 160 4 071 16 110 19 826 10 624 28 409 <1 11 6 157 28 34 24 62 39 <1 40 73 10 39 3 28 41 12 14 24 14 39 226 21 2 81 28 15 <1 82 73 7 40 70 15 50 193 277 62 52 49 89 213 2.2 19 16 68 25 20 43 42 27 0.8 30 39 5.9 29 16 19 42 11 16 19 20 48 76 19 2.4 68 17 11 6.5 47 67 9.4 27 37 13 20 73 80 28 39 47 70 69 1.2 1.8 0.3 0.8 2.1 2.3 1.7 1.6 1.1 1.9 1.8 1.6 2.5 2.3 2.2 1.6 1.4 0.5 1.9 0.6 2.3 1.9 0.9 0.5 2.3 2.0 1.3 3.5 1.6 2.2 1.8 3.9 2.1 1.4 0.9 1.8 0.9 2.0 0.5 1.1 1.8 1.9 10 9.2 10 10 13 9.4 8.3 11 18 10 12 8.8 8.7 10 9.4 12 8.2 < 0.05 10 28 9.2 7.9 5.7 3.9 7.5 11 10 3.3 8.0 10 9.4 9.4 17 10 23 6.7 9.1 10 4.4 7.9 2.3 8.3 287 1 919 102 208 1 196 820 825 23 422 869 8 302 2 427 7 336 123 5 979 118 21 1 121 677 112 3 532 208 407 1 555 1 162 5 3 394 425 791 11 700 1 818 1 250 <1 619 15 914 226 757 805 2 079 1 249 2 863 Percentage of new re-treat 542 6 296 771 624 2 849 2 441 2 944 176 1 404 1 889 77 1 068 6 171 13 311 65 633 20 331 420 366 9 242 1 692 405 5 957 446 1 226 4 615 5 829 5 671 1 219 50 4 979 1 188 2 792 33 147 4 917 44 3 326 6 2 173 28 592 684 3 475 12 333 10 825 10 228 14 710 232 149 45 2 60 15 46 32 43 24 50 47 31 15 44 48 35 19 20 40 46 38 59 28 40 25 28 57 38 62 74 63 5 37 84 36 35 67 38 42 9 53 78 79 88 69 42 126 140 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident number rate number rate TB cases (%)
Estimated burden of TB, Africa, 1990 and 2007

MDR, 2007 Number among all cases smear-positive 164 1 416 88 136 793 402 457 16 326 507 5 161 1 235 4 137 67 3 086 74 9 619 591 64 2 016 136 273 872 717 3 1 464 270 487 6 934 934 852 <1 455 10 708 148 423 485 1 301 577 1 620 45 029
Incidence, 1990 All forms* Smear-positive* number rate number rate
9 490 21 634 3 963 4 201 8 429 8 776 9 856 623 4 360 7 671 450 4 102 22 577 62 433 365 2 272 81 263 1 408 1 783 34 713 7 197 1 602 26 256 2 945 4 244 21 339 24 371 21 082 4 429 293 24 543 4 566 9 775 123 296 12 165 157 15 368 31 8 454 109 968 2 310 12 185 29 080 45 408 24 152 34 456
38 205 77 307 95 154 81 175 145 125 85 169 177 165 108 72 159 153 185 223 119 158 112 184 199 177 258 275 228 28 181 322 125 131 167 135 195 43 207 301 267 308 163 178 297 329
4 270 9 676 1 777 1 795 3 577 3 815 4 345 280 1 896 3 407 202 1 702 9 671 27 715 161 1 019 36 004 623 802 15 606 3 220 718 10 783 1 305 1 889 9 602 10 400 9 439 1 993 132 10 853 2 006 4 389 54 646 4 738 71 6 903 14 3 786 48 592 1 019 5 404 11 366 18 727 9 590 13 433
17 92 34 131 40 67 35 79 63 56 38 70 76 73 47 32 70 68 83 100 53 71 46 81 88 80 110 123 102 12 80 142 56 58 65 61 87 20 93 133 118 136 64 73 118 128
11 253 54 122 7 250 4 704 15 915 16 413 23 039 1 595 9 558 15 369 990 5 053 37 280 104 481 573 7 750 159 563 3 294 3 372 82 975 14 558 4 103 29 421 3 596 10 177 44 200 35 906 49 098 11 371 562 38 910 9 208 24 805 265 948 13 856 402 29 972 81 18 995 281 228 5 438 27 797 36 793 54 774 35 402 42 936
45 514 140 344 179 288 188 449 318 251 188 209 292 275 169 245 312 359 350 533 241 404 125 225 476 367 380 640 585 53 287 650 317 282 190 346 380 113 465 769 629 702 206 215 436 409
AFR
860 042
168
373 360
73
1 654 085
324
Indicates no estimate. * Incidence, prevalence and mortality estimates include patients with HIV. Estimates labelled "HIV+" are estimates of HIV+ TB cases in all people. Estimates for all years are re-calculated as new information becomes available and techniques are refined, so they may differ from those published previously. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.3
Number of cases 1995 12 477 29 205 5 211 7 506 15 309 14 840 17 697 683 7 818 14 130 415 7 416 41 525 116 648 641 2 596 150 439 1 798 2 505 39 538 12 259 2 173 72 749 6 350 5 098 28 801 40 183 25 986 5 861 292 45 370 8 368 13 529 222 998 14 920 159 20 356 30 12 371 140 876 3 896 16 163 68 811 89 157 52 618 60 101 168 183 194 206 218 230 242 257 275 296 319 343 364 379 383 12 985 30 510 5 426 8 235 16 911 16 093 19 469 692 8 600 15 676 410 8 188 45 838 127 996 705 2 700 166 228 1 934 2 648 40 282 13 229 2 279 87 461 7 315 5 642 30 289 42 543 26 920 6 148 292 50 052 9 234 14 306 246 072 17 368 159 21 316 30 13 276 155 500 4 736 17 099 72 157 96 910 56 070 65 566 13 498 31 845 5 644 9 059 18 765 17 539 21 500 702 9 488 17 478 404 9 077 50 745 140 811 779 2 824 184 301 2 270 2 799 41 013 14 233 2 388 102 240 8 411 6 269 31 852 45 061 27 896 6 451 291 55 355 10 220 15 129 272 605 20 647 159 22 318 30 14 322 178 852 5 688 18 109 75 857 102 366 58 229 71 713 14 026 33 261 5 874 9 998 20 947 19 283 23 861 712 10 505 19 609 399 10 107 56 358 155 849 865 2 968 205 283 2 434 2 956 41 744 15 289 2 503 116 314 9 635 6 885 33 487 47 100 28 924 6 770 291 61 506 11 343 15 996 303 464 24 435 160 23 367 30 15 563 214 159 7 181 19 158 77 621 107 855 61 680 78 701 14 577 34 798 6 118 11 071 23 529 21 427 26 620 722 11 673 22 141 393 11 305 62 772 173 837 965 3 130 229 766 3 008 3 118 42 483 16 412 2 627 126 537 10 428 7 420 35 194 49 371 30 013 7 107 290 68 716 12 619 16 909 339 454 28 421 160 24 465 30 17 045 261 399 8 481 20 218 83 984 114 827 62 905 86 666 15 152 36 475 6 379 12 141 26 256 23 763 29 473 733 12 849 24 839 388 12 538 69 211 192 965 1 068 3 311 255 109 3 265 3 287 43 234 17 612 2 760 130 816 11 008 7 838 36 974 49 500 31 165 7 463 289 76 205 13 888 17 868 376 658 32 063 160 25 613 29 18 828 314 405 9 848 21 280 91 598 120 263 66 869 94 532 15 753 38 285 6 656 13 134 28 976 26 172 32 244 744 13 954 27 557 382 13 732 75 260 212 141 1 168 3 512 279 806 3 503 3 461 43 991 18 891 2 902 137 823 11 836 8 159 38 829 51 006 32 381 7 837 288 83 498 15 067 18 876 412 846 35 189 160 26 815 29 20 931 363 260 10 827 22 351 101 471 125 247 68 666 101 741 16 380 40 216 6 947 13 852 31 214 28 240 34 417 755 14 778 29 829 376 14 667 79 773 227 995 1 247 3 729 299 420 3 539 3 641 44 748 20 261 3 053 147 257 12 378 8 434 40 762 51 573 33 659 8 228 287 89 238 15 925 19 937 441 419 37 326 160 28 068 29 23 303 401 071 11 856 23 441 107 400 125 842 72 207 106 774 17 033 42 241 7 249 14 149 32 560 29 595 35 569 766 15 165 31 235 370 15 165 81 909 237 622 1 290 3 953 310 363 3 760 3 827 45 495 21 736 3 211 152 921 12 639 8 750 42 779 52 209 34 996 8 633 286 92 311 16 296 21 056 457 037 38 304 160 29 375 29 25 836 426 935 12 552 24 569 107 802 126 389 70 164 108 574 17 712 44 344 7 559 14 142 33 190 30 377 35 927 777 15 233 31 920 364 15 327 82 309 242 326 1 305 4 178 314 615 4 192 4 018 46 226 23 330 3 376 144 631 12 658 9 172 44 882 51 713 36 389 9 051 285 93 283 16 312 22 237 462 603 38 610 160 30 734 29 28 431 443 505 12 830 25 747 107 001 124 868 67 445 108 066 18 420 46 518 7 878 13 952 33 338 30 793 35 766 788 15 108 32 102 358 15 268 81 652 243 855 1 302 4 402 314 563 4 793 4 214 46 937 25 056 3 548 135 441 12 724 9 726 47 076 49 990 37 838 9 481 284 92 868 16 111 23 485 461 640 38 573 159 32 146 28 31 035 453 929 13 257 26 979 104 528 122 692 63 960 106 206 19 156 48 777 8 206 13 761 33 437 31 225 35 556 798 14 985 32 203 352 15 190 80 995 245 333 1 299 4 629 314 267 5 408 4 415 47 632 26 928 3 727 132 357 12 782 10 393 49 360 48 144 39 345 9 923 282 92 295 15 905 24 802 460 149 38 606 159 33 613 28 33 662 460 600 13 674 28 263 101 785 120 291 60 337 104 400 38 205 77 307 95 154 81 175 145 125 85 169 177 165 108 72 159 153 185 223 119 158 112 184 199 177 258 275 228 28 181 322 125 131 167 135 195 43 207 301 267 308 163 178 297 329 38 209 77 341 105 171 89 174 161 139 82 188 196 182 119 73 176 150 189 222 126 161 114 201 203 181 286 277 232 27 201 357 127 145 185 133 198 43 220 301 266 314 250 196 349 364 39 214 78 364 112 182 95 172 172 149 79 200 209 195 127 74 188 148 193 220 132 164 135 218 207 185 314 280 237 27 214 381 130 155 197 131 202 42 233 302 260 320 272 213 411 389 40 218 79 390 120 196 102 171 184 159 75 215 224 209 136 76 201 151 196 219 139 167 160 244 211 189 343 282 241 27 230 409 133 166 212 129 206 41 248 305 267 326 296 229 460 417 41 222 80 415 128 208 109 169 196 170 72 229 239 222 145 77 215 156 200 218 147 170 192 280 215 192 373 285 246 26 245 435 135 176 225 126 211 40 263 309 293 333 306 249 501 444 42 226 80 444 137 223 116 168 209 181 69 245 255 238 155 78 229 151 204 217 154 174 224 323 219 196 390 287 251 26 262 465 138 188 241 124 215 40 279 317 337 339 319 271 536 474 43 231 81 468 145 235 123 166 221 191 67 258 269 251 164 79 242 166 208 216 163 177 258 362 223 200 389 290 256 26 276 491 141 199 254 122 219 39 297 332 398 346 314 290 554 501 44 236 82 503 155 252 132 165 237 205 64 277 289 269 176 81 260 174 212 214 171 181 302 409 228 205 401 292 261 25 297 527 143 214 273 120 223 38 315 360 474 353 320 308 576 538 46 240 83 542 168 272 142 163 256 221 61 299 312 290 190 82 280 200 217 213 180 184 344 461 232 209 412 295 266 25 320 568 146 230 294 118 228 38 334 406 558 360 326 317 583 580 47 245 84 588 182 295 154 162 277 240 59 324 338 315 206 84 304 210 221 212 190 188 382 519 237 213 417 297 272 25 347 616 149 250 319 116 232 37 355 479 691 367 324 327 603 628 48 250 85 640 198 321 168 160 302 262 56 353 368 343 224 85 331 254 225 211 200 192 405 553 242 217 425 300 277 24 378 671 152 272 348 114 237 37 377 576 801 374 340 339 602 685 49 255 86 692 214 347 181 159 327 283 54 382 398 371 242 86 358 271 230 210 211 195 408 576 246 222 414 303 282 24 408 726 155 294 376 112 241 36 400 683 916 382 360 346 627 740 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, Africa, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 50 51 53 54 55 57 260 265 270 276 281 287 86 87 88 89 90 91 740 772 780 770 751 731 229 239 241 238 232 226 371 387 391 387 377 367 194 202 204 202 197 192 157 156 155 153 152 151 349 364 368 363 354 345 302 315 318 315 307 299 52 50 48 46 44 42 408 425 430 425 414 403 425 444 448 443 432 420 396 413 417 413 402 392 259 270 273 270 263 256 88 89 91 92 94 95 383 399 403 398 388 378 285 283 296 325 366 406 234 239 244 248 253 258 209 207 206 205 204 203 222 234 246 259 273 287 199 203 207 211 216 220 419 436 441 406 371 353 613 635 643 639 638 637 251 256 261 266 272 277 226 231 236 241 246 251 416 410 405 391 368 346 305 308 311 313 316 319 288 294 300 305 312 318 24 24 23 23 23 22 436 455 460 454 443 431 776 809 817 808 787 767 158 161 164 168 171 174 314 328 331 327 319 311 402 419 423 418 408 397 110 108 106 105 103 101 246 251 256 261 266 272 35 35 34 33 33 32 425 451 479 509 540 574 780 852 898 925 940 948 994 1 075 1 127 1 141 1 169 1 198 389 397 405 413 421 429 386 396 385 370 350 330 352 344 337 325 311 297 632 652 623 588 547 506 791 825 834 824 803 782 379 371 363
1990
1991
1992
1993
1994
9 490 21 634 3 963 4 201 8 429 8 776 9 856 623 4 360 7 671 450 4 102 22 577 62 433 365 2 272 81 263 1 408 1 783 34 713 7 197 1 602 26 256 2 945 4 244 21 339 24 371 21 082 4 429 293 24 543 4 566 9 775 123 296 12 165 157 15 368 31 8 454 109 968 2 310 12 185 29 080 45 408 24 152 34 456
9 963 22 741 4 151 4 793 9 618 9 954 11 246 633 4 963 8 772 444 4 678 25 902 71 788 413 2 326 93 143 1 415 1 888 35 517 7 881 1 685 27 619 3 263 4 266 22 422 27 638 21 815 4 636 292 27 849 5 250 10 302 140 688 13 027 158 16 123 31 9 060 112 946 2 365 12 759 46 176 51 686 29 138 39 260
10 453 23 955 4 353 5 267 10 579 10 855 12 357 642 5 450 9 664 438 5 141 28 590 79 668 452 2 367 102 890 1 443 1 999 36 338 8 651 1 774 33 698 3 582 4 279 23 565 30 744 22 584 4 855 292 30 713 5 794 10 867 154 662 13 041 158 16 903 31 9 645 116 386 2 361 13 332 52 113 57 990 35 224 43 010
10 955 25 249 4 565 5 801 11 674 11 847 13 614 652 6 007 10 681 432 5 668 31 619 88 656 496 2 404 113 990 1 508 2 115 37 164 9 495 1 870 41 289 4 072 4 322 24 772 33 822 23 386 5 086 292 34 146 6 396 11 470 170 544 12 918 158 17 713 31 10 232 120 397 2 470 13 928 58 808 64 563 40 464 47 172
11 462 26 574 4 781 6 347 12 813 12 831 14 908 663 6 583 11 748 427 6 216 34 745 97 836 542 2 449 125 506 1 605 2 238 37 978 10 389 1 969 50 997 4 751 4 448 26 045 37 049 24 221 5 331 293 37 760 7 014 12 114 187 013 12 945 159 18 556 30 10 860 125 241 2 755 14 582 62 850 72 318 45 189 51 360
11 970 27 898 4 997 6 948 14 091 13 896 16 346 673 7 221 12 958 421 6 830 38 224 107 722 593 2 512 138 315 1 597 2 368 38 771 11 314 2 070 61 306 5 570 4 696 27 386 39 378 25 087 5 589 293 41 715 7 707 12 799 205 460 13 592 159 19 436 30 11 568 131 598 3 230 15 322 67 739 81 159 49 605 55 937
AFR
860 042
962 684 1 049 154 1 144 912 1 244 488 1 354 099 1 457 871 1 593 492 1 747 230 1 926 456 2 135 150 2 347 968 2 557 357 2 725 652 2 824 866 2 863 387 2 870 765 2 879 434
Table A3.4
Prevalence of TB (all forms) 2000 48 530 128 445 338 455 228 380 485 420 112 313 472 592 274 114 486 434 491 368 332 273 393 356 435 359 362 571 619 39 499 481 278 489 442 272 420 52 675 515 740 656 364 391 658 479 436 461 480 497 501 500 487 475 41 43 45 47 47 47 46 45 49 52 51 53 53 53 49 48 49 335 129 497 368 522 241 283 495 450 103 354 571 643 441 111 539 249 499 358 346 276 384 370 437 371 350 573 624 42 535 506 280 526 503 266 430 53 696 581 832 669 367 411 680 523 50 307 137 535 398 581 240 374 468 502 104 402 561 697 470 118 569 302 335 359 363 305 392 399 382 382 358 572 632 40 556 544 288 563 549 261 443 42 743 586 693 701 383 447 517 571 51 281 139 586 419 619 227 370 566 573 107 509 590 708 490 110 601 299 343 358 380 296 402 408 429 375 353 578 642 39 569 560 275 575 581 266 441 66 784 649 739 693 380 476 478 632 52 318 134 598 426 639 228 367 574 548 99 477 604 710 370 122 613 288 341 359 391 287 410 414 370 384 346 584 494 38 567 572 287 573 607 255 454 52 830 676 776 702 373 472 468 652 53 331 135 599 421 654 213 278 507 518 91 482 613 702 366 127 612 332 366 357 425 283 388 421 416 408 342 589 565 39 551 570 285 563 607 256 456 57 866 707 788 713 364 469 453 680 55 302 134 621 411 657 201 285 437 505 86 511 597 692 358 133 604 358 399 355 426 270 340 408 393 400 324 593 556 39 528 556 289 543 595 252 461 56 902 690 801 726 353 450 422 699 56 294 135 622 403 647 195 280 425 497 83 485 582 666 469 134 579 379 404 353 448 276 319 568 398 417 305 599 559 39 504 532 292 521 590 240 468 55 941 692 812 750 337 426 387 714 2 57 12 22 34 46 20 42 47 43 8 21 42 65 22 12 53 38 53 38 35 30 29 16 46 39 23 61 67 3 47 27 30 50 39 30 45 5 71 30 45 66 30 34 47 26 2 36 12 26 37 53 21 32 48 46 8 29 52 70 45 11 59 20 54 38 36 30 29 17 46 40 23 61 68 4 50 26 30 54 46 29 46 5 74 35 50 68 30 37 50 28 2 23 13 28 40 60 21 41 43 51 8 31 51 76 48 12 62 28 37 38 38 32 30 20 40 42 24 60 68 4 51 30 31 57 50 29 48 4 78 33 36 71 32 41 34 32 2 21 13 33 42 64 19 41 54 58 8 51 54 77 50 11 66 26 38 38 39 31 31 19 46 41 23 61 69 3 52 26 30 59 54 27 47 5 82 36 38 70 32 44 30 38 2 25 13 35 43 66 19 40 55 56 7 49 56 77 35 12 67 23 38 38 41 27 32 16 39 42 23 61 54 3 51 32 31 58 57 28 48 4 86 37 40 71 32 44 30 41 2 26 13 35 43 68 16 32 47 53 7 51 57 76 35 13 67 32 40 38 43 29 32 18 43 44 23 62 61 3 50 32 31 58 58 27 49 5 90 39 40 72 31 44 30 45 2 22 12 37 42 69 16 32 39 52 7 53 56 75 34 13 66 34 42 37 44 29 28 18 40 43 22 62 60 3 48 32 31 55 57 26 49 5 94 38 41 73 30 43 28 48 2 22 12 37 41 68 15 31 38 51 6 51 55 72 48 13 64 35 43 37 46 30 26 37 41 45 21 63 60 3 45 29 31 53 57 26 49 5 98 38 40 76 29 41 25 52 <1 18 5 62 29 41 36 <1 66 30 <1 22 83 8 22 2 26 48 12 17 12 13 84 60 19 1 102 24 11 <1 64 60 5 36 78 <1 5 <1 26 153 317 56 59 69 208 159 <1 12 6 80 32 45 38 <1 68 33 <1 28 99 9 38 2 29 23 13 16 13 13 76 63 19 2 96 25 13 <1 74 57 6 39 84 <1 6 <1 29 178 365 57 58 67 224 168 <1 11 6 94 33 46 37 <1 67 39 <1 35 94 10 41 2 30 36 9 16 15 16 73 72 17 2 99 26 15 <1 81 69 6 43 87 <1 7 <1 33 161 201 59 60 69 122 184 <1 9 6 121 34 46 34 <1 80 45 <1 48 94 10 43 2 31 37 9 16 17 16 69 70 19 2 96 27 16 <1 87 71 6 44 87 <1 8 <1 37 191 202 59 59 70 108 215 <1 12 6 127 33 43 33 <1 82 43 <1 42 91 10 34 3 31 34 9 15 19 15 65 77 17 2 93 27 12 <1 89 77 7 44 85 <1 10 <1 42 196 237 59 57 66 107 212 <1 13 6 130 31 41 28 <1 72 40 <1 40 88 10 33 3 30 40 10 15 21 16 59 97 20 2 93 27 15 <1 88 86 7 43 80 <1 11 <1 45 210 268 59 55 63 108 218 <1 7 6 152 29 38 26 <1 63 39 <1 43 80 10 32 3 30 40 12 15 22 14 45 67 20 2 87 28 15 <1 86 91 7 42 73 <1 13 <1 47 194 282 60 52 57 100 220 <1 11 6 157 28 34 24 <1 62 39 <1 40 73 10 39 3 28 41 12 14 24 14 39 226 21 2 81 28 15 <1 82 73 7 40 70 <1 15 <1 50 193 277 62 49 52 89 213 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) Mortality HIV+
Estimated incidence, prevalence and mortality rates (per 100 000 population), Africa, 20002007
2000
2001
2002
2003
2004
2005
2006
2007
<1 34 13 439 58 101 77 124 66 <1 127 179 20 65 12 70 94 23 36 27 35 240 416 40 3 297 49 20 <1 149 417 12 70 170 11 56 394 625 108 171 168 418 541
<1 37 13 478 62 103 83 136 74 <1 133 190 21 71 13 75 104 25 36 31 38 235 434 41 4 289 51 24 <1 170 461 13 77 177 14 64 479 722 110 173 171 435 580
<1 41 14 512 65 104 88 146 81 <1 138 199 23 77 13 79 112 26 35 35 40 235 462 42 4 289 53 27 <1 189 501 14 83 182 16 72 555 789 112 173 178 438 612
<1 44 14 534 66 102 91 153 85 <1 140 202 24 80 13 81 114 27 34 39 41 236 479 44 5 284 54 29 <1 203 528 15 88 182 19 81 613 857 114 168 176 452 629
1 47 14 538 65 96 91 155 87 <1 138 197 24 81 14 81 121 28 33 43 42 230 486 45 5 279 54 31 <1 210 538 15 89 177 22 90 650 901 116 162 165 431 623
1 49 14 530 62 89 89 153 86 <1 133 187 24 79 14 79 134 28 33 47 43 205 483 48 6 268 55 32 1 211 535 16 88 167 26 98 673 914 117 155 153 407 602
1 51 14 515 58 80 86 149 84 <1 128 175 24 76 15 76 152 29 32 52 44 182 482 50 6 252 55 33 1 208 524 16 86 157 30 106 685 938 119 147 139 379 571
1 53 14 500 55 73 83 145 82 <1 122 163 23 74 15 74 170 30 32 55 45 169 481 54 6 235 55 34 1 204 516 16 83 149 34 114 691 962 121 139 128 352 539
AFR
123
133
142
148
149
145
141
136
Table A3.5
Estimated incidence and case detection rates Estimated incidence Case detection rate all forms ss+ all new new ss+ number number % % 109 80 98 102 82 59 39 52 49 7 3 8 Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
Case notifications and case detection rates, DOTS and non-DOTS combined, Africa, 2007
Population All notified thousands number 1 807 14 733 3 092 577 826 6 752 63 0 0 0 0 2 513 0 0 485 76 0 0 52 0 0 5 159 177 84 1 753 0 0 0 0 0 0 1 686 0 0 0 0 41 945 904 80 17 72 16 43 47 0 0 0 0 0 0 3 743 81 540 1 462 1 238 8 110 7 366 76 40 67 42 26 34 35 28 66 64 36 53 25 47 47 70 66 84 19 30 39 65 58 66 36 34 0 0 548 3 552 14 071 66 099 58 27 39 56 42 61 55 82 86 39 61 66 25 22 19 21 35 11 5 9 18 17 23 18 18 51 43 15 6 4 6 6 6 2 9 7 5 7 9 12 2 378 2 938 3 009 10 968 2 086 43 500 1 678 541 3 759 1 167 49 869 904 1 321 10 704 391 494 12 13 064 4 948 1 676 32 088 1 589 28 1 620 0 0 40 3 433 204 23 0 0 0 0 0 0 0 0 0 0 1184 57 116 12 086 16 908 45 171 792 92 109 12 0 0 207 595 596 27 810 477 0 703 2 422 3 391 529 668 500 168 28 342 335 73 1 433 1 804 1 738 1 349 165 7 061 67 34 5 347 135 604 2 764 1 797 21 303 45 041 15 820 10 583 3 197 105 631 3 956 211 13 713 20 521 21 189 21 964 408 964 223322 706 45 738 1 833 356 4 460 12 526 10 015 6 381 27 62 63 8 39 48 74 37 2 879 434 1 187 713 41 3 973 5 195 674 603 4 5 020 2 681 1 349 4 044 1 663 2 1 109 0 0 0 0 0 0 1 055 0 0 1 219 954 207 158 4 1 353 1 430 478 2 269 333 5 460 165 60 145 14 0 205 139 128 835 115 0 130 335 25 71 42 2 188 188 188 1 303 30 0 253 0 0 13 0 0 0 0 0 0 231 0 0 15 344 7 608 3 894 1 714 86 18 214 5 091 5 773 76 104 4 053 58 7 108 42 49 13 28 36 39 87 35 17 19 55 29 69 41 23 39 69 49 84 53 23 25 81 48 37 78 55 15 51 51 58 27 47 18 032 529 0 0 177 98 3 285 13 1 841 12 753 45 269 409 91 1 092 1 708 0 0 52 0 0 0 108 2 035 165 46 463 337 11 262 9 19 127 145 15 637 168 23 91 170 2 282 4 988 18 737 0 0 230 965 4 006 31 235 1 000 88 115 921 907 81 217 104 1 305 513 1 697 3 152 39 0 77 0 0 0 223 179 166 938 14 40 193 34 110 3 129 39 25 417 15 305 51 0 0 0 3 002 2 614 3 595 13 220 190 54 11 20 65 33 57 18 27 91 44 49 82 81 66 71 39 66 57 55 58 17 13 27 13 14 9 11 4 6 11 10 576 2 911 0 547 2 226 57 446 103 645 11 0 8 608 21 422
Notified TB cases, DOTS and non-DOTS combined New pulmonary New extraOther Re-treatment cases . New pulm. ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. Other lab. confirm. number rate number number number number number number number number number
21 540 42 383
21 369 41 292
63 243
8 439 21 422
25 126
8 096 4 243 6 343 24 589 292 23
7 622 3 960 6 284 24 062 274
405 27 74 130 52
3 002 2 614 3 595 13 220 158
160 18 42 71 30
6 200
5 879
55
2 513
9 121 23 383 102 764
9 002 23 033 99 810
239 120 159
3 552 14 071 66 099
94 73 106

92 42 91 78 88 58 51 78 58 72 67 81 63 56 41 89 61 54 39 33 58 70 31 75 58 81 48 33 62 53 53 62 69 57 43 31 74 52 41 29 26 45 18 21 13 20 4 13 18 15 5 22 2 11 7 15 21 15 11 21 22 16 18 8 11 8 7 6 5 11 8 7 6 5 8 4 19 11 5 5 7 12 6 10 19 156 48 777 8 206 13 761 33 437 31 225 35 556 798 14 985 32 203 352 15 190 80 995 245 333 1 299 4 629 314 267 5 408 4 415 47 632 26 928 3 727 132 357 12 782 10 393 49 360 48 144 39 345 9 923 282 92 295 15 905 24 802 460 149 38 606 159 33 613 28 33 662 460 600 13 674 28 263 101 785 120 291 60 337 104 400 8 577 21 041 3 563 5 251 14 227 13 432 14 465 359 6 111 13 608 158 6 376 33 306 108 957 547 2 009 135 311 2 208 1 936 20 694 11 598 1 602 53 226 4 787 4 474 22 092 18 386 17 021 4 359 125 37 165 6 088 10 928 194 731 15 926 72 14 706 13 14 478 173 710 5 055 11 921 41 865 48 508 22 956 39 784 71
3 743 129 743 3 943 2 010 12 961 9 726
3 641 128 844 3 766 1 916 12 743 9 411
75 155 283 112 54 100
694 38 040 1 462 1 238 7 429 6 199
14 46 110 72 32 66
116 723 2 521
106 438 2 319
284 115
38 360 788
102 39
33 858 17 024 9 033 1 882 14 784 8 508 18 549 530 4 343 10 781 839 3 768 19 262 62 636 507 4 851 83 099 1 331 1 709 23 478 9 370 1 695 37 538 2 008 3 750 19 683 13 925 12 337 3 124 1 262 21 397 2 074 14 226 148 093 9 725 158 12 379 87 5 866 48 577 1 141 6 585 30 884 40 454 11 922 13 349
22 441 26 299 5 395 3 025 108 38 044 15 532 9 592 86 241 8 014 93 10 680
21 857 24 461 5 166 2 969 106 37 651 15 205 9 276 82 417 7 638 93 10 297
111 176 42 95 8 176 733 65 56 79 59 83
15 344 7 608 3 894 1 714 86 18 214 5 091 5 773 44 016 4 053 58 7 108
78 55 32 55 7 85 245 41 30 42 37 57
9 623 353 619 9 636 2 493 41 612 62 092 50 415 41 414
9 418 315 315 8 888 2 436 40 909 59 371 46 320 40 277
161 649 779 37 132 147 389 302
5 347 135 604 2 764 1 796 21 303 24 520 13 378 10 583
91 279 242 27 69 61 112 79
AFR
792 378
1 326 692
1 251 735
158
561 149
Table A3.6
. . Other number 0 8 608 21 422 109 80 98 102 82 59 39 52 49 7 3 8 New pulm. lab. confirm. number Estimated incidence and case detection rate Proportions . Estimated incidence DOTS case detection rate ss+ ss+ Extrapulm. Re-treat. all forms ss+ all new new ss+ (% of (% of (% of (% of number number % % pulm.) new+relapse) new+relapse) new+re-treat.)
DOTS coverage, case notifications and case detection rates, Africa, 2007
DOTS coverage % 10 576 2 911 1 305 513 1 697 3 152 39 0 0 0 0 2 513 0 0 485 76 0 0 52 0 0 5 159 177 84 1 753 0 0 0 0 0 0 1 686 0 0 13 0 0 0 0 0 0 231 0 7 108 29 48 15 344 7 608 3 894 1 714 86 18 214 5 091 5 773 76 104 4 053 42 49 13 28 36 39 87 35 17 19 69 41 23 39 69 49 84 53 23 25 92 42 91 78 88 58 51 78 58 72 81 0 0 41 945 904 80 17 72 16 43 47 36 34 70 31 75 58 81 48 33 62 53 53 69 0 0 0 0 0 0 3 743 81 540 1 462 1 238 8 110 7 366 76 40 67 42 26 34 35 28 66 64 36 53 25 47 47 70 66 84 19 30 39 65 58 66 21 35 11 5 9 18 17 23 18 21 13 20 4 13 18 15 5 22 11 0 0 548 3 552 14 071 66 099 58 27 39 56 42 61 55 82 86 39 61 66 25 22 19 4 6 6 6 2 9 7 5 7 9 12 8 11 8 7 6 5 11 8 7 6 8 18 18 51 43 15 6 907 2 282 4 988 18 737 753 45 269 409 91 1 092 1 708 18 032 529 3 973 5 195 674 603 4 5 020 2 681 1 349 4 044 1 663 1 109 40 3 433 204 23 0 0 0 706 45 738 1 833 356 4 460 12 526 10 015 6 381 0 0 1 184 57 111 12 086 16 908 45 171 792 668 442 92 109 12 0 0 207 595 596 27 810 477 0 703 2 422 3 391 529 2 879 434 223 320 0 0 0 0 0 168 28 342 335 73 1 433 1 804 1 738 1 349 165 7 061 67 34 5 347 135 604 2 764 1 797 21 303 45 041 15 820 10 583 0 460 130 253 0 0 0 0 0 0 0 1 055 0 0 1 219 954 207 158 4 1 353 1 430 478 2 269 333 165 60 145 14 0 205 139 128 835 115 335 25 71 42 2 188 188 188 1 303 30 0 0 177 98 3 285 13 1 841 12 0 0 52 0 0 0 108 2 035 165 46 463 337 11 262 9 19 127 145 15 637 168 23 91 170 0 0 230 965 4 006 31 235 1 000 88 115 921 81 217 104 0 77 0 0 0 223 179 166 938 14 40 193 34 110 3 129 39 25 417 15 305 51 0 0 0 3 002 2 614 3 595 13 220 190 54 11 20 65 33 57 18 27 91 44 49 82 81 66 71 39 66 57 55 58 17 13 27 13 14 9 11 4 6 11 0 547 2 226 57 446 103 645 11
100 63
21 369 41 292
63 243
8 439 21 422
25 126
1 807 14 733
100 100 100 100 100
7 622 3 960 6 284 24 062 274
405 27 74 130 52
3 002 2 614 3 595 13 220 158
160 18 42 71 30
3 092 577 826 6 752 63
33
5 879
55
2 513
23
2 378
60 100 100
9 002 23 033 99 810
239 120 159
3 552 14 071 66 099
94 73 106
2 938 3 009 10 968
93 95 31 100 100 60
3 641 128 844 3 766 1 916 12 743 9 411
75 155 283 112 54 100
694 38 040 1 462 1 238 7 429 6 199
14 46 110 72 32 66
2 086 43 500 1 678 541 3 759 1 167
100 100
106 438 2 319
284 115
38 360 788
102 39
49 869 904
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 27 62 63 8 39 48 74 37 1 187 713 41 37 78 55 15 51 51 58 27 47 63 56 41 89 61 54 39 33 58 57 43 31 74 52 41 29 26 45 7 15 21 15 11 21 22 16 18 4 19 11 5 5 7 12 6 10
100 100 100 82 100 100 100 100 91 100 0 100
21 857 24 461 5 166 2 969 106 37 651 15 205 9 276 82 417 7 638
111 176 42 95 8 176 733 65 56 79
15 344 7 608 3 894 1 714 86 18 214 5 091 5 773 44 016 4 053
78 55 32 55 7 85 245 41 30 42
1 321 10 704 391 494 12 13 064 4 948 1 676 32 088 1 589
10 297
83
7 108
57
1 620
100 100 100 100 100 100 100 100
9 418 315 315 8 888 2 436 40 909 59 371 46 320 40 277
161 649 779 37 132 147 389 302
5 347 135 604 2 764 1 796 21 303 24 520 13 378 10 583
91 279 242 27 69 61 112 79
3 197 105 631 3 956 211 13 713 20 521 21 189 21 964
19 156 48 777 8 206 13 761 33 437 31 225 35 556 798 14 985 32 203 352 15 190 80 995 245 333 1 299 4 629 314 267 5 408 4 415 47 632 26 928 3 727 132 357 12 782 10 393 49 360 48 144 39 345 9 923 282 92 295 15 905 24 802 460 149 38 606 159 33 613 28 33 662 460 600 13 674 28 263 101 785 120 291 60 337 104 400
8 577 21 041 3 563 5 251 14 227 13 432 14 465 359 6 111 13 608 158 6 376 33 306 108 957 547 2 009 135 311 2 208 1 936 20 694 11 598 1 602 53 226 4 787 4 474 22 092 18 386 17 021 4 359 125 37 165 6 088 10 928 194 731 15 926 72 14 706 13 14 478 173 710 5 055 11 921 41 865 48 508 22 956 39 784
AFR
93
1 251 642
158
561 091
71
408 936
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 3 800 3 318 5 046 2 624 597 384 8 0 616 11 264 14 484 383 4 370 2 129 383 3 935 2 015 188 1 153 419 0 0 15 0 0 37 0 0 15 0 0 123 0 0 67 0 0 0 0 0 0 0 0 117 13 258 205 5 707 1 365 1 044 17 287 5 106 2 665 562 267 1 0 0 0 1 0 0 0 14 0 0 0 8 0 0 0 3 493 653 8 639 270 3 363 8 139 12 26 0 0 494 3 590 739 337 213 450 280 60 TB pts HIV-positive Lab-confirmed DST MDR Re-treatment Re-treatment MDR in new cases in new cases DST MDR HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, Africa, 20062007
246 130
48 1
3 1
20 50
50 106 168 208 16
1 0 1 3 0
1 0 0 2 0
50 106 143 206 1
47
24 96 1 205
0 1 1
0 1 1
1 95 1 023
0 116 0 5 810 3 931
0 2 0 2 130 188
0 0 0 1 185 170
0 0 0 994 120
0 354 23 99 6 342 4 529 2 658 3 255 645 550 2 136 0 1 621 140 43 954 1 479 0 13 779 0 4 765 103 0 51 731 1 231 16 324 337 82 0 0 0 1 173 140 12 275 140 34 4 403 1 295 645 142 711 1 108 645 0 485 296 0 58 144 0 0 36 82
64 833 12 20 723 719 0 5 695 870 91 841 1 952 145 0 0 7 36 13 0 0 0 9 1 0 0 0 1
0 1 0
0 1 0

85 50 916 641 0 11 244 0 4 348 43 15 447 199 151 69 337 1 470 688 0 17 253 478 4 2 789 0 789 0 1 036 0 114 54 6 4 105 1 0 2 0 0 14 0 86 56 0 0 32 0 0 170 0 0 16 0 4 0 7 0 0 1 85 36 136 1 228 101 0 12 064 70 29 854 6 6 308 0 41 0 30 0 320 21 4 12 0 149 0 41 0 3 0 110 1 100 8 631 4 653 0 7 422 6 300 153 5 6 079 3 117 0 1 558 2 561 3 4 1 058 3 117 0 0 1 124 0 0 22 744 1 362 63 104 26 548 8 185 315 27 849 7 132 93 2 381 63 7 11 667 4 804 27 1 953 1 641 0 235 0 15 491 278 63 7 12 563 4 804 27 6 275 2 673 9 316 5 12 11 14 0 163 291 0 45 102 0 10 2 080 110 235 1 847 23 344 287 174 58 249 1 476 105 57 053 1 298 31 040 1 099 0 7 350 110 1 11 590 1 613 5 485 0 285 826 147 406 137 760 53 262 491 755 250 546 186 941 6 838 841 3 514 0 3 584 418 2 194 0 894 188 2 723 0 3 621 136 247 5 804 134 15 844 31 305 23 574 5 252 58 801 4 875 17 380 10 541 6 434 4 373 414 87 764 4 316 17 9 526 14 669 16 240 4 373 220 4 619 6 595 0 76 547 169 27 0 8 772 0 0 523 0 0 47 500 0 7 043 25 27 0 709
220 52
3 3
3 1
160 31
930
37
243 146 72
1 3 2
1 1 1
1 252 34 163 794 183 1 86
1 1 1 0 2 1 0 3
1 1 1 0 1 1 0 3
131 140 72 54 0 252 34 163 347 183 0 55
80 249 16 51 716 717 156 180
0 15 1 1 3 3 3 1
0 10 1 1 2 1 3 1
80 241 3 52 716
20 0
AFR
8 547
110
45
4 466
Table A3.8
% Not eval. Success 91 18 5 584 356 409 10 148 23 83 2 1 2 1 1 1 1 1 2 1 537 568 3 945 201 66 78 63 25 57 63 28 57 60 52 0 94 59 297 43 225 1 048 1 357 4 639 5 254 929 5 703 36 1 94 0 3 3 0 0 0 94 98 957 72 56 8 33 38 29 54 49 71 23 8 30 7 2 5 7 43 2 35 18 17 20 6 11 10 20 43 39 52 3 17 46 62 16 13 11 3 7 22 7 12 10 1 0 12 13 6 4 10 6 8 5 12 8 12 10 17 7 0 2 1 1 4 0 0 1 3 2 2 2 36 2 1 2 4 2 1 0 1 0 1 8 4 5 75 6 9 13 17 13 3 3 5 1 5 16 2 5 4 5 8 0 3 18 0 7 0 0 19 87 74 43 67 70 85 85 60 10 8 0 76 36 100 94 0 3 3 0 0 11 3 6 12 5 5 8 11 10 2 4 2 2 9 0 2 6 5 2 3 0 3 1 35 0 0 0 0 4 1 78 78 76 41 92 83 76 77 76 86 7 6 3 3 0 11 85 66 1 5 44 2 6 9 2 5 1 1 6 10 0 1 3 33 0 0 90 84 46 58 76 75 69 2 846 115 72 54 28 7 16 23 7 8 3 6 2 3 3 4 1 1 2 1 7 2 0 2 6 7 7 9 5 2 9 6 1 1 1 1 5 4 4 42 8 8 8 1 12 2 10 11 0 7 12 8 10 3 13 7 12 11 10 4 3 7 11 26 10 5 1 6 2 18 2 0 53 73 86 403 1 192 6 345 32 50 63 11 18 4 1 8 8 2 7 3 28 10 14 30 8 0 54 1 3 3 3 5 0 3 10 5 2 6 2 3 6 0 14 6 5 3 5 7 1 3 14 4 4 5 7 5 25 5 6 0 11 3 13 0 0 20 43 68 67 80 69 50 63 75 79 54 72 80 68 33 100 65 63 74 77 72 65 0 3 29 0 2 0 12 6 82 67 28 76 78 81 57 66 10 35 34 17 6 9 1 9 12 17 8 0 29 13 33 70 21 5 10 10 7 9 9 5 7 2 13 0 53 75 44 52 72 73 83 74 79 607 65 14 4 2 9 6 0 79 Number of cases Notified Regist'd Success 0 76 6 0 0 2 4 Not eval. Number Regist'd % New smear-positive cases, non-DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
Treatment outcomes, Africa, 2006 cohort
Number of cases Notified Regist'd 0 0 2 8 1 1 2 7 5 11 13 6 6 1 1 4 5 3 4 4 1
New smear-positive cases, DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred
8 285 21 499
97 135
86 11
5 7
2 1
3 463 2 660 3 233 13 811 131
106 100 104 107 100
43 67 66 64 66
30 6 16 10 13
7 12 4 6 4
8 538 15 915 2 943 3 252 2 659 3 119 12 870 131 4 365 0 67 3 340 12 867 63 488
2 768
35
19
3 340 12 868 63 488
100 100 100
41 61 82
12 12 5
1 8 5
735 36 674 1 145 1 812 7 786 6 075
108 100 100 150 100 103
80 69 34 56 71 66
9 15 13 2 6 9
6 5 5 5 9 4
39 154 725
100 18
73 56
12 11
5 12
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 1 780 1 006 449 280 7 1 818 2 255 730 4 605 618 0 896 0 2 2 48 0 0 0 0 0 1 0 4
680 36 674 1 145 1 209 7 786 5 903 1 030 39 154 4 024 2 906 15 613 8 166 3 802 1 486 85 18 275 5 356 5 279 39 903 4 220 0 6 882
15 668 8 166 3 803 1 652 157 18 275 5 177 5 228 39 903 4 158 0 6 882
100 100 100 111 185 100 97 99 100 99
73 77 70 31 46 82 64 63 65 77
5 1 6 9 46 1 12 14 11 9
5 12 11 2 3 10 7 6 6 5
100
69
4 629 131 099 2 539 2 131 20 364 24 724 14 025 12 718
4 660 139 516 2 538 2 131 20 364 24 724 14 025 16 205
101 106 100 100 100 100 100 127
75 63 27 63 29 80 77 54
12 11 15 4 41 5 8 6
5 7 6 11 6 8 7 8
AFR
555 361
562 884
101
65
10
Table A3.9
After failure, DOTS % of cohort Not eval. Died 7 11 4 18 0 61 99 55 11 2 3 23 6 0 66 Died 0 83 28 46 14 % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, Africa, 2006 cohort
Number regist'd
ComplCured eted
Died
480
69
14
160 0 62
77
12
81
205
64
15
69
44
70
77
1 272
50
12
10
20
281 0 77 992 53 3 9 8 23 4 0 56 997 57 5 7 2 26 3 0 62
37
10
33
17
47
34
21
53
15
88
23
18
16
41
41
3 872
74
10
115 13 0 0 17 16 0 146 58 7 11 9 8 4 3 65 83 51 7 10 11 18 0 2 1 58 19 6 25 13 6 6 25 25 14 57 14 7 0 0 7 79 60 63 82 18 134 44 56 0 12 28 2 11 10 6 9 0 10 11 0 44 68 22 166 50 55 9 13 18 3 5 2 18 16 0 11 0 0 59 68
28
23
42
50

14 71 0 2 2 48 0 0 0 0 178 107 45 50 73 47 8 10 24 7 8 7 9 4 6 14 6 8 16 0 5 15 0 4 31 82 71 15 116 6 266 36 67 57 8 12 21 17 4 12 7 19 9 0 53 59 8 9 9 31 1 4 0 54 63 15 2 6 11 3 6 42 16 9 21 10 1 0 58 148 54 24 5 5 5 5 0 4 6 60 5 14 2 17 2 0 65 1 205 100 49 0 2 0 15 0 5 0 5 8 10 16 7 2 22 2 8 0 0 27 85 58 31 51 1 329 130 66 76 73 80 75 33 100 67 61 77 0 24 3 2 7 3 6 8 0 0 0 2 0 0 6 33 100 51 78 78 67 79 78 25 96 0 113 41 0 308 0 0 0 12 124 97 3 798 50 12 9 8 13 5 3 62 60 52 6 20 11 20 5 5 8 3 10 1 0 0 66 71 1 66 76 79 81 57 257 403 9 409 59 37 56 10 39 18 13 14 5 0 2 4 12 4 7 6 4 6 1 0 5 68 76 74
497 268
46 69
17 13
10 4
3 3
7 3
3 8
3 945 81
71 44
8 16
7 20
1 0
8 1
5 1
1 691 1 006 220 280 6 1 435 1 353 475
69 78 71 25 50 65 46 61
4 2 4 7 50 2 15 16
7 12 9 1 0 11 13 6
3 1 4 2 0 1 9 4
12 2 9 11 0 6 11 7
6 2 2 6 0 14 6 6
359 0 475
70
61
130 19 930 346
75 54 19
10 4 12
5 5 12
2 15 8
7 17 8
0 4 14
1 357 1 817 1 865 929
33 75 71 54
43 4 11 3
8 12 9 17
1 1 1 1
10 4 3 7
4 4 5 7
AFR
44 530
60
12
Table A3.10 DOTS treatment success and case detection rates, Africa, 19942007
2004 91 18 86 73 16 33 57 18 27 91 44 18 127 117 75 98 102 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 2002 2003

87 68
1994
1995
1996
1997
1998
1999
2000
86
87
76 72
72 70 29 77 60 80 77 57 54 35 93 69 78 53 73 86 53 47 76 20 41 25 43 31 49 30 85 44 50 56 42 61 61 72 73 83 74 79 66 14 30 39 42 8
77 71 61
44
73 67 25 45
15 73 70 61 67 80 84 70 12 20 82 87 21 25 5
68 77 47 59 74 75
90 68 81 77 66 79 39 81 90 17 19 11 51 86 72 16 36 21
133 61 82 89 16 30
75
84 66 79 78 65 80 62
89 74 80 71 64 79 70
87 72 87 70 71 79 74 64 65 62 14 57 49 90 34 47 53 83 9 49 42 52 38 59
117 104 84 67 13 25 56
116 104 81 58 13 26 77
109 90 82 58 14 26 78
104 79 86 61 19 24 89 37 71
37 47 90 92 66 73 77 72 96 71 67 78 91 28 75 85 36 54 72 53 40 86 15 49 43 75 9 22 54 55 48 53 86 11 24
64
59 78
85
63 94 69 17 71 89 76 80
68 80 89
56 48 77
62 70
93 61 63 69
91 68 83 65 67 78 71 71 91 69 94 63 71 85 47 29 42 88 34 47 5 7 28 57 34 53
109 84 83 59 16 25 89 39 35 19 48 57 34 60
74
61
73
61 64 82 83 72
73 74
44 76
74 50 68 80 80 70 73 52 42 17 47 21 45 19 44 17 27 67 44 85 66 58 63 56 87 60 61 31 53 41 53
78
76 54 78 38 55 46 53 78 32
80 51 75
70 48 74
59 73
90 84 46 58 76 75 74 16 45 67 14 53 70 32 51 73 33 54 72 16
35 28 66 64 36 53
73 56
77 71
77
55 74 35 78 69 74 60 74 30 65 44 19 60 78 44 67 51 20
51 22 68
75 47 79 55 71 59
68 65
65 63 75 64 71 62
69 70
71 68
80 76 49 71 56 74 51 80 71 76 69 70 50
82 76 47 74 60 72 48 79 52 76 74 72 50
42 30 72 68 41 52 43 63 71 56 65 40 20
55 31 85 65 40 51 55 65 79 36 71 39 21
96 67 55 85 11 35 48
91
39
61 11 34 62 29 66
86 59 22 53 88 31 11 41
65
49
54 66 57 32 61 76 76
67 58 66 73 68
73 72
87 71 51 60 75 67
93 75 56 65 79 61
93 78 63 64 79
92 78 66 58 79 58
69 72 83 51 85 70 34 75 66 75 80 80 70 73 71 73 65 58 87 76 63 70 78 67 85 79 40 86 72 72 75 80 69 70 71 71 71 22 89 77 68 61 73 77 78 78 76 41 92 83 76 77 76 86 83 53 90 33 11 54 93 50 85 37 12 44 88 47 82 41 12 32 66 45 84 44 12 25 67 45 81 42 11 28 77 45 90 51 15 30 69 41 23 39 69 49 84 53 23 25 49 48 88 78 46 87 73 72 69 82 73 76 74 73 75 55 86 79 75 74 75 83 38 28 61 64 37 54 78 70 90 55 65 43 22 29 87 47 83 52 18 26 36 27 58 65 38 55 68 72 84 69 74 43 23 36 68 49 87 51 20 27
4 14 38 65 34 59 75 42 31 86 60 37 53 73 68 90 66 71 43 20 44 92 46 82 46 17 27
38
48
75
44 89 69
44 100 74 69 13 61 55 23 26 30 35 49 37 60 60 57 13
55 100 79 73
65 82 41
74
58 90 75 60
52 82 77 66
57 97 40 7
55 67 36 23
53 83 33 63
54 90 33 60
45 63 78 69 72 71 73 73 74 76 75
60
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 12 60 58 11 60 56 12 51 52 45 36 47 51 44 37 53 67 80 65 36 55 56 81 75 71 86 71 42 71 73 82 84 68 87 74 43 67 70 85 85 60 66 45 81 68 47 68 60 80 83 67 70 100 83 67 42 63 68 81 75 66 74 92 82 70 50 67 70 81 83 54 49 68 32 71 35 4 47 48 45 42 43 53 38 31 77 36 13 47 49 69 36 45 50 100 34 75 41 16 48 51 65 36 46 50 62 36 72 46 17 47 50 58 32 46 35 77 52 19 48 50 58 32 47 37 78 55 15 51 51 58 27 47
80
73
65 33 76
66 40 77
69 62 76
76 61 78
70
73
AFR
59
62
57
63
70
69
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, Africa, 2007
5564 296 699 120 176 177 480 4 82 145 88 307 6 46 29 55 152 0 347 157 360 1 443 18 430 243 392 1 963 17 254 187 276 985 5 123 129 140 483 1 47 88 67 248 3 37 45 38 148 6 71 37 81 273 0 598 390 785 2 835 42 965 685 1 029 4 576 47 696 616 818 2 859 31 386 432 512 1 494 19 167 264 244 728 7 119 190 126 455 12 1.3 2.0 1.7 1.4 2.2 407 465 109 703 1 031 2 943 811 2 721 335 1 812 273 1 041 247 554 391 367 204 1 187 2 419 5 767 2 560 5 918 1 148 4 067 767 2 398 543 1 253 798 832 1.6 1.1 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
95 484
1 388 2 824
1 749 3 197
813 2 255
494 1 357
25 8 26 121 0
251 233 425 1 392 24
535 442 637 2 613 30
442 429 542 1 874 26
263 303 372 1 011 18
28 173 1 343 53 1 051 44 559 2 1 229 70 5 426 89 5 507 56 2 850 47 1 429 21 502 15 213 23 2 284 126 11 948 174 11 621 129 6 395 109 3 467 74 1 553 59 772 1.3 1.2
351 1 576 6 485
635 2 705 9 548
482 1 817 7 925
233 981 5 341
78 532 2 801
63 429 1 752
45 225 1 842
411 1 349 7 130
608 1 973 8 415
334 1 126 5 939
153 596 4 127
71 354 2 352
60 235 1 099
73 398 3 185
762 2 925 13 615
1 243 4 678 17 963
816 2 943 13 864
386 1 577 9 468
149 886 5 153
123 664 2 851
1.1 1.4 1.1
21 1 055
56 6 522
85 6 114
73 3 545
62 2 038
66 46 1 084 52 823 233 291 139 9 149 405 1 853 168 4 329 74 2 511 17 343 238 195 185 10 102 56 594 77 008 43 857 24 129 12 281 7 431 17 755 24 577 427 347 323 119 4 420 120 249 1 341 91 0 251 69 57 685 81 0 73 417 287 4 522 477 9 761 826 412 5 944 468 6 603 513 323 3 088 245 3 378 242 248 1 926 131 3 241 102 157 1 194 70 5 121 76 109 625 35 0 95 126 97 1 188 132 0 130 787 858 8 773 1 000 13 1 814 1 844 1 792 14 485 1 273 18 2 325 1 299 1 281 8 864 801 11 1 253 588 825 5 693 483 7 790 251 562 3 047 238 9 450 438 158 213 83 6 223 109 30 21 0 1 456 768 263 103 4 1 810 1 497 385 152 7 1 354 715 258 92 3 880 342 160 64 5 378 146 113 38 4 192 84 95 42 3 419 170 59 35 0 2 929 1 382 632 309 13 4 163 2 951 1 081 507 16 3 451 1 669 828 353 15 2 551 815 582 208 20 1 201 379 404 177 13 601 28 599 4 4 594 78 5 979 121 2 774 106 1 180 40 542 13 329 13 1 073 10 9 346 110 14 111 256 7 733 179 3 541 127 1 626 65 930 41 630 242 308 125 9 196 358 1 966 126 0 346
596 901
1 164 1 315
1 239 936
861 503
477 240
506 204
75 76
453 631
667 613
564 367
371 207
183 106
207 79
141 122
1 049 1 532
1 831 1 928
1 803 1 303
1 232 710
660 346
713 283
1.9 2.0 1.4 1.1 1.4 1.1 2.0 2.3 2.3 1.3 2.6 1.4 1.7 1.2 2.1

258 4 792 57 73 766 1 317 319 292 12 850 110 773 172 2 021 27 66 505 1 066 204 153 398 14 410 411 184 1 874 1 735 1 335 739 568 21 049 576 256 3 008 3 388 2 193 3 311 468 13 190 232 150 1 742 1 945 1 188 0 255 6 245 98 67 824 947 558 553 143 2 964 39 35 382 535 244 213 79 1 811 18 30 246 388 131 90 936 24 924 634 340 3 615 3 756 2 570 1 239 1 600 42 997 1 055 565 7 414 8 053 5 164 7 004 173 892 1 265 33 266 576 426 5 293 5 800 3 036 0 114 887 775 18 409 280 237 2 505 3 178 1 363 1 269 67 203 401 7 756 96 108 1 148 1 852 563 505 32 878 251 3 832 45 96 751 1 454 335 243 20 281 1.7 1.2 1.0 1.4 1.5 1.7 1.3 1.1 1.3
474 6
4 752 32
8 132 135
4 959 73
2 361 87
196 61 29 14 0
1 473 614 369 206 9
2 353 1 454 696 355 9
2 097 954 570 261 12
1 671 473 422 144 15
57 40 503 51 0 57
370 571 4 251 523 4 1 053
1 018 1 380 8 541 805 12 1 722
786 958 5 776 556 8 875
346 577 3 767 352 4 549
45 1 909
7 234 189 152 138
538 10 514 223 156 1 741 2 021 1 235 500
1 032 21 948 479 309 4 406 4 665 2 971 3 693
797 20 076 344 276 3 551 3 855 1 848 0
520 12 164 182 170 1 681 2 231 805 716
AFR
7 653
54 179
96 884
71 030
43 074
20 597
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, Africa, 2007
65+ 58 260 331 79 107 104 81 14 1 3 4 0 160 11 39 74 30 276 23 68 147 42 275 29 76 116 17 167 33 49 82 5 108 38 40 61 32 91 17 28 41 42 11 1 2 4 0 137 13 42 72 35 299 32 90 169 60 370 47 117 166 55 277 59 97 130 55 212 66 85 95 48 182 42 58 69 55 2 18 28 170 27 237 15 239 19 203 29 180 46 158 2 15 33 167 41 260 26 273 26 245 33 220 51 203 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544
014
1524
2534
Male 3544
4554
5564
2 12
37 165
56 283
36 310
33 292
37 265
8 0 1 3 0
114 15 46 71 40
321 40 114 191 78
461 66 161 216 94
402 91 151 179 128
342 102 144 132 74
4 4 9 101 50 0 7 14 65 21 96 28 73 36 55 21 30 21 16 1 6 12 71 20 102 33 83 48 68 43 48 52 32
93 75 106
223 194 230
264 204 307
210 146 332
112 119 282
122 136 255
6 6 12
108 64 116
216 147 201
185 142 225
127 99 236
86 89 200
86 76 118
5 5 11
100 70 111
220 171 215
225 175 266
167 124 282
98 105 238
102 106 176
2 6
11 78
20 108
39 93
63 83
73 67
1 2 135 73 153 85 114 166 17 391 101 68 97 0 97 6 33 1 5 3 7 7 6 70 137 119 94 74 53 5 68 154 157 1 4 2 6 6 5 29 18 2 2 4 0 3 175 22 30 40 53 60 542 46 59 67 49 68 483 53 46 59 45 65 320 62 41 42 58 62 210 62 40 43 180 46 178 52 26 25 0 35 16 1 2 3 0 3 165 34 29 42 38 71 594 104 72 98 74 133 616 103 67 104 86 110 425 90 62 84 75 106 291 105 53 84 183 88 267 79 45 54 0 65 5 3 1 3 0 75 55 21 34 4 132 161 46 65 7 142 127 51 57 3 135 88 48 56 6 96 55 55 57 7 57 36 38 67 6 5 3 1 3 0 76 50 25 50 7 153 157 66 106 8 182 153 87 107 8 198 112 99 92 12 158 76 118 150 13 101 58 70 111 11 8 1 113 32 213 79 165 128 104 52 84 24 61 23 7 1 115 23 250 90 231 129 163 103 134 72 94 43
24 96
64 202
101 208
107 162
89 125
122 160
2 4
19 70
38 98
47 84
46 66
33 50
45 48
2 3
21 83
51 151
74 147
76 114
61 86
82 96
6 1
116 14
286 102
296 130
228 188
193 147
5 2 1 2 0
76 44 30 65 9
173 154 87 145 8
223 180 130 157 12
262 139 167 129 17
225 101 215 271 19
15 1 2 2 0 2
155 48 28 44 23 82
645 166 84 133 98 199
751 150 88 156 129 159
552 111 84 133 95 155
395 142 68 138 186 132
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 202 243 166 74 153 201 138 76 117 135 71 300 287 27 60 42 106 44 145 537 683 54 152 119 265 319 159 435 434 49 159 111 270 0 120 266 242 32 110 79 179 137 97 188 147 26 76 64 104 79 73 134 83 26 58 57 64 33 84 258 222 25 57 46 101 37 206 537 643 60 185 141 305 326 219 555 609 70 234 166 334 0 191 415 399 57 174 137 233 169 145 271 205 42 123 120 134 107 106 129 176 118 47 100 120 95 51 81
4 25
0 3 2 6 5
97 217 157 23 55 49 97 30
268 538 600 66 218 162 343 333
282 677 834 91 306 220 394 0
268 582 610 85 242 201 294 207
201 373 279 60 178 187 172 144
AFR
66
171
195
179
142
Table A3.13 TB case notifications, Africa, 19802007

1985 12 917 9 363 2 162 2 627 1 018 2 569 2 138 4 464 6 803 5 251 779 1 285 3 120 6 072 27 665 1 80 846 769 972 11 923 5 874 73 017 1 751 16 447 26 094 85 867 864 95 521 721 80 795 912 60 006 906 6 652 91 101 2 743 94 957 2 504 3 473 6 422 27 096 11 2 871 129 1 976 9 563 36 647 309 11 664 120 9 239 12 943 60 627 138 9 735 16 533 66 748 9 618 2 406 6 478 11 307 291 2 550 11 332 11 134 2 162 3 274 1 488 4 883 6 814 11 428 11 272 2 420 4 179 13 345 8 269 2 340 4 654 1 443 4 677 7 064 13 345 7 157 2 119 4 756 861 3 840 7 312 16 647 14 235 2 552 8 647 2 310 6 365 7 660 18 572 16 062 2 706 9 292 2 310 18 250 21 713 21 369 41 292 7 622 3 960 6 284 24 062 274 5 879 112 8 478 20 746 95 666 9 002 23 033 99 810 11 212 8 510 1 901 3 173 1 407 2 739 3 878 285 499 1 086 2 045 2 912 119 618 8 021 33 782 331 2 684 108 1 179 9 093 37 660 262 4 386 60 006 926 3 303 115 2 992 14 000 38 477 356 15 505 99 329 1 034 5 003 4 710 153 5 023 15 056 59 531 21 143 50 419 3 619 8 413 3 941 6 114 23 483 262 6 045 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
2 702 10 117 1 835 2 662 2 577 789 2 434 516 651 220
7 501 1 862 2 605 2 391 643 2 236 344 758 286
13 916 7 911 1 793 2 705 2 265 951 3 765 393 1 475 127
13 681 6 625 1 804 2 883 3 061 1 053 3 445 230 1 686 1 977
13 133 10 153 1 913 3 101 877 1 904 3 338 285 468 1 430
13 832 8 653 2 041 2 706 4 547 2 317 3 393 259 520 1 486
742 4 197 5 122
1 214 4 418 3 051
3 716 5 000 9 905
4 156 6 000 13 021
2 776 6 062 20 415 181
2 648 5 729 26 082 17
11 325 8 184 2 027 2 740 949 3 745 4 982 276 814 2 977 212 3 878 6 556 30 272 20
11 039 9 587 1 941 2 532 1 616 4 608 5 521 210 64 2 572 139 4 363 6 982 31 321 157
18 934 29 996 2 830 10 204 2 376 6 371 11 057 195 4 837 5 077 111 9 888 16 071 70 625
19 730 36 079 2 932 9 862 2 620 6 871 15 964 316 3 932 4 679 73 7 782 17 739 84 687
21 336 37 175 3 270 10 058 3 484 6 585 21 499 292 3 210 6 311 111 9 853 19 681 97 075
40 096 865 239 5 207
52 403 761
56 824 752
65 045 654
71 731 855
11 607 10 271 2 084 2 938 1 497 4 575 5 892 221 2 124 2 591 140 591 7 841 21 131 260 3 699 88 634 917
4 345 1 469 205
1 935 1 203 368
3 641 128 844 3 766 1 916 12 743 9 411

6 017 1 869 1 362 12 592 2 463 6 407 1 988 1 163 11 788 2 525 7 136 2 267 1 246 12 320 2 994 17 004 3 300 1 647 22 930 4 334 1 764 10 671 19 496 3 075 149 17 158 16 522 15 066 2 255 7 287 1 643 5 335 3 952 196 4 459 2 180 134 3 417 13 802 44 783 366 8 321 59 105 1 434 1 357 10 749 4 439 1 445 39 738 6 447 6 037 72 095 1 598 1 514 10 386 5 171 1 164 57 266 8 552 10 933 5 440 1 273 64 159 9 746 1 500 2 805 110 289 2 086 1 859 11 723 6 199 1 566 80 183 10 111 3 419 16 718 24 595 4 457 4 708 117 600 2 208 1 945 11 891 6 570 1 647 91 522 12 007 2 511 19 309 25 841 4 496 106 438 2 319 6 015 14 743 2 631 3 064 134 16 609 2 500 19 626 3 200 120 6 781 7 408 1 665 82 539 2 564 90 292 41 6 913 14 802 3 784 8 449 15 020 3 535 20 676 5 022 3 788 121 18 842 9 947 4 021 16 660 4 710 7 044 2 941 1 059 14 599 3 327 1 948 8 126 14 237 3 113 4 316 130 15 085 1 756 15 329 15 424 2 284 6 636 1 814 3 796 3 049 179 3 623 1 936 138 4 469 13 104 45 999 319 5 220 41 889 951 1 242 10 449 4 357 1 678 34 980 5 598 840 12 718 20 630 3 655 3 837 116 18 443 9 625 3 026 122 198 3 051 1 795 12 471 8 787 2 137 108 342 12 073 4 447 21 966 25 054 4 989 2 694 114 35 257 14 673 8 474 70 734 8 117 153 10 133 24 396 4 466 3 649 154 20 574 10 035 3 900 24 157 6 483 96 7 488 21 123 22 098 13 064 5 115 45 842 5 473 97 8 554 19 4 673 148 257 6 118 8 322 18 3 160 125 913 3 022 1 623 28 349 46 433 43 762 585 773 44 96 598 821 42 91 5 417 9 431 1 626 4 040 129 15 958 3 703 608 13 342 4 741 5 965 6 8 569 3 167 1 558 20 451 3 384 1 766 9 855 17 105 3 204 3 996 159 16 588 5 500 626 11 601 13 507 5 143 2 332 5 665 2 572 3 326 3 292 303 3 339 3 186 123 3 615 11 988 42 819 306 21 453 26 034 1 115 1 023 8 636 3 523 1 613 28 142 5 181 1 393 21 616 19 155 3 087 3 849 131 17 882 1 540 1 980 13 423 3 054 21 857 24 461 5 166 2 969 106 37 651 15 205 9 276 82 417 7 638 93 10 297 3 925 1 128 1 310 10 022 21 232 3 717 6 260 1 851 2 257 119 8 263 4 427 570 14 071 2 460 8 927 24 358 55 013 6 261 12 395 2 933 5 284 119 15 899 2 671 5 200 20 122 6 387 17 4 977 41 632 80 400 745 596 1 392 15 452 8 716 5 233 301 683 41 89 333 842 43 93 373 550 44 96 365 432 41 89 418 530 43 93 412 414 40 87 432 997 37 80 418 995 41 89 550 183 38 83 504 309 45 98 5 877 1 214 752 10 515 225 384 4 007 7 581 2 534 3 722 117 10 996 3 640 556 19 723 3 287 55 6 145 14 130 57 406 1 098 1 184 1 464 16 920 10 025 5 848 68 075 1 394 940 1 045 19 262 14 266 6 822 1 324 14 740 22 249 16 863 9 132 1 223 20 662 28 462 25 448 16 237 1 137 26 994 34 799 35 222 23 959 1 466 77 652 1 531 1 243 19 016 25 210 23 373 11 710 97 6 841 5 2 691 89 786 1 458 1 005 21 579 31 460 30 496 20 125 7 561 8 1 955 73 917 2 050 1 520 25 316 39 847 35 958 30 831 8 525 15 3 241 109 328 2 364 1 654 27 196 44 416 40 417 35 735 47 077 689 253 45 98 148 164 4 167 1 249 31 597 52 437 45 240 50 138 750 086 41 89 23 604 4 216 3 067 160 21 158 10 799 4 701 25 821 6 093 97 8 508 20 3 760 151 239 5 877 1 409 30 372 54 442 49 806 50 855 783 930 38 83 36 829 61 603 46 259 56 222 5 297 1 740 778 10 957 2 346 894 4 393 8 359 2 578 3 928 114 13 863 2 815 631 25 700 4 145 13 5 611 10 120 61 486 1 352 1 071 3 066 18 206 12 876 6 002 15 324 14 296 2 316 7 960 2 074 6 546 5 022 205 4 875 2 784 132 3 863 14 841 58 917 416 7 789 69 472 1 380 1 558 11 352 4 768 846 48 936 7 806 1 753 14 661 22 674 4 142 3 617 120 19 672 11 147 5 046 20 249 6 112 106 8 475 11 3 270 142 281 3 653 1 250 29 228 51 231 139 25 544 13 282 5 185 38 628 6 011 94 8 366 29 4 793 215 120 6 748 1 645 40 695 60 306 54 220 59 170 137 28 602 14 490 7 078 44 184 6 812 457 9 380 10 5 289 227 320 7 749 1 815 41 795 61 579 53 932 53 183 3 549 124 262 2 512 2 031 12 124 6 863 1 774 102 680 10 802 3 432 18 993 25 491 4 697 2 162 125 33 231 14 920 7 873 62 598 7 220 136 9 765 14 6 737 270 178 8 062 2 537 41 040 61 022 49 576 50 454 8 041 303 114 8 278 2 819 40 782 59 282 47 790 44 328 19 809 35 437 3 116 10 131 2 878 7 164 17 655 294 3 908 4 946 89 9 729 20 084 93 336 536 4 239 123 127 2 588 2 142 11 827 7 423 1 835 100 573 11 404 4 337 20 001 27 030 4 525 3 326 137 31 150 15 026 6 822 57 246 6 487 121 9 098 18 5 710 267 290 8 071 2 212 43 721 62 512 54 106 56 162 9 418 315 315 8 888 2 436 40 909 59 371 46 320 40 277 861 423 1 004 557 1 079 333 1 179 378 1 186 800 1 243 560 1 251 735 37 44 44 46 45 43 39 80 96 96 100 98 93 85
645 11 049 4 082 774 9 082 4 758 839 7 576 132 7 457
42 423 796 58 4 041 1 884 465 10 027 3 830 1 002 7 464 5 033 933 9 427 157 6 984
4 932 835 3 573 4 411 187 2 327 121 5 787
2 651 832 376 11 966 3 443 885 3 588 4 707 532 2 333 152 5 937
2 923
8 673 4 404 1 872 3 977 118 5 204
717 9 877 1 495 131 2 014 16 750 55 310
754 10 949
665 11 439 1 419 49
10 816 62 717
3 235 1 317 530 10 460 2 927 425 3 220 5 335 1 621 4 406 111 5 645 4 840 698 14 937 1 327 40 1 065 10 865 59 349
208 1 058 11 483 5 321 4 057
2 871 10 838 1 386 37 2 573 0 847 59 943 143 126 1 170 12 122 6 162 4 051
40 1 612 16 889 64 115 3 059 204 497 11 748 6 525 4 577
673 10 212 1 364 59 2 417 16 293 62 556 1 955 174 2 029 11 753 6 860 3 881
343
12 092 7 272 5 694
13 698 8 246 4 759
AFR Number reporting % reporting
219 802 40 87
224 102 41 89
240 263 39 85
258 842 41 89
264 928 37 80
296 627 41 89
Table A3.14 TB case notification rates, Africa, 19802007

1987 44 103 40 233 16 84 54 75 52 33 549 20 95 70 63 65 55 14 230 110 158 239 120 159 405 27 74 130 52 43 100 43 289 49 71 40 313 15 77 53 48 60 35 311 9 62 53 55 105 36 508 20 97 49 61 115 37 537 19 59 152 63 305 41 453 27 75 129 51 142 63 243 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
1985
1986
14 129 49 267 38 19 27 178 28 5 156 56 79 3 185 103 97 58 70 228 55 99 218 199 83 163 102 113 96 181 131 72 133 208 75 155 283 112 54 100 66 46 22 25 61 86 95 43 22 75 68 86 85 367 17 288 76 120 19 296 95 128 41 19 46 67 92 74 138 110 95 48 19 110 96 87 95 487 170 101 132 58 23 161 90 120
93 49 253 34 15 24 117 32 6
69 94 45 254 32 22 39 131 60 3
66 76 44 262 42 23 35 75 66 40
61 113 45 273 12 40 33 91 18 28
63 93 46 231 59 47 32 81 19 28
57 98 48 217 13 51 20
28 24
48 87 41 254 17 52 35 86 18 20
41 50 18
65 50 11
194 55 33
210 62 43
136 60 65 63
126 55 80 6
145 55 83 0
47 82 42 213 11 70 43 81 28 52 43 170 55 85 6
45 94 39 191 19 83 46 60 2 43 27 185 57 85 47
60 204 37 575 19 90 66 41 121 56 15 294 91 132
62 238 37 549 20 94 94 65 97 49 10 226 99 153
65 231 39 548 25 84 121 58 77 62 14 273 106 165
108 127 36 46
133 106
140 101
155 86
165 109
180 95
46 98 40 215 17 80 48 62 71 42 27 24 61 56 77 117 173 100
36 31 25 284 115
15 24 42
81 68 315 41 100 77 14 504 14 61 49 152 33 153 13 120 170 13 111 20 45 101 83 89 40 214 62 223 33 78 15 42 8 13 60 195 55 161 11 112 568 40 14 74 46 104 22 213 12 119 272 8 15 65 78 8 216 46 146 13 116 545 36 20 85 70 74 26 10 118 683 44 36 64 68 81 23 99 322 569
111 114 8 34 40 57 59 288 52 80 79 15 611 16 56 40 32 138 56 156 41 33 114 50 158 45 36 119 51 184 43 45 98 58 202 94 64 145 39 211 12 105 116 111 176 42 95 8 176 733 65 56 79 59 83 98 47 143 86 256 85 79 196 36 54 66 93 205 517 49 51 46 139 79 203 86 75 173 39 190 15 112 351 7 11
361 42 37 67 3 147 12 45
21 17 44 66 245 43 36 70 8 143 15 46
203
57 116 34 445 15 84 27 47 123 29 21 116 87 94 91 249 92 129 109 57 57 115 137 361 170 107 138 113 53 64 87 188 461 70 151 170 126 56 73 108 244 523 105 98 201 42 113 157 177 128 55 76 110 271 616 76 109 206 41
85 63 28 238 12 39
53 122 36 414 17 60 21 44 102 26 22 156 85 99 82 160 67 88 103 57 58 137 124 319 37 88 200 41 168 10 112 565 64 151 233 108 54 96 130 296 605 124 115 185 42 89 9 168 717 62 49 86 99 84
12 14 29 138 34 24 23 190 87 23 75 291 303 33 126 147 359 97 108 381 331 401 24 132 159 442 400 115 117 145 177 434 440 126
12 15
10 14 24 48
48 42 38 362 25 53 23 76 97 45 20 129 80 94 80 668 43 106 88 48 48 135 103 301 65 155 190 35 173 12 112 93 21 12 54
15 23 195
24 25 59 53 199 20 31 73 24 257 11 42 428 10 18 22 39 16 15 24 180 52 131 38 272 11 117 188 66 21 88 15 63 57 15 220
28 21 143 49 1 11 35 82 27 128 12 62 375 8 17 38 8 13 35 10 163
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 41 22 80 50 15 18 36 93 36 206 11 82 294 8 23 48 51 85 20 3 167 142 33 9 73 135 61 190 166 24 6 78 181 67 33 83 87 208 87 82 78 80 75 96 86 97 29 108 105 297 147 26 131 120 390 207 74 36 207 172 31 103 96 280 109 79 80 7 65 227 158 24 109 112 347 178 84 11 47 178 214 34 119 133 388 261 92 20 78 258 242 35 124 145 426 298 203 42 120 13 116 575 42 21 75 69 82 25 83 333 555 26 123 161 477 402 12 133 684 43 29 69 65 77 35 97 462 619 29 155 169 499 460 143 150 11 146 736 57 33 76 310 84 12 102 483 703 31 154 168 487 411 160 140 628 730 44 136 150 409 335 157 161 161 649 779 37 132 147 389 302 158 71 78 36 31 81 50 151 41 39 97 35 212 11 104 217 9 29 58 12 75 14 3 176 167 29 19 76 168 61 78 157 195 126 54 76 111 288 545 100 102 193 40 73 10 162 739 59 44 78 89 83 16 121 564 717 41 142 159 432 385
7 8 61 89 56
48 15 26 38 43 0 26 201 23 4 9 63 100 54
41 26 24 26 209 470 7 4 59 103 58
11 13 24 59 38 24 9 199 292 6 15 57 105 47
11
22
57 107 67
63 118 54
17 9 69 121 57
52 108 34 476 19 102 33 48 131 35 20 127 91 121 101 227 106 122 121 59 60 65 165 428 65 96 207 44 149 10 114 620 49 17 87 78 86 14 76 323 358 25 126 159
61 227 38 558 21 95 101 59 95 50 11 276 110 164 113 97 160 204 136 54 84 118 290 580 130 110 210 40 115 11 155 754 53 41 72 81 79 21 106 562 724 36 156 167 480 431
AFR
58
57
60
62
62
67
66
Table A3.15 New smear-positive cases notified, Africa, 19902007

Number of cases 1996 8 328 9 053 2 286 3 091 1 560 3 960 3 057 1 522 3 040 4 695 140 1 382 2 513 3 002 2 614 3 595 13 220 158 160 18 42 71 30 23 7 953 11 923 8 439 21 422 25 126 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Rate (per 100 000 population)
1990
1991
1992
1993
1994
1995
4 874 1 653 1 508
1 861 2 316
6 793 4 337 1 618 1 668 561 1 527 1 883
7 740 8 246 1 939 2 824 1 126 2 022 3 548 103 2 267
7 462 7 333 1 988 3 112 1 331 2 782 4 374 104 2 637
7 845 7 379 2 192 2 746 1 411 2 924 5 832
8 538 21 499 2 943 3 252 2 659 3 119 12 870 131 4 448
1 691
7 012 14 924 590 30 510
5 735 3 804 1 839 1 903 1 028 1 121 2 896 111 1 794 2 002 103 2 013 8 254 20 914 219 2 725 2 920 112 2 222 10 047 34 923 87 4 218 8 497 36 123 3 552 14 071 66 099 92 4 319 10 920 42 054 67 3 340 12 867 63 488 94 73 106 702 33 028 1 137
6 556 8 016 1 868 2 530 1 381 1 533 2 312 117 1 992 870 107 2 505 8 927 24 125 209
8 246 18 087 2 415 3 334 1 544 2 791 7 921 111 2 758 3 519 72 5 019 11 026 44 518
8 549 18 971 2 438 3 050 1 703 3 087 10 692 165 2 818 3 599 48 3 477 11 430 53 578
8 654 20 410 2 739 3 170 2 294 3 262 13 001 135 2 153 2 516 79 3 640 12 496 65 040
5 752 395
2 082 31 307 38 360 788 29 29
5 778 2 158
7 712 4 092
694 38 040 1 462 1 238 7 429 6 199
14 46 110 72 32 66 102 39

100 1 984 9 093 24 609 226 120 15 957 577 820 7 254 2 981 855 19 040 2 398 527 21 597 916 861 6 877 3 563 704 27 197 2 729 7 316 3 920 526 28 773 3 041 1 021 934 11 092 8 309 46 42 13 160 263 743 6 474 2 844 922 16 978 1 788 668 8 456 6 703 2 173 646 36 541 1 033 1 035 7 732 4 300 899 34 337 3 167 1 974 11 387 7 703 2 757 887 39 698 1 233 1 040 7 714 4 495 963 38 158 3 652 1 319 12 881 7 716 3 015 99 10 478 2 849 10 662 2 034 7 587 3 178 2 519 112 11 116 3 220 3 452 11 235 2 820 99 2 044 9 850 33 442 284 135 18 864 889 900 7 757 3 362 541 24 029 2 476 1 190 9 639 8 765 2 558 1 172 109 12 116 3 598 3 195 13 161 4 417 680 36 674 1 145 1 209 7 786 5 903 1 030 39 154 4 024 2 906 15 613 8 166 3 802 1 486 85 18 275 5 356 5 279 39 903 4 220 36 6 882 15 344 7 608 3 894 1 714 86 18 214 5 091 5 773 44 016 4 053 58 7 108 78 55 32 55 7 85 245 41 30 42 37 57 8 132 2 690 2 051 122 12 825 3 760 2 631 15 903 4 298 30 5 011 10 85 13 967 4 535 3 476 23 410 3 252 41 6 094 12 2 692 83 808 1 279 5 430 13 2 296 54 073 5 454 9 2 262 66 047 935 17 254 22 010 14 512 277 591 326 831 349 142 362 527 402 431 459 983 513 029 551 031 14 492 17 291 24 685 13 024 15 370 550 001 904 18 222 23 726 45 46 5 949 11 2 234 42 163 2 226 913 15 312 21 472 12 072 11 965 72 098 1 781 904 18 463 24 125 11 645 14 414 561 064 4 629 131 099 2 539 2 131 20 364 24 724 14 025 12 718 5 347 135 604 2 764 1 796 21 303 24 520 13 378 10 583 561 149 264 659 8 260 2 527 1 583 115 13 257 4 012 3 045 17 423 3 681 30 5 823 11 2 472 75 967 1 823 984 17 246 24 049 12 927 14 392 86 15 236 4 689 3 495 21 936 3 956 42 5 796 9 2 938 98 799 1 410 1 203 19 088 24 136 16 351 15 941 4 4 5 99 16 138 5 487 4 505 28 173 4 627 33 6 587 5 3 113 116 364 1 585 1 306 20 310 24 899 18 934 14 488 19 21 8 285 20 301 2 582 3 127 1 926 3 277 11 218 169 2 923 2 270 63 4 121 12 250 62 192 406 720 41 430 1 323 1 011 7 259 5 015 1 186 41 167 4 272 2 490 13 526 8 566 3 069 1 662 117 17 058 5 155 4 311 33 755 4 179 50 6 437 13 3 735 126 268 1 902 1 608 20 986 25 823 17 247 14 581 687 38 525 1 042 1 127 7 505 5 479 1 132 40 389 4 280 2 167 13 056 8 443 3 523 1 155 110 17 877 5 222 5 050 35 048 4 166 49 6 722 8 4 370 125 460 2 187 1 798 20 559 25 264 14 857 13 155 36 44 45 51 54 91 279 242 27 69 61 112 79 54 59 65 71 75 73 73 71 25 20 23 26 25 26 27 42 36 31 63 64 55 54 65 29 27 30 29 29 29 31 32 101 109 122 158 172 186 161 179 6 10 13 10 12 12 13 31 25 18 24 32 43 45 17 14 21 16 24 29 38 25 28 28 25 24 52 56 63 71 72 28 12 36 17 17 16 15 16 12 62 72 87 67 67 71 132 50 55 58 57 61 60 50 35 46 52 52 69 71 71 57 53 56 69 4 4 15 16 10 15 21 25 29 32 44 38 46 24 52 78 79 67 62 66 70 64 33 15 35 39 40 35 36 31 30 31 38 39 43 44 48 80 75 68 42 53 38 31 39 43 51 60 66 81 89 92 84 78 79 102 134 136 147 161 75 54 29 44 33 52 54 58 59 63 47 58 60 62 65 72 80 72 71 20 21 24 35 27 28 25 93 107 48 82 62 10 9 10 9 10 10 64 63 66 64 66 70 72 73 42 167 184 200 204 213 5 21 16 35 31 25 27 2 9 10 10 11 13 14 33 35 44 63 56 45 22 21 52 60 64 57 56 50 56 3 8 14 17 11 12 14 34 35 54 54 53 55 56 99 125 150 161 167 69 228 171 172 13 20 20 19 18 17 18 60 72 64 70 76 78 77 70 50 55 59 67 70 70 74 73 71 107 108 127 114 124 47 76 100 119 117 115 114 26 26 27 26 26 26 83 123 125 130 127 130 31 31 31 32 34 174 188 170 172 173 175 12 12 13 14 16 19 44 40 42 43 42 38 29 48 63 64 73 71 30 23 34 34 27 25 35 69 69 71 51 104 39 38 23 25 13 10 6 8 10 8 131 149 101 117 101 91 63 62 64 67 67 68 81 83 97 109 111 105 86 18 16 21 17 15 14 46 50 53 54 49 45 94 84 99 104 81 87 70 68 64 70 73 37 37 36 33 33 34 49 51 52 57 61 64 62 64 77 71 63 98 104 113 119 113 107 164 187 217 216 202 29 61 40 74 63 81 67 66 73 75 70 81 70 63 61 66 64 60 26 28 27 30 32 58 39 49 7 7 8 10 9 7 75 80 82 85 87 87 237 241 279 259 259 262 30 29 36 34 38 38 18 17 21 24 25 28 38 45 52 46 45 45 29 29 22 33 32 23 57 53 59 56 57 57 15 11 6 15 9 57 60 60 69 78 81 182 212 247 266 262 272 119 129 144 171 194 224 21 22 26 29 33 68 73 75 75 71 68 71 68 68 69 66 63 122 150 171 153 129 120 120 124 112 112 100 96
6 800
7 000
7 700
11 324 1 330
4 301
4 059
4 630
10 149 1 405 1 547 6 881 5 692
7 366 5 988 1 740
9 526
9 677
463 1 723
1 865
9 040 486 778 2 638 2 263 956 13 934 1 361 1 154 8 026 6 285 1 866 2 074 113 10 566 697 1 492 9 476 1 840
4 599
1 408
11 553
12 008
13 510
545 11 949 15 569
14 763 17 164 9 620
5 331
5 421 6 1 454 23 112 660 887 13 631 19 955 10 038 8 965
AFR
22 654
23 067
25 840
107 012
121 005
212 910
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), Africa, 2009
Available funding Loans Funding gap Total TB control costs Grants (excluding Global Fund) Global Fund Completeness of budget data Cost of utilization of general health-care services .
NTP budget
4.7 3.0 2.2 1.9 0.3
1.8 0.2 0.1 0.3 0.1
0 0 0 0 0
1.1 0.1 0.3 0 0.05
1.0 2.8 1.8 0.5 0
0.8 0 0 1.0 0.2
12 0.7 0.7 5.9 0.2
17 3.7 2.9 7.8 0.4
53 0 0 0 0 0 5.9 12 0.6 20 0 1.0 0.1 7.0 6.2 0 21 18 1.1 0.1 8.5 1.2 38 35 2.7
0.3
3.3
11
39
0.9 12
0.9 66
38 26 1.4
11 1.1 0.2
19
1.1
37
6.6
1.0
12
2.5
15
5.1
42
8.1 8.7 3.0 1.9 0 0 0 0 0 0 0 11 0.1 0.02 0.3 7.9 1.2 0.05 4.4 0.4 0.02 0.2 4.4 1.2 0.8 13 0.7 0.7 2.2 6.0 < 0.01 < 0.01 19 < 0.01 < 0.01 0
0.3 3.8 0.9 0.6
0 0 0 0
< 0.01 1.0 0 0
2.9 4.0 1.3 1.3
4.9 < 0.01 0.8 0
Algeria Angola Benin Botswana Burkina Faso Burundi Cameroon Cape Verde Central African Republic Chad Comoros Congo Cte d'Ivoire DR Congo Equatorial Guinea Eritrea Ethiopia Gabon Gambia Ghana Guinea Guinea-Bissau Kenya Lesotho Liberia Madagascar Malawi Mali Mauritania Mauritius Mozambique Namibia Niger Nigeria Rwanda Sao Tome & Principe Senegal Seychelles Sierra Leone South Africa Swaziland Togo Uganda UR Tanzania Zambia Zimbabwe 1.7 0.9 0.6 0.04 0.4 5.9 2.0 9.8 9.6 3.6 1.9 0.4 31 6.2 0 55 1.4 1.0 3.3 0 0 0 0 0 0 1 46 97 158 333 1.1 0.3 0.1 4.7 2.1 4.1 3.5 1.1 4.8 5.4 7.1 3.4 < 0.01 0 11 7.4 2.4 9.6 251 0.1 0.3 1.2 4.2 1.3 4.1 251 9.3 2.0 18 29 14 22 704 59%
25 4.3 0 44 1.3 0.9 3.1
6.4 1.9 0 7.3 0.2 0.2 0.7
9.2 1.7 17 25 13 17
4.6 0.4 1.3 7.1 0.8 0.6
N N N C C C C C N N N N N C N C C C N C N N C N N C C C C N C C P C C C C N N P C C C C C C
AFR
371
60
N indicates data not available or not applicable; P indicates partial financial data; C indicates complete data and therefore included in analysis presented in chapter 3. Completeness of budget data in total row indicates percentage of countries providing complete financial data. Data can be downloaded from www.who.int/tb
Notes
Botswana
TABLE A3.8: cases not evaluated include 15 cases diagnosed with MDR-TB.
Malawi
TABLE A3.8: patients for whom treatment outcomes are not reported include those who died before starting treatment, and those whose diagnosis was changed.
Mozambique
TABLE A3.6: while DOTS is available in all administrative areas, only 1092 out of 1333 (82%) health facilities were providing DOTS services in 2007. TABLE A3.11: breakdown of notied cases by sex was not available. In 2007, of the 18 324 notied new smear-positive cases, 333 were in patients aged under 15 years, and 17 881 were patients aged 15 years or more.
Zimbabwe
TABLE A3.11: all new smear-positive cases in people aged 2544 years are shown under 2544 years.
THE AMERICAS
The Americas
|NTP MANAGER (OR EQUIVALENT) AND/OR PERSON(S) RESPONSIBLE FOR COMPLETING DATA COLLECTION FORM
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay USA US Virgin Islands Venezuela Lynette Rogers; Lynrod Brooks Oritta Zachariah; Janet Samuel Sergio Arias Alice Neymour R.A. Manohar Singh Marvin Manzanero Miram Nogales Rodriguez Draurio Barreira; Stefano Barbosa Codenotti; Gisele Pinto de Oliveira Athelene Linton Edward Ellis; Victor Galant A. K. Kumar; Timothy E. D. McLaughlin-Munroe Manuel Zuiga Gajardo; Zulema Torres Gaete Gilberto Alvarez Uribe; Ernesto Moreno Naranjo; Csar Castiblanco Montaez Zeidy Mata A. Mara Josefa Llanes Cordero David Johnson; Paul Ricketts Belkys Marcelino; Lourdes McDougall Alarcon Jorge Iiguez Luzuriaga; Christian Acosta Julio Garay Ramos; Marta De Abrego; Xochil Aleman Alister Antoine Carlos Paz Jeetendra Mohanlall Richard DMeza; Fleurimonde Charles Cecilia Elena Varela Martinez Michael Williams Martn Castellanos Joya; Martha A. Garca Avils; Hctor A. Tllez Medina Dorothea L Hazel Orlando Aristides Sequeira Perez Cecilia Lyons de Arango; C. Torres, J. Bravo Juan Carlos Jara Rodrguez; Celia Martnez de Cuellar; Ofelia Cuevas; Tomasa Portillo; Mirian Alvarez Csar Antonio Bonilla Asalde; Rula Aylas Salcedo; Ana Mara Chavez; Remy Quispe; Ronal Jamanca Ada S. Martinez; Mara del Carmen Bermdez Dianne Francis-Delaney; William Turner Alina Montane Jaime Roger Duncan; Jennifer George Dottin Ramoutar; Leilawat Mohammed Jorge Rodriguez de Marco Kenneth G. Castro; Ryan Wallace Mercedes Espaa Cedeo; Andrea Maldonado Saavedra
Table A3.1
TB/HIV Routine Indirect Routine Indirect Indirect Indirect Routine Indirect Routine Indirect Routine Indirect Indirect Indirect Sentinel Routine Indirect Indirect Routine Routine Routine Indirect Indirect Routine Indirect Indirect Routine Routine Routine Indirect Indirect Routine Routine Routine Source of estimates MDR (new) MDR (re-treat) Model Model Model Model DRS DRS Model Model Model Model Model Model Model Model DRS DRS DRS DRS Model Model DRS DRS Model Model DRS DRS DRS Model DRS DRS DRS DRS Model Model DRS DRS DRS DRS DRS DRS Model Model DRS DRS Model Model Model Model DRS DRS Model Model DRS DRS Model Model Model Model DRS DRS Model Model DRS DRS DRS DRS Model Model Model Model Model Model Model Model Model Model Model Model DRS DRS Model Model DRS DRS Cfr ss+ HIVDOTS non-DOTS 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.12 0.12 0.1 0.2 0.1 0.1 0.1 0.15 0.1 0.15 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.15 0.1 0.2 0.1 0.15 0.1 0.2 0.1 0.2 0.1 0.15 0.1 0.2 0.1 0.15 0.1 0.2 0.1 0.225 0.1 0.15 0.1 0.15 0.1 0.2 0.1 0.15 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.12 0.12 0.1 0.1 Duration ss+HIVDOTS non-DOTS 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 Duration ss-HIVDOTS non-DOTS 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5
Methods and assumptions for estimation of TB incidence, prevalence and mortality, the Americas
Trend
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay US Virgin Islands USA Venezuela
Reference year 1997 1997 1997 2000 1997 1997 1997 1997 2005 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 2003 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997 1997
Incidence est. based on Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Mort. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Mort. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif.
Group, exp. Group, moving ave. Country notifs, exp. Not estimated Group, moving ave. Not estimated Group, moving ave. Group, exp. Mortality, exp. Group, moving ave. Group, moving ave. Group, moving ave. Country notifs, exp. Country notifs, exp. Group, exp. Country notifs, exp. Group, exp. Group, exp. Group, exp. Country notifs, exp. Group, exp. Country notifs, exp. Country notifs, moving ave. Not estimated Group, exp. Not estimated Country notifs, exp. Group, exp. Group, moving ave. Country notifs, exp. Not estimated Country notifs, exp. Country notifs, exp. Country notifs, moving ave. Group, exp. Group, exp. Group, exp. Country notifs, moving ave. Not estimated Group, moving ave. Country notifs, exp. Group, moving ave. Country notifs, moving ave. Country notifs, exp.
Table A3.2
TB mortality, 1990 All forms* number rate All forms* number rate 3 5 12 172 146 11 115 2 14 725 92 102 2 1 669 2 2 038 16 333 491 724 9 6 764 13 517 2 715 4 8 479 898 29 333 4 218 178 21 283 <1 14 2 731 1 586 3 570 35 123 161 5 24 30 533 150 3 745 11 12 718 9 290 294 636 32 33 356 4 157 225 17 14 845 2 348 043 38 16 678 2 40 616 4 7 892 <1 11.3 2.1 14 10 214 22 5 31 44 4 40 4 155 48 10 5 4 12 35 11 6 13 69 101 40 4 63 122 306 59 7 20 8 7 49 47 58 126 4 9 14 25 116 11 14 22 10 4 34 923 43 2 24 434 13 019 95 96 945 27 14 1 027 1 222 357 816 233 6 713 440 40 1 017 94 218 293 2 356 125 26 111 1 483 1 160 2 13 <1 8 5 7 <1 <1 2 <1 <1 11 9 5 6 32 70 6 1 <1 2 7 5 8 27 2 3 <1 4 2 2 6 602 62 5 61 1 8 055 49 354 1 741 <1 1 111 8 889 268 397 5 3 618 7 312 1 458 2 4 582 471 15 462 2 276 94 11 604 <1 6 1 492 851 1 934 19 082 72 3 13 16 281 65 2 399 5 5 575 4 994 12 2 17 19 2 21 2 85 26 6 2 2 7 19 6 4 7 37 55 21 2 34 64 161 32 3 11 4 3 27 25 32 68 2 5 8 14 61 5 7 12 5 2 18 415 15 <1 11 196 5 859 33 43 425 12 6 462 550 161 367 105 3 021 198 18 458 42 98 132 1 060 56 9 50 519 522 1 5 <1 4 2 3 <1 <1 <1 <1 <1 5 4 2 3 14 31 3 <1 <1 <1 3 2 4 12 <1 1 <1 2 4 7 13 914 168 10 131 4 18 840 114 417 4 1 326 2 2 009 19 831 480 739 13 8 045 18 642 3 284 7 11 575 1 004 35 099 5 048 195 24 029 <1 29 3 139 1 493 4 495 37 922 206 6 29 47 710 199 4 775 18 9 484 10 662 34 9 35 51 3 46 6 198 60 16 4 5 12 43 11 7 19 82 140 48 6 87 136 366 71 7 23 8 15 56 45 73 136 5 12 18 39 155 15 17 23 16 3 39 462 22 <1 12 217 6 509 47 48 473 13 7 514 611 179 408 117 3 357 220 20 509 47 109 147 1 178 63 13 56 741 580 1 7 <1 4 2 3 <1 <1 1 <1 <1 5 5 3 3 16 35 3 <1 <1 <1 3 2 4 14 <1 2 <1 2 <1 <1 1 759 30 <1 20 <1 2 381 8 419 <1 175 <1 170 2 474 39 60 1 1 296 3 013 494 <1 1 619 174 6 814 686 30 2 552 <1 3 334 139 619 4 368 21 <1 3 6 131 26 <1 84 2 1 267 1 403 4 <1 4 9 <1 7 <1 25 4 2 <1 <1 1 5 <1 <1 2 13 23 7 <1 12 24 71 10 1 2 <1 1 6 4 10 16 <1 1 2 5 29 2 1 3 2 <1 5 196 14 <1 7 122 2 473 11 8 234 3 2 299 454 99 258 62 2 279 118 11 209 21 23 83 428 48 8 18 143 261 <1 4 <1 2 1 1 <1 <1 <1 <1 <1 3 3 1 2 8 24 2 <1 <1 <1 <1 1 2 10 <1 <1 <1 <1 7.6 30 17 21 3.0 14 5.7 4.7 5.8 5.5 2.0 15 9.0 13 10 26 23 10 23 4.8 3.5 14 8.2 6.7 24 17 15 12 12 1.1 2.2 1.2 1.5 1.2 0.9 0.8 0.7 1.5 1.5 < 0.05 1.3 6.6 4.9 0.3 3.0 1.7 1.8 1.8 1.4 2.4 0.6 1.5 2.1 5.3 1.4 1.9 < 0.05 0.5 11 15 11 10 4.7 5.4 7.5 3.8 10 4.8 5.3 11 20 24 7.0 26 9.1 9.3 12 8.9 22 7.8 10 3.9 24 10 17 6.1 13 <1 394 3 3 234 1 443 24 22 310 9 3 <1 646 1 283 22 374 23 595 106 3 986 46 48 89 3 270 <1 2 3 154 119 Percentage of new re-treat <1 1 2 602 28 4 16 <1 2 978 10 881 <1 264 <1 558 3 245 100 321 2 1 986 4 173 758 <1 1 189 43 5 754 808 27 9 173 <1 5 742 159 498 7 415 68 <1 4 6 56 24 <1 104 3 2 396 1 002 57 395 8 4 2 8 11 1 8 <1 45 7 4 <1 1 4 9 3 3 3 27 41 15 <1 13 6 81 17 1 11 2 3 18 7 12 34 2 2 3 5 14 2 5 3 3 <1 5 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident number rate number rate TB cases (%)
Estimated burden of TB, the Americas, 1990 and 2007

MDR, 2007 Number among all cases smear-positive <1 272 2 2 154 1 056 16 15 201 6 3 <1 438 978 18 257 15 342 72 2 754 38 37 54 2 428 <1 2 3 97 7 261
2 6 19 442 113 19 74 4 16 972 125 064 3 2 647 2 4 962 18 440 557 2 695 10 8 323 17 133 4 204 4 6 633 196 21 729 4 779 155 51 481 <1 27 4 458 1 144 2 560 69 063 385 4 22 30 265 138 3 861 20 24 030 6 966
24 10 60 44 7 40 7 255 84 19 10 7 38 53 18 25 15 114 167 82 5 74 27 306 98 7 61 9 14 108 47 60 317 11 10 16 27 66 11 26 28 19 9 35
1 3 10 649 47 8 41 2 9 328 67 773 2 1 183 <1 2 727 10 128 306 1 482 6 4 514 9 387 2 306 2 3 645 105 11 684 2 554 85 28 207 <1 12 2 450 623 1 407 37 890 173 2 12 16 145 62 2 472 9 10 602 3 822
13 5 33 18 3 22 3 140 45 11 4 3 21 29 10 14 8 62 91 45 3 41 14 164 52 4 34 5 6 59 26 33 174 5 6 9 15 36 5 14 15 9 4 19
3 10 31 223 138 22 121 6 25 170 186 010 5 2 036 3 5 913 30 585 911 3 353 17 13 321 28 981 6 815 7 10 104 288 34 062 6 872 245 84 578 2 54 6 012 1 787 4 018 85 772 603 7 36 50 437 206 5 1 075 31 18 111 9 014
38 16 96 54 8 65 10 377 124 32 7 10 45 88 30 32 24 183 282 133 7 113 39 479 141 10 101 14 28 145 74 95 394 17 17 26 45 109 17 42 35 30 7 46
AMR
415 623
57
223 876
31
598 017
82
Table A3.3
Number of cases 1995 2 5 16 662 126 14 88 3 16 324 112 826 3 2 096 2 3 703 17 871 541 1 717 10 7 808 16 221 3 652 4 7 205 473 24 397 4 670 164 38 578 1 20 3 875 1 293 2 923 55 509 420 4 22 30 241 144 3 833 15 20 296 7 821 368 617 360 528 352 823 345 176 338 008 330 965 324 415 318 006 311 897 306 017 300 239 294 636 57 55 54 52 50 48 46 45 43 42 40 39 38 37 35 2 5 16 218 128 14 90 3 16 196 110 862 3 2 048 2 3 516 17 762 539 1 590 10 7 718 16 010 3 568 4 7 302 483 24 850 4 636 166 36 775 1 19 3 771 1 319 2 983 53 376 387 4 23 30 284 144 3 828 15 18 881 7 959 2 5 15 779 130 13 93 3 16 062 108 926 3 1 983 2 3 336 17 648 537 1 472 10 7 627 15 786 3 485 4 7 402 526 25 303 4 597 167 35 031 1 18 3 665 1 346 3 042 51 289 355 4 23 30 340 145 3 823 14 17 697 8 096 3 5 15 346 132 13 95 3 15 925 107 009 3 1 884 2 3 163 17 528 534 1 363 10 7 535 15 551 3 401 4 7 505 533 25 754 4 557 168 33 315 0 17 3 558 1 373 3 101 49 253 310 4 23 30 357 146 3 817 14 16 600 8 232 3 5 14 919 134 12 98 3 15 787 105 104 2 1 818 2 2 998 17 402 531 1 261 10 7 441 15 308 3 315 4 7 614 581 26 201 4 515 170 31 611 0 16 3 450 1 400 3 160 47 273 267 4 23 30 344 146 3 810 13 15 853 8 367 3 5 14 496 136 12 100 3 15 647 103 213 2 1 770 2 2 840 17 270 527 1 166 9 7 347 15 060 3 227 4 7 728 666 26 643 4 473 171 29 921 0 15 3 342 1 426 3 219 45 350 229 5 23 30 347 147 3 801 13 15 073 8 501 3 5 14 081 138 12 103 3 15 505 101 337 2 1 770 2 2 689 17 132 522 1 078 9 7 251 14 806 3 138 4 7 847 764 27 082 4 430 172 28 261 0 15 3 234 1 453 3 278 43 488 197 5 23 30 355 147 3 791 12 14 604 8 634 3 5 13 674 139 11 105 2 15 359 99 473 2 1 716 2 2 545 16 986 517 997 9 7 154 14 550 3 050 4 7 970 848 27 520 4 387 173 26 664 0 15 3 127 1 480 3 337 41 687 198 5 23 30 384 148 3 781 12 14 143 8 767 3 5 13 279 141 11 108 2 15 209 97 619 2 1 698 2 2 408 16 834 511 921 9 7 057 14 291 2 962 4 8 096 871 27 962 4 344 175 25 160 0 14 3 023 1 507 3 395 39 950 189 5 23 30 410 148 3 771 12 13 833 8 899 3 5 12 897 143 11 110 2 15 053 95 773 2 1 689 2 2 278 16 674 505 850 9 6 960 14 033 2 877 4 8 223 908 28 412 4 301 176 23 766 0 14 2 922 1 533 3 454 38 278 188 5 23 30 453 149 3 761 12 13 495 9 030 3 5 12 528 145 11 113 2 14 892 93 933 2 1 679 2 2 155 16 507 498 785 9 6 862 13 774 2 795 4 8 351 904 28 869 4 259 177 22 479 0 14 2 825 1 560 3 512 36 669 174 5 23 30 493 149 3 753 11 13 112 9 161 3 5 12 172 146 11 115 2 14 725 92 102 2 1 669 2 2 038 16 333 491 724 9 6 764 13 517 2 715 4 8 479 898 29 333 4 218 178 21 283 0 14 2 731 1 586 3 570 35 123 161 5 24 30 533 150 3 745 11 12 718 9 290 24 10 60 44 7 40 7 255 84 19 10 7 38 53 18 25 15 114 167 82 5 74 27 306 98 7 61 9 14 108 47 60 317 11 10 16 27 66 11 26 28 19 9 35 24 10 57 44 6 40 6 247 81 18 9 6 35 52 18 23 15 111 162 79 5 74 31 306 95 7 57 9 13 103 47 60 301 10 10 16 27 61 11 24 27 18 10 35 24 9 55 44 6 40 6 240 78 17 9 6 33 50 17 22 15 108 157 75 5 73 26 306 92 7 54 9 13 98 47 60 285 11 10 16 27 49 11 23 27 17 10 35 24 9 53 44 6 40 6 233 76 16 8 6 31 49 17 20 14 104 153 72 5 72 34 306 89 7 50 9 12 94 47 60 270 12 10 16 27 51 11 22 27 16 9 35 23 8 51 44 6 40 6 226 73 15 8 6 29 48 16 18 14 101 148 69 5 72 41 306 87 7 47 9 11 89 47 60 255 12 10 15 27 49 11 21 26 15 9 35 23 8 49 44 5 40 5 220 71 15 7 5 27 47 16 17 14 99 144 66 4 71 55 306 84 7 44 8 11 85 47 60 242 12 10 15 27 51 11 20 26 15 8 35 23 8 47 44 5 40 5 213 69 14 7 5 25 46 15 16 14 96 140 64 4 70 64 306 82 7 41 8 10 81 47 60 229 11 10 15 26 58 11 19 26 14 7 35 23 7 45 44 5 40 5 207 67 14 7 5 24 45 15 14 14 93 136 61 4 70 65 306 80 7 39 8 10 78 47 59 217 10 10 15 26 67 11 18 25 14 7 35 23 7 44 44 5 40 5 201 64 13 7 5 22 44 14 13 14 90 132 58 4 69 71 306 77 7 36 8 10 74 47 59 205 9 10 15 26 79 11 18 25 13 6 34 23 7 42 44 4 40 4 195 62 12 6 4 21 43 14 12 14 88 128 56 4 68 73 306 75 7 34 8 9 71 47 59 195 8 10 15 26 83 11 17 25 12 6 34 23 6 40 44 4 40 4 190 60 12 6 4 19 42 14 11 14 85 124 54 4 68 79 306 73 7 32 8 9 68 47 59 184 7 10 15 26 79 11 16 24 12 6 34 22 6 39 44 4 40 4 184 58 11 6 4 18 41 13 10 14 83 121 51 4 67 91 306 71 7 30 8 8 64 47 59 174 6 10 15 26 79 11 15 24 11 5 34 22 6 37 44 4 40 4 179 57 11 6 4 17 40 13 10 14 80 117 49 4 67 104 306 69 7 28 8 8 62 47 59 165 5 10 15 25 80 11 15 24 11 5 34 22 6 36 44 4 40 4 174 55 11 5 4 16 39 12 9 14 78 114 47 4 66 115 306 67 7 26 8 8 59 47 59 156 5 10 15 25 86 11 15 23 11 5 34 22 6 35 44 4 40 4 169 53 11 5 4 15 38 12 8 14 76 111 45 4 65 118 306 65 7 24 8 8 56 47 59 148 5 9 15 25 91 11 14 23 11 5 34 22 6 33 44 4 40 4 164 51 11 5 4 14 37 12 8 13 73 107 43 4 65 123 306 63 7 23 8 8 53 47 58 140 5 9 14 25 100 11 14 23 10 5 34 34 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 22 6 32 44 4 40 4 159 50 10 5 4 13 36 11 7 13 71 104 41 4 64 122 306 61 7 21 8 8 51 47 58 133 4 9 14 25 108 11 14 23 10 4 34 33 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, the Americas, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 22 5 31 44 4 40 4 155 48 10 5 4 12 35 11 6 13 69 101 40 4 63 122 306 59 7 20 8 7 49 47 58 126 4 9 14 25 116 11 14 22 10 4 34 32
1990
1991
1992
1993
1994
2 6 19 442 113 19 74 4 16 972 125 064 3 2 647 2 4 962 18 440 557 2 695 10 8 323 17 133 4 204 4 6 633 196 21 729 4 779 155 51 481 1 27 4 458 1 144 2 560 69 063 385 4 22 30 265 138 3 861 20 24 030 6 966
2 6 18 962 115 18 76 4 16 867 123 059 3 2 529 2 4 730 18 356 554 2 505 10 8 239 17 016 4 099 4 6 725 225 22 172 4 771 156 49 059 1 25 4 357 1 167 2 621 66 718 349 4 22 30 249 139 3 856 19 25 049 7 114
2 6 18 491 117 17 79 4 16 765 121 003 3 2 433 2 4 509 18 267 552 2 326 10 8 155 16 889 4 002 4 6 819 189 22 614 4 760 158 46 751 1 24 4 262 1 192 2 682 64 409 402 4 22 30 199 140 3 851 18 24 867 7 258
2 6 18 025 119 16 81 4 16 664 118 926 3 2 306 2 4 298 18 174 549 2 157 10 8 070 16 749 3 911 4 6 915 250 23 057 4 745 160 44 553 1 23 4 169 1 216 2 743 62 135 420 4 22 30 207 141 3 847 17 24 211 7 401
2 6 17 566 122 15 83 3 16 558 116 859 3 2 233 2 4 094 18 077 546 2 000 10 7 984 16 592 3 823 4 7 011 303 23 501 4 726 161 42 461 1 22 4 075 1 241 2 803 59 893 427 4 22 30 200 142 3 842 16 22 954 7 542
2 5 17 111 124 15 86 3 16 445 114 824 3 2 147 2 3 896 17 976 543 1 853 10 7 896 16 416 3 736 4 7 108 408 23 947 4 701 163 40 469 1 21 3 977 1 267 2 863 57 683 429 4 22 30 211 143 3 837 16 21 715 7 682
AMR
415 623
408 987
401 292
393 343
384 962
376 797
Table A3.4
Prevalence of TB (all forms) 2000 35 8 52 45 5 39 7 238 83 19 5 7 21 51 14 13 20 119 194 69 7 90 98 403 70 7 42 13 17 85 60 90 210 9 15 20 35 115 15 16 19 4 27 39 51 50 48 46 43 41 38 38 5 5 5 4 4 4 4 4 1 1 <1 <1 <1 <1 <1 <1 35 9 51 45 4 36 6 229 80 18 4 5 19 62 14 12 22 115 185 66 7 91 112 397 70 7 38 13 17 80 51 89 198 8 13 18 36 113 16 23 18 4 25 41 35 7 42 51 4 36 6 223 77 18 4 6 19 60 15 11 20 102 170 62 7 89 126 388 72 7 35 13 17 79 48 88 187 7 12 17 36 113 15 23 18 4 27 41 35 9 41 51 4 40 6 218 72 17 4 6 18 58 14 10 20 93 162 60 7 89 136 380 71 7 33 10 16 73 49 85 182 6 14 19 34 120 15 22 17 4 25 39 35 8 39 50 4 42 6 211 63 16 4 5 15 55 12 9 20 90 155 57 7 86 130 377 72 7 31 13 16 69 44 85 167 6 13 18 36 126 15 22 17 3 23 38 34 8 39 50 4 38 6 205 60 17 4 5 15 53 12 8 21 85 155 52 7 85 132 368 71 7 27 10 15 68 44 81 155 6 15 18 36 136 15 22 16 3 24 38 34 9 37 50 3 41 6 202 56 16 4 6 13 44 12 8 13 84 148 50 7 84 133 368 70 7 25 12 15 64 44 74 143 6 14 18 34 146 15 18 16 3 25 38 34 9 35 51 3 46 6 198 60 16 4 5 12 43 11 7 19 82 140 48 6 87 136 366 71 7 23 8 15 56 45 73 136 5 12 18 39 155 15 17 16 3 23 39 4 <1 5 3 <1 4 <1 29 4 2 <1 <1 2 6 1 1 2 15 27 8 <1 11 11 53 5 <1 5 2 2 11 6 11 22 <1 2 2 4 14 1 1 2 <1 3 4 4 <1 5 3 <1 3 <1 27 4 2 <1 <1 2 7 1 1 3 15 26 8 <1 11 13 52 5 <1 4 2 1 10 5 11 20 <1 2 2 4 14 1 3 2 <1 2 4 4 <1 5 5 <1 2 <1 26 4 2 <1 <1 2 6 1 1 2 13 24 7 <1 10 14 51 6 <1 4 2 1 10 4 11 19 <1 1 2 4 14 2 2 2 <1 2 4 4 <1 4 5 <1 3 <1 26 4 2 <1 <1 2 6 1 1 2 12 22 7 <1 10 15 50 8 <1 4 <1 2 9 4 11 19 <1 2 2 4 15 1 2 2 <1 2 4 4 <1 4 5 <1 5 <1 25 4 2 <1 <1 1 6 <1 <1 2 11 21 7 <1 10 15 49 8 <1 3 2 1 9 3 10 17 <1 2 2 4 15 1 2 2 <1 2 4 4 <1 4 5 <1 3 <1 24 4 2 <1 <1 2 6 <1 <1 3 10 22 6 <1 10 15 48 8 <1 3 <1 1 9 3 10 16 <1 2 2 4 16 1 2 2 <1 2 4 4 <1 4 5 <1 3 <1 24 3 2 <1 <1 1 5 <1 <1 1 10 20 6 <1 10 14 48 8 <1 3 2 1 8 3 9 14 <1 2 2 4 17 1 2 2 <1 2 4 4 <1 4 5 <1 5 <1 24 3 2 <1 <1 <1 5 <1 <1 2 10 19 6 <1 10 15 47 8 <1 2 <1 1 6 3 9 14 <1 1 2 5 18 1 1 2 <1 2 4 <1 <1 <1 3 <1 1 <1 1 2 <1 <1 <1 <1 <1 <1 <1 <1 6 4 2 <1 2 7 26 1 <1 <1 <1 <1 <1 1 1 2 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 1 2 <1 <1 <1 <1 <1 <1 <1 <1 6 4 2 <1 2 8 26 1 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 1 2 <1 <1 <1 <1 <1 <1 <1 <1 4 4 2 <1 2 8 25 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 5 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 1 <1 1 1 <1 <1 <1 <1 <1 <1 <1 <1 4 4 2 <1 2 9 24 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 6 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 2 <1 1 1 <1 <1 <1 <1 <1 <1 <1 <1 4 4 2 <1 2 7 24 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 7 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 1 <1 1 1 <1 <1 <1 <1 <1 <1 <1 <1 3 4 2 <1 2 7 23 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 8 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 2 <1 1 1 <1 <1 <1 <1 <1 <1 <1 <1 3 4 2 <1 2 8 23 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 9 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 2 <1 1 1 <1 <1 <1 <1 <1 <1 <1 <1 3 3 1 <1 2 8 24 2 <1 <1 <1 <1 <1 <1 1 2 <1 <1 <1 <1 10 <1 <1 <1 <1 <1 <1 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) Mortality HIV+
Estimated incidence, prevalence and mortality rates (per 100 000 population), the Americas, 20002007
2000
2001
2002
2003
2004
2005
2006
2007
3 13 <1 8 5 8 <1 <1 2 <1 <1 15 9 6 6 21 66 10 1 1 1 6 3 10 10 2 <1 2 3
3 13 <1 8 5 8 <1 <1 2 <1 <1 14 9 6 7 23 67 9 1 1 1 6 3 10 11 2 <1 2 3
3 13 <1 8 5 8 <1 <1 2 <1 <1 14 9 6 7 27 68 9 1 1 1 6 3 10 13 2 <1 3 3
3 13 <1 8 5 8 <1 <1 2 <1 <1 13 9 6 7 29 68 8 1 1 2 6 4 9 15 2 <1 3 3
3 13 <1 8 5 7 <1 <1 2 <1 <1 12 9 6 7 30 68 7 1 1 2 6 4 9 18 2 <1 3 4
2 13 <1 8 5 7 <1 <1 2 <1 <1 12 9 6 6 31 69 7 1 1 2 6 4 9 21 2 <1 3 4
2 13 <1 8 5 7 <1 <1 2 <1 <1 11 9 5 6 31 69 7 1 1 2 6 5 9 24 2 <1 3 4
2 13 <1 8 5 7 <1 <1 2 <1 <1 11 9 5 6 32 70 6 1 <1 2 7 5 8 27 2 <1 3 4
AMR
Table A3.5
Estimated incidence and case detection rates Estimated incidence Case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
Case notifications and case detection rates, DOTS and non-DOTS combined, the Americas, 2007
Population All notified New and relapse . thousands number number rate
0 2 10 683 48 16 63 100 62 84 100 100 15 15 50 3 11 7 11 18 14 33 6 6 87 63 66 51 100 51 70 50 86 23 223 0 0 0 6 3 130 0 29 2 45 0 0 25 16 17 13 14 10 18 9 7 10 12 4 16 0 0 42 0 0 104 2 351 0 0 0 23
0 2 9 755 46 16 63
0 2 25 14 5 22
0 2 4 985 32 8 54
0 2 13 10 3 19
0 0 3 103 6 0 0
0 0 1 444 7 8 2
0 0 61 0 0 0
0 0 162 1 0 7
0 0 0 1 0
0 0 0 0 0
0 0 456 1 0
0 0 472 0 0
0 2 5 411 38 8 63
0 43 79 31 150 49
0 95 76 52 173 89
0 0 0 0 0 0 0 0
7 67 9 4 7 8 13 16 5 6 12 3 6 2 9

861 23 065 0 449 0 496 1 636 110 184 0 830 480 358 0 376 301 4 472 470 20 3 213 1 0 0 0 0 1 0 0 0 0 0 0 0 6 775 0 0 0 0 2 0 12 133 990 9 993 1 346 4 304 5 395 704 125 098 0 248 0 13 0 90 0 0 0 0 8 828 3 525 38 2 0 7 0 420 10 3 39 260 139 76 105 67 294 636 157 225 71 158 51 86 3 014 0 0 1 0 88 7 1 713 0 0 0 0 50 50 37 489 0 0 0 6 0 120 39 925 0 0 0 0 0 0 74 0 0 0 0 0 1 453 833 1 282 18 571 85 4 17 4 79 97 61 84 61 85 76 40 97 98 66 93 77 155 139 24 201 95 87 68 76 76 64 65 76 66 100 100 33 69 74 46 69 69 1 8 0 13 88 8 0 18 10 19 0 0 101 0 0 0 87 0 0 0 6 0 189 0 359 0 63 52 56 55 57 100 95 33 60 63 37 53 55 0 0 0 0 0 0 0 0 0 0 116 14 3 0 198 210 18 0 45 46 46 0 0 485 0 40 793 0 808 1 1 469 8 029 322 432 3 2 414 3 493 942 3 3 398 519 7 915 1 974 96 11 682 1 51 100 70 81 75 70 100 74 88 72 100 86 44 64 81 80 78 50 10 15 9 16 13 31 100 48 66 59 57 100 57 71 57 100 75 39 56 71 75 63 50 455 470 686 5 510 29 0 0 8 59 132 5 726 1 535 55 041 32564 2 697 1 148 57 17 237 242 215 5 312 13 0 0 0 1 502 10 318 0 484 0 604 1 703 91 98 0 593 503 306 0 282 43 1 437 328 4 2 869 0 525 2 930 0 80 0 152 423 27 48 0 354 446 60 0 134 16 309 0 2 711 0 55 78 0 84 58 111 64 106 99 33 56 33 59 68 35 64 47 66 57 83 432 71 78 0 62 129 105 81 120 109 61 66 47 65 123 51 49 51 87 83 99 393 12 13 7 15 5 33 8 9 20 18 15 20 8 3 5 12 172 146 11 115 2 14 725 92 102 2 1 669 2 2 038 16 333 491 724 9 6 764 13 517 2 715 4 8 479 898 29 333 4 218 178 21 283 0 14 2 731 1 586 3 570 35 123 161 5 24 30 533 150 3 745 11 12 718 9 290 5 9 2 2 6 602 62 5 61 1 8 055 49 354 1 741 1 1 111 8 889 268 397 5 3 618 7 312 1 458 2 4 582 471 15 462 2 276 94 11 604 0 6 1 492 851 1 934 19 082 72 3 13 16 281 65 2 399 5 5 575 4 994
8 701 80 461 0 1 547 3 2 492 10 950 565 773 3 4 361 5 262 1 692 3 3 203 656 14 198 2 961 104 19 385 2
8 574 74 757 0 1 476 1 2 418 10 950 550 762 3 4 150 4 877 1 666 3 3 140 594 14 133 2 772 104 18 324 2
90 39 0 4 2 15 24 12 7 4 43 37 24 3 24 80 147 39 4 17 34
5 686 38 444 0 463 1 1 166 7 188 322 432 3 2 373 3 448 942 3 2 348 233 7 915 1 974 78 11 531 1
60 20 0 1 2 7 16 7 4 4 24 26 14 3 18 32 82 28 3 11 17
2 441 1 773 2 420 34 534 98 4 19 18
2 303 1 596 2 269 32 407 98 4 19 12
41 48 37 116 2 8 12 10
1 453 833 1 276 17 796 56 4 18 4
26 25 21 64 1 8 11 3
260
218
16
130
10
13 85 39 531 331 294 288 65 9 525 191 791 23 32 876 47 16 635 46 156 4 468 11 268 67 9 760 13 341 6 857 106 13 354 738 9 598 7 106 2 714 106 535 6 192 5 603 3 343 6 127 27 903 3 991 50 165 120 458 1 333 26 3 340 111 305 826 27 657
616
607
18
380
11
13 299 6 559
13 299 6 456
4 23
4 864 3 392
2 12
AMR
909 820
230 175
218 426
24
119 838
13
Table A3.6
. . Other number New pulm. lab. confirm. number Estimated incidence and case detection rate Estimated incidence DOTS case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
DOTS coverage, case notifications and case detection rates, the Americas, 2007
TB cases reported from DOTS services DOTS New pulmonary New extraOther Re-treatment cases coverage New and relapse. ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. % number rate number rate number number number number number number number
0 6 6 11
0 0 100 100 100 100 1 444 7 8 2 1 0 0 0 1 502 9 318 0 0 0 0 0 0 0 0 25 16 17 13 0 0 0 0 1 0 0 0 0 0 0 0 4 775 0 0 0 158 51 82 3 014 0 0 1 88 7 1 713 0 0 0 50 50 32 489 0 0 0 0 120 32 925 0 0 0 0 0 58 0 0 0 0 1 453 833 1 118 18 571 85 4 17 79 97 49 84 61 85 76 97 98 58 93 77 155 139 76 64 69 76 66 100 100 63 52 60 55 57 100 95 134 13 293 0 2 711 0 18 4 18 0 0 101 0 45 35 35 0 0 485 0 0 4 0 189 0 359 0 0 0 0 0 0 116 2 818 397 7 594 1 974 96 11 682 1 29 48 45 66 57 83 432 40 39 49 87 83 99 393 83 46 64 81 80 78 50 70 41 56 71 75 63 50 14 10 18 10 7 10 12 4 16 1 8 0 13 85 8 0 0 86 0 0 0 0 0 14 3 0 198 202 18 80 0 152 423 27 48 0 354 436 60 13 16 5 7 11 3 6 2 9 0 0 6 0 0 23 29 2 45 42 0 0 808 1 1 469 8 029 322 432 3 2 414 3 377 942 84 58 111 64 106 99 33 56 32 59 62 129 105 81 120 109 61 66 46 65 51 100 70 81 75 70 100 74 88 72 31 100 48 66 59 57 100 57 71 57 33 7 67 9 4 7 8 2 821 0 36 349 484 0 604 1 703 91 98 0 593 481 306 272 32 1 391 328 4 2 869 0 237 242 146 5 312 13 0 0 525 2 664 23 217 104 2 186 55 70 71 69 87 62 66 51 18 14 7 11 61 0 0 0 162 1 0 7 456 1 0 472 0 0 5 411 38 8 63 79 31 150 49 76 52 173 89 62 84 100 100 51 70 50 86 15 15 50 3
9 755 46 16 63
25 14 5 22
4 985 32 8 54
13 10 3 19
3 103 6 0 0
8 574 66 759
90 35
5 686 34 211
60 18
861 20 566
100 75 0 100 100 100 70 100 100 100 85 96 100 0 70 70 70 100 100 96 100 10 15 8 16 13 12 13 8 15
1 476 1 2 418 10 950 550 762 3 4 150 4 698 1 666
4 2 15 24 12 7 4 43 35 24
463 1 1 166 7 188 322 432 3 2 373 3 332 942
1 2 7 16 7 4 4 24 25 14
449 0 496 1 636 110 184 0 830 449 358
2 620 444 13 632 2 772 104 18 324 2
20 60 142 39 4 17 34
1 838 183 7 594 1 974 78 11 531 1
14 25 79 28 3 11 17
376 215 4 354 470 20 3 213 1
100 99 90 100 100 100 100 0
2 303 1 596 1 845 32 407 98 4 19
41 48 30 116 2 8 12
1 453 833 1 114 17 796 56 4 18
26 25 18 64 1 8 11
455 470 499 5 510 29 0 0
0 57 2 697 1 148 31 389 986 9 684 1 327 4 059 5 076 688 119 082 294 636 12 133 0 248 0 13 0 90 0 0 0 0 8 828 3 525 0 38 2 0 7 0 420
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay US Virgin Islands USA Venezuela 76 105 67 157 225 67 95 87 68 73 74 46 69 69 63 37 53 55 9 20 18 15 8 5 9
100
607
18
380
11
132
100 100
13 299 6 456
4 23
4 864 3 392
2 12
5 726 1 535
3 5 12 172 146 11 115 2 14 725 92 102 2 1 669 2 2 038 16 333 491 724 9 6 764 13 517 2 715 4 8 479 898 29 333 4 218 178 21 283 0 14 2 731 1 586 3 570 35 123 161 5 24 30 533 150 3 745 11 12 718 9 290
2 2 6 602 62 5 61 1 8 055 49 354 1 741 1 1 111 8 889 268 397 5 3 618 7 312 1 458 2 4 582 471 15 462 2 276 94 11 604 0 6 1 492 851 1 934 19 082 72 3 13 16 281 65 2 399 5 5 575 4 994
AMR
91
208 419
23
114 307
13
52 053
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 0 3 0 8 35 8 2 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 TB pts HIV-positive Lab-confirmed DST MDR Re-treatment Re-treatment MDR in new cases in new cases DST MDR HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, the Americas, 20062007
6 688 3 1 6 2 1 0 0 0 0 0 0 0 0 16 0 0 107 77 275 1 140 457 10 0 576 81 13 0 118 0 14 0 0 22 0 63 0 24 40 684 12 0 12 69 238 0 0 0 0 28 362 0 0 0 0 404 0 0 0 7 792 0 360 57 593 0 495 3 0 0 656 0 84 2 236 335 2 0 265 1 0 8 0 78 6 149 550 51 1 1 864 1 993 1 566 505 41 1 0 322 150 206 557 0 3 0 5 103 3 8 141 0 56 0 1 8 141 0 35 832 0 10 0 7 111 1 3 0 0 336 0 1 113 1 98 200 0 275 0 7 0 2 8 1 1 0 2 5 0 0 2 10 3 2 9 0 0 0
0 116 2 1 0
0 19 2
0 199 2
0 4 229 61 5 84 2
0 3 221 33 2 10 0
0 2 326 43 8 63
0 0 314 13 2 10

52 115 0 441 0 61 7 828 345 66 4 1 771 0 1 631 1 960 566 5 996 1 787 81 1 047 16 383 18 426 562 8 464 1 753 86 1 550 0 53 159 1 937 183 19 561 23 8 39 4 0 77 0 0 0 0 0 0 0 2 39 4 0 0 0 7 792 0 62 0 61 453 38 4 0 218 392 176 0 142 75 1 584 202 25 540 1 0 1 854 47 5 200 101 0 0 56 15 10 0 5 24 9 0 0 61 0 6 15 20 5 260 584 87 0 78 11 12 19 0 2 0 1 770 67 15 149 92 2 18 18 1 7 1 5 0 1 0 243 67 112 21 2 1 7 8 5 5 945 2 0 0 0 200 20 184 171 87 0 0 0 208 392 8 5 1 114 2 0 0 0 0 0 237 15 33 1 198 0 0 0 0 40 33 0 0 4 831 0 0 0 0 0 1 250 8 539 1 0 270 47 31 20 0 0 5 24 13 0 81 13 0 0 36 0 22 8 234 3 224 0 96 8 997 113 559 14 619 879 188 0 94 578 13 885 960 400 8 142 3 549 882 443 159 9 259 119 3 2 522 9 274 19 13 061 98 0 532 479 76 4 183 19 3 1 839
8 193 0 10
2 38 0 10
456 1 819 0 10 4 195 2 651 82 480
454 4 044 0 10 4 285 2 932 98 480 2 182 310 200 1 181 14 247 148 3 1 153 1
50 867 27 15 0 6 10 10 0 11 1 0 4 1 56 1
1 4 1 1 0 1 1 1 0 1 0 0 1 1 14
161 310 198 1 35 14
101 6 555 1
177 58 99 1 534
3 8 6 60
1 1 1 6
1 58 72 1 498
1 2 1
0 0 1
0 0 1
1 2 1
547
18
125
AMR
13 874
1 487
111
9 040
Table A3.8
% Not eval. Success 4 11 0 31 20 6 20 1 40 13 20 5 0 43 20 Number of cases Notified Regist'd Success Not eval. Number Regist'd % New smear-positive cases, non-DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
Treatment outcomes, the Americas, 2006 cohort
New smear-positive cases, DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred
4 834 0 4 60 2 1 0 8 654 130 0 100 47 59 66 9 17 9 8 3 0 21 5 19 10 2 14 34 59 143 572 572 100 1 1 0 0 0 0 99 1 1 55 588 1 1 1 1 0 0 1 56 588 102 100 4 63 45 9 4 9 38 13 11 3 0 3 48 72 56 269 153 5 1 384 5 58 66 0 52 5 1 1 273 273 100 14 47 8 18 3 9 62 2 0 0 8 63 149 169 113 53 4 12 1 30 0 3 1 0 87 25 50 0 13 13 0 0 5 12 6 3 1 3 1 2 1 0 0 285 142 1 786 0 14 49 70 43 22 3 15 4 3 2 0 3 26 8 9 1 1 1 0 0 16 10 0 57 71 73 4 25 7 5 39 6 1 3 3 4 2 2 44 0 1 0 0 5 47 68 82 86 41 80 27 6 5 80 7 2 9 10 0 9 4 6 1 0 5 43 13 12 20 14 2 5 5 0 3 18 3 0 0 11 32 64 71 80 59 428 616 136 43 54 76 5 12 0 5 6 4 6 8 4 8 41 10 0 3 1 1 0 3 20 15 7 3 2 0 13 487 156 25 50 4 0 10 3 7 76 0 0 1 2 1 1 2 2 6 7 3 7 8 4 3 1 1 34 57 6 8 4 3 3 12 83 72 694 4 955 66 15 4 28 5 6 2 2 10 16 4 11 9 23 38 0 7 0 0 19 4 9 70 43 48 66 68 83 48 66 76
4 622 40 5
96
125
24 0 100
40 75 0
6 20 0
0 5 0
8 0 0
3 0 0
20 0 0
63 75 100
750 5 0
33 0 0
5 788 32 463
5 642 34 818
97 107
81 33
2 39
3 4
101
51
407 0 1 533 7 648 285 432 8 2 515 2 610 913 0 14 3 0 50 2 1 0 0 0 0 0 0 10 13 0 85 71 88 90 50 78 74 91
411 0 1 142 7 648 296 431 8 2 356 2 610 913
74 100 104 100 100 94 100 100
85 62 83 87 25 73 71 90
9 5 3 25 5 3 1
7 6 3 7
3 3 4
2 501 239 6 873 2 018 61 11 874 0
2 501 224 6 873 1 944 61 11 564
100 94 100 96 100 97
42 4 74 78 8 74
4 63 8 7 33 6
3 4 5 5 18 6
1 285 858 1 179 19 251 69 1 13 8 0 0 75 57
2 504 853 1 179 19 251 69 2 20
195 99 100 100 100 200 154
48 66 54 75 80
3 6 5 2 19
15
41 13 30 3 0 100 65
20
0 0 3 15 0 0 0
89 79 83 78 80 100 80
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay US Virgin Islands USA Venezuela 38 74 3 11 0 11 0 3 76 2 0 11 6 3 10 75 10 509 15 153 144 26 46 4 1 0 3 2 23 0 64 82 10 3 10 72 257 12 282 77 37 0 18 8 6 1 3 11 14 3 6 0 16 77 55
7 305
301
99
82
5 091 3 547
5 140 3 497
101 99
82
64 0
9 5
AMR
114 680
116 925
102
55
20
Table A3.9
After failure, DOTS % of cohort Not eval. Died Died % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, the Americas, 2006 cohort
Number regist'd
ComplCured eted
Died
100 1 0 2 0 0 0 50 50 0 0 0 0 2 0 0 0 0 50 50 0 0 0
31 0
40 100
15 0
0 0
7 0
0 0
7 0
71 100
2 056 37 0 7 7 7 7 66 0 53
25
26
11
23
51
224
10
18
10
46
15
1 542
14
19
27
13
20
33
76 0 100
11
42
47
19
10
14
18 54 67 0 7 0 5 7 0 32 23 6 5 14 0 0 1 0 58 3 24 0 51 71 171 136 18 35 46 61 6 7 0 4 7 0 2 4 11 33 27 22 5 4 14 4 6 41 54 61 20 1 7 57 74 80 19 70 17 0 44 71
72 69
11 19
11 9
0 0
83 87
1 3
100 33
0 0
100 33
14 2
36 50
43 50
0 0
43 50

38 4 0 10 36 0 7 15 14 3 25 36 100 64 0 59 2 400 0 49 50 5 0 10 0 5 50 18 0 3 31 64 27 35 0 57 30 9 0 3 0 11 70 17 0 3 0 0 0 11 30 66 50 54 0 11 2 9 50 3 27 50 36 18 9 0 0 36 100 23 41 52 15 19 6 13 4 5 0 2 0 0 12 9 66 79 76 0 52 27 266 0 46 11 19 0 26 16 38 59 58 0 81 2 100 0 0 0 0 0 0 100 5 40 0 0 0 40 0 20 40 0 14 64 410 20 8 7 18 8 6 33 27 77 2 699 27 14 6 2 26 9 16 41
238 338 101
51 67 80
5 8 0
5 4 5
6 8 2
11 11 6
1 1 0
26 234
4 58
27 6
4 10
4 5
19 12
4 6
2 572
0 57
100 7
0 8
0 5
0 11
0 2
0 61 66 1 520 0
43 52 74
23 27 2
13 2 3
15 8 7
31
77
13
257
77
11
AMR
5 851
50
14
Table A3.10 DOTS treatment success and case detection rates, the Americas, 19942007
2003 100 58 53 63 75 100 98 83 72 57 73 77 82 86 45 46 52 49 54 61 52 43 58 55 39 78 73 77 4 77 4 75 7 78 7 80 9 75 17 75 43 76 51 71 64 71 69 67 85 118 100 111 101 85 101 4 7 71 44 20 67 66 62 396 60 76 52 173 89 136 31 100 46 39 47 67 49 284 67 2004 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 100 64 64 66 82 67 36 83 85 93 9 46 43 2 92 95 13 57 56 56 56 52 56 56 6 82 88 88 94 92 57 88 87 45 62 68 84 75 81 83 80 81 78 77 85 66 62 100 89 60 91 75 100 58 59 2002
1994 100 54
1995
1996
1997
1998
1999
2000
50 55 72 78 79 73 35
50 59 66
88
91 72 55 99 130
66
62
71
77
62 91
74 89
40
39
36
83
79
80
77
83 74
58 130 87
86 79 79
90
92 100
90
94
83 82 81 91
82 80 76 93
86 84 85 92
85 83 94 93
78 71 89 91
87 30 31 96
79 88 120 97
92 8 118 93
58 130 99 18 150 90 95 26 120 100
81
77
78
42 100 83 85 72 93 100 85 82 88 78 84 88 81 84 88 80 85 90 85 83 91 85 71 88 90 50 78 74 91 9 5 58 63 38 53 67 42 58 73 28 69 96 9 76 91 39 40 31 58 130 85 105 100 160 69 35 61
62 129 105 81 120 109 61 66 46 65
62
61
81
73
79
73
67
72 75
79 65
79 93 89 78
81 91 70 88 74 80 67 81 88 57 77 11 2 90 26 22 15 101 36
86 91 73 89 45 76
85 90 75 86 78 83
84 85 78 87 49 84
91 57 78 87 53 83
85 72 80 85 46 82
47 68 82 86 41 80
50 11 19 106 100 64
40 21 25 125 83 89
44 10 33 129 66 72
42 31 37 91 88 86 452
54 27 37 86 75 78
54 41 44 89 57 93 405
55 50 45 88 65 97
40 39 49 87 83 99 393
81
80
79
81 51 102 88 58 113 56 55 48 18 94 72
82 51
81 80
72
81
81
82 12
80 8
81
83 68 100 100 50 80 25 89 64 86 69
89 69
90 69
67 86
92 72 25 82
93 70 50 89 100
82 67 77 90 64 99 66 165 80 18 91 76 82 72 63 37
83 65 86 90 76
82 73 92 92 60
84 74 85 89 66
87 78 83 90 71
85 80 83 91 75
89 79 83 78 80 100 80
78 32 4 88 67
82 70 9 88 72
75 80 8 87 88 40 63
82 74 19 82 70
80 106 20 84 76 86 30
78 105 33 89 71 86 37
83 103 62 97 88 39 101 49
97 98 58 93 77 155 139
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay US Virgin Islands USA Venezuela 85 83 76 81 82 83 83 82 78 75 26 26 29 33 36 83 80 83 82 83 82 82 81 64 83 64 82 85 73 84 75 85 78 86 82 84 78 43 85 82 86 67 84 87 76 94 84 79 94 73 84 75 122 88 79 85 68 42 72 85 66 45 89 86 81 49 90 87 79 57 87 86 75 62 367 76 89 72 72 95 87 68 73
83
80
77
71 84
83
72 68
68 50 76 74
79 80
79 72
81 81
82 82
AMR
76
78
83
82
81
83
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, the Americas, 2007
5564 1 389 1 0 6 1.4 1.7 1.7 1.8 1.5 2.1 1.6 2.1 1.4 2.0 328 2 726 35 1 139 574 17 0 29 57 4 0 242 335 85 0 174 198 50 0 103 133 45 1 53 100 33 0 43 123 56 0 52 99 12 0 645 821 264 1 536 565 160 0 312 415 118 75 0 121 786 31 2 0 8 138 3 32 0 59 599 16 33 0 75 620 24 33 0 63 459 19 11 0 49 393 16 13 0 39 286 16 51 0 78 461 15 7 0 11 282 7 63 0 145 1 217 60 74 0 212 1 324 81 84 0 203 1 153 47 61 0 218 1 105 48 48 1 178 860 33 126 0 199 1 247 46 354 2 075 125 344 736 2 952 453 3 250 243 2 327 193 1 727 162 977 259 972 241 715 1 836 7 351 1 057 9 240 622 7 783 541 6 605 490 3 703 613 3 047 0 324 0 0 3 0 70 0 0 0 0 558 3 0 8 0 500 4 0 2 0 246 3 0 5 0 217 1 3 2 0 172 1 0 2 0 246 0 0 3 0 147 0 0 1 0 1 214 6 0 14 0 1 123 7 0 10 0 647 12 0 13 1 632 5 8 9 1 561 2 0 8 0 570 0 0 6 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
0 77 0 0 1
0 656 3 0 6
0 623 3 0 8
0 401 9 0 8
1 415 4 5 7
116 371
1 100 4 399
604 5 990
379 5 456
348 4 878
5 0 3 144 4
31 0 86 618 44
41 0 137 704 57
51 0 140 694 28
50 0 169 712 32

1 108 178 62 1 159 12 219 123 7 942 183 1 147 29 2 140 246 19 1 107 175 2 742 145 17 632 110 6 694 153 5 344 106 2 748 143 3 182 84 2 642 122 3 131 112 3 788 1 55 23 47 669 1 43 14 29 730 0 330 162 271 6 120 6 1 0 15 62 671 600 26 572 23 95 828 653 26 531 3 0 28 59 832 589 20 804 32 64 969 549 17 690 206 114 181 1 965 15 146 84 147 1 371 7 257 3 251 50 2 285 453 62 2 306 468 12 2 028 371 61 1 392 304 13 1 980 356 46 815 264 19 2 014 0 85 227 95 1 155 8 192 180 3 1 226 0 249 365 63 1 163 20 1 261 185 5 645 0 539 920 142 1 332 35 2 427 389 17 1 626 2 161 278 95 1 302 15 401 207 9 1 584 0 128 350 151 1 277 11 323 292 6 2 014 1 1.3 2.1 2.3 1.3 2.7 3.0 7.5 4 0 21 46 668 419 11 488 10 52 870 525 12 624 2.0 1.7 1.6 1.8 2.0 1.0 2.4 1.1 1.5 2.5 1.6 77 50 94 654 10 91 61 100 702 6 27 7 15 335 0 158 56 100 2 684 0 168 74 98 1 603 2 100 59 46 1 127 4 76 33 46 813 7 45 21 34 402 1 1 0 3 7 135 147 3 707 4 819 3 322 308 230 24 57 13 2 5 1 1 0 0 4 1 0 0 1 12 40 1 719 11 479 10 501 7 248 5 630 257 276 338 271 260 199 225 160 23 26 22 14 5 7 7 4 0 0 0 18 39 533 272 7 781 7 805 562 295 39 5 3 0 1 0 362 213 319 3 842 4 1 3 1 244 175 198 2 712 13 1 3 3 122 71 128 1 056 11 1 4 1 3.2 2.6 2.2 1.6 1.6
0 23 42 8
0 290 555 79
0 403 486 179
1 362 367 110
0 209 282 73
74 2 104 21
145
169 15 1 166 204 12 981
207 43 1 199 293 10 1 286
226 44 760 194 7 1 286
203 41 471 158 17 1 266
16 7 14 395 0
172 106 171 3 436 6 1
130 81 135 1 152 8
194 139 221 2 239 2 1 3 1
144 116 152 1 585 9 1 3 3
2 0
10
16
21
28
39
69
37
50
12 17
414 324
490 382
572 390
744 389
AMR
1 603
15 093
16 030
13 556
12 060
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, the Americas, 2007
65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544
014
1524
2534
Male 3544
4554
5564
1 0 0 2 181 39 4 20 74 25 0 2 1 4 14 4 6 17 7 5 14 6 5 16 7 6 18 11 10 33 10 0 2 1 5 14 7 9 18 11 8 18 8 10 23 10 13 29 12 14 51 17 0 1 1 1 0 1 2 0 1 2 2 1 1 3 7 1 80 17 64 20 46 17 51 16 63 14 106 14 7 1 98 21 75 29 60 29 74 32 100 29 139 25
19 10 0 20
20 12 0 34
17 37 0 50
21 22 22 66
25 9 0 99
20 0 0 52
1 0 0 0
17 10 0 28
16 15 0 9
10 12 0 31
10 5 12 19
10 8 0 34
10 0 0 48
1 0 0 1
18 10 0 24
18 13 0 21
13 24 0 40
15 13 17 43
17 9 0 67
14 0 0 50
6 1
116 25
86 38
74 42
98 49
141 45
0 2 1
6 14 10
11 19 16
11 22 9
16 31 13
21 42 12
1 2 1
32 43 12
54 47 30
59 45 29
47 46 30
2 3 0
32 33 14
28 24 12
23 21 15
19 25 17
15 28 25
2 2 1
43 40 22
43 34 20
35 33 22
3 2 6 1
13 26 112 27 5 11
24 85 172 57 5 15
43 75 162 58 4 18
54 87 140 67 14 25
39 46 35 42 57 41 105 87 9 29 7 1 8 2 0 1 25 38 150 32 1 8 23 35 126 30 3 9 36 13 95 43 1 14 47 14 77 57 3 19 40 13 59 70 3 22 5 1 7 2 0 1 25 62 161 44 3 11 32 57 143 43 4 14 44 53 116 55 7 19
31 59 57 34 56 37 104 130 3 42
28 29 10 9 12 33 122 24 2 6
30 36 11 4 12 30 117 26 3 8
29 35 25 20 52 29 90 71 6 24
23 42 39 14 48 25 79 98 3 31
2 1 1 9 0
28 35 27 125 2
46 52 48 98 1
50 49 45 91 4
65 49 51 91 4
65 46 56 80 5
83 61 71 96 3
3 1 1 8 0
26 19 16 100 0
37 28 22 71 1
33 25 14 63 1
36 20 18 63 3
39 19 21 48 0
45 21 29 76 0
2 1 1 9 0
27 27 21 112 1
41 40 35 84 1
41 37 30 77 2
50 35 35 77 3
52 33 39 64 3
63 40 49 85 1
0 13 22 4 45 23 1 15 15 12 10 10 11 1 17 19 17 0 1 1 11 2 12 1 11 1 12 1 17 1 30 0 1 2 11 2 15 2 16 0 9 11 10 7 4 5 0 12 20 14 16 2 20 16 0 4 6 7 5 6 10 0 5 10 14 19 21 15 2 24 16
23 10 0 0 0 0 0 0 0
28 37
25 0
81 32
58 0
12 0
15 0
11 5
13 19
18 0
40 15
34 0 11 11 2 36 16
14
22
36
38
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia Grenadines Suriname Trinidad & Tobago Islands Uruguay US Virgin Islands USA Venezuela
15
29
18
27
27
0 0
2 12
2 17
3 22
3 29
3 31
AMR
20
23
22
23
22
Table A3.13 TB case notifications, the Americas, 19802007

1985 0 1 11 456 6 9 770 0 0 4 9 406 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
13 887 60 80 8 614 9 431 75 759 2 066 1 791 2 3 429 10 999 851 1 135 4 766 6 015 1 458 9 836 80 114 1 1 574 0 2 226 11 640 527 840 9 748 80 209 0 1 484 2 134 10 360 534 770 5 003 4 416 1 794 59 6 136 0 10 531 74 466 1 1 657 1 3 006 11 480 630 926 99 102 5 85 3 9 014 77 632
0 8 16 406 70 64 21 1 4 412 72 608 13 683 78 3 13 397 59 3 99 0 10 194 87 254 10 619 53 19 83 6 9 801 86 881 2 1 533 1 2 664 11 242 712 784 4 12 276 75 7 123 0 10 132 95 009 3 11 871 76 2 104 0 9 863 78 870 1 968 2 6 151 12 447 230 546 6 2 597 8 243 2 367 0 3 813 168 4 138 8 901 325 1 681 12 4 337 9 685 3 901 3 2 508 266 4 291 109 16 353 0 2 750 827 1 850 48 601 274 2 24 0 53 129 166 708 19 751 5 984 256 656 40 91 254 980 41 93 668 18 287 6 273 262 886 40 91 2 842 1 300 1 745 45 310 262 5 11 13 5 3 003 1 314 2 072 41 739 222 3 35 6 53 204 14 2 806 1 473 1 946 42 062 257 12 22 6 76 260 3 647 123 14 437 1 2 885 750 1 927 52 552 2 798 1 146 2 037 51 675 256 6 4 155 111 14 446 0 3 745 115 15 145 2 145 1 6 854 11 639 418 656 35 2 634 5 687 1 659 1 4 806 190 8 583 4 213 88 13 180 5 2 737 770 1 438 36 908 275 0 32 6 77 108 951 6 22 436 4 557 26 673 5 444 253 255 39 89 166 458 33 75 241 854 35 80 258 188 39 89 25 107 5 169 241 834 41 93 239 594 41 93 231 186 41 93 252 215 42 95 987 4 23 495 4 524 4 26 4 58 142 0 699 13 45 112 0 689 666 10 24 205 4 877 625 4 22 728 5 578 701 8 21 210 5 650 3 106 672 2 270 35 687 314 0 28 3 70 124 5 291 6 908 1 485 0 2 913 422 10 420 6 406 127 18 434 0 5 2 402 1 169 1 950 38 661 174 0 9 16 89 198 645 17 501 6 598 240 619 40 91 16 310 6 466 238 580 40 91 2 419 422 10 224 5 048 121 18 879 0 9 2 447 1 711 2 073 37 197 121 2 15 10 75 206 3 689 15 945 6 251 230 403 40 91 4 549 6 122 1 406 2 3 313 603 14 533 3 594 116 15 101 0 11 2 220 1 701 2 298 33 082 123 2 15 8 97 178 727 15 056 6 204 233 678 43 98 14 838 6 734 228 448 40 91 14 502 6 808 235 511 40 91 1 972 0 6 280 11 437 434 630 27 2 459 5 867 1 647 2 5 700 117 8 514 4 227 133 14 631 13 1 947 0 6 324 11 469 442 628 7 3 081 5 497 2 378 0 5 739 150 8 054 3 962 65 15 371 6 2 035 2 6 728 11 329 311 581 13 3 145 5 480 617 4 4 900 120 8 100 4 026 86 15 489 5 2 012 3 5 498 12 263 201 514 14 1 837 6 879 2 304 1 2 631 134 10 237 4 560 121 15 216 1 2 107 3 5 304 11 199 118 410 13 3 490 7 313 2 495 3 2 517 182 2 011 2 4 598 11 043 313 790 7 4 033 7 050 3 347 0 2 474 91 1 921 2 4 150 9 912 586 1 553 8 4 053 7 893 2 422 4 3 119 296 6 212 4 984 109 11 329 1 849 0 4 178 9 702 636 1 465 10 6 302 8 397 1 686 0 3 232 314 6 632 4 176 121 20 722 4 11 767 82 3 106 0 10 127 77 899 1 1 667 5 3 021 11 630 585 1 183

0 7 14 681 52 7 23 6 6 837 83 731 0 0 13 368 43 3 41 2 8 960 81 826 0 3 13 267 51 4 28 1 10 664 82 395 0 3 12 636 52 5 30 2 12 563 80 048 0 1 12 309 46 5 57 0 11 166 74 570 0 0 12 185 53 5 89 3 11 223 84 990 0 6 12 606 63 6 65 4 9 520 85 955 2 0 13 450 57 3 95 4 14 422 91 013 0 4 12 621 88 5 107 4 9 853 83 309 3 1 969 0 3 880 8 042 692 1 346 6 5 381 9 435 1 662 2 2 948 407 10 116 4 030 118 23 575 3 365 639 14 311 3 333 90 18 524 1 1 907 1 637 2 075 33 421 113 0 14 7 117 166 622 14 080 6 847 227 599 34 77 0 1 10 728 38 0 2 9 755 46 16 63 8 574 74 757 0 1 476 1 2 418 10 950 550 762 3 4 150 4 877 1 666 3 3 140 594 14 133 2 772 104 18 324 2 2 303 1 596 2 269 32 407 98 4 19 12 218 607 13 779 6 705 224 687 41 93 13 299 6 456 218 426 39 89 4 696 6 442 1 383 2 2 642 631 14 004 3 858 120 17 078 1 9 2 283 1 620 2 175 31 273 115 1 14 14 95 147 6 643 1 434 0 2 486 11 128 488 765 19 4 561 4 594 1 644 1 3 626 710 13 959 3 197 95 17 887 0 5 1 997 1 636 2 447 34 311 112 1 15 13 127 232 7 557 5 767 5 756 1 623 5 2 820 407 9 124 4 568 115 19 802 2 4 2 558 1 387 2 115 40 345 200 3 16 9 95 159 17 627 2 617 709 1 628 24 702 363 0 34 9 60 119 2 1 082 1 22 768 4 974 227 206 42 95 233 192 42 95 2 983 765 1 502 30 571 303 0 25 3 77 122 12 1 023 2 22 517 4 954 2 944 846 2 167 37 905 159 0 13 2 82 120 0 886 4 25 701 5 457 2 797 863 2 283 40 580 241 1 25 1 47 141 0 759 4 26 283 5 216 1 773 3 3 652 9 155 730 1 234 5 5 114 7 164 1 700 2 2 755 318 9 770 4 916 121 21 514 1 7 2 604 1 422 1 831 43 723 201 5 20 8 85 199 0 4 11 548 44 5 135 0 10 201 81 436 1 1 602 0 2 448 11 376 543 898 2 4 040 5 829 1 550 1 2 909 590 12 066 4 485 106 17 790 0 15 2 092 1 575 2 107 36 092 129 3 17 10 97 133 3 536
0 3 16 693 67 3 33 2 5 072 86 411
4 0 17 292 54 30 44 5 4 777 87 822
0 1 17 305 58 17 140 10 5 178 86 617
0 3 16 359 53 14 35 3 4 131 88 365
1 2 15 987 63 12 25 3 7 679 84 310
2 762 0 8 523 11 589 396 1 133 20 2 174 3 950 2 255 17 5 624 124 8 306 1 674 176 31 247 1
2 526 2 7 337 11 483 521 833 26 1 778 3 966 2 091 1 6 641 117 6 550 1 696 178 32 572 0
2 473 0 6 941 12 126 459 815 18 2 457 3 880 2 171 1 7 277 135 3 337 1 714 153 24 853 0
2 355 1 6 989 13 716 479 762 16 2 959 3 985 2 053 6 6 013 149 6 839 1 935 157 22 795 1
2 356 1 6 561 12 792 393 705 5 3 100 4 301 1 564 4 6 586 165 5 803 2 120 160 14 531 7
2 144 4 6 644 12 024 376 680 8 2 335 4 798 1 461 2 6 570 215 4 959 3 377 130 15 017 9
1 300 643 1 354 16 011 686 7 41 78 78 80 2 1 874 0 27 749 4 233
3 723 580 1 388 21 925 521 4 39 11 81 82 0 1 699 1 27 373 4 093
3 082 580 1 415 21 579 473 6 37 14 56 62 2 1 450 1 25 520 4 159
2 773 429 1 800 22 753 452 2 48 4 78 112 5 1 359 2 23 846 4 266
2 705 413 1 718 22 792 418 3 55 23 76 108 0 1 389 3 22 255 4 737
2 604 614 1 931 24 438 338 0 21 14 50 112 4 1 201 1 22 201 4 822
AMR Number reporting % reporting
227 697 42 95
248 122 42 95
237 274 42 95
238 465 42 95
226 812 42 95
227 186 42 95
Table A3.14 TB case notification rates, the Americas, 19802007

1987 0 1 31 7 25 0 0 5 24 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
1985
1986
41 22 40 120 129 48 7 13 23 12 7 53 34 27 6 5 23 27 22 10 54 48 23 111 44 5 5 0 14 27 13 7 106 43 0 5 28 2 54 0 124 42 5 5 2 19 27 16 8 38 37 2 30 5 96 41
0 11 58 33 26 15 2 82 60 40 28 4 38 21 1 45 0 133 53 28 17 7 31 9 109 47 9 5 2 17 25 17 7 5 34 25 2 53 0 127 56 4 33 25 1 44 0 121 46 7 8 47 36 7 5 9 36 80 46 0 43 23 29 24 10 15 17 55 87 71 3 26 36 79 4 18 0 60 32 39 207 7 5 17 0 13 10 13 22 7 26 32 32 29 7 27 6 28 6 26 28 20 19 61 49 36 190 7 12 8 12 3 63 48 42 172 6 7 24 5 13 16 22 6 25 27 5 24 27 5 26 26 5 26 27 8 58 53 39 171 7 27 15 5 18 20 35 51 35 123 3 0 9 6 26 13 19 5 26 26 26 86 154 49 3 18 18 75 5 17 9 66 30 43 232 63 45 44 224 7 14 80 5 17 0 71 5 17 7 0 50 35 15 6 38 36 61 34 2 69 16 128 94 6 18 118 69 33 36 177 8 0 24 6 19 9 31 6 9 24 10 26 34 22 31 33 32 9 24 34 33 32 34 32 4 9 24 10 18 4 14 11 0 22 12 11 9 0 22 21 9 9 23 19 4 8 25 22 7 8 25 77 28 55 167 9 0 21 3 18 10 61 56 24 0 26 57 122 103 5 18 0 3 47 40 36 151 5 0 6 14 20 15 41 48 37 116 2 8 12 10 16 18 5 25 25 4 23 24 21 57 117 80 5 19 0 5 47 57 38 143 3 4 10 9 17 16 15 21 77 34 38 150 9 0 19 3 20 10 117 34 2 9 27 34 71 35 51 174 5 0 9 2 20 10 0 29 4 10 28 66 35 52 183 7 2 18 1 12 11 0 24 4 10 26 67 47 27 5 26 55 108 75 4 20 35 2 51 48 40 159 5 7 11 8 22 12 95 19 51 50 21 2 22 86 156 59 5 17 20 5 43 52 38 117 3 2 9 12 21 11 27 19 49 47 21 2 27 82 159 54 4 15 0 6 41 54 40 123 3 4 9 7 22 13 7 0 50 34 15 6 10 44 56 48 0 67 20 118 86 3 19 55 7 8 52 33 10 6 19 44 55 12 4 56 16 116 85 4 19 46 7 11 41 34 6 5 20 25 65 44 1 29 18 141 91 5 18 9 7 10 39 31 4 4 19 46 68 47 3 27 25 7 7 33 30 9 7 10 52 64 62 0 26 12 7 6 29 26 17 14 12 51 69 43 4 31 40 79 89 4 12 6 0 29 25 18 13 15 77 72 29 0 32 42 83 73 5 22 6 8 24 23 19 11 7 61 60 28 2 26 43 118 83 5 22 15 4 53 50 36 175 5 11 13 7 20 15 5 32 27 1 43 0 122 45 5 5 12 20 28 15 11 4 0 15 24 11 7 28 47 35 24 1 28 96 148 46 4 17 0 3 36 50 41 124 3 2 9 11 28 17 28 17 90 39 0 4 2 15 24 12 7 4 43 37 24 3 24 80 147 39 4 17 34
0 4 59 31 1 22 4 93 69
57 0 60 25 12 29 9 85 69
0 1 59 26 7 91 18 91 66
0 4 55 23 5 22 5 71 66
14 3 53 27 5 15 5 129 62
0 11 48 22 3 14 10 112 60
0 0 43 18 1 24 3 144 58
0 5 42 21 1 16 2 167 57
0 5 39 21 2 17 3 193 54
0 2 38 18 2 31 0 167 50
0 0 37 20 2 47 5 164 56
0 10 38 24 2 33 7 136 56
19 0 39 20 1 44 7 193 56
11 0 76 41 17 12 27 37 50 49 19 80 16 146 46 8 45 8
10 11 65 40 22 8 35 29 48 45 1 92 15 113 45 8 46 0
10 0 60 41 18 8 25 40 46 46 1 99 18 56 44 7 34 0
9 5 60 45 19 8 22 47 46 44 6 80 20 112 49 7 31 9
9 5 55 41 15 7 7 48 49 33 4 85 22 93 52 7 19 61
8 19 55 38 14 7 11 35 53 31 2 83 29 78 80 6 20 80
8 5 56 36 15 6 49 39 61 34 1 59 25 131 97 4 17 45
0 6 35 30 2 47 6 126 50 16 7 0 26 20 19 12 9 65 80 28 2 28 55 124 69 5 25
40 33 42 92 21 16 35 78 22 7 27 64 0 12 28
111 29 42 123 16 9 33 11 23 7 0 58 1 12 26
90 28 42 119 14 14 30 14 15 6 24 49 1 11 26
78 21 52 122 14 5 39 4 21 10 58 46 2 10 26
75 19 48 119 12 7 44 22 20 9 0 46 3 9 28
70 28 52 125 10 0 17 13 13 10 42 40 1 9 28
69 32 43 124 11 0 26 9 15 10 20 36 1 9 28
0 5 31 14 2 53 0 118 45 5 5 0 16 26 13 8 3 45 46 24 1 25 80 136 70 4 17 0 8 40 51 38 137 3 6 11 9 22 10 14 16
0 1 28 12
0 2 25 14 5 22
AMR
37
39
37
37
34
34
33
Table A3.15 New smear-positive cases notified, the Americas, 19902007

Number of cases 1996 0 1 4 961 29 17 15 25 96 94 25 2 17 24 21 17 15 62 59 15 20 2 14 1 21 3 62 22 68 23 0 1 7 15 8 4 29 36 16 31 23 16 6 4 709 1 13 9 7 12 0 1 5 595 0 0 4 4 834 0 0 0 1 15 0 0 5 12 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 0 Rate (per 100 000 population)
1990
1991
1992
1993
1994
1995
5 937 41
5 696 41
50
36
5 307 57 5 32 4 60 2 5 788 41 117 2 2 2 2 7 19 19
0 2 4 985 32 8 54 16 14 1 17 3 94 28 3 16 9 1 21 0 91 27 14 10 1 22 0 85 26 1 13 12 1 20 0 82 24
0 2 13 10 3 19
6 833
6 905 39 167 455 2 1 497 8 329 458 720 1 186 6 870 330 467 2 949 3 048 1 059 2 24 12 41 4 10 2 622 4 439 1 003 1 0 11 20 7 8 7 35 52 1 5 10 20 12 6
5 698 38 3 36 2 7 010 45 650 6 53 0 6 672 38 478 0 458 1 1 355 8 022 385 559 6 344 39 938 0 332 0 1 276 7 972 346 507 6 278 42 093 0 433 72 22 0 1 0 8 18 8 5 2 21 0 79 22 0 1 2 9 19 10 5
2 5 787 25 3 46 0 6 949 44 503 5 186 30 4 52 0 6 750 43 554 4 760 37 19 34 0 6 213 42 881 2 438 1 1 297 7 640 419 453 12 12 7 13 0 69 23 9 1 2 8 17 10 4
1 4 830 37 2 48 0 6 673 41 619
549
543
506
488 2 2 629 6 987
483

3 4 749 56 3 44 0 6 458 41 186 1 492 5 1 290 8 358 349 675 4 13 18 1 18 0 78 24 5 2 12 8 20 9 6 5 9 30 49 46 0 22 7 38 3 9 44 2 11 0 14 17 7 8 12 40 60 39 3 20 8 430 0 1 562 7 572 302 835 7 3 733 6 426 965 0 2 224 71 3 524 1 808 81 8 495 2 420 240 7 340 2 069 53 11 997 1 6 458 43 490 0 473 0 1 582 6 090 320 765 5 3 162 7 214 882 1 2 218 105 5 497 1 928 84 15 440 1 0 11 19 8 8 10 46 55 17 0 22 10 44 32 3 9 5 686 38 444 0 463 1 1 166 7 188 322 432 3 2 373 3 448 942 3 2 348 233 7 915 1 974 78 11 531 1 83 26 0 2 0 11 15 9 7 7 38 61 15 1 21 14 68 33 3 16 19 32 79 30 2 12 18 60 20 0 1 2 7 16 7 4 4 24 26 14 3 18 32 82 28 3 11 17 5 1 670 592 859 27 498 126 23 22 2 806 4 488 870 2 1 795 244 7 015 2 139 81 12 933 1 4 1 404 778 1 166 18 504 62 31 35 13 2 15 33 78 33 3 13 20 2 26 25 21 69 2 1 453 833 1 276 17 796 56 4 18 4 130 380 4 864 3 392 125 189 119 838 <1 <1 <1 26 25 21 64 1 8 11 3 10 12 4 13 13 12 3 13 18 13 3 14 18 17 18 11 2 15 17 10 2 15 16 2 14 16 11 2 14 15 2 14 15 2 15 14 2 14 14 11 2 14 14 11 2 13 14 2 12 13 7 423 6 935 3 234 142 556 139 253 135 153 131 294 129 944 127 575 125 815 126 345 124 810 6 624 3 450 6 275 3 670 5 883 3 525 5 650 3 476 5 439 3 444 5 368 3 882 5 277 3 776 5 111 3 653 5 091 3 547 374 348 373 355 3 1 722 904 894 26 800 110 2 22 3 39 58 14 2 31 52 1 253 860 1 260 18 490 60 0 11 6 49 95 8 6 35 77 6 373 438 2 1 576 6 969 353 746 5 2 669 4 900 1 071 2 2 255 85 6 442 2 311 90 11 473 1 6 1 648 1 393 850 27 707 106 4 10 3 32 82 2 907 5 064 1 008 0 2 052 119 5 887 3 404 90 11 676 0 2 1 471 460 900 22 580 81 0 7 9 37 115 2 3 38 35 34 36 34 41 29 40 33 21 19 22 19 16 18 17 155 145 135 111 112 3 4 3 3 3 5 5 9 5 12 8 15 9 10 0 4 3 2 9 7 4 1 5 4 1 669 174 5 607 3 141 75 15 103 0 7 1 510 671 915 21 685 74 0 6 3 36 152 1 340 11 2 3 14 13 5 3 14 2 720 4 340 926 2 2 339 164 7 044 2 011 69 11 214 0 8 1 327 884 1 199 18 289 65 0 11 5 37 71 33 41 16 0 18 16 69 55 3 12 0 1 29 16 17 88 2 0 5 8 8 9 3 278 4 300 1 023 3 2 264 178 6 828 2 415 90 11 968 2 2 1 564 432 1 041 24 511 106 2 9 4 36 87 2 392 38 35 17 3 21 24 81 40 4 12 35 1 31 15 20 97 3 4 6 3 8 7 11 12 15 24 64 50 3 15 0 4 29 22 17 83 2 0 4 3 8 12 5 10 1 5 10 17 9 7 7 32 41 18 2 21 12 78 39 4 12 15 3 33 49 17 111 3 9 7 3 7 6 29 34 14 2 19 22 77 30 3 11 0 4 25 28 21 68 2 0 7 4 8 5 5 5 8 6 27 11 23 27 21 68 2 0 7 5 11 7 0 2 5 498 32 5 71 0 6 829 41 371 1 408 0 1 412 7 787 328 540 2 2 179 4 223 980 0 1 865 138 6 188 3 080 60 11 555 0 9 1 320 773 1 004 20 533 78 1 8 0 42 60 2 308 407 0 1 533 7 648 285 432 8 2 658 3 182 913 1 2 501 294 7 461 2 018 61 11 874 0 5 1 285 858 1 452 19 251 69 1 13 8 63 149 7 305 1 0 9 17 6 4 12 28 24 14 1 19 40 79 29 2 11 0 3 23 26 24 70 2 2 8 7 14 11 28 9 0 3 15 10 2 28 0 79 23 5 1 0 9 18 8 5 3 24 33 15 0 16 19 70 48 2 11 0 5 25 25 18 78 2 2 5 0 9 5 9 9 426 5 7 454 3 195 136 987
565 6 2 297 5 325 2 471 0 2 128 51
1 951 6 532 230 914 8 3 177 6 674 2 144 3 1 994 61
436 0 1 561 7 530 245 834 5 2 787 5 890
2 2 368 85
2 016 83 8 164
2 385 61 9 726 0
2 306 93 9 220
993
943
862
1 714 1 046 985 35 646 122 2
11
1 615 748 873 33 925 139 2 17 0
1 568 1 066 748 32 096 128 4 11 5
55
388
381
9 429 2 849
8 964 2 738
349 2 8 093 3 056
AMR
1 542
1 486
1 368
98 265
137 645
138 932
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), the Americas, 2009
Available funding Loans Funding gap 0 0 0 0.03 4.0 0 Total TB control costs 0 1.7 0 0 0 0 0.01 0 0 Grants (excluding Global Fund) Global Fund Completeness of budget data Cost of utilization of general health-care services .
NTP budget
0.03 4.0 0
0.02 2.3 0
0 64 28 63 0 0 0 0
0.9 50
0 0.6
0 1.5
1.0 0
< 0.01 11
0 92
63
63
5.6
4.8
0.7
1.7
7.2
12 20 8.3 0 0 0 0 0 0 0.9 0.7 0.7 24 0.1 0 0 0.01 0 0 1.6 1.8 10 0 0 0 3.8 < 0.01 0 1.7 0.02 0 2.8 9.0 0 12 3.6 0.7 28
1.2 7.6 3.9
0 0 0
< 0.01 0 0
2.3 2.0 0
5.4 10 4.4
1.3 0.9 0.7
14 21 9.0
6.2 0 11 2.9 0.02 4.1
0.7 0 0.6 1.2 0 4.1
0.3 0 0 0 0 18 0.9 1.7 0.1 0 < 0.01 10 < 0.01 1.2 4.8 3.6 62 2.1
0.2
0.1
1.3
1.5
2.4 57 2.1
0.7 29 1.2
7.9
7.9
0.9
8.8
Anguilla Antigua & Barbuda Argentina Bahamas Barbados Belize Bermuda Bolivia Brazil British Virgin Islands Canada Cayman Islands Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Montserrat Netherlands Antilles Nicaragua Panama Paraguay Peru Puerto Rico Saint Kitts & Nevis Saint Lucia St Vincent & Grenadines Suriname Trinidad & Tobago Turks & Caicos Islands Uruguay US Virgin Islands USA Venezuela 0 2.3 21 21 44 0 0 0 70 146 487 39%
146
N C C N N N N P C N C P N C N N N C C C N C P C C P C N N C N C C C N N N N C N N N P N
AMR
417
180
Notes
Cuba
TABLE A3.11: breakdown of notied cases differs from WHO convention. In 2007, breakdown of the 432 notied new smear-positive cases is as follows: 014 years, no cases; 1524 years, 38 cases; 2559 years, 282 cases; 6064 years, 21 cases; 65 years+, 91 cases.
USA
In addition to the 51 reporting areas, the United States includes 8 territories (American Samoa, Federated States of Micronesia, Guam, Marshall Islands, Northern Mariana Islands, Puerto Rico, Republic of Palau, US Virgin Islands) that report separately to WHO. The data for these 8 territories are not included with the data for the USA. Denitions of case types and outcomes do not exactly match those used by WHO. One state reporting area (representing approximately 20% of TB cases in 2007 and 12% of the population of the USA) did not provide data on HIV testing.
EASTERN MEDITERRANEAN
|NTP MANAGER (OR EQUIVALENT) AND/OR PERSON(S) RESPONSIBLE FOR COMPLETING DATA COLLECTION FORM
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen Khaled Seddiq; Shah Wali Maroo; Sayed Daoud Mahmoodi; Homayoon Manochehr Saeed Alsaffar Said Guelleh Essam El-Moghazy; Amal Galal Mahshid Nasehi; Shahnaz Ahmadi Dhafer S. Hashim; Mohemmed R. Tbena Khaled Abu Rumman; Nadia Abu Sabra Rashed Al-Owaish; Mohamed Gaafar Mtanios Saade Bashir Saa Naima Ben Cheikh; lahsen laasri Hassan Al-Tuhami Noor Ahmad Baloch; Ejaz Qadeer Abdul Latif Al-Khal Nailah A. Abulgadayl; Mohammad Salama Abouzeid Bashir Suleiman Hashim Sulieman Elwagea; Joseph Lasu; Samia Ali Alagab; Khadiga Adam; Sindani Ireneaus Sebit Fadia Maamari Dhikrayet Gamara; Salah Ben Mansour Juma Bilol Fairouz; Kifah Ibrahim Walid Daoud Amin N. Al-Absi
Table A3.1
TB/HIV Indirect Routine Indirect Survey Indirect Routine Routine Indirect Sentinel Routine Indirect Routine Indirect Sentinel Indirect Routine Source of estimates MDR (new) MDR (re-treat) Model Model Model Model Model Model DRS DRS DRS DRS Model Model DRS DRS Model Model DRS DRS Model Model DRS DRS DRS DRS Model Model Model Model Model Model Model Model Model Model Model Model Model Model Model Model DRS DRS Cfr ss+ HIVDOTS non-DOTS 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.15 0.3 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.15 Duration ss+HIVDOTS non-DOTS 1 2.5 1 1.5 1 2.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2 1 1.5 1 1.5 0.75 1.5 1 1.5 1 2.5 1 1.5 1 1.5 1 2.5 1 2.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2 Duration ss-HIVDOTS non-DOTS 1 2.5 1 1.5 1 2.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2 1 1.5 1 1.5 0.75 1.5 1 1.5 1 2.5 1 1.5 1 1.5 1 2.5 1 2.5 1 1.5 1 1.5 1 1.5 1 1.5 1 2
Methods and assumptions for estimation of TB incidence, prevalence and mortality, Eastern Mediterranean

TB mortality, 1990 All forms* number rate All forms* number rate 45 676 305 6 769 15 873 15 447 16 241 441 674 762 1 060 28 617 332 297 108 588 11 442 21 634 93 808 4 698 2 682 692 799 17 121 582 767 105 20 517 4 258 877 47 7 179 1 772 039 168 40 813 21 22 56 7 24 19 17 92 13 181 70 46 249 243 24 26 16 20 76 <1 1 895 295 485 20 141 6 238 1 481 9 927 34 <1 227 <1 <1 <1 <1 4 17 26 <1 20 554 137 2 856 6 765 6 902 7 308 135 303 232 477 12 863 149 133 075 264 5 149 9 587 41 221 1 436 1 204 311 244 7 704 76 18 343 9 10 25 2 11 6 8 41 6 81 31 21 110 107 7 12 7 6 34 <1 663 103 170 5 49 2 183 519 3 474 12 <1 80 <1 <1 <1 <1 1 6 9 <1 64 699 238 449 60 9 198 1 104 20 066 27 19 526 27 22 866 79 534 9 712 25 942 23 1 060 17 24 955 80 369 14 364 793 223 684 81 16 004 65 30 647 352 154 933 402 5 348 27 2 930 28 1 044 24 1 250 31 29 031 130 6 274 44 705 2 309 2 357 2 218 46 111 157 219 3 330 43 55 749 28 807 5 780 15 970 725 273 64 119 2 182 99 510 26 50 9 126 4 4 12 1 5 5 5 13 2 49 6 5 86 62 6 3 3 6 18 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate <1 947 148 243 10 71 3 119 741 4 963 17 < 139 1 10 258 <1 114 <1 <1 <1 <1 2 9 13 <1 2 TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident number rate number rate TB cases (%) 8 169 35 1 304 1 845 1 844 3 190 46 68 82 77 2 586 30 47 587 61 1 327 5 483 27 450 442 282 80 125 2 188 104 300 30 5 157 2 3 11 <1 2 2 1 8 1 29 7 5 63 71 2 3 2 3 10 19 <1 543 66 108 4 20 1 426 682 4 872 5 7 726 <1 65 <1 <1 <1 <1 <1 8 13 <1 1 < 0.05 28 1.9 3.1 2.6 0.5 2.1 6.8 11 1.3 3.5 Percentage of new re-treat 3.3 2.0 3.3 2.2 5.0 3.0 5.4 1.8 1.1 2.4 0.5 1.3 3.2 2.1 1.8 1.8 1.6 2.6 2.3 3.0 2.9 2.8 36 35 32 38 48 38 40 35 63 35 12 36 35 35 10 10 11 36 37 35 11 27 MDR, 2007 Number among all cases smear-positive 2 202 6 411 781 1 138 988 29 12 14 57 136 6 13 218 415 484 2 336 92 87 30 27 580 23 049 1 371 3 282 579 715 719 12 6 9 43 61 4 7 939 282 269 1 402 41 49 21 10 303 14 120
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen
Reference year 2005 1997 1997 2007 2002 2002 2002 1997 2002 1997 1997 1997 1997 2002 1997 2001 1997 2007 2001 1997 1997 1997
Incidence est. based on Notif. Notif. Notif. Notif./C-ReC. Notif. ARI Notif. Notif. Notif. ARI Notif. ARI Prev. Notif. ARI ARI ARI Notif./C-ReC. Notif. ARI ARI ARI
Trend Not estimated Group, moving ave. Group, exp. Group, moving ave. Country notifs, moving ave. Not estimated Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, exp. Country notifs, moving ave. Not estimated Country notifs, moving ave. Country notifs, moving ave. Not estimated Group, exp. Country notifs, exp. Country notifs, moving ave. Group, moving ave. Group, moving ave. Group, moving ave.
Table A3.2
Estimated burden of TB, Eastern Mediterranean, 1990 and 2007
21 301 376 3 265 20 170 20 308 10 371 538 954 1 487 1 306 36 934 482 204 820 282 6 957 16 705 45 221 7 711 2 583 555 745 16 384
168 76 582 37 36 56 17 45 50 30 149 26 181 60 43 249 174 61 31 30 35 133
9 586 169 1 462 8 621 9 138 4 667 164 429 454 588 16 618 217 92 134 127 3 131 7 511 20 106 2 357 1 162 250 228 7 373
76 34 261 16 16 25 5 20 15 13 67 12 82 27 19 112 78 19 14 13 11 60
55 257 436 593 120 8 323 1 485 26 244 48 28 133 50 16 326 88 619 19 1 908 89 1 913 64 1 989 46 33 232 134 745 40 485 491 430 330 71 10 975 68 40 120 597 106 085 409 11 952 94 4 047 49 876 47 1 181 55 32 651 265
EMR
419 455
110
186 491
49
868 989
227
Table A3.3
Number of cases 1995 31 941 335 4 206 20 133 24 512 12 501 560 579 1 457 1 315 34 305 300 237 467 383 8 399 15 669 59 348 6 505 2 798 568 838 19 082 483 201 489 400 497 708 507 006 516 769 525 495 533 979 542 116 550 322 560 010 571 155 582 767 110 109 110 109 109 109 109 108 107 107 107 106 106 106 105 32 772 332 4 432 19 226 22 133 12 891 511 588 1 257 1 258 33 811 304 243 619 356 8 906 15 999 62 089 6 303 2 730 584 815 18 483 33 379 326 4 678 18 681 20 902 13 281 470 603 1 164 1 224 33 307 287 249 874 356 9 473 16 469 64 919 6 107 2 639 594 806 18 169 34 023 314 4 928 18 370 20 434 13 663 433 607 1 089 1 206 32 790 294 255 958 390 9 780 17 003 67 808 5 919 2 535 592 808 18 061 34 894 307 5 170 18 203 20 429 14 033 417 615 1 018 1 197 32 262 296 261 684 405 9 879 17 547 70 734 5 742 2 430 599 815 18 095 36 033 303 5 399 17 918 20 086 14 389 392 622 878 1 181 31 723 310 266 992 415 9 748 18 087 73 679 5 576 2 321 608 817 18 016 37 378 307 5 620 17 603 19 541 14 733 394 642 769 1 162 31 178 287 271 973 415 9 617 18 638 76 656 5 419 2 292 634 817 17 904 38 894 301 5 836 17 201 18 617 15 064 387 640 697 1 138 30 635 287 276 764 410 9 604 19 202 79 711 5 268 2 311 638 813 17 700 40 512 301 6 055 16 716 17 318 15 380 409 648 670 1 109 30 104 277 281 573 432 9 756 19 783 82 914 5 121 2 387 653 803 17 402 42 180 303 6 283 16 356 16 432 15 682 429 658 668 1 087 29 590 305 286 555 463 10 189 20 385 86 319 4 977 2 453 668 799 17 228 43 896 304 6 522 16 122 15 938 15 968 435 667 715 1 074 29 095 318 291 743 526 10 808 21 004 89 953 4 836 2 566 682 800 17 183 45 676 305 6 769 15 873 15 447 16 241 441 674 762 1 060 28 617 332 297 108 588 11 442 21 634 93 808 4 698 2 682 692 799 17 121 168 76 582 37 36 56 17 45 50 30 149 26 181 60 43 249 174 61 31 30 35 133 168 72 594 36 37 56 16 42 49 29 145 23 181 59 38 249 178 57 30 28 34 131 168 68 606 36 41 56 15 40 49 30 141 19 181 59 37 249 181 54 31 27 34 132 168 64 618 35 39 56 14 37 48 29 137 16 181 64 38 249 185 51 32 25 33 127 168 61 630 34 40 56 14 36 48 28 133 14 181 72 41 249 189 49 33 24 33 125 168 58 642 34 40 56 13 34 46 28 129 14 181 76 43 249 192 46 31 23 32 122 168 57 655 33 39 56 13 33 41 27 125 13 181 71 45 249 196 43 31 22 31 119 168 55 668 31 35 56 11 32 35 25 122 13 181 64 46 249 200 41 30 21 29 111 168 52 681 29 32 56 10 31 32 24 118 12 181 63 48 249 204 39 28 20 28 106 168 49 695 28 31 56 9 29 29 23 115 12 181 66 48 249 208 37 27 19 27 102 168 47 708 27 31 56 9 28 27 22 112 12 181 66 47 249 212 35 25 18 26 100 168 46 722 26 30 56 8 27 23 22 109 13 181 64 46 249 216 33 24 18 25 96 168 45 737 26 29 56 8 26 20 21 106 12 181 60 44 249 221 31 23 18 24 93 168 43 751 24 27 56 7 25 18 20 103 12 181 56 43 249 225 29 23 17 23 89 168 42 766 23 25 56 8 25 17 19 100 11 181 57 42 249 229 28 24 17 22 85 168 42 781 22 24 56 8 24 17 18 97 12 181 58 43 249 234 26 24 16 21 82 105 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 168 41 797 22 23 56 8 24 18 18 94 12 181 64 45 249 239 25 25 16 21 79 105 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, Eastern Mediterranean, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 168 40 813 21 22 56 7 24 19 17 92 13 181 70 46 249 243 24 26 16 20 76 105
1990
1991
1992
1993
1994
21 301 376 3 265 20 170 20 308 10 371 538 954 1 487 1 306 36 934 482 204 820 282 6 957 16 705 45 221 7 711 2 583 555 745 16 384
22 757 367 3 443 20 240 21 485 10 681 543 880 1 510 1 312 36 556 445 210 524 285 6 407 16 520 47 271 7 513 2 485 552 762 16 884
24 719 361 3 588 20 779 24 034 11 016 540 795 1 542 1 349 36 148 376 215 827 293 6 360 16 207 49 456 7 313 2 684 552 798 17 856
26 926 349 3 714 20 389 23 332 11 372 566 699 1 576 1 325 35 714 328 220 928 320 6 632 15 857 51 769 7 113 2 809 545 799 18 056
29 012 345 3 848 20 498 24 335 11 741 561 634 1 635 1 335 35 259 296 226 120 372 7 297 15 599 54 194 6 911 2 899 551 820 18 655
30 718 338 4 009 20 390 24 684 12 117 578 589 1 594 1 330 34 788 302 231 604 401 7 804 15 526 56 718 6 708 2 827 554 832 18 983
EMR
419 455
429 421
442 594
451 118
462 914
473 393
Table A3.4
Prevalence of TB (all forms) 2000 346 57 761 36 40 71 11 33 35 22 98 13 413 78 67 414 375 41 30 27 40 164 203 200 187 181 172 159 150 139 24 23 22 22 21 20 19 326 56 775 34 38 69 9 33 30 22 95 14 406 78 65 398 389 37 28 27 39 154 304 55 932 32 37 65 9 30 26 21 87 13 376 75 62 391 363 35 27 27 37 149 308 283 267 251 238 53 48 45 45 60 960 1 034 1 046 1 093 1 104 31 29 28 27 27 35 32 31 29 27 67 71 75 78 79 9 9 8 9 9 29 29 30 25 25 24 22 21 23 23 20 19 18 18 17 91 89 85 82 80 13 12 13 13 14 355 333 289 260 223 71 71 69 77 81 60 60 60 62 65 362 334 325 341 352 371 376 384 391 402 33 31 30 29 27 26 27 27 28 28 25 25 24 24 24 36 35 33 32 31 146 138 137 135 130 41 5 70 3 4 10 <1 3 3 2 10 <1 48 7 6 67 53 3 3 2 4 12 39 5 69 3 3 10 <1 3 2 2 10 1 47 7 5 61 54 3 2 2 4 12 36 4 80 3 3 9 <1 3 2 2 9 1 44 7 5 61 53 3 3 2 4 12 37 4 82 3 3 9 <1 3 2 1 9 1 42 7 5 58 54 3 3 2 4 11 34 4 86 3 3 10 <1 3 2 1 9 <1 40 6 5 49 55 2 3 2 3 11 33 4 88 3 3 10 <1 3 2 1 9 1 36 6 5 45 56 2 3 2 3 10 31 4 90 2 3 11 <1 2 2 1 8 <1 33 7 5 49 57 2 3 2 3 10 30 5 91 2 2 11 <1 2 2 1 8 1 28 7 5 55 59 2 3 2 3 10 17 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) 2000 <1 <1 35 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 7 11 <1 <1 <1 <1 <1 1
Estimated incidence, prevalence and mortality rates (per 100 000 population), Eastern Mediterranean, 20002007
Mortality HIV+ 2001 <1 <1 33 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 8 12 <1 <1 <1 <1 <1 1 2002 <1 <1 53 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 8 11 <1 <1 <1 <1 <1 1 2003 <1 <1 55 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 8 11 <1 <1 <1 <1 <1 1 2004 <1 <1 60 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 7 12 <1 <1 <1 <1 <1 1 2005 <1 <1 61 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 7 12 <1 <1 <1 <1 <1 1 2006 <1 <1 64 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 7 12 <1 <1 <1 <1 <1 1 2007 <1 <1 65 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 8 13 <1 <1 <1 <1 <1 1
2000
2001
2002
2003
2004
2005
2006
2007
<1 179 <1 <1 <1 <1 2 14 21 <1
<1 190 <1 <1 <1 <1 2 15 22 <1
<1 198 <1 <1 <1 <1 3 16 23 <1
<1 205 <1 <1 <1 <1 3 16 23 <1
<1 211 <1 <1 <1 <1 3 16 24 <1
<1 217 <1 <1 <1 <1 3 17 25 <1
<1 222 <1 <1 <1 <1 4 17 25 <1
<1 227 <1 <1 <1 <1 4 17 26 <1
EMR
Table A3.5
Case notifications and case detection rates, DOTS and non-DOTS combined, Eastern Mediterranean, 2007
Population All notified New and relapse . thousands number number rate 0 0 0 0 0 0 0 0 0 0 0 0 0 1 275 0 0 22 31 0 1 0 1 638 2 652 48 131 262 337 582 767 258 877 63 60 53 0 0 0 0 0 0 0 0 0 0 5 35 0 0 131 0 2 357 0 58 0 82 25 0 0 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 1 078 2 166 382 270 554 3 1 3 0 2 3 0 0 48 126 135 0 0 14 77 39 0 0 0 0 4 1 7 6 5 7 3 0 1

8 251 71 329 1 703 1 830 2 293 70 94 118 523 2 059 33 103 629 75 582 2 490 9 486 706 305 20 2 2 196 0 0 0 0 0 0 0 0 0 0 0 0 9 560 41 6 4 106 0 92 497 1 986 57 27 5 0 325 4 4 7 4 1 5 3 4 20 4 136 865 76898 6 227 114 1 492 2 869 2 515 2 290 154 277 212 824 11 566 102 33 986 208 1 297 2 013 5 171 2 169 1 009 16 18 2 369 13 213 109 1 208 6 643 4 735 3 280 154 314 143 1 544 12 067 220 192 376 116 1 984 6 130 12 627 1 861 0 62 14 3 537 45 676 305 6 769 15 873 15 447 16 241 441 674 762 1 060 28 617 332 297 108 588 11 442 21 634 93 808 4 698 2 682 692 799 17 121 20 554 137 2 856 6 765 6 902 7 308 135 303 232 477 12 863 149 133 075 264 5 149 9 587 41 221 1 436 1 204 311 244 7 704 61 96 45 60 59 45 76 96 62 200 89 97 76 68 34 49 29 86 84 13 4 47 64 79 42 72 68 37 81 90 62 162 93 125 67 44 39 64 31 80 78 18 5 46 62 61 79 74 72 54 61 74 55 60 85 85 46 61 77 71 57 62 76 74 87 62 46 37 38 50 50 35 32 42 30 36 47 57 39 29 50 55 43 28 41 58 39 42 22 39 47 29 27 29 46 43 45 39 45 31 15 52 33 18 18 53 44 16 55 28 . New pulm. lab. confirm. number Estimated incidence and case detection rate Estimated incidence DOTS case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.) 0 0 0 0 0 0 0 0 0 0 0 0 1 275 0 0 22 31 0 1 0 1 638 2 652 0 0 0 0 0 0 48 0 5 35 0 0 131 0 0 0 131 0 2 357 0 58 0 82 25 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 1 078 2 166 382 270 554 3 1 3 0 0 0 48 126 135 0 0 14 77 39 0 0 0 0 4 1 7 6 5 7 3 0 1 6 227 114 1 492 2 869 2 515 2 290 154 277 212 824 11 566 102 33 986 208 1 297 2 013 5 171 2 169 1 009 16 18 770 0 0 0 0 0 0 0 0 0 0 0 0 9 559 6 4 106 0 92 497 1 986 57 27 5 0 324 75 299 261 551 582 767 13 213 109 1 208 6 643 4 735 3 280 154 314 143 772 12 067 220 192 376 116 1 984 6 130 12 627 1 861 0 62 14 3 523 45 676 305 6 769 15 873 15 447 16 241 441 674 762 1 060 28 617 332 297 108 588 11 442 21 634 93 808 4 698 2 682 692 799 17 121 20 554 137 2 856 6 765 6 902 7 308 135 303 232 477 12 863 149 133 075 264 5 149 9 587 41 221 1 436 1 204 311 244 7 704 258 877 61 96 45 60 59 45 76 96 62 200 89 97 76 68 34 49 29 86 84 13 4 30 63 64 79 42 72 68 37 81 90 62 162 93 125 67 44 39 64 31 80 78 18 5 46 60 62 61 79 74 72 54 61 74 55 60 85 85 46 61 77 71 57 62 76 74 87 82 53 46 37 38 50 50 35 32 42 30 36 47 57 39 29 50 55 43 28 41 58 39 65 41 22 39 47 29 27 29 46 43 45 39 45 31 15 52 33 18 18 53 44 16 55 14 20 2 3 4 4 7 4 1 5 3 6 4
27 145 753 833 75 498 71 208 28 993 5 924 2 851 4 099 6 160 31 224 2 595 163 902 841 24 735 8 699 38 560 19 929 10 327 4 380 4 017 22 389
28 769 296 3 257 10 044 9 490 7 863 344 646 476 2 119 25 562 328 234 100 399 4 013 11 130 29 379 4 309 2 282 97 34 8 427
28 769 296 3 195 9 841 9 316 7 863 336 646 476 2 119 25 562 328 230 468 399 3 955 11 130 29 270 4 087 2 282 97 33 8 427
106 39 384 13 13 27 6 23 12 34 82 13 141 47 16 128 76 21 22 2 1 38
13 213 49 109 14 1 208 145 4 887 6 4 701 7 2 726 9 109 2 274 10 143 3 772 13 11 937 38 187 7 88 747 54 116 14 1 984 8 6 130 70 12 627 33 1 155 6 941 9 56 1 13 0 3 537 16
EMR
555 064
383 364
378 895
68
155 572
28
Table A3.6
DOTS coverage, case notifications and case detection rates, Eastern Mediterranean, 2007
DOTS coverage %
TB cases reported from DOTS services New pulmonary New extraOther Re-treatment cases . New and relapse . ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. Other number rate number rate number number number number number number number number
97 100 100 100 100 87 100 100 100 100 100 100 99 100 100 100 91 100 100 20 45 100
28 769 296 3 195 9 841 9 316 7 863 336 646 476 2 119 25 562 328 230 468 399 3 955 11 130 29 270 4 087 2 282 97 33 5 389
106 39 384 13 13 27 6 23 12 34 82 13 141 47 16 128 76 21 22 2 1 24
13 213 109 1 208 4 887 4 701 2 726 109 274 143 772 11 937 187 88 747 116 1 984 6 130 12 627 1 155 941 56 13 3 523
49 14 145 6 7 9 2 10 3 13 38 7 54 14 8 70 33 6 9 1 0 16
8 251 71 329 1 703 1 830 2 293 70 94 118 523 2 059 33 103 629 75 582 2 490 9 486 706 305 20 2 772
EMR
97
375 857
68
155 558
28
135 441
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 0 0 0 0 0 0 7 12 210 0 0 2 5 24 15 0 9 2 0 12 9 0 0 2 0 9 16 0 1 2 0 9 24 0 1 2 0 116 14 0 1 0 97 1 7 0 0 272 486 2 216 87 0 74 0 1 0 13 938 0 43 4 0 21 2 0 135 22 0 30 10 277 43 9 5 8 2 1 59 5 0 8 4 0 1 7 0 1 39 3 0 0 506 144 34 33 1 11 269 39 9 4 1 2 0 0 0 TB pts HIV-positive Lab-confirmed DST MDR Re-treatment Re-treatment MDR in new cases in new cases DST MDR 167 361 1 087 0 104 644 5 0 334 0 339 10 0 0 0 20 0 3 0 6 275 58 126 4 160 477 102 0 0 0 0 34 0 0 0 0 0 0 20 0 5 0 0 0 3 0 490 14 98 0 97 1 7 0 59 0 0 10 0 0 10 0 0 14 0 1 14 0 1 0 189 267 112 42 6 3 657 0 393 386 0 70 645 8 1 52 141 0 399 0 95 12 4 0 0 2 0 0 200 396 482 732 0 112 646 113 116 0 328 0 399 0 4 54 9 171 0 1 2 0 116 HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, Eastern Mediterranean, 20062007
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 0 51 12 12 1 0 1 1 0 1 377
500 11 14 293 314 20 150 12 168 24 158 205 1 131 1 320 47 321 65 66 24 5 245
1 2 0 18 27 1 50 1 4 3 14 10 3 1 11 0 1 1 7 3 1 3
2 0 1 2 1 1 1 1 3 2 1 1 1 11 0 1 1 5
360 1 13 216 314 19 12 12 6 24 158 205 360 1 0 12 186 14 0
0 1
0 245
EMR
4 094
162
36
2 158
Table A3.8
% Not eval. Success Number of cases Notified Regist'd New smear-positive cases, non-DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred Not eval.
Treatment outcomes, Eastern Mediterranean, 2006 cohort

% Number Regist'd 1 132 276 799 485 748 26 0 8 Success 74 59 47 66 63 31 63 5 10 22 8 12 46 38 3 4 6 11 2 0 0 2 4 12 3 5 4 0 2 20 6 6 16 15 0 6 3 6 2 2 4 0 8 0 0 5 0 0 0 0 79 69 69 74 75 77 100 % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
% of notif regist'd
66
100
1 732 5 5 566 101 534 2 043 279
54 100 59 53 73 52 28 25
18 0 18 10 5 28 43 50
3 0 4 6 9 1 5 25
3 0 3 1 4 0 4 0
16 0 11 14 7 7 18 0
5 0 4 1 2 8 2 0
0 0 0 15 0 2 0
72 100 77 63 78 80 71 75
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 62 62 57 123 92 198 54 25 18 8 2 1 0 0 19 9 1 6 3 1 86
12 468 98 1 153 4 745 4 802 2 886 104 284 112 745 12 280 184 65 253 115 1 914 6 861 12 194 1 352 922 52 16 3 280
12 468 14 1 143 4 745 4 923 2 886 104 284 112 745 12 280 118 65 589 115 1 863 6 861 12 150 1 352 901 52 16 3 280
100 14 99 100 103 100 100 100 100 100 100 64 101 100 97 100 100 100 98 100 100 100
80 86 70 71 77 77 58 45 83 45 80 86 75 62 62 86 67 74 84 44 50 74
5 0 8 16 6 8 13 33 7 32 7 0 13 7 7 3 14 13 7 35 44 9
2 14 1 3 7 2 8 0 4 1 2 12 3 1 6 3 2 3 3 4 6 3
1 0 1 3 3 3 4 0 0 0 1 0 1 0 1 1 1 2 1 2 0 2
2 0 16 3 3 9 17 5 5 20 9 0 6 0 7 4 7 7 3 15 0 7
6 0 4 3 3 2 0 16 1 2 1 2 2 27 0 3 2 2 2 0 0 4
5 0 0 0 1 0 0 0 0 1 0 0 0 3 17 0 5 0 0 0 0 1
84 86 78 87 83 84 71 78 90 77 87 86 88 69 69 89 82 86 91 79 94 83
7 57
0 0
72 33
4 0 301 14 039
66 58
7 18
5 4
3 3
5 11
2 5
0 0 11 2
73 76
EMR
131 820
132 001
100
75
11
Table A3.9
After failure, DOTS % of cohort Not eval. Died Died 8 0 0 5 0 0 0 0 0 0 52 22 5 5 8 8 0 74 49 20 4 3 20 4 0 69 15 0 0 0 0 38 21 61 67 11 10 8 5 11 10 11 5 0 5 0 0 71 76 66 25 16 19 6 3 3 3 9 44 0 6 0 0 81 44 0 32 36 0 11 2 78 1 322 50 22 6 7 9 6 0 72 2 435 44 23 4 4 21 4 0 73 75 63 78 89 67 76 100 82 83 0 724 67 6 7 17 2 0 67 231 0 1834 49 5 4 38 3 0 49 100 69 73 73 75 75 58 40 73 60 80 16 23 5 13 0 8 9 5 3 0 6 12 3 13 20 8 7 7 10 0 3 8 3 0 0 0 1 4 0 0 74 63 78 73 80 36 49 54 47 18 18 11 27 9 8 11 1 18 11 0 2 14 9 17 22 5 5 6 0 0 0 0 0 55 67 66 74 79 % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, Eastern Mediterranean, 2006 cohort
Number regist'd
ComplCured eted
Died
1 132
74
192 445 315 603 4 0 8
63 50 65 65 75
7 23 9 10 0
2 5 13 2 0
2 12 3 4 0
25 4 3 16 25
3 5 2 2 0
63
38
62 194 135 60 5 0 0
22 160 35 85 0 0 0
1334 5 3008
70 100 67
6 0 15
3 0 4
3 0 3
13 0 7
5 0 4
101 534 141 66
53 73 75 50
10 5 13 17
6 9 4 9
1 4 2 6
14 7 5 15
1 2 0 3

0 0 0 0 0 0 67
4 0 301
25
50
25
66
EMR
8 193
67
11
Table A3.10 DOTS treatment success and case detection rates, Eastern Mediterranean, 19942007
2003 4 12 2004 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 2002
1994
1995
1996
1997
1998
1999
2000
45
75 50 42 106 41 91 93 121 24
52
77 81 87
76 82 84
96 1
100 13 12
90
33 13 79 87 83 83 92 84 20 35 5 76
89
86 73 62 87 85 92 90 69 92
84 87 78 82 85 89 86 73 91
29 17 57 59 61 55 78 62 64
86
88 87 1 33 33 2
74 83
90 84 70 81
72
89 91 67 79
93 121 2 27
90 121 4 43
86
84
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 89 93 74 66 73 83 79 79 91 74 43 1 16 75 83 83 84 83 83 83 80 1 86 12 8 10 29 12 87 90 77 60 77 86 80 81 90 62 43 27 40 37 19 51 21 25
92
90 70 88
73 68 88 86 66 84 57 88 65 88 91
87 95 72 87 82 85 88 66 96 67 88 95 70 74 66 88 81 84 91
11 15 75 38 54 13 77 62 75 148 91 91 2 33 21 46 27 56 94
39 12 53 65 61 59 75 71 63 138 92 117 13 34 39 58 31 87 90 20 90 112 5 41 38 58 29 88 103 25 12 52 27 48 32
66
78
81
80
79
87 88 82 88 85 91 89 55 91 61 89 92 78 75 76 89 78 87 92 79 100 80
86 97 73 80 84 85 87 62 92 62 86 90 79 73 79 90 82 88 91 64 80 82
89 82 80 70 84 85 85 63 90 64 87 90 82 78 82 91 77 86 90 70 50 82
90 93 80 79 83 86 83 63 92 69 81 90 83 83 65 89 82 89 90 73 100 80
84 86 78 87 83 84 71 78 90 77 87 86 88 69 69 89 82 86 91 79 94 83
18 17 63 54 58 51 70 65 65 113 89 123 3 29 36 48 32 84 101 27 15 55
37 12 49 70 62 53 91 70 63 149 93 85 17 52 38 61 31 96 85 27 6 45 34
45 51 42 76 63 49 73 85 72 175 91 128 25 38 38 74 33 100 88 19 2 41 39
52 74 42 75 62 44 66 63 65 176 96 95 38 46 38 78 34 89 83 21 3 41 46
63 72 42 69 67 40 78 95 52 154 94 129 50 49 39 74 31 91 80 17 7 42 52
64 79 42 72 68 37 81 90 62 162 93 125 67 44 39 64 31 80 78 18 5 46 60
EMR
82
87
86
79
77
83
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, Eastern Mediterranean, 2007
5564 630 4 44 359 261 188 7 8 11 12 545 13 6 258 4 111 296 729 49 71 3 3 165 9 771 8 472 3 735 18 893 15 998 12 044 9 003 6 743 5 333 5 549 36 706 34 748 26 430 21 449 16 514 13 805 1.2 507 3 23 214 680 126 5 5 5 10 529 8 5 156 0 92 289 556 59 75 10 1 119 475 1 8 25 42 34 0 0 1 4 123 3 2 443 1 30 135 334 14 11 1 0 50 2 224 10 129 500 394 289 9 26 17 23 1 177 22 11 522 4 298 602 992 148 69 8 0 430 2 357 15 131 325 236 228 12 53 30 17 837 13 9 162 6 197 520 1 318 106 54 6 1 374 1 708 5 62 245 173 154 6 18 13 12 444 11 7 352 5 110 378 990 41 42 3 0 272 1 143 3 35 225 268 134 1 13 5 8 354 10 5 496 3 71 243 729 43 28 2 0 189 771 0 14 173 387 130 12 7 3 7 306 7 4 065 0 39 181 467 30 29 0 2 113 353 1 18 72 813 74 7 4 2 11 370 14 2 934 0 64 129 324 41 45 0 0 57 661 1 22 60 52 54 0 1 1 6 197 3 3460 1 38 260 622 21 12 3 1 73 3 080 18 370 1088 705 608 16 42 29 84 3275 38 21120 30 544 1841 2347 346 193 13 1 918 3 197 41 395 1178 747 759 32 122 49 160 3207 38 17952 44 509 1528 3221 328 225 12 4 1000 2 305 20 204 874 503 430 20 43 26 90 1989 36 15069 24 329 956 2530 164 159 6 2 651 1 709 11 118 868 553 357 10 42 17 34 1519 30 12733 13 258 650 1831 117 132 6 0 441 1 401 4 58 532 648 318 19 15 14 19 851 20 10323 4 150 477 1196 79 100 3 5 278 860 4 41 286 1493 200 12 9 7 21 899 22 8090 0 156 418 880 100 120 10 1 176 0.5 1.8 2.0 2.1 1.0 1.6 1.3 1.3 1.0 4.0 2.3 1.3 1.1 5.1 1.5 1.8 1.4 1.7 2.4 1.7 3.7 1.4 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
186 0 14 35 10 20 0 1 0 2 74 0 1 017 0 8 125 288 7 1 2 1 23
856 8 241 588 311 319 7 16 12 61 2 098 16 9 598 26 246 1 239 1 355 198 124 5 1 488
840 26 264 853 511 531 20 69 19 143 2 370 25 8 790 38 312 1 008 1 903 222 171 6 3 626
597 15 142 629 330 276 14 25 13 78 1 545 25 7 717 19 219 578 1 540 123 117 3 2 379
566 8 83 643 285 223 9 29 12 26 1 165 20 7 237 10 187 407 1 102 74 104 4 0 252
EMR
1 814
17 813
18 750
14 386
12 446
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, Eastern Mediterranean, 2007
65+ 173 26 200 13 44 33 5 15 3 8 70 21 163 0 26 281 87 20 25 34 2 49 82 4 32 38 40 42 51 47 3 31 39 43 8 1 5 0 0 1 0 0 0 0 3 1 9 1 1 7 4 0 1 0 0 1 86 18 145 7 5 10 2 13 5 4 36 8 64 9 13 74 26 7 7 3 0 18 138 26 206 6 4 11 2 20 9 3 31 6 79 11 10 81 47 6 6 2 0 25 150 9 136 6 4 10 2 9 4 3 22 10 88 10 8 88 51 4 6 1 0 29 155 9 116 6 9 14 1 13 2 4 22 13 88 12 10 84 55 6 5 2 0 29 163 0 70 8 20 23 10 18 2 5 35 17 107 0 10 107 51 8 9 0 3 29 115 8 125 4 51 16 7 17 1 9 41 39 88 0 19 104 43 12 13 0 0 20 5 1 7 0 0 0 0 0 0 0 2 0 6 1 0 7 4 0 0 0 0 1 57 15 207 7 4 10 1 9 4 7 51 7 57 26 12 113 30 8 9 2 0 19 89 27 307 10 6 18 3 17 7 13 62 8 75 22 11 120 56 9 12 1 1 33 96 15 223 11 6 14 3 7 5 11 51 11 87 14 9 114 65 8 11 1 1 35 111 11 199 12 9 18 3 15 4 7 48 14 98 11 13 116 70 9 12 2 0 34 48 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 All 3544 5564 145 11 151 12 18 29 8 14 5 6 48 20 133 11 17 148 68 11 16 3 4 38 63 65+ 143 17 159 8 47 24 6 16 2 8 54 30 124 0 22 184 63 16 18 20 1 33 64
014
1524
2534
Male 3544
4554
5564
3 0 9 0 0 0 0 0 0 0 2 0 3 0 0 6 4 0 0 0 0 0
31 12 267 8 3 11 1 7 3 10 65 6 50 38 11 153 34 9 11 1 0 20
45 28 407 14 8 25 4 15 6 23 97 9 71 26 12 160 66 13 18 1 1 40
48 18 310 15 8 18 3 7 5 19 84 12 86 15 10 140 79 11 16 0 1 41
71 13 286 18 9 23 5 15 6 9 73 15 107 11 15 151 85 11 19 1 0 40
128 17 241 16 16 35 6 12 8 7 63 23 158 14 23 193 86 13 24 3 5 46
EMR
29
41
45
54
75
Table A3.13 TB case notifications, Eastern Mediterranean, 19802007

1985 43 3 311 3 911 13 021 19 733 443 237 940 30 316 304 11 145 15 936 9 697 498 336 983 1 440 29 829 276 13 142 304 30 227 298 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
71 685 219 140 2 884 8 876 14 121 14 905 504 282 884 1 164 25 403 367 114 3 489 3 426 20 569 18 553 427 217 49 3 332 12 338 14 189 29 196 468 400 836 1 282 31 771 300 4 307 257
52 502 232
1 637 42 717 11 809 298 847 442 27 658 482 156 759 184 2 415 2 016 37 516 2 565 2 504 14 320 4 404 2 383 27 626 281 73 175 200 2 386 2 518 2 023 23 178 5 127 2 376 426 11 510 119 374 16 73 121 745 18 82 145 373 20 91 136 232 17 77 233 878 22 100 171 734 21 95 141 748 22 100 165 904 21 95 77 14 428 12 013 13 085 3 920 20 230 5 200 2 387 507 40 14 364 11 677 191 744 21 95 212 3 138 4 450 20 894 4 972
16 051 142 2 030 1 378 9 967 11 384 553 480
14 386 122 2 040 1 492 12 005 14 312 484 468
4 332 117 2 100 2 142 9 255 14 735 439 277
1 290 45 3 830 13 971 12 659 26 607 397 528 701
10 139 188 4 198 10 549 11 783 10 478 342 496 516
718 24 878 1 872 316 340 257 10 956
71 554 262 2 265 1 306 11 728 10 614 646 819 67 481 28 637 928 324 576 213 8 263
41 752 156 671 1 805 9 509 7 741 860 880 75 512 28 095 897 326 492 172 8 529
1 932 8 589 6 970 856 855 284 610 26 944 802 117 739 206 7 551 2 838 416 25 717 477 194 323 223 2 433 2 728 693 4 952 2 309 339 85 3 446 212 6 018 2 054 285 64 4 650 11 076 201 620 15 68 234 620 20 91 315 483 21 95 109 087 18 82 16 423 5 651 2 064 234 89 6 844 19 503 5 437 2 164 227 97 10 113 28 285 292 34 066 284 3 327 6 852 23 997 4 997 1 945 74 67 13 029 207 375 22 100 235 943 22 100 280 126 21 95 261 441 21 95 265 26 756 478 170 562 191 2 583 1 323 701 5 504 2 403 308 145 4 913
18 784 208 1 489 1 572 10 493 6 807 672 812 410 357 22 279 843 91 572 203 7 163 2 719
23 067 142 2 900 3 634 14 246 13 527 390 330 884 239 27 638 442 194 323 195 2 221
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 230 427 21 95 288 805 21 95 287 352 22 100 322 306 22 100
32 971 1 689 2 504 522 191
47 431 1 908 2 316 638 139
1 838 2 554 597 136
1 867 3 062 507 136
2 111 2 501 534 123
10 742 194 2 262 1 308 8 728 6 485 769 717 1 943 325 26 790 861 111 419 250 3 966 2 722 1 509 2 163 2 510 568 113
14 351 156 1 864 1 209 8 032 6 846 592 611 2 257 276 27 553 1 265 149 004 220 3 696 3 079 2 460 3 942 2 487 464 63
18 091 120 1 978 22 063 10 034 6 517 537 540 2 478 331 27 159 616 179 480 248 3 029 7 322 800 4 290 2 272 818 82
3 084 83 3 785 12 662 11 794 29 410 380 564 640 1 575 29 087 287 89 599 253 3 235 4 320 22 318 5 417 2 211 773 18 12 383
3 314 145 4 133 11 763 12 062 29 897 373 515 679 1 615 29 854 249 20 936 259 3 507 4 802 26 875 5 447 2 158 66
7 107 207 3 971 10 762 11 850 9 697 306 513 571 1 341 28 852 321 11 050 279 3 452 5 686 24 807 5 090 2 038 115 82 13 651
13 794 191 3 191 11 177 11 464 11 898 312 585 437 1 824 29 804 290 52 762 278 3 374 7 391 24 554 4 766 1 885 90
13 808 261 3 231 11 490 10 900 11 656 310 566 380 1 917 26 789 255 70 485 276 3 317 9 278 25 105 4 820 1 965 117 36 10 413
18 404 244 2 940 11 620 10 171 10 498 324 557 393 1 653 25 909 292 94 327 272 3 312 11 747 26 567 4 588 1 994 92 23 10 016
21 844 280 3 109 11 446 9 192 9 454 367 517 391 2 098 26 269 261 142 211 325 3 539 12 904 27 562 4 310 2 079 103 28 9 063
25 475 278 3 011 10 046 9 361 8 043 359 644 375 2 022 26 099 339 176 678 339 3 774 11 864 28 937 3 931 2 131 90 42 8 468
28 769 296 3 195 9 841 9 316 7 863 336 646 476 2 119 25 562 328 230 468 399 3 955 11 130 29 270 4 087 2 282 97 33 8 427 378 895 22 100

1987 7 542 7 21 94 11 13 28 114 14 18 26 45 12 19 28 30 111 13 10 58 109 13 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 135 31 406 3 19 65 19 23 10 111 26 139 39 15 12 134 30 40 49 30 27 106 14 60 40 14 14 32 81 36 27 19 77 28 3 93 28 38 16 69 67 32 27 487 15 24 76 14 14 28 26 99 19 21 580 6 34 91 11 12 8 519 20 22 131 11 23 23 26 116 13 3 48 119 26 382 3 22 79 16 22 34 24 375 4 16 80 13 13 7 7 577 22 20 116 9 29 19 47 28 562 16 18 41 7 21 14 171 28 500 6 25 71 11 16 29 5 109 23 167 40 13 152 27 427 43 19 38 19 28 85 8 116 37 175 61 21 111 3 37 30 52 4 10 108 28 183 52 16 41 3 41 29 20 4 30 1 47 25 15 3 38 78 49 61 80 27 62 43 25 12 4 53 72 40 25 11 4 75 62 67 35 26 20 1 89 33 72 30 77 70 6 110 27 156 42 16 20 3 45 30 17 7 42 74 50 36 82 29 16 13 551 20 18 124 8 29 17 31 103 12 65 44 16 65 70 34 24 27 1 72 16 23 583 18 18 123 8 24 18 31 105 11 15 44 17 70 82 34 23 2 34 32 544 16 18 39 6 23 15 25 100 13 8 45 17 81 74 31 21 4 3 75 97 12 23 44 16 94 70 29 20 2 2 70 34 62 28 418 16 17 45 6 24 11 33 101 12 35 40 15 99 71 27 19 2 61 38 60 38 416 16 16 43 6 22 10 34 90 10 46 38 15 120 71 27 20 3 1 52 40 76 34 372 16 15 38 6 21 10 29 86 12 61 36 14 148 74 25 20 2 1 49 45 87 39 387 16 13 34 7 19 10 35 86 10 90 41 15 157 75 23 21 3 1 43 54 98 38 368 14 13 28 6 23 9 33 85 13 110 41 16 140 77 20 21 2 1 39 59 106 39 384 13 13 27 6 23 12 34 82 13 141 47 16 128 76 21 22 2 1 38 68
EMR Number reporting % reporting
522 110 18 82
514 791 20 91
433 271 19 86
234 482 19 86
171 652 20 91
186 344 21 95
Table A3.14 TB case notification rates, Eastern Mediterranean, 19802007
1980
1981
1982
1983
1984
1985
1986
514 63
403 60
4 109 84 13 62
23 127 158 399 112 114
521 73 640 3 29 73 28 57 2 15 143 74 396 85 81
312 42 184 4 22 52 36 58 3 15 136 68 384 62 79
4 19 45 34 55 10 17 127 58 133 68 66 43
149 52 388 3 23 43 26 50 14 10 102 58 100 61 59 42
168 19 39 51 13
234 20 35 58 9
19 38 51 9
19 44 40 8
20 35 40 7
87 47 562 3 18 40 28 42 67 8 120 56 117 69 31 42 7 20 34 40 6
119 36 434 2 16 41 21 34 78 7 121 79 151 57 27 47 10 35 33 31 3
EMR
184
176
144
75
53
56
67
Table A3.15 New smear-positive cases notified, Eastern Mediterranean, 19902007

Number of cases 1996 3 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Rate (per 100 000 population)
1990 17
1991
1992
1993
1994
1995
82 1 668
1 587
1 512
2 304
5 240 173 148
1 743 1 811 4 615 5 781 161 155 148 9 8 7 9 15 4 10 6
4 229 5 347 3 194 187 175 197
618 22 1 904 5 469 5 253 8 164 136 201 206 15 277 285 3 8 12 26 28 4 4 8 9 4
1 833 25 1 690 4 915 5 105 8 933 110 185 224
4 639 23 1 312 4 514 5 529 3 559 94 174 171
123 11 020 5 19 13 12 11
135
14 171 135 2 578 60 6 9 6 39 1 568 3 093 10 835 1 423 25 30 9 14
31 1 744 5 084 5 373 10 320 170 153 198 515 14 278 164 1 849 46 14 134 165 53 6 2 11
800
1 168 3 728
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 2 894 8 978 1 523 1 005 13 426 156 14 974 69 1 644 3 121 10 820 1 593 1 196 24 4 371 4 717 57 947 74 923 69 140 60 959 69 101 76 125 81 313 94 775 113 864 131 882 155 572 <1 <1 <1 5 5 11 13 5 427 4 259 0 0 0 0 0 58 720 13 8 4 896 12 804 156 10 935 77 1 686 4 640 11 136 1 507 1 077 69 31 4 968 0 24 16 15 13 14 15 16 18 21 24 28
1 006
983
1 572 8 761 1 295 1 243
1 669 21 1 564 5 094 5 426 9 908 102 169 249 803 13 420 120 6 248 58 1 680 3 461 11 047 1 577 1 066 31
6 509 17 1 253 4 889 5 366 3 895 91 206 148 722 12 914 151 16 380 64 1 674 4 818 10 338 1 447 927 57
9 3 681
2 892 23 1 391 4 606 5 361 3 194 89 180 202 607 12 872 164 3 285 53 1 595 3 776 12 311 1 584 1 099 73 37 5 565
6 510 16 1 202 5 118 5 188 3 577 108 201 134 764 12 842 110 21 301 95 1 646 5 190 11 003 1 545 878 77 15 3 793
8 273 69 1 086 5 383 4 900 3 381 91 247 146 872 12 280 160 31 557 73 1 683 6 479 12 095 1 561 944 57 4 3 434
9 949 101 1 120 5 217 4 581 3 096 86 187 131 860 12 757 131 48 319 96 1 722 7 068 12 730 1 350 915 62 7 3 379
12 468 98 1 153 4 745 4 802 2 886 104 284 112 745 12 280 184 65 253 115 1 914 6 861 12 194 1 352 922 52 16 3 342
13 213 109 1 208 4 887 4 701 2 726 109 274 143 772 11 937 187 88 747 116 1 984 6 130 12 627 1 155 941 56 13 3 537
3 9 8 14 22 29 28 34 40 48 49 5 4 4 3 4 3 3 2 10 14 13 14 272 287 246 220 191 176 164 155 137 139 141 145 8 9 8 8 7 7 7 7 8 7 6 6 9 8 8 8 8 8 8 8 7 7 7 7 46 35 38 41 13 14 15 13 12 11 10 9 4 3 2 2 2 2 2 2 2 2 2 2 9 11 9 8 8 7 8 8 9 7 10 10 6 6 6 7 5 4 4 3 4 3 3 3 10 15 11 13 13 15 15 12 13 52 51 48 47 45 44 44 43 41 42 40 38 7 7 7 5 7 6 6 4 6 5 7 7 1 11 4 2 7 11 14 20 31 41 54 9 7 12 10 9 12 9 13 10 12 14 14 8 8 8 8 8 8 7 7 7 8 8 46 48 47 51 54 64 64 67 81 86 81 70 30 35 34 34 37 33 30 31 33 34 32 33 10 9 10 10 10 9 8 9 8 7 7 6 11 13 11 11 11 9 9 9 9 9 9 1 2 2 2 2 1 2 1 1 1 0 1 1 0 0 0 0 0 27 28 29 31 31 27 22 19 17 16 15 16
EMR
1 587
1 512
2 304
20 260
20 428
46 851
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), Eastern Mediterranean, 2009
Available funding Loans Funding gap 0 < 0.01 1 20 0 0 0 < 0.01 25 1 7 1 0 1 1 2 4 0 < 0.01 3 0 1 0.03 3 28 52 1 0 0 0 0 0.02 0 0 0 0 12 6 < 0.01 1 0 0 0 < 0.01 1 0 0 0 0 0 0 2 5 4 Grants (excluding Global Fund) Global Fund Cost of utilization of general health-care services . Total TB control costs 11 1 19 42 2 6 1 6 58 0 Completeness of budget data
NTP budget
10
0 12
0 9
41 2 5 0
20 1 5 0
54
10
Afghanistan Bahrain Djibouti Egypt Iran (Islamic Republic of) Iraq Jordan Kuwait Lebanon Libyan Arab Jamahiriya Morocco Oman Pakistan Qatar Saudi Arabia Somalia Sudan Syrian Arab Republic Tunisia United Arab Emirates West Bank and Gaza Strip Yemen 0 0 0 0 0 0 0 19 0 0 1 1 0 1 0 0 1 5 2 3 2 2 1 1 0 0.05 1 25
0 10 0 5
0 1 6 1
1 6
0 2
2 12 1 6 0 1 7 176
C N C C N C C C C N C N C N N P C C C N C C 64%
EMR
151
60
Notes
Bahrain
TABLES A3.5 AND A3.6: of the 296 notied TB cases, 231 were in non-nationals; of the 109 new smear-positive cases notied, 91 were in non-nationals.
Lebanon
TABLES A3.1A3.4: estimates will be further reviewed in 2009 based on additional in-depth analysis of national and subnational notication data.
Pakistan
TABLES A3.5 AND A3.6: according to data from three provinces (which account for 90% of notied cases), 19% of all notied new cases were reported from PPM initiatives.
Somalia
Sudan
TABLE A3.6: DOTS coverage is the weighted average of coverage in the northern (100% coverage) and southern (55% coverage) parts of the country, which account for 80% and 20% of the total population, respectively. TABLE A3.7: the numbers of laboratories performing culture and DST do not include those in the southern part of the country.
Yemen
EUROPE
Europe
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan Hasan Hazi; Donika Bardhi Carmen Pallares Papaseit; Jennifer Fernandez Vagan Rasailovich Pogosyan; Narine Mejlimyan Jean-Paul Klein Faig Frudinovich Agayev; Natavan Alikhanova Gennady Lvovich Gurevich; Andrei Petrovich Astrovko Maryse Wanlin; Patrick De Smet Zehra Dizdarevic; Hasan Zutic Vladimir Milanov Aleksandar Simunovic Andreas Georghiou; Chrystalla Hadjianastassiou Ji r Wallenfels; Zdenka Novakova Peter Henrik Andersen; Charlotte Kjels Piret Viiklepp; Kai Kliiman Petri Ruutu Marie Claire Paty; Delphine Antoine Archil Salakaia; Ucha Nanava Walter Haas; Bonita Brodhun Georgia Spala; Rengina Vorou Janos Strausz; Gbor Kovcs Thorsteinn Blndal Joan ODonnell Daniel Chemtob; Yana Roshal Maria Grazia Pompa; Stefania DAmato Shahimurat Shaimovich Ismailov; Klar Khasanovna Baimukhanova Avtandil Shermamatovitch Alisherov; Elmira Djusupbekovna Abdrakhmanova Janis Leimans; Vija Riekstina Edita Davidavi cien e Pierre Weicherding; Norbert Charl Gianfranco Spiteri Olivera Bojovi c ; Boidarka Rakocevic Vincent Kuyvenhoven; Connie Erkens Brita Askeland Winje Kazimierz Roszkowski; Maria Korzeniewska-Kosela Antnio Fonseca Antunes Dmitrii Sain; Ana Ciobanu Constantin Marica; Domnica Chiotan Mikhail I. Perelman; Yulia V. Mikhailova; Elena I. Skachkova Gordana Radosavljevi c-Ai c ; Radmila Cur ci c; Rukije Mehmeti Ivan Solovic; Jana Svecova Damijan Eren Odorina Tello Anchuela; Elena Rodrguez Valn Victoria Romanus Peter Helbling Sadulo Makhmadalievich Saidaliev; Firuza Teshaevna Sharipova Stefan Talevski; Maja Zakoska Feyzullah Gmsl; lgen Gullu Babakuli Dzhumaev Olga Stelmakh; Elena Pavlenko; Oksana Smetanina, Inna Motrich John Watson; Brian Smyth; Jim McMenamin; Roland Salmon; Michelle Kruijshaar; Eisin Shakir Dilrabo Ulmasova; Gulnoz Uzakova; Nulifar Abdieva
Table A3.1
TB/HIV Indirect Indirect Indirect Indirect Indirect Indirect Routine Indirect Indirect Indirect Indirect Indirect Sentinel Indirect Indirect Indirect Indirect Indirect Routine Indirect Indirect Indirect Routine Indirect Indirect Routine Indirect Indirect Indirect Routine Routine Indirect Routine Indirect Routine Indirect Indirect Indirect Indirect Indirect Indirect Indirect Source of estimates MDR (new) MDR (re-treat) Model Model DRS Model DRS DRS DRS DRS DRS DRS Model Model DRS DRS DRS DRS Model Model DRS DRS Model Model DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS Model Model Model Model DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS Model Model DRS DRS DRS DRS DRS Model DRS Model Model Model Model Model DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS Model Model DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS DRS Model Model Model Model Model Model DRS DRS DRS DRS DRS DRS DRS DRS Cfr ss+ HIVDOTS non-DOTS 0.15 0.15 0.12 0.12 0.15 0.2 0.12 0.12 0.15 0.15 0.15 0.15 0.12 0.12 0.15 0.15 0.15 0.15 0.15 0.15 0.1 0.1 0.12 0.12 0.12 0.12 0.15 0.15 0.12 0.12 0.12 0.12 0.15 0.2 0.12 0.12 0.12 0.12 0.15 0.15 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.12 0.12 0.12 0.12 0.12 0.12 0.15 0.15 0.12 0.12 0.12 0.12 0.15 0.15 0.12 0.12 0.15 0.15 0.15 0.15 0.15 0.2 0.12 0.12 0.15 0.15 0.15 0.2 0.15 0.15 0.12 0.12 0.12 0.12 0.12 0.12 0.15 0.15 0.15 0.2 0.15 0.15 0.15 0.15 0.15 0.15 0.12 0.12 0.15 0.15 Duration ss+HIVDOTS non-DOTS 1 1.5 0.75 1 1 1.5 0.75 0.75 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 Duration ss-HIVDOTS non-DOTS 1 1.5 0.75 1 1 1.5 0.75 0.75 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 0.75 0.75 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5 1 1.5 1 1.5 0.75 0.75 0.75 0.75 0.75 0.75 1 1.5 1 1.5 1 1.5 1 1.5 1 1.5 0.75 0.75 1 1.5
Methods and assumptions for estimation of TB incidence, prevalence and mortality, Europe
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan
Reference year 1997 1997 1999 1997 1999 1997 1997 1997 1997 1997 1997 1997 1997 2002 1997 1997 1997 1997 1997 1999 1997 1999 2004 1997 1999 1999 1997 1997 1997 1997 2000 1997 1997 1999 1997 1997 1999 1997 1995 1997 1997 1997 1997 1997 1999 1997 1997 1997 1997 1997 1997 1999 1997
Incidence est. based on Notif. Notif. Comparison Notif. Comparison Notif. Notif. Notif. Notif. Notif. ARI Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Comparison Comparison Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Comparison Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif. Notif.
Trend Country notifs, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Group, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave. Country notifs, moving ave.
Table A3.2
TB mortality, 1990 All forms* number rate All forms* number rate 538 14 2 171 1 035 6 530 5 910 1 235 2 012 2 962 1 834 42 893 438 509 313 8 548 3 703 4 910 1 984 1 672 11 567 522 4 336 19 894 6 451 1 208 2 305 57 24 <1 193 1 234 261 9 584 3 149 5 348 24 635 157 321 2 3 190 896 259 13 103 544 460 15 542 597 22 136 3 399 46 916 9 308 30 813 431 518 49 42 322 5 189 951 21 14 813 2 455 580 51 21 161 2 63 765 7 8 096 <1 9.8 10 43 92 554 17 19 72 12 77 61 12 51 39 40 5 9 8 38 6 14 84 6 18 17 4 13 8 7 129 121 53 68 12 6 2 32 8 6 25 30 141 115 110 6 32 17 13 30 6 6 231 29 30 68 102 15 113 63 32 219 209 46 54 5 14 84 5 484 128 114 69 20 <1 18 24 282 563 186 62 53 2 2 36 6 177 625 198 598 25 715 74 1 044 13 39 614 9 491 311 646 2 <1 3 2 <1 <1 <1 <1 6 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 4 3 3 2 <1 <1 <1 <1 <1 6 5 3 18 <1 2 <1 <1 9 21 <1 2 242 6 971 462 2 916 2 639 551 905 1 328 825 19 401 196 221 140 3 798 1 654 2 198 886 750 5 253 233 1 923 8 896 2 884 537 1 032 25 11 <1 87 552 117 4 295 1 355 2 387 11 026 68 223 <1 1 428 403 116 5 792 244 203 6 933 269 9 961 1 530 20 163 4 158 13 801 8 9 32 6 34 27 5 23 17 18 2 4 4 17 3 6 38 3 8 7 2 6 3 3 58 54 24 30 5 3 1 15 3 2 11 13 63 51 48 3 14 7 6 13 3 3 103 13 13 31 44 7 50 22 11 77 73 16 19 2 5 29 2 170 45 40 24 7 <1 6 8 99 197 65 22 18 <1 <1 13 2 62 219 69 209 9 000 26 365 5 14 215 3 322 109 226 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 1 1 <1 <1 <1 <1 <1 <1 <1 2 2 <1 6 <1 <1 <1 <1 3 7 <1 <1 709 14 2 428 796 7 320 6 706 989 2 168 3 130 2 443 49 945 352 526 242 6 794 3 640 3 789 1 776 1 908 8 455 417 3 688 21 485 7 147 1 263 2 353 44 19 <1 295 950 201 10 697 2 418 5 740 27 437 163 861 2 4 004 1 098 304 10 320 420 347 21 680 672 25 189 3 732 47 008 7 157 38 445 22 19 81 10 86 69 9 55 41 54 6 9 6 39 5 11 83 5 16 19 3 11 6 6 139 134 55 69 9 5 2 49 6 4 28 23 151 128 115 5 41 20 15 23 5 5 322 33 34 75 102 12 140 31 16 109 104 23 27 2 7 42 3 242 64 57 34 10 <1 9 12 141 282 93 31 26 <1 <1 18 3 88 312 99 299 12 857 37 522 7 20 307 4 745 155 323 1 <1 1 1 <1 <1 <1 <1 3 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 2 2 1 <1 <1 <1 <1 <1 <1 3 3 1 9 <1 1 <1 <1 5 10 <1 1 98 2 313 103 882 799 129 293 398 293 4 103 46 81 31 894 408 491 251 224 1 59 55 532 2 680 949 179 295 6 3 <1 26 123 26 1 319 350 722 3 516 25 355 <1 479 146 37 1 375 54 46 3 066 103 3 789 460 6 744 930 4 497 3 2 10 1 10 8 1 7 5 6 <1 1 <1 6 <1 1 9 <1 2 2 <1 1 <1 <1 17 18 8 9 1 <1 <1 4 <1 <1 3 3 19 16 18 <1 5 3 2 3 <1 <1 46 5 5 9 15 2 16 12 3 39 38 5 9 <1 2 18 <1 57 19 11 12 4 <1 2 3 43 100 35 12 9 <1 <1 3 <1 34 81 35 129 5 105 20 122 1 4 212 1 726 30 159 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 3 4 <1 <1 2.9 3.1 3.3 3.5 3.7 1.8 0.5 3.1 17 1.6 5.7 3.4 2.3 3.5 1.2 3.2 3.2 4.5 6.5 2.8 2.9 5.2 2.3 3.4 7.4 2.9 2.3 1.8 20 3.7 2.4 16 2.3 8.0 2.5 8.6 4.0 20 3.3 2.1 1.5 < 0.05 9.4 1.9 22 10 1.2 0.4 9.4 0.5 1.1 1.2 1.6 13 1.0 1.1 6.8 1.8 1.1 1.4 < 0.05 0.5 5.7 1.6 14 13 11 10 < 0.05 < 0.05 0.7 1.6 0.3 0.9 19 2.8 13 0.4 1.6 < 0.05 0.1 0.5 0.6 16 1.6 1.4 3.8 16 0.7 15 10 10 43 13 56 44 7.3 6.6 37 4.9 10 30 < 0.05 52 4.5 7.1 27 12 11 19 < 0.05 10 < 0.05 18 56 41 36 48 11 10 3.3 < 0.05 8.2 9.3 51 11 49 4.1 7.1 3.6 4.3 12 6.7 41 10 10 18 44 2.6 60 12 <1 486 25 3 916 1 101 21 18 371 19 <1 26 7 123 4 138 728 150 46 91 <1 8 30 274 11 102 1 290 202 464 <1 <1 10 4 133 59 2 231 1 555 42 969 26 25 <1 65 6 7 4 688 20 563 177 9 835 74 9 450 Percentage of new re-treat 141 2 191 180 365 526 208 649 313 535 6 242 81 65 87 1 542 361 1 552 426 575 2 86 64 888 1 284 351 118 160 9 5 <1 212 46 2 886 672 377 1 955 10 852 <1 976 347 99 2 265 59 125 1 084 216 4 872 343 2 879 672 2 012 43 963 5 4 4 5 2 5 5 2 15 4 12 <1 2 2 4 2 3 7 2 4 6 <1 2 1 2 8 8 4 4 2 1 <1 1 1 8 7 9 8 7 1 10 7 5 6 <1 2 20 11 8 9 6 1 10 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident number rate number rate TB cases (%)
Estimated burden of TB, Europe, 1990 and 2007

MDR, 2007 Number among all cases smear-positive 8 <1 373 14 3 109 758 13 14 217 13 <1 20 3 85 2 87 590 100 34 78 <1 7 13 235 9 540 813 129 339 <1 <1 6 2 117 44 1 656 1 171 31 397 19 17 <1 56 4 6 3 286 15 398 106 5 568 39 6 936 67 440
819 19 1 173 1 801 2 546 3 948 1 997 4 029 2 353 3 326 63 2 143 779 500 874 14 810 2 106 15 522 3 404 4 254 15 861 641 7 864 9 647 2 412 916 1 472 88 41 1 2 115 443 19 858 6 735 2 832 17 068 66 955 3 6 010 2 085 824 21 644 594 1 253 5 927 1 023 28 324 2 356 21 320 6 722 14 026
25 36 33 23 35 38 20 94 27 74 9 21 15 32 18 26 39 20 33 41 6 24 14 14 58 55 34 40 23 11 4 14 10 52 67 65 74 45 12 59 40 43 56 7 18 112 54 49 64 41 12 68
369 8 528 810 1 146 1 776 896 1 813 1 059 1 497 28 964 350 225 393 6 641 948 6 971 1 529 1 914 7 387 287 3 493 4 341 1 085 412 663 39 18 <1 949 199 8 935 2 984 1 274 7 678 30 130 1 2 705 938 371 9 616 266 557 2 667 460 12 746 1 060 9 594 3 022 6 312
11 16 15 10 16 17 9 42 12 33 4 9 7 14 8 12 17 9 15 18 3 11 6 6 26 25 15 18 10 5 2 6 5 23 30 29 33 20 5 27 18 19 25 3 8 50 24 22 29 19 5 31
1 375 21 1 831 1 400 4 154 6 393 1 614 6 893 3 812 5 690 96 2 238 630 791 680 11 959 2 783 12 040 3 083 6 990 12 670 496 6 200 15 627 3 934 1 480 2 352 71 35 1 1 638 359 33 462 5 111 4 588 27 416 102 085 2 10 239 2 880 1 271 17 199 460 956 10 247 1 759 47 535 3 843 34 704 5 221 23 301
42 39 52 18 58 62 16 160 43 126 14 22 12 50 14 21 51 15 30 67 5 19 11 11 95 90 56 64 19 10 3 11 8 88 51 105 118 69 9 101 55 66 44 5 14 193 92 83 105 67 9 114
EUR
318 540
37
143 062
17
439 626
52
Table A3.3
Number of cases 1995 840 17 1 678 1 395 4 438 6 186 1 701 2 810 3 213 3 026 51 2 041 590 817 654 11 306 3 047 12 551 2 668 5 017 10 582 582 5 899 11 374 4 382 1 791 2 637 71 32 1 1 632 339 18 424 5 692 4 474 26 217 128 565 2 5 685 1 982 624 16 305 539 835 4 777 934 25 543 2 558 29 280 6 987 16 702 389 505 409 910 428 724 437 374 445 657 445 527 440 916 6 987 18 941 6 966 20 448 6 915 21 589 6 860 22 928 7 122 25 532 7 190 27 898 7 567 29 303 435 397 8 043 29 737 432 139 8 698 31 240 432 704 9 003 31 033 432 102 9 308 30 813 431 518 12 68 37 12 64 36 12 63 37 12 73 38 12 73 40 12 76 42 12 72 45 12 80 47 12 85 49 12 89 50 12 93 51 12 102 51 12 110 50 13 113 49 13 113 49 862 17 1 815 1 353 4 903 6 673 1 625 2 815 3 501 2 956 50 2 030 574 895 643 10 981 3 288 11 922 2 601 4 885 11 567 579 5 718 13 932 5 186 2 007 2 854 69 31 1 1 590 331 17 342 5 578 4 847 27 133 139 131 2 5 605 1 864 593 15 820 497 806 5 113 924 26 463 3 211 31 788 860 16 1 956 1 299 5 371 7 329 1 530 2 821 3 637 2 840 49 1 898 553 923 615 10 563 3 529 11 263 2 509 4 548 11 576 569 5 491 16 953 5 983 2 050 2 916 67 30 1 1 534 319 16 042 5 347 5 203 27 841 148 651 2 5 434 1 680 538 15 219 490 803 5 862 901 27 217 3 911 35 563 839 15 2 067 1 223 5 753 7 633 1 536 2 624 3 606 2 534 47 1 746 523 942 599 9 977 3 710 10 514 2 374 4 096 12 563 548 5 176 19 594 6 341 2 044 2 826 64 28 1 1 453 302 14 805 5 033 5 461 29 152 157 465 2 4 876 1 549 493 14 405 476 731 6 385 814 24 401 4 118 37 396 781 15 2 178 1 172 6 137 7 385 1 586 2 380 3 525 2 229 45 1 560 502 897 540 9 580 3 887 9 272 2 280 3 681 10 549 535 4 960 21 110 6 672 1 983 2 687 62 27 1 1 397 291 13 524 4 696 5 711 30 190 166 211 2 4 294 1 413 457 13 896 458 656 7 250 723 21 327 4 156 40 989 724 14 2 209 1 133 6 295 6 558 1 623 2 234 3 460 2 057 44 1 397 485 844 500 9 280 3 919 8 187 2 204 3 367 10 514 527 4 793 21 813 6 753 1 952 2 558 61 26 1 1 354 282 12 671 4 617 5 746 31 528 163 951 2 3 946 1 356 423 13 563 421 596 8 477 671 19 798 4 013 43 915 699 15 2 190 1 126 6 303 5 924 1 518 2 187 3 367 1 999 44 1 284 482 751 453 9 242 3 861 7 282 2 187 3 149 8 500 532 4 761 22 121 6 743 1 852 2 535 60 26 1 1 348 281 12 162 4 488 5 646 31 841 157 162 2 3 803 1 308 386 13 640 410 600 9 697 653 19 751 3 921 45 529 696 14 2 169 1 086 6 295 5 902 1 436 2 129 3 093 1 945 43 1 189 464 683 404 8 926 3 797 6 943 2 103 2 889 7 494 520 4 586 22 210 6 551 1 710 2 347 59 25 1 1 300 271 11 570 4 232 5 537 31 835 152 646 2 3 658 1 161 343 13 315 418 596 10 536 634 19 859 3 727 46 172 660 14 2 157 1 069 6 313 5 965 1 378 2 081 3 059 1 904 43 1 122 456 627 365 8 799 3 751 6 446 2 064 2 536 8 499 519 4 507 21 725 6 449 1 577 2 247 58 25 1 1 279 268 10 811 3 847 5 453 30 493 152 278 2 3 546 1 040 315 13 255 476 567 11 683 620 20 478 3 563 45 962 629 14 2 167 1 058 6 395 5 978 1 384 2 043 3 081 1 870 43 1 065 450 573 326 8 720 3 743 5 909 2 037 2 220 10 526 520 4 454 20 850 6 449 1 443 2 175 57 25 1 201 1 265 265 10 136 3 617 5 426 29 006 152 537 2 3 256 934 288 13 242 512 534 12 591 608 21 109 3 373 47 649 584 14 2 168 1 047 6 460 5 944 1 310 2 028 3 021 1 853 42 979 444 541 320 8 636 3 722 5 411 2 010 1 945 10 546 521 4 396 20 374 6 449 1 325 2 241 57 25 1 196 1 250 263 9 860 3 385 5 384 26 810 154 940 2 3 220 915 273 13 189 528 497 14 042 603 21 619 3 387 47 278 538 14 2 171 1 035 6 530 5 910 1 235 2 012 2 962 1 834 42 893 438 509 313 8 548 3 703 4 910 1 984 1 672 11 567 522 4 336 19 894 6 451 1 208 2 305 57 24 1 193 1 234 261 9 584 3 149 5 348 24 635 157 321 2 3 190 896 259 13 103 544 460 15 542 597 22 136 3 399 46 916 25 36 33 23 35 38 20 94 27 74 9 21 15 32 18 26 39 20 33 41 6 24 14 14 58 55 34 40 23 11 4 14 10 52 67 65 74 45 12 59 40 43 56 7 18 112 54 49 64 41 24 34 32 22 34 34 19 92 30 73 9 21 14 32 16 25 37 19 32 42 6 24 13 13 54 58 36 42 22 11 4 13 10 52 65 62 79 42 11 58 41 40 53 7 18 95 53 48 62 40 25 32 33 21 36 38 18 93 34 73 8 21 14 35 14 23 39 19 30 44 5 23 13 12 54 58 37 46 21 10 4 13 9 53 62 65 86 46 11 59 44 38 50 7 16 66 53 47 64 43 26 30 37 20 39 40 19 92 37 72 8 20 13 42 12 22 43 18 28 46 5 22 12 12 54 59 41 51 19 9 4 12 9 53 61 71 96 51 10 58 45 37 47 7 14 47 52 45 62 46 26 29 41 19 43 49 19 89 38 70 7 20 12 48 12 21 47 17 27 48 5 20 11 11 55 65 49 58 19 9 4 11 8 52 59 79 105 60 9 56 44 34 45 7 14 51 51 43 59 48 27 27 47 18 50 54 18 84 38 66 7 20 12 53 13 20 54 16 26 48 5 18 11 11 62 77 60 65 18 9 3 11 8 51 59 91 112 73 9 53 41 33 43 6 13 65 48 40 52 51 27 26 53 17 56 60 17 83 39 65 7 20 11 58 13 19 62 15 25 49 4 16 11 10 72 94 73 73 17 8 3 10 8 48 57 103 116 86 9 52 37 32 41 6 12 82 47 40 60 58 28 26 58 17 62 65 16 81 43 64 7 20 11 64 13 19 67 15 24 47 4 15 10 10 90 110 82 80 16 8 3 10 7 45 55 113 121 94 8 51 35 30 40 6 11 86 47 41 74 63 28 25 63 16 67 72 15 79 45 62 6 19 10 66 12 18 73 14 23 44 4 16 10 10 111 125 85 82 16 8 3 10 7 42 53 122 125 100 8 50 31 27 38 6 11 97 45 41 89 71 27 23 67 15 71 76 15 71 45 56 6 17 10 68 12 17 78 13 22 40 4 15 9 9 130 130 85 80 15 7 3 9 7 38 49 130 131 106 8 45 29 25 36 5 10 105 41 36 93 76 25 22 71 14 75 73 16 63 44 49 6 15 9 66 10 16 82 11 21 36 4 14 9 9 141 135 83 77 14 7 3 9 6 35 46 138 136 113 7 40 26 23 35 5 9 117 36 31 92 84 23 21 72 14 77 66 16 58 44 46 6 14 9 62 10 16 84 10 20 33 3 13 8 8 146 135 83 73 14 7 3 8 6 33 45 141 143 112 7 37 25 21 33 5 8 136 33 29 88 91 23 21 72 14 77 60 15 56 43 44 5 13 9 55 9 15 84 9 20 31 3 13 8 8 148 133 79 73 14 7 3 8 6 32 43 140 145 108 7 36 24 19 33 5 8 153 32 28 85 95 22 20 71 13 76 60 14 55 39 43 5 12 9 50 8 15 83 8 19 28 2 12 8 8 148 128 73 68 13 6 2 8 6 30 41 139 146 105 7 35 22 17 32 5 8 165 31 28 79 97 21 20 71 13 76 61 13 53 39 42 5 11 8 46 7 15 83 8 19 25 3 12 8 8 144 125 68 65 13 6 2 8 6 28 37 139 140 105 7 34 19 16 31 5 8 181 31 28 75 97 20 19 72 13 77 61 13 52 40 41 5 10 8 43 6 14 84 7 18 22 3 13 8 8 137 124 63 63 13 6 2 33 8 6 27 34 140 134 106 6 33 17 14 31 6 7 192 30 29 70 102 14 117 49 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 18 19 72 13 77 61 13 52 39 41 5 10 8 40 6 14 84 7 18 19 4 13 8 7 133 123 58 66 12 6 2 33 8 6 26 32 140 125 108 6 33 17 14 30 6 7 211 30 29 69 102 15 115 49 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, Europe, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 17 19 72 12 77 61 12 51 39 40 5 9 8 38 6 14 84 6 18 17 4 13 8 7 129 121 53 68 12 6 2 32 8 6 25 30 141 115 110 6 32 17 13 30 6 6 231 29 30 68 102 15 113 49
1990
1991
1992
1993
1994
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine
819 19 1 173 1 801 2 546 3 948 1 997 4 029 2 353 3 326 63 2 143 779 500 874 14 810 2 106 15 522 3 404 4 254 15 861 641 7 864 9 647 2 412 916 1 472 88 41 1 2 115 443 19 858 6 735 2 832 17 068 66 955 3 6 010 2 085 824 21 644 594 1 253 5 927 1 023 28 324 2 356 21 320
803 18 1 114 1 712 2 480 3 461 1 864 3 850 2 616 3 305 60 2 172 737 492 780 14 048 2 001 15 065 3 238 4 328 15 831 624 7 431 8 988 2 568 949 1 545 84 39 1 2 009 420 20 008 6 472 2 723 18 326 62 912 3 6 004 2 191 773 20 469 599 1 212 5 148 1 017 27 858 2 328 20 503
815 18 1 152 1 643 2 653 3 873 1 832 3 674 2 929 3 347 58 2 146 703 536 701 13 431 2 074 14 889 3 108 4 569 13 819 615 7 080 8 836 2 610 978 1 687 81 37 1 1 923 401 20 290 6 198 2 870 19 833 68 186 3 6 114 2 352 743 19 516 620 1 088 3 668 1 027 27 944 2 470 21 904
847 18 1 232 1 554 2 951 4 100 1 857 3 417 3 130 3 336 55 2 103 661 623 625 12 656 2 227 14 720 2 944 4 765 13 777 598 6 652 8 750 2 680 1 041 1 880 77 35 1 1 815 378 20 356 6 069 3 141 22 007 76 507 2 6 130 2 416 720 18 346 626 1 013 2 651 1 019 27 463 2 472 23 469
839 18 1 338 1 501 3 332 5 018 1 877 3 143 3 178 3 260 54 2 048 636 709 611 12 189 2 427 14 039 2 850 4 912 12 712 595 6 389 8 858 2 957 1 240 2 134 75 34 1 1 751 365 20 117 5 944 3 486 23 901 89 486 2 6 028 2 329 675 17 633 610 957 2 918 995 26 546 2 436 24 797
861 18 1 501 1 438 3 865 5 570 1 811 2 886 3 143 3 101 52 2 087 608 769 647 11 651 2 727 13 201 2 737 4 988 12 639 585 6 092 9 834 3 532 1 498 2 372 72 33 1 1 677 349 19 519 5 873 3 971 25 309 108 860 2 5 776 2 194 641 16 827 567 899 3 742 949 24 902 2 198 26 181
United Kingdom Uzbekistan
6 722 14 026
6 852 13 412
7 065 13 582
7 106 16 147
7 019 16 440
6 928 17 491
EUR
318 540
308 459
314 704
326 181
341 420
363 185
Table A3.4
Prevalence of TB (all forms) 2000 40 20 94 11 113 110 12 70 64 76 9 16 7 72 8 13 98 9 19 43 3 12 7 7 141 156 91 115 11 6 2 7 5 53 36 215 197 164 6 60 32 27 27 4 7 56 191 49 130 120 9 139 68 67 63 62 60 55 52 51 7 7 7 9 148 9 144 10 152 10 149 11 144 11 134 12 140 1 12 1 14 1 15 1 15 7 1 16 7 1 16 6 1 15 6 1 16 6 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 <1 <1 34 20 99 11 117 100 13 63 63 73 8 14 7 68 7 12 95 8 18 39 3 11 7 7 148 169 89 96 11 6 2 7 5 50 34 174 206 158 6 49 30 25 26 4 6 39 221 45 115 128 32 21 97 11 99 89 12 66 52 69 7 13 7 62 7 12 95 7 18 36 2 10 6 7 150 153 85 83 11 5 2 6 5 35 33 211 180 148 6 48 29 22 26 4 6 40 248 44 110 133 32 18 91 10 109 68 11 63 42 68 6 12 7 56 6 12 94 6 17 33 2 10 6 6 155 145 78 72 10 5 2 6 5 34 32 176 185 140 5 44 26 21 25 4 6 37 256 43 103 135 29 19 85 10 90 68 11 55 40 67 6 11 7 50 6 12 90 6 17 29 2 10 6 6 152 139 72 72 10 5 2 6 4 33 29 152 178 135 5 44 25 19 24 4 6 34 277 44 98 132 29 18 79 10 85 68 11 58 41 65 6 11 6 46 5 11 86 6 16 26 3 10 6 6 147 136 66 66 10 5 2 52 6 4 31 27 151 148 121 5 35 21 16 24 4 5 34 282 44 91 113 26 17 79 10 86 69 10 58 40 65 6 10 7 44 5 11 83 5 16 22 3 10 6 6 144 135 61 65 10 5 2 50 6 4 29 24 151 138 117 5 35 20 16 24 4 5 34 301 32 85 99 22 19 81 10 86 69 9 55 41 54 6 9 6 39 5 11 83 5 16 19 3 11 6 6 139 134 55 69 9 5 2 49 6 4 28 23 151 128 115 5 41 20 15 23 5 5 33 322 34 75 102 4 2 11 1 10 10 2 9 5 7 <1 2 <1 9 1 2 14 1 3 5 <1 1 <1 <1 15 20 12 10 1 <1 <1 <1 <1 5 4 20 18 19 <1 6 4 3 3 <1 <1 7 22 5 13 10 4 3 12 1 10 9 2 8 6 7 <1 2 <1 8 <1 2 14 <1 2 4 <1 1 <1 <1 17 20 12 10 1 <1 <1 <1 <1 4 3 20 19 18 <1 5 4 3 3 <1 <1 6 26 5 13 11 4 3 12 1 10 8 1 8 6 7 <1 1 <1 8 <1 2 14 <1 2 4 <1 1 <1 <1 17 19 11 10 1 <1 <1 <1 <1 4 3 20 19 17 <1 5 4 3 3 <1 <1 6 29 5 12 11 4 2 11 1 11 8 1 8 5 7 <1 1 <1 7 <1 1 13 <1 2 4 <1 1 <1 <1 19 18 10 9 1 <1 <1 <1 <1 4 4 20 19 16 <1 5 3 2 3 <1 <1 6 30 5 12 11 4 2 10 1 10 8 1 7 5 7 <1 1 <1 6 <1 1 13 <1 2 3 <1 1 <1 <1 19 18 9 9 1 <1 <1 <1 <1 4 3 18 18 15 <1 5 3 2 3 <1 <1 5 34 5 11 11 4 2 10 1 10 8 1 8 5 7 <1 1 <1 5 <1 1 11 <1 2 3 <1 1 <1 <1 18 18 9 8 1 <1 <1 5 <1 <1 4 3 18 18 14 <1 4 3 2 3 <1 <1 5 36 5 10 11 3 2 10 1 10 8 1 8 5 6 <1 1 <1 5 <1 1 9 <1 2 3 <1 1 <1 <1 17 17 8 7 1 <1 <1 4 <1 <1 4 3 18 17 14 <1 4 3 2 3 <1 <1 5 39 5 10 11 3 2 10 1 10 8 1 7 5 6 <1 1 <1 5 <1 1 9 <1 2 2 <1 1 <1 <1 17 17 7 8 1 <1 <1 4 <1 <1 3 3 18 16 14 <1 5 3 2 3 <1 <1 5 42 5 9 11 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 5 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 4 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) Mortality HIV+
Estimated incidence, prevalence and mortality rates (per 100 000 population), Europe, 20002007
2000
2001
2002
2003
2004
2005
2006
2007
1 <1 <1 2 <1 <1 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 <1 <1 <1 <1 <1 <1 8 <1 3 5 <1 3 <1 <1 <1 8
2 <1 <1 2 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 1 2 1 <1 <1 <1 <1 <1 8 <1 3 8 <1 3 <1 <1 1 9
2 <1 <1 2 <1 <1 <1 <1 6 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 2 2 1 <1 <1 <1 <1 <1 8 <1 4 11 <1 3 <1 <1 2 12
2 <1 <1 2 <1 <1 <1 <1 7 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 2 3 1 <1 <1 <1 <1 <1 8 1 4 14 <1 2 <1 <1 3 14
2 <1 1 2 <1 <1 <1 <1 7 <1 <1 1 <1 <1 <1 <1 <1 <1 <1 3 2 3 1 <1 <1 <1 <1 <1 7 2 4 16 <1 2 <1 <1 4 16
2 <1 2 2 <1 <1 <1 <1 7 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 3 3 3 1 <1 <1 <1 <1 <1 7 3 3 17 <1 2 <1 <1 6 19
2 <1 2 2 <1 <1 <1 <1 7 <1 <1 2 <1 <1 <1 <1 <1 <1 <1 3 3 3 1 <1 <1 <1 <1 <1 6 4 3 17 <1 2 <1 <1 7 20
2 <1 3 2 <1 <1 <1 <1 6 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 4 3 3 2 <1 <1 <1 <1 <1 6 5 3 18 <1 2 <1 <1 9 21
<1 <1
<1 <1
<1 <1
<1 <1
<1 1
<1 2
<1 2
<1 2
EUR
Table A3.5
New pulm. lab. confirm. number Estimated incidence and case detection rates Estimated incidence Case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
Case notifications and case detection rates, DOTS and non-DOTS combined, Europe, 2007
Population All notified New and relapse . thousands number number rate 0 0 62 2 0 76
Notified TB cases, DOTS and non-DOTS combined New pulmonary New extra- Other Re-treatment cases . ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. Other number rate number number number number number number number number
0 28 1
0 44
18

231 22 8 169 72 15 44 2 2 1 612 21 129 1 2 408 3 42 105 1 699 486 2 338 3 486 367 1 252 1 010 394 27 407 137 209 112 1 856 964 2 326 229 957 5 171 163 1 100 12 056 2 220 464 779 35 18 31 21 3 0 1 14 152 2 337 136 750 335 266 228 653 108 6 116 83 32 102 1 289 1 234 977 81 86 5 111 80 616 3 306 1 727 137 278 4 11 16 0 149 0 1 077 479 0 156 105 67 0 0 0 47 1 248 245 123 26 116 0 8 6 0 3 220 431 148 253 0 1 7 1 309 63 1 826 405 73 27 132 31 0 81 36 11 13 137 1 200 316 21 168 0 43 2 1 772 11 482 609 4 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 137 2 48 22 0 0 10 0 60 0 0 0 0 0 0 179 3 497 441 1 356 1 988 583 1 266 1 314 575 28 478 216 303 158 2 933 1 979 2 725 349 653 7 212 227 1 360 7 184 1 720 788 1 218 26 14 78 35 71 78 68 82 77 110 93 48 97 88 81 80 96 59 110 91 29 85 111 74 74 62 108 88 89 86 68 152 68 32 51 41 46 40 58 81 81 46 42 67 69 76 61 51 113 54 29 51 42 53 61 51 70 60 89 90 0 74 61 67 42 28 37 23 47 37 52 49 23 40 50 45 43 51 66 34 53 28 29 44 47 47 34 44 51 54 38 40 30 23 25 20 34 31 38 40 20 34 38 37 28 36 43 26 43 25 17 32 36 36 25 28 39 41 35 40 20 17 14 6 28 10 23 11 15 15 23 7 34 24 29 21 14 6 42 26 20 23 13 28 11 12 10 29 6 17 28 7 40 15 7 8 10 10 2 9 9 16 4 7 31 11 11 19 14 11 3 40 46 16 14 18 78 354 128 4 150 908 2 043 6 543 73 560 4 364 1 174 129 98 314 982 13 13 0 2 24 24 0 4 1 18 375 116 592 735 513 3 284 11 704 10 14 0 450 136 691 3 338 8 971 11 16 24 468 69 832 745 87 586 0 0 1 0 4 0 0 0 76 400 138 4 523 1 784 1 940 10 456 50 262 71 74 108 79 89 78 78 75 84 47 34 33 66 87 67 85 49 80 34 35 23 41 56 44 59 31 28 20 13 35 40 33 42 26 12 40 41 7 25 11 15 9 14 5 8 12 10 35 24 45 538 14 2 171 1 035 6 530 5 910 1 235 2 012 2 962 1 834 42 893 438 509 313 8 548 3 703 4 910 1 984 1 672 11 567 522 4 336 19 894 6 451 1 208 2 305 57 24 1 193 1 234 261 9 584 3 149 5 348 24 635 157 321 2 3 190 242 6 971 462 2 916 2 639 551 905 1 328 825 19 401 196 221 140 3 798 1 654 2 198 886 750 5 253 233 1 923 8 896 2 884 537 1 032 25 11 0 87 552 117 4 295 1 355 2 387 11 026 68 223 1 1 428 1 015 640 375 289 71 3 583 198 281 2 117 177 4 492 1 288 20 255 2 707 7 167 76 4 59 0 55 7 214 0 384 4 887 4 150 100 0 0 0 2 0 0 0 0 0 0 0 0 130 0 118 317 416 141 324 165 777 53623 0 25 841 506 229 277 120 37 1 447 165 49 1 733 117 5 790 681 3 608 3 505 5 280 224 187 37 37 14 0 1 0 219 32 1 069 81 2 626 0 1 006 53 53 0 54 3 420 31 53 1 653 26 543 270 3 126 436 3 127 1 867 1 251 616 308 148 3 614 240 331 2 228 247 8 741 2 666 11 028 3 221 6 326 896 259 13 103 544 460 15 542 597 22 136 3 399 46 916 9 308 30 813 431 518 403 116 5 792 244 203 6 933 269 9 961 1 530 20 163 4 158 13 801 189 951 65 77 56 84 92 39 83 80 98 74 84 61 75 44 77 40 39 47 32 74 76 90 55 39 46 55 53 59 39 38 56 39 33 25 51 53 63 52 35 38 47 39 40 46 26 28 42 32 21 22 35 38 40 40 29 21 32 30 18 12 30 19 17 20 36 12 28 22 31 20 10 45 27 15 11 14 4 14 8 5 7 11 25 12 10 9 14 5 20 32
447 6 2 129 874 7 347 5 756 1 028 2 400 3 052 982 42 871 391 487 313 5 588 5 912 5 067 659 1 752 14 478 397 4 527 40 279 6 707 1 255 2 408 39 38
438 5 1 682 811 5 521 5 351 955 2 373 2 848 951 41 790 355 456 300 5 314 4 310 4 609 593 1 540 12 425 392 2 695 24 777 6 098 1 227 2 235 39 38
14 7 56 10 65 55 9 60 37 21 5 8 7 34 6 9 98 6 5 15 4 10 6 5 161 115 54 66 8 9
165 2 497 189 1 356 1 051 322 737 1 080 382 8 267 135 168 85 1 921 1 867 1 183 257 381 2 135 143 979 6 195 1 720 478 925 0 8
5 3 17 2 16 11 3 19 14 8 1 3 2 13 2 3 42 1 2 4 1 3 2 2 40 32 21 27 0 2
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia - Serbia (without Kosovo) - Kosovo Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan
3 190 75 3 002 8 361 8 467 9 689 10 457 3 935 7 639 4 555 855 10 186 5 442 1 335 5 277 61 647 4 395 82 599 11 147 10 030 301 4 301 6 928 58 877 15 422 5 317 2 277 3 390 467 407 33 598 16 419 4 698 38 082 10 623 3 794 21 438 142 499 31 9 858
159 960 307 8 616 3 127 6 367 25 491 214 924
147 930 282 8 019 2 952 4 857 22 590 127 338
25 6 6 21 28 128 105 89
41 187 38 2 827 1 173 1 610 9 425 33 103
7 1 1 7 11 42 44 23
29
12
5 390 2 002 44 279 9 119 7 484 6 736 2 038 74 877 4 965 46 205 60 769 27 372
2 981 2 051 930 682 218 7 767 491 478 8 081 563 19 694 3 698 40 643 8 417 23 390
2 891 1 961 930 622 212 7 347 460 425 6 297 526 18 878 3 428 37 517 7 851 19 779
12 11 17 5 6 93 26 25 69 81 13 72
1 146 905 241 176 90 2 317 96 95 2 228 200 7 527 1 378 11 028 1 639 6 326
3 4 5 1 1 33 10 10 28 24 3 23
EUR
889 278
478 299
350 529
39
105 288
12
Table A3.6
. . Other number New pulm. lab. confirm. number Estimated incidence and case detection rate Estimated incidence DOTS case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
DOTS coverage, case notifications and case detection rates, Europe, 2007
DOTS coverage % 0 0 62 1 0 76
TB cases reported from DOTS services New pulmonary New extraOther Re-treatment cases New and relapse . ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. number rate number rate number number number number number number number
0 28 1
0 44
18
64 67 42 28 37 23 47 37 52 49 23 40 50 46
39 40 30 23 25 20 34 31 38 40 20 34 38 38
35 40 20 17 14 6 28 10 23 11 15 15 23 7
6 17 28 7 40 15 7 8 10 10 2 9 9 16
231 11 44 28 25 6
169 36
66 34
43 26
29 21
31 10 19
1 2 142 3 42 21 129 1 554 34 44 51 54 31
47
36 25 28 39 41 21
20 13 29 11 12 29
3 43 16 14 18 3
75 100 100 100 100 100 100 100 100 100 100 100 100 100 0 0 100 100 0 100 100 0 100 65 100 100 100 100 100 100
331 5 1 682 811 5 521 5 351 955 2 373 2 848 951 41 790 355 442 0 0 4 310 4 609 0 1 540 0 0 392 0 24 667 6 054 1 227 2 235 1 38
10 7 56 10 65 55 9 60 37 21 5 8 7 33 0 0 98 6 0 15 0 0 6 0 160 114 54 66 0 9
130 2 497 189 1 356 1 051 322 737 1 080 382 8 267 135 167 0 0 1 867 1 183 0 381 0 0 143 0 6 146 1 720 478 925 0 8
4 3 17 2 16 11 3 19 14 8 1 3 2 13 0 0 42 1 0 4 0 0 2 0 40 32 21 27 0 2
73 1 699 486 2 338 3 486 367 1 252 1 010 394 27 407 137 198 0 0 964 2 326 0 957 0 0 163 0 12 015 2 176 464 779 1 18
117 2 337 136 750 335 266 228 653 108 6 116 83 31 0 0 1 234 977 0 86 0 0 80 0 3 293 1 727 137 278 0 11
11 0 149 0 1 077 479 0 156 105 67 0 0 0 46 0 0 245 123 0 116 0 0 6 0 3 213 431 148 253 0 1
7 1 309 63 1 826 405 73 27 132 31 0 81 36 11 0 0 1 200 316 0 168 0 0 2 0 9 444 609 4 2 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 48 0 0 0 0 0 0 0 0 0 0 0 0
141 3 497 441 1 356 1 988 583 1 266 1 314 575 28 478 216 296 0 0 1 979 2 725 0 653 0 0 227 0 7 130 1 720 788 1 218 1 14
59 35 71 78 68 82 77 110 93 48 97 88 81 78 0 0 110 91 0 85 0 0 74 0 108 87 89 86 2 152
54 32 51 41 46 40 58 81 81 46 42 67 69 76 0 0 113 54 0 51 0 0 61 0 69 60 89 90 0 74
10
0 100 100 100 100 100 100 100 4 364 1 174 129 98 314 982 13 13 0 2 24 24 0 4 1 84
0 179 282 8 019 2 952 4 857 22 590 127 338
0 1 6 21 28 128 105 89
0 59 38 2 827 1 173 1 610 9 425 33 103
0 0 1 7 11 42 44 23
0 68 128 4 150 908 2 043 6 543 73 560
0 49 116 592 735 513 3 284 11 704
0 3 0 450 136 691 3 338 8 971
0 2 24 468 69 832 745 87 586
0 0 1 0 4 0 0 0
0 107 138 4 523 1 784 1 940 10 456 50 262
0 14 108 79 89 78 78 75
0 11 33 66 87 67 85 49 80
46 23 41 56 44 59 31 53 59 39 38 56
33 13 35 40 33 42 26 40 46 26 28 42
27 41 7 25 11 15 9 18 12 30 19 17
8 8 12 10 35 24 45 11 14 4 14 8
100
29
12
538 14 2 171 1 035 6 530 5 910 1 235 2 012 2 962 1 834 42 893 438 509 313 8 548 3 703 4 910 1 984 1 672 11 567 522 4 336 19 894 6 451 1 208 2 305 57 24 1 193 1 234 261 9 584 3 149 5 348 24 635 157 321 2 3 190
242 6 971 462 2 916 2 639 551 905 1 328 825 19 401 196 221 140 3 798 1 654 2 198 886 750 5 253 233 1 923 8 896 2 884 537 1 032 25 11 0 87 552 117 4 295 1 355 2 387 11 026 68 223 1 1 428
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Serbia (without Kosovo) Kosovo Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan 506 229 277 120 37 0 0 0 1 645 117 5 790 459 3 608 0 4 828 76 4 59 0 55 7 214 0 384 4 602 4 032 113 302 99 896 259 13 103 544 460 15 542 597 22 136 3 399 46 916 9 308 30 813 57 127 865 431 518 45 094 0 25 517 224 187 37 37 14 0 0 0 219 32 1 069 81 2 626 0 1 000 53 53 0 54 3 0 0 0 1 653 26 543 270 3 126 0 3 101 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 1 867 1 251 616 308 148 0 0 0 2 075 247 8 741 2 387 11 028 0 6 217 403 116 5 792 244 203 6 933 269 9 961 1 530 20 163 4 158 13 801 189 951 65 77 0 0 0 37 83 80 84 74 0 58 69 44 77 0 0 0 30 74 76 84 55 0 45 51 51 53 63 54 35 48 39 35 38 40 44 29 33 30 28 22 31 16 10 26 14 26 12 10 11 14 20 33
100 100 0 0 20 100 100 100 80 100 0 100
2 891 1 961 930 622 212 0 0 0 5 905 526 18 878 2 927 37 517 0 18 908
12 11 0 0 0 88 26 25 59 81 0 69
1 146 905 241 176 90 0 0 0 2 075 200 7 527 1 288 11 028 0 6 217
3 4 0 0 0 31 10 10 26 24 0 23
1 015 640 375 289 71 0 0 0 1 966 177 4 492 1 099 20 255 0 6 863
EUR
75
322 132
36
97 156
11
154 365
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 3 25 15 11 17 335 8 5 4 0 3 37 1 0 1 TB pts HIV-positive Lab-confirmed MDR DST in new cases MDR in new cases Re-treatment DST Re-treatment MDR 51 332 HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, Europe, 20062007
17 8 46
1 8 2
1 8 1
0 0 4
69 55 6 0 0 0 0 0 0 0 0 6 0 0
31 152 52
163 14 35 17
17 4 22 7
927 0 247
5 756 871 0 199
42 0 0 0 0
1 3
0 163 11 414 6 649 17 10 9 842 29 21 21
0 4 11 41 6
42 161 6 450
0 7 6 54 10
8 11 300 30 230
155 6 33 17 1 42 1 2 11 300 2 192
14 1 2 1 100 1 79

0 15 7 16 213 55 21 2 0 32 0 0 1 2 30 25 22 1 10 45 2 13 15 234 47 13 2 1 43 0 1 32 195 0 0 5 0 0 34 1 1 27 36 1 066 90 0 37 24 532 43 204 1 128 1 17 201 0 2 677 2 523 8 402 87 041 0 0 0 1 0 1 0 0 0 0 0 0 2 345 371 6 710 0 1 443 97 0 0 62 1 0 0 0 0 0 0 5 0 1 9 682 99 9 0 0 1 037 5 0 1 9 0 1 508 20 60 1 979 0 4 0 16 2 299 4 349 6 727 87 444 15 456 161 187 2 401 3 0 125 9 196 870 14 8 82 7 3 11 2 80 2 20 269 66 14 11 1 5 18 56 5 568 322 98 314 1 1 11 17 522 144 934 2 311 4 828 25 7 0 15 8 9 240 0 1 130 343 174 346 264 167 4 142 0 7 3 0 12 5 0 120 0 185 53 15 19 37 26 775 0 2 1 43 13 585 655 1 338 18 4 0 3 3 9 120 0 168 3 429 481 213 1 874 707 1 267 883 5 28 487 269 316 216 1 255 1 366 2 998 488 456 10 127 257 653 7 997 1 018 810 1 257 32 18 1 0 50 8 13 302 10 3 36 5 2 8 2 52 2 12 87 44 13 8 0 3 14 16 1 596 168 58 126 1 1 18 0 213 31 257 1 243 52 156 121 2 1 45 21 65 8 102 556 244 43 84 1 15 11 79 7 509 200 165 425 0 0 2 0 75 1 183 455 4 3 46 2 1 3 0 28 0 7 182 22 0 3 1 2 4 21 3 972 154 40 188 0 0 2 6 3 51 34 896 754 5 297 76 553 225 2 716 1 446 1 311 2 355 30 370 0 3 2 8 21 311 99 3 959 5 708 70 3 566 0 0 1 639 96 0 0 3 0 0 0 1 987 238 5 339 275 1 184 169 397 154 9 31 682 0 0 0 0 0 37 565 191 698 347 405 14 138 55 484 16 062 4 510 385 76 601 41 119 7 351 221 463 22 228 14 365 8 572
13
13
3 2
446 122 26 12
22 10 8 5
22 1 1 5
24 11
1 53 19 96 60 57 136 4 048
1 53 12 96 60 4 106 965
1 17 4 55 16 4 55 280
0 31 0 0 122
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden
51 16
41 11
9 5
6 11
Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan
97 13 172
0 3 23
0 1 7
42 5 0 0
310
9 2
21
EUR
6 744
2 216
762
284
Table A3.8
% Not eval. Success 87 87 100 22 66 1 0 3 0 8 87 8 63 13 13 0 13 0 0 75 Number of cases Notified Regist'd Success Not eval. Number Regist'd % % of notif regist'd New smear-positive cases, non-DOTS % of cohort ComplTransCured eted Died Failed Default ferred % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
Treatment outcomes, Europe, 2006 cohort
Number of cases Notified Regist'd 1 5
% of notif regist'd
99 8 580 213 1 454 1 072 343 562 1 307 396 10 0 3 8 0 1 3 0 0 0 0 1 1 84 1 911 6 1 167 210 15 0 4 1 305 16 5 1 2 21 0 58 0 1 0 11 3 15 2 346 2 6 0 1 179 275 71 17 8 0 28 0 63 2 006 106 112 65 4 1 5 1 1 0 3 3 0 84 81 92 0 9 4 12 4 10 7 1 1 3 1 5 0 6 3 2 4 0 93 75 87 62 83 58 58 100 7 26 5 0 3 0 59 33 5 488 181 1 105 4 993 17 109 189 42 4 60 42 14 31 42 33 62 55 0 0 7 62 4 9 5 12 5 75 0 8 9 16 11 14 8 29 25 0 1 1 20 11 26 2 2 0 0 32 7 17 13 14 12 2 0 20 1 2 8 1 8 2 0 0 20 9 5 4 13 0 2 7 0 60 49 77 35 51 38 75 60 75 0 0 0 100 5 5 6 10 2 2 0 0 1 0 9 3 72 82 73 74 54 11 731 448 133 350 0 0 0 0 0 0 100 0 24 67 43 36 7 4 2 0 17 8 18 27 18 10 2 4 7 9 10 18 3 2 0 0 24 0 26 15 31 71 44 36 100 0 133 0 5 4 2 74 4 186 140 0 2 50 64 25 6 0 2 25 27 50 66 0 0 0 0 0 0 100 8 6 14 46 94 21 17 13 22 6 5 15 38 20 20 10 0 4 0 46 40 10 4 2 75 1 154 38 11 8 18 17 5 3 49 0 0 100 0 0 0 0 0 14 9 12 2 1 1 6 2 0 2 0 5 304 17 1 272 549 32 93 125 82 1 8 13 38 26 6 34 47 22 89 68 61 0 25 38 50 10 71 12 12 31 5 2 1 100 13 46 3 9 0 6 11 9 2 14 18 0 0 0 16 18 0 7 16 0 0 6 0 0 0 0 3 32 18 16 2 0 1 10 2 0 0 8 18 3 0 24 3 0 1 0 2 0 13 8 0 2 6 1 9 38 1 0 15 0 50 0 11 36 76 46 59 53 95 70 62 100 38 85 53
100 100 100 97 100 100 82 177 100
8 257 123 147
99 8 580 206 1 454 1 072 280 993 1 307 898 8 257 31 148
100 100 25 101
73 13 53 16 50 62 24 94 72 25 63 60 35 65
20 63 16 55 10 8 49 3 7 4 25 9 42 3
5 8 2 13 8 1 5 7 0 6 3 14
0 25 1 0 22 4 1 1 2 1 13 1 0 0
0 0 1 12 1 4 16 1 4 60 0 23 19 11
93 75 69 71 60 70 73 97 80 30 88 69 77 68
1 831 1 303
1 813
99
64
11
422 4
430
102
31
15
11
209
290
66
14
72 1 377 6 151 1 833 498 1 029 1 4
6 113 1 830 498 1 028
99 100 100 100
71 80 72 74
1 3 1 0
4 5 11 12
100
100
203 46 2 835 1 300 1 679 9 814 29 989
41 2 819 1 372 1 671 10 075 30 745
89 99 106 100 103 103
68 63 14 59 69 56
24 12 73 4 13 3
0 7 4 11 6 12
1 136 160 83
1 157 149 83
102 93 100
72 78 35
12 3 57
6 9 4
265
63
88
1 986 178 7 866 830 14 206 325 1 350 4 662 48 15 76 325 100 91 2 72 31 6 9 7 3 2 70 9 799 6 1 0 81 1 767 118
1 753 178 7 865 830 10 351
88 100 100 100 73
81 71 58 81 54
4 16 32 2 5
4 5 3 7 12
6 1 1 5 12
4 7 4 4 9
2 0 0 1 4
0 0 2 0 4
84 87 91 84 59
4 7 6
3 0 0
0 1 2
0 2 0
0 18 46
93 72
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium * Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany * Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands * Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom * Uzbekistan 1 076 37 1 262 179 7 480 1 260 46 51 866 60 35 45 65 34 51 34 7 6 32 29 3 6 9 10 14 5 12 15 13 14 12 5 2 8 22 13 19 6 5 11 11 14 14 12 5 5 0 0 1 7 1 8 0 8 9 0 1 0 67 68 74 68 41 60 42
7 093
5 642
80
73
EUR
100 102
94 262
94
61
indicates that "notified cases" in this table include cases with "history unknown", whereas "registered cases" does not. Not eval. indicates not evaluated (percentage of registered cases for which outcomes were not recorded); success, sum of cured and completed; cases regist'd, the denominator for calculating treatment outcomes. The number of cases registered for treatment in 2006 is used as the denominator for calculating treatment outcomes unless it is less than the sum of outcomes, in which case the sum of outcomes is used. If the number of cases registered is not reported, then the number of cases notified in 2006 is used, or the sum of outcomes if the latter is greater. Data can be downloaded from www.who.int/tb
Table A3.9
After failure, DOTS % of cohort Not eval. Died Died 0 2 1 9 1 0 15 1 0 100 0 0 0 0 0 100 95 70 62 46 59 40 72 18 17 14 21 26 1 3 35 63 19 6 8 13 49 5 0 25 75 % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, Europe, 2006 cohort
Number regist'd
ComplCured eted
Died
63
13
13
13
169
33
19
28
1 272 549
34 47
12 12
6 11
7 16
16 2
24 3
93 125 82
89 68 61
5 2 1
2 14 18
0 6 0
1 10 2
1 0 2
28
57
14
11
14
61
10
30
20
10
40
30
231
48
16
14
56
217
23
10
13
29
14
33
231
31
13
14
26
44

15 37 17 24 18 18 12 6 6 18 41 0 4 0 31 13 1 43 0 37 0 0 0 35 100 5 0 12 0 0 0 12 0 37 29 106 48 18 0 0 7 31 3 1 31 31 0 0 51 71 44 45 1 590 25 13 11 27 5 4 16 37 1 726 19 13 15 16 14 5 100 1 100 0 0 0 0 0 0 17 10 19 100 32 48 18 7 6 4 8 0 2 298 1 201 0 24 26 50 5 5 0 15 16 0 27 16 0 15 13 50 8 0 0 5 23 50 30 31 2 6 0 78 55 100 15 3 73 67 0 0 7 0 0 0 20 0 0 0 0 33 73 67 17 5 2 35 80 12 50 54 79 42 62 46 73 72 206 696 38 8 17 28 4 65 5 7 7 10 23 13 3 0 17 8 38 10 27 24 3 3 8 1 7 4 3 18 42 74 21 36 12 20 50 0 41 0 0 0 0 47 80 50 0 4 8 0 4 0 4 54 3 927 27 9 13 22 10 3 65 370 42 11 14 20 12 1 0 15 53 37 71 74 80 71 51 67 3 45 57 0 31 7 33 16 13 0 2 16 33 11 3 0 11 3 0 0 0 33 29 64 33 47 28 11 226 2 654 111 6 285 64 27 31 31 37 27 4 36 27 5 7 9 14 18 4 17 14 15 4 0 1 24 14 17 14 9 28 16 26 19 0 0 0 7 1 5 0 9 9 0 0 8 68 64 58 36 44 36
73
19
18
12
23
100
2 851 448 103 201
50 67 42 45
1 4 2 0
12 8 21 24
23 10 0 5
7 9 4 13
3 2 0 0
281 107 601 3 096 5 238
48 19 39 51 41
7 61 3 12 5
9 8 15 9 15
1 1 18 10 22
28 6 14 10 11
1 0 7 1 6
157 31 2
64 48 0
13 6 100
8 32 0
3 3 0
8 3 0
2 0 0
116 23 955 99 2 172
63 43 49 69 42
8 30 31 2 9
16 13 5 12 11
12 4 2 8 17
0 4 6 9 10
1 0 0 0 6
779
57
12
13
EUR
19 893
46
12
15
10
Table A3.10 DOTS treatment success and case detection rates, Europe, 19942007
2004 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 2002 2003
1994
1995
1996
1997
1998
1999
2000
83 5 9 7 7 7
77
82
100 81 12 25
224 44
14 44
58 41
86
87
86
67 88 77 88
50 87 73 91
98 100 90 64 66 15 47 62 6
90 100 79 78 84
25 46 29 52 0
30 31 30 44 46
93
88
90
94
64 98 87 38 67 71 24
69 95 86
91 100 77 68 70 73 73 94 91 65 80 11 62 53 49
78 100 70 69 60 74 72 98 80
77 80 72 75 59 73 66 97 86
31 109 43 55 29 39 56 51 90
35 47 48 45 47 42 64 95 96
24 78 60 49 55 46 62 70 88
38 125 60 46 50 40 59 62 96
73 70 64 64 57 62
60
66
69
42 65 70 52 64 53 60 62
78
92 73
91 64
43 57
40 57
63
75 73 77 67
79 79 84 70
20 73 88 71
63 72 83 72
93 75 69 71 60 70 73 97 80 30 88 69 77 68 72 63 69 67 52 60 72 75 47 64 64 65 42 58 62 63
54 32 51 41 46 40 58 81 81 46 42 67 69 76
58 63 46 36 25 36 68 39 60 41 31 49 58 42 44 48 85
65 54 64 46 67 80 14 9 74 55 100 48 100 54 50 45 100
78 54
61 58
63 77
67 67
65 69
66 71
68 68
73 71
75
18
35
34 62
45 62
34
58 53
57 57
58 54
78 54
90 52
110 54
113 54 51
80
61
80
82
69
73 10 93
61
88 64
76 65
72 79 82 71 79 72 85 73 72 3 71 4 70 100 100 100 35 22 45 72 41 76 30 41 26 72 82 73 74 100 100 60 100
71 79 83 74 84
78 74 79 82 72 92 13 4 31 72 56 79 58 64 3
79 40 78 81 73 75
81 79 78 82 76 72
80 95 75 84 74 74
78 74 71 85 74 70
7 31 94 42 72 2
69 60 89 90 74
100
100
100
100
75
69 60 95 48 77 56 63 43
65 73 87 56 84 87 119 18
39 53 81 61 83 86 77 18
42 65 74 66 83 99 55 45
31 71 67 64 84 103 4 37
81
72 77 79 78 67
81 80
80 44
77
49 68
44 67
48
69
74
78
65 69 75 74
79 77 69 85
37 34 2 87
47 16 3 83
46 28 4 92
65
62
72 67 100 0 1 101 34 58 40 65 35 74 37 71 82 84 63 88 87 82 80 85 79 91 85 85 89 87 85 91 88 90 85 92 84 84 81 92 26 37 73
85 68
78 65
76 70 72 79 83 80 68 87 77 78 66 78 67 87 1 4 2 10 5 113 93 75 87 62 83 58
68 80 86 82 61 76 67
86 97 78 84 65 80 61
83 89 79 84 62 82 59
84 91 77 89 62 82 58
51 47 3 102 41 10 6
55 25 56 102 22 43 8
48 43 57 95 41 40 9
63 42 57 91 63 43 15
42 40 62 84 70 83 34
36 39 64 89 70 82 45
11 33 66 87 67 85 49
96
64 90
73 87
67 82
85 78
79 88
24 34 75
37 38 75
31 34 63
76 39 84
79 39 67
80 44 77
86 69 75 77
88
79 79
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom 86 84 93 82 84 84 91 86 86 84 89 81 54 17 36 2 49 42 84 87 91 84 59 81 70 3 3 5 0 11 2 11 49 5 43 11 72 3 33 23 65 3 44 32 66 81 54 70 4 12 7 14 22 22 21 24 29 26 38 37 51 53 30 74 76 84 55 45 51 80 77 75 76 75 74 71 76 80 81 78 81
Uzbekistan
78
79
EUR
68
69
72
72
76
77
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, Europe, 2007
5564 16 29 18 3.4 2.0 2.5 0.6 3.4 1.9 4.1 1.8 1.7 2.9 2.0 2.2 2.6 2.2 1.9 1.7 1.7 1.4 3.1 3.0 3.0 20 25 2 2 31 10 11 7 7 2 7 19 3 3 112 22 111 34 36 20 27 44 4.7 1.9 19 2 13 7 11 9 2 32 23 27 28 1.8 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
19
13
16
24
1 1
81 12
87 15
100 27
92 26
9 1 22 14
7 1 7 11
22 1 109 29
31 1 99 37

110 18 0 131 4 0 4 6 0 11 56 43 0 90 28 13 0 63 58 31 0 77 41 23 0 53 35 7 0 38 17 8 0 29 58 22 0 46 85 36 0 126 200 86 0 199 246 58 0 234 279 45 0 214 127 26 0 160 114 65 0 136 0 39 16 21 7 156 96 184 15 50 0 26 10 48 279 62 49 109 0 1 3 5 79 12 25 230 653 26 3 3 23 1 3 61 4 128 36 438 45 235 2 469 4 813 585 17 025 135 28 16 93 12 7 87 8 255 35 861 138 436 2 1 0 22 1 1 34 5 113 8 21 33 43 80 13 1 348 12 20 742 23 1 799 305 2 538 328 1 054 111 13 12 666 31 27 604 34 1 776 404 6 168 508 1 275 27 750 0 29 6 12 24 273 75 362 54 35 0 26 17 106 150 63 19 76 0 3 0 0 1 0 0 20 6 4 0 3 0 0 1 7 38 11 1 0 0 0 1 6 8 2 6 127 153 120 13 12 0 14 4 74 782 216 18 34 0 2 3 8 12 5 4 167 140 176 19 22 0 28 17 94 605 213 27 41 0 0 1 5 8 5 2 91 67 152 11 18 2 22 5 58 367 114 32 48 0 0 0 9 4 8 5 56 54 116 8 17 0 14 3 31 249 67 18 50 0 0 0 5 5 7 0 61 17 46 3 6 0 2 6 19 124 47 12 22 0 0 0 28 8 6 13 188 46 178 24 29 2 4 14 76 157 61 9 37 0 0 0 0 1 0 0 37 13 6 1 3 0 0 2 10 52 14 1 0 0 0 3 20 14 8 10 247 430 236 34 19 0 40 13 149 1 663 459 51 65 0 2 4 34 24 31 9 392 528 424 41 53 0 77 37 264 1 581 487 92 118 0 2 1 40 28 37 7 287 375 466 45 66 2 54 28 171 1 226 300 125 213 1 0 0 72 33 45 15 275 284 460 36 120 0 42 16 118 963 253 120 285 0 0 0 44 21 28 7 217 113 230 18 56 0 28 16 67 403 109 61 131 0 1 0 57 14 18 37 461 121 540 78 64 2 30 31 182 307 124 28 113 0 3 1 15 1 344 82 107 889 2 491 94 15 12 128 3 5 63 21 571 56 2 130 97 282 8 897 6 577 353 7 100 8 888 5 975 4 444 106 23 9 191 9 11 65 19 512 23 1 090 202 380 2 1 0 12 1 1 21 4 63 6 7 20 25 38 5 1 164 5 9 329 11 708 129 982 145 485 52 3 5 291 11 17 243 12 531 132 1 661 222 507 43 5 6 136 8 3 154 9 246 81 1 314 91 342 43 6 2 63 4 0 92 4 165 69 855 58 255 145 23 21 515 18 14 348 36 1 230 305 6 520 314 921 25 447 3 15 2 285 112 35 611 1 291 0 1 1 4 2 2 34 40 3 12 4 65 49 97 665 1 444 3 22 2 149 95 85 634 2 418 4 17 5 120 61 57 439 1 684 3 6 1 132 27 58 332 1 454 1 12 1 277 26 25 448 871 0 2 1 6 6 2 59 60 3 22 8 150 118 278 1 371 3 936 9 44 14 362 273 366 1 783 8 426 7 45 7 515 329 400 1 998 7 558 13 27 4 809 215 372 2 036 7 817 206 57 16 320 9 7 224 50 1 143 206 5 879 227 838 24 318 4 20 1 423 94 132 1 119 3 144 120 18 15 151 4 8 124 25 699 92 2 568 142 517 11 366 4 27 3 562 138 60 1 059 2 162 241 51 25 284 21 18 152 27 767 58 1 951 340 816 11 390 1.4 1.5 1.7 2.4 3.3 3.6 2.4 2.9 1.7 2.5 1.7 1.9 1.3 1.4 1.3 2.8 2.6 1.8 3.2 1.6 1.4 2.5
2 0 7
57 23 0 63
142 55 0 122
205 35 0 181
244 38 0 176
0 0 0 0 0 17 7 2 1 0 0 0 1 3 14 3
0 0 0
2 14 6 6 4 120 277 116 21 7 0 26 9 75 881 243 33 31 0 0
1 26 12 26 5 225 388 248 22 31 0 49 20 170 976 274 65 77 0 2
0 35 20 32 5 196 308 314 34 48 0 32 23 113 859 186 93 165 1 0
0 63 29 37 10 219 230 344 28 103 0 28 13 87 714 186 102 235 0 0
0 1
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium * Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany * Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands * Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom * Uzbekistan
2 4 0 25 20
0 10 4 85 69 181 706 2 492
6 22 12 213 178 281 1 149 6 008
3 28 2 395 268 343 1 559 5 874
10 21 3 677 188 314 1 704 6 363
0 0 0 10 0 0 13 1 50 2 14 13 18
42 8 0 184 7 11 413 12 1 091 176 1 556 183 569
59 10 7 375 20 10 361 22 1 245 272 4 507 286 768
102 18 15 379 10 11 194 27 984 224 5 206 223 579
163 51 14 257 5 7 132 46 978 137 5 024 169 583
EUR
232
9 925
18 862
19 472
19 874
For some countries, breakdown of notified cases by age and sex is missing, or is provided for a subset of cases. For countries marked with *, cases with "history unknown" are included in Tables A2.2 and A2.3 but not in this table. For some countries, breakdown of notified cases by age and sex is missing, or is provided for a subset of cases. See Explanatory notes for further details. Data can be downloaded from www.who.int/tb
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, Europe, 2007
65+ 14 14 4 1 0 10 2 10 3 5 1 3 2 6 0 3 2 1 0 19 2 26 3 30 2 22 3 17 2 8 3 1 4 4 3 4 9 6 0 5 5 5 8 11 10 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544
014
1524
2534
Male 3544
4554
5564
12
12
0 0
27 2
45 3
62 4
46 4
32 4
0 0 1
7 4 0 12 0 0 1 0 0 1
19 8 0 21
31 4 0 34
34 5 0 33
27 3 0 27
13 6 0 17
4 2 0 13
8 5 0 14
6 3 0 10
4 1 0 7
3 1 0 5
6 2 0 6
5 3 0 13
14 6 0 18
18 4 0 22
18 3 0 20
13 2 0 16
8 4 0 10
0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 0
0 0 0 9 0 3 2 12 18 8 5 1 2 1 0 1 55 4 5 31 15 1 41 5 6 0 2 59 0 0 4 17 13 7 29 21 3 27 20 16 7 8 2 1 1 61 6 11 26 17 0 0 0 0 0 0 1 1 1 1 0 6 2 0 7 1 2 48 7 13 28 36 8 1 4 9 3 3 66 11 14 50 89 11 3 7 7 1 1 48 12 12 47 102 15 7 5 5 1 1 43 18 15 43 84 3 33 20 11 3 6 3 0 1 58 12 15 43 52 2 47 12
3 2 2 6 1 3 75 2 3 1 0 8 2 3 58 42 18 11 0 0
2 3 3 27 2 6 131 5 2 4 0 13 4 4 81 65 40 33 0 6
0 5 5 37 1 5 110 5 4 7 0 10 6 2 85 57 59 67 3 0
0 9 8 43 3 5 79 5 4 15 0 11 4 2 80 72 67 104 0 0
0 6 4 32 2 4 53 4 2 9 0 12 4 1 63 54 45 72 0 4
0 5 2 16 7 7 30 5 6 6 0 12 6 2 36 54 15 42 0 13
0 0 0 0 0 0 2 0 0 0 0 0 0 0 2 1 1 0 0 0
2 1 3 2 2 3 42 3 2 2 0 5 1 3 53 38 10 13 0 7
5 1 4 5 1 4 44 4 2 3 0 8 3 2 48 50 17 18 0 0
2 1 2 5 1 2 21 2 1 3 10 7 1 1 33 34 20 19 0 0
0 1 1 8 1 1 16 2 1 2 0 5 1 1 24 23 10 20 0 0
0 1 1 8 0 2 8 1 0 1 0 1 2 1 20 35 8 11 0 0
0 3 2 4 3 3 12 2 2 3 10 1 3 1 20 34 3 11 0 0
0 0 0 0 0 0 2 0 0 0 0 0 0 0 1 1 0 0 0 0
2 2 2 4 2 3 59 2 3 2 0 6 1 3 55 40 14 12 0 3
3 2 4 16 1 5 86 4 2 3 0 11 4 3 64 57 28 26 0 3
1 3 3 21 1 3 63 3 3 5 5 9 3 2 58 45 39 42 1 0
0 5 4 24 2 3 45 4 2 8 0 8 2 1 50 47 37 59 0 0
0 3 3 18 1 3 28 2 1 4 0 7 3 1 38 44 24 37 0 2
0 4 2 8 4 5 19 3 4 4 6 6 4 2 26 42 7 21 0 5
0 0
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Moldova Romania Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine 8 1 1 15 15 23 47 21 17 10 7 6 1 2 57 19 27 26 43 5 71 13 0 11 14 9 7 0 1 4 16 6 23 2 20 1 19 0 0 0 0 0 0 2 2 1 1 0 5 1 1 7 1 2 43 7 11 24 28 7 1 3 8 2 4 52 8 8 32 48 7 1 4 4 1 0 41 6 5 25 40 6 1 1 2 1 0 34 3 4 27 23 17 8 8 4 1 2 59 12 18 26 26 3 64 9 0 0 0 0 0 1 2 0 6 1 1 2 8 27 43 13 7 2 1 5 12 33 37 22 10 1 1 5 8 25 28 17 7 1 0 4 4 19 22 12 2 1 0 9 2 9 24 7 0 0 0 0 0 0 2 0 3 1 1 3 9 37 43 17 11 2 2 6 17 69 51 38 9 2 1 11 21 87 64 38 16 1 1 14 15 68 70 34 7 1 0 10 8 36 48 22 5 1 0 11 8 14 33 11
0 0 0 1 0
0 1 1 3 11 47 44 21
14 2 4 7 21 105 65 55
8 2 1 16 34 152 99 60
25 2 1 23 27 125 121 60
4 1 0 17 14 66 82 41
0 0 0 0 0 0 1 1 0 0 0
6 2 0 7 1 2 53 7 16 32 43
8 2 5 10 3 2 82 14 19 67 130
15 5 10 10 2 2 56 18 18 70 169
24 13 9 9 1 1 53 32 25 60 156
18 5 10 6 0 1 61 21 24 57 102
0 0
4 19
7 35
5 35
4 47
3 54
EUR
15
29
30
33
21
Table A3.13 TB case notifications, Europe, 19802007

1985 916 15 590 1 267 3 036 4 134 1 503 680 3 213 2 279 37 1 864 411 532 542 9 551 3 741 14 161 12 982 4 163 18 544 395 5 816 10 519 2 726 1 131 2 135 33 25 1 1 811 242 16 653 5 619 2 626 21 422 70 822 2 3 606 1 760 526 537 924 892 728 4 209 11 598 419 4 734 10 425 2 427 994 1 895 35 26 1 157 1 481 1 630 4 854 1 380 2 132 3 245 2 114 36 1 834 448 624 661 8 723 1 625 12 198 939 4 339 12 458 398 5 627 11 310 3 393 1 541 2 362 32 11 1 156 1 127 269 8 203 3 303 5 141 26 104 127 930 167 1 002 276 8 017 3 218 4 990 24 295 124 689 832 1 377 3 804 4 128 1 893 4 605 2 530 3 355 48 2 553 299 522 1 546 10 535 1 833 17 906 1 566 4 522 13 602 239 4 077 13 090 2 122 982 1 412 45 14 2 13 474 762 3 658 15 640 505 3 719 10 821 2 515 943 1 556 48 26 0 1 465 288 16 551 5 927 1 835 18 097 53 148 1 238 343 20 603 6 624 3 022 12 860 71 764 6 126 2 022 816 13 755 640 881 2 610 31 029 1 614 22 946 2 751 19 964 6 481 9 774 242 425 48 91 6 841 9 427 302 602 49 92 290 606 49 92 277 143 49 92 267 232 50 94 242 429 51 96 231 651 49 92 248 519 50 94 5 732 9 794 5 793 10 134 6 059 10 632 5 908 9 414 6 088 6 411 9 370 30 531 1 956 22 145 27 884 1 904 20 744 26 669 2 169 20 182 24 468 2 325 16 465 25 166 2 358 16 713 6 042 1 830 792 9 468 545 1 018 2 727 5 583 1 651 760 8 497 536 1 201 2 474 5 045 1 501 768 8 058 595 1 104 2 621 1 227 307 19 757 7 099 2 810 13 361 70 132 1 341 294 18 537 6 363 2 510 14 137 67 553 1 317 255 16 185 6 664 2 281 14 676 62 987 766 1 390 3 677 3 911 1 772 4 522 2 352 3 326 35 2 196 322 446 1 419 10 241 1 810 17 102 1 193 4 125 12 581 184 3 278 13 286 2 088 948 1 372 48 14 2 651 1 402 3 340 3 769 1 588 4 093 2 387 2 973 39 2 047 304 471 1 078 9 191 1 598 16 282 907 4 016 16 534 226 3 610 13 501 2 159 938 1 339 16 12 1 21 235 1 354 2 821 2 414 1 335 600 3 096 2 189 39 1 986 359 403 700 8 605 2 130 14 113 920 3 960 16 604 345 4 685 10 920 2 582 955 1 598 25 30 1 989 915 759 628 24 741 1 426 2 771 3 745 1 462 3 546 2 606 2 158 43 2 079 334 406 771 8 510 707 24 753 1 264 2 839 4 348 1 521 1 595 5 296 2 217 37 1 960 495 623 553 9 093 641 543 10 1 538 946 3 840 5 106 1 030 1 740 3 069 1 356 35 1 101 378 557 392 5 740 4 212 6 526 571 2 507 5 354 505 4 234 26 936 6 172 1 686 2 586 54 6 547 7 1 660 895 5 404 5 443 1 128 2 353 3 025 1 170 30 1 027 356 537 319 5 004 4 011 6 007 668 2 251 11 380 497 3 968 26 493 6 104 1 579 2 036 31 18 506 10 2 206 928 6 034 5 308 1 076 2 111 3 225 1 050 34 973 395 479 339 4 887 4 501 5 539 626 1 808 10 387 402 3 828 25 739 6 329 1 409 2 114 37 21 469 12 1 767 855 5 705 5 142 1 043 1 778 3 136 1 029 36 941 341 422 280 4 817 4 554 5 021 580 1 687 13 416 384 4 145 23 728 6 174 1 290 2 365 33 30 438 5 1 682 811 5 521 5 351 955 2 373 2 848 951 41 790 355 456 300 5 314 4 310 4 609 593 1 540 12 425 392 2 695 24 777 6 098 1 227 2 235 39 38 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984

695 12 649 1 334 2 989 3 708 1 648 4 176 2 301 2 861 23 1 905 328 422 970 9 027 1 609 15 385 1 068 3 769 18 672 160 3 996 13 307 2 132 857 1 381 45 16 1 653 23 590 1 521 2 620 3 039 1 577 4 073 2 256 2 576 29 1 937 350 423 772 9 030 1 537 14 653 877 3 588 18 624 234 4 246 10 969 2 306 906 1 471 48 13 1 738 17 928 1 290 2 480 5 598 1 348 2 220 3 109 2 174 24 1 969 484 683 645 7 656 3 522 11 814 945 4 403 11 434 369 4 155 13 944 4 093 1 761 2 608 41 28 0 655 19 1 026 1 394 4 635 5 985 1 263 2 869 3 437 2 054 47 1 834 554 744 573 6 832 8 446 11 163 767 4 240 10 416 422 4 596 16 109 5 189 2 003 2 926 38 11 0 694 8 1 455 1 302 4 672 6 150 1 203 2 711 4 117 2 118 45 1 805 529 820 629 5 981 6 302 10 440 1 152 3 999 17 424 656 5 727 20 623 5 706 2 182 3 016 44 16 0 733 10 1 488 1 085 4 654 7 339 1 124 2 923 3 530 1 765 39 1 605 587 754 565 6 052 4 793 9 974 936 3 532 10 455 490 4 429 24 979 6 376 1 891 2 800 37 22 3 604 12 1 333 1 185 5 187 6 799 1 278 2 476 3 349 1 630 33 1 414 587 791 527 6 122 4 397 9 064 703 3 073 13 386 557 3 501 25 843 6 205 1 982 2 657 44 16 0 555 10 1 389 1 013 4 898 5 505 1 321 2 469 3 862 1 376 40 1 291 494 708 460 5 814 4 006 6 959 503 2 923 12 393 546 4 287 26 224 6 654 2 000 2 598 31 16 0 594 5 1 433 1 044 5 142 5 139 1 211 1 691 3 335 1 443 20 1 156 403 620 449 5 709 4 490 6 931 570 2 720 8 375 485 3 925 27 546 6 613 1 803 2 414 31 24 0 147 930 282 8 019 2 952 4 857 22 590 127 338 1 369 285 16 136 6 214 1 728 16 256 50 641 1 4 194 1 448 722 7 600 557 1 278 2 460 3 771 1 733 640 9 703 610 987 1 671 1 602 25 455 2 074 18 140 20 622 6 196 14 890 243 691 47 89 6 176 9 866 290 031 51 96 6 238 11 919 322 080 52 98 1 345 290 16 496 5 980 1 910 15 482 50 407 1 4 502 1 620 583 9 007 521 1 134 2 116 1 587 256 16 828 5 447 2 426 20 349 63 591 3 3 843 1 799 646 9 441 616 930 652 1 712 1 619 236 15 958 5 577 2 925 23 271 84 980 2 2 798 1 540 525 8 764 564 830 2 029 786 22 981 1 939 21 459 6 355 13 352 353 361 52 98 6 176 14 558 349 795 52 98 1 678 217 15 358 5 248 2 922 24 189 111 075 0 4 017 1 503 563 8 331 497 765 1 647 724 20 212 2 072 23 414 1 486 205 13 967 5 110 2 908 23 903 119 123 1 4 062 1 298 481 9 347 456 747 2 143 693 25 685 3 438 28 344 1 341 244 13 302 5 260 2 625 25 758 110 935 0 3 028 1 282 449 8 927 446 750 2 448 620 25 501 3 839 27 763 1 398 213 12 168 4 599 2 711 26 107 134 360 0 2 646 1 100 423 8 393 479 756 2 553 557 22 088 4 092 32 879 6 183 15 080 373 765 52 98 1 244 221 10 931 4 227 2 935 27 470 140 677 1 2 864 1 010 368 7 993 417 544 2 779 641 18 038 4 038 32 945 6 220 15 750 373 081 52 98 1 408 276 10 153 4 320 3 608 28 580 132 477 0 4 556 986 359 6 851 394 539 3 508 648 17 263 3 948 36 784 6 027 17 391 368 433 52 98 1 355 243 10 069 4 381 3 769 29 752 128 873 1 4 232 975 338 7 283 375 591 4 052 686 18 043 3 671 40 175 6 889 20 588 373 670 52 98 1 282 320 9 677 3 861 3 619 28 335 124 041 1 3 895 904 275 7 343 386 554 4 260 653 17 923 3 771 37 043 6 400 20 700 358 978 51 96 1 316 278 8 698 3 600 4 806 28 570 121 426 0 3 600 664 249 6 015 416 528 4 529 644 17 543 3 382 38 403 7 039 20 289 354 954 51 96 3 208 710 269 7 281 539 508 5 460 598 19 744 3 191 39 608 8 173 21 513 365 346 51 96 3 146 673 207 7 815 489 461 5 362 561 19 629 3 223 41 265 8 157 23 900 359 735 51 96 2 891 622 212 7 347 460 425 6 297 526 18 878 3 428 37 517 7 851 19 779 350 529 51 96
1 050
954
978
891
975
756 2 191 3 080 5 954 2 687 4 421 3 280 3 999 69 4 962 430 614 2 247 17 199 2 098 29 991 5 412 5 412 25 1 152 249 3 311 14 442 1 973 1 194 1 636 71 24 1
924 2 061 3 180 6 198 2 837 4 376 3 007 4 021 69 4 312 394 560 2 204 16 459 2 124 27 083 7 334 5 322 23 1 018 227 3 182 13 876 2 085 1 140 1 599 45 26 0
759 1 942 3 217 5 468 2 652 4 678 2 999 3 718 86 4 146 378 563 2 170 15 425 2 168 25 397 5 193 5 181 25 975 232 3 850 13 808 2 051 1 077 1 495 41 13 0
702 1 825 3 176 5 509 2 190 4 468 2 892 3 632 73 4 016 348 587 1 882 13 831 1 881 22 977 3 880 5 028 24 924 222 4 253 13 357 1 981 1 072 1 477 41 24 0
774 1 765 3 506 5 065 2 149 4 691 2 856 3 612 39 3 653 302 546 1 791 12 302 1 855 20 243 1 956 4 472 26 837 257 3 472 12 563 2 022 1 054 1 420 46 15 0
768 1 442 3 772 4 873 1 956 4 666 2 555 3 605 61 3 117 312 541 1 819 11 290 1 822 20 074 1 556 4 852 13 804 368 4 113 12 423 2 094 1 223 1 453 42 11 1
1 701 499 25 807 6 873 2 781 13 553 74 270
1 734 461 24 087 7 249 2 852 13 602 73 369
1 514 448 23 685 7 309 3 197 13 588 72 236
1 423 396 23 411 7 052 2 858 13 570 73 280
1 400 373 22 527 6 908 2 554 12 952 74 597
1 362 374 21 650 6 889 2 732 12 677 64 644
6 232 2 465 1 085 4 853 926 1 160 2 647
6 381 2 304 939 5 552 875 1 193 2 631
6 274 2 263 982 7 961 784 1 167 2 628
6 443 2 252 925 8 987 832 1 097 2 509
6 454 2 152 896 10 078 754 946 2 427
6 246 1 989 923 10 749 702 961 2 485
36 716 1 677 26 095
39 992 1 625 25 646
26 457 1 559 24 710
28 634 1 541 24 216
27 589 1 604 24 356
30 960 1 607 24 058
10 488 9 163
9 290 9 682
8 436 8 697
7 814 8 817
7 026 8 544
6 666 8 717
EUR Number reporting % reporting
348 921 49 92
346 104 49 92
324 580 49 92
319 220 49 92
308 401 49 92
298 933 49 92
Table A3.14 TB case notification rates, Europe, 19802007

1987 29 25 17 16 40 40 15 18 38 49 5 18 8 36 11 17 72 18 16 40 7 15 8 10 65 60 45 58 8 7 3 12 6 43 56 60 94 47 8 34 33 27 6 13 16 37 26 7 6 21 31 133 121 89 28 6 6 21 30 130 113 87 25 6 6 21 28 128 105 89 41 4 17 8 8 64 54 39 52 9 7 36 18 21 47 14 62 39 45 5 18 9 43 13 15 32 15 9 42 4 13 7 10 71 74 62 65 8 3 3 22 18 53 39 18 106 26 74 5 21 6 29 29 18 34 22 12 39 5 16 4 6 82 50 36 38 13 4 7 17 7 35 6 18 11 7 66 57 36 42 12 7 0 10 7 43 59 42 78 36 8 7 52 71 65 58 48 61 35 42 25 6 15 56 56 58 43 10 51 69 39 11 44 40 11 66 28 33 37 28 41 35 33 32 29 27 29 50 55 40 10 52 47 61 39 11 53 43 63 32 10 46 43 62 32 11 56 32 40 22 6 18 49 50 29 40 21 7 16 51 9 7 49 64 58 61 46 9 6 43 67 52 63 43 19 18 48 37 16 94 27 66 6 20 6 30 22 16 29 21 9 38 6 15 5 6 83 51 35 37 4 3 3 36 7 17 38 23 13 15 36 48 6 19 7 26 14 15 40 18 9 38 6 17 7 8 66 58 37 43 6 8 3 24 19 44 21 18 38 36 15 85 30 47 6 20 6 26 15 15 22 38 23 16 37 42 15 45 63 48 5 19 10 43 11 16 20 17 14 51 12 46 52 10 45 39 30 4 11 7 41 8 10 92 8 5 25 2 9 8 7 179 121 72 75 12 2 17 10 55 11 65 55 11 60 39 26 4 10 7 40 6 8 89 7 6 22 4 9 8 7 175 118 68 59 7 4 16 14 73 11 72 54 10 54 42 23 4 10 7 36 6 8 101 7 6 18 3 9 6 7 169 122 61 62 8 5 15 16 59 10 68 53 10 45 41 23 4 9 6 31 5 8 103 6 5 17 4 10 6 7 155 117 56 69 7 7 14 7 56 10 65 55 9 60 37 21 5 8 7 34 6 9 98 6 5 15 4 10 6 5 161 115 54 66 8 9 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
1985
1986
39
35
35
31
34
31
33
24 29 50 62 27 113 37 91 11 48 8 42 47 32 41 38 56 51 11 34 7 6 97 54 48 48 19 7 4
29 27 51 64 29 111 34 91 11 42 8 38 46 30 42 35 75 50 10 30 6 6 92 56 45 47 12 8 0
24 26 51 56 27 117 34 84 14 40 7 38 45 28 42 33 53 48 11 28 6 7 91 54 43 43 11 4 0
22 24 49 56 22 111 32 82 12 39 7 39 39 25 36 30 39 47 10 26 6 8 87 51 42 42 11 7 0
24 23 53 51 22 115 32 81 6 35 6 36 37 22 35 26 20 42 11 24 6 6 81 51 41 40 13 4 0
23 19 57 49 20 113 29 81 9 30 6 35 37 20 34 26 16 46 5 23 9 7 79 52 47 41 11 3 4
24 18 56 41 19 110 28 75 7 25 6 34 31 19 34 23 16 43 5 17 6 7 82 52 38 39 12 4 7
21 23 18 17 42 36 17 96 26 64 3 18 6 27 20 16 29 19 11 36 7 19 4 7 81 49 32 38 12 4 3
20 44 17 20 36 30 16 95 26 57 4 19 7 27 15 16 28 18 9 35 7 18 5 7 66 52 34 40 13 4 3
24 26 29 16 31 55 13 65 38 47 3 19 9 48 13 13 71 14 9 43 4 12 7 7 89 88 72 72 10 7 0
21 29 33 17 58 59 12 83 42 44 6 18 11 53 11 12 173 14 7 41 4 11 7 8 104 110 82 82 9 3 0
22 12 47 16 58 61 12 76 51 46 6 18 10 59 12 10 131 13 11 39 6 11 11 10 135 119 90 85 10 4 0
24 15 48 13 58 73 11 79 44 39 5 16 11 55 11 10 100 12 9 34 4 12 8 8 166 131 79 79 9 6 9
20 18 43 15 64 68 13 65 42 36 4 14 11 58 10 10 93 11 6 30 5 10 9 6 173 125 83 76 10 4 0
18 15 45 12 60 55 13 64 49 31 5 13 9 52 9 10 86 8 5 29 4 10 9 7 176 133 85 75 7 4 0
19 7 47 13 62 52 12 44 42 32 2 11 8 46 9 10 97 8 5 27 3 10 8 7 184 131 77 70 7 6 0
12 12 73 70 69 61 54
12 11 67 74 70 61 53
11 11 65 74 78 61 51
10 10 64 71 69 60 52
10 9 61 69 61 57 52
9 9 58 69 65 56 45
8 8 55 66 71 56 50
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan 9 7 42 62 39 70 34 4 41 28 37 20 7 19 46 36 33 33 25 7 14 30 83 43 53 35 11 44 40 43 43 9 7 43 60 43 67 34 4 44 31 30 23 6 16 39 10 6 44 55 55 89 43 12 36 34 33 24 7 13 12 88 10 5 41 56 67 103 57 8 26 29 27 22 6 12 35 40 37 46 42 11 43 42 43 11 5 40 52 67 107 75 0 37 28 29 21 6 11 28 37 32 49 46 11 51 9 5 36 51 68 106 80 4 37 24 24 24 5 10 36 35 40 79 56 11 56 9 6 35 52 62 115 75 0 28 24 23 23 5 10 41 31 39 87 56 11 61 9 5 32 45 65 117 91 0 24 20 21 21 5 10 42 28 33 92 67 11 62 8 5 28 41 71 124 95 4 27 19 19 20 5 7 45 32 26 90 67 11 64 9 6 26 42 88 130 90 0 42 18 18 17 4 7 56 32 25 86 76 10 69 8 5 26 42 93 136 88 4 40 18 17 18 4 8 64 34 26 79 84 12 81 8 7 25 37 91 130 85 3 37 17 14 17 4 8 67 32 25 80 78 11 80 41 8 6 23 34 122 132 84 0 34 12 12 14 5 7 70 32 24 71 81 12 77 40 33 13 13 17 6 7 83 29 27 66 84 14 81 41 32 12 10 18 5 6 81 28 27 66 89 13 89 41 29 12 11 17 5 6 93 26 25 69 81 13 72 39
65 50 59 13 11 18 67
66 46 51 15 11 19 65
65 45 53 21 9 18 63
66 44 50 24 10 17 58
66 42 48 26 9 15 55
63 39 49 28 8 15 54
62 39 43 36 8 13 55
79 59 52 19 57
84 55 51 16 59
54 52 49 15 52
57 50 48 14 51
54 51 48 12 48
59 50 47 12 48
58 49 45 12 51
EUR
44
43
40
39
38
36
36
Table A3.15 New smear-positive cases notified, Europe, 19902007

Number of cases 1996 4 225 2 511 220 1 661 25 7 15 5 37 7 17 4 8 38 10 7 3 17 3 20 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 139 Rate (per 100 000 population)
1990
1991
1992
1993
1994
1995
15
250 24 319
499 1 493 484
513 1 775 427
3 096
548 243 303 8 6 18 13 2 2 3 15 18 19 4 2 8 1 5 6
524 120 347
212 1 475 381 727 5 047 418 640 1 325 1 129 20 545 132 299 188 5 5 20 5 2 24
7 2 15 5 9 50 4 18 16 25 3 5 2 22 4
4 455
3 196
4 730 796 2 3
4 177
436 467 669 1 845 400 865 1 087 1 204 6 487 128 369 244 3 449 221 3 852
173 8 327 442 990 2 117 364 927 903 1 228 3 586 97 240 240 3 002 482 3 689 14 6 9 18 4 25 13 26 1 5 2 26 5 6 4 5
6 12 10 5 13 21 4 27 11 26 0 6 2 17 5 5 10 5
1 905
1 357 6

168 4 576 323 763 2 769 403 786 1 697 748 9 449 172 274 179 2 325 746 2 918 143 660 2 117 170 1 277 6 977 1 642 588 787 2 19 18 20 27 1 9 2 419 526 1 007 437 8 329 135 203 130 2 276 987 1 868 212 556 2 100 164 1 275 9 452 1 587 636 822 17 5 0 10 0 9 3 3 27 21 23 31 7 1 0 7 20 14 41 11 4 3 6 1 3 4 4 41 17 28 22 6 2 0 2 6 4 14 13 10 1 3 3 15 2 4 21 2 2 5 1 3 3 2 63 31 27 24 4 1 0 5 6 19 4 9 27 4 21 21 17 1 4 3 20 3 4 16 4 1 6 1 3 3 2 46 34 25 22 5 1 066 1 339 147 1 738 4 290 991 575 1 121 29 5 0 241 17 400 434 981 2 273 434 803 1 037 1 073 19 481 114 269 186 2 430 595 3 346 285 702 4 123 207 1 903 4 332 1 536 634 1 200 31 3 0 547 3 124 313 667 2 116 221 2 361 6 180 830 668 787 24 6 0 171 1 621 324 890 2 547 409 759 2 524 0 4 420 171 255 205 1 815 601 0 235 412 1 138 17 687 8 903 1 296 637 776 21 5 0 171 3 572 262 927 2 341 472 800 897 421 0 391 127 212 150 2 398 1 014 1 935 213 546 3 123 172 1 361 9 079 0 661 935 11 3 0 211 7 575 269 1 161 1 018 362 493 1 254 438 14 338 143 201 138 2 219 989 1 679 234 526 1 141 150 1 481 8 665 1 643 641 912 31 2 201 3 602 216 1 472 1 109 391 889 1 315 416 10 302 146 203 124 1 923 1 311 1 562 176 560 2 127 91 1 058 7 927 1 761 582 863 20 2 196 5 581 234 1 561 1 235 380 640 1 214 372 9 308 129 162 130 1 941 1 509 1 379 197 423 2 130 98 1 275 6 911 1 972 536 964 14 5 186 8 580 213 1 454 1 072 343 562 1 307 396 8 257 123 147 84 1 911 1 831 1 303 210 422 4 133 72 1 377 6 205 1 833 498 1 029 22 4 165 2 497 189 1 356 1 051 322 737 1 080 382 8 267 135 168 85 1 921 1 867 1 183 257 381 2 135 143 979 6 195 1 720 478 925 0 8 8 26 13 5 12 22 4 23 13 23 3 5 2 19 4 4 12 4 3 7 1 3 4 3 28 33 26 34 7 1 0 6 2 20 4 11 25 4 20 32 0 1 4 3 19 4 3 13 0 2 4 0 4 0 1 60 26 27 22 5 1 0 6 4 19 3 11 23 5 21 11 9 0 4 2 16 3 4 22 2 2 5 1 3 3 2 61 0 28 27 2 1 0 7 10 19 3 14 10 4 13 16 10 2 3 3 15 3 4 22 2 2 5 0 4 2 3 58 32 28 26 7 1 6 4 20 3 18 11 4 23 17 9 1 3 3 15 2 3 29 2 2 6 1 3 1 2 52 34 25 25 4 0 6 7 19 3 19 13 4 16 16 8 1 3 2 12 2 3 34 2 2 4 1 3 1 2 45 38 23 28 3 1 6 11 19 3 17 11 3 14 17 9 1 3 2 11 2 3 41 2 2 4 1 3 1 2 41 35 22 30 5 1 5 3 17 2 16 11 3 19 14 8 1 3 2 13 2 3 42 1 2 4 1 3 2 2 40 32 21 27 0 2 64 237 48 2 823 1 302 1 696 10 801 32 605 58 203 46 2 835 1 300 1 679 9 814 32 335 41 187 38 2 827 1 173 1 610 9 425 33 103 2 10 21 16 46 20 4 1 18 20 15 46 25 11 1 1 7 12 44 50 23 10 1 1 7 12 44 46 23 7 1 1 7 11 42 44 23 358 103 6 819 1 938 219 10 359 42 534 0 1 783 760 221 1 105 162 109 2 511 134 108 1 745 178 7 450 995 312 100 3 497 1 628 397 11 666 42 094 1 1 702 283 156 308 21 3 177 1 801 609 10 317 21 744 0 2 517 246 165 17 19 4 8 8 15 1 7 2 2 18 19 5 46 29 0 16 14 11 2 2 9 16 9 52 28 4 16 5 8 2 0 8 18 14 46 15 0 23 5 8 11 3 5 6 1 1 27 9 10 21 12 16 0 92 233 96 101 109 901 105 288 5 1 693 5 119 1 821 5 695 1 767 7 211 1 639 6 326 17 0 33 10 1 2 4 11 4 13 15 12 12 7 14 13 1 2 6 10 5 18 19 1 14 12 1 1 0 6 6 22 21 2 15 13 1 16 10 90 172 232 209 2 816 557 7 827 4 147 3 350 110 614 106 700 111 772 89 199 94 275 86 239 83 455 844 3 388 1 342 3 504 797 3 977 1 204 3 825 946 4 608 1 365 4 783 1 455 4 690 101 657 94 144 373 192 3 439 764 9 533 254 49 3 502 2 016 477 10 841 42 219 0 1 873 303 157 1 906 97 165 435 179 3 692 790 10 586 117 98 0 122 4 124 964 10 412 1 136 160 83 2 006 106 112 2 051 178 7 866 1 155 14 206 1 146 176 90 2 317 96 95 2 228 200 7 527 1 378 11 028 289 37 3 180 1 863 651 10 202 27 467 1 0 236 145 3 423 118 118 434 167 4 315 1 017 10 738 307 59 3 155 2 042 1 060 11 184 26 605 0 461 226 139 2 456 105 116 719 164 4 444 1 243 0 330 31 3 060 1 976 1 146 10 703 27 865 0 402 202 130 3 317 109 123 687 200 0 1 254 0 282 52 2 983 1 742 1 214 10 418 28 868 0 611 200 116 2 876 109 107 0 200 5 816 1 197 12 785 360 50 2 777 1 514 1 536 10 888 30 890 0 1 244 157 89 2 082 120 119 1 058 200 5 870 1 103 0 14 15 15 7 1 3 18 16 7 13 16 2 1 9 20 11 49 28 0 17 6 8 5 1 2 7 9 6 18 21 2 1 8 18 16 46 19 4 0 4 7 9 1 2 7 8 6 23 22 2 15 11 2 1 8 20 26 51 18 0 4 4 7 6 1 2 12 8 6 27 0 2 18 10 2 1 8 19 28 49 19 0 4 4 7 8 1 2 11 10 0 27 0 2 19 9 2 1 8 17 31 48 20 0 6 4 6 7 1 1 0 10 8 25 27 2 18 12 2 1 7 14 39 50 21 0 12 3 4 5 1 2 16 10 8 23 0 3 20 10 12 3 4 5 1 2 31 9 11 24 31 3 21 11 3 27 12 12 3 4 5 1 1 33 10 10 28 24 3 23 12
150
129 1 441
681
470 688
1 413 3 022 832 504 979
13
1 063
7 606
615 9 339
86 4 000 2 072 704 10 385 30 389
575 62 6 955 2 019 665 10 469 37 512
882 361
409 294
312 528
106 507
472 8 314
8 471
1 497 788 303 2 605 102 185 1 042 319 4 383 544 8 263
283
270 7 487
2 735
EUR
45 771
83 568
104 444
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), Europe, 2009
Available funding Loans Funding gap 0 < 0.01 0.1 0.1 0.1 Total TB control costs 0 0 0 1.1 0 1.4 Grants (excluding Global Fund) Global Fund Completeness of budget data Cost of utilization of general health-care services .
NTP budget
0.1 0
0.1 0
15 0 0 0 0
10
4.4
5.0
20
0.04
0.04
1.0
1.0
0.1 0.2 849 0.6
0.2 0.2 849 1.6
18
6.9
1.0
10
0.7
19
384 0 0 0 30 2.5 33
84
0.02
2.0
298
14
398
30
0.1 0 0 0.9 0.1 0 0.1 0 < 0.01 0 0 50
0.1
< 0.01
0.1
0 49
0 49
7.4 18 18 1249 0 0 0 0 0.7 0 2.2 0 0.4 0.6
7.4 16 16 1014
0 0 0 0
0 0.1 0 1.4
0 1.8 1.5 6.9
0 0 0.5 226
2.4 1.0 12 24
9.8 19 30 1273 23 0.6
23 0.02
20 0.02
N P P N N N N N C N C N N C N N C N N N N N N N C N P N N C N P C N N C C C C N C
4.0 0 0 0 0 0.5 0 0.04 0
2.7
1.3
1.4
0.1 0.3 10
4.1 1.5 80
Albania Andorra Armenia Austria Azerbaijan Belarus Belgium Bosnia & Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Estonia Finland France Georgia Germany Greece Hungary Iceland Ireland Israel Italy Kazakhstan Kyrgyzstan Latvia Lithuania Luxembourg Malta Monaco Montenegro Netherlands Norway Poland Portugal Republic of Moldova Romania Russian Federation San Marino Serbia Slovakia Slovenia Spain Sweden Switzerland Tajikistan TFYR Macedonia Turkey Turkmenistan Ukraine United Kingdom Uzbekistan 0 0 9 35 3.7 3.7 0 555 62 986 96 2 907 C N N N C N C C N N N 31%
1.2 70
0.6 70
33
30
EUR
1 921
1 328
Notes
Denmark
Data for Denmark exclude Greenland. A total of 54 TB cases were notied in Greenland for 2007 (93 per 100 000 population). No MDR-TB cases were identied in Greenland.
Russian Federation
TABLE A3.5: cases notied as Other re-treatment in 2007 included smear-negative cases; these cases were not notied in previous years.
SOUTH-EAST ASIA
South-East Asia
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste Mohammed Abdul Awal Miah; Roksana Haz Chewang Rinzin Kim Jong Guk; Hong Sung Il L.S. Chauhan Jane Soepardi; Sudarman Soemrah Shameema Hussain; Fathmeth Reeza Win Maung; Thandar Lwin Pushpa Malla; Badri Nath Jnawali Chandra Sarukkali Yutichai Kasetjaroen; Pinan Daengharn; Sirinapha Jittimanee Constantino Lopes
Table A3.1
TB/HIV Indirect Indirect Indirect Indirect Indirect Routine Sentinel Sentinel Sentinel Survey Indirect Source of estimates MDR (new) MDR (re-treat) Model Model Model Model Model Model DRS DRS DRS Model Model Model DRS DRS DRS DRS DRS Model DRS DRS Model Model Cfr ss+ HIVDOTS non-DOTS 0.1 0.3 0.1 0.2 0.1 0.3 0.1 0.3 0.1 0.3 0.05 0.2 0.1 0.3 0.05 0.2 0.1 0.3 0.1 0.2 0.1 0.2 Duration ss+HIVDOTS non-DOTS 1 2.5 1 2.5 1 2.5 0.8 2.65 0.8 1.12 0.8 2.5 1 2.5 1 2.5 1 2.5 1 2.5 1 2 Duration ss-HIVDOTS non-DOTS 1 2.5 1 2.5 1 2.5 1.8 3.8 0.8 1.12 0.8 2.5 1 2.5 1 2.5 1 2.5 1 2.5 1 2
Methods and assumptions for estimation of TB incidence, prevalence and mortality, South-East Asia
Trend
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste
Reference year 1997 1997 2007 2002 2004 1997 1997 1997 1997 1997 2007
Incidence est. based on Prev. ARI ARI ARI Prev. Notif. ARI Prev. Notif. Prev. Comparison
ARI Country notifs, exp. Not estimated Not estimated Expert opinion Country notifs, exp. Not estimated ARI Not estimated Not estimated Not estimated

TB mortality, 1990 All forms* number rate All forms* number rate 353 103 1 620 81 944 1 961 825 528 063 143 83 403 48 766 11 676 90 878 3 718 3 165 139 181 146 042 8 1 409 708 81 51 115 3 4 880 642 223 246 344 168 228 47 171 173 60 142 322 995 28 174 103 068 15 996 1 9 114 1 175 9 15 481 <1 <1 4 <1 9 7 <1 19 4 <1 24 <1 158 797 726 36 857 872 514 236 029 64 36 620 21 827 5 253 39 347 1 673 100 110 155 75 102 21 75 77 27 62 145 348 10 61 36 074 5 599 <1 3 190 411 3 5 418 <1 <1 1 <1 3 2 <1 7 1 <1 8 <1 613 652 2 390 104 953 3 304 976 565 614 147 78 846 67 546 15 322 122 826 4 371 387 363 441 283 244 48 162 240 79 192 378 280 87 087 550 22 830 360 835 168 956 16 20 958 9 712 1 724 16 047 538 689 251 53 77 101 113 42 92 7 52 51 10 30 73 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate 498 14 87 51 534 7 998 <1 4 557 588 5 7 741 <1 73 021 <1 2 <1 4 3 <1 9 2 <1 12 <1 4 TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident TB number rate number rate cases, 2007 (%) 70 901 288 15 409 331 268 91 368 12 6 297 6 436 1 504 13 589 544 537 616 45 44 65 28 39 4 13 23 8 21 47 31 421 8 49 29 508 5 444 <1 911 268 2 3 853 <1 40 465 <1 1 <1 3 2 <1 2 <1 <1 6 <1 2 0 1.7 0.2 5.3 3.0 0.8 11 2.4 0.1 17 < 0.05 4.6 Percentage of new re-treat 3.5 3.0 3.9 2.8 2.0 2.7 4.0 2.9 0.2 1.7 2.9 2.8 20 20 23 17 20 21 16 12 21 35 20 18 MDR, 2007 Number among all cases smear-positive 14 506 67 7 183 130 526 12 209 5 4 181 1 937 152 2 774 118 173 660 7 694 41 5 407 99 639 6 427 3 2 331 1 164 141 1 923 58 124 826
Table A3.2
Estimated burden of TB, South-East Asia, 1990 and 2007
298 205 2 955 69 382 1 443 567 626 867 278 68 616 46 445 10 353 77 232 2 383
264 540 344 168 343 129 171 243 60 142 322
134 192 1 330 31 222 649 377 282 090 125 30 503 20 893 4 659 33 862 1 073
119 243 155 75 154 58 76 109 27 62 145
721 902 5 057 169 458 5 044 476 809 592 308 165 017 120 250 18 614 182 330 5 225
639 924 841 586 443 143 411 629 109 336 706
SEAR
2 646 286
202
1 189 326
91
7 242 230
554
Table A3.3
Number of cases 1995 264 540 344 168 343 129 171 243 60 142 322 202 201 199 198 196 195 194 192 191 190 189 142 322 142 322 142 322 142 322 142 322 142 322 142 322 142 322 142 322 142 322 142 322 188 142 322 187 142 322 185 142 322 184 261 516 344 168 335 121 171 238 60 259 492 344 168 327 114 171 233 60 256 470 344 168 319 108 171 229 60 253 449 344 168 311 102 171 224 60 251 428 344 168 304 96 171 220 60 248 409 344 168 297 90 171 216 60 246 391 344 168 290 85 171 211 60 244 373 344 168 283 80 171 207 60 241 356 344 168 276 75 171 203 60 239 340 344 168 270 71 171 199 60 236 325 344 168 263 67 171 195 60 234 310 344 168 257 63 171 191 60 232 296 344 168 251 59 171 187 60 229 283 344 168 245 56 171 184 60 227 270 344 168 239 53 171 180 60 142 322 183 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 225 258 344 168 234 50 171 176 60 142 322 182 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, South-East Asia, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 223 246 344 168 228 47 171 173 60 142 322 181
1990
1991
1992
1993
1994
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka 82 756 2 726 83 689 2 681 84 607 2 628 85 483 2 604 86 300 2 636 87 048 2 732 87 735 2 885 88 378 3 072 89 002 3 263 89 625 3 437 90 252 3 586 90 878 3 718
298 205 302 065 305 909 309 695 313 372 316 904 320 270 323 486 326 605 329 697 332 806 335 951 339 104 342 211 345 197 348 013 350 641 353 103 2 955 2 807 2 633 2 455 2 297 2 172 2 082 2 018 1 973 1 935 1 899 1 864 1 832 1 798 1 761 1 719 1 671 1 620 69 382 70 452 71 556 72 669 73 758 74 796 75 778 76 704 77 562 78 342 79 037 79 641 80 159 80 602 80 992 81 343 81 659 81 944 1 443 567 1 474 771 1 506 338 1 538 106 1 569 868 1 601 462 1 632 821 1 663 943 1 694 808 1 725 418 1 755 777 1 785 851 1 815 627 1 845 155 1 874 508 1 903 739 1 932 852 1 961 825 626 867 621 961 616 801 611 432 605 907 600 266 594 523 588 686 582 785 576 852 570 906 564 955 558 989 552 983 546 901 540 720 534 439 528 063 278 270 262 254 246 237 228 220 211 202 194 186 178 170 163 156 149 143 68 616 69 685 70 722 71 733 72 731 73 722 74 712 75 695 76 655 77 569 78 422 79 207 79 933 80 620 81 296 81 983 82 687 83 403 46 445 46 666 46 907 47 158 47 409 47 649 47 877 48 093 48 288 48 452 48 581 48 670 48 724 48 753 48 766 48 772 48 772 48 766 10 353 10 481 10 605 10 724 10 836 10 938 11 031 11 116 11 191 11 260 11 321 11 377 11 426 11 473 11 519 11 568 11 620 11 676
Thailand Timor-Leste
77 232 2 383
78 166 2 462
79 086 2 553
79 999 2 641
80 912 2 706
81 829 2 738
SEAR
2 646 286 2 679 787 2 713 371 2 746 866 2 780 040 2 812 714 2 844 806 2 876 331 2 907 313 2 937 815 2 967 878 2 997 483 3 026 592 3 055 214 3 083 367 3 111 072 3 138 330 3 165 139
Table A3.4
Prevalence of TB (all forms) 2000 500 515 713 443 326 96 267 312 107 223 644 417 390 370 337 309 296 286 280 42 40 38 35 194 644 197 345 189 359 188 367 184 370 189 385 192 378 17 70 15 70 15 37 15 45 15 46 32 15 46 30 15 48 29 491 512 650 411 314 84 238 304 99 478 472 577 389 297 83 202 285 88 458 460 527 349 287 69 175 271 89 444 443 499 311 274 71 168 260 87 416 412 508 299 261 63 161 247 75 392 406 500 290 251 69 161 246 80 387 363 441 283 244 48 162 240 79 58 60 105 38 61 7 32 28 10 57 58 98 35 58 7 30 27 9 55 55 90 34 53 6 26 26 9 53 53 86 31 50 5 20 24 9 51 50 82 28 45 5 16 23 9 48 48 84 27 41 5 11 23 7 45 46 83 26 38 5 11 22 8 44 43 65 26 37 4 11 22 8 15 47 28 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) 2000 <1 <1 <1 5 <1 <1 10 1 <1 8 <1 4
Estimated incidence, prevalence and mortality rates (per 100 000 population), South-East Asia, 20002007
Mortality HIV+ 2001 <1 <1 <1 5 1 <1 9 1 <1 7 <1 4 2002 <1 <1 <1 4 1 <1 7 1 <1 7 <1 4 2003 <1 <1 <1 4 2 <1 3 1 <1 6 <1 3 2004 <1 <1 <1 3 2 <1 3 <1 <1 6 <1 3 2005 <1 <1 <1 3 2 <1 2 <1 <1 6 <1 3 2006 <1 1 <1 3 2 <1 2 <1 <1 6 <1 2 2007 <1 1 <1 3 2 <1 2 <1 <1 6 <1 2
2000
2001
2002
2003
2004
2005
2006
2007
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka
<1 <1 <1 11 2 <1 23 4 <1
<1 <1 <1 11 3 <1 23 4 <1
<1 <1 <1 11 4 <1 23 4 <1
<1 <1 <1 10 4 <1 22 4 <1
<1 1 <1 10 5 <1 21 4 <1
<1 3 <1 10 6 <1 21 4 <1
<1 4 <1 9 6 <1 20 4 <1
<1 4 <1 9 7 <1 19 4 <1
28 <1
27 <1
26 <1
25 <1
25 <1
25 <1
24 <1
24 <1
SEAR
Table A3.5
Estimated incidence and case detection rates Estimated incidence Case detection rate all forms ss+ all new new ss+ number number % % ss+ (% of pulm.) Proportions . ss+ Extrapulm. Re-treat. (% of (% of (% of new+relapse) new+relapse) new+re-treat.)
Case notifications and case detection rates, DOTS and non-DOTS combined, South-East Asia, 2007
Population All notified thousands number 0
798 0 0 0 0 798 115 293 23 131 80 523 91 082 220 930 587 3 165 139 1 409 708 60 69 61 48 10 5 0 0 0 220 14 355 5 262 28 487 1 021 15 0
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste 6 2 414 19 041 104 0 1 250 230 76 5 543 83 027 42 2 2 468 0 0 0 3 1 418 77 618 321 0 748 269 141 56 622 795 295866 14
158 665 658 23 790 1 169 016 231 627 306 48 798 28 196 19 299 63 884 1 155
147 342 1 008 68 177 1 475 629 275 660 129 133 547 33 439 9 155 54 793 3 270
147 342 999 58 802 1 295 943 275 193 127 129 081 32 940 8 718 54 793 3 255
93 152 247 111 119 42 265 117 45 86 282
104 296 328 23 575 592 587 160 617 59 42 588 14 355 4 528 28 487 1 021
66 50 99 51 69 19 87 51 23 45 88
23 152 253 25 789 398 862 102 613 37 41 826 9 350 1 985 17 156 1 772
16 106 373 7 579 206 840 8 048 30 40 002 6 986 1 984 7 485 433
3 788 45 1 859 96 856 3 915 1 4 665 2 249 221 1 665 29
104 296 328 23 575 592 587 160 617 59
353 103 1 620 81 944 1 961 825 528 063 143 83 403 48 766 11 676 90 878 3 718
158 797 726 36 857 872 514 236 029 64 36 620 21 827 5 253 39 347 1 673
41 59 69 61 51 88 149 63 73 58 87
66 45 64 68 68 92 116 66 86 72 61
82 56 48 60 61 61 50 61 70 62 37
71 33 40 46 58 46 33 44 52 52 31
11 37 13 16 3 24 31 21 23 14 13
3 5 16 19 2 2 7 8 5 3 1
SEAR
1 745 394
2 202 149
2 007 193
115
972 441

. New pulm. lab. confirm. number Estimated incidence and case detection rate Proportions . Estimated incidence DOTS case detection rate ss+ ss+ Extrapulm. Re-treat. all forms ss+ all new new ss+ (% of (% of (% of (% of number number % % pulm.) new+relapse) new+relapse) new+re-treat.) 0 798 0 0 0 0 798 115 290 23 131 80 520 91 082 218 10 5 0 0 0 218 14 355 5 211 28 487 1 021 930 536 0 16 106 373 7 579 206 840 8 048 30 40 002 6 986 1 975 7 485 433 6 2 414 19 041 104 0 1 250 230 76 5 543 83 027 42 2 2 468 0 0 0 3 1 418 77 618 321 0 748 269 138 295 857 3 165 139 3 788 45 1 859 96 856 3 915 1 4 665 2 249 218 1 665 29 104 296 328 23 575 592 587 160 617 59 353 103 1 620 81 944 1 961 825 528 063 143 83 403 48 766 11 676 90 878 3 718 158 797 726 36 857 872 514 236 029 64 36 620 21 827 5 253 39 347 1 673 1 409 708 41 59 69 61 51 88 149 63 72 58 87 60 66 45 64 68 68 92 116 66 85 72 61 69 82 56 48 60 61 61 50 61 69 62 37 61 71 33 40 46 58 46 33 44 52 52 31 48 11 37 13 16 3 24 31 21 23 14 13 15 3 5 16 19 2 2 7 8 5 3 1 14
Table A3.6
DOTS coverage, case notifications and case detection rates, South-East Asia, 2007
DOTS coverage %
TB cases reported from DOTS services New pulmonary New extraOther Re-treatment cases . ss+ ss- / unk. pulmonary new Relapse After failure After default Other re-treat. Other number rate number number number number number number number number
100 100 100 100 100 100 95 100 98 100 100
147 342 999 58 802 1 295 943 275 193 127 129 081 32 940 8 636 54 793 3 255
93 152 247 111 119 42 265 117 45 86 282
104 296 328 23 575 592 587 160 617 59 42 588 14 355 4 477 28 487 1 021
66 50 99 51 69 19 87 51 23 45 88
23 152 253 25 789 398 862 102 613 37 41 826 9 350 1 966 17 156 1 772
SEAR
100
2 007 111
115
972 390
56
622 776
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 0 8 785 151 1 600 163 8 721 926 29 1 473 388 134 7 2 1 0 0 5 552 0 1 7 141 21 630 5 220 2 550 121 872 17 964 6 660 3 062 918 1 649 31 1 275 287 664 0 5 4 551 0 282 0 5 2 260 0 2 825 0 590 37 744 873 0 2 7 615 4 846 0 6 5 080 4 437 0 5 2 456 80 425 288 9 324 146 724 162 146 0 0 414 146 0 3 0 0 0 2 0 0 0 0 0 TB pts HIV-positive Lab-confirmed DST MDR Re-treatment Re-treatment MDR in new cases in new cases DST MDR 0 59 654 243 2 626 0 343 26 552 89 418 HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, South-East Asia, 20062007
753 28 245 12 184 4 855 70 324 414 176 1 023 18
4 1
2 1
753
11 41 1 2 3 1 65 0
11 11 0 1 2 1 14 0
245 11 386 4 855 7 54 0 31 1 023 18
SEAR
20 090
129
43
18 372
Table A3.8
% Not eval. Success Number of cases Notified Regist'd New smear-positive cases, non-DOTS % % of cohort of notif ComplTransregist'd Cured eted Died Failed Default ferred Not eval.
Treatment outcomes, South-East Asia, 2006 cohort

% Number Regist'd Success % . Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
Number of cases Notified Regist'd 2
% of notif regist'd
54
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste 3 1 2 4 2 3 0 3 3 11 1 0 87 65 0 0 2 5
101 967 312 18 435 553 797 175 320 53 40 241 14 028 4 431 29 081 907
101 761 320 18 435 553 302 175 320 53 40 350 14 028 4 431 28 856 908
100 103 100 100 100 100 100 100 100 99 100
91 80 82 84 83 91 77 86 83 71 69
1 9 4 2 9 0 7 2 4 6 10
3 5 3 5 2 0 6 5 5 8 5
1 1 4 2 1 2 3 1 1 2 0
2 1 4 6 5 4 5 3 7 6 12
1 5 0 0 0 0 0 0 0 4 0
92 89 86 86 91 91 84 88 87 77 79
4 211 61 8 820 259 130 4 227 5 8 866 2 920 435 2 191 44 290 910
70 62 68 45 61 60 50 82 66 53 73 47
7 13 8 26 16 20 20 1 5 9 7 25
5 2 4 7 5 20 12 6 6 13 5 7
2 7 13 4 2 0 7 4 3 6 0 4
4 0 4 15 11 0 7 3 17 7 16 14
4 0 3 2 5 0 4 3 4 5 0 2
8 16 0 0 0 0 0 0 0 7 0 0
77 75 77 72 77 80 70 84 71 62 80 72
SEAR
938 572
937 764
100
84
Table A3.9
After failure, DOTS % of cohort Not eval. Died 0 5 9 5 1 0 888 252 136 50 70 46 18 2 8 11 10 6 5 2 2 11 11 33 4 5 5 0 0 0 68 73 54 4 2 33 12 14 0 5 18 50 0 0 17 73 58 13 1 186 76 519 46 66 58 15 8 8 0 4 8 0 13 4 0 5 19 38 0 0 62 74 66 Died 6 2 210 19 444 0 675 285 72 616 52 70 74 49 52 8 8 14 16 2 0 60 78 994 58 8 8 4 19 2 0 66 8 1 3 5 10 7 3 11 16 14 6 10 9 4 15 9 5 4 0 6 0 0 0 10 60 71 76 53 23 308 17 65 50 0 9 8 % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, South-East Asia, 2006 cohort
Number regist'd
ComplCured eted
Died
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka Thailand Timor-Leste 0 74
4 211 42 1 501 89 808 4 227 4 4 909 2 383 227 1 575
70 74 71 67 61 75 62 85 75 55
7 14 5 6 16 0 12 1 4 10
5 2 4 7 5 25 11 5 7 14
2 5 13 5 2 0 6 3 2 4
4 0 4 14 11 0 6 3 8 7
3 1 5 0 3 3 4 4
8 5 0 0 0 0 0 0 0 6
77 88 76 73 77 75 74 86 79 65
SEAR
108 887
67
12

2003 6 38 0 1 107 14 33 18 31 23 30 2004 2005 2005 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 2002 83 90 91 84 87 97 82 86 77 69 62 1 4 103 27 5 60 0 4 5 8 14 1 7 96 27 11 70 5 2 12 93 30 16 75 22 83 84 85 85 87 87 87 1 18 84 93 91 85 86 97 81 88 80 75 73 84 86 88 87 86 95 81 86 81 74 81 85 90 88 86 87 91 81 87 81 73 81 90 83 89 86 90 95 84 87 85 74 80 91 91 89 86 91 86 84 88 86 75 82 92 89 86 86 91 91 84 88 87 77 79 23 36 1 7 19 97 34 45 77 41 24 41 13 12 20 75 50 57 67 48 26 43 27 23 21 71 60 58 72 76 26 30 44 40 30 30 75 69 61 71 68 84 33 35 45 45 44 37 89 78 66 71 74 74 44 40 45 51 56 53 90 88 67 76 74 69 55 54 40 49 60 66 94 102 67 93 77 67 62 65 42 50 64 73 79 111 64 85 74 56 67 66 45 64 68 68 92 116 66 85 72 61 69
Table A3.10 DOTS treatment success and case detection rates, South-East Asia, 19942007
1994
1995
1996
1997
1998
1999
2000
73 71
71 97
72 96
78 85
83 94 95
79 91 97 66
77
79
79 81 93 79 85 80 78
82 54 94 82 87 76 62
80 90 91 84 58 94 82 89 76 68
81 85 94 82 50 94 81 87 84 77
SEAR
80
74
77
72
72
73
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, South-East Asia, 2007
5564 9 830 13 674 31 922 6 762 5 2 155 919 412 3 748 65 56 505 10 144 78 671 81 784 60 475 43 330 28 955 16 092 16 515 186 977 214 333 197 583 166 464 118 021 72 597 2.0 829 3 406 7 575 920 1 159 175 16 50 10 8 562 59 1 233 50 289 13 371 5 2 719 1 149 279 885 120 8 164 28 1 682 49 519 16 055 2 3 500 1 027 228 1 481 98 6 678 21 2 672 32 407 13 211 5 2 998 793 183 1 418 89 5 220 10 1 723 20 316 11 391 5 2 486 619 182 1 302 76 3 057 10 1 056 13 195 7 965 0 1 601 578 176 1 281 36 1 818 6 440 7 395 2 896 1 1 198 258 111 1 938 31 1 352 5 759 11 880 1 769 1 286 325 26 98 14 18 772 119 3 180 124 236 28 206 19 6 310 3 174 567 2 146 248 20 606 72 4 430 133 369 37 352 6 10 069 2 618 705 4 879 227 19 681 50 6 389 120 452 31 817 11 9 824 2 429 847 5 905 178 18 527 36 4 554 96 724 29 674 10 7 993 2 339 984 5 470 153 13 710 27 3 149 66 609 22 141 6 4 753 2 293 825 4 403 105 11 648 19 1 114 39 317 9 658 6 3 353 1 177 523 5 686 96 2.0 1.4 1.6 2.3 1.4 2.1 1.9 2.1 2.8 2.4 1.2 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
523 2 353 4 305 849 0 127 150 10 48 4
10 210 60 1 947 73 947 14 835 14 3 591 2 025 288 1 261 128
12 442 44 2 748 83 850 21 297 4 6 569 1 591 477 3 398 129
13 003 29 3 717 88 045 18 606 6 6 826 1 636 664 4 487 89
13 307 26 2 831 76 408 18 283 5 5 507 1 720 802 4 168 77
10 653 17 2 093 53 414 14 176 6 3 152 1 715 649 3 122 69
SEAR
6 371
108 306
132 549
137 108
123 134
89 066
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, South-East Asia, 2007
65+ 352 82 86 113 114 81 175 204 70 170 418 133 4 49 60 55 52 55 33 3 56 77 88 3 3 15 4 3 2 3 3 1 1 4 55 82 66 47 63 14 59 41 16 18 108 67 57 101 56 80 8 81 49 15 29 141 70 63 132 47 80 31 84 49 13 26 162 80 41 128 38 96 43 92 54 14 27 192 76 65 96 39 105 0 103 77 19 43 145 59 38 32 23 39 18 79 43 16 65 188 2 2 14 3 3 1 2 3 1 1 3 58 78 83 55 66 25 67 55 16 22 108 82 64 130 72 93 12 116 63 25 49 156 101 67 156 84 96 33 140 81 30 58 167 136 68 169 87 124 42 153 109 38 59 194 98 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 All 3544 5564 170 81 148 97 153 47 160 167 46 77 222 112 65+ 199 60 52 66 72 51 122 111 40 109 300 79
014
1524
2534
Male 3544
4554
5564
2 2 13 2 3 0 2 3 0 1 2
62 75 100 63 69 37 76 69 16 25 109
96 69 159 87 106 15 152 77 35 69 171
129 71 178 118 112 34 199 117 49 94 172
189 91 209 133 152 42 219 172 63 94 195
264 95 204 154 205 94 224 272 76 113 306
SEAR
63
92
120
141
170
Table A3.13 TB case notifications, South-East Asia, 19802007

1985 45 599 1 582 45 355 608 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka
39 774 1 539
42 644 2 657
49 870 720
52 961 1 017
45 679 904
41 802 1 073
705 600 25 235 73 12 744 1 020 6 212
769 540 32 461 112 12 461 337 6 288
923 095 1 075 098 1 109 310 1 168 804 1 279 536 1 403 122 33 000 31 809 32 432 17 681 16 750 111 143 123 91 111 115 12 069 11 012 11 045 10 506 10 840 11 986 1 459 700 190 52 252 1 012 7 334 6 666 6 376 5 889 6 596 6 411
44 280 45 191 48 673 56 052 31 400 54 001 48 276 56 437 63 471 63 420 72 256 79 339 75 557 76 302 81 963 88 156 98 336 123 118 145 186 147 342 1 126 1 525 1 154 996 140 108 1 159 1 299 1 271 1 211 1 292 1 174 1 140 1 037 1 089 1 026 988 1 007 917 999 0 11 050 1 152 12 287 34 131 29 284 40 159 41 810 44 602 42 722 44 558 58 802 1 457 288 1 510 500 1 519 182 1 555 353 1 121 120 1 081 279 1 114 374 1 218 183 1 290 343 1 132 859 1 102 002 1 218 743 1 115 718 1 085 075 1 060 951 1 073 282 1 136 182 1 156 248 1 228 827 1 295 943 97 505 105 516 74 470 60 808 98 458 62 966 49 647 35 529 24 647 22 184 40 497 69 064 84 591 92 792 155 188 174 174 210 229 254 601 277 589 275 193 85 203 152 123 92 175 249 231 212 173 176 153 132 139 125 137 119 122 99 127 9 348 10 940 12 416 14 905 17 000 19 009 15 583 18 229 22 201 17 122 14 756 19 626 30 840 42 838 57 012 75 744 96 662 107 009 122 472 129 081 1 603 11 003 10 142 8 983 13 161 15 572 19 804 22 970 24 158 24 135 27 356 29 519 29 519 30 359 30 925 31 979 33 448 32 670 32 940 6 092 6 429 6 666 6 174 6 802 6 809 6 132 5 956 5 366 6 542 6 925 7 157 8 413 7 499 8 939 8 998 8 562 9 249 8 510 8 718
Thailand Timor-Leste SEAR Number reporting 82 82 73 91 82 82 82 73 82 82 82 82 91 91 91 91 91 130 100 100
45 704 0 837 901 10
49 452 48 553 65 413 69 240 77 611 52 152 51 835 50 021 44 553 46 510 43 858 47 697 49 668 47 767 45 428 39 871 30 262 15 850 29 413 34 187 49 656 49 581 54 504 55 306 57 895 56 230 54 793 2 760 2 760 3 716 3 767 3 586 3 255 915 952 1 076 211 1 244 819 1 275 299 1 323 509 1 413 418 1 520 444 1 667 348 1 735 860 1 719 365 1 747 252 1 322 709 1 287 176 1 298 759 1 401 096 1 470 352 1 308 981 1 279 041 1 464 312 1 414 228 1 414 141 1 488 126 1 551 516 1 686 681 1 789 186 1 920 644 2 007 193 9 9 9 9 9 9 8 10 9 9 9 8 9 9 9 9 10 10 10 10 10 11 11 11 11 11 11 100 100 100
% reporting
91
82
82
82
82

1987 43 118 174 59 31 6 39 99 39 86 97 93 92 97 100 88 124 133 135 131 131 84 177 55 42 24 9 37 94 95 179 59 97 28 59 38 83 177 41 70 31 53 39 86 177 33 55 37 46 36 80 125 52 40 41 118 33 74 45 64 38 88 119 26 103 37 74 34 84 128 18 93 42 91 33 79 133 12 84 51 103 29 69 41 212 41 281 43 211 48 183 27 26 45 21 39 226 45 256 49 250 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 48 234 50 114 11 67 39 106 36 51 90 54 244 5 109 20 67 33 103 37 27 58 216 54 119 33 57 43 115 38 49 54 204 149 107 40 48 67 121 45 56 54 181 127 102 43 50 92 118 40 81 89 57 184 173 98 71 44 122 119 47 80 308 92 60 169 179 98 79 48 161 119 47 88 289 94 65 159 190 102 94 41 203 120 45 88 367 101 80 158 181 102 113 41 223 123 48 92 353 105 93 141 188 107 121 33 253 118 44 89 322 112 93 152 247 111 119 42 265 117 45 86 282 115
Table A3.14 TB case notification rates, South-East Asia, 19802007
1980
1981
1982
1983
1984
1985
1986
45 364
47 612
53 162
55 223
47 193
42 223
44 319
102 17 46 38 7 42 98
109 21 69 37 2 41 104
128 21 66 35 9 48 100
146 20 83 31 4 43 133
147 20 69 31 1 40 138
152 11 50 29 0 37 153
162 10 59 29 1 41 101
SEAR
79
85
97
110
110
112
117
Table A3.15 New smear-positive cases notified, South-East Asia, 19902007

Number of cases 1996 29 674 308 25 33 53 16 1 69 16 72 23 61 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Rate (per 100 000 population)
1990
1991
1992
1993
1994
1995
18 993
1 710 352
20 524 367
Bangladesh Bhutan DPR Korea India Indonesia Maldives Myanmar Nepal Sri Lanka 290 953 11 790 106 9 716 10 365 2 958 16 36 <1 <1 <1 23 22 25 25 25 25 31 32 35 37 35 29 22 13 25 29 46 17 18 32 19 16 997 372 867 369 583 382 171 481 332 510 053 561 939 606 730 673 171 779 530 857 371 938 637 972 441 13 214 7 962 14 934 17 754 28 363 25 593 1 090 28 459 1 027 28 421 1 014 29 762 1 035 29 081 907 28 487 1 021 41 46 45 122 108 100 41 47 47 97 51 24 26 52 2 49 19 28 16 46 20 40 17 30 6 42 22 47 16 46 81 55 45 88 56
225 256 62 966 126
2 769
3 023
3 218
6 679 3 335
226 543 49 647 125 946 10 442 3 405
264 515 31 768 114 8 681 8 591 3 049
33 117 284 3 980 274 877 19 492 95 9 695 11 323 3 506
37 737 270 403 278 275 32 280 88 10 089 11 306 3 761
37 821 315 5 073 345 150 49 172 88 11 458 13 410 3 911
38 484 347 16 440 349 374 52 338 65 17 254 13 683 4 314
40 777 359 14 429 384 827 53 965 59 21 161 13 683 4 316
46 811 364 18 576 395 833 76 230 60 24 162 13 714 4 297
53 618 360 17 392 433 564 92 566 68 27 448 14 348 4 321
62 694 356 18 479 489 195 128 981 66 31 408 14 614 4 302
84 848 308 17 796 508 890 158 640 66 36 541 14 617 4 868
101 967 312 18 435 553 851 175 320 53 40 241 14 028 4 442
104 296 328 23 575 592 587 160 617 59 42 588 14 355 4 528
25 55 18 28 10 37 22 50 19
28 51 2 28 16 33 22 48 20
28 58 22 34 24 33 25 56 21
28 62 72 33 25 24 38 56 23
29 63 62 36 25 21 46 55 23
32 62 80 37 35 21 52 54 23
36 59 74 39 42 24 58 55 23
42 57 79 44 58 23 66 55 23
55 48 75 45 70 22 76 54 25
65 48 78 48 77 18 83 51 23
66 50 99 51 69 19 87 51 23
20 260
20 273
SEAR
2 769
3 023
3 218
317 355
313 430
357 882
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), South-East Asia, 2009
Available funding Loans Funding gap 3.1 0 13 30 16 0 4.3 0.2 0.5 3.2 0.01 70 59 5.8 < 0.01 1.7 38 4.8 0.1 1.9 1.8 3.8 1.0 1.1 0 0 37 0 0 0 0 0 0 0 38 29 49 0 0 0 9.8 13 0.03 5.3 0.2 0 0 0 9.2 0.5 0 14 17 0 0 3.8 2.4 0.8 1.6 Grants (excluding Global Fund) Global Fund Cost of utilization of general health-care services . Total TB control costs 21 2.0 18 138 85 0.3 13 6.7 12 51 1.8 348 Completeness of budget data C C C C C C C C C C P 91%
NTP budget
15 1.9 16 100 80 0.2 11 4.8 8.3 50 1.8
4.9 1.4 2.9 9.2 34 0.2 1.2 0.6 5.4 46 0.3
SEAR
289
107
Notes
Bangladesh
TABLE A3.5: the population estimate used by the NTP (142 million) is lower than that of the United Nations Population Division (159 million). Using the smaller population estimate gives a notication rate of new smear-positive cases of 74 per 100 000 population, and a smear-positive case detection rate of 73%.
India
TABLE A3.5: the population estimate used by the NTP (1131 million) is lower than that of the United Nations Population Division (1169 million). Using the smaller population estimate gives a notication rate of new smear-positive cases of 52 per 100 000 population, and a smear-positive case detection rate of 70%. ANNEX 1 (COUNTRY PROFILE): low treatment success rates in 20002002 are because a large number of non-DOTS cases were not evaluated.
Myanmar
ANNEX 1 (COUNTRY PROFILE); TABLE A3.10: treatment outcomes of the 2005 cohort of new smear-positive cases published in the 2008 report did not include HIV-positive patients; in this report these patients are now included.
EUROPE WESTERN PACIFIC
Western Pacic
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna Faafetai Teo-Yandall Yasmine Gray; Kate Robinson Hjh Kalsom Binti Abdul Latif; B. Badesab Mao Tan Eang; Tieng Sivanna Wang Lixia; Cheng Shiming Cheuk-ming Tam Chou Kuok Hei Joe Koroivueta Henri-Pierre Mallet; Jean-Paul Pescheux Cecilia Teresa T. Arciaga Tamami Umeda; Seiya Kato Bereka Reiher; Katua Tianuare Phannasinh Sylavanh; Phonenaly Chittamany Hasan bin Abdul Rahman; Mohamed Paid bin Yusof Kenner Briand; Risa J. Bukbuk Mayleen Jack Ekiek Khandaasuren Dovdon; Nasanjargal Purev Isabella Amwano Bernard Rouchon; Oksana Segur Alison Roberts; Ingrid Hamilton Marina Pulu; Minemaligi Pulu Richard Brostrom; Marites Fabul Henrietta Merei Paul K. Aia; Andrew Kamarepa Rosalind Vianzon; Anna Marie Celina Garn; Arlene Rivera Hee Byoung Yoo; En Hi Cho Wang Yee Tang; Khin Mar Kyi Win Noel Itogo Tekie Iosefa Saia Penitani Nese Ituaso Conway Markleen Tagaro Dinh Ngoc Sy Laurent Morisse
Table A3.1
TB/HIV Indirect Indirect Survey Indirect Survey Routine Indirect Survey Routine Indirect Routine Routine Sentinel Indirect Routine Indirect Indirect Indirect Indirect Routine Indirect Source of estimates MDR (new) MDR (re-treat) Model Model Model Model DRS DRS DRS DRS DRS DRS DRS DRS Model Model Model Model DRS DRS Model Model Model Model DRS DRS Model Model Model Model DRS Model Model Model DRS DRS Model Model Model Model Model Model DRS DRS DRS DRS Model Model DRS DRS Model Model Model Model Model Model Model Model DRS DRS Model Model Cfr ss+ HIVDOTS non-DOTS 0.1 0.2 0.12 0.12 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.15 0.15 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.12 0.12 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.3 0.1 0.3 0.12 0.12 0.1 0.2 0.12 0.12 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 Duration ss+HIVDOTS non-DOTS 1 2 1 1 1 1.5 0.945 1.2 2 3.18 1 1 1 1.5 1 2 1 2 1 2 1 2 1.3 1.3 1 2 1.5 2.5 1 1.5 1 2 1 2 1 2.5 1 2 1 2 1 1 1 2 1 2 1 2 2 2 1.5 2 1 1.5 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Duration ss-HIVDOTS non-DOTS 1 2 1 1 1 1.5 1 1.95 2 3.18 1 1 1 1.5 1 2 1 2 1 2 1 2 1.3 1.3 1 2 1.5 2.5 1 1.5 1 2 1 2 1 2.5 1 2 1 2 1 1 1 2 1 2 1 2 2 2 1.5 2 1 1.5 1 2 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Methods and assumptions for estimation of TB incidence, prevalence and mortality, Western Pacific
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna
Reference year 2005 2002 1998 2002 2003 1997 2000 2005 2005 2005 2005 1999 2005 1997 1997 2005 2005 1997 2005 2005 1999 2005 2005 2000 1997 2007 1997 2005 1997 2005 2005 2005 2005 2005 1997 2005
Incidence est. based on Notif. Notif. Prev. Prev. ARI/Prev. Notif. Comparison Notif. Notif. Notif. Notif. Notif. Notif. ARI Notif. Notif. Notif. Prev. Notif. Notif. Notif. Notif. Notif. Notif. Prev. Prev. Prev. Notif. Notif. Notif. Notif. Notif. Notif. Notif. ARI Notif.
Trend Constant CDR Country notifs, moving ave. Constant CDR Group, exp. ARI Country notifs, moving ave. Country notifs, moving ave. Constant CDR Country notifs, exp. Constant CDR Constant CDR Country notifs, moving ave. Group, exp. Group, exp. Country notifs, exp. Group, exp. Country notifs, exp. Not estimated Constant CDR Constant CDR Country notifs, moving ave. Constant CDR Constant CDR Constant CDR Not estimated Prevalence Country notifs, moving ave. Country notifs, exp. Country notifs, moving ave. Country notifs, exp. Constant CDR Group, exp. Country notifs, exp. Country notifs, exp. Group, exp. Constant CDR
Table A3.2
TB mortality, 1990 All forms* number rate All forms* number rate 3 1 295 230 71 504 1 305 770 4 461 301 2 174 71 59 26 994 347 8 851 27 439 128 108 5 400 3 52 299 <1 49 12 15 796 255 084 43 222 35 1 176 634 <1 24 18 174 149 588 2 1 919 306 108 51 483 3 858 539 48 18 019 1 3 500 160 197 25 741 1 290 546 16 14 503 <1 2.7 4.3 24 135 411 5 6 59 495 98 62 63 15 21 27 34 21 365 151 103 215 97 205 33 22 7 <1 58 60 250 290 90 19 27 128 <1 24 166 77 171 15 41 <1 5 560 24 705 4 126 295 4 433 8 4 2 930 874 413 40 12 052 <1 <1 38 2 <1 <1 5 17 <1 <1 46 <1 <1 <1 14 <1 579 151 31 621 585 126 2 007 135 <1 78 21 6 12 135 156 3 954 11 904 57 49 2 429 3 13 134 <1 16 6 6 815 114 701 19 409 16 525 285 <1 11 8 78 66 109 1 <1 3 39 219 44 28 28 7 9 8 3 9 164 67 45 97 44 92 33 6 3 <1 19 27 108 130 40 8 12 58 <1 11 75 35 76 7 14 <1 1 946 8 647 1 44 103 1 552 3 1 1 026 306 144 14 4 218 <1 <1 13 <1 <1 <1 2 6 <1 <1 16 <1 <1 <1 5 3 1 303 252 95 974 2 582 469 4 561 301 4 255 83 63 35 767 402 16 906 32 251 166 111 6 142 3 60 303 <1 60 14 27 197 440 035 60 969 47 1 190 891 <1 29 21 231 192 092 4 5 6 65 664 194 63 63 31 30 32 36 28 423 289 121 281 100 234 33 25 7 <1 72 71 430 500 126 25 27 180 <1 28 203 102 220 25 20 <1 2 780 12 353 2 63 147 2 217 4 2 1 465 437 206 20 6 026 <1 <1 19 <1 <1 <1 3 8 <1 <1 23 <1 <1 <1 7 <1 129 27 12 925 200 614 384 22 <1 29 8 4 3 331 46 1 410 4 830 19 10 762 <1 4 30 <1 6 2 3 817 36 305 4 887 5 122 105 <1 2 2 27 20 678 <1 <1 <1 7 89 15 5 5 4 4 3 2 3 49 24 18 32 9 29 3 2 <1 <1 7 8 60 41 10 3 3 21 <1 2 17 12 24 3 4 <1 1 843 6 774 1 14 99 1 296 1 <1 1 049 271 45 4 3 101 <1 <1 13 <1 <1 <1 2 5 <1 <1 17 <1 <1 <1 4 3.2 < 0.05 7.8 1.9 2.0 0.5 3.3 16 0.1 1.2 19 0.3 1.0 3.4 8.1 2.0 < 0.05 5.0 0.9 2.3 2.1 0.7 3.1 3.5 0.1 2.8 3.0 1.0 0.4 2.2 3.5 4.0 2.7 2.9 0.2 2.7 2.7 20 3.1 26 8.0 16 20 10 20 20 < 0.05 20 21 26 < 0.05 20 20 21 14 20 1.0 20 19 38 7 94 112 348 82 12 <1 2 <1 389 13 386 27 6 6 198 <1 1 <1 <1 864 12 125 2 337 1 4 <1 6 468 Percentage of new re-treat 2 112 27 11 567 285 172 461 19 <1 65 14 14 7 033 83 1 538 3 890 32 32 1 069 2 18 35 <1 6 2 2 816 53 419 8 024 8 169 221 <1 6 6 47 21 727 2 397 633 26 5 <1 10 119 25 8 5 <1 9 7 11 6 116 38 21 68 33 48 19 10 1 13 13 12 68 87 19 5 6 70 33 6 62 31 33 15 Incidence, 2007 All forms HIV+ Smear-positive* Smear-positive HIV+ number rate number rate number rate Prevalence, 2007 All forms* All forms HIV+ number rate number rate TB mortality, 2007 . HIV prevalence All forms* All forms HIV+ in incident TB number rate number rate cases, 2007 (%)
Estimated burden of TB, Western Pacific, 1990 and 2007

MDR, 2007 Number among all cases smear-positive 5 94 76 154 61 8 <1 285 8 217 12 4 4 169 <1 <1 553 6 451 1 696 <1 3 <1 4 199 89 926
10 1 120 148 56 742 1 338 563 5 355 258 <1 366 66 69 58 085 369 7 278 21 435 143 182 4 552 8 159 346 1 31 10 10 307 240 889 70 946 51 1 493 980 1 32 28 207 133 898 9
21 7 58 585 116 94 69 <1 51 34 51 47 513 179 118 302 188 205 85 93 10 59 71 64 250 393 165 32 50 312 69 34 296 139 202 63
5 503 67 25 258 602 242 2 410 116 <1 165 30 31 26 128 166 3 275 9 635 64 82 2 049 4 72 155 <1 14 4 4 636 108 400 31 926 23 672 441 <1 14 13 93 60 245 4
10 3 26 260 52 42 31 <1 23 15 23 21 231 80 53 136 85 92 38 42 5 26 32 29 112 177 74 14 22 141 31 15 133 62 91 28
20 42 1 139 7 234 91 90 001 928 3 758 426 327 5 475 96 258 69 <1 <1 495 68 131 67 137 103 76 340 62 737 1 026 17 449 428 28 851 159 286 605 254 263 10 580 477 16 170 191 112 351 10 3 118 62 142 14 96 20 579 498 489 394 799 95 626 223 58 36 1 560 52 1 960 625 2 139 43 45 56 593 415 278 241 512 365 17 126
WPR
1 954 134
129
878 939
58
4 842 675
320
Table A3.3
Number of cases 1995 21 7 58 585 116 94 69 <1 51 34 51 47 513 179 118 302 188 205 85 93 10 59 71 64 250 393 165 32 50 312 69 34 296 139 202 63 129 127 126 124 123 121 120 119 118 116 115 114 113 112 111 7 7 58 579 115 92 69 6 48 27 50 46 503 177 117 296 181 205 143 89 10 58 101 44 250 386 145 31 50 296 70 33 287 134 200 176 2 7 58 574 114 90 63 37 46 45 48 44 493 175 117 291 174 205 140 87 9 56 150 28 250 380 129 30 51 281 72 32 277 130 198 32 9 7 58 568 113 89 63 31 43 42 55 42 483 173 116 285 168 205 137 63 9 55 97 172 250 373 112 29 48 267 56 32 268 125 196 87 9 7 58 563 112 86 69 24 41 47 73 41 474 172 115 279 161 205 45 57 10 54 93 275 250 366 106 28 47 253 <1 31 259 121 195 86 11 7 58 557 111 84 87 12 39 54 46 39 464 170 114 274 155 205 132 50 10 53 92 124 250 360 98 27 47 240 150 31 250 117 193 47 <1 7 58 552 110 86 101 6 37 43 45 38 455 168 113 268 149 205 129 58 10 101 94 32 250 353 93 26 48 228 <1 30 242 113 191 62 12 7 58 546 109 91 104 13 35 45 45 38 446 167 112 263 143 205 127 48 10 <1 166 92 250 347 87 26 48 216 56 29 234 109 189 107 6 6 58 541 108 86 95 <1 33 51 44 37 437 165 111 258 138 205 124 48 10 <1 167 54 250 341 80 25 46 205 56 29 226 105 187 54 8 6 93 536 106 81 86 20 32 45 43 37 428 163 110 253 133 205 22 41 11 57 110 188 250 335 71 24 43 195 <1 28 218 102 185 53 6 6 102 530 105 76 85 7 30 29 39 34 420 162 109 248 128 205 44 49 11 <1 121 52 250 329 72 23 37 185 <1 28 211 98 183 52 6 6 70 525 104 78 79 14 28 29 44 32 412 160 108 243 123 205 33 31 9 <1 90 51 250 323 74 23 35 175 <1 27 204 95 182 7 4 6 73 520 103 76 74 7 27 29 35 29 403 159 108 238 118 205 55 32 10 253 80 62 250 317 83 22 33 166 56 27 197 92 180 141 5 6 64 515 102 71 63 <1 26 22 40 28 396 157 107 233 114 205 33 19 10 <1 66 50 250 312 80 21 32 158 <1 26 191 89 178 111 9 6 53 510 101 68 60 8 24 26 33 26 388 156 106 229 109 205 110 29 9 <1 75 28 250 306 83 21 30 150 56 26 184 86 176 48 10 6 48 505 100 66 60 8 23 27 42 24 380 154 105 224 105 205 121 22 9 <1 79 55 250 301 85 20 28 142 <1 25 178 83 175 52 110 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 7 6 59 500 99 64 61 8 22 30 29 23 372 153 104 220 101 205 132 22 8 <1 69 66 250 295 87 19 27 135 <1 25 172 80 173 46 109 Rate (per 100 000 population)
Estimated incidence of TB (all forms) in all people, Western Pacific, 19902007

1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 5 6 59 495 98 62 63 15 21 27 34 21 365 151 103 215 97 205 33 22 7 <1 58 60 250 290 90 19 27 128 <1 24 166 77 171 15 108
1 990
1991
1992
1993
1994
American Samoa 10 3 1 4 4 6 0 7 3 4 3 3 2 3 6 7 4 3 Australia 1 120 1 142 1 133 1 174 1 197 1 243 1 277 1 211 1 196 1 156 1 188 1 165 1 129 1 159 1 172 1 252 1 274 1 295 Brunei Darussalam 148 153 157 162 166 170 175 179 184 302 341 240 256 229 196 181 224 230 Cambodia 56 742 58 170 59 596 60 984 62 286 63 473 64 536 65 485 66 329 67 087 67 773 68 391 68 946 69 458 69 956 70 460 70 976 71 504 China 1 338 563 1 341 945 1 343 909 1 344 766 1 344 997 1 344 933 1 344 658 1 344 043 1 342 951 1 341 180 1 338 609 1 335 229 1 331 154 1 326 540 1 321 589 1 316 456 1 311 184 1 305 770 China, Hong Kong SAR 5 355 5 308 5 316 5 331 5 245 5 233 5 436 5 837 5 600 5 310 5 056 5 244 5 220 4 915 4 745 4 640 4 552 4 461 China, Macao SAR 258 264 248 251 280 358 421 439 409 374 374 355 334 292 282 283 292 301 Cook Islands 0 1 7 6 4 2 1 2 0 3 1 2 1 0 1 1 1 2 Fiji 366 350 336 323 311 299 286 274 262 251 240 229 219 209 199 190 182 174 French Polynesia 66 54 92 87 99 116 96 101 117 103 69 69 71 56 67 70 77 71 Guam 69 69 67 78 104 68 67 67 66 66 60 70 57 65 56 70 49 59 Japan 58 085 56 533 55 276 52 967 50 773 48 402 47 566 47 914 47 425 46 380 43 196 40 220 37 326 35 177 33 074 30 708 28 857 26 994 Kiribati 369 368 366 363 361 359 357 356 354 354 353 352 352 351 351 350 348 347 Lao PDR 7 278 7 425 7 571 7 714 7 850 7 976 8 092 8 198 8 294 8 379 8 454 8 518 8 572 8 622 8 671 8 726 8 786 8 851 Malaysia 21 435 21 843 22 239 22 629 23 021 23 422 23 834 24 250 24 662 25 057 25 426 25 765 26 078 26 370 26 649 26 920 27 183 27 439 Marshall Islands 143 144 144 143 141 140 137 135 133 131 129 128 127 127 127 127 127 128 Micronesia 182 179 177 174 171 166 161 155 148 142 137 132 127 123 119 116 112 108 Mongolia 4 552 4 649 4 731 4 800 4 858 4 908 4 950 4 983 5 011 5 040 5 073 5 111 5 155 5 203 5 252 5 301 5 351 5 400 Nauru 8 13 13 13 4 13 13 13 12 2 4 3 6 3 11 12 13 3 New Caledonia 159 156 156 116 108 97 116 98 100 87 104 68 72 42 68 52 53 52 New Zealand 346 351 325 331 356 384 374 364 397 405 410 368 383 381 382 368 334 299 Niue 1 1 1 1 1 1 2 0 0 1 0 0 4 0 0 0 0 0 Northern Mariana Islands 31 47 74 51 51 53 57 103 108 73 83 64 59 50 59 63 57 49 Palau 10 7 4 28 46 21 6 17 10 36 10 10 12 10 6 11 13 12 Papua New Guinea 10 307 10 577 10 854 11 141 11 439 11 748 12 068 12 399 12 738 13 081 13 426 13 773 14 120 14 466 14 808 15 144 15 473 15 796 Philippines 240 889 242 185 243 429 244 606 245 697 246 693 247 584 248 379 249 118 249 848 250 599 251 377 252 160 252 917 253 609 254 203 254 694 255 084 Rep. of Korea 70 946 62 852 56 587 49 299 47 082 44 219 42 424 39 654 36 967 32 769 33 691 34 743 39 234 38 162 39 381 40 867 42 044 43 222 Samoa 51 50 49 48 47 46 45 44 43 42 41 40 40 39 38 37 36 35 Singapore 1 493 1 541 1 614 1 566 1 598 1 632 1 723 1 791 1 752 1 680 1 505 1 419 1 373 1 337 1 290 1 210 1 193 1 176 Solomon Islands 980 956 934 912 890 869 848 828 807 787 767 748 728 709 690 671 652 634 Tokelau 1 1 1 1 0 2 0 1 1 0 0 0 1 0 1 0 0 0 Tonga 32 31 31 31 30 30 29 29 28 28 27 27 26 26 25 25 24 24 Tuvalu 28 27 27 26 25 25 24 23 23 22 21 21 20 20 19 19 18 18 Vanuatu 207 206 205 204 203 201 198 195 192 189 186 184 183 181 180 178 176 174 Viet Nam 133 898 135 536 137 147 138 678 140 063 141 262 142 255 143 066 143 754 144 399 145 058 145 748 146 453 147 156 147 831 148 461 149 044 149 588 Wallis & Futuna 9 24 4 12 12 7 9 16 8 8 8 1 21 17 7 8 7 2
WPR
1 954 134 1 953 163 1 952 822 1 949 018 1 949 523 1 948 576 1 949 824 1 950 655 1 949 201 1 944 776 1 942 425 1 939 819 1 940 021 1 934 413 1 930 914 1 927 186 1 923 413 1 919 306
Table A3.4
Prevalence of TB (all forms) 2000 8 6 108 758 269 78 87 12 42 40 44 45 546 344 135 431 173 297 44 51 11 <1 135 104 486 600 113 27 39 300 <1 34 422 143 248 103 260 255 250 235 218 207 201 197 20 20 19 18 17 16 16 16 <1 <1 <1 <1 <1 <1 <1 <1 6 6 85 750 265 79 82 29 35 42 45 41 607 337 133 381 171 273 56 43 10 <1 120 102 482 578 112 33 36 286 <1 42 408 128 243 13 5 6 78 728 259 78 78 11 36 32 44 39 587 330 132 382 152 258 57 34 10 506 95 69 477 561 126 28 34 277 112 35 394 149 235 275 6 6 73 712 241 73 67 <1 29 29 47 36 477 324 128 358 142 258 48 28 10 <1 83 64 471 542 108 28 32 254 <1 36 381 128 234 147 9 6 63 696 220 69 61 15 33 28 41 34 439 313 128 263 128 233 162 29 10 <1 80 31 463 534 112 24 31 229 112 39 368 118 226 63 11 6 55 676 206 67 60 9 31 31 42 32 419 298 126 256 124 232 121 29 9 <1 83 102 453 520 118 27 28 204 <1 32 245 131 227 57 9 6 59 672 200 65 61 16 30 31 39 30 405 291 123 242 112 217 174 25 8 <1 83 74 441 505 122 26 27 197 <1 34 261 104 222 60 5 6 65 664 194 63 63 31 30 32 36 28 423 289 121 281 100 234 33 25 7 <1 72 71 430 500 126 25 27 180 <1 28 203 102 220 25 1 <1 9 83 19 7 8 <1 5 5 4 4 62 27 15 47 20 37 4 4 1 <1 10 8 56 57 9 3 4 33 <1 3 40 16 23 11 <1 <1 7 83 19 7 7 10 4 5 5 4 71 27 15 44 19 36 8 4 <1 <1 13 7 54 53 8 4 4 32 <1 5 39 14 22 2 <1 <1 6 80 19 7 7 2 4 3 6 4 68 26 15 43 17 34 5 3 <1 82 8 6 49 50 9 2 4 30 24 3 37 16 21 28 <1 <1 7 78 18 6 6 <1 3 3 5 3 55 26 14 41 16 35 5 3 <1 <1 9 8 46 46 9 3 3 28 <1 3 36 15 21 12 <1 <1 7 78 16 6 5 5 4 2 5 3 45 25 14 30 15 29 19 2 <1 <1 7 5 42 45 9 3 3 26 12 4 35 14 21 5 <1 <1 6 76 15 6 4 1 4 3 3 3 49 23 14 29 14 28 6 2 <1 <1 6 12 41 43 10 3 3 24 <1 3 29 15 21 4 1 <1 5 77 15 5 4 2 3 2 5 3 46 23 14 28 13 21 24 2 <1 <1 8 6 40 41 10 3 2 23 <1 3 30 12 20 7 <1 <1 7 77 15 5 5 4 3 3 2 3 49 22 13 32 9 29 3 2 <1 <1 7 8 44 41 10 3 3 21 <1 2 17 12 20 3 <1 <1 <1 29 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 27 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 <1 <1 <1 <1 24 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 5 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 21 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 6 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 19 <1 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 6 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 16 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 4 <1 <1 <1 <1 <1 <1 <1 <1 <1 7 <1 <1 <1 <1 <1 <1 <1 <1 <1 3 <1 <1 <1 <1 14 <1 <1 <1 <1 <1 <1 <1 <1 <1 1 5 <1 <1 <1 <1 <1 <1 <1 <1 <1 10 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 <1 <1 <1 13 <1 <1 <1 <1 <1 <1 <1 <1 <1 2 5 <1 <1 <1 <1 <1 <1 <1 <1 <1 17 <1 <1 <1 <1 <1 <1 <1 <1 <1 4 <1 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 2000 2001 2002 2003 2004 2005 2006 2007 Mortality (excluding HIV+) Mortality HIV+
Estimated incidence, prevalence and mortality rates (per 100 000 population), Western Pacific, 20002007
2000
2001
2002
2003
2004
2005
2006
2007
<1 <1 75 1 <1 <1 <1 10 <1 <1 9 <1 <1 <1 7
<1 <1 71 1 <1 <1 1 11 <1 <1 11 <1 <1 <1 9
<1 <1 66 2 <1 <1 2 13 <1 <1 15 <1 <1 <1 10
<1 <1 60 2 <1 <1 2 14 <1 <1 19 <1 <1 <1 12
<1 <1 54 2 <1 <1 3 15 <1 <1 24 <1 <1 <1 13
<1 <1 47 2 <1 <1 3 15 <1 <1 31 <1 <1 <1 13
<1 <1 43 2 <1 <1 4 16 <1 <1 39 <1 <1 <1 14
<1 <1 38 2 <1 <1 5 17 <1 <1 46 <1 <1 <1 14
WPR
Table A3.5
Case notifications and case detection rates, DOTS and non-DOTS combined, Western Pacific, 2007
Population All notified New and relapse . thousands number number rate 3 372 8 7 120 430 634 2 779 147 0 0 0 54 87 88 88 95 43 57 119 127 81 90 82 90 34 27 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 0 479 202 106 61 535 436 0 4 304 90 90 94 54 80 96 50 90 90 31 75 56 33 63 27 64 37 47 49 32 45 14 62 29 37 36 5 27 47 1 13 13 25 1 2 1 1 153 6 122 358 6 0 293 0 4 4 0 0 0 96 3 087 2 844 0 0 0 0 0 17 33 1 1 90 0 0 0 0 0 0 0 0 0 0 0 12 214 2 4 35 0 0 0 0 0 0 0 0 1 532 18 0 542 2 0 191 1 0 13 0 0 0 1 181 974 3 101 0 0 0 0 0 76 0 0 3 0 0 0 0 0 0 0 57 62 38 14 657 103 3 080 15 506 33 31 1 856 0 32 158 0 14 5 2 647 86 464 16 230 67 90 90 78 66 78 80 33 97 76 90 90 60 88 37 10 51 57 88 70 16 43 73 100 44 43 55 30 9 38 31 79 59 12 34 40 100 26 30 36 17 8 21 44 7 13 23 20 39 1 3 4 7 7 4 7 7 4 12 25 9 6 0 0 41 49 90 61 80 75 102 43 94 73 52 35 48 25 66 55 48 28 40 38 25 24 4 13 8 4 6 4 11 10 13 7 32 43 9 051 78 437 4 086 97 62 673 0 15 108 0 28 3 5 731 49 422 18 778 34 11 4 5 142 147 266 2 107 36 28 1 832 0 16 75 0 2 3 7 088 1 513 5 005 0 428 51 8 412 36 612 693 29 0 0 0 0 34 12 648 46 379 390 28 0 0 0 75 2 534 1 0 0 2 0 20 2 814 21 4 0 11 0 799 61 089 160 14 0 5 2 0 634 136 19 421 465 877 3 273 250 90 83 85 49 71 111 104

8 4 16 11 2 0 0 0 0 2 0 0 8 62 302 4 033 4 450 68 661 4 438 631 675 1 919 306 0 0 1 32 0 0 0 0 0 7 0 0 0 0 0 861 142 0 14 14 79 564 147 0 5 1 38 17 554 1 548 024 88538 858 539 181 99 0 4 2 43 18 675 0 110 9 0 0 1 0 6 714 0 1 0 0 0 0 0 599 0 6 0 0 0 0 0 345 0 3 1 295 230 71 504 1 305 770 4 461 301 2 174 71 59 26 994 347 8 851 27 439 128 108 5 400 3 52 299 0 49 12 15 796 255 084 43 222 35 1 176 634 0 24 18 174 149 588 2 95 97 70 61 90 68 129 152 52 82 90 78 74 92 52 76 50 55 61 67 34 56 50 49 17 11 35 19 6 6 8 10 0 579 151 31 621 585 126 2 007 135 1 78 21 6 12 135 156 3 954 11 904 57 49 2 429 3 13 134 0 16 6 6 815 114 701 19 409 16 525 285 0 11 8 78 66 109 1 38
3 1 133 209 36 495 1 045 939 5 545 401
3 1 115 207 35 601 979 502 5 363 342
4 5 53 246 74 74 71
0 281 136 19 421 465 877 1 501 138
0 1 35 134 35 21 29
67 20 743 390 14 444 1 328 630 7 206 481 13 839 263 173 127 967 95 5 859 26 572 59 111 2 629 10 242 4 179 2 84 20 6 331 87 960 48 224 187 4 436 496 1 100 11 226 87 375 15
94 64 54 25 311 352 4 010 16 918 163 145 4 970 4 47 287 0 44 11 16 183 142 576 45 597
94 64 53 24 779 334 3 905 16 129 158 137 4 654 3 47 274 0 44 11 15 002 140 588 37 554
11 24 31 19 351 67 61 267 123 177 30 19 7 0 52 54 237 160 78
52 19 5 9 433 103 3 080 9 578 19 47 1 856 3 12 81 0 14 5 2 087 86 566 10 927
6 7 3 7 108 53 36 32 42 71 30 5 2 0 17 25 33 98 23
1 405 397 0 23 18 122 98 344 2
1 359 397 0 23 18 122 97 400 2
31 80 0 23 171 54 111 13
504 142 0 14 12 41 54 457 1
11 29 0 14 114 18 62 7
WPR
1 776 440
1 446 866
1 365 284
77
666 412
Table A3.6
. . Other number 0 5 2 0 0 0 54 87 88 87 95 43 57 119 127 81 90 82 90 34 27 0 0 0 0 0 76 0 0 3 0 0 0 0 0 0 0 67 90 90 77 66 78 80 33 97 76 90 90 60 88 37 10 51 57 88 70 16 43 73 100 44 43 55 30 9 38 31 79 59 12 34 40 100 26 30 36 17 8 21 44 7 13 23 20 39 1 3 4 7 7 4 7 7 4 12 25 9 6 49 90 61 80 60 102 43 94 73 52 36 48 25 66 55 48 29 40 38 25 24 4 13 8 4 6 4 11 10 13 New pulm. lab. confirm. number Estimated incidence and case detection rate Estimated incidence DOTS case detection rate all forms ss+ all new new ss+ number number % % Proportions . ss+ ss+ Extrapulm. Re-treat. (% of (% of (% of (% of pulm.) new+relapse) new+relapse) new+re-treat.)
DOTS coverage, case notifications and case detection rates, Western Pacific, 2007
DOTS coverage % 0 428 51 8 412 36 612 546 29 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6 0 0 0 0 0 106 61 96 50 479 2 858 535 151 974 660 90 90 31 54 17 47 49 90 90 15 75 14 33 63 37 64 37 32 45 21 62 32 37 36 5 27 42 1 1 13 25 2 4 21 11 2 1 2 1 1 151 6 122 358 6 0 293 0 4 4 0 0 0 96 3 087 1 149 0 0 0 0 0 17 33 1 1 90 0 0 0 0 0 0 0 0 0 0 0 12 214 2 4 35 0 0 0 0 0 0 0 0 1 527 18 0 542 2 0 191 1 0 13 0 0 0 57 62 38 14 597 103 3 080 14 692 33 31 1 856 0 32 158 0 14 5 1 147 86 464 4 063 34 11 4 5 102 147 266 2 107 36 28 1 832 0 16 75 0 2 3 2 108 1 513 113 0 0 0 0 34 12 648 46 379 292 28 0 0 0 75 2 534 0 0 0 2 0 20 2 814 17 4 0 11 0 799 61 089 138 14 0 634 136 19 421 465 877 2 474 250 90 83 85 49 71 87 104
100 100 100 100 100 100 100
3 1 115 207 35 601 979 502 4 157 342
4 5 53 246 74 58 71
0 281 136 19 421 465 877 1 204 138
0 1 35 134 35 17 29
3 372 8 7 120 430 634 2 115 147
100 100 100 99 100 100 100 96 89 100 100 100 100 100 100 100 14 100 100
94 64 53 24 674 334 3 905 16 129 158 137 4 654 3 47 274 0 44 11 5 049 140 588 8 707
11 24 31 19 351 67 61 267 123 177 30 19 7 0 52 54 80 160 18
52 19 5 9 400 103 3 080 9 578 19 47 1 856 3 12 81 0 14 5 1 051 86 566 2 764
6 7 3 7 108 53 36 32 42 71 30 5 2 0 17 25 17 98 6
7 32 43 9 021 78 437 4 086 97 62 673 0 15 108 0 28 3 1 794 49 422 4 681
0 0 0 0 2 0 0 8 60 507 3 832 4 161 65 012 951 616 335 1 919 306 858 539 0 0 1 95 97 70 61 90 66 129 152 52 82 90 77
32 0 0 0 0 0
7 0 0 0 0 0
861 142 0 14 14 79
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna 181 99 0 4 2 43 18 675 0 78 479 110 9 0 0 1 0 6 714 0 1 0 0 0 0 0 599 0 6 0 0 0 0 0 345 0 74 92 52 76 50 55 61 67 34 56 50 50 17 11 35 19 6 6 8 10
100 100 0 100 100 83 100 100
1 359 397 0 23 18 122 97 400 2
31 80 0 23 171 54 111 13
504 142 0 14 12 41 54 457 1
11 29 0 14 114 18 62 7
564 147 0 5 1 38 17 554 1
3 1 295 230 71 504 1 305 770 4 461 301 2 174 71 59 26 994 347 8 851 27 439 128 108 5 400 3 52 299 0 49 12 15 796 255 084 43 222 35 1 176 634 0 24 18 174 149 588 2
0 579 151 31 621 585 126 2 007 135 1 78 21 6 12 135 156 3 954 11 904 57 49 2 429 3 13 134 0 16 6 6 815 114 701 19 409 16 525 285 0 11 8 78 66 109 1
WPR
100
1 325 173
75
656 883
37
529 296
Table A3.7
Collaborative TB/HIV activities 2006 TB pts tested for HIV TB pts HIV-positive 0 0 1 101 679 17 0 0 610 519 9 1 0 3 460 0 14 245 34 557 4 075 360 0 15 0 2 922 1 187 41 4 0 25 0 16 79 25 5 0 793 148 0 50 3 238 251 0 17 0 0 13 19 4 0 39 2 56 236 145 31 0 8 0 16 66 6 1 TB pts HIV-positive Lab-confirmed MDR DST in new cases MDR Re-treatment Re-treatment in new cases DST MDR HIV+ TB pts CPT HIV+ TB pts ART TB pts tested for HIV HIV+ TB pts CPT HIV+ TB pts ART 2007 Management of MDR-TB, 2007
Laboratory services, collaborative TB/HIV activities and management of MDR-TB, Western Pacific, 20062007
127 1 201 3 294 26 1
33 1 3 327 20 1
6 1 1 187 3 1
127 1 186 3 294 21 1
4 3 3 0 0 0 0
1 2 2
0 2 2
4 2 3 0
3 423 4 4 721 1 440 4 511 399 0 67 26 40 57 19 58 16 104 0 0 0 75
0 15 4 1 628 108 33 4 0 3 0 0
0 3 0 954 26 21 0 0 2 0 0
0 1 0 385 60 15 2 0 2 0 0
154 29 10
2 42 38 4 457 0 0 1

0 404 13 039 103 18 1 0 25 131 0 50 9 424 10 082 98 11 149 0 0 0 0 0 0 0 0 0 0 0 0 0 75 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 21 106 0 41 11 117 46 155 1 629 0 0 3 0 0 4 0 0 0 17 0 9 0 42 271 0 14 4 0 16 0 1 2 0 0 0 0 0 0 0 4 180 0 4 17 0 0 0 0 325 65 0 0 2 0 0 0 0 270 0 0 0 26 0 0 0 2 1 443 0 0 0 0 0 32 0 0 0 91 1 438 0 0 1 0 0 10 0 0 0 0 91 0 0 0 1 0 0 0 85 0 0 0 1 0 0 0 0 0 58 0 0 41 1 1 123 0 0 2 0 0 0 0 568 0 0 0 0 0 0 1 098 551 95 300 6 679 1 946 1 214 0 0 0 0 948 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 827 0 0 0 0 0 0 10 231 3 0 0 0 0 0 0 89 105 0 0 0 0 0 0 1 596 1 0 0 0 0 0 0 468 4 0 0 0 0 14 230 2 39 650 4 043 0 0 0 0 0 708 0 3 0 23 0 0 14 377 2 0 0 0 0 0 627 0
3 4 37 0 1
2 155 656 3 4 37 1 3 10 1 1 1 70 2 374 260
0 0 18 1 0 1 0 3 10 1 1 1 1 3 12
0 3 1 0 1 0 1 3 1 1 1 0 3 1
1 1 1 34 2 374
4 9
2 0
2 0
4 0
1 1 6 737 1
1 0 0 17 1
0 0 0 2 1
1 1 6
WPR
7 997
463
224
6 262
Table A3.8
% Not eval. Success 31 Number of cases Notified Regist'd Success Number Regist'd % New smear-positive cases, non-DOTS % % of cohort % of notif ComplTrans- Not . regist'd Cured eted Died Failed Default ferred eval. Success Smear-positive re-treatment cases, DOTS % of cohort ComplTrans- Not Cured eted Died Failed Default ferred eval.
Treatment outcomes, Western Pacific, 2006 cohort
% of notif regist'd
0 370 153 19 349 470 436 1 238 144 0 0 0 1 11 0 299 299 100 3 1 2 1 0 2 91 4 1 0 2 1 3 3 8 11 2 3 2 2 0 0 0 0 1 3 85 84 93 94 78 88 7 100 48 85 47 45 79 0 37 5 25 45 4 0 6 2 5 3 0 0 2 2 13 0 1 0 2 1 7 0 7 0 4 5 2 0 87 100 85 89 72 91
155 120 100 100 100 100
13 84 90 92 72 88
72 0 3 2 6 0
6 5 3 1 5 4
0 67 3 1 389 78 146 509 33
0 0 0 0 0 2 6
50 13 20 78 19 31 50 41 31 60 5 17 6 0 30 12 7 8 5 6 0 9 2 0 4 1 0 0 12 9 13 2 6 0 0 5 1 0 4 6 0 0 2
50
50 45 80 82 35 38 50 72
100 108 100 85 98 100 100 98 190 100 100 100 104 0 0 2 0 0 0 91 47 52 9 19 32 0 13 2 26 28 1 7 0 4 11 71 0 0 90 29 10 0 0 1 2 0 0 5 3 0 1 3 7 1 1 0 0 0 0 0 4 0 1 029 15 170 995 16 2 531 0 7 20 0 0 0 0 0 32 0 0 47 56 50 1 0 0 0 0 0 0
66 85 90 20 61 88 46 73 60 84 50 89
0 0 33 29 3 3 2 29 4 50
30 4 0 6 1 2 3
70
4 12 5 21 10 5 6 11 6 2 0 11 7
0 0 0 15 0 0 40 7 0 0 0 0 8
66 85 90 53 90 92 48 75 90 88 100 89 70
71 90
73 26 21 8 562 126 3 047 9 414 44 78 2 129 2 9 101 0 26 5 1 494 85 797 3 422 0 0 2 1 1 467 8 082 47 60 3 293 2 261 63 69 17 3 29 40 5 1 18 0 4 1 0 0 5 5 4 0 2 21 1 0 3 0 0 1 1 5 0 2 1 0 84 90 0 0 21 4 3 15 20 0 2 15 0 0 0 2 0 85 60 73 88 81
173 83 101 100 100
42 40 59 80 78
42 20 15 8 2
0 20 3 2 1
80 72 76 100
100 100
70 73
14 16
14 3
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna 0 0 2 1 0 1 1 3 1 92 8 970 346 4 4 3 6 1 2 2 82 8 0 25 0 2 0 0 0 5 2 0 0 0 0 1 0 100 75 90 92 100 164 5 0 0 0 0 7 500 0 96 159 79 80 4 6 6 3 5 3 3 2 3 5 1 0 0 0 0 0 0 0 1 83 87
3 238 128 19 294 468 291 1 238 144 0 73 24 21 10 068 129 3 041 9 414 45 41 2 129 2 9 97 0 15 6 1 481 85 740 3 431 13 537 124 0 14 4 42 56 437 0
537 124 0 14 4 42 56 470 4
100 100 100 100
100 75 88 90 50
2 2 50
0 0 2 3 0
WPR
662 273
663 261
100
89
Table A3.9
After failure, DOTS % of cohort Not eval. Died 0 76 20 57 4 43 12 0 24 0 32 0 4 0 4 0 24 100 18 6 0 0 0 0 94 0 0 0 0 100 0 0 Died 0 0 0 51 51 25 7 4 14 27 4 0 0 55 0 0 0 0 0 0 2 8 85 100 85 89 75 88 0 1 0 17 % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success Number regist'd ComplCured eted TransFailed Default ferred Not eval. % Success After default, DOTS % of cohort
DOTS re-treatment outcomes, Western Pacific, 2006 cohort
Number regist'd
ComplCured eted
Died
0 54 3 660 47 526 312 25
9 100 80 85 68 44
76 0 5 5 7 44
6 0 7 2 6 4
0 0 2 2 10 0
2 0 3 1 6 0
7 0 3 5 1 0
50
50
50
0 0 0 17 23 65 26 0 17 18 17 6 0 0 13 12 9 0 17 65 43 85 26 5 9 0 4 0 1 5 6 5 5 0 49 90 34 0 20 164
0 0
18 75 78 35 31 50 52 91 0 47 20 7 20 4 1 1 67 0 35 0 40 26 9 9 11 6 0 66
37 0 5 3 6 0 16
15 25 8 5 6 0 12
3 0 4 0
8 0 2 5
1 0 2 5
0 12
0 4
0 3
18 0 0 46 56 50 1
54 75 83 38 38 50 68
60 0 0 0 3 0 2 0 72 100 100 0 0 0 0 0 0 100 69 25 0 0 0 82 66 597 0 55 18 5 9 6 4 2 74 242 120 53 53 25 4 10 0 3 1 9 23 0 19 6 0 0 0 0 0 0

0 0 60 89 78 57 94 0 1 87 1 341 58 11 6 13 6 4 2 69 1 010 50 16 85 4 0 0 0 0 0 558 0 64 3 5 16 5 6 1 67 58 17 10 7 1 2 16 0 0 0 0 0 363 0 10 11 3 5 0 8 75 66
4 0 688 4 133 381 16 2 274 0 5 9 0 0 0
89
40 11
2 225 1 174
67 64
15 2
5 2
4 1
4 5
3 27
57 60
16 40
24 0
0 0
2 0
0 0
109 5 0 0 0 0 6 571 0
81
WPR
60 180
82
Table A3.10 DOTS treatment success and case detection rates, Western Pacific, 19942007
2003 90 22 40 15 88 90 51 63 90 58 90 83 90 150 34 29 44 32 48 32 2004 2005 2006 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2001 2002
1994
1995
1996
1997
1998
1999
2000
100
66
84 94
91 96
94 96
91 96
50 75 85 95 97 85 85 84 93 94 78 88 136 90 54 90 164 90 54 90 49 90 61 80 60 102
75 100 90
100 74 63 91 95 76 89
100 66 56 92 96 78 86
100 82 60 93 94 78 88
67 85 71 91 94 80 89
90 29 90 54 30 64
90 23 90 50 31 67 95
100 86 67
100 86 95
81 100 91 100
90 74
90 19 90 48 31 61 98 90 71
90 9 90 62 43 66 99
90 42 90 62 80 60 110
70 69 64 18 12 8 31 90 90 65 90 50 60 67 90 90 19 6 29
55
65
83 80 24 68
7 33
33 40
37 45
83
64
80
78 75 36 90 90 7 9 62 89 39 126 80 123 67 196 95 26 8 18 7 44 8 52 90 90 94 68
86
84
86 83 96 76 88 79 72 90 92 87 80 100 57 94 86 56 90 80 88 90 32 40 41 73 26 13 71 90 90 41 46 63 48 69 35 47 66 90 90 62
90 32 90 62 64 64 101 90 69 90 90 51 90 57 67 68 65 77 90 90 90 78 82 77 80 79 82 88 90 90 65 67 90 90 77 66 78 80 33 97 76 90 90 60
90 39 90 68 80 61 107 90 74 90 90 67 79 72 72 84 62 78
62
75
70
100 84 76 93 96 78 78 67 92 85 94 76 88 79 90 82 95 86 50 77 85 97 93 70 91 77 78 91 93 87 25 89 30 81 63 88 0 30 73 62 30 85 70 16 32 70 60 28 35 107 51 33 85 80 71 75 86 76 79 86 100 87 100 84 9 66 85 90 53 90 92 48 75 90 88 100 89 70 58 90 90 23 34 40 73 19 24 61 90 90 40
75 80 71 93 94 77 93 100 71 89 85 60 93 90 70 87 50 88 67 94 60
80
64
67
75
80 71 50 88 92 85 81 77 87 67 106 84 90 93 92 83 77 88 89
76 80 86 65
82 71 100
93 83 82
72 84
66 87
74 100 67 88 90 1 3 56 71
75 80 58 88 82
85 60 73 88 81
90 25 90 57 30 65 90 90 75 90 90 37 52 48 70 31 38 72 90 90 51 90 90 90 15 57 90 90 15 75 14
86
94 95
73
92
92
100 78 84 92 93 79 89 100 78 82 68 76 94 75 76 100 91 87 50 85 60 100 71 38 53 88 83 84 87 90 88 100 65 87 80 100 81 87 0 60 45 27 24 73 100 71 89 83 91 83 85 90 90 17 64 26 69 57 43 90 90 18 69 23 65 87 49 90 90 20 71 20 66 102 56 90 90 22 75 18 80 101 42 96 50
89
75
82
75
94
80
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna 88 92 30 15 28 31 33 31 37 38 39 59 78 83 92 93 90 91 91 92 92 88 93 100 79 92 100 75 92 100 90 93 100 28 83 31 82 58 84 90 38 87 90 73 100 81 92 49 86 90 50 100 75 90 92 100 73 89 65 98 60 44 84 90 77 127 49 53 86 77 129 152 52 82 90 77
91
91
90
85
93
88 92
WPR
90
91
93
93
95
94
Table A3.11 New smear-positive case notification by age and sex, DOTS and non-DOTS, Western Pacific, 2007
5564 37 17 1 644 70 376 425 13 4 0.9 0.5 0.7 2.3 1.1 1.5 2.0 0.7 0.7 1.2 5.0 0.8 1.3 4.0 1.3 2.4 1.5 3.0 1.0 1.8 1.0 0.6 2.8 112 114 102 025 125 374 2.3 144 11 0 5 2 4 11 170 0 4 0 64 1 235 1 2 26 6 749 29 960 59 10 37 6 1 351 24 914 94 4 20 12 1 698 23 542 74 6 12 15 2 105 18 129 64 8 7 9 1 839 17 647 37 3 23 2 1 459 21 339 137 6 7 0 114 2 113 6 2 56 11 1 632 73 971 122 24 70 16 2 877 71 288 174 16 40 27 3 888 79 766 184 20 27 36 4 207 73 089 241 38 21 19 3 600 73 935 212 19 60 19 3 103 91 715 562 19 1.2 1.6 1.1 2.4 2.2 2.5 65+ 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544 Male/female ratio
014
1524
2534
Male 3544
4554
3 0 50 878 5 0 1 0 1 174 10 361 1 394 1 1 48 0 3 4 0 0 1 50 8 481 906 80 8 0 1 0 2 5 046 0 91 686 2 102 39 574 37 234 34 619 28 916 26 189 33 688 3 828 99 401 108 791 119 903 105 6 0 5 2 2 7 026 0 1 5 0 0 2 1 59 0 13 12 0 3 0 6 1 939 0 13 25 0 1 0 8 2 354 0 25 9 0 1 0 1 1 923 0 23 10 0 0 1 6 2 170 0 11 5 0 0 3 1 1 891 0 39 5 0 0 0 2 4 144 0 1 10 0 0 3 2 107 0 28 27 0 5 1 9 5 526 0 31 41 0 2 0 10 9 785 0 88 21 0 1 2 5 10 314 0 121 19 0 0 1 8 10 621 1 91 13 0 1 3 3 6 937 0 0 3 678 3 350 1 395 0 0 34 0 2 8 0 2 0 6 4 862 1 684
30 5 883 44 011 63 14
33 10 1 526 46 374 80 12
20 15 2 190 56 224 110 14
15 21 2 102 54 960 177 30
14 10 1 761 56 288 175 16

7 1 0 3 8 7 226 1 5 23 0 0 1 0 0 0 32 380 34 11 1 0 134 13 126 1 098 3 11 273 0 0 14 0 0 0 148 4 389 570 4 1 0 318 6 175 1 101 3 6 250 0 0 7 0 2 0 153 5 594 807 6 5 0 231 8 215 849 2 2 139 0 1 8 0 1 0 84 5 291 466 5 0 1 156 9 293 782 3 2 80 0 0 6 0 1 0 36 4 612 387 1 3 1 212 4 206 585 3 2 36 0 0 6 0 1 1 15 3 313 347 2 2 1 1 832 2 207 514 0 0 29 0 1 4 0 2 0 3 2 217 1 716 8 1 0 4 10 18 442 1 6 27 1 0 1 0 0 0 48 846 50 18 1 0 276 28 276 2 389 4 19 553 1 1 25 0 0 0 326 12 913 1 159 11 3 0 690 13 433 3 325 4 11 520 0 1 8 0 2 1 324 17 375 1 760 13 7 2 743 18 522 2 931 4 6 371 1 3 15 0 4 0 196 19 101 1 610 9 2 1 824 15 711 2 621 8 2 238 0 1 10 0 5 2 103 17 458 1 695 2 3 1 1 386 14 567 1 979 4 3 84 0 3 10 0 1 2 65 11 794 1 253 6 2 1 5 510 5 557 1 909 0 0 63 0 3 12 0 4 0 9 7 079 3 400
0 1 2 11 216 0 1 4 1 0 0 0 0 0 16 466 16
0 142 15 150 1 291 1 8 280 1 1 11 0 0 0 178 8 524 589
7 2 0 372 7 258 2 224 1 5 270 0 1 1 0 0 1 171 11 781 953
7 2 2 512 10 307 2 082 2 4 232 1 2 7 0 3 0 112 13 810 1 144
4 2 0 668 6 418 1 839 5 0 158 0 1 4 0 4 2 67 12 846 1 308
0 5 0 0 1 1 48 0
15 15 0 2 1 3 3 587 0
18 16 0 1 0 2 7 431 0
63 12 0 0 2 4 8 391 0
98 9 0 0 0 2 8 451 1
WPR
1 726
59 827
71 557
85 284
83 198
75 836
Table A3.12 New smear-positive case notification rates by age and sex, DOTS and non-DOTS, Western Pacific, 2007
65+ 3 262 1008 140 105 80 24 0 33 383 249 0 76 26 3 0 0 0 5 0 3 5 3 0 2 0 3 11 1 0 0 2 4 3 1 8 2 4 2 16 2 18 2 24 7 91 92 84 105 37 73 44 64 76 62 0 48 14 4 74 92 76 109 58 98 22 98 57 76 0 60 1 6 19 44 40 53 69 48 135 57 180 73 180 80 1 5 21 47 50 79 86 82 167 93 264 121 270 159 0 0 3 1 0 6 2 18 44 28 13 24 3 15 137 25 16 11 1 40 202 20 10 12 1 84 337 22 9 17 1 122 450 31 10 14 2 33 476 39 29 29 0 0 2 1 1 3 2 16 47 33 14 29 2 21 147 35 16 24 1 46 245 33 14 23 1 88 376 43 19 41 1 99 515 64 29 40 2 152 660 87 64 52 014 1524 2534 Female 3544 4554 5564 65+ 014 1524 2534 4554 5564 65+ All 3544
014
1524
2534
Male 3544
4554
5564
0 0 2 1 1 0
2 14 51 38 14 34
2 27 158 44 16 40
1 51 294 46 19 39
1 91 425 63 29 66
1 85 607 95 47 62
0 0
0 2
11 10 0 4
14 9 15 6
9 13 0 8
0 13
5 3 0 0
14 4 0 2
7 5 0 4
12 25 0 3
11 0 10 2
3 36 15 2
9 26 16 12
3 1 0 0
11 2 0 2
9 8 0 4
13 17 8 4
10 7 5 5
4 17 7 7
16 14 9 21
1 5
23 50
60 105
104 115
200 127
359 166
5 1
60 92
67 112
81 124
0 134
38 90
0 0
5 4
5 0
11 2
7 1
30 2
1 3 0 57 80 168 51 310 130 1 28 28 24 27 34 41 1 34 40 40 51 66 83 2 0 26 22 50 32 8 31 74 50 21 86 57 159 2 0 19 31 31 66 20 85 48 123 30 161 54 229 0 29 15 22 0 0 0 0 23 15 11 0 19 76 0 5 5 25 5 66 6 35 6 62 4 51 18 68 0 5 5 27 6 51 11 40 15 59 18 66 36 74
28 96 17
36 170 24
31 269 27
29 354 35
40 385 40
8 312 83
3 2 1
25 51 18
32 82 21
22 104 11
15 124 11
12 145 15
4 114 59
2 3 1
26 74 17
34 126 23
26 187 20
22 238 23
26 263 27
6 202 69
0 5
5 29
6 38
16 46
24 57
32 81
17
14
42
American Samoa Australia Brunei Darussalam Cambodia China SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Islands Palau Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna
2 0
12 39
13 100
32 140
24 199
38 241
WPR
39
51
56
74
96
Table A3.13 TB case notifications, Western Pacific, 19802007

1985 3 950 1 073 14 603 515 764 6 212 402 2 203 3 192 93 14 857 504 758 6 501 570 1 200 86 16 946 445 704 7 673 465 0 166 105 10 903 345 000 6 283 329 1 247 49 4 225 89 94 44 425 253 1 135 11 708 43 078 830 11 778 172 2 780 90 365 0 97 11 291 162 360 34 661 22 2 120 295 30 18 178 87 468 834 599 30 83 107 3 592 42 122 327 1 440 12 691 59 126 4 062 42 190 464 1 923 13 539 44 016 276 2 149 14 115 49 123 2 915 40 800 255 2 420 14 908 41 15 172 363 804 6 319 9 1 016 143 6 501 375 481 6 510 343 0 226 59 51 821 68 1 826 11 702 4 1 057 0 6 1 145 160 15 629 466 394 7 072 575 2 171 91 3 899 4 1 073 272 19 266 449 518 5 605 3 1 115 207 35 601 979 502 5 363 342 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
6 1 386 285 1 980
7 729 585 2 180 66 41 65 867 187 50 612 91 1 951 11 059 26 350 1 611 140 335 104 274 1 25 7 451 178 134 46 999 49 1 830 367 21 184 77 838 14 870 920 31 86 10 520 119 914 21 782 43 1 728 302 0 24 16 152 89 792 820 469 32 89 786 285 34 94 104 352 2 51 5 3 195 165 453 39 315 31 1 951 299 0 22 126 74 711 8 873 425 31 86 12 658 107 133 37 268 22 1 536 292 0 12 16 175 90 728 1 805 105 35 97 88 321 0 93 15 7 977 195 767 33 215 32 1 977 318
10 970 7 367 1 659 7 143 348 0 28

5 952 128 7 906 310 607 6 704 274 2 218 73 75 53 112 121 2 952 10 686 7 68 2 233 0 128 303 61 371 0 53 5 12 743 130 530 34 389 34 1 414 340 12 115 98 173 811 482 35 97 29 13 101 95 044 19 8 906 212 10 325 265 095 7 432 420 3 199 85 49 56 690 129 1 514 10 735 37 60 2 819 8 98 320 5 16 13 2 877 153 129 88 789 65 1 760 292 0 35 27 131 47 557 28 3 3 396 217 272 70 012 37 1 617 488 0 36 26 144 52 270 30 2 497 317 008 63 904 44 1 591 382 1 23 23 140 50 203 33 28 114 52 994 11 718 783 33 92 724 290 33 92 824 954 29 81 894 073 32 89 760 863 31 86 754 463 35 97 6 3 401 207 371 57 864 44 1 841 309 1 20 30 230 59 784 22 741 913 35 97 140 317 2 67 4 2 540 236 172 48 070 26 1 778 364 1 29 30 193 56 594 4 173 1 730 4 97 352 2 46 41 5 335 180 044 38 155 45 1 677 332 0 23 19 152 51 763 11 87 391 0 48 19 8 041 119 186 42 117 45 1 889 352 2 20 36 79 55 739 6 3 348 2 78 447 1 66 32 13 003 145 807 32 075 31 1 805 289 0 22 14 120 88 879 651 840 35 97 655 006 36 100 716 427 36 100 9 907 189 9 106 251 600 7 269 389 2 173 80 34 56 496 110 3 468 11 068 32 98 2 433 6 74 296 0 56 38 2 251 163 740 87 419 29 1 616 334 9 24 22 90 55 505 34 13 954 126 10 691 304 639 7 021 320 0 162 63 41 54 357 208 7 279 10 944 11 77 2 538 8 111 295 3 27 17 4 261 183 113 74 460 29 1 666 372 1 14 24 118 52 463 1 1 1 011 180 16 148 320 426 6 534 294 6 240 83 60 48 956 100 994 11 420 52 111 1 516 4 991 160 13 270 344 218 6 537 285 5 183 78 70 48 461 99 2 093 12 285 61 151 1 418 3 1 043 307 18 891 454 372 6 015 449 1 144 62 54 39 384 252 2 227 15 057 34 91 3 109 4 94 344 0 75 3 980 216 19 170 470 221 6 788 465 2 183 62 63 35 489 189 2 418 14 830 56 104 3 526 3 61 377 0 58 2 1 013 230 24 610 462 609 6 277 388 1 148 64 51 32 828 196 2 621 14 389 51 127 3 829 5 65 329 4 53 11 11 197 118 408 34 967 31 1 516 256 3 949 206 28 216 615 868 5 914 371 0 185 50 22 31 638 284 2 748 15 671 60 99 3 918 3 38 386 0 45 9 12 798 132 759 33 843 27 1 581 293 0 16 30 104 92 741 15 5 1 059 176 30 838 790 603 5 684 309 1 134 60 50 29 736 310 3 162 14 986 117 118 4 542 6 1 046 163 35 535 894 428 5 660 355 1 132 63 63 27 194 332 3 777 15 342 111 98 4 601 11 47 332 0 57 10 12 564 137 100 38 290 24 1 356 397 0 18 12 76 94 916 7 4 1 159 202 34 660 940 889 5 536 374 1 114 69 44 25 304 378 3 958 16 051 138 104 5 049 12 48 344 0 51 12 12 620 147 305 37 861 25 1 313 371 0 18 9 126 97 363 94 64 53 24 779 334 3 905 16 129 158 137 4 654 3 47 274 0 44 11 15 002 140 588 37 554 1 359 397 0 23 18 122 97 400 2 980 890 1 160 130 1 274 124 1 331 512 1 365 284 36 32 36 35 34 100 89 100 97 94
2 1 457 196 2 576 0 8 065 1 101 8 210 76 55 70 916 146 7 630 11 218 6 0 1 160 0 108 474 1 0 17 2 525 112 307 89 803 59 2 710 266 0 64 33 178 43 062 23
1 094 2 128 448 0 26 10 2 508 116 821 98 532 49 2 425 313 1 49 18 92 43 506 24
6 1 270 245 8 158 98 654 7 527 233 12 163 65 49 63 940 193 4 706 11 944 12 67 1 325 8 120 437 2 75 17 2 742 104 715 100 878 43 2 179 324 0 45 12 173 51 206 5
8 1 219 276 7 572 117 557 7 301 455 15 185 78 48 62 021 127 4 700 11 634 15 73 1 514 0 171 415 3 74 14 2 955 106 300 91 572 41 2 065 302 0 50 23 196 43 185 17
12 1 299 256 10 241 151 564 7 843 671 3 165 80 54 61 521 111 6 528 10 577 12 75 1 652 0 144 404 1 58 20 3 505 151 863 85 669 37 2 143 337 0 54 9 188 43 875 14
5 1 088 238 10 145 226 899 7 545 571 8 230 78 37 58 567 103 4 258 10 569 15 66 2 994 0 104 359 0 64 26 3 453 151 028 87 169 43 1 952 377 2 49 32 124 46 941 14
WPR Number reporting % reporting
356 452 36 100
355 337 33 92
461 550 36 100
462 181 36 100
540 985 36 100
615 153 36 100
Table A3.14 TB case notification rates, Western Pacific, 19802007

1987 6 6 6 128 42 100 98 11 26 18 24 40 127 41 103 136 6 26 39 138 36 118 108 0 21 46 109 30 109 86 6 34 25 22 30 42 66 36 332 25 58 34 18 57 160 116 44 10 0 150 221 222 75 13 56 75 31 179 98 114 50 49 47 47 47 57 12 55 117 67 99 148 33 417 30 60 115 117 169 33 582 39 62 35 340 43 64 95 114 119 32 309 47 66 79 137 30 104 19 6 56 67 33 114 92 0 31 30 42 95 45 65 8 6 0 11 6 52 130 38 111 136 11 22 41 5 5 7 6 84 154 36 85 4 5 53 246 74 74 71 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
1980
1981
1982
1983
1984
1985
1986
6 10 102 38
18 9 143 29
160 437 45 33 50 52 61 267 246 82 20 41 124 46 59 54 354 71 80 10 57 8 44 155 167 272 106 30 56 107 34 289 70 75 78 72 100 55 54 53 103 103 96 46 46 51 21 195 157 47 24 43 73 0 24 157 80 114 29 126 51 117 127 73 229 138 79 12 37 68 0 12 156 90 113 7 53 9 91 85 29 66 236 87 18 54 80 0 23 31 80 0 23 171 54 111 13 75 77 44 9 0 149 83 161 273 73 19 53 83 26 9 0 68 25 215 158 72 19 33 74 381 75 77 84 10 0 64 60 518 149 27 53 122 62 24 244 94 76 59 50 49 39 80 331 134 27 59 96 63 21 315 150 88 158 78 9 89 135 25 58 368 110 16 56 110 64 30 312 122 82 29 45 11 0 83 111 171 174 94 27 54 97 135 21 367 46 76 42 136 20 37 12 51 99 169 248 195 69 18 46 71 0 22 138 65 114 11 24 31 19 351 67 61 267 123 177 30 19 7 0 52 54 237 160 78
150 226 11 28 42 38 56 333
78 22
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna 68 21 84 363 165 23 55 160 0 38 280 99 81 216 50 163 73 41 51 10 88 83 247 116 268 86 27 50 94 0 24 195 90 72 77 45 49
70 0 76 15 29
139 79 234 236 38 112 116 0 66 410 152 81 200
64 26 88 14 0 139 80 77 237 255 32 98 132 64 51 221 77 80 200
17 8 120 114 10 144 87 68 24 41 44 54 335 145 83 36 86 76 104 81 14 64 355 134 82 207 257 28 86 132 0 47 145 141 93 40
22 8 131 102 11 137 163 85 27 47 42 52 214 141 78 43 91 84 0 114 13 100 308 108 86 205 230 26 80 119 0 53 274 156 76 130
32 8 118 132 14 145 229 17 24 47 46 51 182 191 69 33 90 89 0 94 13 35 214 150 99 286 212 24 81 128 0 58 106 146 76 104
13 7 107 125 21 138 186 45 32 45 31 48 164 121 67 39 77 157 0 67 11 0 213 191 95 278 214 27 72 139 126 53 370 94 79 101
19 6 92 123 24 135 131 17 28 48 40 47 200 42 67 92 68 143 96 62 10 190 49 94 77 275 215 41 64 104 0 38 307 97 79
21 6 80 104 23 131 117 11 24 44 27 46 166 93 67 76 109 120 70 46 9 0 157 269 59 287 210 18 57 116 559 26 245 65 90 243
29 6 52 118 27 126 92 0 23 34 32 44 304 190 64 25 84 121 91 68 9 125 70 118 109 314 177 18 58 125 62 15 263 83 83 7
11 6 51 84 27 119 76 11 30 38 57 43 172 75 61 15 72 103 0 76 9
2 6 66 155 27 111 75 33 32 41 43 39 135 23 60 105 110 66
8 6 57 124 29 109 72 28 24 38 50 39 132 47 63 122 146 61
5 5 92 148 36 90 102 6 18 26 35 31 300 43 65 65 85 126 40 44 9 0 109
5 5 63 147 37 101 104 13 23 26 40 28 221 45 62 106 97 142 30 28 10 0 81
3 5 66 186 36 92 85 7 18 26 32 26 225 49 59 95 118 153 50 29 8 228 72 56 198 149 74 17 36 58
5 5 58 209 47 86 80 0 23 20 13 25 320 50 63 110 91 155 30 17 10 0 59 45 221 164 71 15 37 65 0 16 290 51 112 100
8 5 48 225 61 81 66 7 16 24 30 23 343 57 59 211 108 178
9 5 44 255 68 80 75 7 16 25 37 21 361 67 60 196 89 178 109 20 8 0 71 50 207 162 80 13 31 84 0 18 115 35 112 46
6 6 53 244 71 78 78 7 14 27 26 20 404 69 61 238 94 194 118 20 8 0 62 59 203 171 79 13 30 77 0 18 86 57 113
WPR
27
27
34
34
39
44
46
Table A3.15 New smear-positive cases notified, Western Pacific, 19902007

Number of cases 1996 0 2 203 100 9 2 3 24 8 0 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Rate (per 100 000 population)
1990
1991
1992
1993
1994
1995
1 557 68
11 058 104 729 0 0 12 6 10 33 10
0 0 65 33 11
3 285 102 15 744 201 775 1 536 7 41 27 28 8 97 103 11 17 0 28 34 62 11 6 9 9 17
0 281 136 19 421 465 877 1 501 138
0 84
1 75
6 75
84 898 2 429 108 5 61
11 101 134 488 0 141 2 68
12 065 203 670 1 774 258 1 69 37 22 8 18 28 14 13 132 241 36 24 0 9 3 0 50 66 0 0 34 10 32
6 226 0 12 686 236 021 1 943 325 2 66 41 13 865 202 817 2 091 276 0 74 34
17 890 99
4 62 38 40 16 770 184 13 571 50 1 234 7 496 12 909 59 1 706 8 207 17
14 367
6 954 12 9 455 26 106 0 26 6 20 15 2 0 9 1 171
6 861
478 6 688
12 867 144 886 7 271 12 14 769
11 935 52 1 494 7 802 11 14 1 356
2 285 115 18 978 384 886 1 693 128 1 62 30 22 10 471 142 2 226 7 843 39 35 1 808 10 184 18 34 23 8 13 19 32
16 91 0
145 2 28 61 0
2 251 84 14 822 204 765 1 940 160 0 62 29 43 11 853 54 1 526 8 156 11 15 1 389 4 20 74 0 27 52 19 5 9 433 103 3 080 9 578 19 47 1 856 3 12 81 0 14 5 2 087 86 566 10 927
2 228 95 14 361 204 591 1 857 157 2 73 0 47 11 408 64 1 563 8 309 15 8 1 631 2 19 68 0 19

26 90 1 26 4 447 86 695 11 420 9 519 90 0 14 2 107 69 476 10 359 7 482 140 16 38 54 889 379 698 383 613 376 109 371 806 372 528 453 812 579 566 671 612 671 243 666 412 < 1 59 58 394 8 141 130 38 30 13 11 16 26 45 32 0 17 18 21 10 37 11 66 50 016 1 416 954 50 48 911 3 388 142 1 933 67 056 8 216 13 248 109 0 15 0 63 53 169 23 0 38 56 698 1 <1 504 142 0 14 12 41 54 457 1 <1 14 15 20 1 351 59 341 11 805 11 357 118 0 8 0 57 54 238 1 24 83 0 21 7 1 195 80 163 9 957 14 436 113 1 210 112 17 258 194 972 1 892 147 1 74 28 31 10 807 82 1 829 7 958 18 22 1 670 2 21 88 1 21 9 1 345 65 148 11 345 19 549 108 15 111 0 14 5 1 896 78 163 11 471 11 501 152 11 13 2 2 0 45 24 43 53 23 35 9 138 124 26 25 9 5 13 14 30 24 68 0 9 14 61 17 28 51 66 21 21 24 25 1 513 2 22 94 1 15 20 2 140 73 373 9 559 17 465 93 0 10 0 43 53 805 23 2 113 121 18 923 267 414 1 794 138 0 78 21 0 10 843 99 1 866 7 989 20 26 1 541 1 12 106 0 16 5 2 310 72 670 10 976 12 583 138 0 11 0 40 55 937 7 23 22 22 22 26 33 38 38 38 3 241 101 21 001 472 719 1 561 136 1 63 21 27 10 931 124 2 806 8 446 48 32 1 868 0 16 83 0 15 3 1 805 81 647 11 638 11 552 169 0 11 5 35 55 492 1 3 269 128 19 294 468 291 1 537 144 0 73 24 21 10 159 129 3 041 9 414 45 41 2 129 2 9 97 0 15 6 1 948 85 740 11 513 13 537 124 0 14 4 42 56 437 11 4 5 4 3 2 3 3 5 5 0 1 1 2 1 1 1 1 1 1 1 1 0 31 25 28 32 34 31 27 34 35 106 113 126 116 110 130 140 138 150 136 134 19 16 16 16 16 15 21 29 36 35 35 30 32 23 29 28 28 26 24 22 22 21 77 64 36 35 32 30 27 29 30 29 11 0 0 0 13 7 0 7 7 0 8 9 8 8 9 9 10 8 8 9 6 18 15 14 12 0 11 8 12 8 9 7 28 30 19 0 13 16 12 3 11 9 10 9 9 8 8 8 9 8 7 63 64 71 64 75 94 112 157 135 138 108 25 30 33 29 29 34 34 40 50 53 53 35 35 36 35 35 33 32 31 33 36 36 21 33 21 28 34 37 70 85 78 32 8 13 14 7 20 24 32 29 37 42 48 56 62 56 66 67 61 71 72 82 71 20 40 20 20 10 0 20 30 12 13 10 9 9 9 5 7 7 4 5 2 3 2 2 2 2 3 3 2 2 2 0 0 51 0 0 57 0 0 0 0 0 34 40 22 39 27 29 21 18 19 18 17 39 106 46 25 25 15 30 25 24 41 41 36 24 24 40 32 30 31 33 112 95 98 88 76 82 90 94 97 99 98 22 22 21 18 25 24 23 24 24 24 23 8 4 10 7 6 11 7 6 6 7 12 13 12 6 9 13 14 12 13 12 11 30 36 23 26 28 25 31 33 36 26 29 0 0 0 0 0 0 0 11 16 10 15 8 23 11 8 11 14 14 0 0 0 0 0 48 38 114 37 21 23 33 29 19 20 28 16 19 18 66 71 69 67 68 70 68 70 65 65 62 7 7 7 47 7 7
11
92 279 16 630 21 513 155
16 2
87 401 13 266 18 861 114 0 17 1 62
21 78 0 14 9 1 652 94 768 11 754 15 455 109 1 9 6 30 37 550 3
WPR
84
76
81
222 813
241 737
314 271
Table A3.16 NTP budgets, available funding, cost of utilization of general health-care services and total TB control costs (US$ millions), Western Pacific, 2009
Available funding Loans Funding gap 0 0.1 Total TB control costs 0 0 0 Grants (excluding Global Fund) Global Fund Completeness of budget data Cost of utilization of general health-care services .
NTP budget
0.1
0.1
0.6 11 225 20 2.5 58
0.6 1.1 163 20
0 0 11 0
0 1.3 0.7 0
0 4.6 41 0
0 3.7 9.8 0
0.6 13 225 79
1.7 165 0.1 9.0 0 0 0 0 0 0 2.2 0.7 1.2 4.9 0 0 0 0.1 0 3.0 0 0 < 0.01 0 0 0
1.4
0.3
0.02
0.1 3.1 0.8 0.2
0.1 0.04 0.8 0.1
1.7 165 0.2 3.1 9.8 0.2
3.8
0.8
< 0.01 0.6 0.2 3.6 23 11
0 0.2 0.1 0.6 7.9
0 0 0 0 0
0 0.3 0.1 0.3 0
< 0.01 0 0.02 2.7 10
0 0.2 0.01 0 4.4
< 0.01 0.6 0.2 3.6 34
0.3 < 0.01
1.7 0 0.1 0 0 11 7 70 19 261 4.3 3.9 0 0.2 13
0.01 0 0.1 0.1
0 0 0 0
0 0 < 0.01 0
1.7 0 0 0
0 0 < 0.01 < 0.01
American Samoa Australia Brunei Darussalam Cambodia China China, Hong Kong SAR China, Macao SAR Cook Islands Fiji French Polynesia Guam Japan Kiribati Lao PDR Malaysia Marshall Islands Micronesia Mongolia Nauru New Caledonia New Zealand Niue Northern Mariana Islands Palau Papua New Guinea Philippines Rep. of Korea Samoa Singapore Solomon Islands Tokelau Tonga Tuvalu Vanuatu Viet Nam Wallis & Futuna 2.0 0 0.1 0 0.2 27 570 47%
13
5.3
C N P C C C N N N N C N C C C C N C N N N N C C C C N N N C N C P N C N
WPR
308
202
Notes
China, Hong Kong SAR

FIGURE 2.12: at least one case of XDR-TB was reported by the end of 2008. TABLE A3.8: the majority of treatment-after-failure cases are still on treatment at 12 months.
China, Macao SAR

TABLE A3.5: 41 cases treated outside the public sector, with site and history of treatment unspecied, were reported as other, non-DOTS.
Japan
TABLE A3.8: cases not evaluated include some cases still on treatment.
ANNEX 4
Surveys of tuberculosis disease and availability of death registration data at WHO, by country and year
Table A4.1 National and subnational surveys of prevalence of tuberculosis disease

Table A4.1.1 National surveys
Bangladesh Cambodia China Eritrea Gambia Ghana Indonesia Iraq Japan Kenya Liberia Libyan Arab Jamahiriya Malaysia Mauritius Myanmar Netherlands Nigeria Pakistan Philippines Rep. of Korea Samoa Sierra Leone Somalia Sri Lanka Uganda Viet Nam
1
Table A4.1.3 Planned or recommended surveys 2 (national or subnational)

Afghanistan Bangladesh3 3,4 Cambodia China3 Djibouti4 Ethiopia Gambia Ghana3 3 Indonesia 3 Kenya Lao PDR4 Malawi3,4 Mali3 Myanmar3 Mozambique3 Nigeria3,4 Pakistan3 Philippines3 3,4 Rwanda 3 Sierra Leone South Africa3 Syrian Arab Republic4 Thailand3,4 UR Tanzania3 Uganda3,4 Viet Nam3 Zambia 3,4
1964, 1987 2002 1979, 1984, 1990, 2000 2005 1960 1957 2004 1970 1953, 1958, 1963, 1968 1948, 1958 1959 1976 2003 1958 2006 1970 1957 1959, 1987 1981, 1997, 2007 1965, 1970, 1975, 1980, 1985, 1990, 1995 1975 1958 1956 1970 1958 2007
2010 2008 2010 2010 2010 ND 2010 2010 2014 2010 ND 2009 2009 2009 ND 2009 2009 ND 2010 ND 2010 2012 2011 2008 2009 ND 2010
Table A4.1.2 Subnational surveys 1

Afghanistan Bangladesh Botswana Brunei Darussalam China Cambodia Colombia Cyprus Egypt Ethiopia India Indonesia Iraq Japan Kenya Liberia Malawi Malaysia Mozambique Myanmar Nepal Nigeria Pakistan South Africa Spain Syrian Arab Republic Thailand Tunisia Turkey Uganda UR Tanzania Viet Nam Zambia
1982 1995, 2001, 2002, 2006 1981, 1995 1985 1957, 1959 1981, 1982, 1983, 1984, 1985, 1988, 1995, 1998 1988 1963 2007 2001 19481993 (numerous surveys), 2007, 2008 1979, 19831993, 1994 1961 1954, 1964 1958, 2006 1959 1960 1970 1961 1972, 1989, 1990, 1991, 1994, 2006 1965, 1976, 1994 1957, 1973 1962 19721985 1991 1960 1962, 1970, 1977, 1983, 1987, 1991, 2007 1957, 1961 1971 2000 1958 1961 1980, 2006
ND indicates not determined.

1
Exact timing of surveys not always clear from reports; year given here is year in which survey apparently started. In some cases more than one subnational survey was completed in a country in a given year. Detailed reference list available at www.who.int/tb. References to surveys done in 2006 and 2007 have generally not yet been published in peer reviewed journals, but will be added to the web site when they are published. Countries indicating on the data collection form that they are planning to undertake a prevalence of disease survey in the near future but for which this information has not been confirmed are not included here. These tables will be updated as the information is confirmed. See www.who.int/tb The WHO Task Force on TB Impact Measurement has recommended that these 21 countries should carry out two prevalence of TB disease surveys between now and 2015 (or one more survey if at least one survey was done between 1990 and 2007). These surveys are needed as part of an effort to produce credible regional and global assessments of progress towards the 2015 impact targets, as well as for demonstrating the impact of control programmes on the burden of TB (see Chapter 1 for definition of the impact targets and Chapter 2 for an explanation of how the 21 countries were selected). For those countries that already have concrete plans (protocols and funding) to carry out at least one survey in the near future the expected year when the survey will start is provided. Funding for surveys in these countries has been approved by the Global Fund.
Table A4.2 Availability of death registrations by cause of death, WHO Mortality Database, 2008
Albania Anguilla Antigua & Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Barbados Belarus Belgium Belize Bermuda Bosnia & Herzegovina Brazil British Virgin Islands Brunei Darussalam Bulgaria Canada Cayman Islands Chile China, Hong Kong SAR China, Macao SAR Colombia Costa Rica Croatia Cuba Cyprus Czech Republic Denmark Dominica Dominican Republic Ecuador Egypt El Salvador Estonia Fiji Finland France Georgia Germany Greece Grenada Guatemala Guyana Haiti Honduras Hungary Iceland Iran (Islamic Republic of) Ireland Israel Italy Jamaica Japan Kazakhstan Kiribati Kuwait Kyrgyzstan Latvia
Cov Qual Year(s) 72 L 19871989, 19922004 19851995, 20002001, 20032006 74 M 19851995, 20002004 100 L 19852005 63 L 19852003 1987 100 H 19852003 99 H 19852006 68 M 19852004 83 H 1985, 1987, 19932000 83 L 1985, 19871988, 19972001 76 M 19851995, 20002001 98 M 19852003 100 M 19851997 81 M 19861987, 19891991, 19932001 19852002 88 L 19851991 79 M 19852004 19852003 100 M 19962000 100 M 19852004 100 H 19852004 19852000, 2004 94 H 19852005 19852006 1994 78 M 19852002, 20042005 88 H 19852005 95 M 19852006 100 H 19852005 70 L 19992000, 2004, 2006 100 M 19852005 100 M 19852001 100 M 19852004 19851992, 19942001, 20032004 74 M 19852005 81 L 1987, 19911992, 2000 75 L 19901993, 19952005 100 H 19852005 100 L 1999 100 H 19852006 100 M 19852005 97 M 19851992, 19942001 99 M 19852006 99 L 19852006 86 M 1985, 19881996, 20012002 89 M 19862004 72 L 19881996, 19981999, 20012005 1997, 1999, 20012003 19871990 100 H 19852005 95 H 19852006 66 L 19851987 100 H 19852006 100 H 19852004 100 M 19852003 60 L 19851991 100 H 19852006 77 M 19852006 76 L 19912001 100 H 19851987, 19932002 70 M 19852006 93 H 19852006
Lithuania Luxembourg Malaysia Maldives Malta Mauritius Mexico Monaco Mongolia Montserrat Netherlands New Zealand Nicaragua Norway Panama Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Rep. of Korea Republic of Moldova Romania Russian Federation Saint Kitts & Nevis Saint Lucia San Marino Sao Tome & Principe Serbia Serbia & Montenegro Seychelles Singapore Slovakia Slovenia South Africa Spain Sri Lanka St Vincent & Grenadines Suriname Sweden Switzerland Syrian Arab Republic TFYR Macedonia Tajikistan Thailand Trinidad & Tobago Turkey Turkmenistan Turks & Caicos Islands US Virgin Islands USA USSR, Former Ukraine United Kingdom Uruguay Uzbekistan Venezuela Yugoslavia, Former Zimbabwe
Cov 1 Qual1 Year(s) 98 H 19852006 96 M 19852005 M 1997 51 L 20002005 95 H 19852005 93 M 19852005 95 H 19852005 19861987 84 M 1994 19902003 100 M 19852006 100 H 19852004 58 L 19881994, 19962005 98 M 19852005 91 M 19851989, 19962004 74 L 19851991, 19942004 54 L 19861992, 19942000 85 M 19921998 100 L 19851996, 19992006 100 M 19852003 19852003, 2005 83 L 1995 87 M 19852006 80 H 19852006 100 H 19852007 99 M 19852006 100 M 19852005 99 M 19862002 73 L 19952000, 2002, 2005 19851987 20042006 89 M 19972002 100 M 19851987, 20012005 82 H 19852006 98 H 19922005 100 M 19852006 79 L 19932005 100 M 19852005 74 L 19851989, 19911992, 1995 93 H 19851987, 1990, 19952003 73 M 19851992, 19952000 100 M 19852005 99 M 19852005 100 L 1985 19912003 54 L 19852005 87 L 19851987, 19901992, 19942000, 2002 83 H 19852002 1987 76 M 19851998 19852005 19972003, 2005 100 H 19852005 19851989 100 M 19852005 99 H 19851999, 20012006 100 M 19851990, 19932001, 2004 73 H 19852000, 20022005 99 H 19851990, 19921994, 19962005 19851989 1990
Shown are years for which cause-of-death data (19852007) were available in the WHO Mortality Database by August 2008 (see also www.who.int/healthinfo/morttables). In some cases more recent data are available in the country in question, but have not yet been sent to WHO.
Cov, Qual: Coverage and quality. Coverage is calculated by dividing the total deaths reported for a country in a given year from the vital registration system by the total deaths estimated by WHO for that year for the national population (shown is coverage for most recent year, but not for data before 2000). Coverage can be low because vital registration is implemented in only part of the country, or because only a proportion of deaths is recorded, or both. Source: EIP/WHO. Assessment of data quality based on coding system used, and on proportion of deaths assigned to ill-defined codes; L, indicates low; M, medium; H, high. Source: Mathers, C et al. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bulletin of the World Health Organization, 2005, 83: 171177.
T h eWo r l dH e a l t hO r g a n i z a t i o nmo n i t o r s t h eg l o b a l t u b e r c u l o s i s e p i d e mi c i ns u p p o r t o f n a t i o n a l T Bc o n t r o l p r o g r a mme s .
F o r f u r t h e r i n f o r ma t i o na b o u t t u b e r c u l o s i s c o n t a c t : I n f o r ma t i o nR e s o u r c eC e n t r eH T M / S T B Wo r l dH e a l t hO r g a n i z a t i o n 2 0A v e n u eA p p i a , 1 2 1 1 G e n e v a 2 7 , S w i t z e r l a n d E ma i l : t b d o c s @w h o . i n t We bs i t e : w w w . w h o . i n t / t b
I S B N9 7 89 241 5 6 3 8 02

World Health Organization Global Tuberculosis Control 2009 Epidemiology, Strategy, Financing Nonserial Publication 2009

Transféré par

Informations du document

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

World Health Organization Global Tuberculosis Control 2009 Epidemiology, Strategy, Financing Nonserial Publication 2009

Transféré par

Droits d'auteur :

Formats disponibles

G l o b a l T u b e r c u l o s i s C o n t r o l 2 0 0 9

WHO REPORT 2009

Global Tuberculosis Control

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 iii

iv WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 v

vi WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 vii

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 1

2 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 3

4 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 5

Goals, targets and indicators for TB control

Stop TB Partnership targets

TB incidence, prevalence and mortality

 TABLE 1.2 Estimated epidemiological burden of TB, 2007

PREVALENCEa ALL FORMS

HIV PREV. IN INCIDENT TB CASESb %

26 15 37 53 38 44 64 28 41 72 14 20 26 3.1 29 41 52 15 45 11 77 30 25 45 3.6 17 6.3 28 16 20

High-burden countries AFR AMR EMR EUR SEAR WPR Global

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 7

 FIGURE 1.1 Estimated number of new TB cases, by country, 2007

 FIGURE 1.2 Estimated TB incidence rates, by country, 2007

8 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

 FIGURE 1.3 Estimated HIV prevalence in new TB cases, 2007

Incidence of TB among people infected with HIV

Incidence (per 100 000 population per year)

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 9

Estimated incidence of MDR-TB

10 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

DRS Model 50 000 100 000

Percentage of global estimated HIV-positive TB cases

400 350 300 250 200

HIV prevalence in general population

3.0 2.5 2.0

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 11

Prevalence (all forms, including HIV)

Mortality (including HIV)

 FIGURE 1.9 Trends in estimated incidence rates in nine subregions, 19902007

107 70 14 60 12 50 105 106

14 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

Standardized prevalence rate

1.0 0.6 0.8 0.5 0.4 0.4 0.4 0.5 0.6

0.8 1.0 0.7 0.8 0.7 0.6 0.6 0.8

Standardized mortality rate

0.9 1.2 0.8

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 15

Measuring TB incidence rates

1.3.1 Measurement of incidence

Measuring TB prevalence rates

Measuring TB mortality rates

Evaluating the impact of TB control

16 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

Are data reliable and complete?

If not, IMPROVE surveillance system

Do changes in notications over time reect trends in incidence?

Evaluate epidemiological TRENDS and IMPACT of TB control

Do notications include all incident TB cases?

UPDATE estimates of burden if appropriate, CERTIFY or VALIDATE surveillance data

GLOBAL TUBERCULOSIS CONTROL WHO REPORT 2009 17

Estimating TB incidence using capture-recapture methods: an example from Egypt

18 WHO REPORT 2009 GLOBAL TUBERCULOSIS CONTROL

1.3.2 Measurement of prevalence

TABLE 1.2 Estimated epidemiological burden of TB, 2007

FIGURE 1.1 Estimated number of new TB cases, by country, 2007

FIGURE 1.2 Estimated TB incidence rates, by country, 2007

FIGURE 1.3 Estimated HIV prevalence in new TB cases, 2007

FIGURE 1.9 Trends in estimated incidence rates in nine subregions, 19902007

TABLE 1.5 Case notications, 2007

FIGURE 1.15 Tuberculosis notication rates, by country, 2007

TABLE 2.1 Components of the Stop TB Strategy

TABLE 2.2 Technical elements of the DOTS strategy

TABLE 2.4 Progress in DOTS implementation, 19952007